From e86c87add6ff098c06f498dec319764c906510d0 Mon Sep 17 00:00:00 2001 From: Trish Whetzel Date: Thu, 11 Apr 2019 15:04:53 +0100 Subject: [PATCH 1/6] initial commit, code for efo_trait data changes --- .../remove_background_trait_links.py | 160 ++ .../study_background_traits-ALL.txt | 1518 +++++++++++++++++ .../study_background_traits-ALL.xlsx | Bin 0 -> 95862 bytes .../study_background_traits-TEST.txt | 19 + .../study_background_traits.xlsx | Bin 0 -> 11063 bytes 5 files changed, 1697 insertions(+) create mode 100644 trait-representation-migration/remove_background_trait_links.py create mode 100644 trait-representation-migration/study_background_traits-ALL.txt create mode 100644 trait-representation-migration/study_background_traits-ALL.xlsx create mode 100644 trait-representation-migration/study_background_traits-TEST.txt create mode 100644 trait-representation-migration/study_background_traits.xlsx diff --git a/trait-representation-migration/remove_background_trait_links.py b/trait-representation-migration/remove_background_trait_links.py new file mode 100644 index 0000000..97d779e --- /dev/null +++ b/trait-representation-migration/remove_background_trait_links.py @@ -0,0 +1,160 @@ +# Activate Python venv for the script - uncomment to run script on commandline +activate_this_file = "/path/to/bin/activate_this.py" +execfile(activate_this_file, dict(__file__ = activate_this_file)) + +import cx_Oracle +import contextlib +import argparse +import sys +from tqdm import tqdm +import csv +import os.path + +sys.path.insert(0, '/path/to/gwas_data_sources') +import gwas_data_sources + +import datetime + + +def read_file(filename): + ''' + Read file. + + Args: + filename: Name of file provided as a commandline argument. + + Returns: + data: File object. + ''' + data = [] + + with open(filename, 'r') as file: + lines = file.readlines()[1:] + + for line in lines: + formatted_line = line.split('\t') + + study_accession = formatted_line[2].strip() + + background_column = formatted_line[4].strip() + + delimiter = '||' + + if not background_column == '': + study_traits = {} + if delimiter in background_column: + background_column = background_column.split(delimiter) + background_traits = [item.strip().lower() for item in background_column] + else: + background_traits = background_column.strip().lower() + + study_traits[study_accession] = background_traits + data.append(study_traits) + else: + pass + + return data + + +def database_connection(DATABASE_NAME): + ''' + Connect to the database and returns a cursor object. + + Args: + database_name (str): The name of the database. + + Raises: + DatabaseError: Error reponse if unable to connect to the database. + + Returns: + cursor: Database cursor object. + ''' + + try: + ip, port, sid, username, password = gwas_data_sources.get_db_properties(DATABASE_NAME) + dsn_tns = cx_Oracle.makedsn(ip, port, sid) + connection = cx_Oracle.connect(username, password, dsn_tns) + + cursor = connection.cursor() + + return cursor + + except cx_Oracle.DatabaseError, exception: + print exception + + +def get_efo_id_map(cursor): + ''' + Get mapping of term labels to EFO IDs. + + Args: + cursor: Database cursor object. + + + Returns: + efo_map: A mapping of term labels to it's EFO ID + ''' + efo_map = {} + + efo_sql = ''' + SELECT ID, LOWER(TRAIT) + FROM EFO_TRAIT + ''' + + cursor.execute(efo_sql) + efo_data = cursor.fetchall() + + for row in tqdm(efo_data, desc='Build EFO map'): + efo_map[row[0]] = row[1] + + return efo_map + + +def _execute_query(cursor, query): + ''' + Run the query. + + Args: + query (str): The query to run. + + Raises: + ''' + + cursor.execute(query) + + # commit or rollback changes + # if args.mode == 'production': + # cursor.execute('COMMIT') + # else: + # cursor.execute('ROLLBACK') + pass + + +if __name__ == '__main__': + ''' + Remove background trait link to Studies. + ''' + + # Commandline arguments + parser = argparse.ArgumentParser() + parser.add_argument('--filename', default='study_background_traits-ALL.txt', + help='Name of data file (default: study_background_traits).') + parser.add_argument('--database', default='DEV3', choices=['DEV3', 'SPOTPRO'], + help='Run as (default: DEV3).') + parser.add_argument('--mode', default='debug', choices=['debug', 'production'], + help='Run as (default: debug).') + args = parser.parse_args() + + global DATABASE_NAME + DATABASE_NAME = args.database + + read_file(args.filename) + + # cursor = database_connection() + + # get_efo_id_map(cursor) + + # remove_study_efo_trait_links() + + + diff --git a/trait-representation-migration/study_background_traits-ALL.txt b/trait-representation-migration/study_background_traits-ALL.txt new file mode 100644 index 0000000..5b52d4a --- /dev/null +++ b/trait-representation-migration/study_background_traits-ALL.txt @@ -0,0 +1,1518 @@ +DISEASE/TRAIT MAPPED_TRAIT STUDY ACCESSION Other Background +Cannabis use (age at onset) Cannabis use|| age at onset GCST006386 Cannabis use|| age at onset +Cannabis use (age at onset) Cannabis use|| age at onset GCST002917 Cannabis use|| age at onset +Schizophrenia (age at onset) schizophrenia|| age at onset GCST001115 schizophrenia|| age at onset +Parkinson's disease in GBA mutation carriers (age at onset) Parkinson's disease|| GBA carrier status|| age at onset GCST003060 age at onset|| Parkinson's disease GBA carrier status +Bipolar disorder (age of onset and psychotic symptoms) age at onset|| psychotic symptoms|| bipolar disorder GCST000969 age at onset|| psychotic symptoms|| bipolar disorder +Curve progression in adolescent idiopathic scoliosis adolescent idiopathic scoliosis|| disease progression measurement GCST004981 adolescent idiopathic scoliosis|| disease progression measurement +Severe progression in rheumatoid arthritis rheumatoid arthritis|| disease progression measurement GCST004998 rheumatoid arthritis|| disease progression measurement +Liver transplant-free survival in primary sclerosing cholangitis (time to event) event free survival time|| sclerosing cholangitis GCST005859 event free survival time|| sclerosing cholangitis +Cholangiocarcinoma in primary sclerosing cholangitis (time to event) event free survival time|| cholangiocarcinoma|| sclerosing cholangitis GCST005860 event free survival time|| cholangiocarcinoma|| sclerosing cholangitis +Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy diffuse large B-cell lymphoma|| event free survival time|| response to immunochemotherapy GCST003178 diffuse large B-cell lymphoma|| event free survival time|| response to immunochemotherapy +Breast cancer (survival) event free survival time|| survival time|| breast carcinoma GCST001373 event free survival time|| survival time|| breast carcinoma +Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event) event free survival time|| type I diabetes mellitus|| carrier status|| autoantibody measurement GCST006197 event free survival time|| type I diabetes mellitus|| autoantibody measurement carrier status +Overall survival in osteosarcoma osteosarcoma|| overall survival GCST005158 osteosarcoma|| overall survival +Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab) progression free survival|| metastatic colorectal cancer|| response to cetuximab|| response to CAPOX-B GCST003058 progression free survival|| metastatic colorectal cancer|| response to cetuximab|| response to CAPOX-B +Progression free survival in metastatic colorectal cancer (chemotherapy interaction) progression free survival|| metastatic colorectal cancer|| response to cetuximab|| response to CAPOX-B GCST003057 progression free survival|| metastatic colorectal cancer|| response to cetuximab|| response to CAPOX-B +Breast cancer (survival) survival time|| breast carcinoma GCST005106 survival time|| breast carcinoma +Breast cancer (survival) survival time|| breast carcinoma GCST002727 survival time|| breast carcinoma +Breast cancer (survival) estrogen-receptor negative breast cancer|| survival time|| estrogen-receptor positive breast cancer|| breast carcinoma GCST002861 survival time|| estrogen-receptor negative breast cancer|| estrogen-receptor positive breast cancer|| breast carcinoma +Survival in breast cancer (estrogen-receptor positive) event free survival time|| estrogen-receptor positive breast cancer GCST005901 event free survival time|| estrogen-receptor positive breast cancer +Survival in endocrine treated breast cancer (estrogen-receptor positive) event free survival time|| estrogen-receptor positive breast cancer|| response to endocrine therapy GCST005900 event free survival time|| estrogen-receptor positive breast cancer|| response to endocrine therapy +Survival in colorectal cancer (distant metastatic) metastasis measurement|| colorectal cancer|| survival time GCST003230 metastasis measurement|| colorectal cancer|| survival time +Survival in colorectal cancer (non-distant metastatic) metastasis measurement|| colorectal cancer|| survival time GCST003231 metastasis measurement|| colorectal cancer|| survival time +Survival in breast cancer (TP53 expression interaction) overall survival|| breast carcinoma|| TP53 mutation status GCST004229 overall survival|| breast carcinoma|| TP53 mutation status +Survival in TP53 positive breast cancer overall survival|| TP53 Positive Breast Carcinoma GCST004228 overall survival|| TP53 Positive Breast Carcinoma +Survival in pancreatic cancer overall survival|| pancreatic carcinoma GCST004485 overall survival|| pancreatic carcinoma +Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin overall survival|| ovarian carcinoma|| response to cisplatin|| response to paclitaxel GCST004896 overall survival|| ovarian carcinoma|| response to cisplatin|| response to paclitaxel +Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel progression free survival|| response to carboplatin|| ovarian carcinoma|| response to paclitaxel GCST003328 progression free survival|| response to carboplatin|| ovarian carcinoma|| response to paclitaxel +Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel progression free survival|| ovarian carcinoma|| response to cisplatin|| response to paclitaxel GCST004897 progression free survival|| ovarian carcinoma|| response to cisplatin|| response to paclitaxel +Progression free survival in EGFR-mutation-positive never-smoking lung adenocarcinoma treated with gefitinib or erlotinib progression free survival|| response to gefitinib|| response to erlotinib|| lung adenocarcinoma GCST003794 progression free survival|| response to gefitinib|| response to erlotinib|| lung adenocarcinoma +Survival in colorectal cancer colorectal cancer|| survival time GCST003229 colorectal cancer|| survival time +Survival in breast cancer (estrogen-receptor negative) estrogen-receptor negative breast cancer|| survival time|| breast carcinoma GCST002902 estrogen-receptor negative breast cancer|| survival time|| breast carcinoma +Survival in breast cancer (estrogen-receptor positive) survival time|| estrogen-receptor positive breast cancer|| breast carcinoma GCST002903 survival time|| estrogen-receptor positive breast cancer|| breast carcinoma +Survival in head and neck cancer head and neck malignant neoplasia|| survival time GCST003541 head and neck malignant neoplasia|| survival time +Sepsis from pneumonia (survival) survival time|| pneumonia|| septic shock|| sepsis GCST002725 survival time|| pneumonia|| septic shock|| sepsis +Survival in sporadic amyotrophic lateral sclerosis sporadic amyotrophic lateral sclerosis|| survival time GCST003632 sporadic amyotrophic lateral sclerosis|| survival time +Survival in endocrine treated breast cancer (estrogen-receptor positive) survival time|| estrogen-receptor positive breast cancer|| breast carcinoma|| response to endocrine therapy GCST002901 survival time|| estrogen-receptor positive breast cancer|| breast carcinoma|| response to endocrine therapy +Age-related cataracts (age at onset) age at onset|| age-related cataract GCST002618 age at onset|| age-related cataract +Alcohol dependence (age at onset) age at onset|| alcohol dependence GCST002477 age at onset|| alcohol dependence +Alzheimer disease and age of onset Alzheimer's disease|| age at onset GCST003427 Alzheimer's disease|| age at onset +Alzheimer's disease (age of onset) Alzheimer's disease|| age at onset GCST006120 Alzheimer's disease|| age at onset +Alzheimer's disease (age of onset) Alzheimer's disease|| age at onset GCST001280 Alzheimer's disease|| age at onset +Alzheimer's disease (survival time) Alzheimer's disease|| survival time GCST002775 Alzheimer's disease|| survival time +Amyotrophic lateral sclerosis (age of onset) amyotrophic lateral sclerosis|| age at onset GCST001663 amyotrophic lateral sclerosis|| age at onset +Bipolar disorder (age of onset <21) or attention deficit hyperactivity disorder attention deficit hyperactivity disorder|| bipolar disorder GCST004002 attention deficit hyperactivity disorder|| bipolar disorder +Frontotemporal dementia (age at onset) age at onset|| Frontotemporal dementia GCST006147 age at onset|| Frontotemporal dementia +Frontotemporal dementia (age at onset) age at onset|| Frontotemporal dementia GCST004096 age at onset|| Frontotemporal dementia +Frontotemporal dementia with GRN mutation (age at onset) age at onset|| Frontotemporal dementia GCST006149 age at onset|| Frontotemporal dementia +Multiple myeloma (survival) overall survival|| multiple myeloma GCST003051 overall survival|| multiple myeloma +Multiple sclerosis (age of onset) multiple sclerosis|| age at onset GCST000267 multiple sclerosis|| age at onset +Myopia (age of diagnosis) age at onset|| Myopia GCST006290 age at onset|| Myopia +Narcolepsy (age of onset) narcolepsy with cataplexy|| age at onset GCST002261 narcolepsy with cataplexy|| age at onset +Non-small cell lung cancer (survival) survival time|| non-small cell lung carcinoma GCST002577 survival time|| non-small cell lung carcinoma +Non-small cell lung cancer (survival) survival time|| non-small cell lung carcinoma GCST002032 survival time|| non-small cell lung carcinoma +Non-small cell lung cancer (survival) survival time|| non-small cell lung carcinoma GCST000871 survival time|| non-small cell lung carcinoma +Parkinson's disease (age of onset) Parkinson's disease|| age at onset GCST003653 Parkinson's disease|| age at onset +Parkinson's disease (age of onset) Parkinson's disease|| age at onset GCST000490 Parkinson's disease|| age at onset +"Parkinson's disease (familial, age at onset)" Parkinson's disease|| age at onset GCST003652 Parkinson's disease|| age at onset +"Parkinson's disease (non-familial, age at onset)" Parkinson's disease|| age at onset GCST003651 Parkinson's disease|| age at onset +Prostate cancer (survival) survival time|| prostate carcinoma GCST003100 survival time|| prostate carcinoma +Spherical equivalent or myopia (age of diagnosis) age at onset|| Myopia|| refractive error measurement GCST006291 age at onset|| Myopia|| refractive error measurement +Restricted and repetitive behaviours in autism spectrum disorder autism spectrum disorder|| behavior or behavioral disorder measurement GCST004377 behavior or behavioral disorder measurement autism spectrum disorder +Serum metabolite concentrations in chronic kidney disease chronic kidney disease|| serum metabolite measurement GCST005648 serum metabolite measurement chronic kidney disease +Serum metabolite ratios in chronic kidney disease chronic kidney disease|| serum metabolite measurement GCST005650 serum metabolite measurement chronic kidney disease +3-hydroxy-1-methylpropylmercapturic acid levels in smokers smoking behavior|| 3-hydroxy-1-methylpropylmercapturic acid measurement GCST002957 3-hydroxy-1-methylpropylmercapturic acid measurement smoking behavior +3-hydroxypropylmercapturic acid levels in smokers smoking behavior|| 3-hydroxypropylmercapturic acid measurement GCST002956 3-hydroxypropylmercapturic acid measurement smoking behavior +Change in HbA1c levels in response to metformin treatment in type 2 diabetes A1C measurement|| type II diabetes mellitus|| response to metformin GCST005753 A1C measurement|| response to metformin type II diabetes mellitus +Paneth cell defects in Crohn's disease abnormal paneth cell measurement|| Crohn's disease GCST004251 abnormal paneth cell measurement Crohn's disease +Acute kidney injury in critical illness Acute kidney injury|| illness severity status GCST003656 Acute kidney injury illness severity status +Acute kidney injury in coronary artery bypass surgery (creatinine rise) coronary artery bypass|| Acute kidney injury|| serum creatinine measurement GCST002982 Acute kidney injury|| serum creatinine measurement coronary artery bypass +Acute-on-chronic liver failure in hepatitis B acute-on-chronic liver failure|| hepatitis B infection GCST004165 acute-on-chronic liver failure hepatitis B infection +Adult onset asthma in ever-smokers smoking behavior|| adult onset asthma GCST004222 adult onset asthma smoking behavior +Cannabis-related aggression Cannabis use|| aggressive behavior GCST006175 aggressive behaviour Cannabis use +Aggressiveness in attention deficit hyperactivity disorder attention deficit hyperactivity disorder|| aggressive behaviour measurement|| childhood aggressive behaviour measurement GCST003473 aggressive behaviour measurement|| childhood aggressive behaviour measurement attention deficit hyperactivity disorder +Airway responsiveness in chronic obstructive pulmonary disease airway responsiveness measurement|| chronic obstructive pulmonary disease GCST002724 airway responsiveness measurement chronic obstructive pulmonary disease +Problematic alcohol use in trauma-exposed individuals response to trauma exposure|| alcohol dependence measurement GCST005236 alcohol dependence measurement|| response to trauma exposure +Allergic rhinitis in asthma allergic rhinitis|| asthma GCST002552 allergic rhinitis asthma +Alloimmunization response to red blood cell transfusion in sickle cell anemia Sickle cell anemia|| alloimmunization|| response to red blood cell transfusion GCST002691 alloimmunization|| response to red blood cell transfusion Sickle cell anemia +Thiopurine-induced alopecia in inflammatory bowel disease Alopecia|| response to thiopurine|| inflammatory bowel disease GCST006206 Alopecia|| response to thiopurine inflammatory bowel disease +Thiopurine-induced alopecia in inflammatory bowel disease (conditioned on rs116855232) Alopecia|| response to thiopurine|| inflammatory bowel disease GCST006214 Alopecia|| response to thiopurine inflammatory bowel disease +Thiopurine-induced severe alopecia in inflammatory bowel disease Alopecia|| response to thiopurine|| inflammatory bowel disease GCST006207 Alopecia|| response to thiopurine inflammatory bowel disease +Thiopurine-induced severe alopecia in inflammatory bowel disease (conditioned on rs116855232) Alopecia|| response to thiopurine|| inflammatory bowel disease GCST006199 Alopecia|| response to thiopurine inflammatory bowel disease +Amygdala volume in trauma-exposed individuals response to trauma exposure|| amygdala volume GCST005239 amygdala volume|| response to trauma exposure +Plasma androstenedione levels in resected early stage-receptor positive breast cancer androstenedione measurement|| estrogen-receptor positive breast cancer GCST004363 androstenedione measurement estrogen-receptor positive breast cancer +Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer androstenedione measurement|| estrogen-receptor positive breast cancer|| estrone measurement GCST004361 androstenedione measurement|| estrone measurement estrogen-receptor positive breast cancer +Anthropometric traits in newborns anthropometric measurement|| neonate GCST001964 anthropometric measurement neonate +Antibody status in Tripanosoma cruzi seropositivity antibody measurement|| Trypanosoma cruzi seropositivity GCST002280 antibody measurement Trypanosoma cruzi seropositivity +Antipsychotic drug-induced weight gain in schizophrenia schizophrenia|| antipsychotic drug related weight gain GCST003579 antipsychotic drug related weight gain schizophrenia +antipsychotic drug dosage in schizophrenia or schizoaffective disorder schizophrenia|| antipsychotic drug use measurement|| schizoaffective disorder GCST003341 antipsychotic drug use measurement schizophrenia|| schizoaffective disorder +Anti-saccade error rate in psychotic disorders antisaccade response measurement|| schizophrenia|| bipolar disorder|| schizoaffective disorder GCST005027 antisaccade response measurement schizophrenia|| bipolar disorder|| schizoaffective disorder +Anxiety in major depressive disorder unipolar depression|| anxiety GCST002202 anxiety unipolar depression +AR-C124910XX levels in individuals with acute coronary syndromes treated with ticagrelor AR-C124910XX measurement|| acute coronary syndrome GCST002883 AR-C124910XX measurement acute coronary syndrome +Asparaginase hypersensitivity in acute lymphoblastic leukemia asparaginase hypersensitivity|| acute lymphoblastic leukemia GCST002915 asparaginase hypersensitivity acute lymphoblastic leukemia +Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia asparaginase-induced acute pancreatitis|| acute lymphoblastic leukemia GCST003500 asparaginase-induced acute pancreatitis acute lymphoblastic leukemia +Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time) asparaginase-induced acute pancreatitis|| acute lymphoblastic leukemia GCST003501 asparaginase-induced acute pancreatitis acute lymphoblastic leukemia +Postoperative atrial fibrillation in coronary artery bypass grafting surgery coronary artery bypass|| atrial fibrillation GCST002975 atrial fibrillation coronary artery bypass +Atrioventricular septal defects in Down syndrome Atrioventricular canal defect|| Down syndrome GCST003047 Atrioventricular canal defect Down syndrome +Suicide attempts in bipolar disorder bipolar disorder|| attempted suicide GCST001015 attempted suicide bipolar disorder +Suicide attempts in major depressive disorder unipolar depression|| attempted suicide GCST002972 attempted suicide unipolar depression +Suicide attempts in depression or bipolar disorder unipolar depression|| bipolar disorder|| attempted suicide GCST002503 attempted suicide unipolar depression|| bipolar disorder +Attention function in attention deficit hyperactive disorder attention deficit hyperactivity disorder|| attention function measurement GCST003025 attention function measurement attention deficit hyperactivity disorder +Gastric parietal cell autoantibody levels in type 1 diabetes type I diabetes mellitus|| autoantibody measurement GCST004382 autoantibody measurement type I diabetes mellitus +Glutamate decarboxylase autoantibody levels in type 1 diabetes type I diabetes mellitus|| autoantibody measurement GCST004380 autoantibody measurement type I diabetes mellitus +Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes type I diabetes mellitus|| autoantibody measurement GCST004381 autoantibody measurement type I diabetes mellitus +Autoimmune hepatitis in primary sclerosing cholangitis Autoimmune Hepatitis|| sclerosing cholangitis GCST005853 Autoimmune Hepatitis sclerosing cholangitis +Infective endocarditis in Staphylococcus aureus infection bacterial endocarditis|| Staphylococcus aureus infection GCST006805 bacterial endocarditis Staphylococcus aureus infection +Behavioural changes in frontotemporal lobe dementia Frontotemporal dementia|| behavior GCST006146 behavior Frontotemporal dementia +Temperament (bipolar disorder) behavior or behavioral disorder measurement|| personality trait|| bipolar disorder GCST001419 behavior or behavioral disorder measurement|| personality trait bipolar disorder +Behavioral disturbance or psychiatric symptoms in prion disease behavioral abnormality|| prion disease GCST002863 behavioral abnormality prion disease +Cerebrospinal AB1-42 levels in Alzheimer's disease dementia Alzheimer's disease|| beta-amyloid 1-42 measurement GCST002531 beta-amyloid 1-42 measurement Alzheimer's disease +Total bilirubin levels in HIV-1 infection HIV-1 infection|| bilirubin measurement GCST002745 bilirubin measurement HIV-1 infection +Bilirubin levels in extreme obesity bilirubin measurement|| obesity GCST002628 bilirubin measurement obesity +Bilirubin levels in tenofovir-treated HIV infection bilirubin measurement|| response to tenofovir|| HIV infection GCST006074 bilirubin measurement|| response to tenofovir HIV infection +Binge eating behaviour in bipolar disorder binge eating|| bipolar disorder GCST005387 binge eating bipolar disorder +Binge eating behaviour in bipolar disorder binge eating|| bipolar disorder GCST002420 binge eating bipolar disorder +Bone mineral density x blood lead interaction in current smokers (1df test) smoking behavior|| blood lead measurement|| bone density GCST006132 blood lead measurement|| bone density smoking behavior +Bone mineral density x blood lead interaction in current smokers (2df test) smoking behavior|| blood lead measurement|| bone density GCST006133 blood lead measurement|| bone density smoking behavior +Waist circumference adjusted for BMI in active individuals BMI-adjusted waist circumference|| physical activity measurement GCST004564 BMI-adjusted waist circumference physical activity measurement +Waist circumference adjusted for BMI in inactive individuals BMI-adjusted waist circumference|| physical activity measurement GCST004565 BMI-adjusted waist circumference physical activity measurement +Waist circumference adjusted for BMI in smokers smoking behavior|| BMI-adjusted waist circumference GCST004503 BMI-adjusted waist circumference smoking behavior +Waist-to-hip ratio adjusted for BMI in active individuals BMI-adjusted waist-hip ratio|| physical activity measurement GCST004578 BMI-adjusted waist-hip ratio physical activity measurement +Waist-to-hip ratio adjusted for BMI in inactive individuals BMI-adjusted waist-hip ratio|| physical activity measurement GCST004577 BMI-adjusted waist-hip ratio physical activity measurement +Waist-to-hip ratio adjusted for BMI in smokers smoking behavior|| BMI-adjusted waist-hip ratio GCST004509 BMI-adjusted waist-hip ratio smoking behavior +Fat distribution (HIV) HIV-1 infection|| body fat distribution GCST001343 body fat distribution HIV-1 infection +Body mass index in asthmatics body mass index|| asthma GCST001945 body mass index asthma +Body mass in chronic obstructive pulmonary disease chronic obstructive pulmonary disease|| body mass index GCST000850 body mass index chronic obstructive pulmonary disease +Body mass index in physically active individuals physical activity measurement|| body mass index GCST004559 body mass index physical activity measurement +Body mass index in physically inactive individuals physical activity measurement|| body mass index GCST004560 body mass index physical activity measurement +BMI in smokers smoking behavior|| body mass index GCST004498 body mass index smoking behavior +Weight loss (gastric bypass surgery) gastric bypass|| body weight loss GCST001991 body weight loss gastric bypass +Weight loss (gastric bypass surgery) gastric bypass|| body weight loss GCST001985 body weight loss gastric bypass +Bone fracture in osteoporosis bone fracture|| osteoporosis GCST004403 bone fracture osteoporosis +Bone mineral accretion in asthma (oral corticosteroid dose interaction) bone mineral accretion measurement|| response to corticosteroid|| asthma GCST002926 bone mineral accretion measurement|| response to corticosteroid asthma +Breast Cancer in BRCA1 mutation carriers carrier status|| breast carcinoma GCST005075 breast carcinoma carrier status +Breast cancer in childhood cancer survivors breast carcinoma|| childhood cancer GCST005111 breast carcinoma childhood cancer +Breast cancer in childhood cancer survivors treated with less than 10 gray radiotherapy breast carcinoma|| childhood cancer GCST005110 breast carcinoma childhood cancer +Breslow thickness in cutaneous melanoma cutaneous melanoma|| Breslow thickness GCST003639 Breslow thickness cutaneous melanoma +Bronchopulmonary dysplasia in preterm infants Bronchopulmonary dysplasia|| premature birth GCST006460 Bronchopulmonary dysplasia premature birth +C-peptide levels in type I diabetes C-peptide measurement|| type I diabetes mellitus GCST005436 C-peptide measurement type I diabetes mellitus +Fasting C-peptide levels in type I diabetes C-peptide measurement|| type I diabetes mellitus GCST005438 C-peptide measurement type I diabetes mellitus +Random C-peptide levels in type I diabetes C-peptide measurement|| type I diabetes mellitus GCST005437 C-peptide measurement type I diabetes mellitus +Stimulated C-peptide levels in type I diabetes C-peptide measurement|| type I diabetes mellitus GCST005435 C-peptide measurement type I diabetes mellitus +C-reactive protein levels in ischemic stroke Ischemic stroke|| C-reactive protein measurement GCST003211 C-reactive protein measurement Ischemic stroke +Exhaled carbon monoxide levels in smokers with chronic obstructive pulmonary disease smoking status measurement|| chronic obstructive pulmonary disease|| carbon monoxide exhalation measurement GCST005919 carbon monoxide exhalation measurement smoking status measurement|| chronic obstructive pulmonary disease +Cardiomyopathy in childhood cancer survivors childhood cancer|| cardiomyopathy GCST003299 cardiomyopathy childhood cancer +Anthracycline-induced cardiotoxicity in childhood cancer childhood cancer|| cardiotoxicity|| response to anthracycline-based chemotherapy GCST003062 cardiotoxicity|| response to anthracycline-based chemotherapy childhood cancer +Cardiovascular heart disease in diabetics cardiovascular disease|| type II diabetes mellitus GCST002153 cardiovascular disease type II diabetes mellitus +Cardiovascular disease in hypertension (ACE inhibitor interaction) hypertension|| cardiovascular disease|| response to angiotensin-converting enzyme inhibitor GCST003186 cardiovascular disease|| response to angiotensin-converting enzyme inhibitor hypertension +Cardiovascular disease in hypertension (calcium channel blocker interaction) hypertension|| cardiovascular disease|| response to calcium channel blocker GCST003205 cardiovascular disease|| response to calcium channel blocker hypertension +Major coronary event in cardiovascular disease (time to event) (darapladib treatment interaction) response to darapladib|| acute coronary syndrome|| coronary heart disease|| cardiovascular event measurement GCST004958 cardiovascular event measurement|| response to darapladib acute coronary syndrome|| coronary heart disease +Major coronary event in placebo-treated cardiovascular disease (time to event) acute coronary syndrome|| coronary heart disease|| cardiovascular event measurement|| response to placebo GCST004961 cardiovascular event measurement|| response to placebo acute coronary syndrome|| coronary heart disease +Cataracts in type 2 diabetes cataract|| type II diabetes mellitus GCST001736 cataract type II diabetes mellitus +Caudate volume in trauma-exposed individuals response to trauma exposure|| caudate nucleus volume GCST005240 caudate nucleus volume|| response to trauma exposure +Cerebral amyloid deposition in APOEe4 carriers (PET imaging) APOE carrier status|| cerebral amyloid deposition measurement GCST003076 cerebral amyloid deposition measurement APO carrier status +Cerebrospinal fluid clusterin levels in APOEe4+ carriers APOE carrier status|| cerebrospinal fluid clusterin measurement GCST003131 cerebrospinal fluid clusterin measurement APOE carrier status +Chagas cardiomyopathy in Tripanosoma cruzi seropositivity Chagas cardiomyopathy|| Trypanosoma cruzi seropositivity GCST002285 Chagas cardiomyopathy Trypanosoma cruzi seropositivity +Cholangiocarcinoma in primary sclerosing cholangitis cholangiocarcinoma|| sclerosing cholangitis GCST005855 cholangiocarcinoma sclerosing cholangitis +Cholelithiasis-related traits in sickle cell anemia Sickle cell anemia|| cholelithiasis|| bilirubin measurement GCST001497 cholelithiasis|| bilirubin measurement Sickle cell anemia +Chronic bronchitis in chronic obstructive pulmonary disease chronic obstructive pulmonary disease|| chronic bronchitis GCST002621 chronic bronchitis chronic obstructive pulmonary disease +End stage renal disease in APOL1 risk genotype-negative individuals chronic kidney disease|| APOL1 risk genotype carrier status GCST006815 chronic kidney disease APOL1 risk genotype carrier status +End stage renal disease in APOL1 risk genotype-positive individuals chronic kidney disease|| APOL1 risk genotype carrier status GCST006816 chronic kidney disease APOL1 risk genotype carrier status +Chronic kidney disease in diabetes chronic kidney disease|| diabetes mellitus GCST005880 chronic kidney disease diabetes mellitus +End-stage renal disease in diabetes chronic kidney disease|| diabetes mellitus GCST005886 chronic kidney disease diabetes mellitus +End stage renal failure in renal transplantation (recipient effect) renal transplant outcome measurement|| chronic kidney disease GCST005427 chronic kidney disease renal transplant outcome measurement +End-stage renal disease in Type 1 diabetics type I diabetes mellitus|| chronic kidney disease GCST002182 chronic kidney disease type I diabetes mellitus +Chronic kidney disease in type 2 diabetes chronic kidney disease|| type II diabetes mellitus GCST005882 chronic kidney disease type II diabetes mellitus +End-stage renal disease in type 2 diabetes chronic kidney disease|| type II diabetes mellitus GCST005885 chronic kidney disease type II diabetes mellitus +Chronic kidney disease and diabetic kidney disease in diabetes chronic kidney disease|| diabetes mellitus|| diabetic nephropathy GCST005884 chronic kidney disease|| diabetic nephropathy diabetes mellitus +End-stage renal disease or diabetic nephropathy in type 1 diabetes type I diabetes mellitus|| chronic kidney disease|| diabetic nephropathy GCST002464 chronic kidney disease|| diabetic nephropathy type I diabetes mellitus +Chronic kidney disease and diabetic kidney disease in type 2 diabetes chronic kidney disease|| diabetic nephropathy|| type II diabetes mellitus GCST005883 chronic kidney disease|| diabetic nephropathy type II diabetes mellitus +Chronic mucus hypersecretion in chronic obstructive pulmonary disease chronic obstructive pulmonary disease|| chronic mucus hypersecretion GCST002612 chronic mucus hypersecretion chronic obstructive pulmonary disease +Clostridium difficile infection in multiple myeloma clostridium difficile infection|| multiple myeloma GCST005686 clostridium difficile infection multiple myeloma +Response to cognitive-behavioural therapy in anxiety disorder anxiety disorder|| cognitive behavioural therapy GCST003469 cognitive behavioural therapy anxiety disorder +Cognitive decline rate in late mild cognitive impairment cognitive impairment|| cognitive decline measurement GCST003075 cognitive decline measurement cognitive impairment +Rate of cognitive decline in mild cognitive impairment (time interaction) cognitive impairment|| cognitive decline measurement|| disease progression measurement GCST004371 cognitive decline measurement|| disease progression measurement cognitive impairment +Neurocognitive impairment in HIV-1 infection (continuous) HIV-1 infection|| cognitive impairment measurement GCST004406 cognitive impairment measurement HIV-1 infection +Neurocognitive impairment in HIV-1 infection (dichotomous) HIV-1 infection|| cognitive impairment measurement GCST004407 cognitive impairment measurement HIV-1 infection +Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder attention deficit hyperactivity disorder|| cognitive inhibition measurement GCST004336 cognitive inhibition measurement attention deficit hyperactivity disorder +Colorectal carcinoma in primary sclerosing cholangitis colorectal cancer|| sclerosing cholangitis GCST005856 colorectal cancer sclerosing cholangitis +Mucinous adenocarcinoma in colorectal cancer colorectal cancer|| colorectal mucinous adenocarcinoma GCST006411 colorectal mucinous adenocarcinoma colorectal cancer +Common carotid intima-media thickness in HIV infection common carotid intimal medial thickness|| HIV infection GCST005184 common carotid intimal medial thickness HIV infection +Carotid atherosclerosis in HIV infection HIV-1 infection|| common carotid intimal medial thickness|| internal carotid intimal medial thickness|| carotid artery disease GCST000555 common carotid intimal medial thickness|| internal carotid intimal medial thickness|| carotid artery disease HIV-1 infection +Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio) unipolar depression|| schizophrenia|| bipolar disorder|| concentration dose ratio|| response to anticonvulsant GCST002887 concentration dose ratio|| response to anticonvulsant unipolar depression|| schizophrenia|| bipolar disorder|| +Pharmacokinetics of antidepressant drugs in severe mental disorder (concentration dose ratio) unipolar depression|| schizophrenia|| bipolar disorder|| concentration dose ratio|| response to antidepressant GCST002891 concentration dose ratio|| response to antidepressant unipolar depression|| schizophrenia|| bipolar disorder|| +Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio) unipolar depression|| schizophrenia|| bipolar disorder|| concentration dose ratio|| response to antipsychotic drug GCST002888 concentration dose ratio|| response to antipsychotic drug unipolar depression|| schizophrenia|| bipolar disorder|| +Coronary arterial lesions in patients with Kawasaki disease mucocutaneous lymph node syndrome|| coronary aneurysm GCST002026 coronary aneurysm mucocutaneous lymph node syndrome +Coronary arterial lesions in patients with Kawasaki disease mucocutaneous lymph node syndrome|| coronary aneurysm GCST001878 coronary aneurysm mucocutaneous lymph node syndrome +Coronary artery aneurysm in Kawasaki disease mucocutaneous lymph node syndrome|| coronary aneurysm GCST003560 coronary aneurysm mucocutaneous lymph node syndrome +Coronary artery aneurysm in Kawasaki disease mucocutaneous lymph node syndrome|| coronary aneurysm GCST003192 coronary aneurysm mucocutaneous lymph node syndrome +Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes coronary artery calcification|| type II diabetes mellitus GCST005173 coronary artery calcification type II diabetes mellitus +Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes coronary artery calcification|| type II diabetes mellitus GCST005175 coronary artery calcification type II diabetes mellitus +Coronary artery calcified atherosclerotic plaque score in type 2 diabetes coronary artery calcification|| type II diabetes mellitus GCST005174 coronary artery calcification type II diabetes mellitus +Coronary artery disease in diabetes diabetes mellitus|| coronary artery disease GCST006405 coronary artery disease diabetes mellitus +Coronary artery disease in type 1 diabetes type I diabetes mellitus|| coronary artery disease GCST006281 coronary artery disease type I diabetes mellitus +Coronary heart disease in familial hypercholesterolemia familial hypercholesterolemia|| coronary heart disease GCST002478 coronary heart disease familial hypercholesterolemia +Baseline cortisol levels in response to low dose short synacthen test in corticosteroid treated asthma childhood onset asthma|| cortisol measurement|| response to corticosteroid|| response to synacthen GCST005925 cortisol measurement|| response to corticosteroid|| response to synacthen childhood onset asthma +Cotinine levels in smokers with chronic obstructive pulmonary disease smoking status measurement|| cotinine measurement|| chronic obstructive pulmonary disease GCST005916 cotinine measurement smoking status measurement|| chronic obstructive pulmonary disease +Creatine kinase in statin users response to statin|| creatine kinase measurement GCST002603 creatine kinase measurement|| response to statin +Mixed cryoglobulinemia vasculitis in chronic hepatitis C infection cryoglobulinemia|| Chronic Hepatitis C infection GCST002534 cryoglobulinemia Chronic Hepatitis C infection +Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab) cumulative dose response to bevacizumab|| chemotherapy-induced hypertension|| breast carcinoma GCST002566 cumulative dose response to bevacizumab breast carcinoma|| chemotherapy-induced hypertension +Response to paclitaxel in ovarian cancer (MTT IC50) ovarian carcinoma|| cytotoxicity measurement|| response to paclitaxel GCST003441 cytotoxicity measurement|| response to paclitaxel ovarian carcinoma +Depressive episodes in bipolar disorder depressive episode measurement|| bipolar disorder GCST003091 depressive episode measurement bipolar disorder +Depression in response to interferon-based therapy in chronic hepatitis C Chronic Hepatitis C infection|| response to interferon|| depressive symptom measurement GCST003824 depressive symptom measurement|| response to interferon Chronic Hepatitis C infection +Diabetes in response to antihypertensive drug treatment (treatment strategy interaction) response to antihypertensive drug|| diabetes mellitus|| hypertension|| response to beta blocker|| response to calcium channel blocker GCST003797 diabetes mellitus|| response to antihypertensive drug|| response to beta blocker|| response to calcium channel blocker hypertension +Foot ulcer in diabetes and neuropathy type I diabetes mellitus|| diabetic foot|| type II diabetes mellitus|| neuropathy GCST004724 diabetic foot type I diabetes mellitus|| type II diabetes mellitus|| neuropathy +Foot ulcer and neuropathy in diabetes type I diabetes mellitus|| diabetic foot|| type II diabetes mellitus|| neuropathy GCST004725 diabetic foot|| neuropathy type I diabetes mellitus|| type II diabetes mellitus +Diabetic macular edema in type 2 diabetes diabetic macular edema|| type II diabetes mellitus GCST006282 diabetic macular edema type II diabetes mellitus +Diabetic kidney disease in diabetes diabetes mellitus|| diabetic nephropathy GCST005881 diabetic nephropathy diabetes mellitus +Diabetic kidney disease in diabetes (ESRD vs. no ESRD) diabetes mellitus|| diabetic nephropathy GCST005894 diabetic nephropathy diabetes mellitus +Early diabetic kidney disease in diabetes diabetes mellitus|| diabetic nephropathy GCST005890 diabetic nephropathy diabetes mellitus +Late diabetic kidney disease in diabetes diabetes mellitus|| diabetic nephropathy GCST005888 diabetic nephropathy diabetes mellitus +Diabetic kidney disease in type 2 diabetes diabetic nephropathy|| type II diabetes mellitus GCST005895 diabetic nephropathy type II diabetes mellitus +Early diabetic kidney disease in type 2 diabetes diabetic nephropathy|| type II diabetes mellitus GCST005889 diabetic nephropathy type II diabetes mellitus +Late diabetic kidney disease in type 2 diabetes diabetic nephropathy|| type II diabetes mellitus GCST005887 diabetic nephropathy type II diabetes mellitus +Sight-threatening diabetic retinopathy in type 2 diabetes diabetic retinopathy|| type II diabetes mellitus GCST003042 diabetic retinopathy type II diabetes mellitus +Diabetic retinopathy in type 2 diabetes diabetic retinopathy|| type II diabetes mellitus GCST002684 diabetic retinopathy type II diabetes mellitus +Severe diabetic retinopathy in type 2 diabetes diabetic retinopathy|| type II diabetes mellitus GCST006424 diabetic retinopathy type II diabetes mellitus +Diarrhoea in darapladib-treated cardiovascular disease (time to event) response to darapladib|| diarrhea|| acute coronary syndrome|| coronary heart disease GCST004962 diarrhea|| response to darapladib acute coronary syndrome|| coronary heart disease +Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event) response to darapladib|| diarrhea|| acute coronary syndrome|| coronary heart disease GCST004967 diarrhea|| response to darapladib acute coronary syndrome|| coronary heart disease +Diastolic blood pressure night-to-day ratio in hypertension diastolic blood pressure change measurement|| hypertension GCST006273 diastolic blood pressure change measurement hypertension +Diastolic blood pressure response to hydrochlorothiazide in hypertension response to hydrochlorothiazide|| diastolic blood pressure change measurement|| hypertension GCST003805 diastolic blood pressure change measurement|| response to hydrochlorothiazide hypertension +Thiopurine-induced digestive symptoms in inflammatory bowel disease digestive system disease|| response to thiopurine|| inflammatory bowel disease GCST006210 digestive system disease|| response to thiopurine inflammatory bowel disease +Type 1 diabetes in high risk HLA genotype individuals (time to event) disease free survival|| type I diabetes mellitus|| carrier status GCST006196 disease free survival|| type I diabetes mellitus carrier status +Poor prognosis in Crohn's disease Crohn's disease|| disease prognosis measurement GCST004053 disease prognosis measurement Crohn's disease +Relapse in multiple sclerosis multiple sclerosis|| disease recurrence GCST004752 disease recurrence multiple sclerosis +Breast cancer-free interval (treatment with aromatase inhibitor) disease recurrence|| response to aromatase inhibitor|| breast carcinoma GCST003816 disease recurrence|| response to aromatase inhibitor breast carcinoma +Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia drug-induced agranulocytosis|| treatment refractory schizophrenia|| response to clozapine GCST003628 drug-induced agranulocytosis|| response to clozapine treatment refractory schizophrenia +Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia drug-induced agranulocytosis|| treatment refractory schizophrenia|| response to clozapine GCST003450 drug-induced agranulocytosis|| response to clozapine treatment refractory schizophrenia +Thionamide-induced agranulocytosis in Graves' disease drug-induced agranulocytosis|| response to thioamide|| Graves disease GCST003018 drug-induced agranulocytosis|| response to thioamide Graves disease +Liver injury in anti-retroviral drug treated HIV response to efavirenz|| HIV infection|| drug-induced liver injury GCST004261 drug-induced liver injury|| response to efavirenz HIV infection +Drug-induced liver injury in interferon-beta-treated multiple sclerosis multiple sclerosis|| response to interferon beta|| drug-induced liver injury GCST006270 drug-induced liver injury|| response to interferon beta multiple sclerosis +Liver injury in anti-tuberculosis drug treatment response to rifampicin|| Tuberculosis|| drug-induced liver injury GCST003792 drug-induced liver injury|| response to rifampicin Tuberculosis +Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis response to rifampicin|| Tuberculosis|| response to efavirenz|| HIV infection|| drug-induced liver injury GCST004262 drug-induced liver injury|| response to rifampicin|| response to efavirenz HIV infection|| Tuberculosis +Eating disorder in bipolar disorder eating disorder|| bipolar disorder GCST003132 eating disorder bipolar disorder +Ejection fraction in Tripanosoma cruzi seropositivity Trypanosoma cruzi seropositivity|| ejection fraction measurement GCST002281 ejection fraction measurement Trypanosoma cruzi seropositivity +Emphysema distribution in smoking smoking behavior|| emphysema pattern measurement GCST003761 emphysema pattern measurement smoking behavior +Erectile dysfunction in type 1 diabetes type I diabetes mellitus|| erectile dysfunction GCST001572 erectile dysfunction type I diabetes mellitus +Erythema nodosum in inflammatory bowel disease erythema nodosum|| inflammatory bowel disease GCST002380 erythema nodosum inflammatory bowel disease +Estrogen receptor status in breast cancer estrogen-receptor negative breast cancer|| estrogen-receptor positive breast cancer|| breast carcinoma GCST003821 estrogen-receptor negative breast cancer|| estrogen-receptor positive breast cancer breast carcinoma +Plasma estrone conjugates levels in resected early stage estrogen-receptor positive breast cancer estrone conjugate measurement|| estrogen-receptor positive breast cancer GCST004359 estrone conjugate measurement estrogen-receptor positive breast cancer +Estrone conjugates/estrone ratio in resected early stage estrogen-receptor positive breast cancer estrone conjugate measurement|| estrogen-receptor positive breast cancer|| estrone measurement GCST004360 estrone conjugate measurement|| estrone measurement estrogen-receptor positive breast cancer +Plasma estrone levels in resected estrogen-receptor positive breast cancer estrogen-receptor positive breast cancer|| estrone measurement GCST004362 estrone measurement estrogen-receptor positive breast cancer +Executive function in ADHD attention deficit hyperactivity disorder|| executive function measurement GCST006219 executive function measurement attention deficit hyperactivity disorder +Eye movement in schizophrenia (horizontal position gain) eye movement measurement|| schizophrenia GCST006448 eye movement measurement schizophrenia +Eye movement in schizophrenia (integrated eye movement score) eye movement measurement|| schizophrenia GCST006451 eye movement measurement schizophrenia +Eye movement in schizophrenia (scanpath length) eye movement measurement|| schizophrenia GCST006459 eye movement measurement schizophrenia +Family history of upper gastrointestinal cancer in esophageal squamous cell carcinoma esophageal squamous cell carcinoma|| family history of upper gastrointestinal cancer GCST004799 family history of upper gastrointestinal cancer esophageal squamous cell carcinoma +Bone mineral density (femoral neck) in inflammatory bowel disease inflammatory bowel disease|| femoral neck bone mineral density GCST005784 femoral neck bone mineral density inflammatory bowel disease +Fetal hemoglobin levels in sickle cell anemia fetal hemoglobin measurement|| Sickle cell anemia GCST002687 fetal hemoglobin measurement Sickle cell anemia +High fetal hemoglobin in sickle cell disease fetal hemoglobin measurement|| Sickle cell disease and related diseases GCST006251 fetal hemoglobin measurement Sickle cell disease and related diseases +Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1) FEV change measurement|| response to bronchodilator|| chronic obstructive pulmonary disease GCST003830 FEV change measurement|| response to bronchodilator chronic obstructive pulmonary disease +Response to inhaled glucocorticoid treatment in asthma (change in FEV1) FEV change measurement|| response to glucocorticoid|| asthma GCST002754 FEV change measurement|| response to glucocorticoid asthma +Response to montelukast in asthma (change in FEV1) FEV change measurement|| response to montelukast|| asthma GCST002979 FEV change measurement|| response to montelukast asthma +Response to zileuton treatment in asthma (FEV1 change interaction) FEV change measurement|| response to zileuton|| asthma GCST002951 FEV change measurement|| response to zileuton asthma +Post bronchodilator FEV1/FVC ratio in smoking smoking behavior|| FEV/FEC ratio GCST006310 FEV/FEC ratio smoking behavior +Pre bronchodilator FEV1/FVC ratio in never-smokers smoking status measurement|| FEV/FEC ratio GCST003826 FEV/FEC ratio smoking status measurement +Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction) allergen exposure measurement|| asthma|| FEV/FEC ratio GCST004108 FEV/FEC ratio|| allergen exposure measurement asthma +Thiopurine-induced fever in inflammatory bowel disease fever|| response to thiopurine|| inflammatory bowel disease GCST006209 fever|| response to thiopurine inflammatory bowel disease +Fibrinogen levels in ischemic stroke Ischemic stroke|| fibrinogen measurement GCST003212 fibrinogen measurement Ischemic stroke +Follicule stimulating hormone levels in polycystic ovary syndrome polycystic ovary syndrome|| follicle stimulating hormone measurement GCST005270 follicle stimulating hormone measurement polycystic ovary syndrome +Post bronchodilator percent predicted FEV1 in smoking smoking behavior|| forced expiratory volume GCST006309 forced expiratory volume smoking behavior +Lung function (FEV1) in asthma (dust mite allergen exposure interaction) forced expiratory volume|| allergen exposure measurement|| asthma GCST004107 forced expiratory volume|| allergen exposure measurement asthma +Post bronchodilator FEV1 in COPD forced expiratory volume|| response to bronchodilator|| chronic obstructive pulmonary disease GCST003263 forced expiratory volume|| response to bronchodilator chronic obstructive pulmonary disease +Electroencephalographic traits in alcoholism frontal theta oscillation measurement|| alcohol dependence GCST001503 frontal theta oscillation measurement alcohol dependence +Moderate functional decline in sporadic amyotrophic lateral sclerosis functional decline measurement|| sporadic amyotrophic lateral sclerosis GCST003333 functional decline measurement sporadic amyotrophic lateral sclerosis +Rapid functional decline in sporadic amyotrophic lateral sclerosis functional decline measurement|| sporadic amyotrophic lateral sclerosis GCST003332 functional decline measurement sporadic amyotrophic lateral sclerosis +"Functional impairment in major depressive disorder, bipolar disorder and schizophrenia" unipolar depression|| schizophrenia|| bipolar disorder|| functional impairment measurement GCST002188 functional impairment measurement unipolar depression|| schizophrenia|| bipolar disorder +Relative hand skill in reading disability functional laterality|| dyslexia GCST002183 functional laterality dyslexia +Gallbladder carcinoma in primary sclerosing cholangitis gallbladder neoplasm|| sclerosing cholangitis GCST005857 gallbladder neoplasm sclerosing cholangitis +Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia schizophrenia|| gamma wave measurement GCST004953 gamma wave measurement schizophrenia +MGMT methylation in smokers smoking behavior|| gene methylation measurement GCST003031 gene methylation measurement smoking behavior +Glomerular filtration rate change in heart transplantation response to transplant|| GFR change measurement GCST006496 GFR change measurement|| response to transplant +Glomerular filtration rate in chronic kidney disease glomerular filtration rate|| chronic kidney disease GCST003139 glomerular filtration rate chronic kidney disease +Glomerular filtration rate in diabetes glomerular filtration rate|| diabetes mellitus GCST005891 glomerular filtration rate diabetes mellitus +Glomerular filtration rate in type 2 diabetes glomerular filtration rate|| type II diabetes mellitus GCST005892 glomerular filtration rate type II diabetes mellitus +Glomerular filtration rate in diabetics (creatinine) glomerular filtration rate|| diabetes mellitus|| serum creatinine measurement GCST003373 glomerular filtration rate|| serum creatinine measurement diabetes mellitus +Change in glucose in response to thiazide diuretic treatment in hypertension response to thiazide|| hypertension|| glucose measurement GCST005577 glucose measurement|| response to thiazide hypertension +Gout in chronic kidney disease gout|| chronic kidney disease GCST006425 gout chronic kidney disease +Thyroid-associated orbitopathy in graves' disease Graves disease|| Graves ophthalmopathy GCST003640 Graves ophthalmopathy Graves disease +Plasma haptoglobin levels in type 2 diabetes haptoglobin measurement|| type II diabetes mellitus GCST005808 haptoglobin measurement type II diabetes mellitus +Urinary haptoglobin levels in type 2 diabetes haptoglobin measurement|| type II diabetes mellitus GCST005807 haptoglobin measurement type II diabetes mellitus +Hemoglobin A2 levels in sickle cell anemia Sickle cell anemia|| hemoglobin A2 measurement GCST002536 hemoglobin A2 measurement Sickle cell anemia +Liver fibrosis severity in HIV/hepatitis C co-infection HIV-1 infection|| Hepatic fibrosis|| hepatitis C infection GCST003606 Hepatic fibrosis HIV-1 infection|| hepatitis C infection +Liver fibrosis in pediatric non-alcoholic fatty acid liver disease non-alcoholic fatty liver disease|| Hepatic fibrosis GCST004938 Hepatic fibrosis non-alcoholic fatty liver disease +Hepatic lipid content in extreme obesity hepatic lipid content measurement|| obesity GCST002632 hepatic lipid content measurement obesity +Hepatitis B surface antigen seroclearance in chronic hepatitis B infection Hepatitis B virus surface antigen seropositivity|| chronic hepatitis B infection GCST006364 Hepatitis B virus surface antigen seropositivity chronic hepatitis B infection +Familial hepatitis B virus-related hepatocellular carcinoma hepatocellular carcinoma|| hepatitis B infection GCST004736 hepatocellular carcinoma hepatitis B infection +Hepatocellular carcinoma in hepatitis B infection hepatocellular carcinoma|| hepatitis B infection GCST005746 hepatocellular carcinoma hepatitis B infection +Hepatocellular carcinoma in hepatitis B infection hepatocellular carcinoma|| hepatitis B infection GCST003189 hepatocellular carcinoma hepatitis B infection +Hepatocellular carcinoma in hepatitis C infection hepatocellular carcinoma|| hepatitis C infection GCST006037 hepatocellular carcinoma hepatitis C infection +Hepatocellular carcinoma in primary sclerosing cholangitis hepatocellular carcinoma|| sclerosing cholangitis GCST005858 hepatocellular carcinoma sclerosing cholangitis +HER2 status in breast cancer HER2 status|| breast carcinoma GCST004528 HER2 status breast carcinoma +HDL Cholesterol in HIV-infection HIV-1 infection|| high density lipoprotein cholesterol measurement GCST002744 high density lipoprotein cholesterol measurement HIV-1 infection +Hippocampal volume in schizophrenia schizophrenia|| hippocampal volume GCST002076 hippocampal volume schizophrenia +Setpoint viral load in HIV-1 infection HIV-1 infection|| HIV viral set point measurement GCST003183 HIV-1 infection HIV viral set point measurement +Hypertension risk in short sleep duration hypertension|| short sleep GCST001405 hypertension short sleep +Immunoglobulin G index levels in multiple sclerosis multiple sclerosis|| IgG index GCST002757 IgG index multiple sclerosis +Inflammatory biomarkers in Kawasaki disease mucocutaneous lymph node syndrome|| inflammatory biomarker measurement|| C-reactive protein measurement GCST002640 inflammatory biomarker measurement|| C-reactive protein measurement mucocutaneous lymph node syndrome +Initial pursuit acceleration in psychotic disorders schizophrenia|| initial pursuit acceleration|| bipolar disorder|| schizoaffective disorder GCST005026 initial pursuit acceleration schizophrenia|| bipolar disorder|| schizoaffective disorder +Interferon alpha levels in systemic lupus erythematosus interferon alpha measurement|| systemic lupus erythematosus GCST002666 interferon alpha measurement systemic lupus erythematosus +Plasma kynurenine levels in major depressive disorder unipolar depression|| kynurenine measurement GCST005342 kynurenine measurement unipolar depression +Plasma kynurenine to tryptophan ratio in major depressive disorder unipolar depression|| kynurenine:tryptophan ratio GCST005343 kynurenine:tryptophan ratio unipolar depression +Language impairment in frontotemporal lobe dementia language impairment|| Frontotemporal dementia GCST006152 language impairment Frontotemporal dementia +Laterality in neovascular age-related macular degeneration laterality measurement|| wet macular degeneration GCST004813 laterality measurement wet macular degeneration +Thiopurine-induced acute severe leukopenia in inflammatory bowel disease leukopenia|| response to thiopurine|| inflammatory bowel disease GCST006205 leukopenia|| response to thiopurine inflammatory bowel disease +Thiopurine-induced acute severe leukopenia in inflammatory bowel disease (conditioned on rs116855232) leukopenia|| response to thiopurine|| inflammatory bowel disease GCST006215 leukopenia|| response to thiopurine inflammatory bowel disease +Thiopurine-induced leukopenia in inflammatory bowel disease leukopenia|| response to thiopurine|| inflammatory bowel disease GCST006201 leukopenia|| response to thiopurine inflammatory bowel disease +Thiopurine-induced leukopenia in inflammatory bowel disease leukopenia|| response to thiopurine|| inflammatory bowel disease GCST003603 leukopenia|| response to thiopurine inflammatory bowel disease +Thiopurine-induced leukopenia in inflammatory bowel disease (conditioned on rs116855232) leukopenia|| response to thiopurine|| inflammatory bowel disease GCST006202 leukopenia|| response to thiopurine inflammatory bowel disease +Thiopurine-induced severe leukopenia in inflammatory bowel disease leukopenia|| response to thiopurine|| inflammatory bowel disease GCST006204 leukopenia|| response to thiopurine inflammatory bowel disease +Thiopurine-induced severe leukopenia in inflammatory bowel disease (conditioned on rs116855232) leukopenia|| response to thiopurine|| inflammatory bowel disease GCST006200 leukopenia|| response to thiopurine inflammatory bowel disease +Lichen planus in hepatitis C lichen planus|| hepatitis C infection GCST004090 lichen planus hepatitis C infection +Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease response to darapladib|| acute coronary syndrome|| lipoprotein-associated phospholipase A(2) change measurement|| coronary heart disease GCST004966 lipoprotein-associated phospholipase A(2) change measurement|| response to darapladib acute coronary syndrome|| coronary heart disease +Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease (adjusted for baseline) response to darapladib|| acute coronary syndrome|| lipoprotein-associated phospholipase A(2) change measurement|| coronary heart disease GCST004968 lipoprotein-associated phospholipase A(2) change measurement|| response to darapladib acute coronary syndrome|| coronary heart disease +Lipoprotein phospholipase A2 activity in cardiovascular disease lipoprotein-associated phospholipase A(2) measurement|| acute coronary syndrome|| coronary heart disease GCST004963 lipoprotein-associated phospholipase A(2) measurement acute coronary syndrome|| coronary heart disease +Liver disease severity in Alagille syndrome Alagille syndrome|| liver disease GCST003616 liver disease Alagille syndrome +Liver disease in chronic hepatitis B virus infection liver disease|| chronic hepatitis B infection GCST002204 liver disease chronic hepatitis B infection +Body mass index (change over time) in cancer cancer|| longitudinal BMI measurement GCST004106 longitudinal BMI measurement cancer +Body mass index (change over time) in cancer or chronic obstructive pulmonary disease cancer|| longitudinal BMI measurement|| chronic obstructive pulmonary disease GCST004103 longitudinal BMI measurement cancer|| chronic obstructive pulmonary disease +Body mass index (change over time) in chronic obstructive pulmonary disease longitudinal BMI measurement|| chronic obstructive pulmonary disease GCST004105 longitudinal BMI measurement chronic obstructive pulmonary disease +Body mass index (change over time) in gastrointestinal cancer longitudinal BMI measurement|| Digestive System Carcinoma GCST004101 longitudinal BMI measurement Digestive System Carcinoma +Body mass index (change over time) in gastrointestinal cancer or chronic obstructive pulmonary disease longitudinal BMI measurement|| Digestive System Carcinoma|| chronic obstructive pulmonary disease GCST004100 longitudinal BMI measurement Digestive System Carcinoma|| chronic obstructive pulmonary disease +Body mass index (change over time) in lung cancer lung carcinoma|| longitudinal BMI measurement GCST004104 longitudinal BMI measurement lung carcinoma +Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease lung carcinoma|| longitudinal BMI measurement|| chronic obstructive pulmonary disease GCST004102 longitudinal BMI measurement lung carcinoma|| chronic obstructive pulmonary disease +Lipid levels in hepatitis C treatment Chronic Hepatitis C infection|| low density lipoprotein cholesterol measurement GCST001418 low density lipoprotein cholesterol measurement Chronic Hepatitis C infection +Lung cancer in ever smokers smoking status measurement|| lung carcinoma GCST006400 lung carcinoma smoking status measurement +Lung cancer in ever smokers smoking status measurement|| lung carcinoma GCST004749 lung carcinoma smoking status measurement +Lung cancer in never smokers smoking status measurement|| lung carcinoma GCST004747 lung carcinoma smoking status measurement +Lung disease severity in cystic fibrosis Cystic fibrosis|| lung disease severity measurement GCST003143 lung disease severity measurement Cystic fibrosis +Lupus nephritis in systemic lupus erythematosus systemic lupus erythematosus|| lupus nephritis GCST002479 lupus nephritis systemic lupus erythematosus +Luteinizing hormone levels in polycystic ovary syndrome luteinizing hormone measurement|| polycystic ovary syndrome GCST005269 luteinizing hormone measurement polycystic ovary syndrome +Hypersomnia during a major depressive episode in bipolar disorder major depressive episode|| bipolar disorder|| hypersomnia GCST003016 major depressive episode|| hypersomnia bipolar disorder +Depressive and manic episodes in bipolar disorder manic episode measurement|| depressive episode measurement|| bipolar disorder GCST003090 manic episode measurement|| depressive episode measurement bipolar disorder +Manic episodes in bipolar disorder manic or hypomanic episode|| bipolar disorder GCST003089 manic or hypomanic episode bipolar disorder +Mean corpuscular hemoglobin concentration in sickle cell disease Sickle cell anemia|| mean corpuscular hemoglobin concentration GCST004378 mean corpuscular hemoglobin concentration Sickle cell anemia +Total mean fractional anisotropy measurement in first episode schizophrenia schizophrenia|| mean fractional anisotropy measurement|| white matter microstructure measurement GCST004996 mean fractional anisotropy measurement|| white matter microstructure measurement schizophrenia +Medication adherence in chronic diseases diabetes mellitus|| hypertension|| medication adherence behavior GCST002637 medication adherence behavior diabetes mellitus|| hypertension +Memory dysfunction in frontotemporal lobe dementia memory impairment|| Frontotemporal dementia GCST006151 memory impairment Frontotemporal dementia +Metastasis at diagnosis in osteosarcoma metastasis measurement|| date of diagnosis|| osteosarcoma GCST002978 metastasis measurement|| date of diagnosis osteosarcoma +Methadone dose in opioid dependence opioid dependence|| methadone dose measurement GCST006856 methadone dose measurement opioid dependence +Methadone dose in opioid dependence opioid dependence|| methadone dose measurement GCST004136 methadone dose measurement opioid dependence +Migraine in bipolar disorder bipolar disorder|| migraine disorder GCST002656 migraine disorder bipolar disorder +Migraine in psychiatric disorder bipolar disorder|| migraine disorder GCST000695 migraine disorder bipolar disorder +Mood disorder in prion disease prion disease|| mood disorder GCST002864 mood disorder prion disease +Mortality in heart failure heart failure|| mortality GCST003539 mortality heart failure +Mortality in heart failure heart failure|| mortality GCST000661 mortality heart failure +Mortality in sepsis sepsis|| mortality GCST003817 mortality sepsis +Platinum-induced myelosuppression in non-small cell lung cancer myelosuppression|| response to platinum based chemotherapy|| non-small cell lung carcinoma GCST002833 myelosuppression|| response to platinum based chemotherapy non-small cell lung carcinoma +Myocardial infarction in placebo-treated cardiovascular disease (time to event) acute coronary syndrome|| coronary heart disease|| myocardial infarction|| response to placebo GCST004965 myocardial infarction|| response to placebo acute coronary syndrome|| coronary heart disease +Perioperative myocardial infarction in coronary artery bypass surgery coronary artery bypass|| myocardial infarction GCST002892 myocardial infarction coronary artery bypass +Myocardial infarction in coronary artery disease coronary heart disease|| myocardial infarction GCST000946 myocardial infarction coronary heart disease +Myocardial infarction in cardiovascular disease (time to event) (darapladib treatment interaction) response to darapladib|| acute coronary syndrome|| coronary heart disease|| myocardial infarction GCST004959 myocardial infarction|| response to darapladib acute coronary syndrome|| coronary heart disease +Myocardial infarction in darapladib-treated cardiovascular disease (time to event) response to darapladib|| acute coronary syndrome|| coronary heart disease|| myocardial infarction GCST004964 myocardial infarction|| response to darapladib acute coronary syndrome|| coronary heart disease +Surgical necrotising enterocolitis in extremely premature birth necrotizing enterocolitis|| premature birth GCST005800 necrotizing enterocolitis premature birth +Neuropathic pain in head and neck cancer head and neck malignant neoplasia|| neuropathic pain GCST005934 neuropathic pain head and neck malignant neoplasia +Possible neuropathic pain in post total joint replacement surgery for osteoarthritis neuropathic pain|| osteoarthritis GCST003963 neuropathic pain osteoarthritis +Neuropathic pain in type 2 diabetes neuropathic pain|| type II diabetes mellitus GCST003063 neuropathic pain type II diabetes mellitus +Neuropathic pain in type 2 diabetes neuropathic pain|| type II diabetes mellitus GCST002507 neuropathic pain type II diabetes mellitus +Neutrophil count in HIV-infection neutrophil count|| HIV-1 infection GCST002743 neutrophil count HIV-1 infection +nicotine metabolite ratio in current smokers smoking behavior|| nicotine metabolite ratio GCST003629 nicotine metabolite ratio smoking behavior +nicotine metabolite ratio in current smokers smoking behavior|| nicotine metabolite ratio GCST004976 nicotine metabolite ratio smoking behavior +Non-small cell lung cancer in heavy smokers smoking behavior|| non-small cell lung carcinoma GCST005747 non-small cell lung carcinoma smoking behavior +Obesity in adult survivors of childhood cancer not exposed to cranial radiation childhood cancer|| obesity GCST002904 obesity childhood cancer +Oligoclonal band status in multiple sclerosis multiple sclerosis|| oligoclonal band measurement GCST002758 oligoclonal band measurement multiple sclerosis +Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder attention deficit hyperactivity disorder|| oppositional defiant disorder measurement GCST003472 oppositional defiant disorder measurement attention deficit hyperactivity disorder +Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder attention deficit hyperactivity disorder|| oppositional defiant disorder measurement GCST003030 oppositional defiant disorder measurement attention deficit hyperactivity disorder +Ovarian cancer in BRCA1 mutation carriers carrier status|| ovarian carcinoma GCST004414 ovarian carcinoma carrier status +Ovarian cancer in BRCA2 mutation carriers carrier status|| ovarian carcinoma GCST004416 ovarian carcinoma carrier status +Pre-treatment pain in head and neck squamous cell carcinoma pain|| head and neck squamous cell carcinoma GCST003760 pain head and neck squamous cell carcinoma +Pallidum volume in trauma-exposed individuals pallidum volume|| response to trauma exposure GCST005242 pallidum volume|| response to trauma exposure +Thiopurine-induced pancreatitis in inflammatory bowel disease pancreatitis|| response to thiopurine|| inflammatory bowel disease GCST006208 pancreatitis|| response to thiopurine inflammatory bowel disease +Parasitemia in Tripanosoma cruzi seropositivity parasitemia measurement|| Trypanosoma cruzi seropositivity GCST002282 parasitemia measurement Trypanosoma cruzi seropositivity +Abnormal white matter microstructure in first episode schizophrenia (multivariate analysis) parietal cortex measurement|| schizophrenia|| white matter microstructure measurement|| cingulate cortex measurement GCST004997 parietal cortex measurement|| white matter microstructure measurement|| cingulate cortex measurement schizophrenia +Parkinsonism in frontotemporal lobe dementia Parkinson's disease|| Frontotemporal dementia GCST006153 Parkinson's disease Frontotemporal dementia +Response to anthracycline-based chemotherapy in breast cancer (pathologic complete response) pathologic complete response measurement|| breast carcinoma|| response to anthracycline-based chemotherapy GCST003224 pathologic complete response measurement|| response to anthracycline-based chemotherapy breast carcinoma +Bortezomib-induced peripheral neuropathy in multiple myeloma peripheral neuropathy|| multiple myeloma|| response to bortezomib GCST003964 peripheral neuropathy|| response to bortezomib multiple myeloma +Bortezomib-induced peripheral neuropathy in multiple myeloma peripheral neuropathy|| multiple myeloma|| response to bortezomib GCST003438 peripheral neuropathy|| response to bortezomib multiple myeloma +Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer peripheral neuropathy|| response to docetaxel|| metastatic prostate cancer GCST003672 peripheral neuropathy|| response to docetaxel metastatic prostate cancer +Neuropathy in taxane-treated breast cancer peripheral neuropathy|| response to docetaxel|| breast carcinoma|| response to paclitaxel GCST003627 peripheral neuropathy|| response to docetaxel|| response to paclitaxel breast carcinoma +Taxane-induced peripheral neuropathy in breast cancer peripheral neuropathy|| breast carcinoma|| response to taxane GCST005804 peripheral neuropathy|| response to taxane breast carcinoma +Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia peripheral neuropathy|| acute lymphoblastic leukemia|| response to vincristine GCST002792 peripheral neuropathy|| response to vincristine acute lymphoblastic leukemia +Personality traits in bipolar disorder personality trait|| bipolar disorder GCST000995 personality trait bipolar disorder +Betaine levels in individuals undergoing cardiac evaluation plasma betaine measurement|| angiographic measurement GCST003358 plasma betaine measurement angiographic measurement +Response to clopidogrel therapy in coronary heart disease platelet reactivity measurement|| response to clopidogrel|| coronary heart disease GCST003899 platelet reactivity measurement|| response to clopidogrel coronary heart disease +Pneumoconiosis in silica exposure pneumoconiosis|| response to silica exposure GCST002515 pneumoconiosis|| response to silica exposure +Post traumatic stress disorder symptom count in trauma-exposed individuals response to trauma exposure|| post-traumatic stress disorder symptom measurement GCST005550 post-traumatic stress disorder symptom measurement|| response to trauma exposure +PR interval in Tripanosoma cruzi seropositivity PR interval|| Trypanosoma cruzi seropositivity GCST002279 PR interval Trypanosoma cruzi seropositivity +Proliferative diabetic retinopathy in type 2 diabetes proliferative diabetic retinopathy|| type II diabetes mellitus GCST006283 proliferative diabetic retinopathy type II diabetes mellitus +Proteinuria in chronic kidney disease chronic kidney disease|| Proteinuria GCST003142 Proteinuria chronic kidney disease +Prothrombin fragments F1+2 levels in ischemic stroke Ischemic stroke|| prothrombin fragments F1+2 measurement GCST003235 prothrombin fragments F1+2 measurement Ischemic stroke +Psychosis in Alzheimer's disease Alzheimer's disease|| psychotic symptoms GCST001282 psychotic symptoms Alzheimer's disease +Psychotic symptoms in prion disease prion disease|| psychotic symptoms GCST002867 psychotic symptoms prion disease +Pulmonary artery enlargement in chronic obstructive pulmonary disease pulmonary artery enlargement|| chronic obstructive pulmonary disease GCST002797 pulmonary artery enlargement chronic obstructive pulmonary disease +Post-bronchodilator lung function in asthma (FEV1) pulmonary function measurement|| forced expiratory volume|| response to bronchodilator|| asthma GCST003110 pulmonary function measurement|| forced expiratory volume|| response to bronchodilator asthma +Post-bronchodilator lung function in asthma (FEV1/FVC) pulmonary function measurement|| response to bronchodilator|| asthma|| FEV/FEC ratio GCST003107 pulmonary function measurement|| response to bronchodilator|| FEV/FEC ratio asthma +Pulse pressure in young-onset hypertension pulse pressure measurement|| early onset hypertension GCST002470 pulse pressure measurement early onset hypertension +Pursuit maintenance gain in psychotic disorders schizophrenia|| pursuit maintenance gain measurement|| bipolar disorder|| schizoaffective disorder GCST005028 pursuit maintenance gain measurement schizophrenia|| bipolar disorder|| schizoaffective disorder +Putamen volume in trauma-exposed individuals response to trauma exposure|| putamen volume GCST005244 putamen volume|| response to trauma exposure +Pyoderma gangrenosum in inflammatory bowel disease pyoderma gangrenosum|| inflammatory bowel disease GCST002379 pyoderma gangrenosum inflammatory bowel disease +QRS duration in Tripanosoma cruzi seropositivity QRS duration|| Trypanosoma cruzi seropositivity GCST002284 QRS duration|| Trypanosoma cruzi seropositivity +QT interval in Tripanosoma cruzi seropositivity QT interval|| Trypanosoma cruzi seropositivity GCST002278 QT interval Trypanosoma cruzi seropositivity +Red blood cell density in sickle cell anemia Sickle cell anemia|| red blood cell density measurement GCST004379 red blood cell density measurement Sickle cell anemia +Renal elimination rate in vancomycin therapy renal elimination rate measurement|| response to vancomycin GCST002947 renal elimination rate measurement|| response to vancomycin +Serum uric acid levels in response to allopurinol in gout response to allopurinol|| gout|| uric acid measurement GCST004751 response to allopurinol|| uric acid measurement gout +Myocardial infarction in hypertension (ACE inhibitor interaction) hypertension|| response to angiotensin-converting enzyme inhibitor|| myocardial infarction GCST003187 response to angiotensin-converting enzyme inhibitor|| myocardial infarction hypertension +Cardiomyopathy in childhood cancer survivors (anthracycline treatment interaction) childhood cancer|| response to anthracycline-based chemotherapy|| cardiomyopathy GCST003300 response to anthracycline-based chemotherapy|| cardiomyopathy childhood cancer +Adverse response to antithyroid drugs in Graves disease Graves disease|| response to anti-thyroid drug GCST006278 response to anti-thyroid drug Graves disease +Remission after antidepressant treatment in major depression unipolar depression|| response to antidepressant GCST006818 response to antidepressant unipolar depression +Response to antidepressants in depression unipolar depression|| response to antidepressant GCST006817 response to antidepressant unipolar depression +Response to antipsychotic treatment in schizophrenia schizophrenia|| response to antipsychotic drug GCST006292 response to antipsychotic drug schizophrenia +Response to lurasidone in schizophrenia schizophrenia|| response to antipsychotic drug GCST006248 response to antipsychotic drug schizophrenia +Cardiovascular disease in hypertension (beta blocker interaction) hypertension|| response to beta blocker|| cardiovascular disease GCST003203 response to beta blocker|| cardiovascular disease hypertension +Myocardial infarction in hypertension (beta blocker interaction) hypertension|| response to beta blocker|| myocardial infarction GCST003201 response to beta blocker|| myocardial infarction hypertension +Response to chemotherapy in breast cancer (hypertension) (bevacizumab) response to bevacizumab|| breast carcinoma|| chemotherapy-induced hypertension GCST002567 response to bevacizumab|| chemotherapy-induced hypertension breast carcinoma +Adverse response to chemotherapy (congestive heart failure) in breast cancer response to bevacizumab|| congestive heart failure|| breast carcinoma|| response to anthracycline-based chemotherapy GCST003939 response to bevacizumab|| congestive heart failure|| response to anthracycline-based chemotherapy breast carcinoma +Asthma (bronchodilator response) response to bronchodilator|| asthma GCST002154 response to bronchodilator asthma +Asthma (bronchodilator response) response to bronchodilator|| asthma GCST001911 response to bronchodilator asthma +Asthma (bronchodilator response) response to bronchodilator|| asthma GCST001597 response to bronchodilator asthma +Bronchodilator response in asthma response to bronchodilator|| asthma GCST002796 response to bronchodilator asthma +Post bronchodilator FEV1/FVC ratio in COPD response to bronchodilator|| chronic obstructive pulmonary disease|| FEV/FEC ratio GCST003265 response to bronchodilator|| FEV/FEC ratio chronic obstructive pulmonary disease +Myocardial infarction in hypertension (calcium channel blocker interaction) hypertension|| response to calcium channel blocker|| myocardial infarction GCST003206 response to calcium channel blocker|| myocardial infarction hypertension +Carboplatin disposition in epthelial ovarian cancer Malignant epithelial tumor of ovary|| response to carboplatin GCST005351 response to carboplatin Malignant epithelial tumor of ovary +Response to cholinesterase inhibitors in Alzheimer's disease response to cholinesterase inhibitor|| Alzheimer's disease GCST001835 response to cholinesterase inhibitor Alzheimer's disease +Response to inhaled corticosteroid treatment in asthma (change in FEV1) FEV change measurement|| response to corticosteroid|| asthma GCST003567 response to corticosteroid|| FEV change measurement asthma +Response to inhaled corticosteroid treatment in asthma (change in FEV1) FEV change measurement|| response to corticosteroid|| asthma GCST002432 response to corticosteroid|| FEV change measurement asthma +Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis response to cyclophosphamide|| systemic lupus erythematosus|| lupus nephritis GCST003445 response to cyclophosphamide systemic lupus erythematosus|| lupus nephritis +Response to Dalcetrapib treatment in acute coronary syndrome response to dalcetrapib|| acute coronary syndrome|| cardiovascular event measurement GCST002747 response to dalcetrapib|| cardiovascular event measurement acute coronary syndrome +Response to dendritic cell-based immunotherapy in HIV infection response to dendritic cell-based immunotherapy|| HIV infection GCST003852 response to dendritic cell-based immunotherapy HIV infection +Myocardial infarction in hypertension (diuretic interaction) response to diruetic|| hypertension|| myocardial infarction GCST003202 response to diruetic|| myocardial infarction hypertension +Cardiovascular disease in hypertension (diuretic interaction) response to diruetic|| hypertension|| cardiovascular disease GCST003204 response to diuretic|| cardiovascular disease hypertension +Response to tocilizumab in rheumatoid arthritis rheumatoid arthritis|| response to drug GCST001476 response to drug rheumatoid arthritis +Duloxetine response in major depressive disorder (% change in symptom score) unipolar depression|| response to duloxetine GCST004738 response to duloxetine unipolar depression +Duloxetine response in major depressive disorder (remitter/non-remitter status) unipolar depression|| response to duloxetine GCST004740 response to duloxetine unipolar depression +Duloxetine response in major depressive disorder (responder/non-responder status) unipolar depression|| response to duloxetine GCST004741 response to duloxetine unipolar depression +Response to efavirenz-containing treatment in HIV 1 infection (virologic failure) HIV-1 infection|| response to efavirenz|| virologic response measurement GCST002771 response to efavirenz|| virologic response measurement HIV-1 infection +Response to gemcitabine in pancreatic cancer response to gemcitabine|| pancreatic carcinoma GCST001390 response to gemcitabine pancreatic carcinoma +Response to gemcitabine in pancreatic cancer response to gemcitabine|| pancreatic carcinoma GCST001346 response to gemcitabine pancreatic carcinoma +Response to haloperidol in psychosis psychosis|| response to haloperidol GCST002465 response to haloperidol psychosis +Response to haloperidol in schizophrenia schizophrenia|| response to haloperidol GCST006298 response to haloperidol schizophrenia +Response to chemotherapy in multiple myeloma (oral mucositis) (high-dose melphalan) multiple myeloma|| response to high-dose melphalan|| chemotherapy-induced oral mucositis GCST002605 response to high-dose melphalan|| chemotherapy-induced oral mucositis multiple myeloma +Response to interferon beta in multiple sclerosis multiple sclerosis|| response to interferon beta GCST003193 response to interferon beta multiple sclerosis +Response to interferon beta in multiple sclerosis multiple sclerosis|| response to interferon beta GCST002910 response to interferon beta multiple sclerosis +Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years) multiple sclerosis|| response to interferon beta|| antibody measurement GCST005708 response to interferon beta|| antibody measurement multiple sclerosis +Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels) multiple sclerosis|| response to interferon beta|| antibody measurement GCST005709 response to interferon beta|| antibody measurement multiple sclerosis +Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels) multiple sclerosis|| response to interferon beta|| antibody measurement GCST005707 response to interferon beta|| antibody measurement multiple sclerosis +Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies) multiple sclerosis|| response to interferon beta|| antibody measurement GCST005706 response to interferon beta|| antibody measurement multiple sclerosis +Neutralising antibody response to interferon beta therapy in multiple sclerosis (time to production) multiple sclerosis|| response to interferon beta|| antibody measurement GCST005710 response to interferon beta|| antibody measurement multiple sclerosis +Response to irinotecan in non-small-cell lung cancer response to irinotecan|| non-small cell lung carcinoma GCST001558 response to irinotecan non-small cell lung carcinoma +Response to ketogenic dietary therapies in epilepsy response to ketogenic diet|| epilepsy GCST006567 response to ketogenic diet|| epilepsy +Objective response to lithium treatment in bipolar disorder bipolar disorder|| response to lithium ion GCST003161 response to lithium ion bipolar disorder +Response to lithium treatment in bipolar disorder bipolar disorder|| response to lithium ion GCST003378 response to lithium ion bipolar disorder +Subjective response to lithium treatment in bipolar disorder bipolar disorder|| response to lithium ion GCST003160 response to lithium ion bipolar disorder +Response to mepolizumab in severe asthma response to mepolizumab|| asthma GCST005115 response to mepolizumab asthma +Response to metformin in type 2 diabetes (HbA1c reduction) A1C measurement|| type II diabetes mellitus|| response to metformin GCST004522 response to metformin|| A1C measurement type II diabetes mellitus +Methotrexate-induced interstitial lung disease in rheumatoid arthritis response to methotrexate|| rheumatoid arthritis|| interstitial lung disease GCST004358 response to methotrexate|| interstitial lung disease rheumatoid arthritis +Response to methylphenidate treatment in attention-deficit/hyperactivity disorder attention deficit hyperactivity disorder|| response to methylphenidate GCST005318 response to methylphenidate attention deficit hyperactivity disorder +Response to olanzapine in schizophrenia schizophrenia|| response to olanzapine GCST006293 response to olanzapine schizophrenia +Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio) unipolar depression|| schizophrenia|| bipolar disorder|| response to olanzapine|| concentration dose ratio GCST002885 response to olanzapine|| concentration dose ratio unipolar depression|| schizophrenia|| bipolar disorder +Paclitaxel disposition in epithelial ovarian cancer Malignant epithelial tumor of ovary|| response to paclitaxel GCST005352 response to paclitaxel Malignant epithelial tumor of ovary +Response to paliperidone in schizophrenia (CGI-S score) schizophrenia|| response to paliperidone|| schizophrenia symptom severity measurement GCST004039 response to paliperidone|| schizophrenia symptom severity measurement schizophrenia +Response to paliperidone in schizophrenia (Multivariate) schizophrenia|| response to paliperidone|| schizophrenia symptom severity measurement GCST004043 response to paliperidone|| schizophrenia symptom severity measurement schizophrenia +Response to paliperidone in schizophrenia (negative Marder score) schizophrenia|| response to paliperidone|| schizophrenia symptom severity measurement GCST004041 response to paliperidone|| schizophrenia symptom severity measurement schizophrenia +Response to paliperidone in schizophrenia (PANSS score) schizophrenia|| response to paliperidone|| schizophrenia symptom severity measurement GCST004042 response to paliperidone|| schizophrenia symptom severity measurement schizophrenia +Response to paliperidone in schizophrenia (positive Marder score) schizophrenia|| response to paliperidone|| schizophrenia symptom severity measurement GCST004040 response to paliperidone|| schizophrenia symptom severity measurement schizophrenia +Response to Pazopanib in cancer (hepatotoxicity) cancer|| response to pazopanib|| serum alanine aminotransferase measurement GCST003232 response to pazopanib|| serum alanine aminotransferase measurement cancer +Response to perphenazine in schizophrenia schizophrenia|| response to perphenazine GCST006297 response to perphenazine schizophrenia +Placebo response in major depressive disorder (% change in symptom score) unipolar depression|| response to placebo GCST004739 response to placebo unipolar depression +Placebo response in major depressive disorder (remitter/non-remitter status) unipolar depression|| response to placebo GCST004742 response to placebo unipolar depression +Placebo response in major depressive disorder (responder/non-responder status) unipolar depression|| response to placebo GCST004743 response to placebo unipolar depression +Response to platinum-based chemotherapy in non-small-cell lung cancer response to platinum based chemotherapy|| non-small cell lung carcinoma GCST001629 response to platinum based chemotherapy non-small cell lung carcinoma +Response to platinum-based chemotherapy in non-small-cell lung cancer response to platinum based chemotherapy|| non-small cell lung carcinoma GCST001035 response to platinum based chemotherapy non-small cell lung carcinoma +Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50) response to platinum based chemotherapy|| ovarian carcinoma|| cytotoxicity measurement|| response to paclitaxel GCST003443 response to platinum based chemotherapy|| cytotoxicity measurement|| response to paclitaxel ovarian carcinoma +Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50) response to platinum based chemotherapy|| ovarian carcinoma|| cytotoxicity measurement|| response to paclitaxel GCST003444 response to platinum based chemotherapy|| cytotoxicity measurement|| response to paclitaxel ovarian carcinoma +Response to carboplatin in ovarian cancer (Caspase 3/7 EC50) response to platinum based chemotherapy|| ovarian carcinoma|| cytotoxicity measurement GCST003442 response to platinum based chemotherapy|| cytotoxicity measurement ovarian carcinoma +Response to carboplatin in ovarian cancer (MTT IC50) response to platinum based chemotherapy|| ovarian carcinoma|| cytotoxicity measurement GCST003440 response to platinum based chemotherapy|| cytotoxicity measurement ovarian carcinoma +Response to paclitaxel in ovarian cancer (Caspase 3/7 EC50) response to platinum based chemotherapy|| ovarian carcinoma|| cytotoxicity measurement GCST003439 response to platinum based chemotherapy|| cytotoxicity measurement ovarian carcinoma +Platinum-induced hepatotoxicity in non-small cell lung cancer response to platinum based chemotherapy|| non-small cell lung carcinoma|| drug-induced liver injury GCST002993 response to platinum based chemotherapy|| drug-induced liver injury non-small cell lung carcinoma +Response to platinum-based neoadjuvant chemotherapy in cervical cancer cervical carcinoma|| response to platinum-based neoadjuvant chemotherapy GCST004097 response to platinum-based neoadjuvant chemotherapy cervical carcinoma +Response to quetiapine in schizophrenia schizophrenia|| response to quetiapine GCST006295 response to quetiapine schizophrenia +Response to radiotherapy in prostate cancer (overall toxicity) response to radiation|| prostate carcinoma GCST003583 response to radiation prostate carcinoma +"Response to radiotherapy in prostate cancer (toxicity, decreased urine stream)" response to radiation|| prostate carcinoma GCST003581 response to radiation prostate carcinoma +"Response to radiotherapy in prostate cancer (toxicity, rectal bleeding)" response to radiation|| prostate carcinoma GCST003584 response to radiation prostate carcinoma +"Response to radiotherapy in prostate cancer (toxicity, urinary frequency)" response to radiation|| prostate carcinoma GCST003582 response to radiation prostate carcinoma +Response to radiotherapy in prostate cancer (toxicity) response to radiation|| prostate carcinoma GCST002511 response to radiation prostate carcinoma +Breast cancer in childhood cancer survivors treated with more than 10 gray radiotherapy response to radiation|| breast carcinoma|| childhood cancer GCST005112 response to radiation|| breast carcinoma childhood cancer +Obesity in adult survivors of childhood cancer exposed to cranial radiation response to radiation|| childhood cancer|| obesity GCST002900 response to radiation|| obesity childhood cancer +Response to ranibizumab in age-related macular degeneration (exudative) response to ranibizumab|| wet macular degeneration GCST006277 response to ranibizumab wet macular degeneration +Response to ranibizumab in age-related macular degeneration (dry maculae) response to ranibizumab|| age-related macular degeneration|| macula measurement GCST004802 response to ranibizumab|| macula measurement age-related macular degeneration +Response to ranibizumab in age-related macular degeneration (additional treatment requirement) response to ranibizumab|| age-related macular degeneration|| treatment outcome measurement GCST004803 response to ranibizumab|| treatment outcome measurement age-related macular degeneration +Response to rate control therapy in atrial fibrillation response to rate control therapy|| atrial fibrillation GCST002473 response to rate control therapy atrial fibrillation +Nevirapine-induced hypersensitivity in HIV (hypersensitivity syndrome) response to reverse transcriptase inhibitor|| drug hypersensitivity syndrome|| HIV infection GCST004116 response to reverse transcriptase inhibitor|| drug hypersensitivity syndrome HIV infection +Nevirapine-induced hypersensitivity in HIV (drug-induced liver injury) response to reverse transcriptase inhibitor|| HIV infection|| drug-induced liver injury GCST004114 response to reverse transcriptase inhibitor|| drug-induced liver injury HIV infection +Nevirapine-induced hypersensitivity in HIV response to reverse transcriptase inhibitor|| hypersensitivity reaction disease|| HIV infection GCST004118 response to reverse transcriptase inhibitor|| hypersensitivity reaction disease HIV infection +Nevirapine-induced hypersensitivity in HIV (rash) response to reverse transcriptase inhibitor|| maculopapular eruption|| HIV infection GCST004117 response to reverse transcriptase inhibitor|| maculopapular eruption HIV infection +Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis) response to reverse transcriptase inhibitor|| Stevens-Johnson syndrome|| toxic epidermal necrolysis|| HIV infection GCST004115 response to reverse transcriptase inhibitor|| Stevens-Johnson syndrome|| toxic epidermal necrolysis HIV infection +Response to risperidone in schizophrenia schizophrenia|| response to risperidone GCST006294 response to risperidone schizophrenia +Remission after SSRI treatment in major depression unipolar depression|| response to selective serotonin reuptake inhibitor GCST006266 response to selective serotonin reuptake inhibitor unipolar depression +Response to selective serotonin reuptake inhibitors in depression unipolar depression|| response to selective serotonin reuptake inhibitor GCST006267 response to selective serotonin reuptake inhibitor unipolar depression +Response to serotonin reuptake inhibitors in major depressive disorder unipolar depression|| response to selective serotonin reuptake inhibitor GCST002868 response to selective serotonin reuptake inhibitor unipolar depression +Response to serotonin reuptake inhibitors in non-psychotic unipolar depression unipolar depression|| response to selective serotonin reuptake inhibitor GCST003118 response to selective serotonin reuptake inhibitor unipolar depression +Response to stavudine in HIV (lipoatrophy) HIV-1 infection|| response to stavudine|| Lipoatrophy GCST002968 response to stavudine|| Lipoatrophy HIV-1 infection +Response to tamoxifen in oestrogen receptor positive/HER2 negative breast cancer response to tamoxifen|| HER2 status|| estrogen-receptor positive breast cancer GCST006615 response to tamoxifen HER2 status|| estrogen-receptor positive breast cancer +Tenofovir clearance in HIV infection response to tenofovir|| HIV infection GCST006073 response to tenofovir HIV infection +Tenofovir clearance in HIV infection (concomitant antiretroviral treatment interaction) response to tenofovir|| HIV infection GCST006071 response to tenofovir HIV infection +6-month creatinine clearance change response to tenofovir treatment in HIV infection (concomitant antiretroviral treatment interaction) response to tenofovir|| HIV infection|| creatinine clearance measurement GCST006070 response to tenofovir|| creatinine clearance measurement HIV infection +6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction) response to tenofovir|| HIV infection|| creatinine clearance measurement GCST006072 response to tenofovir|| creatinine clearance measurement HIV infection +Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction) response to tenofovir|| HIV infection|| creatinine clearance measurement GCST006069 response to tenofovir|| creatinine clearance measurement HIV infection +Thiopurine-induced liver dysfunction in inflammatory bowel disease response to thiopurine|| inflammatory bowel disease|| liver disease GCST006212 response to thiopurine|| liver disease inflammatory bowel disease +Thiopurine-induced infection in inflammatory bowel disease response to thiopurine|| inflammatory bowel disease|| susceptibility to infectious disease measurement GCST006211 response to thiopurine|| susceptibility to infectious disease measurement inflammatory bowel disease +Response to thiopurine immunosuppressants in inflammatory bowel disease (pancreatitis) (azathioprine and mercaptopurine) response to thiopurine|| thiopurine immunosuppressant-induced pancreatitis|| inflammatory bowel disease GCST002607 response to thiopurine|| thiopurine immunosuppressant-induced pancreatitis inflammatory bowel disease +Response to anti-TNF therapy in rheumatoid arthritis rheumatoid arthritis|| response to TNF antagonist GCST003329 response to TNF antagonist rheumatoid arthritis +Response to anti-TNF therapy in rheumatoid arthritis rheumatoid arthritis|| response to TNF antagonist GCST001927 response to TNF antagonist rheumatoid arthritis +"Response to anti-TNF treatment (adalimumab, etanercept or infliximab) in rheumatoid arthritis" rheumatoid arthritis|| response to TNF antagonist GCST002869 response to TNF antagonist rheumatoid arthritis +Response to TNF-alpha inhibitors in rheumatoid arthritis rheumatoid arthritis|| response to TNF antagonist GCST001772 response to TNF antagonist rheumatoid arthritis +Response to TNF-alpha inhibitors in rheumatoid arthritis rheumatoid arthritis|| response to TNF antagonist GCST001510 response to TNF antagonist rheumatoid arthritis +Response to TNF inhibitor in rheumatoid arthritis (change in disease activity score) rheumatoid arthritis|| response to TNF antagonist|| arthritis disease activity score measurement GCST006610 response to TNF antagonist|| arthritis disease activity score measurement rheumatoid arthritis +Response to TNF inhibitor in rheumatoid arthritis (erythrocyte sedimentation rate) rheumatoid arthritis|| response to TNF antagonist|| blood sedimentation GCST006607 response to TNF antagonist|| blood sedimentation rheumatoid arthritis +Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count) rheumatoid arthritis|| response to TNF antagonist|| joint damage measurement GCST006606 response to TNF antagonist|| joint damage measurement rheumatoid arthritis +Response to TNF inhibitor in rheumatoid arthritis (change in tender 28-joint count) rheumatoid arthritis|| response to TNF antagonist|| joint damage measurement GCST006609 response to TNF antagonist|| joint damage measurement rheumatoid arthritis +Response to TNF inhibitor in rheumatoid arthritis (change in patient global heath assessment score) rheumatoid arthritis|| self rated health|| response to TNF antagonist GCST006608 response to TNF antagonist||self rated health rheumatoid arthritis +Adverse response to dabrafenib or dabrafenib-trametinib treatment in melanoma (pyrexia) response to trametinib|| fever|| melanoma|| response to dabrafenib GCST003456 response to trametinib|| fever|| response to dabrafenib melanoma +Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 12 weeks) response to venlafaxine|| generalized anxiety disorder GCST004272 response to venlafaxine generalized anxiety disorder +Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 24 weeks) response to venlafaxine|| generalized anxiety disorder GCST004271 response to venlafaxine generalized anxiety disorder +Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks) response to venlafaxine|| generalized anxiety disorder GCST004274 response to venlafaxine generalized anxiety disorder +Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks) response to venlafaxine|| generalized anxiety disorder GCST004273 response to venlafaxine generalized anxiety disorder +Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks) response to venlafaxine|| generalized anxiety disorder GCST004270 response to venlafaxine generalized anxiety disorder +Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks) response to venlafaxine|| generalized anxiety disorder GCST004275 response to venlafaxine generalized anxiety disorder +Response to ziprazidone in schizophrenia schizophrenia|| response to ziprasidone GCST006296 response to ziprasidone schizophrenia +Risky sexual behaviors in alcohol dependence alcohol dependence|| risky sexual behaviour measurement GCST004955 risky sexual behaviour measurement alcohol dependence +Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis salivary gland lesion|| autoimmune pancreatitis type 1|| lachrymal gland lesion GCST002913 salivary gland lesion|| lachrymal gland lesion autoimmune pancreatitis type 1 +Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL) serum alanine aminotransferase measurement|| response to combination chemotherapy|| acute lymphoblastic leukemia GCST004250 serum alanine aminotransferase measurement|| response to combination chemotherapy acute lymphoblastic leukemia +Creatinine levels in ischemic stroke Ischemic stroke|| serum creatinine measurement GCST003213 serum creatinine measurement Ischemic stroke +Peak creatinine levels in vancomycin therapy response to vancomycin|| serum creatinine measurement GCST002948 serum creatinine measurement|| response to vancomycin +IgE levels in asthmatics serum IgE measurement|| asthma GCST002122 serum IgE measurement asthma +IgE levels in asthmatics (D.f. specific) serum IgE measurement|| asthma GCST002125 serum IgE measurement asthma +IgE levels in asthmatics (D.p. specific) serum IgE measurement|| asthma GCST002124 serum IgE measurement asthma +Sex hormone-binding globulin levels in polycystic ovary syndrome polycystic ovary syndrome|| sex hormone-binding globulin measurement GCST005271 sex hormone-binding globulin measurement polycystic ovary syndrome +Sexual dimorphism in anthropometric traits anthropometric measurement|| sexual dimorphism GCST002063 sexual dimorphism anthropometric measurement +Sex difference in attention deficit hyperactivity disorder attention deficit hyperactivity disorder|| sexual dimorphism GCST005363 sexual dimorphism attention deficit hyperactivity disorder +Thiopurine-induced skin symptoms in inflammatory bowel disease skin disease|| response to thiopurine|| inflammatory bowel disease GCST006213 skin disease|| response to thiopurine inflammatory bowel disease +Skin fluorescence in type 1 diabetes skin fluorescence measurement|| type I diabetes mellitus GCST003418 skin fluorescence measurement type I diabetes mellitus +Current cigarettes per day in chronic obstructive pulmonary disease chronic obstructive pulmonary disease|| smoking behaviour measurement GCST006042 smoking behaviour measurement chronic obstructive pulmonary disease +Current cigarettes per day in chronic obstructive pulmonary disease chronic obstructive pulmonary disease|| cigarettes per day measurement GCST005917 smoking behaviour measurement chronic obstructive pulmonary disease +Current cigarettes per day in chronic obstructive pulmonary disease chronic obstructive pulmonary disease|| smoking behaviour measurement GCST001111 smoking behaviour measurement chronic obstructive pulmonary disease +Lifetime average cigarettes per day in chronic obstructive pulmonary disease chronic obstructive pulmonary disease|| smoking behaviour measurement GCST001112 smoking behaviour measurement chronic obstructive pulmonary disease +Smoking cessation in chronic obstructive pulmonary disease chronic obstructive pulmonary disease|| smoking cessation GCST005918 smoking cessation chronic obstructive pulmonary disease +Smoking cessation in chronic obstructive pulmonary disease chronic obstructive pulmonary disease|| smoking cessation GCST001108 smoking cessation chronic obstructive pulmonary disease +Bone mineral density (lumbar spine) in inflammatory bowel disease inflammatory bowel disease|| spine bone mineral density GCST005783 spine bone mineral density inflammatory bowel disease +Bone mineral density change response to combined chemotherapy in acute lymphoblastic leukemia spine bone mineral density change measurement|| response to combination chemotherapy|| acute lymphoblastic leukemia GCST005214 spine bone mineral density change measurement|| response to combination chemotherapy acute lymphoblastic leukemia +Suicidal ideation in depression or bipolar disorder unipolar depression|| suicidal ideation|| bipolar disorder GCST002505 suicidal ideation unipolar depression|| bipolar disorder +Suicide in bipolar disorder suicide behaviour measurement|| bipolar disorder|| attempted suicide GCST002699 suicide behaviour measurement|| attempted suicide bipolar disorder +Suicide ideation score in major depressive disorder suicide ideation measurement|| unipolar depression GCST002974 suicide ideation measurement unipolar depression +Systolic blood pressure in sickle cell anemia Sickle cell anemia|| systolic blood pressure GCST002187 systolic blood pressure Sickle cell anemia +Systolic blood pressure night-to-day ratio in hypertension hypertension|| systolic blood pressure change measurement GCST006274 systolic blood pressure change measurement hypertension +Systolic blood pressure response to hydrochlorothiazide in hypertension response to hydrochlorothiazide|| hypertension|| systolic blood pressure change measurement GCST003807 response to hydrochlorothiazide|| systolic blood pressure change measurement hypertension +Blood pressure response to hydrochlorothiazide in hypertension response to hydrochlorothiazide|| diastolic blood pressure change measurement|| hypertension|| systolic blood pressure change measurement GCST002784 systolic blood pressure change measurement|| response to hydrochlorothiazide|| diastolic blood pressure change measurement hypertension +Testosterone levels in polycystic ovary syndrome polycystic ovary syndrome|| testosterone measurement GCST005272 testosterone measurement polycystic ovary syndrome +Thalamus volume in trauma-exposed individuals response to trauma exposure|| thalamus volume GCST005245 thalamus volume|| response to trauma exposure +Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines thiopurine methyltransferase activity measurement|| response to mercaptopurine|| acute lymphoblastic leukemia GCST003609 response to mercaptopurine|| thiopurine methyltransferase activity measurement acute lymphoblastic leukemia +Thrombin-antithrombin complex levels in ischemic stroke Ischemic stroke|| thrombin-antithrombin complex measurement GCST003233 thrombin-antithrombin complex measurement Ischemic stroke +Thrombocytopenia in coronary artery bypass surgery coronary artery bypass|| thrombocytopenia GCST006435 thrombocytopenia coronary artery bypass +Thrombomodulin levels in ischemic stroke Ischemic stroke|| thrombomodulin measurement GCST003234 thrombomodulin measurement Ischemic stroke +Thyroid peroxidase autoantibody levels in type 1 diabetes type I diabetes mellitus|| thyroid peroxidase antibody measurement GCST004383 thyroid peroxidase antibody measurement type I diabetes mellitus +Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor ticagrelor measurement|| acute coronary syndrome GCST002882 ticagrelor measurement acute coronary syndrome +Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes response to simvastatin|| type II diabetes mellitus|| total cholesterol change measurement|| response to fenofibrate GCST004765 response to simvastatin|| total cholesterol change measurement|| response to fenofibrate type II diabetes mellitus +Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes triglyceride change measurement|| response to simvastatin|| type II diabetes mellitus|| response to fenofibrate GCST004766 response to simvastatin|| triglyceride change measurement|| response to fenofibrate type II diabetes mellitus +Triglyceride levels in chylomicrons and largest VLDL chylomicron measurement|| triglyceride measurement|| very low density lipoprotein cholesterol measurement GCST005512 triglyceride measurement chylomicron measurement|| very low density lipoprotein cholesterol measurement +Triglyceride levels in small HDL triglyceride measurement|| high density lipoprotein cholesterol measurement GCST005509 triglyceride measurement high density lipoprotein cholesterol measurement +Triglyceride levels in very large HDL triglyceride measurement|| high density lipoprotein cholesterol measurement GCST005498 triglyceride measurement high density lipoprotein cholesterol measurement +Triglyceride levels in IDL triglyceride measurement|| intermediate density lipoprotein measurement GCST005480 triglyceride measurement intermediate density lipoprotein measurement +Triglyceride levels in large VLDL triglyceride measurement|| very low density lipoprotein cholesterol measurement GCST005460 triglyceride measurement very low density lipoprotein cholesterol measurement +Triglyceride levels in medium VLDL triglyceride measurement|| very low density lipoprotein cholesterol measurement GCST005467 triglyceride measurement very low density lipoprotein cholesterol measurement +Triglyceride levels in small VLDL triglyceride measurement|| very low density lipoprotein cholesterol measurement GCST005472 triglyceride measurement very low density lipoprotein cholesterol measurement +Triglyceride levels in very large VLDL triglyceride measurement|| very low density lipoprotein cholesterol measurement GCST005452 triglyceride measurement very low density lipoprotein cholesterol measurement +Triglyceride levels in very small VLDL triglyceride measurement|| very low density lipoprotein cholesterol measurement GCST005475 triglyceride measurement very low density lipoprotein cholesterol measurement +CSF tryptophan concentration in tuberculous meningitis tryptophan measurement|| meningeal tuberculosis GCST005331 tryptophan measurement meningeal tuberculosis +Depression in smokers smoking behavior|| unipolar depression GCST006427 unipolar depression smoking behavior +Serum urate levels in chronic kidney disease urate measurement|| chronic kidney disease GCST006426 urate measurement chronic kidney disease +Urate levels in obese individuals obese body mass index status|| urate measurement GCST002828 urate measurement obese body mass index status +Urate levels in overweight individuals urate measurement|| overweight body mass index status GCST002829 urate measurement overweight body mass index status +Urate levels in lean individuals urate measurement|| underweight body mass index status GCST002830 urate measurement underweight body mass index status +Change in serum uric acid levels in response to thiazide diuretic treatment (hydrochlorothiazide) in hypertension response to hydrochlorothiazide|| hypertension|| uric acid measurement GCST005646 uric acid measurement|| response to hydrochlorothiazide hypertension +"Urinary 1,3-butadiene metabolite levels in smokers" "smoking status measurement|| urinary 1,3-butadiene measurement" GCST004254 "urinary 1,3-butadiene measurement" smoking status measurement +Urinary albumin-to-creatinine ratio in diabetes diabetes mellitus|| urinary albumin to creatinine ratio GCST003250 urinary albumin to creatinine ratio diabetes mellitus +Fractional excretion of metabolites in chronic kidney disease chronic kidney disease|| urinary metabolite measurement GCST005666 urinary metabolite measurement chronic kidney disease +Urinary metabolite concentrations in chronic kidney disease chronic kidney disease|| urinary metabolite measurement GCST005651 urinary metabolite measurement chronic kidney disease +Urinary metabolite ratios in chronic kidney disease chronic kidney disease|| urinary metabolite measurement GCST005649 urinary metabolite measurement chronic kidney disease +S-phenylmercapturic acid levels in smokers smoking behavior|| urinary S-phenylmercapturic acid measurement GCST003483 urinary S-phenylmercapturic acid measurement smoking behavior +Uveitis in juvenile idiopathic arthritis chronic childhood arthritis|| uveitis GCST006126 uveitis chronic childhood arthritis +Vancomycin trough in vancomycin therapy vancomycin trough measurement|| response to vancomycin GCST002946 vancomycin trough measurement|| response to vancomycin +Vaso-occlusive pain in sickle-cell anemia Sickle cell anemia|| vaso-occlusive pain measurement GCST004644 vaso-occlusive pain measurement Sickle cell anemia +Vein graft stenosis in coronary artery bypass grafting coronary artery bypass|| vein graft stenosis GCST002793 vein graft stenosis coronary artery bypass +Response to abacavir-containing treatment in HIV-1 infection (virologic failure) HIV-1 infection|| virologic response measurement|| response to abacavir GCST002769 virologic response measurement|| response to abacavir HIV-1 infection +Vision loss in proton beam irradiation treatment of choroidal melanoma response to radiation|| choroidal melanoma|| visual acuity measurement GCST005589 visual acuity measurement|| response to radiation choroidal melanoma +Response to ranibizumab in age-related macular degeneration (visual acuity) visual acuity measurement|| response to ranibizumab|| age-related macular degeneration GCST004801 visual acuity measurement|| response to ranibizumab age-related macular degeneration +Vitamin B levels in ischemic stroke stroke|| vitamin B measurement GCST002559 vitamin B measurement stroke +vWF levels in ischaemic stroke and hyperhomocysteinaemia Ischemic stroke|| von Willebrand factor measurement|| homocysteine measurement GCST004598 von Willebrand factor measurement Ischemic stroke|| homocysteine measurement +White matter hyperintensities in ischemic stroke Ischemic stroke|| white matter hyperintensity measurement GCST003245 white matter hyperintensity measurement Ischemic stroke +White matter microstructure in first episode schizophrenia (left anterior cingulate cortex) schizophrenia|| white matter microstructure measurement|| cingulate cortex measurement GCST004994 white matter microstructure measurement|| cingulate cortex measurement schizophrenia +White matter microstructure in first episode schizophrenia (left posterior cingulate cortex) schizophrenia|| white matter microstructure measurement|| cingulate cortex measurement GCST004995 white matter microstructure measurement|| cingulate cortex measurement schizophrenia +White matter microstructure in first episode schizophrenia (right anterior cingulate cortex) schizophrenia|| white matter microstructure measurement|| cingulate cortex measurement GCST004993 white matter microstructure measurement|| cingulate cortex measurement schizophrenia +White matter microstructure in first episode schizophrenia (right posterior cingulate cortex) schizophrenia|| white matter microstructure measurement|| cingulate cortex measurement GCST004992 white matter microstructure measurement|| cingulate cortex measurement schizophrenia +White matter microstructure in first episode schizophrenia (left inferior parietal cortex) parietal cortex measurement|| schizophrenia|| white matter microstructure measurement GCST004991 white matter microstructure measurement|| parietal cortex measurement schizophrenia +Yu-Zhi constitution type in type 2 diabetes Yu-Zhi constitution type|| type II diabetes mellitus GCST003026 Yu-Zhi constitution type type II diabetes mellitus +Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation response to allogeneic hematopoietic stem cell transplant|| acute graft vs. host disease GCST002958 response to allogeneic hematopoietic stem cell transplant|| acute graft vs. host disease +Acute graft versus host disease in bone marrow transplantation (donor effect) acute graft vs. host disease|| donor genotype effect measurement GCST003942 acute graft vs. host disease|| donor genotype effect measurement +Subjective response to lithium treatment bipolar disorder|| response to lithium ion GCST003158 bipolar disorder|| response to lithium ion +Uncontrolled blood pressure in combination therapy (beta blocker and thiazide diuretic) blood pressure|| response to thiazide|| response to beta blocker GCST005039 blood pressure|| response to thiazide|| response to beta blocker +Odor events in darapladib-treated cardiovascular disease (time to event) response to darapladib|| body odor measurement|| acute coronary syndrome|| coronary heart disease GCST004960 body odor measurement|| response to darapladib acute coronary syndrome|| coronary heart disease +Bronchopulmonary dysplasia in preterm infants infant|| Bronchopulmonary dysplasia GCST004783 Bronchopulmonary dysplasia infant +Major coronary event in darapladib-treated cardiovascular disease (time to event) response to darapladib|| acute coronary syndrome|| coronary heart disease|| cardiovascular event measurement GCST004957 cardiovascular event measurement|| response to darapladib acute coronary syndrome|| coronary heart disease +Cerebrospinal fluid clusterin levels in APOEe4- carriers Alzheimer's disease|| cerebrospinal fluid clusterin measurement GCST003137 cerebrospinal fluid clusterin measurement Alzheimer's disease +Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule) chemotherapy-induced alopecia|| response to antimicrotubule agent GCST002177 chemotherapy-induced alopecia|| response to antimicrotubule agent +Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel) chemotherapy-induced alopecia|| response to docetaxel GCST002180 chemotherapy-induced alopecia|| response to docetaxel +Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel) chemotherapy-induced alopecia|| response to paclitaxel GCST002179 chemotherapy-induced alopecia|| response to paclitaxel +Resistance to antipsychotic treatment in schizophrenia (childhood trauma interaction) childhood trauma measurement|| response to antipsychotic drug|| treatment refractory schizophrenia GCST004374 childhood trauma measurement|| response to antipsychotic drug treatment refractory schizophrenia +Diabetic kidney disease in type 2 diabetes (ESRD vs. no ESRD) chronic kidney disease|| diabetic nephropathy GCST005893 chronic kidney disease|| diabetic nephropathy +Chronic kidney disease (chronic kidney disease vs normal or mildly reduced eGFR) in type 1 diabetes type 1 diabetes nephropathy|| chronic kidney disease GCST003867 chronic kidney disease|| type 1 diabetes nephropathy +Chronic kidney disease (severe chronic kidney disease vs normal kidney function) in type 1 diabetes type 1 diabetes nephropathy|| chronic kidney disease GCST003863 chronic kidney disease|| type 1 diabetes nephropathy +Kidney disease (early and late stages) in type 1 diabetes type 1 diabetes nephropathy|| chronic kidney disease GCST003864 chronic kidney disease|| type 1 diabetes nephropathy +Kidney disease (early stage) in type 1 diabetes type 1 diabetes nephropathy|| chronic kidney disease GCST003865 chronic kidney disease|| type 1 diabetes nephropathy +Kidney disease (end stage renal disease vs non-end stage renal disease) in type 1 diabetes type 1 diabetes nephropathy|| chronic kidney disease GCST003862 chronic kidney disease|| type 1 diabetes nephropathy +Kidney disease (end stage renal disease vs normoalbuminuria) in type 1 diabetes type 1 diabetes nephropathy|| chronic kidney disease GCST003861 chronic kidney disease|| type 1 diabetes nephropathy +Kidney disease (late stage) in type 1 diabetes type 1 diabetes nephropathy|| chronic kidney disease GCST003866 chronic kidney disease|| type 1 diabetes nephropathy +Phospholipid levels in chylomicrons and largest VLDL chylomicron measurement|| very low density lipoprotein cholesterol measurement|| phospholipid measurement GCST005511 chylomicron measurement|| very low density lipoprotein cholesterol measurement|| phospholipid measurement +Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma childhood onset asthma|| cortisol measurement|| response to corticosteroid|| response to synacthen GCST005926 cortisol measurement|| response to corticosteroid|| response to synacthen childhood onset asthma +Cough in response to angiotensin-converting enzyme inhibitor drugs response to angiotensin-converting enzyme inhibitor|| Cough GCST004049 Cough|| response to angiotensin-converting enzyme inhibitor +Cough in response to angiotensin-converting enzyme inhibitor drugs response to angiotensin-converting enzyme inhibitor|| Cough GCST003027 Cough|| response to angiotensin-converting enzyme inhibitor +Diabetic nephropathy in type 1 diabetes type I diabetes mellitus|| diabetic retinopathy GCST002716 diabetic nephropathy type I diabetes mellitus +Diastolic blood pressure in combination therapy (beta blocker and thiazide diuretic) diastolic blood pressure|| response to thiazide|| response to beta blocker GCST005041 diastolic blood pressure|| response to thiazide|| response to beta blocker +Disease-free survival in breast cancer disease free survival|| breast carcinoma GCST002847 disease free survival|| breast carcinoma +Survival in colon cancer disease free survival|| colonic neoplasm|| overall survival GCST002822 disease free survival|| colonic neoplasm|| overall survival +Survival in microsatellite instability low/stable colorectal cancer disease free survival|| colorectal cancer|| microsatellite instability measurement|| overall survival GCST002820 disease free survival|| colorectal cancer|| microsatellite instability measurement|| overall survival +Survival in rectal cancer disease free survival|| rectum cancer|| overall survival GCST002821 disease free survival|| rectum cancer|| overall survival +Disease progression in age-related macular degeneration age-related macular degeneration|| disease progression measurement GCST005359 age-related macular degeneration|| disease progression measurement +Disease progression to geographic atrophy form in age-related macular degeneration atrophic macular degeneration|| disease progression measurement GCST005360 atrophic macular degeneration|| disease progression measurement +Age at loss of ambulation in Duchenne muscular dystrophy Duchenne muscular dystrophy|| disease progression measurement GCST006286 Duchenne muscular dystrophy|| disease progression measurement +Huntington's disease progression Huntington disease|| disease progression measurement GCST004691 Huntington disease|| disease progression measurement +Disease progression to choroidal neovascularization form in age-related macular degeneration disease progression measurement|| wet macular degeneration GCST005358 disease progression measurement|| wet macular degeneration +Depression (age of onset) mental or behavioural disorder|| age at onset GCST001643 age at onset mental or behavioural disorder +Schizophrenia (age at onset) (sex interaction) schizophrenia|| age at onset GCST001114 +Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction) schizophrenia|| dorsolateral prefrontal cortex functional measurement GCST000271 dorsolateral prefrontal cortex functional measurement|| schizophrenia +Cholesterol ester levels in medium HDL esterified cholesterol measurement|| high density lipoprotein cholesterol measurement GCST005506 esterified cholesterol measurement|| high density lipoprotein cholesterol measurement +Cholesterol ester levels in very large HDL esterified cholesterol measurement|| high density lipoprotein cholesterol measurement GCST005501 esterified cholesterol measurement|| high density lipoprotein cholesterol measurement +Cholesterol ester levels in very large HDL esterified cholesterol measurement|| high density lipoprotein cholesterol measurement GCST005495 esterified cholesterol measurement|| high density lipoprotein cholesterol measurement +Cholesterol ester levels in large LDL esterified cholesterol measurement|| low density lipoprotein cholesterol measurement GCST005484 esterified cholesterol measurement|| low density lipoprotein cholesterol measurement +Cholesterol ester levels in medium LDL esterified cholesterol measurement|| low density lipoprotein cholesterol measurement GCST005489 esterified cholesterol measurement|| low density lipoprotein cholesterol measurement +Estrogen receptor status in HER2 positive breast cancer estrogen-receptor negative breast cancer|| HER2 status|| estrogen-receptor positive breast cancer|| breast carcinoma GCST003822 estrogen receptor status HER2 status|| breast carcinoma +F-cell distribution in sickle cell anaemia fetal hemoglobin measurement|| Sickle cell anemia GCST000982 fetal hemoglobin measurement Sickle cell anemia +Pulmonary function in asthmatics pulmonary function measurement|| asthma GCST002608 pulmonary function measurement asthma +Gestational age at birth in labor-initiated deliveries (child effect) gestational age|| birth measurement GCST003687 gestational age birth measurement +Gestational age at birth in labor-initiated deliveries (maternal effect) gestational age|| birth measurement GCST003684 gestational age birth measurement +Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect) gestational age|| birth measurement GCST003689 gestational age birth measurement +Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect) gestational age|| birth measurement GCST003685 gestational age birth measurement +Glomerular filtration rate in non diabetics (creatinine) glomerular filtration rate|| serum creatinine measurement GCST003401 glomerular filtration rate|| serum creatinine measurement +Decline in glucose metabolism in posterior cingulate cortex glucose metabolism decline measurement|| cingulate cortex measurement GCST006632 glucose metabolism decline measurement|| cingulate cortex measurement +HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes HDL cholesterol change measurement|| response to simvastatin|| type II diabetes mellitus|| response to fenofibrate GCST004763 HDL cholesterol change measurement|| response to fenofibrate|| response to simvastatin type II diabetes mellitus +Antipsychotic drug-induced QTc interval change in schizophrenia heart rate variability measurement|| response to antipsychotic drug GCST004987 heart rate variability measurement|| response to antipsychotic drug schizophrenia +Estrogen receptor status in HER2 negative breast cancer estrogen-receptor negative breast cancer|| HER2 status|| estrogen-receptor positive breast cancer|| breast carcinoma GCST003823 estrogen receptor status breast carcinoma|| HER2 status +Hippocampal volume in trauma-exposed individuals response to trauma exposure|| hippocampal volume GCST005243 hippocampal volume||response to trauma exposure +HIV-1 viral setpoint HIV-1 infection|| HIV viral set point measurement GCST002976 HIV viral set point measurement HIV-1 infection +Change in intraocular pressure in response to steroid treatment (triamcinolone acetonide) response to triamcinolone acetonide|| intraocular pressure change measurement GCST002837 intraocular pressure change measurement|| response to triamcinolone acetonide +Joint damage progression in ACPA-positive rheumatoid arthritis ACPA-positive rheumatoid arthritis|| joint damage measurement GCST002139 joint damage measurement ACPA-positive rheumatoid arthritis +Joint damage progression in ACPA-negative rheumatoid arthritis ACPA-negative rheumatoid arthritis|| joint damage measurement GCST003256 joint damage measurement ACPA-negative rheumatoid arthritis +LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes LDL cholesterol change measurement|| response to simvastatin|| type II diabetes mellitus|| response to fenofibrate GCST004764 LDL cholesterol change measurement|| response to fenofibrate|| response to simvastatin type II diabetes mellitus +Change in LVEF in response to paclitaxel in HER2+ breast cancer left ventricular diastolic function measurement|| response to paclitaxel GCST004789 left ventricular diastolic function measurement|| response to paclitaxel +Change in LVEF in response to paclitaxel and in response to paclitaxel and trastuzumab in HER+ breast cancer response to trastuzumab|| left ventricular diastolic function measurement|| response to paclitaxel GCST004788 left ventricular diastolic function measurement|| response to trastuzumab|| response to paclitaxel +Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer response to trastuzumab|| left ventricular diastolic function measurement|| response to paclitaxel GCST004790 left ventricular diastolic function measurement|| response to trastuzumab|| response to paclitaxel +Phospholipid levels in large LDL low density lipoprotein cholesterol measurement|| phospholipid measurement GCST005482 low density lipoprotein cholesterol measurement|| phospholipid measurement +Phospholipid levels in medium LDL low density lipoprotein cholesterol measurement|| phospholipid measurement GCST005487 low density lipoprotein cholesterol measurement|| phospholipid measurement +Brain activation in response to working memory task memory performance|| functional brain measurement|| short-term memory GCST003698 memory performance|| functional brain measurement|| short-term memory +Remission after SSRI treatment in MDD or neuroticism unipolar depression|| neuroticism measurement|| response to selective serotonin reuptake inhibitor GCST005835 neuroticism measurement|| response to selective serotonin reuptake inhibitor unipolar depression +Cisplatin-induced hearing loss in brain tumor patients ototoxicity|| hearing loss|| response to cisplatin GCST002780 ototoxicity|| hearing loss|| response to cisplatin +Phospholipid levels in large HDL phospholipid measurement|| high density lipoprotein cholesterol measurement GCST005499 phospholipid measurement|| high density lipoprotein cholesterol measurement +Phospholipid levels in medium HDL phospholipid measurement|| high density lipoprotein cholesterol measurement GCST005504 phospholipid measurement|| high density lipoprotein cholesterol measurement +Phospholipid levels in very large HDL phospholipid measurement|| high density lipoprotein cholesterol measurement GCST005493 phospholipid measurement|| high density lipoprotein cholesterol measurement +Phospholipid levels in IDL phospholipid measurement|| intermediate density lipoprotein measurement GCST005477 phospholipid measurement|| intermediate density lipoprotein measurement +Acute graft rejection in renal transplantation (donor effect) renal transplant outcome measurement|| donor genotype effect measurement GCST005432 renal transplant outcome measurement|| donor genotype effect measurement +Acute graft rejection in renal transplantation (donor-recipient interaction) renal transplant outcome measurement|| donor genotype effect measurement GCST005433 renal transplant outcome measurement|| donor genotype effect measurement +Angioedema in response to angiotensin-converting enzyme inhibitor response to angiotensin-converting enzyme inhibitor|| angioedema GCST002091 response to angiotensin-converting enzyme inhibitor|| angioedema +Response to antidepressants in depression unipolar depression|| mood disorder|| response to antidepressant GCST003803 response to antidepressant unipolar depression|| mood disorder +Response to aripiprazole in schizophrenia schizophrenia|| response to aripiprazole|| response to antipsychotic drug GCST006285 response to aripiprazole|| response to antipsychotic drug schizophrenia +Bronchodilator response in asthma (inhaled corticosteroid treatment interaction) response to bronchodilator|| asthma GCST002291 response to bronchodilator|| response to corticosteroid asthma +Response to bupropion in depression unipolar depression|| response to bupropion|| mood disorder GCST003800 response to bupropion unipolar depression|| mood disorder +Response to angiotensin II receptor blocker therapy response to candesartan|| hypertension GCST001520 response to candesartan hypertension +Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) response to candesartan|| hypertension GCST001518 response to candesartan hypertension +Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU) response to cyclophosphamide|| chemotherapy-induced alopecia|| response to 5' fluorouracil|| response to doxorubicin GCST002178 response to cyclophosphamide|| chemotherapy-induced alopecia|| response to 5' fluorouracil|| response to doxorubicin +Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU) response to epirubicin|| response to cyclophosphamide|| chemotherapy-induced alopecia|| response to 5' fluorouracil GCST002176 response to epirubicin|| response to cyclophosphamide|| chemotherapy-induced alopecia|| response to 5' fluorouracil +Response to citalopram or escitalopram in depression unipolar depression|| response to escitalopram|| response to citalopram|| mood disorder GCST003802 response to escitalopram|| response to citalopram unipolar depression|| mood disorder +Thiazide-induced adverse metabolic effects in hypertensive patients response to hydrochlorothiazide|| triglyceride measurement|| fasting blood glucose measurement GCST001859 response to hydrochlorothiazide|| triglyceride measurement|| fasting blood glucose measurement +Hepatocellular carcinoma in post hepatitis C eradication by interferon therapy response to interferon|| hepatocellular carcinoma|| virologic response measurement GCST004160 response to interferon|| hepatocellular carcinoma virologic response measurement +Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer response to irinotecan|| non-small cell lung carcinoma GCST001901 response to irinotecan non-small cell lung carcinoma +Response to long-chain n-3 polyunsaturated fatty acid supplementation (change in triglyceride levels) triglyceride change measurement|| response to long-chain n-3 PUFA dietary supplementation GCST006055 response to long-chain n-3 PUFA dietary supplementation|| triglyceride change measurement +Urinary symptoms in response to radiotherapy in prostate cancer response to radiation|| prostate carcinoma|| lower urinary tract symptom GCST001847 response to radiation|| lower urinary tract symptom prostate carcinoma +Response to SSRI in MDD or conscientiouness conscientiousness measurement|| unipolar depression|| response to selective serotonin reuptake inhibitor GCST005836 conscientiousness measurement|| response to selective serotonin reuptake inhibitor unipolar depression +Response to selective serotonin reuptake inhibitors in depression unipolar depression|| response to selective serotonin reuptake inhibitor|| mood disorder GCST003801 response to selective serotonin reuptake inhibitor unipolar depression|| mood disorder +Response to SSRI in MDD or openness unipolar depression|| response to selective serotonin reuptake inhibitor|| openness measurement GCST005834 response to selective serotonin reuptake inhibitor|| openness measurement unipolar depression +Remission after SSRI treatment in MDD or openness unipolar depression|| response to selective serotonin reuptake inhibitor|| openness measurement GCST005833 response to selective serotonin reuptake inhibitor|| openness measurement unipolar depression +Nucleus accumbens volume in trauma-exposed individuals response to trauma exposure|| nucleus accumbens volume GCST005241 response to trauma exposure|| nucleus accumbens volume +Rheumatoid factor seropositivity in rheumatoid arthritis rheumatoid arthritis|| rheumatoid factor seropositivity measurement|| rheumatoid factor measurement GCST003330 rheumatoid factor seropositivity measurement|| rheumatoid factor measurement rheumatoid arthritis +Age at smoking initiation in chronic obstructive pulmonary disease chronic obstructive pulmonary disease|| smoking initiation GCST001113 smoking initiation chronic obstructive pulmonary disease +Response to angiotensin II receptor blocker treatment (losartan) (change in systolic blood pressure levels) systolic blood pressure|| blood pressure|| response to losartan GCST002583 systolic blood pressure|| blood pressure|| response to losartan +Systolic blood pressure in combination therapy (beta blocker and thiazide diuretic) systolic blood pressure|| response to thiazide|| response to beta blocker GCST005040 systolic blood pressure|| response to thiazide|| response to beta blocker +Tacrolimus trough concentration in kidney transplant patients tacrolimus measurement|| renal transplant outcome measurement GCST005144 tacrolimus measurement renal transplant outcome measurement +Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous) tuberculin skin test reactivity measurement|| decreased susceptibility to bacterial infection GCST004689 tuberculin skin test reactivity measurement|| decreased susceptibility to bacterial infection +Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous) tuberculin skin test reactivity measurement|| decreased susceptibility to bacterial infection GCST004690 tuberculin skin test reactivity measurement|| decreased susceptibility to bacterial infection +Cholesterol ester levels in large VLDL very low density lipoprotein cholesterol measurement|| esterified cholesterol measurement GCST005461 very low density lipoprotein cholesterol measurement|| esterified cholesterol measurement +Cholesterol ester levels in medium VLDL very low density lipoprotein cholesterol measurement|| esterified cholesterol measurement GCST005465 very low density lipoprotein cholesterol measurement|| esterified cholesterol measurement +Phospholipid levels in large VLDL very low density lipoprotein cholesterol measurement|| phospholipid measurement GCST005454 very low density lipoprotein cholesterol measurement|| phospholipid measurement +Phospholipid levels in medium VLDL very low density lipoprotein cholesterol measurement|| phospholipid measurement GCST005463 very low density lipoprotein cholesterol measurement|| phospholipid measurement +Phospholipid levels in small VLDL very low density lipoprotein cholesterol measurement|| phospholipid measurement GCST005469 very low density lipoprotein cholesterol measurement|| phospholipid measurement +Phospholipid levels in very large VLDL very low density lipoprotein cholesterol measurement|| phospholipid measurement GCST005451 very low density lipoprotein cholesterol measurement|| phospholipid measurement +Phospholipid levels in very small VLDL very low density lipoprotein cholesterol measurement|| phospholipid measurement GCST005474 very low density lipoprotein cholesterol measurement|| phospholipid measurement +Response to anti-VEGF treatment in neovascular age-related macular degeneration (visual acuity) visual acuity measurement|| wet macular degeneration|| response to anti-vascular endothelial growth factor drug GCST006808 visual acuity measurement|| response to anti-vascular endothelial growth factor drug wet macular degeneration +Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer's disease (Alzhiemer's diagnosis trajectory interaction) cognitive impairment|| Alzheimer's disease|| cognitive decline measurement GCST004253 cognitive impairment|| Alzheimer's disease|| cognitive decline measurement +ACPA-negative rheumatoid arthritis (smoking interaction) rheumatoid arthritis|| smoking status measurement|| ACPA-negative rheumatoid arthritis GCST006807 rheumatoid arthritis|| smoking status measurement|| ACPA-negative rheumatoid arthritis +ACPA-positive rheumatoid arthritis (smoking interaction) rheumatoid arthritis|| smoking status measurement|| ACPA-positive rheumatoid arthritis GCST006410 rheumatoid arthritis|| smoking status measurement|| ACPA-positive rheumatoid arthritis +Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) urticaria|| response to non-steroidal anti-inflammatory|| angioedema GCST002263 urticaria|| response to non-steroidal anti-inflammatory|| angioedema +Acylcarnitine levels acylcarnitine measurement|| blood metabolite measurement GCST002961 acylcarnitine measurement|| blood metabolite measurement +Adult onset asthma (smoking interaction) smoking behavior|| adult onset asthma GCST004220 smoking behavior|| adult onset asthma +Advanced age-related macular degeneration atrophic macular degeneration|| age-related macular degeneration|| wet macular degeneration GCST003219 atrophic macular degeneration|| age-related macular degeneration|| wet macular degeneration +Advanced glycation end-product levels advanced glycation end-product measurement|| type II diabetes mellitus GCST003457 advanced glycation end-product measurement|| type II diabetes mellitus +Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) response to 5' fluorouracil|| response to antineoplastic agent GCST001997 response to 5' fluorouracil|| response to antineoplastic agent +Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) response to antineoplastic agent|| response to anthracycline-based chemotherapy GCST002008 response to antineoplastic agent|| response to anthracycline-based chemotherapy +Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) response to antineoplastic agent|| response to antimetabolite GCST002005 response to antineoplastic agent|| response to antimetabolite +Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) response to antineoplastic agent|| response to antimicrotubule agent GCST002001 response to antineoplastic agent|| response to antimicrotubule agent +Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) response to platinum based chemotherapy|| response to antineoplastic agent GCST001998 response to platinum based chemotherapy|| response to antineoplastic agent +Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) response to topoisomerase inhibitor|| response to antineoplastic agent GCST001994 response to topoisomerase inhibitor|| response to antineoplastic agent +Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) response to camptothecin|| response to antineoplastic agent GCST001993 response to camptothecin|| response to antineoplastic agent +Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) response to carboplatin|| response to antineoplastic agent GCST002004 response to carboplatin|| response to antineoplastic agent +Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) response to cisplatin|| response to antineoplastic agent GCST002007 response to cisplatin|| response to antineoplastic agent +Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) response to cyclophosphamide|| response to antineoplastic agent GCST002002 response to cyclophosphamide|| response to antineoplastic agent +Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) response to docetaxel|| response to antineoplastic agent GCST001995 response to docetaxel|| response to antineoplastic agent +Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) response to antineoplastic agent|| response to doxorubicin GCST002009 response to antineoplastic agent|| response to doxorubicin +Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) response to epirubicin|| response to antineoplastic agent GCST001996 response to epirubicin|| response to antineoplastic agent +Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) response to etoposide|| response to antineoplastic agent GCST002000 response to etoposide|| response to antineoplastic agent +Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) response to gemcitabine|| response to antineoplastic agent GCST002003 response to gemcitabine|| response to antineoplastic agent +Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) response to carboplatin|| response to paclitaxel|| response to antineoplastic agent GCST002006 response to carboplatin|| response to paclitaxel|| response to antineoplastic agent +Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) response to paclitaxel|| response to antineoplastic agent GCST001999 response to paclitaxel|| response to antineoplastic agent +Affective disorder and suicide attempts attempted suicide|| mood disorder GCST006420 attempted suicide|| mood disorder +Age of smoking initiation age at onset|| smoking initiation GCST002394 age at onset|| smoking initiation +Age-related disease endophenotypes total cholesterol measurement|| diastolic blood pressure|| triglyceride measurement|| systolic blood pressure|| hematocrit|| ventricular rate measurement|| glucose measurement|| body mass index|| high density lipoprotein cholesterol measurement GCST004046 total cholesterol measurement|| diastolic blood pressure|| triglyceride measurement|| systolic blood pressure|| hematocrit|| ventricular rate measurement|| glucose measurement|| body mass index|| high density lipoprotein cholesterol measurement +Age-related diseases and mortality cancer|| heart failure|| diabetes mellitus|| stroke|| coronary heart disease|| atrial fibrillation|| mortality GCST004044 cancer|| heart failure|| diabetes mellitus|| stroke|| coronary heart disease|| atrial fibrillation|| mortality +"Age-related diseases, mortality and associated endophenotypes" total cholesterol measurement|| hematocrit|| stroke|| ventricular rate measurement|| coronary heart disease|| body mass index|| atrial fibrillation|| high density lipoprotein cholesterol measurement|| cancer|| diastolic blood pressure|| triglyceride measurement|| systolic blood pressure|| heart failure|| diabetes mellitus|| glucose measurement|| mortality GCST004045 total cholesterol measurement|| hematocrit|| stroke|| ventricular rate measurement|| coronary heart disease|| body mass index|| atrial fibrillation|| high density lipoprotein cholesterol measurement|| cancer|| diastolic blood pressure|| triglyceride measurement|| systolic blood pressure|| heart failure|| diabetes mellitus|| glucose measurement|| mortality +Age-related macular degeneration glaucoma|| age-related macular degeneration GCST001899 glaucoma|| age-related macular degeneration +Age-related macular degeneration (CNV vs. GA) atrophic macular degeneration|| wet macular degeneration GCST001577 atrophic macular degeneration|| wet macular degeneration +Age-related macular degeneration (smoking status interaction) smoking status measurement|| age-related macular degeneration GCST001990 smoking status measurement|| age-related macular degeneration +Aggressive periodontitis (sex interaction) sex interaction measurement|| aggressive periodontitis GCST002635 sex interaction measurement|| aggressive periodontitis +Aggressive prostate cancer cancer aggressiveness measurement|| prostate carcinoma GCST003585 cancer aggressiveness measurement|| prostate carcinoma +Aging (time to death) longevity|| aging GCST001167 longevity|| aging +Aging traits age at menopause|| aging|| exercise test|| age at death GCST000096 age at menopause|| aging|| exercise test|| age at death +Alcohol consumption (drinkers vs non-drinkers) alcohol consumption measurement|| alcohol drinking GCST004404 alcohol consumption measurement|| alcohol drinking +Alcohol consumption (drinks per week) alcohol consumption measurement|| alcohol drinking GCST004405 alcohol consumption measurement|| alcohol drinking +Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis alcoholic liver cirrhosis|| alcohol dependence|| alcoholic pancreatitis GCST004757 alcoholic liver cirrhosis|| alcohol dependence|| alcoholic pancreatitis +Alcohol misuse (trauma interaction) stressful life event measurement|| alcohol dependence measurement GCST004225 stressful life event measurement|| alcohol dependence measurement +Alzheimer's disease (APOE e4 interaction) Alzheimer's disease|| APOE carrier status GCST002814 Alzheimer's disease|| APOE carrier status +Alzheimer's disease or family history of Alzheimer's disease Alzheimer's disease|| family history of Alzheimer’s disease GCST005922 Alzheimer's disease|| family history of Alzheimer’s disease +Alzheimer's disease or small vessel stroke Alzheimer's disease|| small vessel stroke GCST003423 Alzheimer's disease|| small vessel stroke +Alzheimer's disease or type 2 diabetes (pleiotropy) Alzheimer's disease|| type II diabetes mellitus GCST004880 Alzheimer's disease|| type II diabetes mellitus +Amino acid levels blood metabolite measurement|| amino acid measurement GCST002966 blood metabolite measurement|| amino acid measurement +Amyotrophic lateral sclerosis and immune-mediated diseases (pleiotropy) rheumatoid arthritis|| type I diabetes mellitus|| psoriasis|| amyotrophic lateral sclerosis|| celiac disease|| ulcerative colitis|| Crohn's disease GCST005321 rheumatoid arthritis|| type I diabetes mellitus|| psoriasis|| amyotrophic lateral sclerosis|| celiac disease|| ulcerative colitis|| Crohn's disease +Amyotrophic lateral sclerosis or frontotemporal dementia amyotrophic lateral sclerosis|| Frontotemporal dementia GCST002510 amyotrophic lateral sclerosis|| Frontotemporal dementia +Amyotrophic lateral sclerosis or schizophrenia (pleiotropy) schizophrenia|| amyotrophic lateral sclerosis GCST004252 schizophrenia|| amyotrophic lateral sclerosis +Androgen levels dihydrotestosterone measurement|| testosterone measurement GCST001653 dihydrotestosterone measurement|| testosterone measurement +Anorexia nervosa or obsessive-compulsive disorder anorexia nervosa|| obsessive-compulsive disorder GCST006576 anorexia nervosa|| obsessive-compulsive disorder +Anti-thyroid drug induced agranulocytosis drug-induced agranulocytosis|| response to anti-thyroid drug GCST003527 drug-induced agranulocytosis|| response to anti-thyroid drug +Antiepileptic drug-induced maculopapular exanthema maculopapular eruption|| response to anticonvulsant GCST005197 maculopapular eruption|| response to anticonvulsant +Antipsychotic drug-induced weight gain (time interaction) longitudinal BMI measurement|| antipsychotic drug related weight gain GCST003108 longitudinal BMI measurement|| antipsychotic drug related weight gain +Antithyroid drug-induced agranulocytosis drug-induced agranulocytosis|| response to thioamide GCST003580 drug-induced agranulocytosis|| response to thioamide +Anxiety and major depressive disorder unipolar depression|| anxiety GCST002200 unipolar depression|| anxiety +Asthma (sex interaction) sex interaction measurement|| asthma GCST002445 sex interaction measurement|| asthma +Asthma and hay fever seasonal allergic rhinitis|| asthma GCST002322 seasonal allergic rhinitis|| asthma +Asthma or atopy (farm exposure interaction) farm exposure measurement|| asthma GCST000934 farm exposure measurement|| asthma +Asthma or chronic obstructive pulmonary disease chronic obstructive pulmonary disease|| asthma GCST002519 chronic obstructive pulmonary disease|| asthma +Asymmetrical dimethylarginine levels asymmetrical dimethylarginine measurement|| serum dimethylarginine measurement GCST002241 asymmetrical dimethylarginine measurement|| serum dimethylarginine measurement +Atopic march childhood onset asthma|| atopic eczema|| atopic march GCST003180 childhood onset asthma|| atopic eczema|| atopic march +Attention deficit hyperactivity disorder (sex interaction) attention deficit hyperactivity disorder|| sex interaction measurement GCST005361 attention deficit hyperactivity disorder|| sex interaction measurement +Attention deficit hyperactivity disorder and conduct disorder attention deficit hyperactivity disorder|| conduct disorder GCST000253 attention deficit hyperactivity disorder|| conduct disorder +Attention deficit hyperactivity disorder and obsessive compulsive disorder obsessive-compulsive disorder|| attention deficit hyperactivity disorder GCST004223 obsessive-compulsive disorder|| attention deficit hyperactivity disorder +Attention deficit hyperactivity disorder or educational attainment (years of education) (pleiotropy) attention deficit hyperactivity disorder|| self reported educational attainment GCST006216 attention deficit hyperactivity disorder|| self reported educational attainment +Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction) attention deficit hyperactivity disorder|| parental emotion expression measurmement GCST000247 attention deficit hyperactivity disorder|| parental emotion expression measurmement +Autism spectrum disorder or schizophrenia schizophrenia|| autism spectrum disorder GCST004521 schizophrenia|| autism spectrum disorder +Autism spectrum disorder-related traits autism spectrum disorder|| autism|| autism spectrum disorder symptom GCST002639 autism spectrum disorder|| autism|| autism spectrum disorder symptom +"Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)" attention deficit hyperactivity disorder|| unipolar depression|| schizophrenia|| autism spectrum disorder|| bipolar disorder GCST001877 attention deficit hyperactivity disorder|| unipolar depression|| schizophrenia|| autism spectrum disorder|| bipolar disorder +Autoimmune thyroid diseases (Graves disease or Hashimoto's thyroiditis) autoimmune thyroid disease|| Hashimoto's thyroiditis|| Graves disease GCST005524 autoimmune thyroid disease|| Hashimoto's thyroiditis|| Graves disease +Axial length or spherical error (univariate decomposition analysis) axial length measurement|| refractive error measurement GCST006864 axial length measurement|| refractive error measurement +"B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy)" Hodgkins lymphoma|| multiple myeloma|| chronic lymphocytic leukemia GCST004099 Hodgkins lymphoma|| multiple myeloma|| chronic lymphocytic leukemia +Barrett's esophagus or Esophageal adenocarcinoma esophageal adenocarcinoma|| Barrett's esophagus GCST003740 esophageal adenocarcinoma|| Barrett's esophagus +Barrett's esophagus x BMI interaction Barrett's esophagus|| body mass index GCST006529 Barrett's esophagus|| body mass index +Barrett's esophagus x gastroesophageal reflux disease interaction Barrett's esophagus|| gastroesophageal reflux disease GCST006526 Barrett's esophagus|| gastroesophageal reflux disease +Barrett's esophagus x pack-years of smoking exposure interaction pack-years measurement|| Barrett's esophagus GCST006528 pack-years measurement|| Barrett's esophagus +Barrett's esophagus x smoking interaction smoking status measurement|| Barrett's esophagus GCST006527 smoking status measurement|| Barrett's esophagus +Behavioral disturbance or psychiatric symptoms and prion disease behavioral abnormality|| prion disease GCST002866 behavioral abnormality|| prion disease +Behavioural disinhibition (generation interaction) nicotine use|| generational effect measurement|| illegal drug consumption|| non-substance related disinhibited behaviour|| alcohol drinking|| alcohol dependence GCST002131 nicotine use|| generational effect measurement|| illegal drug consumption|| non-substance related disinhibited behaviour|| alcohol drinking|| alcohol dependence +Benign prostatic hyperplasia and/or lower urinary tract symptoms lower urinary tract symptom|| benign prostatic hyperplasia GCST004638 lower urinary tract symptom|| benign prostatic hyperplasia +Binge eating behaviour and bipolar disorder binge eating|| bipolar disorder GCST005386 binge eating|| bipolar disorder +Binge eating behaviour and bipolar disorder binge eating|| bipolar disorder GCST002419 binge eating|| bipolar disorder +Biochemical measures serum albumin measurement|| total cholesterol measurement|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| fibrinogen measurement|| uric acid measurement|| high density lipoprotein cholesterol measurement GCST000328 serum albumin measurement|| total cholesterol measurement|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| fibrinogen measurement|| uric acid measurement|| high density lipoprotein cholesterol measurement +Biomedical quantitative traits diastolic blood pressure|| systolic blood pressure|| bone density|| heart rate|| waist-hip ratio|| body mass index GCST000381 diastolic blood pressure|| systolic blood pressure|| bone density|| heart rate|| waist-hip ratio|| body mass index +Bipolar disorder (body mass index interaction) bipolar disorder|| body mass index GCST002306 bipolar disorder|| body mass index +Bipolar disorder (inflammation and infection response interaction) HSV1 seropositivity|| bipolar disorder|| cytomegalovirus seropositivity GCST002815 HSV1 seropositivity|| bipolar disorder|| cytomegalovirus seropositivity +Bipolar disorder and eating disorder eating disorder|| bipolar disorder GCST003135 eating disorder|| bipolar disorder +Bipolar disorder and schizophrenia schizophrenia|| bipolar disorder GCST001567 schizophrenia|| bipolar disorder +Bipolar disorder lithium response (categorical) or schizophrenia schizophrenia|| bipolar disorder|| response to lithium ion GCST005082 schizophrenia|| bipolar disorder|| response to lithium ion +Bipolar disorder lithium response (continuous) or schizophrenia schizophrenia|| bipolar disorder|| response to lithium ion GCST005081 schizophrenia|| bipolar disorder|| response to lithium ion +Bipolar disorder or attention deficit hyperactivity disorder attention deficit hyperactivity disorder|| bipolar disorder GCST004001 attention deficit hyperactivity disorder|| bipolar disorder +Bipolar disorder or major depressive disorder unipolar depression|| bipolar disorder GCST000641 unipolar depression|| bipolar disorder +Blood metabolite levels urate measurement|| mannose measurement|| blood metabolite measurement|| X12063 measurement GCST002872 urate measurement|| mannose measurement|| blood metabolite measurement|| X12063 measurement +Blood pressure diastolic blood pressure|| systolic blood pressure GCST004705 diastolic blood pressure|| systolic blood pressure +Blood pressure (age interaction) blood pressure|| age at assessment GCST002495 blood pressure|| age at assessment +Blood pressure (anthropometric measures interaction) anthropometric measurement|| diastolic blood pressure|| systolic blood pressure GCST002471 anthropometric measurement|| diastolic blood pressure|| systolic blood pressure +Blood pressure (response to antihypertensive medication) blood pressure|| response to antihypertensive drug GCST002262 blood pressure|| response to antihypertensive drug +Blood pressure (smoking interaction) pack-years measurement|| smoking behavior|| smoking status measurement|| diastolic blood pressure|| systolic blood pressure|| blood pressure|| smoking behaviour measurement|| cigarettes per day measurement GCST002587 pack-years measurement|| smoking behavior|| smoking status measurement|| diastolic blood pressure|| systolic blood pressure|| blood pressure|| smoking behaviour measurement|| cigarettes per day measurement +Blood pressure measurement (cold pressor test) blood pressure|| response to cold pressor test GCST002247 blood pressure|| response to cold pressor test +Blood pressure measurement (high sodium and potassium intervention) blood pressure|| response to high sodium diet|| response to dietary potassium supplementation GCST002252 blood pressure|| response to high sodium diet|| response to dietary potassium supplementation +Blood pressure measurement (high sodium intervention) blood pressure|| response to high sodium diet GCST002249 blood pressure|| response to high sodium diet +Blood pressure measurement (low sodium intervention) blood pressure|| response to low sodium diet GCST002250 blood pressure|| response to low sodium diet +Blood pressure traits (multi-trait analysis) pulse pressure measurement|| diastolic blood pressure|| systolic blood pressure|| hypertension GCST004388 pulse pressure measurement|| diastolic blood pressure|| systolic blood pressure|| hypertension +BMI (adjusted for smoking behaviour) smoking behavior|| body mass index GCST004495 smoking behavior|| body mass index +BMI (smoking interaction) smoking behavior|| body mass index GCST004496 smoking behavior|| body mass index +BMI x dairy intake interaction (1df interaction test) energy intake|| body mass index GCST006173 energy intake|| body mass index +Body mass index physical activity measurement|| body mass index GCST004557 physical activity measurement|| body mass index +Body mass index (smoking years interaction) smoking behaviour measurement|| body mass index GCST004581 smoking behaviour measurement|| body mass index +Body mass index (alcohol intake interaction) alcohol consumption measurement|| body mass index GCST001753 alcohol consumption measurement|| body mass index +Body mass index (dietary energy interaction) diet measurement|| body mass index GCST004587 diet measurement|| body mass index +Body mass index (ever vs never smoking interaction) smoking behaviour measurement|| body mass index GCST004586 smoking behaviour measurement|| body mass index +Body mass index (joint analysis main effects and physical activity interaction) physical activity measurement|| body mass index GCST004558 physical activity measurement|| body mass index +Body mass index (joint analysis main effects and smoking interaction) smoking behavior|| body mass index GCST004497 smoking behavior|| body mass index +Body mass index (physical activity interaction) physical activity measurement|| body mass index GCST004568 physical activity measurement|| body mass index +Body mass index (recreational physical activity interaction) physical activity measurement|| body mass index GCST004580 physical activity measurement|| body mass index +Body mass index (sex interaction) sex interaction measurement|| body mass index GCST000930 sex interaction measurement|| body mass index +Body mass index and cholesterol (psychopharmacological treatment) total cholesterol measurement|| response to drug|| body mass index GCST001440 total cholesterol measurement|| response to drug|| body mass index +Body mass index and fat mass adipose tissue measurement|| body mass index GCST000443 adipose tissue measurement|| body mass index +Body mass index and waist-hip ratio (pleiotropy) waist-hip ratio|| body mass index GCST006430 waist-hip ratio|| body mass index +Body mass index x age interaction body mass index|| age at assessment GCST005954 body mass index|| age at assessment +Body mass index x sex interaction sex interaction measurement|| body mass index GCST005949 sex interaction measurement|| body mass index +Body mass index x sex x age interaction sex interaction measurement|| body mass index|| age at assessment GCST005955 sex interaction measurement|| body mass index|| age at assessment +Body mass index x sex x age interaction (4df test) sex interaction measurement|| body mass index|| age at assessment GCST005950 sex interaction measurement|| body mass index|| age at assessment +Bone mineral density (hip) and age at menarche hip bone mineral density|| age at menarche GCST003102 hip bone mineral density|| age at menarche +Bone mineral density (sex interaction) sex interaction measurement|| bone density GCST001566 sex interaction measurement|| bone density +Bone mineral density (spine) and age at menarche age at menarche|| spine bone mineral density GCST003101 age at menarche|| spine bone mineral density +Brain structure (hippocampal volume) brain measurement|| hippocampal volume GCST000615 brain measurement|| hippocampal volume +Breast cancer (menopausal hormone therapy interaction) breast carcinoma|| hormone replacement therapy GCST002265 breast carcinoma|| hormone replacement therapy +Breast cancer (menopausal hormone therapy interaction) breast carcinoma|| hormone replacement therapy GCST001869 breast carcinoma|| hormone replacement therapy +Breast cancer and/or colorectal cancer colorectal cancer|| breast carcinoma GCST006035 colorectal cancer|| breast carcinoma +Breast milk fatty acid composition (infant genotype effect) fatty acid measurement|| fetal genotype effect measurement|| breast milk measurement GCST005587 fatty acid measurement|| fetal genotype effect measurement|| breast milk measurement +Breast milk fatty acid composition (maternal genotype effect) fatty acid measurement|| breast milk measurement|| parental genotype effect measurement GCST005586 fatty acid measurement|| breast milk measurement|| parental genotype effect measurement +Burning and freckling freckles|| sunburn GCST000196 freckles|| sunburn +C-reactive protein (red blood cell fatty acid level interaction) fatty acid measurement|| C-reactive protein measurement GCST004815 fatty acid measurement|| C-reactive protein measurement +C-reactive protein and white blood cell count leukocyte count|| C-reactive protein measurement GCST001605 leukocyte count|| C-reactive protein measurement +C-reactive protein levels or HDL-cholesterol levels (pleiotropy) C-reactive protein measurement|| high density lipoprotein cholesterol measurement GCST003680 C-reactive protein measurement|| high density lipoprotein cholesterol measurement +C-reactive protein levels or LDL-cholesterol levels (pleiotropy) low density lipoprotein cholesterol measurement|| C-reactive protein measurement GCST003679 low density lipoprotein cholesterol measurement|| C-reactive protein measurement +C-reactive protein levels or total cholesterol levels (pleiotropy) total cholesterol measurement|| C-reactive protein measurement GCST003678 total cholesterol measurement|| C-reactive protein measurement +C-reactive protein levels or triglyceride levels (pleiotropy) triglyceride measurement|| C-reactive protein measurement GCST003681 triglyceride measurement|| C-reactive protein measurement +Calcific aortic valve stenosis aortic stenosis|| aortic valve calcification GCST005785 aortic stenosis|| aortic valve calcification +Cancer cancer|| lung carcinoma|| estrogen-receptor negative breast cancer|| colorectal cancer|| ovarian endometrioid carcinoma|| prostate carcinoma|| ovarian serous carcinoma|| breast carcinoma|| ovarian carcinoma|| lung adenocarcinoma|| squamous cell lung carcinoma GCST003587 cancer|| lung carcinoma|| estrogen-receptor negative breast cancer|| colorectal cancer|| ovarian endometrioid carcinoma|| prostate carcinoma|| ovarian serous carcinoma|| breast carcinoma|| ovarian carcinoma|| lung adenocarcinoma|| squamous cell lung carcinoma +Cancer (pleiotropy) cancer|| lung carcinoma|| estrogen-receptor negative breast cancer|| colorectal cancer|| ovarian endometrioid carcinoma|| prostate carcinoma|| ovarian serous carcinoma|| breast carcinoma|| ovarian carcinoma|| lung adenocarcinoma|| squamous cell lung carcinoma GCST003588 cancer|| lung carcinoma|| estrogen-receptor negative breast cancer|| colorectal cancer|| ovarian endometrioid carcinoma|| prostate carcinoma|| ovarian serous carcinoma|| breast carcinoma|| ovarian carcinoma|| lung adenocarcinoma|| squamous cell lung carcinoma +Carbamazepine-induced maculopapular exanthema maculopapular eruption|| response to carbamazepine GCST005198 maculopapular eruption|| response to carbamazepine +Cardiac muscle measurement cardiovascular measurement|| left ventricular hypertrophy GCST000936 cardiovascular measurement|| left ventricular hypertrophy +Cardiovascular disease risk factors aspartate aminotransferase measurement|| butyrylcholinesterase measurement|| triglyceride measurement|| ferritin measurement|| serum gamma-glutamyl transferase measurement|| low density lipoprotein cholesterol measurement|| C-reactive protein measurement|| uric acid measurement|| high density lipoprotein cholesterol measurement GCST001247 aspartate aminotransferase measurement|| butyrylcholinesterase measurement|| triglyceride measurement|| ferritin measurement|| serum gamma-glutamyl transferase measurement|| low density lipoprotein cholesterol measurement|| C-reactive protein measurement|| uric acid measurement|| high density lipoprotein cholesterol measurement +Cardiovascular risk factors waist circumference|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| cardiovascular disease|| high density lipoprotein cholesterol measurement GCST004704 waist circumference|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| cardiovascular disease|| high density lipoprotein cholesterol measurement +Cardiovascular risk factors (age interaction) waist circumference|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| cardiovascular disease|| high density lipoprotein cholesterol measurement|| age at assessment GCST000789 waist circumference|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| cardiovascular disease|| high density lipoprotein cholesterol measurement|| age at assessment +Carotenoid and tocopherol levels carotenoid measurement|| tocopherol measurement GCST000324 carotenoid measurement|| tocopherol measurement +Carotid artery intima media thickness (sex interaction) sex interaction measurement|| carotid artery intima media thickness GCST002856 sex interaction measurement|| carotid artery intima media thickness +Carotid plaque burden (smoking interaction) smoking behaviour measurement|| carotid plaque build GCST002482 smoking behaviour measurement|| carotid plaque build +Caudate activity during disappointment caudate nucleus measurement|| response to disappointment|| functional brain measurement GCST004969 caudate nucleus measurement|| response to disappointment|| functional brain measurement +Caudate activity during reward caudate nucleus measurement|| functional brain measurement|| response to reward GCST004970 caudate nucleus measurement|| functional brain measurement|| response to reward +Cellular adhesion molecule (red blood cell fatty acid level interaction) fatty acid measurement|| cellular adhesion molecule measurement GCST004820 fatty acid measurement|| cellular adhesion molecule measurement +Cerebrospinal fluid AB1-42 levels beta-amyloid 1-42 measurement|| cerebrospinal fluid biomarker measurement GCST003072 beta-amyloid 1-42 measurement|| cerebrospinal fluid biomarker measurement +Cerebrospinal fluid levels of Alzheimer's disease-related proteins matrix metalloproteinase measurement|| angiotensin-converting enzyme measurement|| Alzheimer's disease|| CCL4 measurement|| interleukin-6 measurement|| Alzheimer's disease biomarker measurement|| CCL2 measurement GCST002665 matrix metalloproteinase measurement|| angiotensin-converting enzyme measurement|| Alzheimer's disease|| CCL4 measurement|| interleukin-6 measurement|| Alzheimer's disease biomarker measurement|| CCL2 measurement +Cerebrospinal fluid α-synuclein levels cerebrospinal fluid biomarker measurement|| alpha synuclein measurement GCST006279 cerebrospinal fluid biomarker measurement|| alpha synuclein measurement +Cerebrospinal P-tau181p levels p-tau measurement|| cerebrospinal fluid biomarker measurement GCST003071 p-tau measurement|| cerebrospinal fluid biomarker measurement +Cerebrospinal T-tau levels cerebrospinal fluid biomarker measurement|| t-tau measurement GCST003070 cerebrospinal fluid biomarker measurement|| t-tau measurement +Cerivastatin-induced rhabdomyolysis response to statin|| rhabdomyolysis GCST001002 response to statin|| rhabdomyolysis +Childhood onset asthma (traffic air pollution exposure interaction) childhood onset asthma|| traffic air pollution measurement GCST003975 childhood onset asthma|| traffic air pollution measurement +Childhood onset systemic lupus erythematosus age at onset|| systemic lupus erythematosus GCST006260 age at onset|| systemic lupus erythematosus +Cholesterol and Triglycerides triglyceride measurement|| high density lipoprotein cholesterol measurement GCST001704 triglyceride measurement|| high density lipoprotein cholesterol measurement +Chronic alcoholic pancreatitis or alcohol-related cirrhosis alcoholic liver cirrhosis|| alcoholic pancreatitis GCST004755 alcoholic liver cirrhosis|| alcoholic pancreatitis +Chronic bronchitis and chronic obstructive pulmonary disease chronic obstructive pulmonary disease|| chronic bronchitis GCST002625 chronic obstructive pulmonary disease|| chronic bronchitis +"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)" ankylosing spondylitis|| psoriasis|| ulcerative colitis|| Crohn's disease|| sclerosing cholangitis GCST005537 ankylosing spondylitis|| psoriasis|| ulcerative colitis|| Crohn's disease|| sclerosing cholangitis +Chronic kidney disease cystatin C measurement|| chronic kidney disease|| serum creatinine measurement GCST000649 cystatin C measurement|| chronic kidney disease|| serum creatinine measurement +Chronic kidney disease and serum creatinine levels chronic kidney disease|| serum creatinine measurement GCST000742 chronic kidney disease|| serum creatinine measurement +Chronic obstructive pulmonary disease-related biomarkers tumor necrosis factor-alpha measurement|| interleukin-6 measurement|| chronic obstructive pulmonary disease|| interleukin-8 measurement|| fibrinogen measurement|| C-reactive protein measurement|| CC16 measurement|| surfactant protein D measurement GCST001737 tumor necrosis factor-alpha measurement|| interleukin-6 measurement|| chronic obstructive pulmonary disease|| interleukin-8 measurement|| fibrinogen measurement|| C-reactive protein measurement|| CC16 measurement|| surfactant protein D measurement +Chronic venous disease chronic venous insufficiency|| Varicose veins GCST004343 chronic venous insufficiency|| Varicose veins +Chylomicron and largest VLDL particle concentration chylomicron measurement|| very low density lipoprotein cholesterol measurement GCST005510 chylomicron measurement|| very low density lipoprotein cholesterol measurement +Cingulate cortical amyloid beta load amyloid-beta measurement|| cingulate cortex measurement GCST003113 amyloid-beta measurement|| cingulate cortex measurement +Circulating chromogranin peptide levels CHGB cleavage product measurement|| CHGA cleavage product measurement GCST004038 CHGB cleavage product measurement|| CHGA cleavage product measurement +Cisplatin-induced ototoxicity ototoxicity|| response to cisplatin GCST003898 ototoxicity|| response to cisplatin +Cleft lip with or without cleft palate cleft palate|| cleft lip GCST004050 cleft palate|| cleft lip +Cleft lip with or without cleft palate (maternal periconceptional alcohol intake interaction) cleft lip|| alcohol exposure measurement GCST005653 cleft lip|| alcohol exposure measurement +Cleft lip with or without cleft palate (maternal periconceptional cigarette smoking interaction) tobacco smoke exposure measurement|| cleft lip GCST005654 tobacco smoke exposure measurement|| cleft lip +Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction) vitamin supplement exposure measurement|| cleft lip GCST005652 vitamin supplement exposure measurement|| cleft lip +Cleft plate (environmental tobacco smoke interaction) cleft palate|| environmental tobacco smoke exposure measurement GCST002348 cleft palate|| environmental tobacco smoke exposure measurement +Clinical laboratory measurements alkaline phosphatase measurement|| calcium measurement|| hemoglobin measurement|| clinical laboratory measurement|| mean corpuscular hemoglobin|| glucose measurement|| erythrocyte measurement|| bilirubin measurement GCST003540 alkaline phosphatase measurement|| calcium measurement|| hemoglobin measurement|| clinical laboratory measurement|| mean corpuscular hemoglobin|| glucose measurement|| erythrocyte measurement|| bilirubin measurement +Clozapine-induced agranulocytosis drug-induced agranulocytosis|| response to clozapine GCST002595 drug-induced agranulocytosis|| response to clozapine +Clozapine-induced cytotoxicity cytotoxicity measurement|| response to clozapine GCST002777 cytotoxicity measurement|| response to clozapine +Cluster headache smoking status measurement|| cluster headache GCST003900 smoking status measurement|| cluster headache +Coffee consumption coffee consumption|| cups of coffee per day measurement GCST003621 coffee consumption|| cups of coffee per day measurement +Coffee consumption (cups per day) coffee consumption|| cups of coffee per day measurement GCST002650 coffee consumption|| cups of coffee per day measurement +Cognitive ability (MTAG) intelligence|| self reported educational attainment GCST005141 intelligence|| self reported educational attainment +Cognitive impairment (brain beta-amyloid deposition interaction) cognitive impairment|| cerebral amyloid deposition measurement GCST003399 cognitive impairment|| cerebral amyloid deposition measurement +Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement Stevens-Johnson syndrome|| toxic epidermal necrolysis|| response to cold medicine GCST002779 Stevens-Johnson syndrome|| toxic epidermal necrolysis|| response to cold medicine +Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications Stevens-Johnson syndrome|| toxic epidermal necrolysis|| response to cold medicine GCST004072 Stevens-Johnson syndrome|| toxic epidermal necrolysis|| response to cold medicine +Colorectal cancer (alcohol consumption interaction) colorectal cancer|| alcohol consumption measurement GCST003873 colorectal cancer|| alcohol consumption measurement +Colorectal cancer (aspirin and/or NSAID use interaction) drug use measurement|| aspirin use measurement|| NSAID use measurement|| colorectal cancer GCST002816 drug use measurement|| aspirin use measurement|| NSAID use measurement|| colorectal cancer +Colorectal cancer (calcium intake interaction) calcium intake measurement|| colorectal cancer GCST002596 calcium intake measurement|| colorectal cancer +Colorectal cancer (diet interaction) colorectal cancer|| diet measurement GCST002415 colorectal cancer|| diet measurement +Colorectal cancer (environment interaction) smoking status measurement|| colorectal cancer|| alcohol consumption measurement|| overweight body mass index status GCST001731 smoking status measurement|| colorectal cancer|| alcohol consumption measurement|| overweight body mass index status +Colorectal cancer (menopausal hormone therapy interaction) colorectal cancer|| hormone replacement therapy GCST003385 colorectal cancer|| hormone replacement therapy +Colorectal cancer (oestrogen hormone therapy interaction) colorectal cancer|| hormone replacement therapy GCST003387 colorectal cancer|| hormone replacement therapy +Colorectal cancer (oestrogen-progestogen hormone therapy interaction) colorectal cancer|| hormone replacement therapy GCST003386 colorectal cancer|| hormone replacement therapy +Colorectal cancer (smoking interaction) smoking status measurement|| colorectal cancer GCST003874 smoking status measurement|| colorectal cancer +Colorectal or endometrial cancer colorectal cancer|| endometrial neoplasm GCST003209 colorectal cancer|| endometrial neoplasm +Colorectal or endometrial cancer colorectal cancer|| endometrial neoplasm GCST003208 colorectal cancer|| endometrial neoplasm +Common traits (Other) sensory perception of taste|| functional laterality|| hair morphology|| circadian rhythm|| personality|| braces|| sensory perception of smell|| Attached earlobe|| Astigmatism|| Sneeze GCST000706 sensory perception of taste|| functional laterality|| hair morphology|| circadian rhythm|| personality|| braces|| sensory perception of smell|| Attached earlobe|| Astigmatism|| Sneeze +Complement C3 and C4 levels complement C4 measurement|| complement C3 measurement GCST001679 complement C4 measurement|| complement C3 measurement +Comprehensive strength and appendicular lean mass comprehensive strength index|| muscle measurement GCST001656 comprehensive strength index|| muscle measurement +Conduct disorder (maternal expressed emotions interaction) parental emotion expression measurmement|| conduct disorder GCST000245 parental emotion expression measurmement|| conduct disorder +Congenital left-sided heart lesions (maternal effect) congenital left-sided heart lesions|| parental genotype effect measurement GCST002574 congenital left-sided heart lesions|| parental genotype effect measurement +Coronary artery calcification (smoking interaction) smoking status measurement|| coronary artery calcification GCST002213 smoking status measurement|| coronary artery calcification +Coronary artery disease and/or body mass index (pleiotropy) body mass index|| coronary artery disease GCST004838 body mass index|| coronary artery disease +Coronary artery disease or ischemic stroke stroke|| coronary heart disease GCST002287 stroke|| coronary heart disease +Coronary artery disease or large artery stroke large artery stroke|| coronary heart disease GCST002290 large artery stroke|| coronary heart disease +Coronary artery disease-related phenotypes coronary heart disease|| angiographic measurement GCST002659 coronary heart disease|| angiographic measurement +Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction) coronary atheroscleroris measurement|| traffic air pollution measurement GCST004224 coronary atheroscleroris measurement|| traffic air pollution measurement +Coronary heart disease event reduction (statin therapy interaction) response to statin|| coronary heart disease GCST001545 response to statin|| coronary heart disease +Coronary heart disease events during statin therapy response to statin|| cardiovascular event measurement GCST006217 response to statin|| cardiovascular event measurement +Corrected insulin response adjusted for insulin sensitivity index insulin sensitivity measurement|| insulin response measurement GCST005216 insulin sensitivity measurement|| insulin response measurement +Corticobasal degeneration and immune-mediated diseases (pleiotropy) Corticobasal degeneration|| rheumatoid arthritis|| type I diabetes mellitus|| psoriasis|| celiac disease|| ulcerative colitis|| Crohn's disease GCST005322 Corticobasal degeneration|| rheumatoid arthritis|| type I diabetes mellitus|| psoriasis|| celiac disease|| ulcerative colitis|| Crohn's disease +Corticosteroid-induced adrenal suppression (peak cortisol < 350 nmol/L) adrenal suppression measurement|| response to corticosteroid GCST005927 adrenal suppression measurement|| response to corticosteroid +Corticosteroid-induced adrenal suppression (peak cortisol < 500 nmol/L) adrenal suppression measurement|| response to corticosteroid GCST005924 adrenal suppression measurement|| response to corticosteroid +Crohn's disease and celiac disease celiac disease|| Crohn's disease GCST000955 celiac disease|| Crohn's disease +Crohn's disease and psoriasis psoriasis|| Crohn's disease GCST001473 psoriasis|| Crohn's disease +Crohn's disease and sarcoidosis (combined) Sarcoidosis|| Crohn's disease GCST000212 Sarcoidosis|| Crohn's disease +Crohn's disease-related phenotypes stricture|| ileocolitis|| erythema nodosum|| perianal Crohn's disease|| Crohn's disease|| mild disease course|| complicated disease course GCST002729 stricture|| ileocolitis|| erythema nodosum|| perianal Crohn's disease|| Crohn's disease|| mild disease course|| complicated disease course +Cutaneous psoriasis cutaneous psoriasis measurement|| psoriasis GCST003269 cutaneous psoriasis measurement|| psoriasis +Cystic fibrosis-related diabetes Cystic fibrosis|| type II diabetes mellitus GCST002025 Cystic fibrosis|| type II diabetes mellitus +Cytokine and corticosteroid-stimulated IL-6 production interleukin-6 measurement|| response to corticosteroid|| response to cytokine GCST002858 interleukin-6 measurement|| response to corticosteroid|| response to cytokine +Cytokine-stimulated IL-6 production interleukin-6 measurement|| response to cytokine GCST002859 interleukin-6 measurement|| response to cytokine +Delta-5 desaturase activity response to n3-polyunsaturated fat supplement delta-5 desaturase measurement|| response to polyunsaturated fatty acid supplementation GCST005668 delta-5 desaturase measurement|| response to polyunsaturated fatty acid supplementation +Delta-6 desaturase activity response to n3-polyunsaturated fat supplement delta-6 desaturase measurement|| response to polyunsaturated fatty acid supplementation GCST005669 delta-6 desaturase measurement|| response to polyunsaturated fatty acid supplementation +Dementia and core Alzheimer's disease neuropathologic changes dementia|| Alzheimer's disease neuropathologic change GCST002593 dementia|| Alzheimer's disease neuropathologic change +Depressed affect unipolar depression|| mood disorder GCST006475 unipolar depression|| mood disorder +Depression unipolar depression|| depressive symptom measurement GCST003769 unipolar depression|| depressive symptom measurement +Depressive symptom measurement or major depressive disorder unipolar depression|| depressive symptom measurement GCST004024 unipolar depression|| depressive symptom measurement +Depressive symptoms (SSRI exposure interaction) drug use measurement|| depressive symptom measurement|| SSRI use measurement GCST002755 drug use measurement|| depressive symptom measurement|| SSRI use measurement +Depressive symptoms (stressful life events interaction) depressive symptom measurement|| stressful life event measurement GCST003835 depressive symptom measurement|| stressful life event measurement +Dermatomyositis or juvenile dermatomyositis dermatomyositis|| juvenile dermatomyositis GCST006053 dermatomyositis|| juvenile dermatomyositis +Developmental language disorder (linguistic errors) linguistic error measurement|| specific language impairment GCST003397 linguistic error measurement|| specific language impairment +Developmental language disorder (syntactic complexity) syntactic complexity measurement|| specific language impairment GCST003398 syntactic complexity measurement|| specific language impairment +Diabetes related insulin traits insulin sensitivity measurement|| A1C measurement|| insulin resistance|| fasting blood insulin measurement GCST000077 insulin sensitivity measurement|| A1C measurement|| insulin resistance|| fasting blood insulin measurement +Diastolic blood pressure (alcohol consumption interaction) diastolic blood pressure|| alcohol drinking GCST002309 diastolic blood pressure|| alcohol drinking +Diastolic blood pressure (cigarette smoking interaction) smoking status measurement|| diastolic blood pressure GCST006187 smoking status measurement|| diastolic blood pressure +Diastolic blood pressure (cigarette smoking interaction) diastolic blood pressure|| smoking behaviour measurement GCST003366 diastolic blood pressure|| smoking behaviour measurement +Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test) diastolic blood pressure|| alcohol consumption measurement GCST006169 diastolic blood pressure|| alcohol consumption measurement +Diastolic blood pressure x alcohol consumption interaction (2df test) diastolic blood pressure|| alcohol drinking GCST006166 diastolic blood pressure|| alcohol drinking +Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test) smoking status measurement|| diastolic blood pressure GCST006194 smoking status measurement|| diastolic blood pressure +Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test) smoking status measurement|| diastolic blood pressure GCST006193 smoking status measurement|| diastolic blood pressure +Diastolic blood pressure x smoking status (ever vs never) interaction (1df test) smoking status measurement|| diastolic blood pressure GCST006191 smoking status measurement|| diastolic blood pressure +Diastolic blood pressure x smoking status (ever vs never) interaction (2df test) smoking status measurement|| diastolic blood pressure GCST006190 smoking status measurement|| diastolic blood pressure +Diastolic blood pressure x sodium interaction (1df test) sodium measurement|| diastolic blood pressure GCST006112 sodium measurement|| diastolic blood pressure +Diastolic blood pressure x sodium interaction (2df test) sodium measurement|| diastolic blood pressure GCST006111 sodium measurement|| diastolic blood pressure +Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) esophageal adenocarcinoma|| digestive system disease|| Barrett's esophagus GCST002231 esophageal adenocarcinoma|| digestive system disease|| Barrett's esophagus +Diisocyanate-induced asthma response to diisocyanate|| asthma GCST002875 response to diisocyanate|| asthma +Drug-induced liver injury response to flupirtine|| drug-induced liver injury GCST003426 response to flupirtine|| drug-induced liver injury +Drug-induced liver injury (anti-tuberculosis drugs) response to anti-tuberculosis drug|| drug-induced liver injury GCST004084 response to anti-tuberculosis drug|| drug-induced liver injury +Drug-induced liver injury (diclofenac) response to diclofenac|| drug-induced liver injury GCST004083 response to diclofenac|| drug-induced liver injury +Drug-induced liver injury (fluoroquinolones) response to fluoroquinolones|| drug-induced liver injury GCST004085 response to fluoroquinolones|| drug-induced liver injury +Drug-induced liver injury (nitrofurantoin) response to nitrofurantoin|| drug-induced liver injury GCST004082 response to nitrofurantoin|| drug-induced liver injury +Drug-induced liver injury (nonsteroidal anti-inflammatory drugs) response to non-steroidal anti-inflammatory|| drug-induced liver injury GCST004087 response to non-steroidal anti-inflammatory|| drug-induced liver injury +Drug-induced liver injury (statins) response to statin|| drug-induced liver injury GCST004080 response to statin|| drug-induced liver injury +Drug-induced liver injury (terbinafine) drug-induced liver injury|| response to terbinafine GCST004078 drug-induced liver injury|| response to terbinafine +Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN) Stevens-Johnson syndrome|| toxic epidermal necrolysis GCST001181 Stevens-Johnson syndrome|| toxic epidermal necrolysis +Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN) Stevens-Johnson syndrome|| toxic epidermal necrolysis GCST000942 Stevens-Johnson syndrome|| toxic epidermal necrolysis +Drug-induced torsades de pointes torsades de pointes|| response to drug GCST002269 torsades de pointes|| response to drug +Early gestational weight gain (fetal effect) early gestational weight gain|| fetal genotype effect measurement GCST005032 early gestational weight gain|| fetal genotype effect measurement +Echocardiographic traits cardiovascular measurement|| left ventricular function|| left atrial function GCST000110 cardiovascular measurement|| left ventricular function|| left atrial function +Egg allergy (maternal genetic effects) egg allergy measurement|| parental genotype effect measurement GCST005728 egg allergy measurement|| parental genotype effect measurement +Egg allergy (parent-of-origin effect) egg allergy measurement|| parental genotype effect measurement GCST005725 egg allergy measurement|| parental genotype effect measurement +Electrocardiographic traits QRS complex|| QRS duration|| electrocardiography|| PR interval|| heart rate|| QT interval GCST000561 QRS complex|| QRS duration|| electrocardiography|| PR interval|| heart rate|| QT interval +Electrodermal activity skin conductance level|| skin conductance response frequency|| electrodermal activity measurement|| skin conductance response amplitude GCST002706 skin conductance level|| skin conductance response frequency|| electrodermal activity measurement|| skin conductance response amplitude +Electroencephalogram traits theta wave measurement|| delta wave measurement|| alpha peak frequency measurement|| alpha wave measurement|| electroencephalogram measurement|| beta wave measurement GCST002709 theta wave measurement|| delta wave measurement|| alpha peak frequency measurement|| alpha wave measurement|| electroencephalogram measurement|| beta wave measurement +End stage renal disease x APOL1 genotype interaction chronic kidney disease|| APOL1 risk genotype carrier status GCST006813 chronic kidney disease|| APOL1 risk genotype carrier status +End-stage coagulation factor VIII measurement|| von Willebrand factor measurement|| coagulation factor measurement GCST001798 factor VIII measurement|| von Willebrand factor measurement|| coagulation factor measurement +Endometriosis or endometrial cancer (pleiotropy) endometrial carcinoma|| endometriosis GCST005906 endometrial carcinoma|| endometriosis +Endothelial growth factor levels endothelial growth factor measurement|| angiopoietin-2 receptor measurement|| angiopoietin-2 measurement|| hepatocyte growth factor measurement GCST002731 endothelial growth factor measurement|| angiopoietin-2 receptor measurement|| angiopoietin-2 measurement|| hepatocyte growth factor measurement +Entorhinal cortical thickness (Alzheimer's disease interaction) Alzheimer's disease|| cortical thickness GCST000889 Alzheimer's disease|| cortical thickness +Entorhinal cortical volume (Alzheimer's disease interaction) Alzheimer's disease|| entorhinal cortical volume GCST000893 Alzheimer's disease|| entorhinal cortical volume +Epilepsy (remission after treatment) response to drug|| epilepsy GCST002141 response to drug|| epilepsy +Epilepsy and lamotrigine-induced maculopapular eruptions response to lamotrigine|| maculopapular eruption|| epilepsy GCST002949 response to lamotrigine|| maculopapular eruption|| epilepsy +Epstein Barr virus nuclear antigen 1 IgG levels or multiple sclerosis multiple sclerosis|| Epstein Barr virus nuclear antigen 1 IgG measurement GCST003340 multiple sclerosis|| Epstein Barr virus nuclear antigen 1 IgG measurement +Epstein-Barr virus immune response (EBNA-1) antibody measurement|| Epstein-Barr virus infection GCST001812 antibody measurement|| Epstein-Barr virus infection +Erectile dysfunction and prostate cancer treatment response to radiation|| prostate carcinoma|| erectile dysfunction GCST001700 response to radiation|| prostate carcinoma|| erectile dysfunction +Erectile dysfunction and prostate cancer treatment response to radiation|| prostate carcinoma|| erectile dysfunction GCST000824 response to radiation|| prostate carcinoma|| erectile dysfunction +Esophageal adenocarcinoma x BMI interaction esophageal adenocarcinoma|| body mass index GCST006525 esophageal adenocarcinoma|| body mass index +Esophageal adenocarcinoma x gastroesophageal reflux disease interaction esophageal adenocarcinoma|| gastroesophageal reflux disease GCST006531 esophageal adenocarcinoma|| gastroesophageal reflux disease +Esophageal adenocarcinoma x pack-years of smoking exposure interaction esophageal adenocarcinoma|| pack-years measurement GCST006532 esophageal adenocarcinoma|| pack-years measurement +Esophageal adenocarcinoma x smoking interaction esophageal adenocarcinoma|| smoking status measurement GCST006530 esophageal adenocarcinoma|| smoking status measurement +Esophageal cancer (squamous cell) squamous cell carcinoma|| esophageal carcinoma GCST001674 squamous cell carcinoma|| esophageal carcinoma +Esophageal cancer and gastric cancer esophageal carcinoma|| gastric carcinoma GCST000777 esophageal carcinoma|| gastric carcinoma +Exhaled carbon monoxide levels smoking behavior|| carbon monoxide exhalation measurement GCST002584 smoking behavior|| carbon monoxide exhalation measurement +"Facial morphology (factor 13, vertical position of alar curvature relative to upper lip)" nose morphology measurement|| mouth morphology measurement GCST004317 nose morphology measurement|| mouth morphology measurement +Familial lung adenocarcinoma lung adenocarcinoma|| family history of lung cancer GCST006087 lung adenocarcinoma|| family history of lung cancer +Familial lung cancer lung carcinoma|| family history of lung cancer GCST006086 lung carcinoma|| family history of lung cancer +Familial squamous cell lung carcinoma squamous cell lung carcinoma|| family history of lung cancer GCST006088 squamous cell lung carcinoma|| family history of lung cancer +Fast beta electroencephalogram alcohol dependence measurement|| electroencephalogram measurement GCST003902 alcohol dependence measurement|| electroencephalogram measurement +Fasting blood glucose (BMI interaction) body mass index|| fasting blood glucose measurement GCST001527 body mass index|| fasting blood glucose measurement +Fasting blood insulin (BMI interaction) body mass index|| fasting blood insulin measurement GCST001526 body mass index|| fasting blood insulin measurement +Fasting insulin (dietary factor interaction) diet measurement|| fasting blood insulin measurement GCST002248 diet measurement|| fasting blood insulin measurement +Femoral neck bone mineral density or breast cancer (pleiotropy) breast carcinoma|| femoral neck bone mineral density GCST004836 breast carcinoma|| femoral neck bone mineral density +Femoral neck bone mineral density or plasma lipids (pleiotropy) lipid measurement|| femoral neck bone mineral density GCST005317 lipid measurement|| femoral neck bone mineral density +Femoral neck bone mineral density or type 2 diabetes (pleiotropy) type II diabetes mellitus|| femoral neck bone mineral density GCST006861 type II diabetes mellitus|| femoral neck bone mineral density +"Fibrinogen levels (smoking status, alcohol consumption or body mass index interaction)" smoking status measurement|| alcohol drinking|| fibrinogen measurement|| body mass index GCST002734 smoking status measurement|| alcohol drinking|| fibrinogen measurement|| body mass index +Folate pathway vitamin levels vitamin B measurement|| vitamin B12 measurement|| vitamin B6 measurement GCST000358 vitamin B measurement|| vitamin B12 measurement|| vitamin B6 measurement +Food addiction eating behaviour|| food addiction measurement GCST003489 eating behaviour|| food addiction measurement +Food allergy (maternal genetic effects) food allergy measurement|| parental genotype effect measurement GCST005724 food allergy measurement|| parental genotype effect measurement +Food allergy (parent-of-origin effect) food allergy measurement|| parental genotype effect measurement GCST005721 food allergy measurement|| parental genotype effect measurement +Food antigen IgG levels serum IgG measurement|| response to dietary antigen GCST002518 serum IgG measurement|| response to dietary antigen +Forced expiratory volume in 1 second (environmental tobacco smoke interaction) forced expiratory volume|| environmental tobacco smoke exposure measurement GCST004800 forced expiratory volume|| environmental tobacco smoke exposure measurement +Forced expiratory volume in 1 second (occupational environmental exposures interaction) response to biological dust exposure|| response to gases and fumes exposure|| forced expiratory volume|| response to mineral dust exposure GCST002955 response to biological dust exposure|| response to gases and fumes exposure|| forced expiratory volume|| response to mineral dust exposure +Free cholesterol levels in IDL free cholesterol measurement|| intermediate density lipoprotein measurement GCST005479 free cholesterol measurement|| intermediate density lipoprotein measurement +Free cholesterol levels in large HDL free cholesterol measurement|| high density lipoprotein cholesterol measurement GCST005502 free cholesterol measurement|| high density lipoprotein cholesterol measurement +Free cholesterol levels in large LDL free cholesterol measurement|| low density lipoprotein cholesterol measurement GCST005485 free cholesterol measurement|| low density lipoprotein cholesterol measurement +Free cholesterol levels in large VLDL free cholesterol measurement|| very low density lipoprotein cholesterol measurement GCST005459 free cholesterol measurement|| very low density lipoprotein cholesterol measurement +Free cholesterol levels in medium VLDL free cholesterol measurement|| very low density lipoprotein cholesterol measurement GCST005466 free cholesterol measurement|| very low density lipoprotein cholesterol measurement +Free cholesterol levels in small VLDL free cholesterol measurement|| very low density lipoprotein cholesterol measurement GCST005471 free cholesterol measurement|| very low density lipoprotein cholesterol measurement +Free cholesterol levels in very large HDL free cholesterol measurement|| high density lipoprotein cholesterol measurement GCST005496 free cholesterol measurement|| high density lipoprotein cholesterol measurement +Frontotemporal dementia and immune-mediated diseases (pleiotropy) rheumatoid arthritis|| psoriasis|| celiac disease|| Frontotemporal dementia|| ulcerative colitis|| Crohn's disease GCST005319 rheumatoid arthritis|| psoriasis|| celiac disease|| Frontotemporal dementia|| ulcerative colitis|| Crohn's disease +Gestational age at birth (child effect) gestational age|| birth measurement GCST003686 gestational age|| birth measurement +Gestational age at birth (maternal effect) gestational age|| birth measurement GCST003688 gestational age|| birth measurement +Gestational age at birth (maternal effect) gestational age|| parental genotype effect measurement GCST004899 gestational age|| parental genotype effect measurement +Gestational age at birth (maternal effect) gestational age|| parental genotype effect measurement GCST004844 gestational age|| parental genotype effect measurement +Gestational weight gain (fetal effect) fetal genotype effect measurement|| gestational weight gain measurement GCST005031 fetal genotype effect measurement|| gestational weight gain measurement +GIP levels in response to oral glucose tolerance test (120 minutes) glucose-dependent insulinotropic peptide measurement|| glucose tolerance test GCST005166 glucose-dependent insulinotropic peptide measurement|| glucose tolerance test +GIP levels in response to oral glucose tolerance test (fasting) glucose-dependent insulinotropic peptide measurement|| glucose tolerance test GCST005167 glucose-dependent insulinotropic peptide measurement|| glucose tolerance test +Glioblastoma central nervous system cancer|| glioblastoma multiforme GCST004349 central nervous system cancer|| glioblastoma multiforme +Glioblastoma (age-stratified) age at onset|| glioblastoma multiforme GCST006480 age at onset|| glioblastoma multiforme +Glioma central nervous system cancer|| glioma GCST004347 central nervous system cancer|| glioma +Glomerular filtration rate (creatinine) glomerular filtration rate|| serum creatinine measurement GCST003371 glomerular filtration rate|| serum creatinine measurement +Glomerular filtration rate (creatinine) glomerular filtration rate|| serum creatinine measurement GCST003372 glomerular filtration rate|| serum creatinine measurement +Glomerular filtration rate (creatinine) glomerular filtration rate|| serum creatinine measurement GCST004292 glomerular filtration rate|| serum creatinine measurement +Glomerular filtration rate (cystatin C) glomerular filtration rate|| cystatin C measurement GCST003375 glomerular filtration rate|| cystatin C measurement +Glomerular filtration rate (cystatin C) glomerular filtration rate|| cystatin C measurement GCST004293 glomerular filtration rate|| cystatin C measurement +GLP-1 levels in response to oral glucose tolerance test (120 minutes) glucagon-like peptide-1 measurement|| glucose tolerance test GCST005165 glucagon-like peptide-1 measurement|| glucose tolerance test +GLP-1 levels in response to oral glucose tolerance test (fasting) glucagon-like peptide-1 measurement|| glucose tolerance test GCST005164 glucagon-like peptide-1 measurement|| glucose tolerance test +Glucagon levels in response to oral glucose tolerance test (120 minutes) glucagon measurement|| glucose tolerance test GCST005163 glucagon measurement|| glucose tolerance test +Glucagon levels in response to oral glucose tolerance test (fasting) glucagon measurement|| glucose tolerance test GCST005162 glucagon measurement|| glucose tolerance test +Glucocorticoid-induced osteonecrosis response to glucocorticoid|| osteonecrosis GCST003084 response to glucocorticoid|| osteonecrosis +Glucocorticoid-induced osteonecrosis (age 10 years and older) response to glucocorticoid|| osteonecrosis GCST003081 response to glucocorticoid|| osteonecrosis +Glucocorticoid-induced osteonecrosis (time dependent analysis) response to glucocorticoid|| osteonecrosis GCST003083 response to glucocorticoid|| osteonecrosis +Glucocorticoid-induced osteonecrosis (time independent analysis) response to glucocorticoid|| osteonecrosis GCST003080 response to glucocorticoid|| osteonecrosis +Glucose homeostasis traits insulin metabolic clearance rate measurement|| disposition index measurement|| insulin sensitivity measurement|| glucose homeostasis measurement|| glucose effectiveness measurement|| acute insulin response measurement GCST002726 insulin metabolic clearance rate measurement|| disposition index measurement|| insulin sensitivity measurement|| glucose homeostasis measurement|| glucose effectiveness measurement|| acute insulin response measurement +Glycemic traits (multi-trait analysis) fasting blood glucose measurement|| glucose tolerance test|| fasting blood insulin measurement GCST006404 fasting blood glucose measurement|| glucose tolerance test|| fasting blood insulin measurement +Glycemic traits (pregnancy) C-peptide measurement|| fasting blood glucose measurement|| glucose tolerance test GCST002110 C-peptide measurement|| fasting blood glucose measurement|| glucose tolerance test +Glycerophospholipid levels glycerophospholipid measurement|| blood metabolite measurement GCST002965 glycerophospholipid measurement|| blood metabolite measurement +Gout vs. Hyperuricemia gout|| hyperuricemia GCST005801 gout|| hyperuricemia +Graft survival time in renal transplantation (donor effect) renal transplant outcome measurement|| donor genotype effect measurement GCST005429 renal transplant outcome measurement|| donor genotype effect measurement +Graft survival time in renal transplantation (donor-recipient interaction) renal transplant outcome measurement|| donor genotype effect measurement GCST005430 renal transplant outcome measurement|| donor genotype effect measurement +Gray matter volume (schizophrenia interaction) schizophrenia|| grey matter volume measurement GCST002203 schizophrenia|| grey matter volume measurement +Gut microbiota (bacterial taxa) gut microbiome measurement|| taxonomic microbiome measurement GCST003875 gut microbiome measurement|| taxonomic microbiome measurement +Hashimoto thyroiditis versus Graves' disease autoimmune thyroid disease|| Hashimoto's thyroiditis|| Graves disease GCST002705 autoimmune thyroid disease|| Hashimoto's thyroiditis|| Graves disease +HDL Cholesterol - Triglycerides (HDLC-TG) triglyceride measurement|| high density lipoprotein cholesterol measurement GCST001005 triglyceride measurement|| high density lipoprotein cholesterol measurement +HDL cholesterol and triglyceride levels triglyceride measurement|| high density lipoprotein cholesterol measurement GCST006682 triglyceride measurement|| high density lipoprotein cholesterol measurement +HDL cholesterol and triglyceride levels (pleiotropy) triglyceride measurement|| high density lipoprotein cholesterol measurement GCST006669 triglyceride measurement|| high density lipoprotein cholesterol measurement +Hearing function (0.25 kHz) hearing threshold measurement|| hearing measurement GCST003039 hearing threshold measurement|| hearing measurement +Hearing function (0.5 kHz) hearing threshold measurement|| hearing measurement GCST003037 hearing threshold measurement|| hearing measurement +Hearing function (1 kHz) hearing threshold measurement|| hearing measurement GCST003041 hearing threshold measurement|| hearing measurement +Hearing function (2 kHz) hearing threshold measurement|| hearing measurement GCST003032 hearing threshold measurement|| hearing measurement +Hearing function (4 kHz) hearing threshold measurement|| hearing measurement GCST003035 hearing threshold measurement|| hearing measurement +Hearing function (8 kHz) hearing threshold measurement|| hearing measurement GCST003034 hearing threshold measurement|| hearing measurement +Hearing function (high tone) pure tone hearing measurement|| hearing measurement GCST003040 pure tone hearing measurement|| hearing measurement +Hearing function (low tone) pure tone hearing measurement|| hearing measurement GCST003036 pure tone hearing measurement|| hearing measurement +Hearing function (medium tone) pure tone hearing measurement|| hearing measurement GCST003033 pure tone hearing measurement|| hearing measurement +Heart rate response to beta blockers response to beta blocker|| heart rate GCST005519 response to beta blocker|| heart rate +Heart rate response to beta blockers (atenolol add-on therapy) response to beta blocker|| heart rate GCST005520 response to beta blocker|| heart rate +Heart rate response to beta blockers (atenolol monotherapy) response to beta blocker|| heart rate GCST005521 response to beta blocker|| heart rate +Heavy vaginal discharge quality of life during menstruation measurement|| vaginal discharge GCST006639 quality of life during menstruation measurement|| vaginal discharge +Hematological and biochemical traits serum albumin measurement|| aspartate aminotransferase measurement|| alkaline phosphatase measurement|| hemoglobin measurement|| serum alanine aminotransferase measurement|| serum gamma-glutamyl transferase measurement|| hematocrit|| creatine kinase measurement|| protein measurement|| uric acid measurement|| high density lipoprotein cholesterol measurement|| serum creatinine measurement GCST000583 serum albumin measurement|| aspartate aminotransferase measurement|| alkaline phosphatase measurement|| hemoglobin measurement|| serum alanine aminotransferase measurement|| serum gamma-glutamyl transferase measurement|| hematocrit|| creatine kinase measurement|| protein measurement|| uric acid measurement|| high density lipoprotein cholesterol measurement|| serum creatinine measurement +Hematological parameters leukocyte count|| erythrocyte count|| mean corpuscular volume|| mean corpuscular hemoglobin|| platelet count GCST000498 leukocyte count|| erythrocyte count|| mean corpuscular volume|| mean corpuscular hemoglobin|| platelet count +Hematology traits hemoglobin measurement|| leukocyte count|| erythrocyte count|| hematocrit GCST001779 hemoglobin measurement|| leukocyte count|| erythrocyte count|| hematocrit +Hematology traits mean corpuscular volume|| mean corpuscular hemoglobin|| platelet count GCST000510 mean corpuscular volume|| mean corpuscular hemoglobin|| platelet count +Hemostatic factors and hematological phenotypes platelet aggregation|| hemoglobin measurement|| erythrocyte count|| mean corpuscular hemoglobin|| blood viscosity|| tissue plasminogen activator measurement|| plasminogen activator inhibitor 1 measurement GCST000080 platelet aggregation|| hemoglobin measurement|| erythrocyte count|| mean corpuscular hemoglobin|| blood viscosity|| tissue plasminogen activator measurement|| plasminogen activator inhibitor 1 measurement +Heparin-induced thrombocytopenia response to heparin|| thrombocytopenia GCST006144 response to heparin|| thrombocytopenia +Heparin-induced thrombocytopenia response to heparin|| thrombocytopenia GCST002722 response to heparin|| thrombocytopenia +Hepatitis B (viral clearance) seroconversion|| hepatitis B infection GCST003718 seroconversion|| hepatitis B infection +Hepatitis B virus-related hepatocellular carcinoma hepatocellular carcinoma|| hepatitis B infection GCST005570 hepatocellular carcinoma|| hepatitis B infection +Hepatitis C induced liver fibrosis hepatitis C infection|| cirrhosis of liver GCST001623 hepatitis C infection|| cirrhosis of liver +Hereditary hemochromatosis-related traits (HFE mutation homozygotes) hereditary hemochromatosis type 1|| transferrin measurement|| serum iron measurement GCST002660 hereditary hemochromatosis type 1|| transferrin measurement|| serum iron measurement +Hexose levels blood metabolite measurement|| hexose measurement GCST002959 blood metabolite measurement|| hexose measurement +Hip bone mineral density and alcohol drinking hip bone mineral density|| alcohol consumption measurement GCST003920 hip bone mineral density|| alcohol consumption measurement +Hip circumference (psychosocial stress interaction) hip circumference|| psychosocial stress measurement GCST002641 hip circumference|| psychosocial stress measurement +Hip circumference adjusted for BMI hip circumference|| body mass index GCST004067 hip circumference|| body mass index +Hip osteoarthritis or femoral neck bone mineral density osteoarthritis|| hip|| femoral neck bone mineral density GCST005229 osteoarthritis|| hip|| femoral neck bone mineral density +Hip osteoarthritis or lumbar spine bone mineral density osteoarthritis|| hip|| spine bone mineral density GCST005226 osteoarthritis|| hip|| spine bone mineral density +Hippocampal volume (Alzheimer's disease interaction) Alzheimer's disease|| hippocampal volume GCST000897 Alzheimer's disease|| hippocampal volume +HIV-1 susceptibility HIV-1 infection|| Susceptibility to viral and mycobacterial infections GCST002818 HIV-1 infection|| Susceptibility to viral and mycobacterial infections +HIV-1 susceptibility HIV-1 infection|| Susceptibility to viral and mycobacterial infections GCST001353 HIV-1 infection|| Susceptibility to viral and mycobacterial infections +HIV-associated neurocognitive disorder (asymptomatic neurocogntive impairment) HIV-associated neurocognitive disorder|| asymptomatic neurocognitive impairment GCST004410 HIV-associated neurocognitive disorder|| asymptomatic neurocognitive impairment +HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment) HIV-associated neurocognitive disorder|| mild neurocognitive disorder|| asymptomatic neurocognitive impairment GCST004411 HIV-associated neurocognitive disorder|| mild neurocognitive disorder|| asymptomatic neurocognitive impairment +HIV-associated neurocognitive disorder (mild neurocognitive disorder) HIV-associated neurocognitive disorder|| mild neurocognitive disorder GCST004408 HIV-associated neurocognitive disorder|| mild neurocognitive disorder +Homeostasis model assessment of beta-cell function (dietary factor interaction) diet measurement|| HOMA-B GCST002251 diet measurement|| HOMA-B +Homeostasis model assessment of insulin resistance (dietary factor interaction) diet measurement|| HOMA-IR GCST002253 diet measurement|| HOMA-IR +Hormone measurements estradiol measurement|| sex hormone-binding globulin measurement|| testosterone measurement GCST002195 estradiol measurement|| sex hormone-binding globulin measurement|| testosterone measurement +Immune reponse to smallpox (secreted IFN-alpha) response to vaccine|| cytokine measurement GCST001538 response to vaccine|| cytokine measurement +Immune reponse to smallpox (secreted IL-10) response to vaccine|| cytokine measurement GCST001534 response to vaccine|| cytokine measurement +Immune reponse to smallpox (secreted IL-12p40) response to vaccine|| cytokine measurement GCST001537 response to vaccine|| cytokine measurement +Immune reponse to smallpox (secreted IL-1beta) response to vaccine|| cytokine measurement GCST001533 response to vaccine|| cytokine measurement +Immune reponse to smallpox (secreted IL-2) response to vaccine|| cytokine measurement GCST001535 response to vaccine|| cytokine measurement +Immune reponse to smallpox (secreted TNF-alpha) response to vaccine|| cytokine measurement GCST001536 response to vaccine|| cytokine measurement +Immune response to smallpox vaccine (IL-6) response to vaccine|| cytokine measurement GCST001532 response to vaccine|| cytokine measurement +Immunoglobulin light (AL) amyloidosis (serum Ig kappa profile) AL amyloidosis|| IgG isotype profile measurement GCST004810 AL amyloidosis|| IgG isotype profile measurement +Immunoglobulin light chain (AL) amyloidosis (heart and kidney involvement) heart amyloid deposition measurement|| AL amyloidosis|| kidney amyloid deposition measurement GCST004806 heart amyloid deposition measurement|| AL amyloidosis|| kidney amyloid deposition measurement +Immunoglobulin light chain (AL) amyloidosis (heart involvement) heart amyloid deposition measurement|| AL amyloidosis GCST004805 heart amyloid deposition measurement|| AL amyloidosis +Immunoglobulin light chain (AL) amyloidosis (kidney involvement) AL amyloidosis|| kidney amyloid deposition measurement GCST004812 AL amyloidosis|| kidney amyloid deposition measurement +Immunoglobulin light chain (AL) amyloidosis (liver involvement) AL amyloidosis|| liver amyloid deposition measurement GCST004807 AL amyloidosis|| liver amyloid deposition measurement +Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile) AL amyloidosis|| IgG isotype profile measurement GCST004809 AL amyloidosis|| IgG isotype profile measurement +Immunoglobulin light chain (AL) amyloidosis (serum Ig light chain only lambda based profile) AL amyloidosis|| IgG isotype profile measurement GCST004804 AL amyloidosis|| IgG isotype profile measurement +Immunoglobulin light chain (AL) amyloidosis (serum Ig light chain only lambda/kappa based profile) AL amyloidosis|| IgG isotype profile measurement GCST004811 AL amyloidosis|| IgG isotype profile measurement +Immunoglobulin light chain (AL) amyloidosis (serum IgG profile) AL amyloidosis|| IgG isotype profile measurement GCST004808 AL amyloidosis|| IgG isotype profile measurement +Inflammatory biomarkers interleukin-1 beta measurement|| interleukin 1 receptor antagonist measurement GCST002255 interleukin-1 beta measurement|| interleukin 1 receptor antagonist measurement +Inflammatory biomarkers blood sedimentation|| interleukin-6 measurement|| C-reactive protein measurement|| CCL2 measurement GCST001385 blood sedimentation|| interleukin-6 measurement|| C-reactive protein measurement|| CCL2 measurement +Inflammatory bowel disease ulcerative colitis|| Crohn's disease|| inflammatory bowel disease GCST005837 ulcerative colitis|| Crohn's disease|| inflammatory bowel disease +Insulin levels in response to oral glucose tolerance test (120 minutes) insulin measurement|| glucose tolerance test GCST005161 insulin measurement|| glucose tolerance test +Insulin levels in response to oral glucose tolerance test (30 minutes) insulin measurement|| glucose tolerance test GCST005160 insulin measurement|| glucose tolerance test +Insulin levels in response to oral glucose tolerance test (fasting) insulin measurement|| glucose tolerance test GCST005159 insulin measurement|| glucose tolerance test +Intercellular adhesion molecule 1 (red blood cell fatty acid level interaction) fatty acid measurement|| ICAM-1 measurement GCST004818 fatty acid measurement|| ICAM-1 measurement +Interleukin-6 (red blood cell fatty acid level interaction) fatty acid measurement|| interleukin-6 measurement GCST004814 fatty acid measurement|| interleukin-6 measurement +"Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy)" thoracic aortic aneurysm|| Abdominal Aortic Aneurysm|| brain aneurysm GCST003683 thoracic aortic aneurysm|| Abdominal Aortic Aneurysm|| brain aneurysm +Iron status biomarkers (ferritin levels) iron biomarker measurement|| ferritin measurement GCST002677 iron biomarker measurement|| ferritin measurement +Iron status biomarkers (iron levels) iron biomarker measurement|| serum iron measurement GCST002679 iron biomarker measurement|| serum iron measurement +Iron status biomarkers (transferrin levels) iron biomarker measurement|| transferrin measurement GCST002678 iron biomarker measurement|| transferrin measurement +Iron status biomarkers (transferrin saturation) iron biomarker measurement|| transferrin saturation measurement GCST002680 iron biomarker measurement|| transferrin saturation measurement +Ischemic stroke (cardioembolic) Ischemic stroke|| cardiac embolism GCST003490 Ischemic stroke|| cardiac embolism +Ischemic stroke (cardioembolic) Ischemic stroke|| cardiac embolism GCST003323 Ischemic stroke|| cardiac embolism +Ischemic stroke (cardioembolic) Ischemic stroke|| cardiac embolism GCST003257 Ischemic stroke|| cardiac embolism +Ischemic stroke (large artery atherosclerosis) Ischemic stroke|| large artery stroke GCST003322 Ischemic stroke|| large artery stroke +Ischemic stroke (large artery atherosclerosis) Ischemic stroke|| large artery stroke GCST003259 Ischemic stroke|| large artery stroke +Ischemic stroke (small artery occlusion) Ischemic stroke|| small artery occlusion GCST003260 Ischemic stroke|| small artery occlusion +Itch intensity from mosquito bite adjusted by bite size mosquito bite reaction itch intensity measurement|| mosquito bite reaction size measurement GCST004865 mosquito bite reaction itch intensity measurement|| mosquito bite reaction size measurement +Itch intensity from mosquito bite adjusted by bite size mosquito bite reaction itch intensity measurement|| mosquito bite reaction size measurement GCST004862 mosquito bite reaction itch intensity measurement|| mosquito bite reaction size measurement +Joint destruction and growth retardation Kashin-Beck disease|| joint damage measurement|| height growth measurement GCST003727 Kashin-Beck disease|| joint damage measurement|| height growth measurement +JT interval (sulfonylurea treatment interaction) JT interval|| response to sulfonylurea GCST004032 JT interval|| response to sulfonylurea +Juvenile idiopathic arthritis (oligoarticular or rheumatoid factor-negative polyarticular) "systemic juvenile idiopathic arthritis|| polyarticular juvenile idiopathic arthritis, rheumatoid factor negative|| oligoarticular juvenile idiopathic arthritis" GCST005528 "systemic juvenile idiopathic arthritis|| polyarticular juvenile idiopathic arthritis, rheumatoid factor negative|| oligoarticular juvenile idiopathic arthritis" +Kidney function decline traits chronic kidney disease|| rapid kidney function decline|| GFR change measurement GCST002720 chronic kidney disease|| rapid kidney function decline|| GFR change measurement +Knee osteoarthritis osteoarthritis|| knee GCST003820 osteoarthritis|| knee +Knee osteoarthritis osteoarthritis|| knee GCST004881 osteoarthritis|| knee +Knee osteoarthritis osteoarthritis|| knee GCST000629 osteoarthritis|| knee +Knee osteoarthritis osteoarthritis|| knee GCST000186 osteoarthritis|| knee +Knee osteoarthritis or femoral neck bone mineral density osteoarthritis|| knee|| femoral neck bone mineral density GCST005224 osteoarthritis|| knee|| femoral neck bone mineral density +Knee osteoarthritis or lumbar spine bone mineral density osteoarthritis|| knee|| spine bone mineral density GCST005227 osteoarthritis|| knee|| spine bone mineral density +Lamotrigine-induced maculopapular exanthema response to lamotrigine|| maculopapular eruption GCST005199 response to lamotrigine|| maculopapular eruption +Language performance in older adults (adjusted for episodic memory) cognitive decline measurement|| memory performance|| language measurement GCST004372 cognitive decline measurement|| memory performance|| language measurement +Lapatinib-induced hepatotoxicity response to lapatinib|| drug-induced liver injury GCST002918 response to lapatinib|| drug-induced liver injury +Late gestational weight gain (fetal effect) fetal genotype effect measurement|| late gestational weight gain GCST005030 fetal genotype effect measurement|| late gestational weight gain +Lateral ventricle volume in trauma-exposed individuals lateral ventricle volume measurement|| response to trauma exposure GCST005286 lateral ventricle volume measurement|| response to trauma exposure +LDL peak particle diameter (total fat intake interaction) LDL peak particle diameter measurement|| total fat intake measurement GCST002989 LDL peak particle diameter measurement|| total fat intake measurement +Lean body mass and age at menarche (combined) body fat distribution|| age at menarche GCST001584 body fat distribution|| age at menarche +Left inferior lateral ventricle volume (Cerebrospinal fluid biomarker status interaction) cerebrospinal fluid biomarker measurement|| left inferior lateral ventricle volume measurement GCST002554 cerebrospinal fluid biomarker measurement|| left inferior lateral ventricle volume measurement +Left superior temporal gyrus thickness (schizophrenia interaction) schizophrenia|| left superior temporal gyrus thickness measurement GCST003069 schizophrenia|| left superior temporal gyrus thickness measurement +Left ventricular function change in anthracycline treatment left ventricular function|| response to anthracycline-based chemotherapy GCST004353 left ventricular function|| response to anthracycline-based chemotherapy +Left ventricular QRS voltage QRS amplitude|| S wave amplitude|| R wave amplitude GCST003630 QRS amplitude|| S wave amplitude|| R wave amplitude +Lewy body disease Lewy body dementia|| Lewy body dementia measurement GCST002591 Lewy body dementia|| Lewy body dementia measurement +Lipid traits total cholesterol measurement|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| high density lipoprotein cholesterol measurement GCST002321 total cholesterol measurement|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| high density lipoprotein cholesterol measurement +Lipid traits total cholesterol measurement|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| high density lipoprotein cholesterol measurement GCST002174 total cholesterol measurement|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| high density lipoprotein cholesterol measurement +Lipid traits triglyceride measurement|| low density lipoprotein cholesterol measurement|| high density lipoprotein cholesterol measurement GCST002173 triglyceride measurement|| low density lipoprotein cholesterol measurement|| high density lipoprotein cholesterol measurement +Lipid traits (pleiotropy) (HIPO component 1) total cholesterol measurement|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| high density lipoprotein cholesterol measurement GCST006666 total cholesterol measurement|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| high density lipoprotein cholesterol measurement +Lipid traits (pleiotropy) (HIPO component 2) total cholesterol measurement|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| high density lipoprotein cholesterol measurement GCST006667 total cholesterol measurement|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| high density lipoprotein cholesterol measurement +Lipoprotein-associated phospholipase A2 (red blood cell fatty acid level interaction) fatty acid measurement|| lipoprotein-associated phospholipase A(2) measurement GCST004816 fatty acid measurement|| lipoprotein-associated phospholipase A(2) measurement +Lipoprotein(a) levels adjusted for apolipoprotein(a) isoforms lipoprotein A measurement|| apolipoprotein A 1 measurement GCST004399 lipoprotein A measurement|| apolipoprotein A 1 measurement +Lobular breast cancer (menopausal hormone therapy interaction) invasive lobular carcinoma|| hormone replacement therapy GCST002266 invasive lobular carcinoma|| hormone replacement therapy +lower facial morphology traits (ordinal measurement) lip morphology measurement|| chin morphology measurement GCST003634 lip morphology measurement|| chin morphology measurement +lower facial morphology traits (quantitative measurement) lip morphology measurement|| chin morphology measurement GCST003636 lip morphology measurement|| chin morphology measurement +Lumbar spine bone mineral density or breast cancer (pleiotropy) breast carcinoma|| spine bone mineral density GCST004837 breast carcinoma|| spine bone mineral density +Lumbar spine bone mineral density or coronary artery disease (pleiotropy) spine bone mineral density|| coronary artery disease GCST004717 spine bone mineral density|| coronary artery disease +Lung cancer lung carcinoma|| squamous cell carcinoma|| lung adenocarcinoma GCST002466 lung carcinoma|| squamous cell carcinoma|| lung adenocarcinoma +Lung cancer (asbestos exposure interaction) lung carcinoma|| asbestos exposure measurement GCST003049 lung carcinoma|| asbestos exposure measurement +Lung cancer (asbestos exposure interaction) lung carcinoma|| asbestos exposure measurement GCST001543 lung carcinoma|| asbestos exposure measurement +Lung cancer (household air pollution interaction) lung carcinoma|| household air pollution measurement GCST002739 lung carcinoma|| household air pollution measurement +Lung cancer (smoking interaction) smoking status measurement|| lung carcinoma GCST002392 smoking status measurement|| lung carcinoma +Lung cancer and family history of lung cancer lung carcinoma|| family history of lung cancer GCST002753 lung carcinoma|| family history of lung cancer +Lung cancer x radon exposure interaction (1df) lung carcinoma|| radon exposure measurement GCST006413 lung carcinoma|| radon exposure measurement +Lung function (maximal voluntary ventilation) maximal voluntary ventilation|| pulmonary function measurement GCST005127 maximal voluntary ventilation|| pulmonary function measurement +Major depression and alcohol dependence unipolar depression|| alcohol dependence GCST005022 unipolar depression|| alcohol dependence +Major depressive disorder (stressful life events interaction) unipolar depression|| self rated health|| stressful life event measurement GCST003319 unipolar depression|| self rated health|| stressful life event measurement +Male fertility birth rate|| male fertility|| family size GCST001540 birth rate|| male fertility|| family size +Mammographic density (dense area) dense area measurement|| mammographic density measurement GCST002667 dense area measurement|| mammographic density measurement +Mammographic density (non-dense area) non-dense area measurement|| mammographic density measurement GCST002668 non-dense area measurement|| mammographic density measurement +Maternal genotype effects in autism spectrum disorder families autism spectrum disorder|| genetic variation GCST002368 autism spectrum disorder|| genetic variation +Mean arterial pressure (alcohol consumption interaction) diastolic blood pressure|| alcohol drinking GCST002308 diastolic blood pressure|| alcohol drinking +Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test) mean arterial pressure|| alcohol consumption measurement GCST006172 mean arterial pressure|| alcohol consumption measurement +Mean arterial pressure x alcohol consumption interaction (2df test) mean arterial pressure|| alcohol drinking GCST006167 mean arterial pressure|| alcohol drinking +Mean arterial pressure x sodium interaction (1df test) sodium measurement|| mean arterial pressure GCST006116 sodium measurement|| mean arterial pressure +Mean arterial pressure x sodium interaction (2df test) sodium measurement|| mean arterial pressure GCST006114 sodium measurement|| mean arterial pressure +Mean corpuscular hemoglobin hemoglobin measurement|| mean corpuscular hemoglobin GCST000587 hemoglobin measurement|| mean corpuscular hemoglobin +Mean corpuscular hemoglobin concentration hemoglobin measurement|| mean corpuscular hemoglobin concentration GCST000582 hemoglobin measurement|| mean corpuscular hemoglobin concentration +Menarche and menopause (age at onset) age at menarche|| age at menopause GCST001336 age at menarche|| age at menopause +Menarche and menopause (age at onset) age at menarche|| age at menopause GCST000403 age at menarche|| age at menopause +Menstruation quality of life impact (acne) quality of life during menstruation measurement|| acne GCST006640 quality of life during menstruation measurement|| acne +Menstruation quality of life impact (aggressiveness) quality of life during menstruation measurement|| aggressive behavior GCST006641 quality of life during menstruation measurement|| aggressive behavior +Menstruation quality of life impact (bowel movement) quality of life during menstruation measurement|| abnormal peristalsis GCST006643 quality of life during menstruation measurement|| abnormal peristalsis +Menstruation quality of life impact (depression) quality of life during menstruation measurement|| unipolar depression GCST006644 quality of life during menstruation measurement|| unipolar depression +Menstruation quality of life impact (dysmenorrhea) quality of life during menstruation measurement|| dysmenorrheic pain measurement GCST006636 quality of life during menstruation measurement|| dysmenorrheic pain measurement +Menstruation quality of life impact (edema) quality of life during menstruation measurement|| edema GCST006645 quality of life during menstruation measurement|| edema +Menstruation quality of life impact (fever) quality of life during menstruation measurement|| fever GCST006638 quality of life during menstruation measurement|| fever +Menstruation quality of life impact (headache) quality of life during menstruation measurement|| Headache GCST006646 quality of life during menstruation measurement|| Headache +Menstruation quality of life impact (increased appetite) quality of life during menstruation measurement|| eating behaviour GCST006642 quality of life during menstruation measurement|| eating behaviour +Menstruation quality of life impact (joint pain) quality of life during menstruation measurement|| arthralgia GCST006647 quality of life during menstruation measurement|| arthralgia +Menstruation quality of life impact (loss of concentration) quality of life during menstruation measurement|| decreased attention GCST006648 quality of life during menstruation measurement|| decreased attention +Menstruation quality of life impact (nervousness) nervousness|| quality of life during menstruation measurement GCST006649 nervousness|| quality of life during menstruation measurement +Menstruation quality of life impact (pressure in breast) quality of life during menstruation measurement|| breast pressure measurement GCST006650 quality of life during menstruation measurement|| breast pressure measurement +Menstruation quality of life impact (sleepiness) quality of life during menstruation measurement|| sleepiness GCST006651 quality of life during menstruation measurement|| sleepiness +Menstruation quality of life impact (stiff neck) quality of life during menstruation measurement|| Stiff neck GCST006652 quality of life during menstruation measurement|| Stiff neck +Mental development (prenatal lead exposure interaction) blood lead measurement|| mental development measurement GCST004769 blood lead measurement|| mental development measurement +Metabolic traits inflammatory response|| triglyceride measurement|| insulin measurement|| glucose measurement GCST000292 inflammatory response|| triglyceride measurement|| insulin measurement|| glucose measurement +Metabolite levels serum albumin measurement|| metabolite measurement|| serum alanine aminotransferase measurement|| low density lipoprotein cholesterol measurement|| fasting blood glucose measurement|| uric acid measurement GCST001233 serum albumin measurement|| metabolite measurement|| serum alanine aminotransferase measurement|| low density lipoprotein cholesterol measurement|| fasting blood glucose measurement|| uric acid measurement +Metabolite levels phenylalanine measurement|| acylcarnitine measurement|| carbohydrate measurement|| tyrosine measurement|| sphingolipid measurement|| lysine measurement|| lipid measurement|| phospholipid measurement|| serotonin measurement GCST000274 phenylalanine measurement|| acylcarnitine measurement|| carbohydrate measurement|| tyrosine measurement|| sphingolipid measurement|| lysine measurement|| lipid measurement|| phospholipid measurement|| serotonin measurement +Metabolite levels (5-HIAA/ MHPG Ratio) MHPG measurement|| 5-HIAA measurement GCST001821 MHPG measurement|| 5-HIAA measurement +Metabolite levels (HVA-5-HIAA Factor score) HVA measurement|| 5-HIAA measurement GCST001817 HVA measurement|| 5-HIAA measurement +Metabolite levels (HVA/5-HIAA ratio) HVA measurement|| 5-HIAA measurement GCST001818 HVA measurement|| 5-HIAA measurement +Metabolite levels (HVA/MHPG ratio) HVA measurement|| MHPG measurement GCST001823 HVA measurement|| MHPG measurement +Metabolite levels (lipid measures) lipid measurement|| blood metabolite measurement GCST003664 lipid measurement|| blood metabolite measurement +Metabolite levels (lipoprotein measures) lipoprotein measurement|| blood metabolite measurement GCST003665 lipoprotein measurement|| blood metabolite measurement +Metabolite levels (small molecules and protein measures) blood metabolite measurement|| protein measurement|| amino acid measurement GCST003666 blood metabolite measurement|| protein measurement|| amino acid measurement +middle facial morphology traits (ordinal measurement) nose morphology measurement|| cheekbone morphology measurement GCST003633 nose morphology measurement|| cheekbone morphology measurement +Midgestational circulating levels of organochlorine pesticides gestational serum measurement|| organochlorine pesticide measurement GCST004281 gestational serum measurement|| organochlorine pesticide measurement +Midgestational circulating levels of organochlorine pesticides (fetal genetic effect) gestational serum measurement|| fetal genotype effect measurement|| organochlorine pesticide measurement GCST004282 gestational serum measurement|| fetal genotype effect measurement|| organochlorine pesticide measurement +Midgestational circulating levels of PBDEs polybrominated biphenyl measurement|| gestational serum measurement|| polybrominated diphenyl ether measurement GCST004285 polybrominated biphenyl measurement|| gestational serum measurement|| polybrominated diphenyl ether measurement +Midgestational circulating levels of PBDEs (fetal genetic effect) polybrominated biphenyl measurement|| gestational serum measurement|| fetal genotype effect measurement|| polybrominated diphenyl ether measurement GCST004286 polybrominated biphenyl measurement|| gestational serum measurement|| fetal genotype effect measurement|| polybrominated diphenyl ether measurement +Midgestational circulating levels of PCBs polychlorinated biphenyls measurement|| gestational serum measurement GCST004283 polychlorinated biphenyls measurement|| gestational serum measurement +Midgestational circulating levels of PCBs (fetal genetic effect) polychlorinated biphenyls measurement|| gestational serum measurement|| fetal genotype effect measurement GCST004284 polychlorinated biphenyls measurement|| gestational serum measurement|| fetal genotype effect measurement +Midgestational cytokine/chemokine levels (fetal genetic effect) gestational serum measurement|| fetal genotype effect measurement|| protein measurement GCST006623 gestational serum measurement|| fetal genotype effect measurement|| protein measurement +Midgestational cytokine/chemokine levels (maternal genetic effect) gestational serum measurement|| protein measurement|| parental genotype effect measurement GCST006621 gestational serum measurement|| protein measurement|| parental genotype effect measurement +Migraine or coronary artery disease migraine disorder|| coronary artery disease GCST004944 migraine disorder|| coronary artery disease +Milk allergy (maternal genetic effects) milk allergy measurement|| parental genotype effect measurement GCST005722 milk allergy measurement|| parental genotype effect measurement +Milk allergy (parent-of-origin effect) milk allergy measurement|| parental genotype effect measurement GCST005726 milk allergy measurement|| parental genotype effect measurement +Modified Stumvoll Insulin Sensitivity Index (BMI interaction) insulin sensitivity measurement|| body mass index GCST003659 insulin sensitivity measurement|| body mass index +Modified Stumvoll Insulin Sensitivity Index (model adjusted for BMI) insulin sensitivity measurement|| body mass index GCST003658 insulin sensitivity measurement|| body mass index +Monocyte chemoattractant protein-1 (red blood cell fatty acid level interaction) fatty acid measurement|| CCL2 measurement GCST004821 fatty acid measurement|| CCL2 measurement +Mood disorder and prion disease prion disease|| mood disorder GCST002862 prion disease|| mood disorder +Motor development (prenatal lead exposure interaction) motor development measurement|| blood lead measurement GCST004768 motor development measurement|| blood lead measurement +"Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)" lung carcinoma|| squamous cell carcinoma|| gastric carcinoma GCST001718 lung carcinoma|| squamous cell carcinoma|| gastric carcinoma +Multiple keratinocyte cancers squamous cell carcinoma|| mulitple keratinocyte carcinoma susceptibility measurement|| basal cell carcinoma GCST004134 squamous cell carcinoma|| mulitple keratinocyte carcinoma susceptibility measurement|| basal cell carcinoma +Multiple myeloma and monoclonal gammopathy multiple myeloma|| monoclonal gammopathy GCST002922 multiple myeloma|| monoclonal gammopathy +Multiple sclerosis (OCB status) multiple sclerosis|| oligoclonal band measurement GCST001892 multiple sclerosis|| oligoclonal band measurement +Multiple sclerosis or amyotrophic lateral sclerosis multiple sclerosis|| amyotrophic lateral sclerosis GCST002274 multiple sclerosis|| amyotrophic lateral sclerosis +Neonatal cytokine/chemokine levels (fetal genetic effect) fetal genotype effect measurement|| protein measurement GCST006622 fetal genotype effect measurement|| protein measurement +Neonatal cytokine/chemokine levels (maternal genetic effect) protein measurement|| parental genotype effect measurement GCST006625 protein measurement|| parental genotype effect measurement +Neovascular age-related macular degeneration age-related macular degeneration|| wet macular degeneration GCST004737 age-related macular degeneration|| wet macular degeneration +Neuranatomic and neurocognitive phenotypes neuroimaging measurement|| South Texas Assessment of Neurocognition GCST001037 neuroimaging measurement|| South Texas Assessment of Neurocognition +Neuritic plaques or cerebral amyloid angiopathy (pleiotropy) neuritic plaque measurement|| cerebral amyloid angiopathy GCST005515 neuritic plaque measurement|| cerebral amyloid angiopathy +Neuritic plaques or neurofibrillary tangles (pleiotropy) neuritic plaque measurement|| neurofibrillary tangles measurement GCST005516 neuritic plaque measurement|| neurofibrillary tangles measurement +Neuritic plaques or neurofibrillary tangles or cerebral amyloid angiopathy (pleiotropy) neuritic plaque measurement|| cerebral amyloid angiopathy|| neurofibrillary tangles measurement GCST005514 neuritic plaque measurement|| cerebral amyloid angiopathy|| neurofibrillary tangles measurement +Neurofibrillary tangles or cerebral amyloid angiopathy (pleiotropy) cerebral amyloid angiopathy|| neurofibrillary tangles measurement GCST005517 cerebral amyloid angiopathy|| neurofibrillary tangles measurement +Neuroticism (age interaction) neurotic disorder|| age at assessment GCST000724 neurotic disorder|| age at assessment +Nicotine dependence and major depression (severity of comorbidity) nicotine dependence symptom count|| depressive symptom measurement GCST006631 nicotine dependence symptom count|| depressive symptom measurement +Night sleep phenotypes sleep duration|| nighttime rest measurement|| sleep quality|| sleep latency GCST003542 sleep duration|| nighttime rest measurement|| sleep quality|| sleep latency +Non-alcoholic fatty liver disease histology (AST) non-alcoholic fatty liver disease|| cirrhosis of liver GCST000767 non-alcoholic fatty liver disease|| cirrhosis of liver +Non-alcoholic fatty liver disease histology (lobular) non-alcoholic fatty liver disease|| cirrhosis of liver GCST000766 non-alcoholic fatty liver disease|| cirrhosis of liver +Non-alcoholic fatty liver disease histology (other) serum alanine aminotransferase measurement|| non-alcoholic fatty liver disease|| cirrhosis of liver GCST000765 serum alanine aminotransferase measurement|| non-alcoholic fatty liver disease|| cirrhosis of liver +Non-chemotherapy drug induced agranulocytosis drug-induced agranulocytosis|| response to drug GCST003526 drug-induced agranulocytosis|| response to drug +Non-glioblastoma glioma central nervous system cancer|| glioma GCST004348 central nervous system cancer|| glioma +Non-response to antidepressants and depression unipolar depression|| mood disorder|| response to antidepressant GCST003812 unipolar depression|| mood disorder|| response to antidepressant +Non-response to bupropion and depression unipolar depression|| response to bupropion|| mood disorder GCST003804 unipolar depression|| response to bupropion|| mood disorder +Non-response to citalopram or escitalopram and depression unipolar depression|| response to escitalopram|| response to citalopram|| mood disorder GCST003810 unipolar depression|| response to escitalopram|| response to citalopram|| mood disorder +Non-response to selective serotonin reuptake inhibitors and depression unipolar depression|| response to selective serotonin reuptake inhibitor|| mood disorder GCST003808 unipolar depression|| response to selective serotonin reuptake inhibitor|| mood disorder +Nonalcoholic steatohepatitis-derived hepatocellular carcinoma hepatocellular carcinoma|| non-alcoholic steatohepatitis GCST005309 hepatocellular carcinoma|| non-alcoholic steatohepatitis +Nonsyndromic cleft lip with cleft palate cleft palate|| cleft lip GCST004166 cleft palate|| cleft lip +Nonsyndromic cleft lip with or without cleft palate cleft palate|| cleft lip GCST006415 cleft palate|| cleft lip +Nonsyndromic cleft lip with or without cleft palate cleft palate|| cleft lip GCST004088 cleft palate|| cleft lip +Nonsyndromic cleft lip with or without cleft palate cleft palate|| cleft lip GCST002811 cleft palate|| cleft lip +Nonsyndromic cleft lip with or without cleft palate x sex interaction (2df test) cleft palate|| sex interaction measurement|| cleft lip GCST006680 cleft palate|| sex interaction measurement|| cleft lip +Number of children female fertility|| fertility measurement GCST002801 female fertility|| fertility measurement +Number of children (6+ vs. 0 or 1) female fertility|| fertility measurement GCST002800 female fertility|| fertility measurement +Number of pregnancies female fertility|| fertility measurement GCST002799 female fertility|| fertility measurement +Obesity and osteoporosis obesity|| osteoporosis GCST000469 obesity|| osteoporosis +Obesity-related traits cortisol secretion measurement|| hormone measurement|| antioxidant measurement|| CCL2 measurement|| body mass index|| IGFBP-3 measurement|| fatty acid measurement|| tumor necrosis factor-alpha measurement|| gestational age|| energy expenditure|| sleep measurement|| metabolic rate measurement|| urinary metabolite measurement|| blood urea nitrogen measurement|| vitamin B12 measurement|| energy intake|| ICAM-1 measurement|| body height|| hip circumference|| arm span|| physical activity|| heart rate|| protein measurement|| estradiol measurement|| thyroid stimulating hormone measurement|| waist circumference|| total cholesterol measurement|| interleukin-6 measurement|| body composition measurement|| birth weight|| amino acid measurement|| C-reactive protein measurement|| HOMA-IR|| head circumference|| adiponectin measurement|| high density lipoprotein cholesterol measurement|| aspartate aminotransferase measurement|| leptin measurement|| transforming growth factor beta measurement|| systolic blood pressure|| IGFBP-1 measurement|| bone density|| body weight|| fasting blood glucose measurement|| homocysteine measurement|| folic acid measurement|| serum alanine aminotransferase measurement|| CCL5 measurement|| IGF-1 measurement|| testosterone measurement|| insulin sensitivity measurement|| diastolic blood pressure|| maximal oxygen uptake measurement|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| lean body mass|| fasting blood insulin measurement GCST001762 cortisol secretion measurement|| hormone measurement|| antioxidant measurement|| CCL2 measurement|| body mass index|| IGFBP-3 measurement|| fatty acid measurement|| tumor necrosis factor-alpha measurement|| gestational age|| energy expenditure|| sleep measurement|| metabolic rate measurement|| urinary metabolite measurement|| blood urea nitrogen measurement|| vitamin B12 measurement|| energy intake|| ICAM-1 measurement|| body height|| hip circumference|| arm span|| physical activity|| heart rate|| protein measurement|| estradiol measurement|| thyroid stimulating hormone measurement|| waist circumference|| total cholesterol measurement|| interleukin-6 measurement|| body composition measurement|| birth weight|| amino acid measurement|| C-reactive protein measurement|| HOMA-IR|| head circumference|| adiponectin measurement|| high density lipoprotein cholesterol measurement|| aspartate aminotransferase measurement|| leptin measurement|| transforming growth factor beta measurement|| systolic blood pressure|| IGFBP-1 measurement|| bone density|| body weight|| fasting blood glucose measurement|| homocysteine measurement|| folic acid measurement|| serum alanine aminotransferase measurement|| CCL5 measurement|| IGF-1 measurement|| testosterone measurement|| insulin sensitivity measurement|| diastolic blood pressure|| maximal oxygen uptake measurement|| triglyceride measurement|| low density lipoprotein cholesterol measurement|| lean body mass|| fasting blood insulin measurement +Obesity-related traits fat body mass|| body mass index|| obesity GCST001288 fat body mass|| body mass index|| obesity +Obesity-related traits body weight|| waist-hip ratio|| body mass index GCST000060 body weight|| waist-hip ratio|| body mass index +Objective response to lithium treatment bipolar disorder|| response to lithium ion GCST003159 bipolar disorder|| response to lithium ion +Obsessive-compulsive disorder or autism spectrum disorder obsessive-compulsive disorder|| autism spectrum disorder GCST004703 obsessive-compulsive disorder|| autism spectrum disorder +Obstructive sleep apnea (average oxygen saturation during sleep) sleep apnea measurement|| obstructive sleep apnea GCST003673 sleep apnea measurement|| obstructive sleep apnea +Obstructive sleep apnea trait (apnea hypopnea index) sleep apnea measurement|| obstructive sleep apnea GCST003674 sleep apnea measurement|| obstructive sleep apnea +Obstructive sleep apnea trait (average respiratory event duration) sleep apnea measurement|| obstructive sleep apnea GCST003675 sleep apnea measurement|| obstructive sleep apnea +Occipital cortical area (total cortical area interaction) total cortical area measurement|| visual cortical surface area measurement GCST001411 total cortical area measurement|| visual cortical surface area measurement +Offspring birth weight birth weight|| parental genotype effect measurement GCST005314 birth weight|| parental genotype effect measurement +Open-angle glaucoma and intra-ocular pressure open-angle glaucoma|| intraocular pressure measurement GCST005408 open-angle glaucoma|| intraocular pressure measurement +Open-angle glaucoma and optic cup area optic cup area measurement|| open-angle glaucoma GCST005406 optic cup area measurement|| open-angle glaucoma +Open-angle glaucoma and optic disc area open-angle glaucoma|| optic disc area measurement GCST005410 open-angle glaucoma|| optic disc area measurement +Open-angle glaucoma and vertical cup-disc ratio cup-to-disc ratio measurement|| open-angle glaucoma GCST005409 cup-to-disc ratio measurement|| open-angle glaucoma +Opioid requirements during laparoscopic-assisted colectomy response to opioid|| analgesia requirement measurement GCST005364 response to opioid|| analgesia requirement measurement +Oral cancers (chewing tobacco related) matrix metalloproteinase measurement|| mouth neoplasm GCST001480 matrix metalloproteinase measurement|| mouth neoplasm +Oral cavity and pharyngeal cancer pharynx cancer|| oral cavity cancer GCST003857 pharynx cancer|| oral cavity cancer +Orofacial clefts (cleft lip vs. cleft lip and palate) cleft palate|| Orofacial clefting syndrome|| cleft lip GCST005079 cleft palate|| Orofacial clefting syndrome|| cleft lip +Orofacial clefts (maternal alcohol consumption interaction) alcohol consumption measurement|| Orofacial clefting syndrome|| cleft lip GCST001082 alcohol consumption measurement|| Orofacial clefting syndrome|| cleft lip +Osteoarthritis (with total hip replacement) hip osteoarthritis symptom severity measurement|| osteoarthritis GCST004199 hip osteoarthritis symptom severity measurement|| osteoarthritis +Osteoarthritis of the hip (hospital diagnosed) osteoarthritis|| hip GCST005810 osteoarthritis|| hip +Osteoarthritis of the hip (with total joint replacement) osteoarthritis|| hip GCST005572 osteoarthritis|| hip +Osteoarthritis of the hip or knee osteoarthritis|| hip|| osteoarthritis|| knee GCST005573 osteoarthritis|| hip|| osteoarthritis|| knee +Osteoarthritis of the hip or knee (hospital diagnosed) osteoarthritis|| hip|| osteoarthritis|| knee GCST005812 osteoarthritis|| hip|| osteoarthritis|| knee +Osteoarthritis of the hip or knee (with total joint replacement) osteoarthritis|| hip|| osteoarthritis|| knee GCST005571 osteoarthritis|| hip|| osteoarthritis|| knee +Osteoarthritis of the knee (hospital diagnosed) osteoarthritis|| knee GCST005813 osteoarthritis|| knee +Osteoarthritis of the knee (with total joint replacement) osteoarthritis|| knee GCST005574 osteoarthritis|| knee +Osteoarthritis or femoral neck bone mineral density osteoarthritis|| femoral neck bone mineral density GCST005228 osteoarthritis|| femoral neck bone mineral density +Osteoarthritis or lumbar spine bone mineral density osteoarthritis|| spine bone mineral density GCST005225 osteoarthritis|| spine bone mineral density +Osteoporosis or obesity (pleiotropy) obesity|| osteoporosis GCST005114 obesity|| osteoporosis +Osteoprotegerin (red blood cell fatty acid level interaction) fatty acid measurement|| osteoprotegerin measurement GCST004819 fatty acid measurement|| osteoprotegerin measurement +Other erythrocyte phenotypes erythrocyte count|| mean corpuscular hemoglobin concentration GCST000500 erythrocyte count|| mean corpuscular hemoglobin concentration +P-Selectin (red blood cell fatty acid level interaction) fatty acid measurement|| P-Selectin measurement GCST004822 fatty acid measurement|| P-Selectin measurement +Paclitaxel-induced cytotoxicity cytotoxicity measurement|| response to paclitaxel GCST002924 cytotoxicity measurement|| response to paclitaxel +Paclitaxel-induced neuropathy peripheral neuropathy|| response to paclitaxel GCST002923 peripheral neuropathy|| response to paclitaxel +Paclitaxel-induced neuropathy brain serotonin transporter measurement|| response to paclitaxel GCST002074 brain serotonin transporter measurement|| response to paclitaxel +Paclitaxel-induced neuropathy response to paclitaxel|| neuropathy GCST001755 response to paclitaxel|| neuropathy +Paclitaxel-induced neuropathy response to paclitaxel|| neuropathy GCST001624 response to paclitaxel|| neuropathy +Pain medicine use during menstruation drug use measurement|| quality of life during menstruation measurement GCST006637 drug use measurement|| quality of life during menstruation measurement +Parkinson disease and lewy body pathology Parkinson's disease|| Lewy body measurement GCST002778 Parkinson's disease|| Lewy body measurement +Parkinson's disease (coffee consumption interaction) Parkinson's disease|| coffee consumption GCST001205 Parkinson's disease|| coffee consumption +Parkinson's disease (pesticide exposure interaction) Parkinson's disease|| pesticide exposure measurement GCST003600 Parkinson's disease|| pesticide exposure measurement +Peanut allergy (maternal genetic effects) peanut allergy measurement|| parental genotype effect measurement GCST005723 peanut allergy measurement|| parental genotype effect measurement +Peanut allergy (parent-of-origin effect) peanut allergy measurement|| parental genotype effect measurement GCST005727 peanut allergy measurement|| parental genotype effect measurement +Pediatric autoimmune diseases autoimmune thyroid disease|| type I diabetes mellitus|| Common variable immunodeficiency|| chronic childhood arthritis|| ankylosing spondylitis|| psoriasis|| celiac disease|| ulcerative colitis|| Crohn's disease|| autoimmune disease|| systemic lupus erythematosus GCST003097 autoimmune thyroid disease|| type I diabetes mellitus|| Common variable immunodeficiency|| chronic childhood arthritis|| ankylosing spondylitis|| psoriasis|| celiac disease|| ulcerative colitis|| Crohn's disease|| autoimmune disease|| systemic lupus erythematosus +Pediatric non-alcoholic fatty liver disease activity score non-alcoholic fatty liver disease|| cirrhosis of liver GCST001928 non-alcoholic fatty liver disease|| cirrhosis of liver +Percent mammographic density mammographic density percentage|| mammographic density measurement GCST002669 mammographic density percentage|| mammographic density measurement +Pericardial adipose tissue adjusted for height and weight pericardial adipose tissue measurement|| body weight|| body height GCST006544 pericardial adipose tissue measurement|| body weight|| body height +Pericardial adipose tissue adjusted for height and weight pericardial adipose tissue measurement|| body weight|| body height GCST006543 pericardial adipose tissue measurement|| body weight|| body height +Pericardial adipose tissue adjusted for height and weight pericardial adipose tissue measurement|| body weight|| body height GCST003968 pericardial adipose tissue measurement|| body weight|| body height +Periodontal disease-related phenotypes periodontitis|| periodontal measurement GCST003484 periodontitis|| periodontal measurement +Peripheral arterial disease (traffic-related air pollution interaction) peripheral arterial disease|| traffic air pollution measurement GCST004482 peripheral arterial disease|| traffic air pollution measurement +Phenytoin-induced maculopapular exanthema maculopapular eruption|| response to phenytoin GCST005200 maculopapular eruption|| response to phenytoin +Phenytoin-induced severe cutaneous adverse reactions severe cutaneous adverse reaction|| response to phenytoin GCST002558 severe cutaneous adverse reaction|| response to phenytoin +Plantar fascial disorders Plantar Fasciitis|| Plantar Fibromatosis GCST005558 Plantar Fasciitis|| Plantar Fibromatosis +Platelet thrombus formation platelet reactivity measurement|| thrombus formation measurement GCST001501 platelet reactivity measurement|| thrombus formation measurement +Post bronchodilator FEV1 forced expiratory volume|| response to bronchodilator GCST003262 forced expiratory volume|| response to bronchodilator +Post bronchodilator FEV1/FVC ratio response to bronchodilator|| FEV/FEC ratio GCST003264 response to bronchodilator|| FEV/FEC ratio +Posterior cortical atrophy and Alzheimer's disease Alzheimer's disease|| Posterior cortical atrophy GCST003452 Alzheimer's disease|| Posterior cortical atrophy +Postprandial triglyceride response to high fat diet meal response to high fat food intake|| triglyceride change measurement GCST003014 response to high fat food intake|| triglyceride change measurement +Preterm birth (maternal effect) premature birth|| parental genotype effect measurement GCST004898 premature birth|| parental genotype effect measurement +Preterm birth (maternal effect) premature birth|| parental genotype effect measurement GCST004841 premature birth|| parental genotype effect measurement +Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction) body mass index|| premature birth|| parental genotype effect measurement GCST004842 body mass index|| premature birth|| parental genotype effect measurement +Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction) body mass index|| premature birth|| parental genotype effect measurement GCST004843 body mass index|| premature birth|| parental genotype effect measurement +"Primary sclerosing cholangitis associated immune-mediated diseases (Crohn's disease, celiac disease, psoriasis, rheumatoid arthritis, sarcoidosis, type 1 diabetes or ulcerative colitis) (pleiotropy)" rheumatoid arthritis|| type I diabetes mellitus|| psoriasis|| Sarcoidosis|| celiac disease|| ulcerative colitis|| Crohn's disease|| sclerosing cholangitis GCST005563 rheumatoid arthritis|| type I diabetes mellitus|| psoriasis|| Sarcoidosis|| celiac disease|| ulcerative colitis|| Crohn's disease|| sclerosing cholangitis +Progressive supranuclear palsy and immune-mediated diseases (pleiotropy) rheumatoid arthritis|| type I diabetes mellitus|| psoriasis|| celiac disease|| ulcerative colitis|| Crohn's disease|| Progressive supranuclear palsy GCST005320 rheumatoid arthritis|| type I diabetes mellitus|| psoriasis|| celiac disease|| ulcerative colitis|| Crohn's disease|| Progressive supranuclear palsy +Prostate cancer (SNP x SNP interaction) genetic variation|| prostate carcinoma GCST001370 genetic variation|| prostate carcinoma +Prostate cancer aggressiveness cancer aggressiveness measurement|| Gleason score measurement|| prostate carcinoma GCST002886 cancer aggressiveness measurement|| Gleason score measurement|| prostate carcinoma +Prostate cancer mortality survival time|| metastatic prostate cancer GCST000844 survival time|| metastatic prostate cancer +Proteinuria and chronic kidney disease chronic kidney disease|| Proteinuria GCST003141 chronic kidney disease|| Proteinuria +Psoriatic arthritis vs Cutaneous psoriasis cutaneous psoriasis measurement|| psoriatic arthritis|| psoriasis GCST003271 cutaneous psoriasis measurement|| psoriatic arthritis|| psoriasis +Psychiatric diseases (pleiotropy) (HIPO component 1) attention deficit hyperactivity disorder|| unipolar depression|| schizophrenia|| autism spectrum disorder|| bipolar disorder GCST006668 attention deficit hyperactivity disorder|| unipolar depression|| schizophrenia|| autism spectrum disorder|| bipolar disorder +Psychosis and Alzheimer's disease Alzheimer's disease|| psychotic symptoms GCST001285 Alzheimer's disease|| psychotic symptoms +Psychotic symptoms and prion disease prion disease|| psychotic symptoms GCST002871 prion disease|| psychotic symptoms +Pubertal anthropometrics puberty|| height growth measurement GCST001876 puberty|| height growth measurement +Pulmonary artery enlargement and chronic obstructive pulmonary disease pulmonary artery enlargement|| chronic obstructive pulmonary disease GCST002798 pulmonary artery enlargement|| chronic obstructive pulmonary disease +Pulmonary function pulmonary function measurement|| forced expiratory volume|| FEV/FEC ratio|| vital capacity GCST002113 pulmonary function measurement|| forced expiratory volume|| FEV/FEC ratio|| vital capacity +Pulmonary function (smoking interaction) pulmonary function measurement|| smoking behaviour measurement GCST001784 pulmonary function measurement|| smoking behaviour measurement +Pulmonary function decline forced expiratory volume|| FEV/FEC ratio GCST001444 forced expiratory volume|| FEV/FEC ratio +Pulse pressure (alcohol consumption interaction) pulse pressure measurement|| alcohol drinking GCST002310 pulse pressure measurement|| alcohol drinking +Pulse pressure (dietary potassium intake interaction) pulse pressure measurement|| dietary potassium intake measurement GCST005201 pulse pressure measurement|| dietary potassium intake measurement +Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test) pulse pressure measurement|| alcohol consumption measurement GCST006171 pulse pressure measurement|| alcohol consumption measurement +Pulse pressure x alcohol consumption interaction (2df test) pulse pressure measurement|| alcohol drinking GCST006168 pulse pressure measurement|| alcohol drinking +Pulse pressure x sodium interaction (1df test) pulse pressure measurement|| sodium measurement GCST006117 pulse pressure measurement|| sodium measurement +Pulse pressure x sodium interaction (2df test) pulse pressure measurement|| sodium measurement GCST006118 pulse pressure measurement|| sodium measurement +Putamen activity during reward functional brain measurement|| putamen measurement|| response to reward GCST004971 functional brain measurement|| putamen measurement|| response to reward +Putamen actvity during disappointment response to disappointment|| functional brain measurement|| putamen measurement GCST004972 response to disappointment|| functional brain measurement|| putamen measurement +QRS complex (12-leadsum) QRS amplitude|| QRS complex GCST003872 QRS amplitude|| QRS complex +QRS complex (Cornell) QRS amplitude|| QRS complex GCST003871 QRS amplitude|| QRS complex +QRS complex (Sokolow-Lyon) QRS amplitude|| QRS complex GCST003870 QRS amplitude|| QRS complex +QRS duration QRS complex|| QRS duration GCST003844 QRS complex|| QRS duration +QRS interval (sulfonylurea treatment interaction) QRS duration|| response to sulfonylurea GCST004033 QRS duration|| response to sulfonylurea +QT interval (ambient particulate matter interaction) QT interval|| particulate matter air pollution measurement GCST004642 QT interval|| particulate matter air pollution measurement +QT interval (sulfonylurea treatment interaction) response to sulfonylurea|| QT interval GCST004031 response to sulfonylurea|| QT interval +QT interval (tricyclic/tetracyclic antidepressant use interaction) response to tetracyclic antidepressant|| QT interval|| response to tricyclic antidepressant GCST004010 response to tetracyclic antidepressant|| QT interval|| response to tricyclic antidepressant +Quantitative traits waist circumference|| total cholesterol measurement|| body fat distribution|| C-reactive protein measurement|| body mass index|| high density lipoprotein cholesterol measurement|| body height|| diastolic blood pressure|| triglyceride measurement|| systolic blood pressure|| low density lipoprotein cholesterol measurement|| body weight|| thyroid stimulating hormone measurement GCST000337 waist circumference|| total cholesterol measurement|| body fat distribution|| C-reactive protein measurement|| body mass index|| high density lipoprotein cholesterol measurement|| body height|| diastolic blood pressure|| triglyceride measurement|| systolic blood pressure|| low density lipoprotein cholesterol measurement|| body weight|| thyroid stimulating hormone measurement +Rate of change of FEV1 (time interaction) FEV change measurement|| forced expiratory volume GCST002517 FEV change measurement|| forced expiratory volume +Ratio of apolipoprotein A1 to apolipoprotein B apolipoprotein A 1 measurement|| apolipoprotein B measurement GCST005443 apolipoprotein A 1 measurement|| apolipoprotein B measurement +Reading disability and language impairment language impairment|| dyslexia GCST002175 language impairment|| dyslexia +Reading disability or specific language impairment (pleiotropy) specific language impairment|| dyslexia GCST004401 specific language impairment|| dyslexia +Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy) intelligence|| specific language impairment|| dyslexia GCST004402 intelligence|| specific language impairment|| dyslexia +Reading or mathematical ability reading|| mathematical ability GCST002522 reading|| mathematical ability +Red blood cell fatty acid levels arachidonic acid measurement|| fatty acid measurement|| linolenic acid measurement|| oleic acid measurement|| docosapentaenoic acid measurement|| linoleic acid measurement GCST002712 arachidonic acid measurement|| fatty acid measurement|| linolenic acid measurement|| oleic acid measurement|| docosapentaenoic acid measurement|| linoleic acid measurement +Red blood cell traits mean corpuscular volume|| mean corpuscular hemoglobin GCST002109 mean corpuscular volume|| mean corpuscular hemoglobin +Red blood cell traits hemoglobin measurement|| erythrocyte count|| mean corpuscular hemoglobin concentration|| mean corpuscular volume|| hematocrit|| mean corpuscular hemoglobin|| red blood cell distribution width GCST001873 hemoglobin measurement|| erythrocyte count|| mean corpuscular hemoglobin concentration|| mean corpuscular volume|| hematocrit|| mean corpuscular hemoglobin|| red blood cell distribution width +Red blood cell traits erythrocyte count|| mean corpuscular hemoglobin concentration|| mean corpuscular volume|| mean corpuscular hemoglobin GCST000814 erythrocyte count|| mean corpuscular hemoglobin concentration|| mean corpuscular volume|| mean corpuscular hemoglobin +Renal function and chronic kidney disease renal system measurement|| chronic kidney disease GCST000397 renal system measurement|| chronic kidney disease +Renal function-related traits (BUN) renal system measurement|| blood urea nitrogen measurement GCST001610 renal system measurement|| blood urea nitrogen measurement +Renal function-related traits (urea) renal system measurement|| uric acid measurement GCST001608 renal system measurement|| uric acid measurement +Reporting of stressful life event self rated health|| stressful life event measurement GCST001774 self rated health|| stressful life event measurement +Residual cognition cognition|| aging GCST004291 cognition|| aging +Response to antidepressants and depression unipolar depression|| mood disorder|| response to antidepressant GCST003813 unipolar depression|| mood disorder|| response to antidepressant +Response to bleomycin (chromatid breaks) response to bleomycin|| chromatid break measurement|| response to antibiotic GCST000882 response to bleomycin|| chromatid break measurement|| response to antibiotic +Response to bupropion and depression unipolar depression|| response to bupropion|| mood disorder GCST003806 unipolar depression|| response to bupropion|| mood disorder +Response to citalopram or escitalopram and depression unipolar depression|| response to escitalopram|| response to citalopram|| mood disorder GCST003811 unipolar depression|| response to escitalopram|| response to citalopram|| mood disorder +Response to clopidogrel therapy platelet reactivity measurement|| response to clopidogrel GCST004266 platelet reactivity measurement|| response to clopidogrel +Response to exercise (triglyceride level interaction) triglyceride change measurement|| response to exercise GCST003207 triglyceride change measurement|| response to exercise +Response to fenofibrate (HDL cholesterol levels) HDL cholesterol change measurement|| response to fenofibrate GCST003485 HDL cholesterol change measurement|| response to fenofibrate +Response to fenofibrate (LDL cholesterol levels) LDL cholesterol change measurement|| response to fenofibrate GCST003486 LDL cholesterol change measurement|| response to fenofibrate +Response to fenofibrate (total cholesterol levels) total cholesterol change measurement|| response to fenofibrate GCST003487 total cholesterol change measurement|| response to fenofibrate +Response to fenofibrate (triglyceride levels) triglyceride change measurement|| response to fenofibrate GCST003488 triglyceride change measurement|| response to fenofibrate +Response to Homoharringtonine (cytotoxicity) response to homoharringtonine|| cytotoxicity measurement GCST002749 response to homoharringtonine|| cytotoxicity measurement +Response to metformin (IC50) cytotoxicity measurement|| response to metformin GCST003791 cytotoxicity measurement|| response to metformin +Response to selective serotonin reuptake inhibitors and depression unipolar depression|| response to selective serotonin reuptake inhibitor|| mood disorder GCST003809 unipolar depression|| response to selective serotonin reuptake inhibitor|| mood disorder +Response to simvastatin treatment (PCSK9 protein level change) response to simvastatin|| PCSK9 protein measurement GCST002642 response to simvastatin|| PCSK9 protein measurement +Response to statin therapy (LDL cholesterol subfractions) response to statin|| low density lipoprotein cholesterol measurement GCST002865 response to statin|| low density lipoprotein cholesterol measurement +Response to statins (HDL cholesterol change) HDL cholesterol change measurement|| response to statin GCST003617 HDL cholesterol change measurement|| response to statin +Response to statins (LDL cholesterol change) response to statin|| low density lipoprotein cholesterol measurement GCST002675 response to statin|| low density lipoprotein cholesterol measurement +Response to statins (LDL cholesterol change) response to statin|| LDL cholesterol change measurement GCST001408 response to statin|| LDL cholesterol change measurement +Response to thiazide diuretic treatment (hypokalemia) response to hydrochlorothiazide|| hypokalemia GCST002600 response to hydrochlorothiazide|| hypokalemia +Response to treatment for acute lymphoblastic leukemia acute lymphoblastic leukemia|| response to antineoplastic agent GCST000323 acute lymphoblastic leukemia|| response to antineoplastic agent +Response to ximelagatran treatment (increased serum alanine aminotransferase levels) serum alanine aminotransferase measurement|| response to ximelagatran GCST000034 serum alanine aminotransferase measurement|| response to ximelagatran +Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive) rheumatoid arthritis|| anti-citrullinated protein antibody seropositivity|| rheumatoid factor seropositivity measurement GCST004174 rheumatoid arthritis|| anti-citrullinated protein antibody seropositivity|| rheumatoid factor seropositivity measurement +Ribavirin-induced anemia anemia|| response to ribavirin GCST000729 anemia|| response to ribavirin +Risky sexual behaviors (alcohol dependence interaction) behavioural disinhibition measurement|| alcohol dependence|| risky sexual behaviour measurement GCST003860 behavioural disinhibition measurement|| alcohol dependence|| risky sexual behaviour measurement +Risky sexual behaviors (alcohol dependence interaction) alcohol dependence|| risky sexual behaviour measurement GCST004956 alcohol dependence|| risky sexual behaviour measurement +RR interval (tricyclic/tetracyclic antidepressant use interaction) RR interval|| response to tetracyclic antidepressant|| response to tricyclic antidepressant GCST004011 RR interval|| response to tetracyclic antidepressant|| response to tricyclic antidepressant +Rubella-specific interferon-gamma secretion interferon gamma measurement|| response to vaccine GCST005177 interferon gamma measurement|| response to vaccine +Rubella-specific interleukin-6 secretion interleukin-6 measurement|| response to vaccine GCST005176 interleukin-6 measurement|| response to vaccine +Sasang constitutional medicine type (So-Eum) So-Eum|| Sasang constitutional medicine type GCST002854 So-Eum|| Sasang constitutional medicine type +Sasang constitutional medicine type (So-Yang) So-Yang|| Sasang constitutional medicine type GCST002852 So-Yang|| Sasang constitutional medicine type +Sasang constitutional medicine type (Tae-Eum) Tae-Eum|| Sasang constitutional medicine type GCST002853 Tae-Eum|| Sasang constitutional medicine type +Sasang constitutional medicine type (Tae-Yang) Tae-Yang|| Sasang constitutional medicine type GCST002851 Tae-Yang|| Sasang constitutional medicine type +Schizophrenia (cytomegalovirus infection interaction) schizophrenia|| cytomegalovirus infection GCST001833 schizophrenia|| cytomegalovirus infection +Schizophrenia (inflammation and infection response interaction) schizophrenia|| HSV1 seropositivity|| Toxoplasma gondii seropositivity|| cytomegalovirus seropositivity GCST002812 schizophrenia|| HSV1 seropositivity|| Toxoplasma gondii seropositivity|| cytomegalovirus seropositivity +Schizophrenia or bipolar disorder schizophrenia|| bipolar disorder GCST002295 schizophrenia|| bipolar disorder +Schizophrenia or cigarettes per day (pleiotropy) schizophrenia|| cigarettes per day measurement GCST005266 schizophrenia|| cigarettes per day measurement +Schizophrenia or general cognitive function (pleiotropy) schizophrenia|| cognitive function measurement GCST004975 schizophrenia|| cognitive function measurement +Schizophrenia or lung cancer (pleiotropy) lung carcinoma|| schizophrenia GCST005267 lung carcinoma|| schizophrenia +Schizophrenia or reaction time (pleiotropy) schizophrenia|| reaction time measurement GCST004974 schizophrenia|| reaction time measurement +Schizophrenia or verbal-numerical reasoning (pleiotropy) schizophrenia|| verbal-numerical reasoning measurement GCST004973 schizophrenia|| verbal-numerical reasoning measurement +"Schizophrenia, bipolar disorder and depression (combined)" unipolar depression|| mental or behavioural disorder|| bipolar disorder GCST000774 unipolar depression|| mental or behavioural disorder|| bipolar disorder +"Schizophrenia, schizoaffective disorder or bipolar disorder" schizophrenia|| bipolar disorder|| schizoaffective disorder GCST002254 schizophrenia|| bipolar disorder|| schizoaffective disorder +Sciatica caused by lumbar disc herniation (treated with microdiscectomy) lumbar disc herniation|| Sciatica|| LDH-related sciatica symptom severity measurement GCST004098 lumbar disc herniation|| Sciatica|| LDH-related sciatica symptom severity measurement +Sclerosing cholangitis and ulcerative colitis (combined) ulcerative colitis|| sclerosing cholangitis GCST001615 ulcerative colitis|| sclerosing cholangitis +Sleep traits (multi-trait analysis) sleep duration|| circadian rhythm|| excessive daytime sleepiness measurement|| insomnia measurement GCST003982 sleep duration|| circadian rhythm|| excessive daytime sleepiness measurement|| insomnia measurement +Smoking interaction in lung adenocarcinoma (1df test) smoking behavior|| lung adenocarcinoma GCST005909 smoking behavior|| lung adenocarcinoma +Smoking interaction in non-small cell lung cancer (1df test) smoking behavior|| non-small cell lung carcinoma GCST005910 smoking behavior|| non-small cell lung carcinoma +Smoking interaction in squamous cell lung cancer (1df test) smoking behavior|| squamous cell lung carcinoma GCST005911 smoking behavior|| squamous cell lung carcinoma +Social science traits (pleiotropy) (HIPO component 1) neuroticism measurement|| wellbeing measurement|| depressive symptom measurement GCST006665 neuroticism measurement|| wellbeing measurement|| depressive symptom measurement +Sotalol-induced IKr potassium channel inhibition (T wave peak and end interval change) response to sotalol|| TpTe measurement GCST005134 response to sotalol|| TpTe measurement +Sotalol-induced IKr potassium channel inhibition (ventricular repolarization duration change) response to sotalol|| ventricular repolarisation duration measurement GCST005140 response to sotalol|| ventricular repolarisation duration measurement +Sotalol-induced IKr potassium channel inhibition (T wave maximal amplitude change) response to sotalol|| T wave amplitude GCST005135 response to sotalol|| T wave amplitude +Sotalol-induced IKr potassium channel inhibition (T wave morphology notching) response to sotalol|| T wave morphology measurement GCST005137 response to sotalol|| T wave morphology measurement +Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1) response to sotalol|| T wave amplitude|| TpTe measurement|| ventricular repolarisation duration measurement GCST005139 response to sotalol|| T wave amplitude|| TpTe measurement|| ventricular repolarisation duration measurement +Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2) response to sotalol|| T wave amplitude|| TpTe measurement|| ventricular repolarisation duration measurement GCST005136 response to sotalol|| T wave amplitude|| TpTe measurement|| ventricular repolarisation duration measurement +Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3) response to sotalol|| T wave amplitude|| TpTe measurement|| ventricular repolarisation duration measurement GCST005138 response to sotalol|| T wave amplitude|| TpTe measurement|| ventricular repolarisation duration measurement +Spherical equivalent (joint analysis main effects and education interaction) self reported educational attainment|| refractive error measurement GCST003455 self reported educational attainment|| refractive error measurement +Sphingolipid levels sphingolipid measurement|| blood metabolite measurement GCST002964 sphingolipid measurement|| blood metabolite measurement +Spine bone mineral density and alcohol drinking alcohol consumption measurement|| spine bone mineral density GCST003919 alcohol consumption measurement|| spine bone mineral density +Spontaneous preterm birth (maternal effect) spontaneous preterm birth|| parental genotype effect measurement GCST004845 spontaneous preterm birth|| parental genotype effect measurement +Spontaneous preterm birth (preterm birth) birth measurement|| spontaneous preterm birth GCST002751 birth measurement|| spontaneous preterm birth +Spontaneous preterm birth (preterm delivery) delivery measurement|| spontaneous preterm birth GCST002752 delivery measurement|| spontaneous preterm birth +Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) Stevens-Johnson syndrome|| toxic epidermal necrolysis GCST001239 Stevens-Johnson syndrome|| toxic epidermal necrolysis +Subcutaneous adipose tissue (sex interaction) subcutaneous adipose tissue measurement|| sex interaction measurement GCST005092 subcutaneous adipose tissue measurement|| sex interaction measurement +Suicide risk mental or behavioural disorder|| attempted suicide GCST000854 mental or behavioural disorder|| attempted suicide +Sulfasalazine-induced agranulocytosis drug-induced agranulocytosis|| response to sulfasalazine GCST004781 drug-induced agranulocytosis|| response to sulfasalazine +Susceptibility to persistent hepatitis B virus infection hepatitis B infection|| Susceptibility to viral and mycobacterial infections GCST003615 hepatitis B infection|| Susceptibility to viral and mycobacterial infections +Systemic lupus erythematosus and Systemic sclerosis systemic scleroderma|| systemic lupus erythematosus GCST002069 systemic scleroderma|| systemic lupus erythematosus +Systemic lupus erythematosus or rheumatoid arthritis rheumatoid arthritis|| systemic lupus erythematosus GCST003620 rheumatoid arthritis|| systemic lupus erythematosus +Systolic blood pressure (alcohol consumption interaction) systolic blood pressure|| alcohol drinking GCST002307 systolic blood pressure|| alcohol drinking +Systolic blood pressure (cigarette smoking interaction) smoking status measurement|| systolic blood pressure GCST006188 smoking status measurement|| systolic blood pressure +Systolic blood pressure (cigarette smoking interaction) systolic blood pressure|| smoking behaviour measurement GCST003365 systolic blood pressure|| smoking behaviour measurement +Systolic blood pressure (dietary potassium intake interaction) systolic blood pressure|| dietary potassium intake measurement GCST005204 systolic blood pressure|| dietary potassium intake measurement +Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test) systolic blood pressure|| alcohol consumption measurement GCST006170 systolic blood pressure|| alcohol consumption measurement +Systolic blood pressure x alcohol consumption interaction (2df test) systolic blood pressure|| alcohol drinking GCST006434 systolic blood pressure|| alcohol drinking +Systolic blood pressure x smoking status (current vs non-current) interaction (1df test) smoking status measurement|| systolic blood pressure GCST006186 smoking status measurement|| systolic blood pressure +Systolic blood pressure x smoking status (current vs non-current) interaction (2df test) smoking status measurement|| systolic blood pressure GCST006195 smoking status measurement|| systolic blood pressure +Systolic blood pressure x smoking status (ever vs never) interaction (1df test) smoking status measurement|| systolic blood pressure GCST006189 smoking status measurement|| systolic blood pressure +Systolic blood pressure x smoking status (ever vs never) interaction (2df test) smoking status measurement|| systolic blood pressure GCST006192 smoking status measurement|| systolic blood pressure +Systolic blood pressure x sodium interaction (1df test) sodium measurement|| systolic blood pressure GCST006115 sodium measurement|| systolic blood pressure +Systolic blood pressure x sodium interaction (2df test) sodium measurement|| systolic blood pressure GCST006113 sodium measurement|| systolic blood pressure +TB-LM or TBLH-BMD (pleiotropy) bone density|| lean body mass GCST004771 bone density|| lean body mass +Total ventricular volume (Alzheimer's disease interaction) Alzheimer's disease|| brain volume measurement GCST000892 Alzheimer's disease|| brain volume measurement +Tourette's syndrome or obsessive-compulsive disorder obsessive-compulsive disorder|| Tourette syndrome GCST002682 obsessive-compulsive disorder|| Tourette syndrome +Triptolide cytotoxicity response to triptolide|| cytotoxicity measurement GCST003008 response to triptolide|| cytotoxicity measurement +Tumor necrosis factor receptor II (red blood cell fatty acid level interaction) fatty acid measurement|| tumor necrosis factor receptor II measurement GCST004817 fatty acid measurement|| tumor necrosis factor receptor II measurement +Type 1 diabetes and autoimmune thyroid diseases autoimmune thyroid disease|| type I diabetes mellitus GCST002876 autoimmune thyroid disease|| type I diabetes mellitus +Type 1 diabetes autoantibodies type I diabetes mellitus|| autoantibody measurement GCST001479 type I diabetes mellitus|| autoantibody measurement +Type 2 diabetes (dietary heme iron intake interaction) type II diabetes mellitus|| dietary heme iron intake measurement GCST001843 type II diabetes mellitus|| dietary heme iron intake measurement +Ulcerative colitis or Crohn's disease ulcerative colitis|| Crohn's disease GCST001118 ulcerative colitis|| Crohn's disease +Urate levels (BMI interaction) urate measurement|| body mass index GCST002827 urate measurement|| body mass index +Urate levels (BMI interaction) urate measurement|| body mass index GCST002826 urate measurement|| body mass index +Uveitis (juvenile idiopathic arthritis-associated) chronic childhood arthritis|| uveitis GCST006127 chronic childhood arthritis|| uveitis +Vaginal discharge (metrorrhagia) metrorrhagia|| vaginal discharge GCST006657 metrorrhagia|| vaginal discharge +Vascular brain injury vascular brain injury measurement|| vascular brain injury GCST002590 vascular brain injury measurement|| vascular brain injury +Ventricular ectopy or supraventricular ectopy (pleiotropy) premature cardiac contractions|| supraventricular ectopy|| ventricular ectopy GCST005935 premature cardiac contractions|| supraventricular ectopy|| ventricular ectopy +Visceral adipose tissue (sex interaction) visceral adipose tissue measurement|| sex interaction measurement GCST005086 visceral adipose tissue measurement|| sex interaction measurement +Visceral adipose tissue adjusted for BMI visceral adipose tissue measurement|| body mass index GCST006533 visceral adipose tissue measurement|| body mass index +Visceral adipose tissue adjusted for BMI visceral adipose tissue measurement|| body mass index GCST006534 visceral adipose tissue measurement|| body mass index +Visceral adipose tissue adjusted for BMI visceral adipose tissue measurement|| body mass index GCST003967 visceral adipose tissue measurement|| body mass index +Visceral adipose tissue adjusted for BMI visceral adipose tissue measurement|| body mass index GCST001523 visceral adipose tissue measurement|| body mass index +Visceral adipose tissue adjusted for BMI (sex interaction) visceral adipose tissue measurement|| sex interaction measurement GCST005088 visceral adipose tissue measurement|| sex interaction measurement +Visceral adipose tissue/subcutaneous adipose tissue ratio (sex interaction) sex interaction measurement|| visceral:subcutaneous adipose tissue ratio GCST005090 sex interaction measurement|| visceral:subcutaneous adipose tissue ratio +Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI body mass index|| visceral:subcutaneous adipose tissue ratio GCST006554 body mass index|| visceral:subcutaneous adipose tissue ratio +Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI body mass index|| visceral:subcutaneous adipose tissue ratio GCST006553 body mass index|| visceral:subcutaneous adipose tissue ratio +Vitamin D levels (dietary vitamin D intake interaction) vitamin D measurement|| vitamin D dietary intake measurement GCST005366 vitamin D measurement|| vitamin D dietary intake measurement +Waist circumference (sex interaction) waist circumference|| sex interaction measurement GCST000931 waist circumference|| sex interaction measurement +Waist circumference adjusted for BMI (adjusted for smoking behaviour) smoking behavior|| BMI-adjusted waist circumference GCST004500 smoking behavior|| BMI-adjusted waist circumference +Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction) BMI-adjusted waist circumference|| physical activity measurement GCST004563 BMI-adjusted waist circumference|| physical activity measurement +Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction) smoking behavior|| BMI-adjusted waist circumference GCST004501 smoking behavior|| BMI-adjusted waist circumference +Waist circumference adjusted for BMI (physical activity interaction) BMI-adjusted waist circumference|| physical activity measurement GCST004561 BMI-adjusted waist circumference|| physical activity measurement +Waist circumference adjusted for BMI (smoking interaction) smoking behavior|| BMI-adjusted waist circumference GCST004502 smoking behavior|| BMI-adjusted waist circumference +Waist-to-hip circumference ratio (alcohol intake interaction) alcohol consumption measurement|| waist-hip ratio GCST004579 alcohol consumption measurement|| waist-hip ratio +Waist-to-hip circumference ratio (dietary energy interaction) diet measurement|| waist-hip ratio GCST004582 diet measurement|| waist-hip ratio +Waist-to-hip circumference ratio (ever vs never smoking interaction) smoking behaviour measurement|| waist-hip ratio GCST001754 smoking behaviour measurement|| waist-hip ratio +Waist-to-hip circumference ratio (recreational physical activity interaction) physical activity measurement|| waist-hip ratio GCST004583 physical activity measurement|| waist-hip ratio +Waist-to-hip circumference ratio (smoking years interaction) smoking behaviour measurement|| waist-hip ratio GCST004584 smoking behaviour measurement|| waist-hip ratio +Waist-to-hip ratio (sex interaction) sex interaction measurement|| waist-hip ratio GCST000928 sex interaction measurement|| waist-hip ratio +Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour) smoking behavior|| BMI-adjusted waist-hip ratio GCST004505 smoking behavior|| BMI-adjusted waist-hip ratio +Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction) BMI-adjusted waist-hip ratio|| physical activity measurement GCST004567 BMI-adjusted waist-hip ratio|| physical activity measurement +Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction) smoking behavior|| BMI-adjusted waist-hip ratio GCST004507 smoking behavior|| BMI-adjusted waist-hip ratio +Waist-to-hip ratio adjusted for BMI (physical activity interaction) BMI-adjusted waist-hip ratio|| physical activity measurement GCST004566 BMI-adjusted waist-hip ratio|| physical activity measurement +Waist-to-hip ratio adjusted for BMI (smoking interaction) smoking behavior|| BMI-adjusted waist-hip ratio GCST004506 smoking behavior|| BMI-adjusted waist-hip ratio +Waist-to-hip ratio adjusted for BMI x age interaction BMI-adjusted waist-hip ratio|| age at assessment GCST005961 BMI-adjusted waist-hip ratio|| age at assessment +Waist-to-hip ratio adjusted for BMI x sex interaction BMI-adjusted waist-hip ratio|| sex interaction measurement GCST005959 BMI-adjusted waist-hip ratio|| sex interaction measurement +Waist-to-hip ratio adjusted for BMI x sex x age interaction BMI-adjusted waist-hip ratio|| sex interaction measurement|| age at assessment GCST005960 BMI-adjusted waist-hip ratio|| sex interaction measurement|| age at assessment +Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test) BMI-adjusted waist-hip ratio|| sex interaction measurement|| age at assessment GCST005962 BMI-adjusted waist-hip ratio|| sex interaction measurement|| age at assessment +Waist-to-hip ratio adjusted for body mass index BMI-adjusted waist-hip ratio|| physical activity measurement GCST004576 BMI-adjusted waist-hip ratio|| physical activity measurement +White matter integrity (bipolar disorder risk interaction) white matter integrity|| bipolar disorder GCST001764 white matter integrity|| bipolar disorder +Whole body bone mineral density and alcohol drinking alcohol consumption measurement|| bone density GCST003921 alcohol consumption measurement|| bone density +Whole-brain volume (Alzheimer's disease interaction) Alzheimer's disease|| whole-brain volume GCST000895 Alzheimer's disease|| whole-brain volume +Resistance to antipsychotic treatment in schizophrenia schizophrenia|| response to antispychotic drug GCST004375 response to antispychotic drug schizophrenia \ No newline at end of file diff --git a/trait-representation-migration/study_background_traits-ALL.xlsx b/trait-representation-migration/study_background_traits-ALL.xlsx new file mode 100644 index 0000000000000000000000000000000000000000..255361eba0977429b71dc0499a58ca8a05bb1e13 GIT binary patch literal 95862 zcmeEsgl)MvJdkvYZ_<-_m zAKHV0pp|B3_LvrOi!GdiZ_ZhcJ2L0NemrDaVQp0n4eoAGL=W@rZB@}G z;biUV*`sM8B!<~*Y8-yYBl+-#SVt$qI2kU{uBJort?054r0At7K7qiO)zm*dsyK_? zb?60}dEC9TZA-GM3piZ;`4iZyV=sQ0n=yE3pRT@^0)+iXUo4*S7Ojtth2vK zkZyLMujQE3H9%Nk3;f!IIX}Gktf85c{Nvk~75SlO1)AMoEtpz7KY6;h&_{-y$=}q! z$2Zk^t(Eq{_Z4(}8cyCKtcswR-Fn2UQxHE(X5grua{iWP`2}g`B8g#rTGUrVSt2Sc z=B4bOG*LNjPDZGAZf{>LSF7B<0jZ~T&KU9X*ehs%sdt;# zV{dd_%kSVge%pur;Tas<<0B%R{Qu>aKULVM&j75+0ABYTa7!I~BTENXmZ#7E?~ebA zeel1DUIhCn*TIG!cqn-n)O$HO{}o$U+C@mR;gz!Y7pXa{pAlJLlKB=oQf%dyeuxr2 zP2P9?v-5lrJH4+iR^Aqc;o|X9SGyDkCfwLLAv4n2$BWw)EqCHLPo7U+e3O8<(K|Oq zF&5V5Wk~leQj1RjW!<2!lNL&o7rf*540NOn>Xo4IVSqWTXMSr?Ib3!WzU^mdnLS}1 zI6E|6>+6|Z1T6jkLgoS+i%|j*4sHY)4h{>T03h?KsNW3%f1a%_(j7Y$+7VI(Bq@maXL^~+Bf z!p^8vCPW&IOoj~gR!{*Qn>}m|KjY7RFK3QH{73L!>JJaI*Rll-S`3HGa9e?(NzKdh zRdlf-t@kN?X)a}oQj_c$B0rr1we3_f-)+`gkrEp0RLMAQeZelQ(d{k3MH(@DQ{6a$ zjNL_& z^&yV<@{_i-6T8tR6N%26MKet;bD0x)SF`BwQNOrP*{>)NgNHR>!w5>i7R&pfFC5{; z6Z%XQ^}^OaWxa1Wp`X#Mt6N;hFWSU)TGDLonK2!a!K7&kPtLWb^Gi?HU+0Bs$z@YN zK|xw-cZUk}n1s*okTf%l#0IT{q;o7Rls`gKMi7Ht&Pq0JC>FT1GEz-)3`=cVeadK< z!c~zw$x+DCS_m;4mHD&|6`7u=u~tN3KgjKo!{8ZMqg>7rGReHX1}EOSsO=7Fi*2`G z@Gn+&IO6;f!mE8Xj5>^PgP~0Sk`NYAFF-r3OWS+tU3Nw{JHiC&$)Zmm_UY`2vbs4; za@$WgZLGQ3mN3rP9T_#ot6?S-pSTOD<<|sZ{TIk9^ zdu5>O7?mJ?_qUm`u66r27W$=mhktN_Ywj&SdhU(uiX3(Jx`~@HCVjBlDYj<6p;MAX zRW_MO-fFK59U|Vz1S?%^Orib8)3u!VNFoBA?>qM_6~uIR!{m2`!0|7YX)g8F*d4&< zv)S*DUVie}H?byXK4F$ajG<6ETYbzr`}jL@)8|D;g)u~jNp-HxXB59w@%@(=Oz4+Q zhYB<7oN2_+hd@iqbkS*9rJY%!>SHKU-*2}vH!6!YwL@mU434IuZ{*90Nw-`P1{2ni zmAQR8Y<7baVbX*;MzkC~H9pmL4jkD>L7QAkq%yolBj2)W?g;-UpCh?nDP00WG#cP@ z82|X3gQJ_Jk;7AX{-L5}Gr@-EEwLh~?mc2}_Tmp?pXjVu5(vdiWM%SW%C98W=>15% zPM=LKsaY8jHgRoFPtW1a!%vkL;;2pd&jcM7o524f<#O9yY=QH0wQ8*L$O-e z+YSlyBd3RpkLG*P6Ak>?1n~ZEi5IkHOFS22Js5-Q6ko^LDl)we4k)(voG^zluBL!4 zvnVA!g%Udv+aa;6@HnD^q?)D5nKbeHL?##0272KBNh|6&T3$@$23uLkuYiz9`CPe# zvp*)6D5~a0%2uUtQ)*5_keif)ah;nVjg;^wyII^8L`m+&;wRLm}6uwAYr zQt1}#Hil7-yZH5Y^WS^(<|?}f^1p?1*Uh>lv%t$NR*1bCaMLh*?@jGLQ$XZUqjtj% zD69E^wNNB|B?Z#X;#$HW2@(_|DWfaH`LVXBr=XU8tg}R>_m;-#Li~r-_1Mq$X)k^? zT~4XC7*L9cP>CGJU0(z-CYj*4Py^y>eBUAnD^bNo%0$P0S6n=O>-6>4$+HNLm5Yhs|X!6_nK z@Dw+&Aug@a=36YPnbjv2ZQIy1w7u_{-q~cv<4P$-4_eOY(UmxHA^aRjm+b4kc>lqp z-;0>0?UoC@QJ=tnf$!CGo9IFP(%=r$Ed9Uy8tv?~ZG$aYj&kTDhM* zDy9ViRBabnLRYzvtAup*hv)y3E3^?}H_HNU&`tT&ZU0R_j;2OdMy!87-#j_Qp2koZ z2`3PQZv@dDT<+ejM$s%RjabIagAG$-Nq<)FDX4O=!x~9mAkc81E7JeSP7t=?j~)Mj zh|zQwg$l0PrWm6enx-yZ2Pa!XG@UWRBp#Y_b1&1p-A^5l$D0z}B@&;v!{T+C@6VSi?#%rb;Wi{!Bx} z`uih$os6!h`k2GXcANP)C5oS>N45@P-lv}P-FwZJ>hWB7)3?yLoa$+w-8k#7dKmII zlNk+ahbjXE3!^%pE9=M#q5`JAEBllMQlQr_i9IhBVi5S$5tM42YqC4_9ZyHAV@i5o zTfXMZLS9tLzBZ60;HSAu-5-3z_N~Yl3+R4AO)!QLg|8Tedx}aj>QtQTn&AiR0&rgt z6v0v}eO>5sqbL=%Vf5TfowGC(D7ZF(xU{;p$_y9~m8((#--jIP&}ugJA90^`L)1wW zFI@FI`(&!`n7&VPQnIG;dpsO%p9Zz?`odAz?TT+nHG zINCYp-2O#(+}_!8cRi5M@_5X1UbZra&)V#Da;ul0bKb!~FM_rfs@M{PpeuQx=6iMQ+hI@5q|N4A-8iy6ND))-u*!LgF1!(}z~VQ9eF6%T(dBWhRhfy6 z9n_V8J_Kj+$Ms9mdB|t3^%Q0I)JV*aOYacYDb~U!7^aZ6*kBDUQo9i-8YT(u1P7j< zZJE4nDtmNw7Wns@LByWs#FQ5`7em+z7EnIDKom4|!g**g{=+BH)Iv?mgV^NhC`=PiPC28Vy@~JJswyzc?2%|JLZ~+fRFVvXv&+Sia8jD)wLisjETQ#S7Fp z7LLr8H>*%jS7#1COm&s?E|GaImiqOo9jzc8`=6*$bWIVX`PP(BnR8`V4%+VqKZ2Z? z@Y6?&Z)Hziqar3`P3ns3lk%S+j>cw%kMFvEu_V^C9whWfDA1TRcGCbq zx9VGCcnR9@H*xnEj{I-%^7^bClu?dKGxc_E=1yh>O=3S@Q-?cNMzD>uK?#?cd57X} zHM;A+1^r@|tJAL|vFF%{z{0T*qoS+zrKMFG?c}w-{%MXa0x2 zks)8g{Oosz-uNb$;YY7uyR7K;n@%-`j&sLGQuBn#J7*>urnSEdDH$A-W1=9En@MWR z*k$2MEI_TS1!K1Lz3glI5(}0(Ox#H~ zNaOM^uQ0?mw%6%{>>o86WjjJED-~v|IG9n;<$k@tvT_pV;y*5-6YNbL)O7m5ybDRa zy6K;5oHRyu@#S;3_2J4@+>#fzNuZ{`87JwDeXkof7o!n@ve?K?_xjPB!4i2MGW|OC zrCtlRvY%oGPIX~`Gm+}Rec7iSCq}F#-DrhRm=n7<@SpTX#hlGbd!|?pR@Yw-1>l5* z$>0wH6-`n?2>+;U$A&R2q55LdF^6J2%xA*nNyiL?1|KrqZ z(B|XCz0ZT(;=}d9{i5LA&DGVh#^BLx&|%u+&GG8tVx#Nv@?>e0jgI%#&HQ0h3)0Cz z!zJ)5{PFt1hE?G1;o*3FWcGWFjrJK9)@fJ`tIp%a-30n#V~a_oOUvEK&E)F#e4$UH z*WLbVuGE5Hv)lEXlE;qHQlH18DN7rjd5-zngu};&sKpld^Mn1vH(he2i;WLgrB>sc zBMZ$p8;g$@vkjN5KJG7^A1g_8n%yr(E{`9*?kui$O{#sYTh1=d3oj1^8gJKEr{0`~ z$xZET9O~@pGvGXrYwPLR*Qv^ji8}A&C2g~^k!6uK( z%ebq<<0x|daV!$O)U)-%sM1GQK7nSp)A`em`o71J3yx!*Rb*|xd*O#epZh;ivuO{d zhw1lcCmpND^U06*H=9u{-E!Scr>Co|tdGYVt3Do=n?7!y_cc0#-GZqd7fz?1r>8Bl zQ54!;B@xos^*TNqlMS42Ozv(gYf7gYSl`bN_;}Y}$SGY6OwIEN4BnsJ%@q20UR@pR z>$IG^UFG_gtIoDwjR-#0$1m^J@t<_%>MRuTHQimE+}bR*+@5M!w$}P%wX}S)**r+T z8Y(0tS8G)CL9tFedG%1>#ic z1DuPFw{1F$Py4!wWjF9{Ti2nWOCYLgpHCo~+n_NHPe?2$V>!Ozs_QJb4QcbL@8o|7 zCEhI)iA2y3OLDVa36$zFrnf+?SKqlz8#66?L6;{oC4}3=Xvg`@v8ilXUF_| z(4{`&`vsv7%-0GZn8)+qD6%*(d@=@ZuFTcK{^~9CfhVwAvTkrPY;m^{>QN`deDe~M zg_7W&9(eyEVo0cC1*looptEdyz?au9@_4*! z^jpDX_KLulqAer-Nf<Q<*#Pf7#DApr1>} zRXT)wy;+%O8pY-A!0gkVjv8hCLE7?9)6;^vPg@{!JHYIq397k(wEU??1V9>BJGr@4 z!I4grcg-v`Wb*Dw&nv3wSz$Vb-#yJo%RSBI&)8KSsR9>H~#OP_o)T!@xPq>RT6v)K02wE2_XJBx)vgU%442gEgaM&VZf zOudrG;WsGC^kk9$RglVlYV@DuuF9|87utf7h=ogCo&w%Ub`HRvRN6uZmn?RRwPg2;wh~VeUV5dval26 z*6_M7#E!{X>+U@euvT9}flH4BQtO$)m+fBQ5_hIC%h+x;3AJa_C2A5JSMQ%Lq56|Z zt+_c>SoXQJ-LW~bajcSrNx_OH_g4f**0WZg;ZOu3`()ybcYFeeg;O=X9;|jFIHf_E4>Hswz&IZKtb6>*b z%uG{B+59frY*Pta{6qNS6Ma*qXb+hZNvn(%9LHO@?v+%0*;FDYq_|!_Y0IC+&vnIl zS_eJ<-pU%5yP=G5$y`3^PWr{l$+4<9vb~yzIC9FmBt2D!(awuTXV^oa4F6eTA>u!; z+HxLgn!VCBL(D_6)=&R>1t>{rzn@j?LsLEJN*Pv_(9mvE2qOx%>)K1n%Z1Ck;i(CMAFm_fYE!upxBsq`=px=HgxuqBc?Qj{TRcXq>7hYN)qN*A+a@P!hHw zh3R2igSSKQbL;@I3+_d+X7-Wk#+K>AE|Jwn?^d~yEY02_m|e~?o@o!578up7`bM3V zyrJCwAlu$NxdF#f24}1bKX-GgwsIqjP%~MNSFK5?ThG$!`1uP-iG^CoF4MJr=?L&^ ze`9pa@iUQCgOo(gV1DO$s=qcbDMn(dOu)YDTV3V_;v=JDaMz+r`vau8XjuQUzTMJN z?=6YemvUDCM_oz|jCwwFdOmtOq=1UTjrX^HWKB@_T@V}++gdn1t!22F{G+~qbUCM< z>h)y00pm)M`Y&~We&2j7DMWL>zJr91X%s)p5gb& z04xzI*__7v+}uylYuC{L@CfvrXK<>0FRMcc7{aHwEcvkfyGf}J?Sh*f%lQiHNhj4E zp@7vSRm*G=U)V6mic;8XvmNoR=q2ylyBwb_MRU!=AEmvw^UO+`;a7(FMWnJMoy)9v z9)O3DuO-sPEH1&ZpU&_$c1o{Z`B7uGRw+YnT)#Lt(5Rm zjin()zvyXD;Au8frun=@4qj>aj%dpX>AAg7nu}0u1ZK^GIi2hiKTc-sqcW2QtT=kL ze!ds#sr>4)aV2iKL(Z7r(cNq*$W()4;z~7qB|6uXzQ(f6oVbQ{tf<(REse?c#&6nK zTKpE$=c-z_lBSr#Kz_UdQ5g?D5YoRMmj=+tUA5};70{f4<(F?4o}A>8KYT7wEsfo`lJp0m4o@_vOPvu}U` z&w?7nuCq>^p^KF%B#zMt?`v6m1nI0C)dS|`C!%aFIVg4yBv669*(tI>OXUX|6AjM1 ztfE!rXI1l&Rm#rS(u5xieOY6I6i#lvcE=3jk{O9;h&%AJ@LaO+I1^Y_)TY8=$5vSo z;(#p!3};E^g^@usW%uCO@w{p8&?i0Dq?2n})}JYgkF5s_RHt8^AVSg?f(=I&xvYHkW*H7GbwX`5-7o`-+xvI>NwPi0#v2S#NSxb_=>UGO- zAkMJB4goi=yl;HHN(<4VW`YID+QsD4SkGdeCM!T|YSK-;yk_!JaKcps_C+f!)+|mX zR;usW79wDaKBgtWiP-xkV+&$YHMudD4aTu67i(e1*0JF>Br5&%qLh|Zp_a&VX}Nec zNz4FtxU*`@?*ZxZd?SiLJ^XRh54|-D2Dc2>#7MT5BbAX9Ni1IY2n~W+*fVA2HT4v> zg}3mR`w1L@(UXg8jH_Pba+ChfD(Fl^anv`xgjELFAQv<3rGtA%ZzkjZtLF1imzvOc z{BT%!t2SiO*aKqP)3y>T`6Ggl-L3tKi7A^{YT`DI9c@gQq*U@A(%GUPyRs)1@cY9> znp${0YnFOf|6h}7+Z>ACSpG1!jU zjRYLIPh#Iwx67VWQNt6e^04<1hg)7{AuiQPF;CyM?}m2z)x>Q3Wm;!>iQn)P`l z5n24hh&BEMwfye%Y5l*|^A*Kkomga%Y3_fSjbXKY-rV~73T+`$sgOlWFB?o8q8Z*r?*9eLjQsUaGa`^m}SvQ-m{RY;Bh|*@&Xo73%f<84HKA4nqcZ zU(J~Gc55*|(p(xJ9v~^06aW@#07^&11%VUtoJ%?w#M~9+*|gGpi`R06Q=|;+Ijyrk;fbNUuqf`3li1XAXGOC5WLJ5&I%uF@om=u7{Ks+fArIOL)=yqs}P*GxR&j>q$-1Oz`}2W zu4ICw8E$hv2PuH2(m#IGh9FyGHMj1!5!UiwF{Ty#u2(EvTD+f?TZ5-7*n( zdOk<)>C0*Owq6ClOjkK_D@H9<%)oX9XL|L*Lhk1$*iO8{s*{~-#t zJt^R@b=YpzirOvY(p%1S5N9iIb>9-*vDKgCQWfq=9(ZQWLgKoc*vZJQ&c-OQ*C*Id z3k!HLf)u2{z92aGY%cN?-ljx3|JkehfEb^2j9Riy!~>={4p@j$#}%4g_w5-r>Y-{s zk?5SQ{%iK?bVCrIFbQB2B(*L#|M%fA10p4dYzVO*J*BL6A?Scbi~SjSIlmLpAq#KR zVe*J{VS)Z~8Z7wWCuGbtrBM}iuEKWdpyKqf#>1Q@wOh6dkB(K9@t_N`v{9i_7`-UZ zvwE4VamAS7`UnYGT3G`YREt2?b*X4P+HV-AD02W@g$o%H0=p1udYqQ3@0EWahbq9z ze>imQ+^ceTwL_%3*=BDUsD`R9PoYx)090DlVhXHU$E3Y zCX>$BdI1PO+yn;~3xtZsLj&S~=)qJ*^^4056}{G`h0n*u=+>z5a}hIxkTX>e*S9-3 zJKpT9)h2{O`zW<=m|wyWvuB(Ja}f}UwSDo&xP6899DPRP0C_H=zO+z5F?dfj$L<7;*>+bD zz6PymF&HE^Av~W` z12Q=T^#ETzwME1C^|pjF6(zR^5cv0u; ztX9_n`Y&2?YRAS$p93fkbr_;UQa-l4!z?yV7;$KmSaCieTrD3rArpLCd8YDEt{W@r z$jTd*xVC3x($%zwKG#1Ct!Y|hM9^SkoFdx5ncW->`LQ-w;aC(KSrd*>%Z;{F9IhV+ zWhSD*SsWOqV&?XkA+9yT3k8PNWbrt2yiAtAQ*o)jTFXea_}X}K7@&`)Y8t)mkoA{s zz%@AEQl2hCV{I+oLvM7F$^D@}6B4`jE(>f>s~@|>!s&ZGPoLUirkpSS3JN<#Kg5d^ zW)EZ%M;(sBP6gC8ehu8ijuu_jX#6*~8C8D3R4BYH2VNJi*p& zgr{0Z_>G^l=<~IlsoroWkH5C#gs@}&UXdd`6kk8)33(>D;|rNO|&^uolJW_Ssb^5h|^A6r6|7xwAjUv$wwt$dE++I8>Lm{RgIcX}tB zQD+E5>gNOPc5)2E%qd)cOm@%IRw9=EB!F2toi!QACte+huLrjz2EOT5lE0E^w394n zmD0A}3sZ1DO86J~-ZtZcXVsP(&OkeVoCRDM1FK~vP1bz&uB*#7v=RukG<2L=o8TMR z+In~Mr?+A#D{1}29s2gTq=%8h-9TlsI<%SH40fw4k5M?1MP9Owl{98i780=YMq^+E zj0{oBB9!V681L6pF2VVv!4S@Q2t=9jn1t7dYOuyVF?;)RO>Vn}T(*S+h9zs|VfsIj z`uNd}iwePOYwZYLMal=7%)jB_hBZAb1<4M@jqU=U;u)AO;g|Q_56*ce@2~*tirzBVH5D=(c|B6ORk(d zB{2#2jO-ek<5g%&t>%h0}-e~sG37eZGbX66a!kD>)6OI2k(*v&N6+e@-GoP&RR931#wMK z!?~n&Lu=A=A+UrdfX|CI-hTong{>Atn+=glfkH5NUB7>c-}Wich-cI?`0d_#?G~oq zGYY#s^3%ZL!cut`jT`2a_|(W}<$zRoEP!Kj`T5vUMg*YV|z01fgY-PP$me5M>G*hxpJ)d+n zKLh7E4JuMV*GMPH$B5=1u65&uXcS6Xbf)G{q;>KuBnGll{>YZ5>yN-mgs)?+jh}+&F6(5=9T08Q%p_#Ex=-V z(L6dY2H<@X1a2;*+EZ(3wux-6nU7Rq+KK=)?Cecm{%QRvl3YuJ$0I0xZbG)mmo=S$ z$I5vTlQpeCefyWCsyT(})z0I1`Q9s<^Rr(Hv3RT=3Mq5PAZMaDX%yam1&RPf15r2KQfn#o(en0J4t!n~LIZQ5WvIEp%XwbJK)}8$V^Df6UDw!*ef? z21M3iA?#cUOgh=h#U+tbN!4*+L}(u~iLbxx999m0^AP$UUz9y)jL*Nq&$5rulUNT> zin=c5r@8vaO=S;ch<+d+EC48uG2U>!^yXFgRd&5dil;KHskhe@g) zsPFOFH4+CL7juLI0ahDK=Th`NP~keUBXScO)w$nCxVqn`c9io={jZP-aTTScxHTN% zR2p>#^K7aRb8I|30j7n!FJgb!<;3^*nSwg^(X%8q58O()!uvl)^M|GCDR%>?+HnUw zcOmRsYjHg0ld4;C?ITwH304f3$_$Ynj1qSMv7H?1u)axA?24*0LE}Bw6LJp6#bEY_ zK|o3mL9gWvO|jdXz?m7L!(?loOxF~neGbI%=F5&@fGN(p5c1l0o4&JpCT%vBEkFW= z#d!z<>7Gn%Sn`57up4O6F?pXa4AVnkiA{j~_hlTmE_mG3GfE{?Kx;%M*4=Y99wp!& z3x4AfT{KsT;6Z6k91sbd-a4cJXLAn3rT^^nI6<3eKrR%1O{4H-b*cjeI}q;UKl|NGh9!@ z|80Qvw7CBY$94BrIXGk{?8o{-)F=XH0_Ge!u5Yq5GVo-?^Nw^%cNV(!uW?;CC4MWKSQ|p#<0212^ zE?s;@X`CegEJpu4QkbflkV9x@4lO=8`Gd zdXlAkTphNdHM`z4QiIySnc7b^tKibcIKU%e<2|1WtaA^rn$6)YV$J1!h}M+Irp@nu z>8GeJd+?DYp?2Mw$fl0Wc3>YgGCs63|2N+M*GeSZQ$-Vhv8(VGmai{!BBbY_Ox;@D z-)qfQckcEHLI2+I<4diLV93>7{Y=QJSN6#j36l!Y3!T{8P(8Ej2Agct>VE)ATJlBy z#86+^Q2`h2aUgWYuzTZ^?CF9$>X*>T!|YXY1ee<+QSw8OY!o0QqEo=C05kf4ogfN% z)BB7v?{o*nhLcVKVbBrD$bG3V=M!` z!;`6>DHW^8j-1;M6`rI`4P9`|-Q_zta3+k%=yJ(P2Dj*|6!a&br0u}k4Lxl1YF~!+h zdWi>FVY-3QwsmBVtnpRs9%KFCG#o9G&}%Vl^?Uvqxmu%>>=WaBGnKr?#pSRxKt?)C zsWS9*(7+Ke=%5&!t{oK!Yp}^sw-Dxt{bFaXsR{*27fO~@K~O%r9XJ0-t}9of+M}}) zyQ=Uw%BlvdPlkY`1^h=@u;Z&ZJjP1Gci#t);1;oefU4y9egE}#5r|R1qK~V@uB3Ib~F608A%`)@}%UWU<+3<>^V0>;oI|C zmAZ;0zPGGL`ae$Zb3f&FQ=lx^XDx&T&Ag^#OeFsoHW^ek^rvg%6tNUW_jq_e^MBR#4F@@pgViaO+C|*;v`&{` zGMkj_NqXPr4Z&p~6As`FN~=&6R`Rt`?|S##L*a%j)rq!xd;IfsgI=O9*4TSL5?T{J zO-9cS#xELd%q_^{P8W6UR`rHNlkAb=M@_-$M@@;SoT^3k?2g!dLu`XJnZ^VcL&C{z zHB`n&_=p)}h7^$cR1)6OU>X&wM&jtmCez{81@SAfA^zz}Zoi|iYobd6kiMW`lkR}Z zkMF`LtKp>>`(tKotX+}MDka;~L#&?0G=)+sV; zh^LG~@KIGK;M+hE$k-+7w2aH2cfVfCSwff(3*rX~5d%CsMwA8c ze{OUK<;SmpQ#lmjR&_xxlu3eR!xYI1sCVC&G*EBPdPDJ<@C8M4pUlaGJI6M}DkE;t zimrwp^PDDn5=seaZ0*$&FH5myLIz3>HD#7FB6vEvqL(E1;}kBA>H$aj0JtfIFK z)Z44V0;|L1pmkU@oh}zuH}1dFYxUF_uCeil^VBpH5V zazc5r%o?i}$Vnif-${6hjggNdmWD;_qplXhi-}MU_&%7rM=74Xs!09pnb&!d38pw! zz;f1RL)`5zCva zYgFiryMx`~3Y^$M*G4LUlJj-YLh@WAVvHtwR7jMkRFgI?M8148N$(lCo8U2BiF%IU zSangXSFoZ9VZq#71UM1#RU0V^>c$8EQOxnehmHH0pggBQy=LNUHk|Q4)rOSn0bc}{ z1J{YIiB$UqM8`PLE7hMtry8V|^2>ceVMgFj&KL(3irXTFLRnhISmWSnzqhEW`rtNq zJaCmeUg1jy!*d)NxZw=3`FVVm zG3Dfzw$JqIb#vBmxjBvI!X4a<(QOL{on8y~M#=9GOT#k#B;5n`2nHp~?)*Tf6yRDt z?#IOB5mp+Fu~E}LGTa`JRf@*&zU@3q&X9g*1mjZcsNehPq z$cjMtRJ?h0lCGENq%B!C{2Vo2En0WeEP$hyuA7&rY`zo|I!_j?&m_uHm3 zwgWM}2mewc?@SdumhEuN%v0hZr=lVeXq=N|Sp_Dl^*3XR230UqNCYO;1%Q4qVp~`{ zSe<1s-F5)nW`@d)Ug-a%$)y(kMBEahXV6=*JAV>d|7yMLIT2BzhK0g;uxs$|U+rKM zKw;6$Bcq-#Z0S*>toIyGJ$`D%3U$~&9|Nlgs|q(Rx0~1CYVxFtNO?LMEWVd{{z47? zg>Yj_J8sram^O!uu_=ivqgODTDd~BoFe$2PFm)T69R%f@j@Fw#pFe?d_ESTs3v1-Ce3TDl51e zCr)=UbIzO9%18-SvHe};32W65BMn*R^FLi?d>qpDp5#BP91U`LlX@(lQIT%D8Eul7Y+|UEKX$uXiW1Z9)S&jOXgO4m z@=6u-Pd<;seXc?t0r}=8_K{fz&U6X=LQ)vYZxL-fQ;1@iJtzEADhpjV-fYRFbdAgQ z8J1yUTLSZoKb#s;jgIomqpnw(dO#+oZbKkOCFu1Bus==Jk+u5@l=m( zu(hO%!5mUojMImiUhR*~+9J4Ik1xHF?Z+4jwJ16|Ezg=u>Y34cqx5ocj>p}B8cLBxj6M)BTnFO z5>F}H?5SR@rJx4J zxxZq3&Xe^0_5-x*6)rPov@RAofU~I2iojI_j&FrraAij4QGUmF$dy^T|0YgKA0+`! zBjKGlDC!~)*Co@($0TDAu&*F45@F_;V=Ic)$g|$s`l*Rqq$&-aG#5G&Sp!!oMyYI{ zK77cj|DLs7hXt;^{5q&_IQcdn9prI@Ev(gB0p{n)tJq3(XP(45&N}RN7HI4=CG2hay^0ik^zgNR9A9Of&ZI?B9MkTcm$?IATIfy%mi<{S-cI z?s@P0K3oNrdX$^UcX+uQ9ri*j@N>OwK1#UrgGVxphVf=gMC-3M6uw6c;fHZN=E9U^ zQnl1E&*f=I`P2v916@#B{W}B)WSX}v_wV9kML2=uytJv=T-bm~+`Zi-h-un3v0DB} z`^O)4^U4D?+pzTuuaDHgzt?~WT4T$kv7Dwu;|j$1NcvUZPTEr+wRNC)9b#&{RV@vg=E0zO_&3F?aYARxqsa!g&T_5=2sE56ST8TaQTZyS) zS~VHI`OAnVc461cHjEhW?p_A!Q$3Udb?Dbcgn#$E3pEL)VqrJ1{yJRl*bkL~@a( z^Cin-fgbE>fS?T752}x2%ul-s&9O;+q*X09==yL}i~=Qz2TFe?BXY(WH>)o2yE9!pw=zr%6rnzS}m9tQiY}zdX8QKaCpDOTg5?Q-x-o`TF=uQyw|py#70 zZFBsn8wZCkFvz4cGoB!<>ct7I^Oyvs%7o7wv$?QxR3V-*j=4P=grT|1s(MifmF+a( z?BOJFBsS13S8Pm&Wfuf8dduc$2*7la-s2XvibL_I{YNeBA_|2~^!mV+i87U*$t+gC z7tkyVPG#h9=c7&kU9+IIsbQE)j*#$v6ZnCtpFNR*-`)P3pfjn&C+XP+|3Pvw_`#ojg zb3VFTnLSCU1p5&Go<+fXKZy!H5z=?H-qqHh@Ohqdelx~YMvTP900^*|wbszd`%cjJ zB~=yC$yACRUhcOcfvWK%Q+!Qea^hu@w1RdWW&LkP6wW{7_MLd(4tjhA0w?H{9Q=0J zO}wY7f>34HfxYd-svfUTeJP42roPt@x-MR(8a+5#(i(>+A`y3*B2${;&lD)7Vz6Q& zZNLg$3N&iR=z!D(^}ESB$Md{gSUD^u$^oI#1pRIEp9-3T4Cwcm?XoDaI#xKy<2TsX zSWr>V)M)w#VR^R(R{PdYtJGob6pgX2C2{fsstSI$S#HYzR@$ zh}!O{yxU(RW|(O(T+8#1^hJh5fv=2zt@(v++9mid0o_Bf!HR(t2aqA(o&NR*EF7DL z8dW-jEZFxlp262DwGub!aG^^frr#>ZJ?#ZnE=Bcr#rj26AMu`949MdTkYNLI%YP8n zm!CS#+F{~@QuB`N*U+8A=TJ6|*XfcpkyaU7+a*q=76 ziTvcrZQ`&0x)dn&*}zzd7JZ@}d67T380a9M_7&D{trPUKY)_PTD4PH z*MWr5%)%Z2OPJHyo`N>j2E-{d>@i3yYXB6iZh=5|ZU4l`$24P*@BRNF>?`A<+`4#Y zh7krqNkNcKDUp&8hLjdWQjkz7MMAn6X#_+% zAN-B3XYaMwUin|^86le)pG_V8pvuu6V|o3Q_xM9$EMrvnNQp_*ZulidzNVU}3(@x2 z_TEUlo9qyA^T&10=j^Tzn?Q6O4#uE{2#8Lbpnf zEE(QLRqnu|>hlCWzAh7`OZe*&<=jzI@|yb^qy)6uxej~T1c)g|#-?w0_zPf!G!@EP z+Nbea+`_i{RbvF-S3-)>wIfSLY?NzJk)+~FXxiKd>|2IQLRp#0}O zTIA-g`P3%Bs|_v5PFZ zm#uxlc^~8;>krW+xs4Z_FMI*hjq~2-A=$lr@xU=(nYd8l>(CL)jI6aqfnnjLlf*+K zji>V6JYyfiSaCq}iEpEqj1HG-u&rl`mAR?fl)?2l0&evi9~(vIBrP=KsHHdS*(~1u z@Bd(jX|0?gqE6c9jZ^l%Hg%h+iBz7n z&_>zUfDOMV3Q3kGUCqKJmcOt#aPLA2{G+NeeP}~#3)MINE_6qFlop>HD%=U?w=Ac6 zwHlu=^zy4+56%ata56X9KOp6%WNQL%Gs<6I z2fd3gPUOymEuFZ|z-vzfXy+lHKN!q)TtVh-qgP}d1pUN z45#L9DV4O{@8?#Q_jCr>XthNgXOC~;F^`RN_Lw}2hp*b6XY>(Q6n>*p(z09xX)IgwTMa^pJA$I*e60hd4Rhc;g)E}XjUD`6jHvTHNUW?irOfzxYh zV+*j|N+!jRosTxThs4)er)Unp#AQa$NmK2*dJax`nYjr}qPjc~SkHKUi?ZH`+(1Lk ziQBV((Gm=4-!>&Fu%VHxCxG=2>EF^R*)67Z;2F@c_skqU{6)6bqoNe=s5RNww%exo z=MhLf>*DLHwK17W3d0u+Yo(>Z&@=pX+ZFP}rVBMC+jpa`(Q4~DZsDH8w*e^NjDpC* zu4R3t)<0OiY0~zmO372cSwZH$>!hk8-R7welr2BR$ava~`;1SoUp7jUR?n zPV()#sO`kjtCjK>kyEs(!p`+JBCCERms7(VA=YqQOXmAg{7MwE3pu87I<#Ykh%Ztm z%R>lHHUU^lM@%1~Y1(&9e$~*6I-jPqRjfMSguawF@xK88RteArm;m3MA86}5kT;>4 zMsUwvc|H$i1!{N@-_s!rP$pG6i+S+b zuA9U6Ag|Fwe`~S4^`#!<2AF8y4sT4)BheGoMk9#4c256zidJ_rMz(Ye*wkfdTIXXG z?44CFh*>(V3OXOL4yKOU5wr=M?Q8o3(}5BwGW@4TiPDu1?tv8bc!2gMK@h$_SFDnK z*&`wbZp~&;3+-CU?*2*}$hdjz*Z~Iw7O!y)FP?v&?WKLs9OaHKYpa;dg&$x2;-3Ph zm-V4v-KWj;hh+%%J#FFd18|@GyVs2 z7D0D2O{ICqN9>~(B^;3^ymgnG=(@F99otJ<60HM29R@!hCajxYEr2iE$cTB2WvgTx zm#S(K-mq1>fpe2w-cnzuQ(7z2v7P8~kXgL+{Zc}B!M$g=9|;8ndAQ~oIAy8@#%n_0 zdzs-T^`I7+#kXbde=Vo}*cnLSoWX|JyRfCCt>~gVLMU+HmF>^9Plf0f0{im8zFQ4w z{XdR+_`>^!UrAg~pV9lf7t>|3Z$|GBJbw@}qaV|@j|oT!22Pio1% z$Os!amv8Q?%bWSRDV~fbxtF$ zKdGXNjdZL|$k$E2%Vc9`iLje@LY*~hFg$55-6dA*v*ThCD`}y>vaeIDe;;Vub2W9v z>pOv_qs6~Ej@z$tKf?_j0R3yTw#d%eoh<&0oAu|Oy_GVt0AdnogTh%&9Iwne$VsCQ zUMtmfG*}O2U8;I`+1zde@~3ZMr7T!~TyJCbFv{dH89qg>BIsL$(AmWReH+I$8686& zml8Z*4++Mf;|XG`>OZ6Hkl)-mD(*z~OEkdA_usPM9^>7-Dg{<_%^0cQ4JA)|pqE#j zMxEi|QDnx{RF^!&wnwzS3n1eUO9d4JbIy*pVB96~;p0a0l_q;OZH`HgxnQ^z4Sw3B zF-OPSK$K5?z}}Py6L?12#T8{D8ciJdTYY?dO}@mmV^=%O8xpY+Wcs>)uu)Nrh~Kie z=)xGvXKE^8Wsl?$&wA9}t^ICF_RFefW~K|~@^r|t?qZP_e1`n~JIlY$LnroFrM}j~ zEx!sw*6KFD(49Z>p#Kuq|DG~5JT%89`_O$VO?=mM|NQ^D=en1_ZzIiXx8 zcH_Yjo5nv6f+=}##Jib(S{l@5hNu~Fvr(w)hJT)+42^4N>>+F@?eAh1kWb-0tmTDU zRRHv%)^rF^m?x7X&vc(PL0EZdY8^I8`X|kE<}=~tG@|D^sz}m zConnMsz?iMV7KSvu&Lky31krnY2*&GC zixKc|7p)Wg+OM`cj`!nHRsy6fmB`>^CmJdTZ@m!!Hk7Pr|@@)N4QS;KE86HgBwY9h-`s=X}Cv2u^ z4&l0mRs@jWX0~0PxGSp3ubrfC!!1lkb(ORL{5%3@_~r~0mxvDHc&S)J zaXAVnwNy9T@Pb4^xyc-8^dYm4I$m!jWctca7#OcRKq^9 z^Qs}g)J{jdbe*1>1i2V1%ACTqZ$?T=7mqq1W+dS87W<=k=Q=9L1PQCuDk-Fr;7kGe zy)EUbV8v&6KRc22Q0V-SZ>bhN%u*qSa6*Jos^Nmrd5)rlneV)xx^mt5AmwswQYxmf z@+d+n50a%a1@AL&{R zqchOPkBmR=+N)opt-UwIKUEt-%a}F#QTA^4XjQ~f^z$YhB!n52X2nqG$uZ$o<#7*FOx$TYod^tr+{PvPeZwrlIA|CJI zcDLcskff$nsFG#8!Orj%_SiSaicZ*u~*fUV~g=mBx;QS(3Gc@N9-iIepu} zX`i}#J=Yy?g+k(eUrB2c!|HuVE=$Why!wn^Bs>@&4Ji_ZZrV7*4*EaStH{6pAPw_a zU)=B#yDL*-Tb*vk*f^)4cKxz}wigMc$oQ4kgmYUzoJCe<+VR#G8Po^}*i#vlF?Y`O z{dL)o8h4jTIns972OANnhWl(%^wnD=?gIRt`!7x+!=sen1e4U&FTbRKmisdL1rkAA zSr&*S(!c(`%=&tyqMh&YkRcn)azGLHHZ^o6(4}r%L$+b9X3_V|`{Y38_p0&thY7-l zC#8ukg0bLFsCZCS^tx@-L~>97!hOZko|GhGRCp5a?*6TI`uqFO5vlzFgcG#*Qap2K zN4&pRZGBGPG>rZ}Yxns*?Q?8(I_+~r|NH2T8HnK%2?rxEFs)y@xO!s}j|qkM#uMJ) zT=J5dKAdK+2n1iA5sm3(M`M*uj9@@%8Qrtwp<<=2!uq$iEf(|4_i!<&^6pmq5Vua=-eap;(F1Q;qAPG zfLel?XQYI5jL^+7MB_(|g@~u*531!nmv(P|G)JWJB0i@MUxiNYc#~^X1BUpciRU3c zkJM3t60jX+WvSzU#;fU$A+CL^2}DH1sT`M}@pnm5FHu3Pb+6nOXQC@NQq91DQqv;( z!Z@LnK95pJveuT~;epT-j{uw6rpL%q`=3L?FTyPy8B$N9!xtz>q=DnS{8djp)6bZF zkSj04w;33Yj>MT~B4%F;d(nnr2!aVVj!zCA!V+y{|r3;&!-6oyzbr_6{MU}cgk zq1>1wOEnXO#xIekhFpVA`)HkX%MXTrCayDbBx#aC)vq!%`n-Q@bpPOVhyF0Qo<#y3 zKeFXUgbnK}VY8={>w&r!a49kw*v_N^ta`g)^=kGG!D-!2D1_$MxtUOC zU&Gjsn4i@_@pMM2^ulDR4R0@t925H)a|`b9-pH#d^vGS_YTG2pYtVzKfwZy1&v($~ zo90v6@$*qQ@xbaWV{3w$;>)+9zl1mN{rhNA;C6%$-?{@qqn8b=yq5>kPy`fB(p0_p z^2}X-Hvn1twtj*FMQ?PzarZYt;AWmv?QUs+GZS8@||)+nOC6i&mm4pOd;QeZsCk`-ECugj8zp^B^<%w)?Ew z?_*_@coM`-4BE}{(ut^(CQNjBnW%W7VdwEaA z6zqPuDlq+7X3dwaoutKdYN&uk_vB&!-q(ahn~`hs59fC)?T!`&@gXjk_$|ex19c8Q z>oRYb`CHXP8bdZ6&0|IL+sN!hM58l0lNk<==`DWTj+*F~jSZ$*~K zCz|5#M+jJJ3QHB5_JzfxvhRF+3F82@yBqr zPv_G0tw_I@3ygU0unddWpDv|8C7V*#+^1RDlev zobx9YgJ*eSI8ECV^_{-`*AQ=OM%11?+5xDnSa^&|t`(7_c8Eju_jd`2k^CbFW$xLf zwBhf|31Z5Os4&b?rSf+l;=d^+Wq8CY^=U#Nb5ld>dpuvjXhI?xg!%}N%JF?A>a|TS?1|5@}||{T}BwUc=+q*vcumYp6KffGqY}Lxl(i4J}gOLgHRLV zTLQh4G5S<*KV)t662B2uQha}x&~hu%R=(4?q7tv=erfd&T-$=2&o>6reF1-FG5RoA?C$h!y8Ul;O$qbvgTpz&TblMBr?^t7Rm=#jJBq&R z1oKWYWCsDrG1N6zN-51RpYdyroSJS@IX2ydOe&LZ4{C{D((t!r);#Ppf@vg`!J_T=#7C6`lJ@h)5F6&uoLsreorU2&_DEF zXTi%gMurfanM~pA3J2aAfG144w~3$=!dGrzWXdU-QoW)8b+s=!e#H9R$Gp9xC6a;G znP}?x)Q*nNi`Ae42Ubogh5EFOP6V2Mh+kZ@69f#6ILN30_fCG~9{p@Dux61c;aRWDc z;=P`cpR1H7G_H#~VuG%O!Yz$Cp&w(KS{T3s`hN_niV`z9n%`=R!tQq)x#C)rSZnc=a-g9m?<0up|Qyc@y zDtk3+r;6~hHa#WDaH*>*lR(p287 zK5ynfzAQVb?+Y@HyvUB9niLHl!9)=Yi=tOlZE;}NPU`_jESy*HIgcZ8$9S1UeI`L2dQ2jxvFT} zOt6s=##w{1zuF3Uv<kXuFowO7N%>3;`Dt$ zuby7Z?kj!`AyA)l+{(82OhM1uS`^pg?68Fk88JtGo^iN^t|Ey-1LN0RY?A9ssHUCg zI?_q$QUK=SaDlCmTy{Pqmff$Ky$Z4EcKnbKDhyv@=7a4-UWR(VpHA|pJJ(or^XT1O z4HG@s%Jr;;Zj;S^CYa+G0ct(^o5c0Cefh{kD`CUVI?_~a0jRzZ8EPxz=wbZv12RNI zS)_|X{lu=T$a>1QF0A|so7B{8lukF)vIQ|J!Dqe6t}^Eo&P+C8!+mpj6N>9~tc=?* z7CGA%8eS`jGiGz`8Sza0+mW6pEf!u&bPaQRsMh4*8wa78e5*IMgviEhkk{l8Z4UO0_Oho(WPN8x3RKosxVe*_V}X!eR+wP%E}`ht zaP$s^nq_%XsA-z%9b+ab3T3H%>G7+X*4?P`o4uK}?5Qt9j=P&DHmalK2)*Ak%bLNQ z*s3j(PtW#KNS?UR8RQ9vF1IAj`w~IFjW_mnpDJ)XwPH)1^b+@nxUoQgDZ)%yp}FsS zC)-m!vd3rCNeQ-V$~s3>AJlLas6w=pKch%~5M3`%kn+eJpJ{v9<1tR|Uu`Zkahe`? z6`C)8E|o6LRyb;QglL@kxEE4h^MwXpDG*pQ?KU*$!0LDN(e)jlvi=D14v+<0HR4m}QUlJ<6#FZbH?vPQ0II^QxFZWHz^|!=0#dXY zQejIK<*ch154mqanrh!lfO~?=Hd1G%IAJ)CfazHt6654V@?K`}eAsOem^tZ$kcYUu zcARSSqCpiGgvs=MAQY`x5JV8{VgG9r`lXbkbef z^RVb9FRS@JegmR6al|0y6obBo{fH__4Hv3tB#O@{8KI6^xr#mugd&skqHe^-6)1NV zexo`UyfI=X05T%7eey!`(2d2!Zlx0L?ucOg*P(Aep6n_>Up*QQ3 zOF8%^GX_MIb$%cut=Tr(b%7k5TMI%|>TlpP99tF&*`K9+Ii3D}W_-5#`}8E@_u>BU z16!dMujAg)hLg1tW2b7Lul({qi&tJi^b4b<1z@oFmCg@%ey5KMB?)?23-Y;)9fJ0QMIL zOrR2lv9X9|0sN=^9Z}(sk*IU8o`FM=_C2aFgP8FO5{5+$uV1X z)vQ)Kd=B!@P0ihS#6FfnQ>|Lgp*6%I{;S#Bu}Ae--|^ZbW+|(G<$YgC;gwSPKfUA8U&5J>r}&xHlmhS7!rsD*DmAA&Sb>!lJjbexW}{DU@zg`%E3150L@ z>#6#*<$K~pHJunU{3$2*bMKB)D2qVs)sX4O$gAmv-s_yR9!?Ue{y3>Tm8$vq1ZzXu z`nct26#bd_^aS^i+5a^c8zY$9KP8pL*Sx&SrIk}>jut`q)v zO36zK`XW&Qg?yXucSC^?;o6veo^p$c9{fY8ZG-!7U+vc4>Kkg=9VblBCx{tpivT^O zsfWUy;RwlY)yVuSv13#CGw_v1%+JMKRUqTcqg{k~)d7lSgF^R;uTDa8eaQNDH-hty zs_F*GZC9q_7`1i3yz?PTJ)0CrZBrOF9XbEv$rk+G{Vk=&=jcW_j!MIc zHrPLhqwKy$GqkVk6>4J&F`Kb#ZZ0>xMn;;PoO3x}jE#C5I&XpB*GT5wLB1^&4$lDGs&Og+Re*h_J2VfZ*ZvVCrp$enOH_940t#0anSO!kgt6sI!SN+0((PySGyJV}3Q>+O@K+M{ z-Gppn(O!<-0^_s!mpB>5X`!YOItf%awc=n;*50*>)s&oFKq+j-0`EzVtCDp>8aB5G zMC6$o)3<9&LK~S~zYsUmN8aBVB-#eEE(7DBG{*aomou<;ehpwU6k>tgyPT0>SL_8h zk%)uPF1t2CW}`QJ={!{Xr7K@LvdlECoe`1PAwZ?|`2IE`j5Z%9ZsqE1u+t`q*rL-qQcaG`J*>H!YVfgBr+LMc`Zb402PV~_D$pQtr^JqKA zPjeJbU0S^yqE^wp*u)obx2XXkQ_(VM=SBihDkp}a0 zmsIM}h&oSleQtHHA0fXQ3<%SXSzRuK;qG-GNC?776w7_FOC;sCQ;Gs)-Ek!1WWPG( zTgGhvy$CqR&0oIWG;IRBx%C?l6!05Eo|5MJeZ)G^_PC?tf;6Pz5~b8>4M^Vo$^wJl zG;61bMnhx%`G!%a?LzHcu=H0~*snYy`k~tc0^0fRucRjvPz&4B?Q}ic$6G8Jp815l zvybyRwY?-ZuFovZgh7(VH)h3gW*>)eYD@61T4?4eL*l%8QN{ddM&nxf?hv~H?E$BI zUyeM1XEFD7T}`>IVH5#LJQW<&bfWT92g$R&iy1V)kyv3`ul#2DeYWS?4ruTH z^(Aa;T+7%4K2uoXkd}94#lts7q7&cUG`Kf=rxc#}neDmvYba*C$1BjBbDn_)7r!s? z3N-%tKJbiRU%C$RXx;E5%q*>+I)n;PJ;8~)q6-()T}AHQNuG|Frkd3}ZXl(5dGAUQ z2ubs+o^rxC)3R>3%`L=MH}5t>@9Z+lqIR~97yVER2`BAzodU#Q@l8vxc(0fro_oU+ zU4(YFA|ILit6PsMx>7Sm<46Jz36z6@~k(hj2K^O-nRf1#kw0A02O zfVd+wq;$!8$81N>V5!<{^!=CAfLPL@LCeGXy3J5KdUX`n(>PMCF9VYFkvvFcaBY9} zqWY_ekhNaY)YEY+C?G)!jlbC(ODVc1TyvhP{2_Dd*OWF(Qv}`IUWpDVfK9D7_+$}G4ejY4ajYaL0Le#4TAXU zk4z;B{Ban*u%|loNW@rN&(GW_Ro*)T0z5GepEKz@pNsC^v)~dyT+^~PsENd?A7P<| z*ZIC86xvE3UF8qNDT+{tzVpG5B9uF}=FcrQ89bX>)qZKrDz4X?Pk|@({trkZK@u6N zgBPyvWg*}}anyomZm={OCNwWLeKE@i#T~o;A6(qLm}X#>w5{p-aL5OtuOD$6?PE=wk0%|YF=*Ib-VyT%48F~_58>vh&C3Y zPxi4b%u+U(knZB3KGChBr&}7zeay_BbjluNQZ0;^WA^sIJRe|9AahpTFoeo0L@194 zDoBGx-eH?=@7Q+F7^FhYVE?84&}s&kpg~`{hmbnA8Ap9K=c)N(9=c-bN}9!EOJ=+D+Vcokbj(r=*?ZyO-GIZ$m_fA z7)TGaZm0~fx)QcG=#LkW^-jK)Mf|6y0Mk^pJKgy&A2kmGUOy5cl`#X@M&r}s@?G$b z-<<8Q+CD9I__la-Q_iV3gD>qt{z2HHlIl}d#?394Q@HQN*a6^%?HnF?CUg78Y+nDw zu0p{|1F>#GPk8km%zJtVbG#9EwqE>&43|^bd*5n>w#RQTw+Q_00zMsxd#$iTZMpq* zbVFF@!6xj5F!Uf`qtZ;zUmmT!`r2)kjv|zBbZ>GwC5MX?s#lAn0CU-zi`rIvRi+>+ z9YMI|wz5YB6%=Oia~FY52CaK=_ipSz5ole^`)cvz0=19%B$64m5Ga8I&`tu?_wAuI z^ox997AXgeH`d27BGo66z#APvLnw^tKK?ALSm`ZJuVRE$do7@wF;4+m&t&lTNR%)u z6lc@)*4*}AGIC!QMVJB!2gm$bh^7R!?A+E71o37W)DmfH9^5;)=ndJdqKApoWZTkV z>k4s7PVXu4%DCv%**7gCNHfe%7K!w~p%OCol0zXvTWmI~?g z@YuolHqZd)#+o#^Biu6Y8`i)Ji+QylCse}fGi!yRcafjj`XcnUo7PA-h99i6gvBu_5on1oo`U|t^x3vetQ_OXw_U9YPe z?2yEx-LgLJp0qlB8e^m1g9)Zps+0&UQAtug`FUP(RB`)ziD7Nh8Ghwn;%2L_UM7;p zOB?yWG|kANBEsY-hZgj_VXNE1{G5cgJPFD{7Fwz04QdeCbm1>qLTXO%6-CoM0+|ZO9(o_`(_@k;FXF%3oHMuK%Z=D4Je;Fp z#g%Z`DQz2W$G=0*F6C8=Y1!lx)hpf{i9onFJjDTh17kdrMF&ptqFp%=2zC2bFt+{t z?rCG&>E%J1`YaL5Vg(mvL-0YWqIxdH`prwc=(U1QegR|#ImM6eVwrn#{A(g|Hu7Lv zS-%h5wm)~~K-TO;?0bT@tLgyJm?ra@jobM~?K1*Q`er81^>=vvn*~+i39Xz5v#5Xw ze!msXkf(R(WG(?BObhCcMhlB!iYZ?cIHh*O6>6yn#OYz5f1zEgNR*j8*Z<2e{C`RU zdIaHr6l3?FDuE{bz@41Zn{o3YO}#|?PhU@!hGb2|+errL0{@>8NANk$S@D;=anq&%0H1%W|DybbuWd@PKJcFfL|4b`lXtj#MVf z->7dkc4WE*R$X>vnn#CnqCm5kjjdSZ-IUn*gnO1*6Og8pEjadSc|6W^=_WhQJEBy+y9ml%yrO3#9;(z2UsS@L6ObKT17LPm!1#khyRD<6kIC?5Tp zl`x;8y{z46^%mulc*kGg!%%bhR<3qO6UNh$_Pr+9uS}jU!D`VNf#M>C=YrY<+U_18 z+(&{9@c%DJQ^!H8OAA_E%*|YZC>R3iKQk5iN_G5E^yozv;z)Tr2^#!t`OXd+6v`1v$SibtTe?jr#1p7}e*E@E!Wt9M?`73NBl)+8I zxNlDLpy<8H{9;m6L8z{0>wbYOI?H`qban#p<5CI2jy~daYIQc31RK}NmB+5!93@=_ z1r&eLGg`$i^hDD&{I*5@IDftMUmkrwvEw`W6X0q;UqJ|n7Hj!mt!<-+qZ+<lo%j<-h_sq3&Y+E1T(EN5A#`~c#@urG z1!OIsICWPY9p=+$FD%|Ag3=KVQn*bl00}V*LEw2@58M6zI>#ExDaPmtxFFLFe*Xk! zH0D$QW?UJ#gx(|UCaqc_0-65fjhIvh;KZpc208gh=pVl z446sYqxy2VIE?!C0(ZK3T6LcIKp5FL7(`|JaS zNRsN&1^V=Q3r&TKAJCf^b6*DOflXfbZFi-{tPW$$U9ycF7AmO7w2Z6u(GS=yu@7vq z8&q@ay-JVl=8k?etvr7>`itXs)yE0%g^IYVTDuAbM8d@@;lnr&O6E1|MaT98O1kyZ zCR8iHdd*#_#IUzKc*DK5H(G+8Y_zPjgj>xoeZc!}+WJ&97tKLRi_8;ns4uSde1j8>j+1}ph1bS3*qSOD%Ej*oWDbW_wiWt4V3n8Y9M0RsZ%P*j(~-xsK}n^l23!%c^%JM7^T2QVb=ClR0)UWL27Ko@5UA_k6DjLoaup zUc{QUj~pCa(>MH@ZJdguW(Z!e=I)QpWElpd{1i9qY|5m3b>Rh)%qJdp?{u`RdvgR? zk6}HvH*kX0hI2-f^VD0@2zQ-id~~Pn-z|34-p~xT5i8VES1U2&v$FMII4M}eYFFEF zFeGarR;}~JNHHCvM!Q#f7nnypJ>eQJr}c8C1+b>UE>?2Z>gAtz^VCy@W?7lVRaUY4 zRUHSR+35YDFZYsh{4E}1H8mGvBi5!hF`(r3wZE7yIC|@kTIBn0E5s>(?Pqto*>Me7 zw3oRwa#!m3Dk6_5!Cu=VU4qzRLORVs&-HVp?}P<1LFtyo8eOpF+T+$v67DsHR<1RH zH{I{j6Qba&P0Oze*>!Rln;S-x{dgoD#=``~v{UHZv*{2UY?~a@NY!1ib}ap?Qc*OZ z5I;y+K}%c~=k0hi&k5GFZST>m^hTR4ofr>9chyrino06dJ$1D=W7V z8D`Td&uzV&1~ehEypQ(O`!_PeY{Y1ER|XlKK6eF2dr#YgNHY`YUFs2gx+cr|-8mci zbg!r7NyW8g(Nu5p1V^_ocQTHZvTl%AtaQvy&L#V;Sg0j*$h#!HF4$LLmU!%8KUU-p zq;RwTbY=41t>R=^|AspZ&F{aUR~jWyDY)oFy6nzof)A@!mS*FtSf?QrtA78Ywjg46 zB`Ijt8F*yv2G%Ifj-!WF0~BiR7UDmERZH4EFw6tlCY^$d%LAgPUT0qQf7y>tVZc?_ z`wiKbS2`3@3b)0J^&(qVx3I^~D(pv#IWY7L2Src0v6OtvU&Jhj4V-57sQRyV$tCU_ zJI=`#QLiXStGuZ;n$ydxOBsp_*?c1^l{gfKJ=2_VQhlZCd1Y~RWVJrSw}T!5_hAR@ zU2&NvorZNJ4l9d`Y9T(6@)slavCg9zxh}?}w-RCGQH-2?>*Bm-jnS}`0QIu>T~?yj zs-qo!ogdD-3UYRs6i2^Y%+<2ev7A{g(1qyz!#$8?(#cluu}X=ACa~ro&e2ipVjFrZ zk8Zn5{)dY5W}RKgo9W~NFNt#j_U>^?`_a^rBnFRzn?s}EPKa!-p6@@J^D3z zF@u`>MNxDR_3e4k49wJ|tEyM03>}2LGaz~J5#wkTRB4Wqd0S-9(vi+_8|*@7SjM8t z|1h?48+d=@g^joCSvRd_DvHm^Jg1V!XcY&OZ}IrH^bRP?-Y;RziPvnYDjX$66O{dR0Rl}PbVyxO2vN&Ij-r!*-EcTfF_O4H*?mki z23H_}(6IWwl<}jBB*6QA*&F(HGf3JTM4|cpxjUmm0z7HpFrvq zg_5d;|Gh@hV~x(ok3+Rro8NyN-U!)LO~VF5_F#JM-~feD&F0TF5NW;Se_Z<}Pjz8Q zd4T#gagUk;yk@IEZZ&(GprBN!9qv0kX6RLDMX7V!>QBs4Z8_#6M=HL=xihF8d40iT z;mbMmnMNx97N60PW;Zu~r#}lFud##aaVL8I5In|d+nC-bPY=56IL<;l%C6Akhw zh7Q!1CU4!#mA8C(=kosk-ajgKx0K53 ztO8{cbMb=YyC{Kw{hHtm222SkzRO970Mimrp49IVT1c=P_6fD{Hn+UZS79u$eJ(5T zgOcXyapdSoI?u$EkStTrkl&nXt$OQojJ)!3EB(Av1!iQ=vgv5p8zy3LRxCm^Sg#Fp zi3SCefjU@15nR8vZ%Y(TfB!Q6y|L(X(%bO6-G}R|+dp4F!hiZ($AE9vHwPd94I=-2zQdSn?T2OU z!l$AS&t$xgGK&ie_i>uH0etLT2Jlv)W>#i zBdK=Z9}#+rX{rOPBz54qmbEDLbp!vlUvhLFc#A)36l^yigxCkU57fWo&<_#rYb!L1 zD(1){@fLlFf1eQS-aIk>O?r%5(3@wp_k(>-&Ap$ar@`NN>r{hh8~pCed0U_P1Uj!n zO56CC%Uz2q3$jH$o)pbfeZcAa-}s~AOQPrAwNKMDhSqz8*v9ywJf=ixPT z#epYo+2uNsa*orX#(Rpn9S1SV09=9SlX6AIi)yzw(1U#WC62*qVsH5iKud^Tg~OQo zHH-ShWp%FJ{#ag|rioo-b@r-Q>Crj72_%2E_xgU^S^1IRY5=07C3sV;5FKp17DwRA z1cj7LwHKM2PciX_CUr*V4m$+f1zbc}AR9n5jZ=#ZrsymPZLDN`s3|)#I0e-p1f6V) zo(r5l-gWCEATc5!o)y&qKJs43E?crle68xES2bTjgU45#S*kl&I-6pV+U=v*#gEU?D0bFO?+W{z=$Y&SB&%+vh>ghsPkp4ZNuV0b69Yh{H z#Dy9oCx7zHr=iZyg<@n~?4{4t8zJvTvE4`4TYzM_ra_PK*O!;oa{v@k&(HX=sro#4 z!3%jvi)9S|f?v8Jh)6K_T`k^!(W3Rcr}e$HvTmt}sCYh0}f8^etNRD(bmdY!am`fx)<@&H3pqi#+f$a%Zp9!@mH2_P< z`Y(!N1C=cE#^SzF@TNE(VsZaZmOL6<;`J4$IR7Wv`HP zL>!NXot^VAW`hD#|Byq@cLi8L!C0)0U8J_+EyA+({U5T+u9V~Sim?Tirt#)Rv~B`` z6S>o5v+=V8FP|P)-!Lm9I6fzt>(YG((M|5(r#g#)E_?A*nhCuu=hNbRiQ_qHL4t@J zH3EsiVfgm{F2lb|l%hl~W5vZ-{=pqc%Un`t{%NSif;6CSLK#t1WCSAQvsFnP-|l9d z99TmtV^x5~F;)w*5}s_42=sP`KiI~~TouqX5N<`p@sH5%i#}C)Ww!b?@h^Qw!FJCk zP~gJytgw-$=zNv3b7^Ie{ZbaFjM7;=c_pO z;*xa@SGrij7vgGv$E(*$==Aaau?|S~k4R^^%)6y`B}#_jd4K_r+`$Wce;4m-BDwX8 z74c`~9*Y)?&AO^gwVw(_F(jf249V(0q(7_vOZu~_*CBY5`u$&Z?-x-3Ml5IxppJ|_ z4W%!u*Gzxp_Xnf4Z&o2!>pr0G2h6fx6ufz?6KGe`rm03lb39eAGnnGMk;E-mIZ8Tf zWZ>}66{b35z+RH|3L(7V{aT&vw7pChG=*4cBlDj_lXuimn_nLih{_4KxWcaYf0 zrvawm&zcps;#?0UjH29prbf@>4XJ$6DwG^uHf3B$Wc6W5qG$4)BAeZ=2eM%9@G^5- z)?fF$oNLydKX+JG6qA%fFRZu!CB*X2EmFts?P@eKKgzq z{}TZJ(s%WzuEeiAzq+p@(3>+{k#-*O{7irBXh-(6y#?G7YYTxC%wL32={Bk+W%O_VK&Qm6Q7Z0LAZeYCv>~@h1CzVSqWPQYYj{>hof$!fZ zXBR4O5kIq8(54pktSi9^f5nN#i%YsS@9pm=9kZA0v4JI*(_+ibB%zl5maH6ST#?3rqN7@JoUv1-Y?6Xb(qL(*!0;KF{Xln$IkfK6iHHlw$R ztK4_>8*D3vu)gT2Je-mws9R#R3c}0ng`Jcauke$8xg6CxhP%5nCewW0f5HQ3$onR* zcZHnmYk7YU>wkoM>HAE?!E8x{oJ)@&s29+ty)#xyGJQAfpFjra1P>21bNLrU$a7NLI-5gAS+Ou(zAXq zX1z7bilEAM&$5X6rFm+h;c(KmSy;sm)!&|kS10jZsVI0lz@797JrP zvMD`3q_O*5tim9lg!Whdb$hAr)2>Yhs`5AcIu;eWC?~0MHxz&112sdqZNh{2N3~#! zo$Y<=Uy}m&k(UEbT&4m8MnW9xruPRwDJE%ZDXw2m;`}7`+DK#5+&!h5)+Ry<`om~K z<+drBip2x6fI`^JoE_?ISZ~TOo9$PsX3VhSB5bx?{h3g@P`MmJ2j>#C${WT7oNoEt zFMp`k}IWKq{ZnSgWnzs^a{6X?E?t9P8b<1CwAX@k-t1P+MVr+(v^blCwm<=6V8i{o8e05E8Y<2BOgjTb` zSEbRmJy@s&h79#ownhsfRyO3q7uhrS2n2wQ+bM060`qPC8Xc+H8&Z3&_rldqO_p~A zG>sD%&A)yjy0~7@3bcgw5F9{OCD8-2td?$zl=Y13rFS_=nJ@rQ%)Vor(m!1dz` z$C)$dI0De}HldGgXkxw4YMOas_x> z+f0$lReJvzZ%|OxHL}Qk*ifPJK8Xb*`w^&MB!7#SLazB1kd9WE5VL^0{|SzLbffd@ zOz13b(fhj46juc7)skbx2S7|$p45wT3&gc z%u?~EI8uoJoB01s7XXSpK=No)ls>q06Rs~IF4yK_+NK6(-hlbO*NN`MY1LJeskV=@Iq9Wc{V z>B23QN&byi-uuQB!4tpVFhP#aTrOv=6rVI!qf%}p>M)&CXr`upzczLc{U}bOlHsr^ zkB)1BIpatgG0JPgoMOy;g)hmGqT4zQz>khMTmY=fzk8HF;l6#k{E!O)@Wwy3Qbo-X z_F_4orHJz;;f|ec-vJo#v=pgwg{}?@(8E{b_LO=kJv9N`a*xgW1a;txd_dM7P~gjr z`Bi6K${!mDiz(i$p=*4{nv1So?dNG{?9+vfw|N9n`08# z3hl0!i|J6>0Wx&#^(XHDvQOta-XB)BD2$h}Vteia|7LMuQrgbpLNB~Xfb{$iOgZ3Q zZdxy6!ID}J{pKd-2DsL(=H?rN|D(W>E;6%2>$D6a<3FjHTo`cla|pZev7`x)8_m7p zkC7Sz){QsXG$8E%hC#SMg82FM6|Ky0&>BfiW@dW7CS=4`q`}b+UaI?Tr z|IaA?zZ;@tmDb*5zSR}2!WDmb!JGNogekk}jQ@`)4j}${m*#w0=R+}N$$yg&Facga z42Lt>1SpS=Fk*i3KEz)k#NbTKENDrlPKO{hKD1&{>A1c!A9>i5)0qzWRiFQ{8ZhsD zN~*R2mss=(0JnUZ@zi+t$luE$$@C-%ILpIB#%4t9zSNx;}0!&3Hl!+ zzyruW0%PZy{85~kcIUr0po1Vqy|EX@&vLfA5#syL@Z#JUSC{U8g_hrK=*!zhdHvx4 z38F$SVhGlm<5_|v10qbXtdN?V*CT>b0j<$2({%7!Q9j~$h=fi#%qRVw} zMS|%Jt+^bT@PZ}ajX--y4fek(0z~?LE$lxOJ`Vu6H&XgPWEgN}QkG@2s8%EV>X~|A zb^A_LG#=wB!t9Ik;G0dn0K)o4lz|duV*w~2-n?%f$g+`=|MH_hE(4@PUad`_S_d5I zPw8<^vnB7fRx0lRK?~s)i+VhW%wtNz~+bB_{q`aq@@S z+@Ui^3*0tSnV4COI2|&fsNdmK}hN;%VK%L@;QV8Iie{|eK2bFr$ad#fE(4814)wY@# zl-}yaF&ckg?Y3WFGhqlr$KirGcqf}}va~F{I zA2sD+0X00(Z`qnY(rEzRuk_0E2bc8zy66Or?)i1K8s}|=R%la3NarGrBk`DhFne22{qF<*vSHK5Vg9-tvpa{b5*ma6N6dheT6 z_fVmYmZj=VZ&RX1WpYPdQk(jfwGar;eROeW0f%0TxR$Z6_(NeDf15v-G*OY-&x?}f zIlRHTWgK!LuF$0+tba%e5C{kTb>ZKD&9f67P~5RMKmKCWPqxB^-)Zioo_f#$>-9eh z<1tKug!(yE$x=|KEuDFQW3oRJzg-tqp(3emv?#|<{+8mrXfotNNd}18GHxyhce&C~ zd4-_Ig)A?&?;DK{sl~dmp7=yH^Gqe} zRJ)t4T!pGecVf@39i`!#BAlNywwhxOup=(O7Y3=og0UX3m_!B8^9ghIOB(II*;47N zk4niHTnoHmJbv=UYNMIcU$&IqXIJP(#&f0?xD&@>)a?90{Ok078t%)>#4~N?St_?& zb0DHLn57Ym0EUh*<`Cv%hzF#`bCH1ap|^Z_`h|Uh<^>z5wMQP+nQwP4FwjEK04nSZ z%rqNc7V}Hxbp<13Q#tp}h1HDG?-^4-H7Op(o?~XJc<=ASrae<2?~q;Zv%`{AhP96 z$py6kGz9qyH}xFxfQF!CK;=JOo$K@0;2RvhJP*V9UvuHMN@G|66!m|antX*_X^L+TkJF>){+Ak! zIpCIc6}Yd?vk0=z;oJY$FtrpqbYc-QZH<@xyz|y>+lJS;PUo25!UyaKFfE5KZ(QAi{nGq8 zqKEon;`n(FCQ_7Kr{S+X-Q={UoXEOctVQoNH2?NwfEN`c4rw#@Q8lEU1DilH4F1B; zg3M5>L^E(5a96#5$nGAu)k$$5U^HGJ^N$z*O_}?()rB0h;q%r*9y&m&qx8>Anj6Vm z0r;@%RrbgB|1<|Pr}t?5M366^5qR67#HJkSXo}kQYg6}XDfl^o*abM{$eW^arRIR5 z4rJZ)(tjcvn1FvTioH>6OV*fFKTH%z^vZ4NNHzcgYi-_F8s>ih_|?e}`#FtDrCe&U8aVIw z%{ou1@;_Xs_A+QS{qCslg-Lo2vJsdwl9dXWo_>-X^!4qWf+KD8^MCY~NM~ z{t@l-qv-zAiFunQ>vB@pK~AbDLgJbXJi(<{|0TdQ8ggk=Mu=kMl|FH#DZdPBsbIgH zKa^2&TMa!6iy3cMaHQ3yNCUE_vH~$H$s`Sw#m3U1A35y%5yTArZTr=!TeWWA&Dg5O z<)R~7aEp9GDhf6l@95gYik?yaZm-p6l$o%;a zY^;N-2xcLIqr4ms-H&Dk`6sSFxc+|Ro0vwf&us=)cM^L(8ht9ko495RI4y!V;4Ogz zdO6&dwd5*ot1e6dr=|!7aL;dK1D|6l)$GRQoC&YH1W!cW$pOggX5S)TpR<--A5XK| zAJ5ZVI=mjw_LDmqv*@$DZ+5pidi1uisBT^EJYs|{aHpRp{Yg`9{karAJuVvQ<>#x zbh}%-Dxgt(sa69yThpwd`A2@{ayM>YJ1od?mM!63h5=D4Eif}sXJJ3R$|}K0YDr}X zy&MYgsOLoky&PTq+cTWJ$-Sh68CD4d1KtZ@%!0fpbTi>SYtJ0}1&eYn9b@LumDYf3 z{$F{qyREv<+b*IB#7EehqpHjgxRvUj#u;jz8Cb$b-3Ea=pIoS*~n<+C4=&f4RM#C-VON&>;Wv zaP}x(jq_^U@$#$ZTgU4;(z#Cx#erwS#`(FRr|WCw`s?w4i%o|I)_RxQ!~40E^YxC` zi$@>Nm)WGO*T?6|S69CM(pOLrkk?l*kWbQJ;OHQbAkZKnAS595NBp|v-5?+rPhcSE zfW+03(c!a!y@|1sqrJJcnFE8XmF0|=RopUH?A~2?<7?+daN5yAdG%W9mx@BplHpzJ zfyGtb=;Htke^2@k(dhE*p&NXy>AA!Fs)&_Ib4t zJac}8wz^)`(<{4sJk`@}U!k8HqFj4!TA<|ic6&c8+d3dPGCQ(bFSE64ok9L6duz{z zJ*sQH#pZ)TA12cNdK|uJ$>M=RaP^BQct`ieoCR;a_5N@`=lArt$1L5phkM({%gx2HjOP!HQJ%XjBQy3a(%HbjEYr?an7*5~I$0^Xk2%ax|n>$k^wY_G0Z zi~^NXw$*GtP2aBhG7DP{s-(Y%yC#TU3eaBZ{CMrUJM?)m%k#1D{(b#CARj$=?{4~P z;>g;{;`7j`Ubr51+AMR$cBT(;J>`klJ7UX~p32|;ZDhi{o$gBT^t(y3v|$MGSZ>z2 zb?%q}(RsD^cQNfmnmI)%5llt>aB7-&wOhBrI>?pVU6%S+CDM4J@1L0^YsME#BpSpp zlh|&*Yg6Xq8(mWG3w9%h*0*dM>YPlA)$&@`KN{8;jdX8BG=Q`?DUw`Q>i_Z}Dp5FN|YH0kG`@Ymv@7(O`jV*N? zf_rrhZ&MTD53%%(4TGn|;~n3xxe`eV+Gq17&HFM-?c5nPX%=xc4K!TgwcczxJLkw%7J4F3Gr*qYi=|?v-M9SELTEm$xWm4G@gmN_+437rI@~79Xk7^6azAIl zl1voCsb5O{*ffAqBcC{#Q-g*SHK z(bct2b&-IppT0Td8X|*g_R26g$fizNTCqISO-ymD&1)5YK+WhnNq)cz6@g^iHS;7+ z2c75^Le-lmn8DXa`03cOE^65Ej{EoSsa37im7%=VlxK=S{)k9=M$HLCF{kVu-l!Gr zIfyq6TNy#_c$^tWtHFGs_;*?KVtm`^K^{-=K-FAJ0n&5GLM(_HvZuA>7@2rZsG(#Zy z$BpWQQ>7IT0irhT=4?pi;VL0o`c6`E3;2>a&h8K_8f;{?0LDRf&h;V}JL;TcINjJ1 z+leoZ&cuS%`f739y4lWou5)lhFRD(X$Dsph@YT^m11DGorTKfRhac+k=20!;Ixep> zAFx{#x5vE?hY48PaF`Nwvam)#!86dl{cLk~tm0NEgjLpjmIDcnNN)neFC6^5k~Gpf z$Oy)zvfumpB;$*bpd5T=xE(cTIE~WpMA|{WXwApGuToK>pJULqBkeHOsH?LHvsCQCT-v0kyf^x zGb?tA;{8k5#+Yv#+l`xM&-?fF-kI+Oc%zPPIn%hL)wmDexe1#MFhqi#Umx}w`Ypw_ zU#MfIeNO8+Q-*dZxu&olF0~eUFLX%Rv(&8anfO|(KEE?7*o<5KD3Sy_3TM&^UhV4e zK6}_!95$Ozmpk4UWfpIeiXvRda(FDpoe9 zPmB4onoi;UVc(h#Zsj7Vp1RC)W;w!m2?uL7Lulsg_29+lPq2WkJ6?m$)kr^P`$@J- z>FOD6ytJx}TGvkT$nQ2S`^P7EJE*pNj2~aQabJX7oLkp>qNTijDJrhSn!n9eEx=s& zDK!huwZkjn=A0hrpzM?-!{4u7H^0B~s+Q+)T$p?z+5b?;I-(5V*B>W<6VM>4VQs@kxQ^;mURvJ5`J8S%z`yq)vj0rvnDTkepmde zyHiI(jdFe>_Z1gdwVK!)-4}@eNBCLU2OX)I(5~2o0A=mg~FC}P3`dW zunly+4g9?ogAb0j9`lP;rfzj_#&OTtPlQGlQzhqSns!QndVBKsr^V~ey)HHPY8Nan z#+$RNmXJTU$2Z|`Vg-ot9|}IW8mZE^u?i4s!kcR)uT4S7&Fm0CU8%;>A-I56RI_qq zep(>h9gEqZS4Zt*$U27~gm7^11kTKBCU%N+OhDC~*40Rjb9#yg{n)tDT1=I%gDQc01`-|r2Q`VF+6Mhkk&Dq z2n`hshkO5GWx9km+hXrRVH$$bxL$o*s!w{;p?MU|t|d-xP`7=qvNyc%AV*1Pda-vV znBbj%_R@;S=U{}dLn6@MgYo0(-8oEL2JY>>v=jU0w|6g4-{}#tS`MBvfBoJT((nj2 zXM@h@D?g|&?>CP&l3+;-(q45}$5N*}f~1H@xkmFmiQvM<4|Ovvpv-KASaP=QA<_4N zRTNw1>#^aC$S-dM@?a3IXO<3vtxKJWT5GG`E#i2*J-vl73BUY4V(r1)rKGVn{T`1V z5fZO)=kta-!4^WcwypU?`s4Q@*>Pkw`*(Ix1f=W)d@Qz_;m@{um=*{${e;-p=|BB6 zz|%ZdwbKw!;t*k_Y>4bm0j_LyH8nYTy5-xWN>FV6G60%QG|HTATXlmY#%xM>Khfl#;r~Z|7@>QTB6>TQ6PIa zN5x*w(o!EjQUcg5G07Js96m5dTG|u3|`r*Nm_-E|$lZY^6C46=msM?|{)Zjj1? zZXAXt#gxzmpWF;L92r3+shwTN%$bC0%yhOpJs`@V2S07dk#t&!sj_Cf2=aY2a%TU1 z7y@Mpw#>Gmzsw3&;u6T5WYNe6^HW-0(eB-kVot$)5{(XJ2ku=C=!LMQ)oQsiaGRPk zEY}z_Ust6D^ z;S1%G@Q%NKhNHkC;h>V0q!%^y6KE(@g5+y8==Zr#P=ziD%Pl13C05McKB&6akb2o15^$OERYem&$G&`tOCzsSV-8v-0uY@hbg(PAvZm3+i zu1bnyzN>Tl&D!VwWgiLrX)rFyRINKxY{Y*w;+1_T2!iBes5t^tru~FO=gEWQ`W`ei zZ9N1$qj5k_exj6zNTz2BmdSW-$`ZoT2n0wh{;k{N3-;P*6C3WU!jVE$q#Huxcosvu#?ovgn*fpZwa+WE zWy?SK%8u~vr2VU6y=sNIikR|_y2ADrG|0)w!pBIfiE%X^pP~xYo}PF^b;IeF9qYsi z=}`_ztisC^cM76?LWugdiIBbxtJ(PzOGw)=#(dg>&E(s&rP0Lg*N?Dn#zxrn!yMgZ z(0%VKuY5+C9=w$}gZ(KJf4M@ww7*Wy5-kWeyRXS~3ww}*BGK^9m|DEsm&{l~S3saS z&k0hg;bET5&kv>L3)-t+e&BwBZB@slR1bQmE;10%e zS$_F=10P$flRtBRlgYaWAEf1)obL1Ue}w6wtNL6=cC2y+E>gCA?aubXfUzRs0K|HFi6T&}|pPRaUSRV&|TEm2|jtI6`(_)Ur zTThbik?VA+oMELlN@B2G(5zwbNSr4LMLgv_l*#aGGM?L9V~!4$k&)6xP)5-2(v|ylsK!w4Sc`OcjF6zy+8x~a-j8bZaOVq3 zi1cfK77kAW2%=813&`}iI|wc_HuA@MN>S-e3~G3jM74@-!Yud{^PSQ5v8Wj~*bPD9 z7Np(ucZP>A=o23Jn2ua(=J5xF-2w$%kST7%vcea2it|tGoR3R~DQ)hd z>tuD4_=y+vnbsPP9-OV|5w)D<^ksc@`lpxgC8kmJx($(B7FkedTB=!<2<_LxBLdNs zsIy?3W%of$l7hMS%A2IT-L4;Ze|iz)2!_vUq8t(~&IV)&vLj{g5y-4+^v8GxrhpRS zr8B#Ru!32!{;D_Wx@^)6U?ns^`K)gQ6Q*^k&X>PyVglOL$Y<6e%Tmx#NE+JV5n2qV zZ`%h1w`A=FhzjQ(&(*D4@I1M-P*{|nN+HJvjk@(}WmfKB&8()~7-PSTbk@2v6jf>K&R9yD+ zjyx3(?F`&5_Do0xfgqVZ3)DQ{ML%iPku8LN-lOqVW^Yb}Yyn?!K~}YHFePhzQ7N_O zHh8Fue?aL;dUVBYS!YEjg|?&H9z~8p z$bu+DHx>>Wii)+g4INw7krDjBT{({vtgIutnVQ!Sj3D49!kO`GynL@nJhd#(OPyDD!&s#^YJ?+%{4CjS%2CgFN5f)Q zLxQ);10d|x)#7aunKT>UK~=F>&j;`#0vtz^Ur(tc-z2wQ|#K}9)^Jp5Qp z8uDR!&R?UDKfe+LxHKA^Mh5DH3EepAjwz8h)qjJPyrl1TQeZa+Iomwmda;*=3E#kH zi+GmB{w`T;uY*K7`HaprLOi@DUJ0|}d-np9UfRclQ^R`+#uO^?;)p1lnNHO1 z)EIYI?uMvi`m z&Xsm=+_vlBZf8<%e^@C@KORt)DfatR)^j!*%EYNPO&)b?%h{_2NwYYm8o_ep_%W-H8*(CPk8+ zLRYE}?+26A!o=-Vaz*wW8(O(3u$)A8wLv+%HrI#U`F9xPd95DpS-G>9RrFW&=P^;F zu^R4>?zed|3gZ`+3So~=j~;5_tNAPG4!CEqggwIXs~5MvOJ3QCqom~gc6z@~!nm@9 ze!}{z1nENAu3NK7A}0DPUlI3Ks{W!5u}@zO+}z~1WBd()9pVp=w^wo-`W96wWuQX8 z?K~cfbo3K1LKqT3422)HNQp`^&$^yzr>R=ZWxmn-$r<0PXjWkOSJZ_*@Fb49ET`DG zQhFLSM#S1-vqz-W%(N! z5T&kvI7oFDbyWv;PW9a(Zxu3unJ_j~_4m436#`J-a?hY&^k`TlRKe*6l z#e&0;sQ<>ee$<#F+{{HXfquGXHZn9xsH0j3`f$gLq5*8WI3k8|citL(D2X_ygk-wV z6pNA!_Axf4w3F8XuETmX13BJSK$V1i)ZrGRxE7Kp-w$tkAKd~1vPM~Kaoaq0%RtkiG4o;1?{svy zFfI$EABn|lV)}$=vVNY`BMm+U&vRa&*^Z6Gd(LV>Jf59?QcWqLmC>1VGT@Ul_n6`u zO%Bu_AW|C-IadR}u(((qk_^>Nauq~xftp)|e3xnD@4oB>RAcGG^P zX`au(!AxmzXNvieK_KDzEVZLn2GpV{d1vWM*uCWOD8w*X{&GAMduT|FaZ>Ff11+Kl z`W{OUP0tj%YN9wHKK4{3jnlUS&70--HePyub=j>kvr1VaGo{zXZDF5Ror()9l;inN zk)|!i?4=z!zGM07u6$n(k5yiju2q3tuu)~t7rm;UdI}QrxzNH)d!bJ z$D%9KmO#`umFz#~`G(eTsYp9^cd0~CNYQ-eXLUKcste73MT0L*-IOb_vqTKIRJ+Vh z#d>%RRn$LT$tQ$wI#jayjZAwdgblJ(L#~B^aS~vHr4fFV45|4=$NVRjH)?WXmFUrQ zO5f;yq1A9+X)cnc&ZJoN_g*FWq5SUeL z8Fyi_awtbsRH@E7?V*rfKl`_+Atm-1k`N9!F-W;`3w;S%W@0I0zV}yQ0%CLwMvi)g zS!jyeDbM@V&Ow>#rC}@5su-e8Jcjy7pVkNR_{2xfEN^79p}PtG;vtDId)Yd*Nket&gY-4ik1V#Rw5Z863wK3D*OUuhUQ*Hquo7ca*YAji`XN;t6UbsU~ulIS;K_RTd zbk?b2C{lCt$^~VJetWLGmu?LgEUYLpT(J-XL&cy;{N4&;_+uD~j1Zd%Ce-tRnn;7t z1#ci)0WQ20oj{iNvEh!rb#GJDs+c%Y*iL#$F9{nx%zU`3=qPCu0XQY=878FPND9Zf z?lDHr+O_G`PH3!m(-ryoic@<-NVfC%2XJ)~X#XH*p1WTbE}FN07lfS69r=(ubUDMl zQGM#<+(4$nIz08>b9}Yhy#=E2IsGHSCn^?D`VufwcJW{g??E!JF@{pL%z>NE74Y&g z^4)zEMN>35?Ll>9#CL?w^71!^rqx%hg3YGhHK}xv8>Lb)l3%lINyC038=LNjwzLr) z3tKyFbJbHmQCEw^kKVSaw}ZthE_jQsj3CY`pWZlAmk9NCZv=q!q6{!?{Itl6%kllp zGaS*FLW{jdC^_G$V)BvgAt4^wzQi{iIA@w?u5@pNVdfA)URN3Esi~zFDV9iEd8s9# z{J~?pOpN)`xn2+TnZ_>kh`M!?a569-i^JLXh}pg5k}USUAr1-){_EG30=~pT_Q@?? z!{zKr^9AfN*H0gioW)@>eFIoacs0-Ja zHn(Os_`ooeFQ;{xbEY`CW+3F!368L$4o#YSQMpUWsr@5Z2EKZe7ti*vQJMu7QGs@O z%x416R5nMuTvSqh&Pz4@5E4uMpD_wyGJK>F=Uc0V@{?(ghrW{451(*$By`1s+~iO)5TllnoF%1B%72_&i6awz#{V^s5Xcv6M!q&hwrbO?pf~~Sm zYi56PrrbV)hc+cU^~f!I8&|ov3KTEb$05jUxvFbliQ|xb7<@D#Nk9b~g2=2-#s^!= zQYTmj^r3$L?Uo%ZspJ6xCH8O9Keh~lF7mY5?`emfVmR&ca};M&Z<3B&ne5JWBY#w1 z;j5HAW@$e6m#s;&p2a^=uWH^9@&uk)cH5Aa{r;hi70RWM_NkK9s50HpW`k&zf|>Ga z<$&4g!|KI?W;q%!*~uonlTLP2(K~7SgLC4fRI_?3CZxg2tj!9B-*0#u!1C*y9qN@G7B;)!gIVD(=?IEHw zbV>%a4Shx_LfOGrG+tpfzo)9(TR=*M-npgYF+mXG4^^2KQJ7w>H_+8QKlB39&P(or#lBjaJTKrPXc?J|GG8&WRiN~fDCRQY z-z-zAwT^%3D`~OfR4Qltlw_D6a>u6%n}}7+Pny|mSd zGZ+DUy|xC`9IhGrDUWO`4e1scQ7KN^nJ=VHzgRKVZHMZgbC~PN4bJpQLfkpC5WS-Z zW}KmRE+MfDmB5PVv3cOU8MX_J@2Ie~b-l5&wDH59FA zU*CevJHhY)@&B+*HG+eQ^Rr?wR2DR-P63e+mH15N=r|`XVvI+)m2t-! zMfVG2%C0*EN72ZAKSn?@4AyJRalV?suHRtBPzDe`Qo>ZXxr!qder*LD0W`SAk%7QZ*;4^}q^cK?wExh^fOX zdg!q90)Hu8XBv?0iK7oiBi}!Rut3|$3YB%=hY{Vj4e|*= ztSEUdUo}qC*=8V0zC%q_s9jg?p{aDjocf)^*G&Yi0EVS;f}BrvmOb!(O~{PG$x_$T z&t}0dP%2_hoym(RiLAAIj3mW)ajOtLR5=j%N4sZwnZVW!{SoMAaAQSz-1v zCA3;w$l8m=!rOQI{K{^b=6){r9D;k%Dk^s+C!G4tKKQCkr)NB{El_Zsv_{!>N15QII?mzR4i;3mfOmfJmBhIr*{>~hdP%|J(Y%l<0RcK(KzQ6;kFBDSD?;P z&ms?3th`_sSZ7JI?a*8cvo;$lz1>V$R&zfZDvDnR&P#}zV(#4@itlfR2;t6%V?ZJ_ z3*0ogJA%TS{zfpFzi2N(GgQEFG2N1IAZEfWxMY7VdOBB#R0Qp3hBvVm6%S0MBXrC zh?i98`*)osy@x{;3#7|R{(@&Ob|EyD%5(Jr`LV(;u3M*Pm|VQznVjipEs4xcTPeB| z*f;Fa_b_z8iyz(Ny6Rq`!!@QS5vq?WYffakgf&PGVDa?TGYk6f4CHl-`M= z5~Jfaa@)0B8}O$_F5}&iZN1Ma87?V)_xTIa;OBmkMbEs&xbTSIWuOEfalsI8eheVf z=2G*AE3oL|!yMT#quQnX~5Nrug~>^m;yVO1rOH_;Cf zNFQYgR{pA6=Y92dvyJM3d7}c+^v-}LVn+>! z!`^j3*-=P)9O^FZm$GQnoEOkGiQXx#;1M5f@Mipd5)=5I^Wq?67;(10(67z&`LV4; zWp2dXubxp)u&ChH!Hr{2PQ#|=PPz1ZcwhQYv?PN3h%&c3Fm=f0q$Y(`n2Rxk4t|hu zWs3={1Xq(6xVq%TLF2F!I*Bn7Uy#~e+o*&fu@o}5J#VzHg zwOlwZgr%tv>=zQ#GZV^Wso0P+tO}s5$!Q&E4j=Uj9gH(Dg3>=$AL>AESLaM+;C}9% z)(EWg(J=*bYEfBiEm-jlEaTCN;&U!yM&mn9a z-^&Tn{)^pox)if3*Eu~EF(FU<4^V2Tom-*mtNc%vpBICc?G%n3K2)|;YTbkO;SDDV zy9WuuIwS-tR;4pe*w;7yKIehtIb*_Sg%5E4qLwqCB2@fzn~5XL_gue)t=TYx!WC}js@mCFB_@Zf;it3V_{lv-$k$_72_l5_mW2$Dlp|V%a?Di{ zhxy$9UEm-&_509@6PKr-ijeF@NO9?gi_@Deu)-RvRXdJqFsq+?zT*L!p1C6T^er&afS)I{%sw^JZBgGRxIkGBZw6|^^wZb-Xt>v9hmc}IBv!R{Yj<-q zx#bW=Y|YQgyADrkd-mv|-L0n0ajbivg?}y_J0l}evLkkpON8d)EuiZMG_8k zL!^h*e!BSB%>#Q*_Tf5Oom{UIN-_>?+1!vfO(6%XX&`5F1fN%cD;0(w?O9Y0qz-n_ z*rg{X&fs+Y`RNSpAQv~O89x4bkb-#srE}=xNT{abBL=B#d5%l;fXWgB8Vms-Mq{GW)6)A3nCCUFSZX>=uye57JF; z3=$+rZ>54YJdLWvaL0cVqWlVS5{6^Y#>dh%i4v9(z@o$6=Zk&7j5L4Yyj%#UOgp4d z2U@C)O+yjgQYTyb86nTI0GmS5lTLz7^WnR!r7gr_D^G5Ifwl3}cH<$Id2*pjW;8{EsS3j?2JVqG2? ziXWIf++SY5|12lo;j)N!2z^GK(sp~9Xa31CiZxqZdGpcgrsJ+)FOeO}&LP_8Yfk7) zP8{SX0-C3;XX)+K7J{3ral1P_s|3s@Ykv3PxMRq;=nyRyZy48d=rko2PQO^s;=&{i zbl(y|sn#4C^~`5wQ%?<140C3N;bo|{8s7O)*ZyhNH1rlXXsIY83Ez0r;SX?~Bw=jC zS|4x52R`}!5*luUSo1<B|&Y?pO)N6zpVp&Kbd@HLa)j-G}%C%Xn2eUHvn@uSeUHwR1vXEM z=*v_46fmGqTIlFWKPe(Z3Kc!d1%w{A%&ncp5B4g?GR1?DaKja{J$#6(K)fu4@sSBB z+1uV^XC(-BIvUEtAa59d(vo2B&z$=}mHzG38}i+RkUK6+vdu|SFjDTPr;1zpL|t|0 zRb!s3o1v%-HJcbR1eI-L|Bsq_jsrK1AoBsP#kP`M9^oZ(Es1y4k2p-tsZ77Rn&N#V z8??}&L=mE7N`Z5N5K<}Q*vSm$*~GzgXMePu4j6Y(DB}}E#osrC(2TWeP>~8jxm~xA zR!eXAppv(oQetl7LqtgE`a?haXPX)eB(PVGINoV+wHQ~7yqBz>L{-rrOgBXAawRYR zl|0kSu$DvNQc^gXHns;MUOG&R{S059IHV?Pz|Y)zGA0#c|K7iphPN?Yc5TOf22^Tc zfPz*NE_cmg$Ibfd6YUjb{1G818B44pmv^0cOP%dV+7YkgZBPjeisId;GsHu}CF%;R zVfP$EpW3`7S~G!~t5gph9FYw2Lsxdgq<{~u2)(xNhtEPi!%OHMf63Ex*LZoQDzAM? zWshk>^o8Nt{so1peIgMBLvT|S_@W9CLF||^aAA=X92>Fu_2@&1qKzAmxE|GBqcgv| zGSd0P0RA2}Sx@OSjIs0QyM)hdEs@MdnL$)#{6ru>I8R2%;9-b&286f&*Ye3*-Q zRrg)HV*@!wj>xYtgKEK4gsgb?0zB$Fm&hk5SM?nNzQTYA+`)9QS;ck|dLS@zqnfLt zYe&wK84UuPg$7emvriQC<=gHyFJrh(w^_PFj^;lkxLTz|KX!WCv5zxuQ$PEMa|Zaj zpX(wm8ZStuiNKr=_vFPwbS?EnjSyB z>FEo1)j;=yR|dytQ+@C7-)2>d(Nu_PPRDKDHVo?eC#g1%8i-V2nI=_YQ3U>D(=rYH zHuFUs^7onayIy`8YSaOa${cI*tFx2jIu7JJ7>SXEX7Ur-1Qwm zc{B>C|9%~YA7am7ZD~Nd@913-#k#ygA`Y?Z1(kxF@q7PegKJ|W(bPGxVaZ~>Eou+} zqn4{%%&Id%;aAW*TNP$Bt-3VdB@}Gpj<~P4@a6p9q-YS%RXiil+#1KWFo?Ni{Rka& zs*tLbS}ENE%Tq6>-mRHtMAQysb7Q7d&sqg@=zvjSr-+;=Cg6kS-a6p zs$gR>+2}*|2{=@vcA(9qU3Y1m51t$;GX}?(Re8OOxrEyHK>)2p~UKHjLbm)m@ zh~vs5$8e%PGQMUPh}pU6e)LgWT(iiNo!J#;59`~BOwEGd{62aHq+`^ogWlOiS*brT zs4^T+epO+vDVX`e#d3lC4+e$APzmc{XaTMnrq zs4E;~Ly~a zx^HvC-YdckE%L`#g_`+cQT<&cJR%f5W$UCcq&7jnLs|gtBE8GVKRR za2T2L(vN1Ap>SS3Q!hMmyJAC`OW|~*5ynu8|A2~UDXfFl-Ib}$)zXd zDw7)?mhioMen)Y%(&HO1QKgq1x>&P2i7ln&H4Vzij;|2B2Cxw1FuP;=)lQJM+@E(;LiqF4}iG^Sfk=^Tcc{ z{~EyV^^m>O>=XgtK!Uo%rcPGBIVMQRjVyL>+>K4Pr=TIx&y+#cT~$b%zjq zgrYa$djVu!s|AZM?cF$%;;BRLng@xW&VwoLUJSiE0(uFTAk-e93vlGu$gK>}_IYt; z$)>*Lm}rsMIN~!x%sDi~n;Em_opAvJ$Bx><~*?0yxmvZkNLq3hrB!2qTMfPmfeXi98T}BvZzgCjO4l2 zt!stybipAjv|%xLN}sLxTJ3sgM&^%)a)k$gNOFn7TB!)@hZalGFaRu2LxP~)^R(Qr+3}U&$+MT{pB5ENOGi^>r@7|lMC9MJ6E%DPwJPiia|P6KDt&=S z4gkJojnl&fd+gkQix~&f(HF zDGMEnvL*rShbjF-fYi$bSKvY>>_t!#9cTiJAk^&`b6C%4%-R@H!k_i@Nei|qv#X-iqc>_4WV5-N6f2 zQwCz{L*+LF6v3m0cYsKQ^qA5~T)z^R0Go(d7@0Q87+p5d$YQ|g+MAbYR zPwL`5-nytrxzVENkl*Hjq(#*sq7|()dqnh|-q?6>Nji1fQitX;;^7z;yzdqOBawMT zX@=pbcD<#^;CZD)c?yT1zL;8t*l!#>hyfCn3Hw$)+G@?)#?`KxNDgJdQe@uIhe_ae zo+FDWj!&OE0%wHBBNAPR3qu?Rl=~Kk@e$S`23!S4smKaXskRaS*B-eU9v0{x!SX=b zu@wTyCFay1Y?l|jC(Hol=kEJ(^BzHlX}&AqhZ3ca`ZyEnwtqr(y1MFaUv~n7*jmV% zGSpM3H+}E?nj%94Y@2UUPy#ZXC0I)FgVxpLS$C=X)+wnK>dCe zYX-uMv1h9ipREdH=L)4`FK%O;7h*DOs7lNM-A&#c zQ)pkhiUAu1@VMX*g&>ih6$!D$@f8+GMlL-hD%ev_U5c0>_-$M7)Xxd6E7B_~PftL! z()gN}raHNA_S%49Zvz{9o{D5?0+WT`$p8*|GJC&s=&w#mxw8U7~K=fHS@f_d0@_PD0#f$QtHbLmc}ydHXg+Wj8P?>|5T zhKB@OlT_ip4@Ipx`aSh=$dS1kUAEXtSm2QMLb^e#yrkGaxILOIksW4tXhI!CFr1!- z_}PeOukP;0GCV@^0+TCV?qLZz?O$OC@8N7x)Et`3kef<8jp!$YOi|HoDy_VtBYGFT z9{!7--m!O$5=tiHpxS-jkH*Z&ej2^^yCYIi5eyB3yUo6>6WC|V=Jjd{(DDf#27-z> z2jqF0m{G5!O zEikG8)?a9?r@C1+rB5*`6ba++xUMPl_U^AScF2%3K|sS~$*t%JU1W7xq|kCr8}2+VxZtk5v9<6QlA(j%Q8| zfTJ)6_i&h4D1e7>0&4A!xvIFekT%8g?;k$axdl&AbM^LT=()V+ZJRJ-`_oy<`M)>K z&r#0VhS2Dm9Djg~YMu$?0J7%R0i{Ni4$OKMTa7hH2er{`1iRx;EGwlytq(Z4GSpQ` zH%Ro*)cL@0o^YZSn}N1hP?TRG9(lIB`;O1CZs=?LPt!-Y?5}wJP&fS`!cIh{erZM*xAza&G3%5H22cS= zH{jBU?`iu%U~dvxO7lzDG>{eqFUu8F-ET)E1+U3NCP5%qWmO;YI?>;;Q{-(xb|vsv zmrY=po(A!A(enJX(logRXo2|jaVC*s-{R5nJRNfg<+FBkyTtrLwK9mNC@4gAD57O~ zScwN=yRHP|R#u5<{G2AeOP!#7tg{i1K;q9@A8L5JAIrDPM%`8zICduY8+>%bOfJ$>fTB=zr z9@kuR$b3IK`bZF=1GI+-DWjX#SK~{GW;9{9x;!%KOqW$60fHUtX`3(RF#FS$yZ{RG z)FW1>QJ(~6*Nzim#4`oyk~@iX;PvtyhTi828S!k6o{n}pPGo^a=&Rs|2+QCJ z8pk)-yyxrz-{z|R4l`}>IO^Tju5;g8xN-n+^OU>a-ksR)g_eLWpc<@@1)uUfx1!-h z`Y^9M*2AWQrd@Kzf#JouI5yJ_kIOrWyK`8%Rn^H2Lt91Czq;(!ABO@xoHCqeYqbBD zx^G)@BiFL~6~;t3h9^$*i1(^;geRg@>XtO4?jyI=k~+4Zx=YLiHZBS5>snT0{x$|Tg8-!JU?QE3FKt5k zsxwNv=1~U(y^_WAJ_hNMHqXDk+s?~SDglYPNTTd2W`KU+HD{~8tG@ixZySBY6L=~-7p~u zLDE(RT524}8fKs^%tk^)NZm}}$q*5#ls;l(#GtYjr7j}j4OJ~nz5?sSQd-MEM2*8s z=Yu#t@sEDwTT4c(AB;X4ZsP}tpwv!4S zs`C{az6mnQnhK`_$bShus?m5H-z84BvEA_shhUBbgs0`bvnBjUw{BbJaOZVfwCrK1 zTpOYnekYii2?aIMhZXMKDYtFx!`v6ZvYS&iAW|&hiPV|DOD1|Tl5~i`Cdgf63D(#g zW-Hp7_5)o@MuK+zh|@DvL~WaG6=7-2D`rUo>NjFI#kgEB9AA$?YfXS420BTyS5l4C z3ywAoi(0R)2XELOu40W%wt3ARy$2!cN?BZV$ZZ!$y2|$CqzV?Y`krwvc5-k9RNb*G zX0!(5c{4?*SBF*cOxZey*A3$d5}b6p|IWacFSEFIxK$(pakJYB)sDJ%|ER&jCtM@e zsDtmf9~bJ+mxQkMf{-%GKQ!4}2v+?{Qq-Q(F{w|8>FJ*JUyWT0)5qMO`2*0f5cT** zUUNzfC9k=qq0sp_sL$I@7tiZT3ym`)MlA_c&Bds?#HOy>s-8%=j;_RzF4Mj_G02ZW zIcJ8PDb`M^f-cJb_i5**1jf46P^K1C^B+SoCcAm&AfCu zHV}It`@F*$`}AZ7Pz&&C63GYsr7A1;UyIHW**~&uvh8G%Sy9T|oD+Q|D`F!9O>Fz( z6S&TvmutA8s)4DZh`=R2x#|m~iOY*b@TSS~h%~s1%R^~zjK~QOlNM{4%iW|DY0QuS zE4;WwMD{@rB%}+Yx{A^}g6k!}LFSrq z0mF$(IIv|8r0IBE3;5??mjO%KQ;BCUhSh0u>-LsHUJbNc99azeYdgeUM4cDx$hst= zjyoPh7XPG7M)8aoT8T&_=GY5p^xxp~RaWK6wn^QLUt*XhQ7tz7{`*CSq~Tcs2nli| zGPIN1lE2$E#hL`wV0Zp$!OIOHX+|&UqbG+=wXvTs+!855!yj+ zmwy@5RX^^JqrSj~b$);Q%ZJc9R~?A!v&C3cP#nr%+E}7$%lqsb(r7n`t>I?XfOuWz zF)a4QGag}ko6+!Hjvd5@;@l*u#% zhjUs)LF}Z~y`C0M5PF5R-%4n8KWNiwR`$ga)CV5WP;0A(A=~|XA4Hf!qcEq%$fIE> z;QHRB9=4l?ixa$0PH|a-{>Ee?kz!XVYIs%q|i=@nc?PE_smZ7+()nVGe4Yi zf#s<#I3a9Z!EzBcGD4)!aMWjr&x8W~mG?k#D=#;{A0#D!&ab|Sn|<-aBDu53i4Vkb zA{<9q+}@(PU^NVgB@Fc*;AyUZuBkqKQ>pWULR|$M8-1DSdx6H0r&*3E5ZW~->#vlY zbH4RoHxpFFq6TjGeN$KhiY`Njw0sT_9io@;0}w$3%@ih41E zP}a>Iv>IqRz#mW>OW?DFM@f~L;B+V7)jD9>LHww_)i}X*zgxJ)2~vBNgVSvD817Ky z%AYt;8XiRw9=17l%Vs96C4H7ouA?Sj@)!d{8p1p5Zt|BF^e5SOF7$a_CRqXzasnw* zr4c(q(s^gl?||P5;a6jiyWNC#ueTh=#$FG&5eI{)`DcD2ZYOSwEwSL+;J}B*eF8pw zG@Hd7ZUAWB-n_8p>p(>INbs8k#76v}ig0qCBMinMQve+A=FbPXmk~^g>d%CVubaim z^c9dEzSctL>{Zm{HQJ7;OvYn$&Nh#1jt^5w*=B4_?PB<<(FCH%>wd#dHYc^Y)h5v{ zI(ylCUZVTgkq0{FkOxOj?H1c5VM^;RP?8VyffO3f>v*-Ky=7ZTC}fvlTK(?zhVoS;Deb*FGX-GZgV_Zbj>?NZyPey|R7x`CoD*60%-p7b7BffikNY zpb=jdr80IE?XdB~?uevwEKGdeDd<6^E9CD3?CBFoCT&~+(wl5DK>T^8NXjRJ`ss$fQIX3FHv6ite5 zo|#5L&e>0JnJ>=VI()If%@3fhY}p)N6r-X58RA$f+QR%rA7J4v{xu7Ju*PHjFj z8UonsvYns>9zT`B4Y+_HA3ps0_R=sQJD?Y;0#7Q3$Yh`KG|pEQVR`jDzf~{ zJ$G8$rec!TLK>XNP*yqGU4@6w9Rv$p{F4Lx&1gz^Y`VEWatPK~B%VwOf4@MFjQ6|G zz8v5=;2H_3O^$WrX+$2*8H|dU9vBLP|J;J8GRcshASrTI&6@(|_8JtMyfL?r2lw z>~OLXSWNchXQsqtAW3g&a4=lVbh0oMmR^&-tRKW5@+U6Fn zMk4E`s)@aTz}_z1wZPwAu^Uqpuv}4Rjk)@5d-y&RS}!va)>N7!B?$)e!7)PNv-pT) zaxnKjp-z}8p)b4QoT*O4uk9tBib?|y6PgMK&5t`1*f<@W)7npI{Abu*x>H3B6;cr5 zZcZd~D`3OCsXfo2>o1BEeIHiYn(Arc5W6qF0!l<9V8skDtN-wPLAc#vN9R2JgGl2> zR((;GK^`i4tY&A~bSPce!O1_jOY5SnCc2|)=u3)w9GI+Zga=QAS~bre3e&Q0AlSmX zanyr0HBi=P8SYz#sEqqgtO>9GkV4fYOh)Heht`O*_|}tmKx=_w1_oV4y^p{AWct%C zRP#-(qWSERh~4%9HE<-^aLuij(#GIsC??O`RrL_*eq<2&ZUz7fDy7Qqf9RkB1wMHC zZpdtszuBFU{b_-t1L(mihL+NEyB8g@-b|~-Z^d1IR@3D zDbonb0wS6~G793Y2!C?od4=mMT}b{qi0FtE`mxn`;BIR;S;X=rw0y#p)H`eUwOFlS z{S2>rifx^VaxO9{s=ax(MwBCE7sc_j#LT2Nf7bLsZKbT}hS@3YGg;tyR_B26U6NY) zxGL^pmjG}ORzG3?bB(zF4tWn(Wm=S_y8B@ z+5I+yb&k|)od5M-M7D%N85mR!-VrL@vkhn>p>rHjFSX2~Ug5eGOuz#j ze_h1ZQHa5VA;Q-AXIYhNN(#Sn*)Jxk?CqPUH~&_#aBnMUBC!Jynpq{IkS@AZrMP~a06mvhbE65$*y%X1YdKr~-pCf$+cub1Z z!vxo%7njVP_`BMtY%s9mEWji)`DO80e06W_pUE%9b!djSGNJO! zv*B8_@;=W#o9@wC_!Lf+8uqn*`lMliO+|#cVw2(QpDRR$;oW*9Dwd?%qTD-0#x1ELAI05ai@k*?+VT<5WY}CgV!nq5Krw5d!U&o~BT6U3n(!(fOMNy) z{han?Wn8OfQf2c@NAp>AGY~#_?V29QVA4AzL#SXQ739EKcfl2?dKIzL4|>jLaAzr% zj4Lrfo`A!zxJOzB!E>RSzh*HF1n1hWa@C{%o1ENuHnJPQ)4(og59PXa*14lN}V^r~wBQ=OvrtC8?*eh8g#X=>u;T@YN#X%|F1Z59J)vO6? zqjrbIN`bb&pyodr%9P>nA)Gkl54dF!DeEAIv-)CcLM(EZHldmYpmW@YaU?diq@!#T ziSD^`Tl0^DZ>XkTR9o24%F$pS%pNJplEcjb>=$e{{c=DFn%;;ciKgBfoBqH<$H>YB zQXw=PY{_|mr3_UQ_MM!Z(Ko!g63TY0ZLvtuwgKEW(?pymfAMZP`@F&}K|qHsSUrhA z!P8=3c|6pKi4A-RNWK9!?!LD#dZbY>vJ~k^G14gq0zc4yGOGo+{^XJbgw=;=%!UZO zY5MUNM^vWF7OMhTs*5GL7Wu1-jk)1g8t_^pa=nImiFuUy2svbHDYE$cRp3_Jhffw>tb5I3qCoC^j~m4(M=0 z$tvT#=q#kukyw^G@k>DynkZG3eNQfch}RTeat>ebRQ@9FV^u?K<$a0iFtVv4UE6n} zIfZsw*-4Jw(NxCqqg}L?SBa7ww?9Z6EQcJ5Bzl`75C*tD6q^TE-G& zNsT7>X6Jdm`u6}+n&toD?-y^TFSDelywt_etH`p zH48GFFQ}84Q=KYBha6P#1piXVf5a=Mn3l~xlHuXUBWbgiOv^1B{0KamN5BBUbTU4( z`m|POR)7%8IoaUv*KN5wq5j2n`=?QLl^Kl^D#PEh*og&!f6Ne^Wx_nfXzK(p^JGKT zO+jVb$P%LErMeXyN+kq_gNf{RVm7o}u0ia}uhU|KO1Sg(t#l;PZz0jbN4z1W|3e3b zQM7Q-k?x`reB3S{5vrgfL0Cvt0_VkM8KD8uet4?V*C8NaaDw9{eD?CU5;?NE*4);g z>kQb*DCL>qD%mkQ9*TL1q_^|w-K%%v4yhk@zC~+h?J0#@^w?PyUn}<=6~6%^XrHso zvi_`^)y#>kZ3uOoF8U?p3ry|~sS&Hr8#$4Y=^{#(OH7qi!vaF8@zbjNBvq&9WGu;c z0?oZ`HCl!+Un8%WPEC{n0Wboa#n>Rtn__$|Qk2eVH83pxEW97Z-)8HNr(%@fapTg8 zfb+q329z5@mi9(Jf>=|Y(lGPXGtwRSDB-OdYfr*%$F{!uNTc$J3-Rs)icGdgs=y&Y zD;oiwvYrn2u++eN2fG&8#)ys)#gx!&>K5!HQ@w&j0A_~0~Cup5+`;?S;5J^)+w@E-S$3krpJMGDf6yU@vYCx`6lNKT|$F%-&Jqf z6Iuqj;&19q^zl&K&!SDY)88CX2~vyHz@XZWzAIUrrgO#g*D|K2It-LDGvlu4@UKZ|JGyJoLWa>@b!4 zR{%}XTc3AtLGDd0af`lz9VO7cjrnOTpm+`cv6|@+czSpM{aj$zi z;Z-}K@v(^Ce&`Wd!EvRXz`i4>#qF=RTCmY(H{4kIsmdierPbfQ@hlj`jr|wp;l4d`eom&uRe9>QUNks#X7IGaYy|3I7X`Ufi}nA%DJDA7`XyZi@q~ zMf_iLBCz>{dM)hv2&d|5wc|#f=%2D((JN-N)nUhZM_@B%HyDSz6|Y~5a5o%aqP4~? zGoDK9_?8WQBBunvX&?5`#o*9`+8uGV^Mg?Cg|oryna6g);=9cU^r9TLIx3 zNFlhB;P2gnC>~c;sF={y$4oR``6ey=az{DK@P(6uBf-;k?Viv6XiBhMXXfisO2=5! zK+R3n8ZFlnP$bKzi*G{Owgs%!B`4Q?aiN~jzc`KogG9WCFVjPf1e*1k0@Q#;)$ca$ zh~Z=+ZtSGjRcEf$U;grwBX4FD!LTEk&4mRba8x>gbBi9x+;(Jn%oluGe*tuDjz|b9 z!5*OUAwFc^HAbr`h`bZ&d~EEcSTX?s$^Sg7zxfRBV8!+HdxVaHmSNe{Q2l~6mdPX=;geuHhynEETE%qjREGx^%AVJ^$4yQt5~=-C+}8?5Ip5h(VnA^qA+3%#|ltw*ID1BlVTa5Bnorpl# z9V$lew*?i*5G%y$fRF&WSV(IyOMGwN|M|y!+ymL_7PpoR(A}=SEpmW&ZU4T)PNbEK zw%+Wb8;pd&K2RdJZpi`z2D;%2IgK+Q58;0a!H?BJL{JYaiEL;#RRI>34Y=M0G-k9# z)GnIWwBUd(W;Jm)L%<+T|?)k@%M7|7g*^A@0{_&ZDPCi+Uu zx3Fg6W&pGzBO~L~qMcAfaa$zyjwMn%W_4mVXMY6HXvM=}C#Wp}5pa+yQ^787^9KrN z5cp}7NM3*2BU!z2mMrduc*S+b&|>Tmw?}d7bbtKt>np${{Rucp9s2(OhQZ`o`XKLg zA+gg7&=!56d4nq8`!AxKcE#|NgglA6RgO+lu;Ne<-44D zI2MP-D`oBVz!Zx8egGZr7b@1r3fohhdK#Gy#v$t|+> zv%Ly!BWj(kVKrCi7OxJlH8+$H2Py?-X#-z{8ksO3!jGOR?i6%PZZ~fZFzYst2*1~U z2y+?2&l~trCr#dXDqZM-eNYGRaT=9=wIwJRD2d?I9nl~(Cb=E^?F9VRViD_9?Jgk^ zVMD-?pGyxfgSfLzRzZU(?Yh_kup6?_+t^n8w*TB6OvfSw6nV>^y%3k9aPJ zzF#8Amd@7|((|`)-y`3aIThwPGg~c@PXkXP+=QXfBvqywjnZ0jo6Vt$>9w#~oW|S% zG`D=>2oZD6x8%+W#9y_GXez(i*O4A^FQH*d-61Ak`Y&hJuPF^HKV_~fF@&f7(qbe} zh&Xp&qjnjkVnjgvuw23aUoq3rHUpif_QL^87(1(~bqF}TM`L;BzshI8pWpCqmFC2-wI_MI(kz2(zWG0WCZn6ArXK`lh<{)w6lrClT6{pWwSs_|^(DKW6OpO9y- z=uu&fA>Ak#hQ7J-D6%Dw8D86Fg)-#Lq!tT11Xl~v){Qu27aB;mMuH}J`&n{~au#SBPfVIIUG&%Y=c%2AxkbFerEG|B>bzc^b^3<#?!W@7~|`Dy1}qxvu#Q zNZF3KYd9E*>ov87_5)~~j_Qj~o{s1nt)~NphT;R@VYU(scFXs^`2t=1-?;gNJEOI1 zC*6E?$@05TKN2IO6@#l2K7vNT0SQt!CcnAaN^|>3ugM zY!V2C2R$?`oiA9vmT~Q|$ISPK>$RgT=8_Q#p7LuldrrUK;^dk+&nJh(8qH*NAXy~mIuy+uwz@hKqq~1@dlbo1lSVhQ=mByz*c19 zE&;IR$&IbcEO71rPT!28dsBH@?dlEOcRIykkDLsvG7wwf#JYpYSh_~c@`+^edx)7M zhl)s6n!`-!RjlVNr3U45xanMVA~Dy;{qj!8JHkA2XDmkGOYX}^ssBt}7sb5dNp+43 z%AVEi3i#i^4RGBTla$bt+n81KzQqy|4keZVt?PfQ>f~p~iV(rf01{9Z;x4Gz+t26!xrxm9}4qP~}iRg+V zU1t=VMx^1)^Bsz3vJKsJD6~VxAyNp7jbHA;WEhp(Xzv1&ce({Ub3kSULgSJWhiIX` zzQ7-dGEm{19$~<%KA1>Gp!13pX2%&yMp#cq`TRWpshlD7PTCLd8 zgOWA!PAjd5qG_-~Xb1$>bk{-7%^c9+eCFH}mmTa%6lmiFN;p^Rr`fjgcZ;9mC^P=8 zJ08evJag5P`gWUcCy4o_EMd1H?;IyT*Lo;Z?Xd3M10ho~haocBW871fr?5J}YV;?* z>a3|785uQuM`+=(hbRCAU3;SrQIH%qAf{uaMFIiY1NDaS40neo@G@}X7q2Pe{bhW^ z+I7# z5sX~Lnm=@Nbo6DIba2q2C_4h#%;cxp#y)=&ugG{!e~1tjo-Y(bmw0Qi=Vnw$!Eyvt z5>HaND=dG-?HV^X89Rfp!?X*CKniALjx7t&itj`*h57rA9&o`OH-MR@%z^qEaV~=0 zdEOv#vo%R{z9-6WJ+*H)`Qj7SL1e**xx}|n7ZkeeA^~CRdL;ZeC(Tnzm&tC;&=hH( z)3tOe{BoGBa=<@ivl&P+VKjV)*!d>VhyNr%1YPcmMULReo+8s45Q_Y(I`~S6Xyj+D zp9z97`ktYWwyAk1E+-yu&L0~|nBVW&tIq2$akX`-oVJjYC|ljdY0L9kcNsYF2Ojce zP4pUm*E}8!ub1C&u4=8jfbL`K7-`-{CQX3DFQ7UE2nex#qG%pv*8u}&B2h|16pGm6 zmnt<2kHtL0&Hy4A3;)8$3>+b=B{8*W*inIcuj`m=?{Cl)+1HJ^A#+NMG+OZZf&<6S zK!ShzyK&#go-}|5em>3$AZHT51`4DqAb$-6`Ubf?RnCY3FNF{qr*9zwHr~OiAjG>%K z4}!}93Fjy1O&U*SaQtsSC$RDs2t}=ZlcFQKQyI~XWwD1TJ5DTGZcf+_Y|Zgh+=vP3 z_fhr@;aQHxwtY?gZ7R3N5(+&Yaf^;RHAdFV=^>$Jo1=G8&JnS~vGx);M}&52U!B0o z`Sjy!Vj%&Wwf5#y^=yR$)l{7EYF8Y)$D>?cO^sRROA16ix9B~GMAppu~!K4N2{b$J&y4}Xk;pieW2hT z<%+Z4uMX~Zy6ogr`M^|zL(p2lHv=OsSz_2HCMp*^4)GowhCpya(K&Ogh-E5=?0?B#w;;KtUy&M(B|=_f?5v9< zEGl{@+T0iLmCV%t!jzo!0H_C4KNZM}#th>@Kl-*bas|ahBS3S5o16APbKwyXy&yVY z;HX8k4l-zeKYiNLwlHl&pUCq177d$$(tt(Wmsj=~YotdA=)#KA=Td_++6)dwsM(ho z3bAb}d_x5T6y14g3zZCX*q4EvGl%4anwnRqd;u1!8=LYdkjdXw`>1;SyJBGA9n}{S ziF1|w8UL&TFP$?kVF;YDUQ}L%gwF*s**5VU3FE+iR0L4jJbo@9I7|y^!7;)=`>p_! zN#IWGCDFFo=yQ00C3KcGO9@nBolMNcuoe2k8P($pdBMQbKxkRBA%Fma1cW^ zs~)-Z-|pL!YloK{l3o1EWw4aSeM#--nNK7fpehoDMVL2)r9`lqGmuCqrUZD%mMi26 z<8L1=X+?+SClbJ0fYT$d@x$_d3udV@jVRc=_Q&*PK+rdmAL?N!7us%D0F9nD&v~21 zTI8DZ%cybntafk?|MqTPTd8XqU%d}@(cPnus|>!N zbw>NE<*Pa=^4fFYHnh~~-u?24vDaVU3gxH?HL{&YZ!q!HZ8eJLc;RC)h^WK<#3{Xz zA>P|Zg)2&#&BV-vIxv+S+=%$+AOgCCCV_SXM#)rGcbbyLb1&5whJ98J#gmUH^DqNW z(1|Q7x@F|Tit=TSnBYQeFG^O;DT#o0yoa__Z|i|X$yek&vOJ0sOq6i z+{)Ci@Gn2%c4aIpN|DDC`j<-QVK6mt@@==Mky%RZu4>46kXA^DQ2(RTvws1{R~{F= zZgdS2RBQ$y(qza6jK(){T_R)m;jrqgmJiV0NJnzNUpZR|Va=gu)&(^Vg0tY$>Ez?6 zjQ(INzo}_>h@D`65DQR(;YcJ>U!WKZ{D3kikT@)mrbK}|gquAN%FXGc{E0O6zyIsM z{@Z{1xBpQQ1o;;jNchq_BiV&$U#cvJFIdQYg{dIY(=;IyUeu^lV~IKym_vuYuG2*s z0@CLZ7&?ki)W5PVgH_{e4>=E*V!>?#<0}w7iv=?2ORV2--0O&N%A<6Bn>wJxgL~9WVl@v6;cM=`ON|K!bePuys#};LFZYB=X%+#K0-R= zP{s)$9$d03$|A+r2KlPmLpGzyOnh zCrTbhTKt+bi|r$opD7(UX10(T3~tjoGwQwk`K_x~h<-4^%9mvH6PVV4C-zO&im~W* zL1%o?^#wQaTq2ui)UYW|r!`X(mK98tqZZiK`dC3+OPqfiE}#iNy}_D_feDYtQtMK^ z(v`Ew0BH;jPgJb!a5ez(7%2{*6W=}(_sfF)fqZMkIvja)6xAWA%kc6aJKcv207dyT z9R7;$I-Ia(Kj|0`5i$BVvc~AP663p8am2WchWNbXCOEEExjp+_2 zWT7B1{EmYO1(e=3HmB2Yvl8PeCc4G?F}22aws6N$bLug7fllKhB}2WG&%WW{s{dZ2 z_*gWeKRqA0A{^#aa7eZ14+NT|z#6LT{POE-W+NaMdrC_XHS*zwv>Z=vTdL&rMdEzs z46ooFnJ#=&Q);gJzI4+z5?5C=mDn_0@zML7_eR>O_DkmLOH#un>yI4u(?|!fIl;`E&1Np zz<0w(95umPj1es8_}~b2T{TQcKlvEwV^+ry!0LhovHhXsyt)OhKQO>|Ag|r4(@lri z$n=e&JPYkR&`@B1O*}SCpoPjM6mZ=IUZZb-f2#h+Gs*m_yzdxXc zmMwI^UuZ)@F~Gq z#{7d<6h~Ewg`#|>Pl!qq(+JtC!oyuU`=vAXrRoXQ2h41&GmJU91s@uFI2lwkY?y8U z>&F!{D(qIjRgud$&JAQwpfVZVk@tzOvuN)+XNhmw1+*S=;rMS7qRp?_EwsdrF+bS*y;06jp$zeoA)be-!gYAd;W zGF6h{s4s69AxTwPsMIt<%-5g;CN^pKD0}na(||#@Yfu=ErcBBXeB^67#0r3=K}E5F zWCEYl^*}fvU%EpeYe9d^aVP3%AX7oSt+g@&6ODq2OwJH}BP6yU@QNxh(1k-Ge?-I$ zAHg43<8EV~dNz(3awvNX;!8~W66HQc<{BiUQDk+=qNC<-h8@6X`FA`eRAM-!>bG;v z_oosz=_P|L8l`XkxEiDEIp-;``cY8s#@8Cc%l~OG>`zC{;90}#D-rusvX;C=?swS! zSPk66S2AtJ?pg7|#sWYB?nl!T!YY72DC`3oj&I~C!Yfp3|O;jbWy3#&ZjzCKEgK%r>ROBn=;Y2-w*)q>mobRILytON zPwMnYf0;Wyl*z$a+5A5(_Vq-1L&P8zH)0tEfQ}9Sx}s6muDAul17zw~v7=^^3+zPs zg}b9_>bTYS+dPR+Cyis;JPz560GAnbngTgR3^%DU)Wr9Tv`_pFV8Rt+|Dg!MjV#|gs2D-8gTWA3iN}4v!{So(fm#x&S2IcEWby|T4Tfs9T_aJ*Zh76dg z_+HB5Pl+J<(vlmO4@Ir$njz98x<|ac4B`R0L>$@u(oOpwN3?nq^+KOb+6^;_0>oes z@XB-$E-bi2Ln%;VSq;_>`__8^78fu)?bls>(vYLkn*jyPLte_8AUcpLZS3Ts=!xcD z>_JxfVv%tMt^uDSdjPm0!i1!eJYYL~23VV*jZ;75l-;~LZ0_-jzk~ijT7Y**^|+$GP%8YEVz%rEAhI2EJFp))`t<}C-_ud!`i?#E7f(AhIbRpVGiFFV1G|TCFHn*V z<=cSkgnq_^ogx+(e8ku7X-7HTDFy+~Qn1|A%Ao!wmckR43xZ!J@Hqm|sk>RCLjjR+ z+o80N0-v%dqv@4UqM{>_I(ovgG%5BcN-pfLxa8Xw5(CPWDOVrJyksfHpW1*gWqLaIC*DCfux$%SdauAfE%lV9=E?0L3pp6zzD%D z0%{<94I%}Cg{iyH*|7=1Fxo zAoe!@ihIp%CoXPGA_#1T#{JD}xSE?QXLn3LNK3x>pf?BUy&gWh-;Lg#?vqes^!ofG_=vs*n4-Xr}q+XAYnIjLjR zmuXc#8B2rI3jse>5oY=BMJAgITA&iUrsaqa3W ze!P^syLV&fb7luV8Sl$YZ|eN!!)@_S9$EW$?}iCUGE?cj^Ude~`j`Lt-+Q|wfA3VU z>kG45j4aeI1Tg6Q!mm%7=1qn9WgDL{42^=nCR1Hl@07z~~^8#mYJ=1RJ`9I+|4ooWkUaX!KL zgzCWvAAlo~@KrkSz~d#0wZ*F%9Azk}vrRrU(!f3%zK#HZ*1)IkB9jtTF=cs50$AEP zFlniXXrAd;V&eAMV7Up$O~tC!KchgM129ykfSf0UJczM6USKqp$YytXGHlkLs$MkP ze8x?-BZY{f*z+SpDgEFgDgA)LCk@tw|J_0zCH8C$8b!R}uu|!=z#x9;NNA>pB6Y6} z`fIinPkF9;O{4%qQX=7`(@7pA~PfrEJsPC9P|HWrGAOH$)I z@(3~O2%U9XFq9H-6ApkULdvQ<_agf8=Jm@C<|6w-_hreM<#_GiyuOV-6R;Uk945Le zxkD-?2xb5K;+a5dgjdt}$*}=})~Xm*0`qh2@yfD4b%k7wuc$ksFd6+9yuCEC2kiEY zR#aH6#&3{8J&Hy`BbK=(cS-#seE_|0$-pD@VBVMvOGY_@>4}_`eB@@*uT{!i za|3J72h%|p4EW4Si*41bbZ+rm86D_ zTJtw&3Qaq7R>~J}ZeB?&n7b8~AJDXB^URYy7p-iXHN32&gEtZ`@U8%-2;cA}cz`(C z#S?VEAD$SzYNmc9bnK);rx6gQ#9b#kK!FpruUie&UJR$6OQfR41$_=NS#-KTf4qGy zTA;6f1?U$Y6#}5~iGW#?fh_a9^N{(XwwoQuq}Eg}N8mh`NI21B$WIQeJXmz^X`RYw zu30l0NyM1{!`zv5w~-@X{;Tk5{;D&jF0NY6JlQHQsrp&WG4a=>Q89`V3nxoUgvGfg!|V^{Iz3 zl!rT@uqzjmvpAomum^-6}8@{S^L;}Gdk)UA|wKWg{e7+50neadY# z&z%!nBgEXP!XmMcKs@OgIaUa8^3RJ`=f5{P15sV6-N?0tE_(H}O#~bOFl1o%O_v$yV2#Tj+ zV)7nq))dd+8`5Uf(e!fyk8D6@^6m*zj(uaDQOcuH1Vm*=AD$`)laGC@*C;3~*ML8KLZA~d}?1ch6w+%I> zBACTNg7PVeBne`MdL*3v%^g{Tr37ygW|0CjcMFcpl>;?Lp9tf^V!=(&hKd_2BrF?F z90I<9EO~y*`5l@~{&lgM&HhgCYmpg>Oc-`f2l77~X|U>SoJ#J=ChIQ^bC$XR=gl;3 zcBtn>T!ke?%c##O^So%ADD|O){J|kG3+8UGCtAcg3;c?8siO@jhn*a?8Ub-WfpruC zZv@urn9ZRhu~x5u+6m13~88JRFKzClul;Ge?o0GRBtZ zWL5vrOnn~T)QHUDj4`%z1;B6;TQ7(xNb1BRdn(}AZeSU=U4;j7gzS^;C-!WZ*zDP= z+DwLP^iEm0bJjuMZIxOsZs+@;HlsB@i9|Vrm&~kV1)jsUq#4Y(&`g8KV5);+yI#D5 zgrE+>bihUqxfM4fa*2KpzD+le>l1xLE0J~<@0J1zk`%s7OD>YplR)>qNX0ZRdK|4I zi(b}Ivi+BKrxk!RZd5ok5B8OmtKE;OxTIyOKBKaO z!z9Rn=aJ`l0xa_%75R2dgG{oh0RNbK)y^M3-{VeDV;qWAqq27(bP+p<#Mxj~#KbC~gjWO`x~LRs zVRzp6e0fhSH%)gt0yl1FXM>$2dx_$TnJ#Sl$QjK>o+B5%gt>O5pF7usecA2%*|9Iq z{oZ_Rd^HGBzommD!y`57Oo$tT=qd`JI5m0@_RN}#s z+&u_QBGIGoPrp>yIS+;@rmYrZ*eNrAG>B|-sTmi4lhTyyr49E>-=I^+1(O1d4{;*! z)AX9CmH2-KeJ50>H7sREgHyZbrr&rk6OzN1^+LoOYHvb?U$gVen_PCy#0_7*?#a#X zZ0bkrp6ocGD|0J3u%64f>T0LHl+>DGqXiw!YwUnQr0XR`E=4}BhANK-9K>{yRG%WH z#UaX3#z~9Tyr0N&ck%%bq#ER&3T?;-6G9H?w^Y1Amz&EM>_l|@I*3cuD2by(}|<&6-KaM(N{U0{oO2Sgi(Z zoPnwf=7RdM7WR4pd#*@#t;93YOZ4 zZ$)G1NzAdU+;|G|DglT#5Zkcvy&$x4+Xob=$A9Uc+JeE#tQEc_$goIAQlucv95x^o zxg_Y^T4@mzEqepb=m{E2ojuBj?css9!YY2?SS}OXn1WGC-YX}-CW_2>H%*{~34eJ* zfvqDB%F^-i(`z@*s|??Tty=jaq!2=a;R#Fqyq}zjif>~SfQ~! z`}NLBcU2v?XYg(wTk*Gwb*|~d_01vm%t+gN=J-Upz~tDb7v8{c!b;y}IR5qJB8!30 z$MP>y?TX^&pEJ{rAn87TamPSN_xP8C6?hf7e|^n=N({}!YQB4GJ={Kv-iP;ZMWfaO zvQ+9)tA{bb{E%;B5S2po;|fXrs{{`T!#UwI@}{POZhzQar_v-5T%Ug}DaD|a2^8XH zx=g6~0lJ`U^ar}gfkB#ti2dN|j5R@>zh#ImS9Xs`qrNMuhE->`R;h-!Cc-VpHr(O+|8ZxB`JPGY*K+MF%fq z9T6zg1?~wcD{Z*v%{_?*#3+O)Yl((~ie}zOH6PgEsj`yQAH1B_1hrJ!Okx3vl$zxa zmM?Sx)2Q$p*3f)zc8Ux)$@}t&rqm3(M!*y58<0J(-q?tC!kc@JE^JN`i|9GEPi0i1 zmQ+qMQd%(Ro!`F8xN}8xG1FJi;f7(~*ekHD^^;n}hHdewZ~d_J9`ogL2TCFD#)CJn z|9o{gu-GTw)8S|bS&sE5y0Qqzv0GPlJsV z0mzO)e?}>DDd{thORe~}?$krVPi)FGDNv6jR)a`CQeXi&ocz$>ulXq zHr__=>TKU%JigBKxL9MtX_-WhN6C;VQY${UQ{xTQnU+pUCCxM8gi?n(`3Dl?Wr}B; z9IX&QbJDmXPirT!Rke+^T7xkxkjr)Ux_XTW%vs~c4da+tgimbr?=3)VTn9NN zW!fTDhvwHPGDYS|pa@qtt!sfhA+AVXu&^qKjI~iM93GEM8uKmmlQ6~!p!EmR*%?bz zJn)kJ`Z|nVc@C=Ag9@)O2IqHF2>lXA{gDNAzZGuS=`|VESTv2peg%9aJyf}&1yprx zqaf~~oul&Z(f+m<49iExOgbgAuX9}9B$?d%`j|iw5eP@gF>%W8Xv)X`JD{s^AHF>?916A_F7B%l&v@9j-3hRAfZbvYN*u$8r^85^J2Gxyt8ue82` zd`Vq!HlV68+2iYRzvUoxpVIqI4BEMLYEgj}J9nF;MdSnT=i^!rKnRJny* zm9qSl#Arv#r`~Ra1j}lHG1%w7e+b(ll~BF9I{$QmRgDK0vP>qEZ7pMGZ(al@W6L^F zW1=fVM$W9Gp)Vs=Hkm|R&~$$~W8oL=XlzFToA}sI#+F;9v15e{wWG0|G@sx%{Sh7h zgaC2MVq1${W3fy-X#Zj+`@+Ss1#Q-}htq~|Rb6w(cKJ>ZzUvn)tdC6B%tFh4^p>J$ zSovnld-aR6VisL8T=4bKe{gvjUcHx@D84OMMw$xSgb^%KZ78i1!#f%nB*VKBhQYJ5 zUjk~ogBDMC-s|(+NCz4ZJ>6i=rkVgocx2qsiP;~^KnskNDDmC|8@N2S6V5Ka_WR?L zvGF#_Z_^&)(MIJo1s-V(-vIQmNSX7`nWtVZfhVk_Q#dy&k26zTR^fSNEg%qZ0Emg6V#@-<$aJa0-tBvyL%gF<)PD zP^6M)8vb@gqRt(OH{Yci)?;j4G)khFrF&i82p?;iz#%||Z6{p0fdi&A$#X$?+{_~- z%znM!DABVf3U#LKSq z`7Z|MNW;H&f*`R;iHko8t2v;4C}iOpAQE=<2#<-QuDBw zf8(g@K3X30tk2deTkmUnNAhVR$tRtPl4v` z3ir&$sm~7M-q!xFk_cBsP`YZSDBKGDJM)a7dV&hkDN zyJQ(CSaw8R*CeB1@{CgkW+zR{xALz0Lqw^XA&^?ey4ZU5%#mGSHblBPiV0#YL$|?y zH~*V)0~tD>)|2a&uaxg(GYea59@1goF0hQKO2ZJu19p3W-~2f0} z$Q=xaEDKqS)k_ktTBI!O{d9Xb2k5p&KlMqtsZ?%@xB}8iSXC_R9dNs!3d;hl?X@RoKr4LNbEz6Iv#^*{r@_GB;8)x09KQhO#m>qF5G8e>3 zD%my$(HF^DupIujg<)+A7RY2<7}vL8=cE~tllm5nTW)R8i0=b#ry10H0l&yEvEl1B zs1`D54UyPr)Q)^qO%%&E;)9*_?U;2<+IeuN-b$)MY6~tG>np@vYXPzf`S2I|j&aQ; zA}SLb;cH_8uDD28FQC*T-*_kl&=7ADAJN%eG)nU%MR+m;M2-x~v-$_Q zi*KjP<@AtK0Gdlr`eF&Yc&OA3Kr$)e5*O>4^{C^quaN24ReM0(HOJHyEcP&8bjfn? z_&pR9C-(gJUf(DiVuojm4;%S(MW5IeOhCQ2lGiWG5@mnmrK<8q&JW{i^GikeNaWQ( zZlR7QjmKAj{@7N$ao+XQTU_4T46L5)xK_hn8C({5fDPYS(d3jaHGNQ=Zg+(21kL2pI9iA&2!UY9 zh+i{b-OVrOa&;x#mzX$_g68)W0O5V*;TxPVxFTeNuL*J3BUgEglj0%nmG@}4%df11 zNcKhZGQ;Dc^-rZVNxkvcy#wkySZMR;hs8z1E9-Q~rCLU}(c*4u+NHL@R;zjE;Ml@7 zq+7CwYi&tRSm`UKGIjd~to3AKMX8In&m>H<6Xb@YlgQXH!{O6sYFEe|{$*t0oo_ar z*`>x!c0o=piLdi$7;#%*p$6APVp%4sYF9Gt%G{h;$mRXpH>5!PL733c`tPS(lBYJh zhC`8P)6ozQWUBbRPPBZgOTSykMOv>#%;3n1M8BUsN?0up?Q-8Ijt&k#(kS6l=0ITI4+r^ z%@#OpXN+jI37J##d;YsG)^uoNNpVA|Uc98_0C_B?U~C?SotH4QeFOf0FtpKHEWD@w z9qzzI9(j71x=K1TXgRURomgJN_vim68%97!m28}nUwF5>ro6abRIZo$4Yvu&SG{}^ zUiU11mEV<6N*>S2O@y%VOjM;3_)|e3(mQxwZN&ReA7355j$1ece%sYT%hUNH z7M_1enrQto;3eur6tPdUoQOmlb+m+VLeJ?jlTkZ_gXmhKsiMoPY8ll_1r_9E48&n+ zQam3HtitViR-Akfd6d?*DX8y${Ydd5`Daee*S+(%e;z7XhMAk?1H^YUryaLiMu*;P z(qLkRf7+S!;c(DTB!p?yL_1qII=mm(v};f^t=pB)CT*{oKyBL{rrR_z<5q2c{qt>N zto%=D3I$7Id5MH)-EiXeSdo!BKTq4=b z8Dp-yWzV?~U+uz=GBw%rPZQFR%j@*F>DCpdo=Nw0>YUF9k=2)w@$UQ#nQ;`)g$kkU)p$q=c^mKP0|8{lt_;(r<+*ntE`?faP`hr z52bVgLCu`hNRSvn0;xT3;kFE|3V{m%F`mFYJg9@EuujY6jF_KBV+qi1h_YQ09@EY7FiOA~zoW zGmIUj5%Ior1~$0(jOR5$JZ(hr9D+;A)D{cHR!^_*RJs%f2#5i9XiyA<8HyaF<`dk( z3bc<`zR}^U4d&ex7gs;M^RrhUtGMCRHfjSJYO^GhNG2TpB>R$IYtl@+Gz;wiiWoG3 zPfDCGA&S#H^Hhc5lqD5GYG^;mPP#uKmjz4oc3BIAK`tkHlXzSCGhVp{U-|<9Vfsr`rA6dTMHimh*EOJ)eI<0J6(MFqmiY+2JuWIH})1jK4 zGtz@7ju^Xw%bDGJ{S-|ayYkSzMt|Zdy0#hx$*hvbrg@N%K6N|_&vZXy--RV9ddZ|yn8xp^4F_7Jm zPsV`*x|^qAF2$qc58JtwSg+pVTqXgaS6i=cG>Lnp`8H?j2wvEi_Z^v$_(SNTMa>OV zkki~%W-CX-NwA7J9c428rvO7&hp&Y)#rtMV>AzfS)1_2w1;~||`tP1bvvCa_9a~nL zKMEdSVrjd@&3g5;07y42IQD8c_R{^>T8^}p8%u1K5pwB2GSMqwv8o9tyJDUsJ75{O zUGs0RPfu{ZR0iuvZw^vq+_|6`m2An=8#PhV8?f< zFAc1(eQ>2$M!JVv==V@zy@9P|P!cd0_DUpTov5{@vRz zUYW1O+J0RDM@<6$ODeSVtOo4QAy*6fuZnz>ycIdBVfDje~y+^&gFXJAXTKV-soRD4LWtyVGP z%WB0Kdl7{{6yaB(0kFo3zK>|o!;EB$YD#%i{~ZSVklsegWd1-*E+ixnNkDu$=_NcKShru!)vv?*^_Vx>g$iBa#{Vihq` zKr>X5iJUU0+kzN}MH5N$L#1y~{r78R-LC=un#`Ek5^beA-sQ>b8qc|55*82bS_FLu zGX{-v!SJfZP}?e4l=?tQTS#*vaf{b6r5d-cf~TgTAZZu2+5)F!X`em_CbdAxC^`u* z23v`U!6bSoW!ovCD7{bKi#>{Qy4-m#UthVNwGi*cL4;cK!;Io9K~8MuI1b72J2(Tf zB%0B{Tcl?fJNCum1nbYhb-fHXWlaOsj#jaYW}}+Be=;%qg1#`a#O{T2?vdN44V6X@ z1xxz=m0D_j^Anm~)4r|eQS1FT>MH)d7D(oXXdDCl)b#2p^LRX0c{nH3%ve)_&ng>G z-rS*!e+%Y5t0_qMu@Oj(FhW4_*23uI*KfIvmczK zgv%}w?)^|)Fmr0nm|*|d!s(lwnwaSaE$obYqHf_zPzhm!Fu_YH?nd}{gO8>gFAOAKf=Pd^y`(ke@DlGt=vMzD4;{Uu|fsCb`K4x`np z@J7XRweCrYt?gCt`BYo!y=sHxACDsLv*3LIf(AUUtRfuUcUv}3V$=#T@-*`q$0FhRhuouSUrw$?4bwAh%i z0o|YA#g_0R@taPp*`p(i0&237GBk)K1sh*g5lY}zc!Zs4O#t3!v-5U6GD6F1KlV0O zLQ8^F8u?!z&dd~u>IiSs#>p7Q8%%8d$CmZ{!wxK5OOEj>&v$vkx1daSi|;T(hgULz zNgUQ(LKSh7_4(?#anrTHgTJREjqcG5si^yq9 zqp9|jbPW{31gS=vo#*4S13`K4?#NU4t!tdeL3?CTCs>S$$TD)pu;v49P>_o5{U^=dx*bZF*Q z_%w9`qnYV!ey2<`n&k4E77&AQntYUCk?!K+p6N#^j1C8}qO@j~njwr^EuZiht$RCg zXx{Hz`Cz_31;X}8b#~D0cme8O7 zB21V`Dx=8_tma#LC{(7$O3zj*v7~rM!<>^)2Q`n(W2LEE23$ZvN;fpS=qd zOU1{7nHNC}SU#^juB>OzMA~pLvWFpW+Su|(VOqiL5wd?sMcNf~x6`W#7fpAn5NRec zg`s(~D_I-MgjE2~#xdrZKHS5`yg^X3chm2L(UT^dI9aRCyi^?Na{XOT_%C7dB^+wv zdP)$S(EWmH^Q6tjjcsLf;Re2dy%Fy%X>MfUX)!CV0T%L=QN|x}le*7|QgcGzEa1ZC z6GJ2<(WPqG-h zWy5YY_KWpa$vP?<{tFlk%qSZ%XdgMvr^rr@pbOt?|AN{=h|-1b)!1A5jm^K~3Xq%! zr+e9%A5~cUTqyhny4T0l^R``;(*avP35m}B&*WW8gAEm1cs}i(Cfof4Uw^G`;B8h zKDKG|k2!O5JnahBpeUNk&?)ul*7|yyMl1Uf4*kqZ;6icsoH{PMB&SX%{<)6gHX5pm z$x>E_G0HL*pJjvL$atLhkcB-hP;^xWy=v3o92TSqR#I*eX2ey7_U`FA!qNQz$?VqN z0q-(J`<{Ba`XC`PH&2ME8dm6=t8Fk8P~7qs&F)}-XmjUge)J9|hwsl{z51>9@%`s_ zy)P16GAn`pRJFt1)ojGz#HRKmM!f&`t3%%;O1;8@2DRG8IxAck1oPS(VpB?SLw@s3 zipGcS3m-g<5Wyr`)6R>xW#1<3>BI~_vE>wzr&p$y-RomBuZ~{R3LFXz|S z661eXn!R40nxo9@neb#GRN36|j ze}4V@8#6po$pNra$}fd6=5p?K+hCz?dgGv#>#UWT;89wQr2XDozf#Lldzm+FGq%s~ z4I40M)f;E8qvPwp(#imDyNqyr?HCVjNo=dN<1==47_?`bFK%k~U6(U`ttO`3AcLWR zqm^pw*>4JpmH*47od2&aCXr1mb%={NAFbaf*A;x``WWA1_g5M`I*RzIb5h|l7`US? z;Y-WxmMq!Z8ToW-nRP$T7vBmM?Z{Eav4ftl zWaqF4NkraLBeH5xVL7p-zaKgC3NYw-F(MI%skRbK1ZCj}V@QdO>o|h65J9VZd~}CW zWPkFgKT^V*Uwdd-OI?)z70L?wBLP%2)55?9(+J1nF&?>>I73FbvOi`o0Nsx`>wdmT z`JPq2NLzrg*Ze{HA!x?i6Y#eNP6X8aGIS%8IV?3zBb_Um>~uE-m=?jKq}wM6FPxwHfu}zHUq_zu59OCEXNr z#A#z`TL3YWh2kI1Un(_tU z#}-QdCv-PR_aVzGd;+Xz0o|`01l3zMX9~R#@G9Ccx4{ZF0t;VP6 zWHN{hd*u;ouJ)Ix3d|Q^WYGq}+y!q^hsUosHPvEc-T{-1%O)ce_HgO}|1Ub9+5VjO zHT#Ut#K>?wY|B|>tt*@3($VKNLqO$_)?wB%#_f?YKJHtp`!@)uEIGHT#H?0_5`^! zHOs6ngbZRu)L#BkBQzfS(wC148ZU&62xOQsvPd%43yyO-0ZtS-$h zTFKwA#Vd*ffhZs+CjP^0Tl#mqM_2;s@DY@gh`y1mQhA;~%k$+Bp0!)yQ2`%XsQ3!^iox1QV;jgrPs| z52B^~<^0{-*PjnZ!L3PZT4K74(F&NOhD1EOoJvg84KPDTxuUj!hV9PRz^YM&bb<#`uT-~XHPP$GC;7;|r&aBP7v-BFyHKL;!u;weL?EH5@V(8F2&q@TJZHnb zhS?*3@!L?M$)R;zw7Go7=z?%4%axvN?IRLlfWD=y{dD=4_jD^Xg!o@l#rPmP z#DWD*`2Pc&jQeycLRC1hhqAuxC`c+7d`rAMQH~ovVqMn|uiUnsENW`&-!Rot*ovPo zC~=B2R#3wpObK{MXvNRQ6793s#MZ0rv9;7j0E~)1DbcG(mc%G!s`?)otajf$f$ftQ z&}o)TX<9UDQ|rDvWQL#`t8x@tsV@@Y8d^y|%Q)ws5U9GB6P%>-31`WEDtx@2=&$<6 zx_Fr1|0<1CdmUY1m<@~P0A6QFcNO%_9`9gmPYIuHZnmUO36+<($Z!~g?eiH){*kS| z{e;VPs6l5GAErA#GM8MVt2WcawM$538@8)-;c#3$xH20H0b zpP^q?_(JmQ!@6|AGkVKZ1AQV)gBP)xL0G=g3e~NA;R+UogOzi_6_K1P;ReGYB|>o} z@);zZOmwuomq_quek}_&F%Q6p^J)1BEqZZefz6*(yV~W$q1e2e{SYG`L_zdwP4k+b zGm8=_#m)SYC$joT07(^Sgi$RxvuNIHHCwAdcw&!6D#=VXXOx0s6k~Bmf@pOM9Z7;N z>0U2*^uNjsE42`3Sn{xx6HC_r3Dq?RN!I8A8L1*r^L_h|QrJdq(|C>Pp&&{Tv?+b; zqc(EhYlu=z`c^^08kwhgyV77ZXgOowv#cNVPfTS06O&%p*}bIkfyTewHl)5-!QEy$ zR(=l@k+b|qo?Z!DhRVa@vv3^Yd=88xAOvn#kG7Ccv43k3)_i&^2=r@XXH3aBvD`*< z_-dYA>MK`QT4K6Ocn>JOHw{7Q?eHvPbm|Fd<_=Wsm|@D8(l6@G5T>uj&UPR3Boah# z(f)oNY7%MjCrM9sdxe%=^2 z)*nV|Aq;-14kG@jwkCV&EqMzBH-CzbmW$RFPiagVBNJ-<8?9iNZJt=c9i%RuIxb&z zwcf2B*id-rN=_3I;+uBtFgEP{`S8M}ntoQtl^)Qd&n$TE^Azsshw0;Nk+bhhsx!sC zpQG^1#~Nu!5e-ogps<-RHsTHy7cl~5zY=;HZ&`eUqAJ%cN=_ZD$mwa+k52*iu)qoI z^rXH$QpfM-71A&5D;kfj(xU(6$f7ttJ3V^SOtW5F^*COL zWx&F|KBHSnK&=2AYno<}6LZTHP&`CvXnx~=aS)krg+PNIEXcbXXY}yciiJfQ6_);+ z8@9YMd0AcTA#Rv$Byo5cTFu<3Re2>|J8sjsRgp#-`)za-S*lq5NXc?^(%jEM>-q5f(SRvSmt@(UV%n*B0ceCom%~<&m#OO8Py0AX4p!UEtAbi8gQA_| znK-rO81kZPNPFGMQ&;gkf1Y;0RMkW7%4Tw@mFD$pd}1At!l%etI5R}v0gk{8Ut4Zh zdv@lMs}eTLXX4xKRoiR!#Hivio1su=umr7gM@%u}R8f#+fvy*vc3fX7xNJjmjg)Wb zO=YboPW!{ihF}cRPzJl`4pj6EY9r<~aZToRreSE7hQ>R(nTblZIfi|PYy?hbN$@E# zeg>a4wqzH+l?(l>%l`)An@D>UMmwJV40kZ_@ zPt!(=9LA(?PW+!aOTps=Kjs~Eb3B$c=Ixt*CxkynLz~}BweZ{9f1kOGWPB3Qmi;Q_ zWT%2fMdk;j2UrVT@m?+dW{FzPHiZWmwjH^INh3DK+fCRup4cyrHh>v|aAAqAWS`64 zy-Ke*9Ve;dAlw^1A$s+V?BO{&rPBJ<9r>LWvYn&8J&u1yfO7_B#pR$1CoMsLK%$6Q zEu>C*gLn)iM0BYRsFa&0+xX-(0k~r|w$rfQ&|YCWHXdf6uqP?jtcA&2T-3|HqXm5X z1oMgA6F+aLtf5FGEA|rM1Wr0q;lfVeBagCXNs>&8b1V;+>TUAx%){&*oNd;3t77*5 z8n|)47A{^zoiq0if9-A286g8BD6e08>V*ypFO-kpx`Dsc#)3+cq-7tp#=k9lp%;ZU z&+tj(J(}3NCP((50GP~^$5I9UCh zWj5eo?|jGDO8h~|tb*U#S_&%1x)wjMM;5HBlHfV5r zoO|zk_vF6w58kU@tGauw`o6tu*H^WB_3B!E_k1tx)S=TqCd(Pax8awaNi)i_5xKl5 zC{#u=@~OvV^-}7vxG6X4d2B_T-Qwny)sUe;B*|6Jv$^zvFv+T4k}fJ|Rc-5uGeo!` znMvSSP}B&Hl6?GKH6MNJ&hrm13N^yIZU$@)U%L(?$y<6`MG6y9%XgNynWZCv1eIN2u5A+D3%D9}vjVh}?n#aftxR{a4J({_k z)w0b5#BpcEPKj+YdM&N4v>oHJJOH;V%(g;krNp$U1}L==#5VLp>vHgj#xetXGP`lo z4RqlZ}B`)D=8r&Uu}S$vXTNqn-O*B&MXSm!ov8 z>7TV}pEel}u$UW+OXlBW-qCBq%aUv?ClkwRS?5hQRD8I?$tOzA+lqXpzOWsztQ#lo z@Ik*RwsZ$Q{^PMj^)gyk0))l;|6c$?MYypOD$@w_f{Js5-*odAMx9^PUd z(;ItP`_a+Jf&iO=4#YU0g1Y$p?IZkh0@iEuZwM5JWxBh^W>Sf=9|+CPd(LfpXTr|- z9U7<8iT`tR}7P>fOsW_}~xkj90qK4Fgo0)W5S-XaB829>{TVLNV z(~^l5%{5B(Cx~aCAh_ZsiRo@eUo8`P_6!o9?R;6KbPz}S5MSyQ^(9k@S2Q-3bE3Pv9bwf$-yb)9rh86@#)gv3x|*-K zu2H+0IIqTWSqSGHcHR7jT#Zg(s{=pStN3$L=l6_2@osTF_)Dl57BtC>$u!!NTh>0W zGqeZhh~bo)SmKZ<5D|5MK7PSI$hD^s9>rO+w2oG#@I0pWEaGYKF|fMF;FbV-K)TNI z_&Vx+M+i}SUoH6+E75QT56K(G9)5Do9F{B&Jk8IBlcb(Hd0mrybdZA#H2e6gm>NCC z`D?7EtT{;Fo2FK+0?en+^``UVBLo1_L$K8SRurcJ9tkLv@1(lyT2-Q#}M?D4tb)g_duggM2p1#gK%Def6P5 z)xi|UOlxH=mTvi$1+JH&?W@qc@U>Ku!3}JWxC)o7?M5ry6}@4+Vn31ln9|0N<}PN- zT_Z075w?hWz1%Ust_0nx4`VDkS_^O_->zM8M)7(nFan8^K~?_rVedSN;U~^w9moBk z%-Y)BAr((P?jZU*1sZiU-pX`kI0R_??6bCqbk|U&!c}~8mC0t1i{_`K*5HKN=hY_p z^n^0M3R;gOU)hQ8y0|R7JmjNa46nx=NbJ86?Fo*D$ySyQz2)Q|b|#2X_@Zrp*yRZ+ z1`+A-WL_Gf@Lf(;Ih#F2b7u%UyqeF0?uk8DdfFD+lH9}pUcbGph2x7Zf(-goj>(h0 zyNyNrmB*9JakhK+6wcb4z)^*jg=Z|ae^|~@jg@iW zhafNG9It`rXZzih_(=C;~VE$bWr%E zUE2xRkLjHn!4mgf4C^6F>W%a}2hLVB=B^jb(_w)GP!w@hlheJP67>ubh(Cd%)hfY` zPh%?osIDH}VsgvcsuV2r!7(R3MstPb zJVXV#C?!MN2Zu$68bNA-76yZz7~I(%Q=bhDu;}`ozG1~gUdb}QV?9l=(*(aXksxy# z*zP$Ig)6)oVMZkOOr;ZzeL8_0ev zK$9^Q0EL1y%1v}(E4R4E7*Dmlz%kqvsT$L-blxN{Na65pCgoROD4-|9+g~3_91RM* zh+ncKiEL!?HDhJfa60Vly*^T)lR3B_A*r{d+q9LJw|cD?cF*sUibE0i<8ZuY@Y1f# z_F5=ivU%{~E}1WxNzNuUhl2i(*4IkOhX)@&->*);$LB@OED6fq+y}0kYeKP%qpg4| zf*g&`!&`Mr!Qw=cdNK`qj6fj%T*9!V1@`wq<13-*-mVMcJlaw4rSskPTtGpq-Vpas zm}dz2(gzWwvj36;aebAilYl;=Xm2ur4i71v{r!29la)Za zb&8c~p@Gz}%e{45s&6}300lr)MnfmttZ_a#N{F>r!b)F17Rh4xV;`5_3CA@@$p2cS zs-gBq`6j04HKc|4a)LNJ>pQonxnY}F^QJZad}O|Q2ppLUXB@TirZD4Yb@m;B9^_vI+hW}%IQGD!P|txEe2^F?b@DB0}){q@wR%$nZO zn5d@XGus^CSPH!UClXB zp!j}yoAwgC*>=8Ajj(->;v966Td8h-f${MO?#IxZ`@JJWPO0+i7#|rD+4@*qTM;~h zN-vTd9Ds*0j>+V&v=Ov=ROcn*{N+6$uOV7`y~ERbkcsUeP!d5P6H3{rnxA=^gVUtL zLzKmtiFdR{!l&s!V<{iEp|8iN?M9-7#iB-ybq+b8TLg5%z#-1X=u+|ruC|;Ca zu#)LqF>&WBAANG~52i0YbOasEYL^TWt=w6h)R;sx%}Pt3fMGBWbt{7}J&{ZGLc_$u zCSwAC*b9t9YY|B~mGKj>Vy51#{B7f1+yG`$3B5`y16p$m(N#XN+GX5sTFYGz=GkS> z*fNEMMXW1j9iCX!S}IqCKl?aj!=t>|^6NXzZpL`_(cCo0F+RjpbYe;_)2S1E-tOD{ zZo`viRYGVbZE21cy|8V_x|2rh0Go8E`A>b=0oEO5MYAy4as`yA^`yUl|3zcVMP(VGJ=ae>Nfq}Fev8?zETl9lWsybN2#UFinBacK)~57>ov$_~^5YCn*o z`IR-O-6L0yk?1eN0*!*L)p&}&=@Vb%u)ux|v#3Vt+Gl{BKG=*-{Mi2<1(y6NCqM8_ zQzYh%kVTSS&y-=msD#xssvJ1n$;aF3Nec~_-S9jziQX1If)AHDrwT^|7X)k(j}OH$*XAw{9TWc7Tlf9@ zTW~(oLe6tF371)j?$k78sYm&I!$AX{tutYaIW3bBPv|RJR9$t{i_yG6A;atpT{VoL z-0Xm{Ei08*8QuX%touHpnBilA*aAbTtYrFoJj8u6wn!m}4`QFP4nlY)5v zb+T>_34Ijum+G37g9EV;*4KG_h?-Pf{I49HHDU-b1M9ws3-w;~_(qllXo@w9*Uu?H z3sH5d&a!M0LN2-`Jd5*oZQ6!Hy;X{LCZ4}Hl{GNYbOHcrusQP|)L}-A?v=u5IcC5% zdfsh3;@6fK)W(G6&?TB;LYT@STMNSskUcLCN>f7u`tt3~;_teC&jgtT``libC^Hlu zN;z`bzRDd-BE&{snXY~??2gSC21y5(JFjg z!mS)@M^%2qoH+BXBTg3|x;{wDp00FhA)Iu~e4OhCU9O{Z&C)lWGwpunZo1`K*&jDX zZK6SF*fRGlAmuBAY2iUe9odLaVz7?qR~F8|k>V|S(kHl777@&XW87LMlOFbrm>P`m z0$8V|-v!ueBUDySy*vv}CC^W4QFRfvsaHi0*&GWjV;r~t!$Nfr{h1D1LOaXE=ysA4 zrpI|-W%6nhVBm+>g-6EeVp?;(dqXp0>ca(pMf1SaL_eB2T=XT#-J^B@UpR)Bjy>$k z1Ib=hCc~j?(CYlwn`bFOz6@|cwTY#l80?)ntIvY}B<(~+qL2RYsaxNMblgVCDHpY` zYz8)pr-(z7=NU$+_Z01x9^|?Y*S$5c5$aX(g7m$R5XmIz)JKT_|V_AuyliZcM}9OR+V8MB9-i7ME0@N)vnSPtd6NNlfFRIM<4G{ zYq7wB;bYQrh>MPpqfx=*jE{nKDe9sKeD%7iA*Pf!GdwB|_~EQ?;*TTUG0ZG#foUgR zwKb}2^6@rnl~2xB@ZG8Ja%YPLt|nvT4^f9^A1{Rs`K84G-@I^0!k}i&CE6|YS-y7@^PrPz){*t=lDR_4JyXMRz@SP zhwx+<3lBfOmam{Y2Mt&FMK^Lv-Oo(X-XMxRG z@PGnPmP0`$1fT;j9`9cQXncwuRFMDxOJo4x82|&x3~H+E2z7w5n?fBSY;Jb8)H$d~ zOj&@(CjYlfcxHoV$>o=mS|~>p3y4)GD#Dux|fL6jXXPP zv?q}(=^uov9h*d^HIC5wWXrhT<&dCdH2_r+Ts6#^a0;waQ`rhx(7?B6uXMNS`I(_i zv*_S(`wjt2z9TvaGnA{w^=meXURzMg`~WB(nz%4Ma#c7F|8$I3hawWPA^5eEvy;4= zg2NV_Mu--TDtffA*u!^?gr(?>V3^Fiqo^6bVnim&2aCMYd|^JZsriG?te3@tMR=OH zU3GT3d^>h-52)>Bnc$nEZ1v?bfh-ZCG)I&XtGIG{{)OF1v~dWtAS&5YhF)4p*U?a& z`tu-m`rsQ=u&vr{^KRvb(C1|D);>(Ah00l^iiiL~@k%CD7#mj7>mNt9!@rqbudueJ z9C~G7ow=X+1m{s>rjPBIangVR?uR$m&>yRhLi*oA>;mgxL_eyG3MGovwhbY%n*vn*sb}HC@r6$r^zbZ_SVqGj03rw@C=z>dQ_GgvqCZ^|I z79yzF!D2Z@2e|1V4|y~H@*YQ(P~=w3+Or#3kwZ#0@vx61UN~%Sr9IDNmUhCFtmEGH z^Z<(ofEg?kT>T00X1e>nz(xeD5VII%%xYoy8_&$z2M#EON1_(Q9dz8WZBxp=F{msb z`6c6Fwg%UHEjMYI)7+@6t!KLwX{>x&X(sP=Hhdj3{EWPawT%*6i2f&6f?&PnO6+DX zTS8i)wM_?HDC!%Iz*~B8tlekE+N!e=n#e2kDmJM;%9_ z0szndJ#7EF(vyJNJ3;K74AtEoATWbJg{>_2J3*}m2ko!N=JJm#^3&f4k{+jqp(Df= z#?JO<{hvTTvG}CZM?ljfkn}fT%cHMuw(S4Jx*x`dimO;16Yq>oZrBv*#7{-oZM|8u)phgCoz7T;v=k&`adIQ z|LDe}T_;P39ps-i=id?7OKt^_Bme;3pHTrMzu86r|HpBdB?RIGWB*Oju107Cr2xLi@)v2?>Y6a3^Dddfd7?Y|1*TYuY`YvlfM58 a{9o&$vK-pu=spJg@$h{N{2J`fRQ+Gpd9S7b literal 0 HcmV?d00001 diff --git a/trait-representation-migration/study_background_traits-TEST.txt b/trait-representation-migration/study_background_traits-TEST.txt new file mode 100644 index 0000000..d6faca4 --- /dev/null +++ b/trait-representation-migration/study_background_traits-TEST.txt @@ -0,0 +1,19 @@ +DISEASE/TRAIT MAPPED_TRAIT MAPPED_TRAIT_URI STUDY ACCESSION Trait Background +3-hydroxy-1-methylpropylmercapturic acid levels in smokers "smoking behavior, 3-hydroxy-1-methylpropylmercapturic acid measurement" "http://www.ebi.ac.uk/efo/EFO_0004318, http://www.ebi.ac.uk/efo/EFO_0007015" GCST002957 3-hydroxy-1-methylpropylmercapturic acid measurement smoking behavior +3-hydroxypropylmercapturic acid levels in smokers "smoking behavior, 3-hydroxypropylmercapturic acid measurement" "http://www.ebi.ac.uk/efo/EFO_0004318, http://www.ebi.ac.uk/efo/EFO_0007014" GCST002956 3-hydroxypropylmercapturic acid measurement smoking behavior +6-month creatinine clearance change response to tenofovir treatment in HIV infection (concomitant antiretroviral treatment interaction) "response to tenofovir, HIV infection, creatinine clearance measurement" "http://www.ebi.ac.uk/efo/EFO_0009279, http://www.ebi.ac.uk/efo/EFO_0000764, http://www.ebi.ac.uk/efo/EFO_0007934" GCST006070 "response to tenofovir, creatinine clearance measurement" HIV infection +6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction) "response to tenofovir, HIV infection, creatinine clearance measurement" "http://www.ebi.ac.uk/efo/EFO_0009279, http://www.ebi.ac.uk/efo/EFO_0000764, http://www.ebi.ac.uk/efo/EFO_0007934" GCST006072 "response to tenofovir, creatinine clearance measurement" HIV infection +Abnormal white matter microstructure in first episode schizophrenia (multivariate analysis) "parietal cortex measurement, schizophrenia, white matter microstructure measurement, cingulate cortex measurement" "http://www.ebi.ac.uk/efo/EFO_0008420, http://www.ebi.ac.uk/efo/EFO_0000692, http://www.ebi.ac.uk/efo/EFO_0005674, http://www.ebi.ac.uk/efo/EFO_0007738" GCST004997 "parietal cortex measurement, white matter microstructure measurement, cingulate cortex measurement" schizophrenia +Acute graft versus host disease in bone marrow transplantation (donor effect) "acute graft vs. host disease, donor genotype effect measurement" "http://www.ebi.ac.uk/efo/EFO_0004599, http://www.ebi.ac.uk/efo/EFO_0007892" GCST003942 "acute graft vs. host disease, donor genotype effect measurement" +Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation "response to allogeneic hematopoietic stem cell transplant, acute graft vs. host disease" "http://www.ebi.ac.uk/efo/EFO_0007044, http://www.ebi.ac.uk/efo/EFO_0004599" GCST002958 acute graft vs. host disease response to allogeneic hematopoietic stem cell transplant +Acute kidney injury in coronary artery bypass surgery (creatinine rise) "coronary artery bypass, Acute kidney injury, serum creatinine measurement" "http://www.ebi.ac.uk/efo/EFO_0003776, http://purl.obolibrary.org/obo/HP_0001919, http://www.ebi.ac.uk/efo/EFO_0004518" GCST002982 "Acute kidney injury, serum creatinine measurement" coronary artery bypass +Acute kidney injury in critical illness "Acute kidney injury, illness severity status" "http://purl.obolibrary.org/obo/HP_0001919, http://www.ebi.ac.uk/efo/EFO_0007863" GCST003656 Acute kidney injury illness severity status +Acute-on-chronic liver failure in hepatitis B "acute-on-chronic liver failure, hepatitis B infection" "http://www.ebi.ac.uk/efo/EFO_0007949, http://www.ebi.ac.uk/efo/EFO_0004197" GCST004165 acute-on-chronic liver failure hepatitis B infection +Adult onset asthma in ever-smokers "smoking behavior, adult onset asthma" "http://www.ebi.ac.uk/efo/EFO_0004318, http://www.ebi.ac.uk/efo/EFO_1002011" GCST004222 adult onset asthma smoking behavior +Adverse response to antithyroid drugs in Graves disease "Graves disease, response to anti-thyroid drug" "http://www.ebi.ac.uk/efo/EFO_0004237, http://www.ebi.ac.uk/efo/EFO_0007838" GCST006278 response to anti-thyroid drug Graves disease +Adverse response to chemotherapy (congestive heart failure) in breast cancer "response to bevacizumab, congestive heart failure, breast carcinoma, response to anthracycline-based chemotherapy" "http://www.ebi.ac.uk/efo/EFO_0005943, http://www.ebi.ac.uk/efo/EFO_0000373, http://www.ebi.ac.uk/efo/EFO_0000305, http://www.ebi.ac.uk/efo/EFO_0005257" GCST003939 "response to bevacizumab, congestive heart failure, response to anthracycline-based chemotherapy" breast carcinoma +Bone mineral density change response to combined chemotherapy in acute lymphoblastic leukemia "spine bone mineral density change measurement, response to combination chemotherapy, acute lymphoblastic leukemia" "http://www.ebi.ac.uk/efo/EFO_0008474, http://www.ebi.ac.uk/efo/EFO_0007965, http://www.ebi.ac.uk/efo/EFO_0000220" GCST005214 "spine bone mineral density change measurement, response to combination chemotherapy" acute lymphoblastic leukemia +Bone mineral density x blood lead interaction in current smokers (1df test) "smoking behavior, blood lead measurement, bone density" "http://www.ebi.ac.uk/efo/EFO_0004318, http://www.ebi.ac.uk/efo/EFO_0007040, http://www.ebi.ac.uk/efo/EFO_0003923" GCST006132 "blood lead measurement, bone density" smoking behavior +Bone mineral density x blood lead interaction in current smokers (2df test) "smoking behavior, blood lead measurement, bone density" "http://www.ebi.ac.uk/efo/EFO_0004318, http://www.ebi.ac.uk/efo/EFO_0007040, http://www.ebi.ac.uk/efo/EFO_0003923" GCST006133 "blood lead measurement, bone density" smoking behavior +Bortezomib-induced peripheral neuropathy in multiple myeloma "peripheral neuropathy, multiple myeloma, response to bortezomib" "http://www.ebi.ac.uk/efo/EFO_0003100, http://www.ebi.ac.uk/efo/EFO_0001378, http://www.ebi.ac.uk/efo/EFO_0007808" GCST003964 "peripheral neuropathy, response to bortezomib" multiple myeloma || TEST +Bortezomib-induced peripheral neuropathy in multiple myeloma "peripheral neuropathy, multiple myeloma, response to bortezomib" "http://www.ebi.ac.uk/efo/EFO_0003100, http://www.ebi.ac.uk/efo/EFO_0001378, http://www.ebi.ac.uk/efo/EFO_0007808" GCST003438 "peripheral neuropathy, response to bortezomib" multiple myeloma \ No newline at end of file diff --git a/trait-representation-migration/study_background_traits.xlsx b/trait-representation-migration/study_background_traits.xlsx new file mode 100644 index 0000000000000000000000000000000000000000..202161eefccb7f0876f81a0fb11b24401710cf63 GIT binary patch literal 11063 zcmeHtg?}4K(zeX(7-D8-X2(p4nPZ5VnVFfHIi@&fW@ct)nHge^`Sb4Gy}O&;?=QF; zNz*@#rb<2C^;C6NJ#vy@;O_yD0B8UJKm^b`%QVpf0RUpa0RU70H0T#$YbyssD+g^Q zR~tinO?nqg3&LD*P|9oo=-d7OJN}DDpfq7briT$p^zPG>@D82CYPA3~+o|6G3bj06 zXK#FevHq7VQ`6V1&_^Vp95geIDwK&;cjk*RlWHr=dcTnV76tfl-@#60EgTMpzJU|6 z4h*a~J9V}5?DseVOjz35kw)o&6x)U#1y+$wL5Wgq6Et)_pY6=$fzQam{wDZh^+K+} zm97n$&+EvX!$mVl+f%5sW~Nl`T36e2;^5)L?yKldTHoY|R28Z86q@WFk|o>iDH~bl zbo4>j8G~Zl5ZA_mkS*;T_|mM{)kR^~#p?Yr<}@818Xj&Plu_Z=au3byXeQcpU$O*z ziTtJ)0dnTywdiHcRui7R{AhVnBR{$c*B;3>QE_{LI0nsG(J=-xn8cQ}8{Y=9L}a-* zsQtXY4-PeQcFLaW<9b*XOhN5{i~f9le~WzBeAOw0G}K8%>KS~xF?jgF{bX|Yi~re0 z(xEr=3nT#W`U(b+`wJ}Vlo?5`-)v3l4RvsDu++9Qw6JHO|Ly!gIQ|!7@K29k8YeB= z!w4UA{^==r@NRA`21!WLS@2T}k&>5>`0Bg5$UIV7?>~^#JC_9|KiE1#QIp#xiP@HJ_98pY-OSylew1*fbZU#HE@>>xksJb& zh|OGxR3S~!t6;;Re!~qy=S}rh@0V6v*ZWxxGAE>XS{78$3vKauXekW_Gpz#qaT zbuyibHfXPByj1QnXhC#ykFBg|!ev^imu1II?5b^G(Rn43-huk;K_`%~Z>YcB^(Ps!kqA-`~f!u7WZ^>>i?@+Bl+y^Too8%VGL&>$`r4FAH3 zv$dVMp0&04Z_(>Nm;reUVQ*UgyN^-@X~|wjq&B#hU`FS3Cp6?G2L|F3<>PnIL$y>Z z&K>`|Ne;s$B6-gEB#q$I-%&MP1mxo(;cVl^9QbYwQOpTrw}vzd|F z9iN8)#gj6>+J*+gG%BOr*CyeWTgb0|t^`w8STN!|2(EysgIOY)pIxH2(3h=GM$)e1 z=3RLY@VmGrlK91JydFUggu#O!3B0M|?00ihTa?c?9fTf-sXA6JX-BTljdq3x=74WA z{dbcI@mPSh00RJE-c~>F-tKranLis#sj|Fv9w(9)|KSVRWeXg65Ry`}1n2?vX;!gS z!=q}`26%~&eZA>)$!!O45yrGdGqZUu66M2f$^>xKgC)aj(Xq^VA`!iM0*MPIX5dj` zK3CiLU_?0-b;q>lA+4@@AIoh6+mrM0Dte|&$+OTx-yok`iut zs-oTD3_xuM#q+Q?%FlpS=&mzI`1K$W&%X1(vCY`TFyIh1pI)D=4(U%rR?ulXb#Wq> zbCK|+2jwxY6GIZg&2_R@W27)) zUElUj6->3n>Mx#MQrif{V==Fy{#Wfw?5j^BU%creI@XyZO9Y$zI{lI9aOI>@aQbqd zSYsRu(q&5Tf}f1JjVi+TC=y1gaqtPYYVLGjUmsO{X{hn$+;kJ5UMH@iW2z=j@GqgL zi{9;eTA{Kw9nvJmr4KM?1#^Waxu_+9XuWrc!XO*7l`(S7N|+%gy~g3p+p3MTU>p;~ zM&}lGxCEP_sK=or{RAb?Kji|CNMNyl9yE13#%+04bWpdcRJ6OdZIzV|Q>d{MYFHoh$fQ2zw4FFrUqBE@7Dd8_0Y1G= zRmNDj4Z3ug>kj7q1Z9&G-0bSfO}Pl)3c6Hw#mW){mMe9gbKzB5BWYB$a%ovM>B$Zv zIVrSe+mFoq!m%Z)(QGl0YiNYM867cOIVobPc(o8zZkUU>JzZq!@K#koTNT7pP{Cms zF&AtFQ%7N(WChvY|XvJdh^6-k7v_K!o-#XxI zTbVbK#V>Y#!vBxJ#9ZR3e|q!d%TNFS!oPrN@8D`-X#blJZ&e<$T6uF@7zg}Ftu*R- zT=hg$g%}_p)42i)*(&O}2E-cRVKTeu&v%G*i+1r=Fq7fZh+Nj|qdZZ$$6_|upB%>$ zBC5PMbwvyd?8rwjy_;n-vBc_#m?<>GvA4m>E*vj!rIpgbzB_-AKmdhS8*nj}sV}syfTHPm2l}P>tQ3=OehB3`!GJ3;m1cuqe<^|@k344>oTTpcV=3FotM&A7}M zz`fxouLHL(wX;YsqUqkb>)55+O;YLvR<_|;tu#z1f!QRT3&J^!)Mb(b8*iG>ql$xA zn@aFS>0Bw>Z?V4fg1a8(u_BXa{b4rsbEDXB#F+dJd-D~iPTsPNg>7xS>iBr+U$mVvXGHv;W>sUyUL%QYY6gfqoA711H6;Q5MV*T^@*Xh}~ehPBh*{t}8*D7-d-!UsK zq1UpIA%73_y=J3vz6BP-dNmAVPAZ}7MkGj}Si!NnT*G~$$jbmOaojX<_E^D^-Vvki zkw-JN%6wVYg$cbLL9AF&ePU7%=JiAHx$Nl4E#TaG9bSR*nuzCiBT-O((wSR4F5QJa z5hLTI>10APs6*X;=ag+T=_Ctfc^830{#6{G@oG;=CY|F1O4liFVVAw%lv_JcC5r>y zx+E?(Ejxa<*psYHGR-RKO8MB%sSFMFIve4pV|%GEroM`#GI6FVDLXR*-C$zu`GT?k z`;B{AO`A{76!2jXKhcy(&qE!kZuzK~&Sp7ki7AgZ*v3D$u&Bae$IcN!2sXV)gPueDLu9u0Xx({J;*2EclZ7ah}8J?2}=dRiMo-<~SS1Kz@$L^ntyQ>@N>MEVJT+phl}zZ^^qEe#odKQsLXmJ_wHa2$^J z9T*S%@b=D6Y}?Uf>l+gm@oS_8nF+Xc^(XS5S(xKmaZo|YxNa0E^S>nvS@R}L3xFZC zT}Q)^)*cc}QH(8;lylv_f!jo1Rf}y;Snug>Si&0z~6G8zN17z@iMt5d)~)rU_hVxOfIqusU~cd z{mR@VrQ@MGWq*0tWj0L+?XT|sO&hFGW8miaS-qov`a6gTt6yS4{UY~qqE(D8g51Mg zPK(O9@(B9+q_$>F6JBw2;6k>NcV!R(eDj7VT!kPNpGHq`rqOrfP+>Yr$`=Qs!%vUuHJejHu}ckp^&AKdq7S2xvBOIksZDJq`LMQgu4KVz(Gcf9;K zy5KmRrMT$s?RdH$N$z;P;J&HcT18`M_q@D3jK=_a-t5ap<1Me?;-&l`3a$E4zNvps z9-rpV`YO)Eg&&eBe}gHZlmR^@Z@L+p+Srdj(guAEK3~!+fck;G&5%Dz!qa z3Sw11!U@xvd!smQs!9zqyOXaQ%} zv|>k*fC2>pa^*|9LK9_jYw@Hz;N)Z3^!cnsb8!c3uXDheN~jW+=8j- z5Ydn6-oR(CI;qPtvfnhNLadXBcOp?rGdQk%lc57*7*}jQPi2=3O=Ea>kziSAY;Ei3 zf=(HV49vgB7Fm(O&00Z3oBlFvB9eZMYpnk~jC`(G7xzg~wR)3qgC)5Xmf2w>V2kUrc9z2lig< za~o>>PGsLiXf?%?^Dw?Mh&?1k^p}gr1nzW7!+jCo8kjo*T5~s(tkq7NxKjIhS7m#x zxu36(#YQt)d=-Y{=BZce{WrHaf@Z0$9=^lm=a&arvaMCSEJO)sBM^NpLe8Gxty2+D zjD;)m%@j>$AmhY8)7VmIR})C+wr$DzDVUd|C*jqF4c9s|!lZ7LTv*7n_49)rY0$n- zmOaW`xkN|K$QU=3Hm4QALB!p=P-#R8CrcC@sPmq$m(3n~9Vj`gB|}m!&0y+E8R5t~ zV#;eH3cc4d4$xXkRh@EBosv6B&QTY$-GybeL_>4gz19py*6A@UaaC0qbRD6*5)VI?FXb946 zksLk@x-fTel8EBxQLVd#h z?T*HneA6q@Vt4PIw{(V07Fxrmxe}sCxWna~a#IYly4ga@N2g?I2ry-r(z3LF$ z!EW1R*Ek5~hV3Cu_lyhrsE=kH;tzvA>>!j}3eQ$kf3td)p|dMDr*A?;nRAtB-JJCd z2kT;_`#Q=jt=1~j6IN3rzf#LW3k@$j%l^~SQH+!KqMU+%FmqJhQGoVXBJ=0N@M`Ov z5tOqpkDHA*=XZqzIU(z063T~ZoWTTko$%FowMb}SD;EXbs~438)SAR1T>`dl2a=M% zLJo3$NuU$v=aJ`1jUz|ucN;pf@*0RU#}6PHx|5<#rWFGV^k>_WD;B7K_lPB}sfm&r>&JoycS6ssAw)VdoSu;P!;RVW}yL_r{@>DuvbfPxW-z1MG54 ze{$FV&IzxOI^=)kXZ$^6DgT_iyvKh!eyAf6huuNp0^1CPM&+3RE;Ld?`+0b211d98 z(wJNG@EZ4Q|8~J^;%j3${}KHBv$!!2W_8pDe3#77;~Mekrgi_7#{sR;TO!I*HMJtn z(bJFYYm5s{=rvD(XRNS>(pw9vc6anx=ma0>6wAY_rufTnb`QS_w+-eIgjz}b!XL^m z#9@24X$YGUubJn$Uv=TWujajYtXXG%Jp?M653p8N_dC43VfT&bqGvM98Jm4D$l zmCjWWle&RZU#btUuZ4H4KU$#=7E$J4;To`8{*J_=`facHEfDOzWL8Y#JWp5sYOF=M#aD#wov#Qxfo~%2J(l|6 zPev6nHcQ4P!Oy_u`d|zTnre|IGSE;5e9%xQKG0AL8ax8>6^c8fH5~;i-vqohL39hr zYER-?m8% z#H;5K$mi|_hJ`|{rGL`_rXGO&se}>K6ibXy`SU>V5Ms#H&78=q-TX-T8Q#jeTxD6I zJRb5VM-jp~WM8F^cmz3OjuwnfIeG3-YL#?Dh(%G*`P{@YMrm+hO!&?aRu6(_sPf>T!$`a5ng)1w6TEjYE54%6iU@k~i~4BH@)z%4}F7 zRPXXcND1`|fE}&+SUK<0oWYfCv&5;tc#dxjmrs+ zIVqlK`ndw+k8;tUU6tV5-j4=W)G((E@(PIuVNL3~M+JOamt~}s&c8Is)hSQ+M8|+2 zsTvWS0A_DbDp;AF1m#jmJkyK@AC}XVZtis3tO49D)re)dCVad-^ zf#0ycCk*m>ImqXg!KH$eBDSl0P^F|e>o$I?$xNcNU2h1+Yu*Q0_)K6Sb~nX!fpI}2 zt4%odnG`XmP78zHNj(DZ%9u>{zTwAXWjt&_$b#(0lpeTGo)vJXBZ3l+&)KqqTua(d zaQ~DSl$pn7#(t~BtY85E@Bf{CFwwO$G*EP~Gqp1QR~AA|(td>rZ5`Zpr&$T3N><&JE5SH7)5=&&f-t&-b6Sv!X}+$9jOqU-^Npk51Q14Heo}$HwPp z9qo^BW91drXJ=OY&+^_Lf$_nC;EvM|sNOMU3RGF2!JK1IGs{$oM62|;VqxeVs7(EA zgcN%R;}`=eKT>17+t_U;y)w383lk4YRvP3xqWwUjni#heaNIm=DS%Hv5KLMioB=-) zjGP)iHTEbA#2vtTJgbe4YD42b%csBZxmj!5c9|l5GX07>*>V;+|3Ry3jgI*B9Yge& zHr$LOU$7%ce+`?=9B>7BMHwzZ7!p;ztWImJJvcv7`M`}ZLb@1ojnTe1iTp7be-^Nv z=mziZfecb?YDjKLaHa4Jp}DwG~pEGC{yB#hu-vN(MXlsl7;K^L@z-LVupw) zV;@w=ZA4d;dpczJjLAb2Ykeg|OjQ`+=comk8$?LeJs;oO6suxz)$=*F^uE2lNNc_o<{AdJaj+QZr;p@BN`inZ8gJ z)9Rr80G+Z?CeA09HJM0#F7AC1w4~lgp`0gUxm#9{E$g1C+IQ&GL2?}crh)5X*NQq!jmeId@_RC>a8_?B@s1q5eH{45Mlz>anxc|y4pzS>}`!PJV= z@nf$P)v@U6Kx-C3I=<@kgR2VqWMLK;h!PQsZlq6>euU92Fi}}`Ds;;vEqfPW!r;Y* z@%5-<63f}=5wmr5S-nhzQ?%o`z%dRdP4HPjQRcJU-3$GWVf~PKZMgrNxXS!>q{y z-#9+lHWn6I8$68x+YVh(sBSe`jss(;tXQ(u%p<2FMRmX(#-tb~evDiPw!_K$HGmOPKEz+&ZwMM0oy zUMZ*K0q^+4f)_q!1#fL?CVoVM^$b*e;Vdz|n#T#uT#vi7@tZCNixCwPp@9pxjn%gr z-1IcvA1ntvMtYL{L%b(Hkq)~H4;roDc7O2Dct@MFNlIIn$WR-d`4DNqrZg(5(a(e3 zL4_uZ@YaAy1`f}78UA3}f_%J`xsBKl#_JC<#leDWoh)`ujIx*N>Z#{wnk=;n7}t@Y zk#a|7gs0wE1iyq;pR|u^XW|Uckq4YgjIL6?yYNq;)rGli8?}W8(+D4Yk;wwLqqDPs zAn~8FO=QGWg8)dymwKXP1q6R=EZ)TV>BR1 zFC*)rX)LHZ&9#a$3+O`)OGPq54V!t+>`L2BLLqm1Zp9Hbw&D)1i?1GFahGnUs6%;W zldDhh2#kVkMKg*<)Ndhhr6Z-W@hmxij$mVOZdlkmJALWDp+hYnrQiKP`?LkJYnm!x zhavCk@|h|gK|nCetFWkz^cTlI+%cSF6a2QdB!+Xy~R7ax>%J@z|ut1qAS^& zp0w(B&0rb57YJ5e@-ldRyo|G`$eA%2(x0A9(?B}0f*{pn#`RE;pYj}a)F1adCsV1u zY(^~`b1!AqaN(rKKj`$4o;1@RO?L&|$^KY5I&=)dhFt=NffU1z+Zp+A8x|+(h^Z;J zY&4Za`0MC*y>}@%s92Ia{`~Tz4&dcoI==$?TJCldqh|p2uC>BL%J$4+CV1cmMOj?x zteX=-yq;VwE8jJ#{Z5i$&;6@@4sY2@a!MfSS*ThD#ZZI`q>}&nNQb=VTSfElcG#_@ z1|9Qehd6J)BK_G8b!}|^XNGU~_wOSkPTG3qHzEbt0|ERR4wt1oyl<)ACzb0;J&-sj zW0?Z|oNCgL(%6#)+4`y3C8y;`0tPL<+`==&Od2;S1OJL%JNYosHki7bM+u&De0u(H zKTHnq26BfqCxa5>M7=d!~_HN6Cd=ZQ~U2QMPTEm%OjJl^BbOw z)_877Du%8!7o7*@r3~9ca#B$xS+5JVh(;TE$!knTI%Vy>2c;n66|=JQ`2sncTQCtf zxP^4>`0(6h`^<@44JPYxyLt498Q;y!J2$zbClNS>$oOH8kabmokQT&cZdx}cocVqy z6|J2#@=xI1Af+h0q;Od*8-(d`OirviX zJN;Z+lTC;{2|HqTd}%ZnKt!cKvw&44n8i~haPvlX6Tm`obLzeHx<{o&YSp{ zzy((=r4@9P`FkjtV?MN5{dEI7|Dk4xj)4cwD`$O9|K!8@n@cBot>k-cV>UAWa`o5$ zV?u#|(!H(1|CyrrpIQ4)`wxUgImy2&_$!&}KZ3ut$#2m36SeAB!M_qr{w&z~*4O_( z-Q-t2zp@Vg&~*OBL->V*@T>5zmC-+hL*RcG{-aL%tLU%QqCZ3{-pCJc|NCq0=vM{5 z=DYq-K#%c%9sgVQ>sKwmZm#~&0)_XlC-`-%^{a-zhSWdg0RTl30N`%{_E+)0dcr@8 fuaNyo{NH|2P7>m6b^!p`x0lab49}tb?c4tYDd>@Y literal 0 HcmV?d00001 From 0fb465700d5bf22e1abcdb839d0dda9a22f5b238 Mon Sep 17 00:00:00 2001 From: Trish Whetzel Date: Fri, 12 Apr 2019 00:25:14 +0100 Subject: [PATCH 2/6] update background trait label to match ontology term label format --- .../study_background_traits-ALL.txt | 2 +- .../study_background_traits-ALL.xlsx | Bin 95862 -> 96059 bytes 2 files changed, 1 insertion(+), 1 deletion(-) diff --git a/trait-representation-migration/study_background_traits-ALL.txt b/trait-representation-migration/study_background_traits-ALL.txt index 5b52d4a..c93dbb3 100644 --- a/trait-representation-migration/study_background_traits-ALL.txt +++ b/trait-representation-migration/study_background_traits-ALL.txt @@ -151,7 +151,7 @@ Major coronary event in cardiovascular disease (time to event) (darapladib treat Major coronary event in placebo-treated cardiovascular disease (time to event) acute coronary syndrome|| coronary heart disease|| cardiovascular event measurement|| response to placebo GCST004961 cardiovascular event measurement|| response to placebo acute coronary syndrome|| coronary heart disease Cataracts in type 2 diabetes cataract|| type II diabetes mellitus GCST001736 cataract type II diabetes mellitus Caudate volume in trauma-exposed individuals response to trauma exposure|| caudate nucleus volume GCST005240 caudate nucleus volume|| response to trauma exposure -Cerebral amyloid deposition in APOEe4 carriers (PET imaging) APOE carrier status|| cerebral amyloid deposition measurement GCST003076 cerebral amyloid deposition measurement APO carrier status +Cerebral amyloid deposition in APOEe4 carriers (PET imaging) APOE carrier status|| cerebral amyloid deposition measurement GCST003076 cerebral amyloid deposition measurement APOE carrier status Cerebrospinal fluid clusterin levels in APOEe4+ carriers APOE carrier status|| cerebrospinal fluid clusterin measurement GCST003131 cerebrospinal fluid clusterin measurement APOE carrier status Chagas cardiomyopathy in Tripanosoma cruzi seropositivity Chagas cardiomyopathy|| Trypanosoma cruzi seropositivity GCST002285 Chagas cardiomyopathy Trypanosoma cruzi seropositivity Cholangiocarcinoma in primary sclerosing cholangitis cholangiocarcinoma|| sclerosing cholangitis GCST005855 cholangiocarcinoma sclerosing cholangitis diff --git a/trait-representation-migration/study_background_traits-ALL.xlsx b/trait-representation-migration/study_background_traits-ALL.xlsx index 255361eba0977429b71dc0499a58ca8a05bb1e13..cfcd0b78f6eab3813decb164db368229ce08f8d0 100644 GIT binary patch delta 82808 zcmYhh1yoeu_dbk-gyfJT(#?P%ARS6GB1lLI3?0(lSB8|7A*7KOq*1z4T0o>>00or> zVLs@PDch))g?6c24dq4ZxdpOy~YuUxCz9ayGS)?57aImll39zupu&}Uv z9R++`++SL_xV*gY>*QGee8G7^oIJ?v-8J)mHbtp1JBzouv8d=HV_f?TS(;cyLq&Ei zj?!8CFThHkm4uoOU+u5EqW12}k+wEt&usTFPj?pGiozXjqjJce{Nr@tSE22==%mpvhAruU|!Ua0Xu@xcDF ztNK^zBDpbH_DR>3HK}PNRb%uDp>YozjJhrHxo2-QV;A?Cr3lgF-H#~w!{sO%#wI_z zV7=%JvxG@6gP9}wdUlB#UT!ikMDiUVgC1{SV zmmYZXIRLurK{Q0*V-9nyl2fBY`YLSh?w3`TO1bI9S8ZkN+>1@$R|4|HMQDEBu?SE6 z!P7E9JEE&m^&9HmVMnn1uq8T^snxroyK#YGN_=nn3wfhh{%!oeu&!u@b9-i~jJq`q z*^69~HUgO&a@^@ZL}l)Ow~aNwxPDp5OqHVH&?X2Bg` z?D*6K|J4vVQu4aPi1OYSs}M@L{e$i!9CaMX!cmL#(J!G)99oK(4^NQPeKFkot`JTZ(pu{8oiW`c z;kdI9={%7a4Ue4Cvc2sR$4`igU8@%SRE6Ai9mbz+;xUjH54h`Xet~%3y=Mt;%`-b) z4*X&hd|UXv7M2XUTAV}e)!;n7w%gjO_`XalKqTbCkW*QAEcEfXrYh#ob)!gRv1$qC zjkVze>q@F&m(?Aw!C{Um=JyYn(PzoqLa}dq@uRyUoXhhGOz#(9Mb7n;Y1-EtMP{nh zie4PX>FaHiYI@lC|CC!8?2-JmzEK^p$TtwDkezdE>YqM0bT8*hY+&^GS@%lLI;mgv zI>9p;pP}UoCak1H94Y``{;~2UHWpSlJ{A_qf5GVC>E~$eaTAIkpF6os36fvM_X5=y zGQ&?YC-u}g=kHIlKT@TKm}U3cSDbOUFD4>S_p-7-j?TV%pxDtXo0}W3n{)KAX&YAs zquZc9NEJzYOIbIy%)&i$O|zj%Y~cMvMZGYXnoi(5{&rx*v;%JBf&OEoQu-K+Wr1oh z);_g;B~^-7H6ZUU?`ol*5jl==+wp?3j`pV$6grp+SJ;f4(=DNz>W9Z8+zFraeprfK zlsVq|$h~_s%K0x$U5X|P(T_geDJfJm5uc*?{pUecooqClLFw}k4j#7}+sj_+O%8a{ zUUhT*fD*m|%p$1zgUMw+w@nEsX8g@q7KSm6p^Vg~^0jx0)ZB0tod{EXw1X0xWU#~W ztN83Y@&mfNAm(yU;C(5|w+lmu!oRV;e%CgT;i_k66ZeoJmdU@aW%DcJ1#alPvB1jV z&p9i#TM^ex!{LrBoa-05A+Mj(5F27wSiDb_aQsr;4#&rqQ)ohkW;!rWL>Wh{t!K>inz>9&?F%-&@P zqVW>veTI|I$xB^JOK!_|AL>gBJ;ncu4B_;JzS{(JlwXS-6_UBKPEGK6si zAGYg8*a}2gC(O9;UC~txFm@T4Uop~n9TQ$d8}hCP3N;!i?C%CwR|tCkt*Vy)eEbU+ z=to8q8{BvK?5R73-zS}dH-|}CBlDJa_bpX$ct0!boEDh>=9QtBt^JF0I;r1Tb|u{J zo+-Vo-P}0wOj|qpD^oFR`pE5eRl>F@6h9Fh$Od-ax!MFIdT*HA8HcvpRT)Nim{ctD ziR$}(9}S&e%+#>k=3krck15%jwn-8|avK0lB#QuD!|wI1434b(#-s{{WP_yNUB>FE z5=3Q!FsN52Y3HmNcrNRL`-f`e{!`HOfTKC~lSA=X(Yjy1dB@f%FsI>`68k;XO#7*U zt#?J#pN)Oj`cNQm35&vASYcmfO4%O=+ULmrg-2Z=8GuhDj(p}-l7fX5k)DJ{%LWY8 z6s_Q=T|e44S*v{Ma|cEGmDZe8knUdW=ApWlF^xIOSYfg@==RYHR~dJmN6?4-IXA3@ z+BQ8K{q2$HsOZl|$2%PtmphrZ9dhm0`+t8e`HZ(zG3Cew1Y&;w+ML!28K9dW+ zaJashi%bw$xx6?WooX4_%eh`Z=s5y_vn#pl5|`_fKUV@w!9jr+r+hZPnAMiej^K;a z1u+5BK;Pr7^@X=g?ZJO{4osLkq}zb=L(7YC3=n*<+JH$A08H`Qf{yY5-!!wO?~KS4+_K_OtJ4Vt+Zay&0Md}%ya~uZaTV{Edjzy3vc(X z4`)`|{g3~gG^DMS%($2W7Xy;Nj%;1bf{vw(jS98O8Kwt-!_QaqX*_(!bZU z99~nKO@FtndH~njvm>kFTwv=`3<$bB@)^J0OXzXFFqa)OyA;=y3;q;9mtc0e-}42S zzC2yG@7MwY8?#QX_s%dYR~M3czBRw+&Iioe1FjS>qeYp`mq)ZKK#OzU_3_^W7p9Es ztL^pS+^avQ8wb+^1E=Y`XLSJJ?|)vRFYtDH>u>4V%C*y6lFQX80K5&ln3|e0OZ|2A z@V0EP=JmB zauru@Z4FmDmvyxR>@`dYSkDT1q;bE1F>=mY@FV=E8T0L#OZT{{oaNrEgWU1ucGK2Jj#qC1v+J`4O`VgLsusV%w6}8W zA3A~wUS6LW1H{)Ng2V>+{c_iI;&Op)65snua$k%}bzGbt0_QF(a+f=Xi??FUUWfony#W+D~P!UR7No?qyH#tbdO+ zh1%K@4>gKgUX1usYy{W)8Djc3GW+o`b%vB94mHr*pJqvm9TSqC#L}PcJ|TAYf6d?j z#IZ)^zFR=n3t-Klu@@cO-ivb;&Hv4OGYhx3Sb~e~2k%>%pgkje%+Yi2SwQ7h&9Mfy zsn3!>kcHRF*i7JS!cxN`J-8%_i*djaUDkTUcc%7;Z&Cuv^R@~0!p2q3%tq6Pg;^&2 zl_z9SwP}Q-tJy~d7vrC9@TcIF!Jj1X&qGN2{?W5WU<7R{K-qAn^=LaP>6It;zqe19 zE;nC%p1D)RM(+8J>sfLoGyR8|XoQbc8Q$5^C(=K+v)_5*M^7?YSsoj~9+$mj8|oA+ z;x2fVPyBq&pzRy{ON8lLP?9rEbvPcx4((zr$WfrX3?wIKcvx)hDG(BfLISxd9!EB&6xi*OyLg^R!i;;$(s= z_$BAsINmQABRQe^E6Se)Ot$3PIng6c0G0J*5qDjsWBG;2xoBC?fzd+aL*WCX;=hiA zBbQ~|n3tk@paciARy{wBd|(If2jjEkfE#41#ADb^f0S zYz$He`%ZHKFxvn7Q@z_(%*=d$1%vl@H=cyR$Z3-iq?uwlluRqqc+&vM}g}8Kc+6LG&gU zMtDDTLgT@|{Fxf}3Iz^l{_o>H<2jln(MCI}{gbxVH&^BM(vEE^NA`)xkBxGf!T3;=0}5EWvev!wpv5t6UB zlbl}l|Kx>?3nIPA_`I-eD%cn*-Wn5{gnq>^8th=H58$Qcz!)lKj0w#Y=&ktTs6PfE z%JD`JnepF-D-^5q;)It%fh8Lv;bjXEocri4yS8OG75%*UbPYFvJCb%M?XegG|BRF# z>zsVMUYnFGFIF)Vj=D-}{I{(N#k!)rxfcQ^P(+Iw@Dwgh znjDtR6;|4rf+TSBqEsfke2ta|?*F|A(mtR*3%B_ys3HX??SSOpYH%=8RE?n4n-n2? z=a!AMhRW7){Q{w-_Jh$Xee)L6aHngVf@6Q!Qmxv!hv3RB$C(fKvIefI;H!F) zHc7o=qAu~T3_Y;auWt>3SYY<^)?Kyg?EF;&ICRy4#@4I!Dx7}rCam_#iVPh>pe{@f@Xm{Wm2Qe<<9~}T#^+X+ zbj4W8&&D@ZEr9KZg6i}F!L~b`VjiBJHX0nhW00%z2HdnkUc~Ky@Hs>imWBrFNXl&U zo2n0W4FM+REi=^h;DhfHuOmBMhp??qaX?0gzEj-^OIQS}f6au-S@OYeBHl#5)LDm7 zn$B3ySLtWK%>$Pc?yjN5hhuT9h2KBzj2Xh6yo|(6Y3606IzIFshX=~+optKb zAu37#`=G77yi=+>-q3sa?qO~G{_n%RnEc(kZim;fOTIm0YVJ3;BY1|2`0jd1RN^+} zc>M<}ygN+~BF(7;lkRn@yJHCt-U71NC0gKm)o-dcPN9C`>C^}jaBhSMi_5U95=G7T zz5m`nU8w4(wPy8HRvo=S>6IjlGB3MTI_o7R=fSb>jVrP9!|H6uK~bJi^B zjieVG)tVi1wGl?B@JJb>_AuR_~b#KTi$&ns5c!|G4kzv0&-l$k$>S|lVh$VBLz zHa`FSngyR-c{1BDe-Ck+rjwZORh=BbQMt$AYFzQe{Dar6;w^0T89Z?}lXLhBv(Ga? zKoB_MC>9xCywz>D@KjP#xCAnTf%xyZiXgm&sO#4!Ue);0cFy!AQ33zcP71te8_PQd zbF+BW{?jz_Bgx{euMl|J^ir-)PY4=GV-5n9czF>Iw}hfAs6= zx>!bopZ_x@nbRy2qoddV?#LXxu)66|E4)Zi7~Oxv6lt3e$0a51$k1MRgPsf%|Cs0} z$d4D!Gy>dX7@dT0is>^KWcJiUd`MHu5iEc=p27e-{{Qn5ibfYw;SUli<>)UFmw9!g z#h_Dl@~LNgx##4xVvW6cd?V2<=;tUkw`1iaa}PYCOxQE=79Y@6^5RB98Ln^~Kd=?- zRI@5)N}#CkK|I#t!cjjJGHHpWfdtI%0+!riNDGh=LI zlEibRULSQOi9gAR#soR&awz>|WFI2q`*5qF`L3I6He_?1=iqxtWx#uOBG`Gew%!Z2 z-DWn(jv={(M=O2Nx=sP_FL?|z#R?w7s}?QE<%Zlf=j63gt&~ER<*)WVj(`q>QEq3q z7PrO>{^B%~r}P~^+IUS19n3Q|2E7xnbHk=M@g7RIey+9MOLiaoF{IiRxd2DXi{|fG zl)_P7_5F5cJkW7o{Y9N<;XbyUN?ndPP{Gvk5w@sv_%B~Gp1z=>-64+VNVrft+a~V#2!2MWqi>4&{n>p8De9E6bvU2VB*jG#%@b$JSY&PU144{tNL zioplYPjnXJw55gN?5%5}t^DhpaAP(YYCyv+sg%Qcf$S(#3%R+V`LVs-Q8$w!Rxf-< zvG(Qnmq%P{^_POnai|qQRlh7*E6RJuZZCgeVJZ%@AOr{80uK9p#o+y$$|*ub6a@4Y ztP8gqHhKCgIEO(MGqo0HgTeEC?Nru7uID(gU43p?wmj!?hT^$8j>p6^X}@hJ2wBS2 zigKKtHC`fXoW6W@e)3W{B5`^}u&nP~S?)RIywZbmgf9JrO8Ywo7)RriBW$0&k|W~> zI{lc@J)q~kwlWLEwg7gD-5`#)*p_Q`j~-S8Rr`Gjhlbnb#nEebKo0Q5;BF`R@-N>V z=g=!Jz18BgunynhqF6F@*;D-MSZL!aPQ>7%*&gjeHyuCTmK*gU=)r09?RmSsPM=Oc z#WeA86375Na?x$U3z}Kmu&fhvF?R{$u&_5)2Gn|)mbm+N{D_Xg@Q~f|=aaO@D`3wL z;5X5o>7QWS3^A6!v&bkzq-!cyqb#X@HqN>SLfolO0{-TnEcmu z<$$-%IJ=A{5bV^o9`3%S0$7g!A8mOSh(|%2*3vCZ3Mvd)bSemUGvl%M7x5Qr*3Ngs z^o7ZL{#5>kNnmgl1|#Qc2sp4wj%9K$fD?vCO~*-l(krWVt~6;O>pEOFK)1-?1l>DK zo@z%~YG#3_-8`9{J>V#qZckZlicPExRGoL(&b^Dl)vUC>SFn}`0xN2yFY?{Er1{ix z9$IC$4obYYpa~&8A=BvPR~zs>3hor%YvA6XjzvWUS3|;o0()`WOkp4})v}}8wK3LI z`Dl#w9(c7>UQ$}Cnd;ha8;jKFT<}eCnWkbbw02?TpeJ!j^)9|9Mfd&%%9G<826)ik zYmdBcPbshEcj^n4#r;ge;46;1tZ8iu!a+Z8UE}LB6Kt2*iA5U^aVvgxInhvr`TZ7GmE`|# zE`&?yZmz7X|DNqny_3z2^Y71XC+M<#aZh>=HYOh|zi4)#D~`8FB<1_3aFt{X`6~Dd zdSf!gHeoA9+UG137Dp_*}plgX=^d7jw`))L+ZM%{Kcc4bu=jXKDlV#^pOK zdqP;hZIwIUWOR4{oV7WKxPmgT|26e|V~J<0O9#zLbBU3(fL>}cvs9vG)yso9 zj*>!C=rPG?dz$vod^CD+*7l&|MR*BN(ev;olbT&aT=1$k z-}XzmWMX#ILk(#dld@WG$wx)HqDCihjjojJ_$AySG5fQUM)3B%o3Z*!;MGDwB-*1` zb3R3cP5)%Gd&rTfsJFt1y*oh|)@U2wfQ~tsN%<;LT6hn-T0O|Uu@Uu~X-^9qlQMbG zt{r_2C(N-=@#eVvoDyWhqXXmEg-zSw3X@3q^3WbOHs5_Q}3@%eG5 z!my94+*A$CjIJNH2y>W#M1HlW-uW1DpWVrYs1EC7bZ{CJghK5C)$z+zTrMfCpscoX z;>89tnnk`z-_m*=wEn3f8ua$x(q=4I+ik0=>t0}`(~`~~cm=q5DCNqkiDZqUp@w^W%0iK+|gZPW?u;U1*Rs6EK| zkt+eF)Ptw|Obbxsc_r4%0 z0F$Ar$(U4co*-O^l(9>eq9GQ0oxgxw+T{nI5DH^U#VRRrPT_?1&Z26R@dpLZ$8x%m z^BE=K6%;BX{`O{b>yJrygZX#;GD_5SJM7MY?a~?Q#2VnjPOi(fxxI@?{>ts^Dt<3~ zEm)H$=iw5K`CvC(O;N03O~Z=UHnqsI$f~uJni7-ZFpv;;H~RL9(tIr9<=;_7pnN!Ca&E>|VNWox~wx6QJ zO+?)Qf3dYe_%X-eaLN*0IQ_9|mbLZT3m));HZ*K9Q{>xQ4u+jOB&VdjK8J%O%GTOC z9!zaM4~4?twX^#*)zTNdaqWkHg7%CJ4fR4_ysoRnm+mOxg(?W3Qo((2Z0AlDv%F;1 z%C~rAtv81h@|r$g&PR0!@2q*%Z^1r31cP3d=^1E|(*r9*ey zlJt-kEjkxy_*!ys`_GGC3J5b)>x;Qj_-c+gHb|u^Shm$O($}4e6d^|uH;j{=%SR8k z7qTFOx46sGC#Lti@~&b>lgW0UNlB4nKMgv2~<@99}ik6IQh*VQbel&?Q@MAXFO(ng7Jy^zd81>3H6?YLr^n7F_WA8Hm zv0-BoI}4&zx;_`IYZ{BF8UQ}EeVK=%_a%c@blYlfm>nn)Bw^j1dv_zW_}fcvW75St zm>)^QI8&$u)>VT&@)0iGOua$pzkFAMqrs9u`pM*z=(la)mOJzjz5ID!4o;{QVjITk zcyn^Jw!tabc^zgUb06RB3Af^e`?w~4j>IyA2-@+a%}nh8sHN>2Y$F878^S<5$-{Cc z3}3UCZLtF#=~B_n-G%F80Q%eDEoW+>n@0}b3Tn+-AUY`^r&AUJVu5hHOpyy%5A4D? z2G}Q0{&#OOTNra)`UA`b0{yyi+C*?!TdqsTIwF`NozJnOUa^{~Je3EP62L1KsRia= zFrTKL6XrzIVPZa8b-fp5n?1tyE>B+Doy4={kp(SvGn+F>=r@M~G1iyIgdK+AB(A-h zf5^TciZo9i+q>V^cLcICRMp;ns!*VRlS9OPdrwAgN;XbAA6@zH@jromQh0KC8M8x$-| zRg!SWg`<@eYspL4*A|*qOxbxbeBKct$94b{u`-Kq+0gV2D0$aGW*GsMH9c0!!6BKL zY}h+rr zKs)oJMSthCl`%o0oZ!y_S$NYI)HX?D3rHho}I!n-7(CfgQ5JxdX*+BY;YY zESCSP<`@ZHb8JI#=34M9)c0F1ubRcl|2Eqhq-~Tr!*1X*>+;xZ0PzNd;MzlUWOj%# zKf}M7NX0G>m71t$G_k1IE;6Z@!XI7jpJ|Fv#gu*k;=v#FMYxsF4L3xkwSm?#FqeTe zL@LHMK%lMxs<=6R|LKv6FDL&&JSLkfcGG^^0OVPBA7pE;74=rZ2>0~Cx@Pha-KUPe z_@YmC!%$PdU~9(Rc&ecvx@+(T#MO7X|1laVqOME}ZoU639s;;im?vA|@_F}z%>{7X zH%7diPb#z&Lr6?g)Lx%@;zw!U*TjugV3fh8*AzGrpzAyUd1_>DD6Ozk?O~_IkJsxJ zTOnZ4gEzhv%%L`7$_^tl#enq;Lt~RCSnuG0&iK!e$@l>)xs6^jo~>n~PidURkH_1V5 zDAax(Tg>Uj+6j5o+0uK_g3l|OJU7`v!cQ;}d#(MlFrv%iJD6ud`V^PKYfTKgfgnYw zxaFkH9H+&j#fIGY266TyU~^#XA3A7zla(to#vv|!#?X21pYpD8Nz)MK5z@QT6qP@= zg01WCl#>!N#?3b}3Hyp;cdaLSs$~4lzpIC8-&XP$x_{^VryXvLYFZbWISP^O%TdS> zkGilHI80g!W$M8VIsTS3ia3J--6Snfs(BBK;Mg!ovU!@55&&_8p%BK2xC_zppXr@A zpd+SM+&zLT(TB>LI8U-_EZ~9+2)5H`^9V(GaC9qqwaxos>nZv_CG# z@M)wig^}o800%eV>Id;0&VK%LziXUoZsQ2+69-np)H4*K37;@EkRVUf%a2B87-^mX z^)=V|{-DQQj9A#7)rP+EpoiCQQv)vlq1n%`FXEks;rD+F2ev-`bD z{c@zUpq#cXLN*}RjeF3ka=Ra9^mKs$@MKhecO;0t6|JnQosd`9)KqIcoaRp#QW{B- z=KrQs=un9;NT-!*??JMsn7+4V8iUb8Y|VXts2SGo7BA%m&S{0DHNXFsNGuRL8%Xt# z^zb$fRIB=kM%1V?z>350L7zA^?FHwaG@2U}Z9m{U%x)mj>5ec@3sIv6kSduy0jhIs zN#{^_{*6fDWl24C?HFHo;K5!VZjyF2G_Y?TdPof;^dM!;n)C9$O2ZY46;3e5#y z5F`H3S|S-GZbN5Nicdfvp*B!xNroQD1)WaTD#N)?339Z%*2#>WVV;I3M856$(DvOo zMLN#AS=rfDw^#H0%#0O0)rvgGQ^qRmzJ*a3Ace7?xGJMrUUC!y*ntXar5@H|%RQ2m z%C0?ymXqm_h*5OJAVq@uM=OIr0(Szm;tf1cK6QIF_q(6J$fMwU^P1Uqrl!Gd0_t3D zQ1nA6D&OX!>?{Bh*e7!Q&O&+7iup7;#Pt}_I0$cw9J2A|jDGN@v&0UfPSa!KI{Z;^ z^1=yW$a6-%Gg4UxxX_Za&w?IwqOOdTNlJV}wHkqXwK?Rx%bGMGh#ljqjG!1Ja8BP4 z7`^3cQiqD(WaiCD3_|B^+2QJ~#v%yWf{_CU0+I@UNjsluAA%JFD*a6j#YjjLjqQa! zUusCTc^aqSsG2LEA_o@ zq5^FVY~}fuck)x}xaCXu4gFYd0$YO}yRcFH2J{w*6 zx*1t7Qy|&Zj?u8jq6k;fN?eR&Y7&p0uEv6SmXZs+=TE|mg5}9Tl&&q^M!eQbdisbE zgw|cT8uR}=&{p<#;yH281>@9WCzZT-s9G3Z*WQB*MLkJ=`(V=iIjH8To+L-tkR$(>LT?~lw)CW8qNH7LG zm}d{hPPyM!q*;+3sPPD^6MB;aotkO)Y9W)Bk_u|%p4Mi2HK(bGP|i}Nz?lJJoUUwq z0uYKmOYU$y|MFN@s^wHX+K{tJDe!$SA5K@!&^~23EV9GJ_Val?hxM1o$ub30B%9<{ zrb3~o8DY@d$md?-q0_RepMf$-4!K&i|ql6 zR5fFQBVq+qobvIDsl>P+$oILxbb(1Me$LVLRCNy=shW0;8AYj7D-GppNC82DH%n=0OmGdfR@awei_f5Vt|!8p*bUfV^kX8lBR#FtIS^ z7E-@OO%U@K`Ft(R)e@FENv3tOEgu$|AizHROC1sja{z+7*Z;nKYy+ZZ=_$+aT=O(9 zQ`JsW84`8_Qzc|}33Yc`DLHXW@#f_NBdSL?#2_QbSBp;AS1S#7CHnMrIrj?`ltFPr zIDX#1FcKHG^#)Q*bQDkBD9aXZ=XO~b_v}Ze}GCvN2vW^T^^Z$j-60C zr;WU!*Bg>iysnFxaTpPlNT#SNsh01AmILG^VQ*wN){7zkZTc$0d}B{d5YR-P1+aXq zB?m<2@tCH>OyNR>p`TwxfWgbz1@C4zP@}`0x;67sb;b1_T)Pl<{#$B|u6{>x@Xp%D z+8ssmKrSSL!#ol8RL)tL4?7nV`5+Nzr=B?JBVt&Pd>fh}xB4Hr=mIC?gA;-y+4)v@ zZpg2C#JHFfe)EPJN@MAYPJW@>@MF{)CR=VNHYD1Hr%M-kdxBv}=tDNM*oS1#sB*ik z#*_0W?$KSw_p`e81V+#cVi~}{B(r%WJl1C`C5}q47%6C@x!hq zA!z&^wQ76-!skIN4_swvsD*lxlT3))x{zJ58HPd{^<(KX6 z|4Jdv=eiqVSQ>!~n|^~Rx(g}SWed~Qu;I2(1-ln8|Eb4{Pk|QhbD_T|^q9gCX_Cv# z%d{!s+8D^s%L9E+1c_5Cvo~Y|&Zp}q0)OS5V84vOeuQINtpb5; z8^(lfnJO{Ee$bRXz1xRhr;Z~Rz_BXxXupjBDPZ{Ivr8??_t(4bJe-6prZ_}Mtgrzy zTNidZIVcbCPt;3M!Y}(0X>L@N#{VV}5kidX&42$d1El~&RihFwEF+upen7g#`ISMPjqW=7RSDOnI1R*C0 zQYBq)KVeX<{`#1}^2DvF@hLB?xb|Iv{yVkmuOYY|q|ClcngmYor^I!&85wkGJpT}h z5N=3=?}y+9$7xsPjhZ41N@?@KC4|jn>;?j1xG@Usv!RjXhnSitLj|Ej$av15&bV9T zmbV3_QHaP!UB8bKucN79)&ME*xkN2ZKrGgm{?NoSUM{xTLFgEQ!GfhQ_x3&bPyy`R z=o4L=-iPk|0wz|jE{9L-25i(}f5^}Bsr>!EzdZ*o6} z^F5g?2>p$W|0?~ujoYv5v(82h?c?gNp<(5`S|}O@U5tlS>BIXk+!KJrqHm3^PxUaQR;K|NRZn(@zvp=mC?V1*aUq9u|2>$ zTe-UXWGL^35C@sERgb^K-5^y)?7j>8qpm4Um2#4QJ6MO`tmGwM!}!a)A$Wpp)mX)0 zK_@#^ZWF6~i&l3}pMDC=u6!6v#;A-Ajifk5=Y{D$1N``SA}hB~nwJ9XHaZ=425t5q zg+mvsQ$f7cCS`d3&Eum{IR*MFmC}TG`ULx4oJ)nG= z_adneWn-5-^`rY~-6DY=Vx2gZ4~4)JWhvyZbkq9D$CqwJlVqP-HT5tv1@)baEe-Q* z@XKI(ahdRUXSazJusD6)69FFd$1`dLF3J+98e&fabWm6kBk!g}y6Dr7&#bC4!eS`+ zj?u&$dn`N|L0EuT#=|0xsjuC=_TPSGwAnE+JVeSgzPI{mWmf$aI{$V7Ed%D_-+me= z52q7x6Ra`I!-0{~2*(?_x{eU`)<=t$G`jLBNt=#nJag zYg&?vX!u?nq7O0BS>K&5T#e&;V|e&;vXt{IUjQjZJT(%6EpT%hP%9bLMrFyRn3$`L zOH#8R(p;2$OlpFWnn)!faszY%$IGM4R&0H3;<);%Q;#VaSIE%A8mqJ}URQPlcFG&6 zV8P?3;hpM_Yu+O`YRa8_PYg=%Ur`8h+_v#S&)EX&$|nvof?(E2!p#{4rgBxyHWQWu ze=&ka2)i)?fm64LG6H9b!0{dZ>fK*A1{h!!oPTi|VGRdM4qQwObE7qLVQLDBZ2Bl` zJMB~z>7x8p_PsBo50s!C`dBso^}y@cN$0O$JB=y9yY|D&#r28(OL;-(X(k*eNRqpKB!*Tl_!HU4yv(sZthFl!a6kV5m`U@}~-~$r6qaH%m8HuKjZ&0$L^yHDVKhPJbtKFeTa3eT7~Y%zIJNX_819f)0QVb9?w7mUYOaRNRD>tha*GXRos0-oSBypjI%`(Kn@Xf#IuH;GW@=4Yvdw!TT z2P0}>KTa!kp^V@OY0LkIQSh|dDwcST8n7l4Cv$0j|8;ZwDJ_JLgtH69%TkCku~dV3 zS~o<@Q5Ze{o7J`{k34>%THRwIuX_A)?We{s#w1h^uq{JNeVE1LN*O>QY~c0^cdLnD z^-WN_`-?(}J7WquWP45TCpXnYG6lh=m$nizfQ&z;@aYN4;OBe!>^du-F{9CJe8f5#Z zAq(hQusWm^(<@K*2h|^OA-|_WE=rt~Gd$w`HC@<|?mzSW&eP7R3;Kb$iK@Y;Ht_Q> zbLLaMt z+S?0H&7lMv`(Q{5gwY4o=wg6pO<&TZ<;~MlAI>Hd_9S-}t8Xij2MW}OwO;E(h#8bd z>oU(skYIN&2JG&2l5v1LH=4VD`^ckV0ZVl!qrS+xJZ1n@o?7f_*ONX3%e-HWg%K%K z3Mwf_Sv)D8BFHx3F6hmjOd>cw*3LFtai~pb9m_WGO_kkl2>`gpIz<=eg1h;XavROT zuE?{lalQOs3I2kFdW_6nwY;F~GKc9k&_20|gnf@<0$s3f;Xh488VHe(tS0@R=LNn; zZ*H3iLCP;xke@go?Vse{uuI;XVMksaHiG3V5X=MLAa>+fz@EZa4=trH>HI0P(Ljcg zBV94>xgehHtiiv;lj2S`O_lvr_9c6lhSD2^il=I|4h6h%mF7t}8TFs6r*bcKyT|_2 z#UgAy#Y3~LSXiV6Yoh{}uRoTe-buM|B_ej%A&UZV|Js7&Y3pR@p<*LD?_GiEdd)$p zJl-3sU2yWZVYz+60q%F4$mneA!vk zR(S*&*s9U~JA3v-`hu{5Sh(<|9$Zd$%40K5h+LE}>5nD&KZ}eG-fh*n zY3^t*%=(qY%B`mUB0h8G<6tiP+jOJ{B}~1OglG~ZOcf$x(eDPh2^0Dkw$|>pJy%Bd z*+cj=k`Qi2H$4mReW~U;O_^Bc*%HQBgn5RrL7JZY%su*$aRClyUg_pK7nxXg1Gx-b zsmCC=6sUdH0QP>Qz@Z;6Q?$I*DAxc)o zL&43;J9vPwlZ8jk&?obSAT!xL4c4M7p6jv;XMmJfD`(4N|w3)jIXE^ zR8PV=p#`~+ipCh?*qP<~UNS#C7gG|;d$0K@2SS+oBMD(BOQ^R?bCZkaB0-U@$MQ%& zGV&LQSlnURu>WwlJ5OqcmaQv0@}nu>eZ@#-3wCt>!PK#W*JGcPkY9xQPo44(rG|0IOMcr|qS!beDd^tC zxjr3YHzcOcMOhnpp@)@fXj3|kjt2<>Ifb!v2b162t}QKeYOc+st`TadIJFmK6KoSh z(to3o1p`D4kdc>$FXpEl#C0CNqWDR3^Z2i+EHC*AGWUOtU#|pv z3i&qYzP2E&&ZcuAM#R!&F27eE(cO~zKe4RYNV zfxK#&mD}G07g@~HtY`x21uXg=0s90MxaX~rV<6u}iDv8ic)H|bz`kd(GGgK@0bd61 zYJ_=8{KaSJw^_y@5^QR3Zh|hZttC!TCc4^Ua4)M)}hS zgdDqc%-vzd;LbEgXnL&yp|JlbjJnz6o)ohdcRm=A{KLdrpYssA~0+DzXAfs8;33Tbc#_5Td>C60VG3$i)qK zI!I8yPR}C2^dLo71N;F2`e`MeeRh~dG_+6nxx^B%U@Rc2;9$suuSEjxlVXDnwtb&I zI92`vW*>uph$0ac{bu*+iSy0O=;PV9M8l8vmk8wltw{u}rx5txnsT##sOUF!Tf61O zDM?GUpCY>69ORk#Ooa5Q=C?nDpt(f(rl9V_aEU0Q^xdbEF05T`?VJElU^c^_ptOSHJs$|1(Xw*>bZiO{X^q7NWO9QwZbiIHNVSi#ySk_+5#qcULW5yta z-wav17V*IcME)!9x?l&0f>Nc3H_npZw0VvP+M5r$v-}0I zq=DbJ(D*T$QltxS&JYE3Q$tOfOT70e-bqm2$`HPV?$*Nk`*(=D|4$-IVdfnbT)Q#F zSISD*BDO@GJJoH-j#)dK#0SNh!!X?Uu8Obfg9yLWyI{@3d>8|`e~t(72`i5?@;R_& zIv1Z^v3<7oixpxt|_eQ0K%;im$w1 z5`1Blxiw!w_^3mkF+5FH$lTMTD++5=n&8U_4i=3~@Dq}T1^p>&{d?e~_n)qCU+JH3 zvHm~0zC0f4@B4oSg_1QSB6}qX6^cPbmZ)qYRD{TqeSeMYWl2)m#+H4n5ZRZIY-3-_ znk-`*%UH(J@4iO8-|x@&@%a7qest#EbI(1?^E}TTykp&8$cxjFU09`(izDdkwW!m8 zuaG1H`+EHv^jO*HRw@oB#ZaR7kqB}tIzLOt6xJBaQ_82h(4*7 zS3&*z=ZRBa)*{)`;+|ilu*9E~^P@x_mnOp+N3IQs%Tq!h;w4H`UNWS{<);Bp)*EIA zUm$aeyh&y(JzzN%Nu3(kLQCO>4;Bs!`@YSkBOSgRLg{X$E&cE3i{G&dAdev*&E$HcD5@i z`u9bFePe=G+BKiaS2EBDY90(MkYLul6bmT^Th2PzNw>=$8WSX!YdN>`r8&ws+52NB z1>e=HYLX)_L3!+$-C}b8iCLy()4`eku(+F@HG<+#wN3b29am-LVIYTE8?jt7aJon z9o9(1-x&;^)*S5w_dNHCMv9oCG1$| zT->5%)^|TT&)@^tLxG4RTnPO2Ry$&d?Qhdp+Qi^vos8$=1mvQW$SyqMlT&+(So>b( zd2Xfy{9^o?$=)l7)o5o~GU(A+sh~$J?zE1A!-;&wHbDVY9ym(}MuyaWNMe|B<)mEd zVdQZmD)6Us5LO}E)6kwQw7V+%J8y3_@%Q%cJwgZJ_a697_+Oe4GK^06jaGNxMe?n8 zSLVfLT&T&MxPlQwC*;39nx;&p?^dP=HXe22qCyJNy>?_Brc6o1`(1lD^?o!Q21`a{ z3gMo?cZB`Qz0W1drFmtL>XkqvjAo|1_!;qCzp!+HNG=1qDN%7jma>aKaT@0%#=Iu=Y>X}l9AgFJqM3OgeQe>~KA|3XPHqSHgn z=@m#h>C0c{C+ouY=tO6jkp6Eu`<7>GJ+o)V>{zt?4wo3>ni*^CCPxooCCJRMlu8s% zS1zZ%>QV;TY%DU;Bq+yZM0TN*AO26(Ugl<8SUPJYw}ED0N%@|+s8p%_m5M!c#HQUr z^lx)zIg^*14WKd=);z`~`U&^OcUcz$`~8qfZMI}3|H4>=Xl01_-SA+~;q&qdrazlnQLkmX*EU&KuN*{dd~T@m z1~&A%kPSspy_RuZYhu|AK}o-@8e%~oc!a!T1=Z4{iswHhlaEU|W0lqghoR->nHn;z zugQ72O*7L6A)(m0fRf8SEnMXX4^Oi!J;2)!i-Awf-z#3Xq~5TPugdReXs(%zphH%D z^x^he>1<$ROYDEX-f>{;fhOYII>p!n5oENrbCuBN(A!r5_&F_?QLfW)toN97FfMgStLn8Gsmh+Kk0pW_Lm-!21JS~sj;(UmE>S;(-K7#zUfR6ls6f#O0O z|HV7uME%%LFC9^{;k(!KIcG7183$*wAy%`=A%;r#%J_<{&%8Bx(5#070!#4{o&M_c z{QX!zi7Q5iT%%Ce34^;_qlc5IAH4I_{cid67~1rk#E5TXjmLz7lZTI7SY(I|;=ZP5 zahBqan^Ac zl;X{(H(FvoWwD=R5wldfA*YpTxK7cWxNS9giTRwbP z^UQ7|mnEwFj?$x7i8BRyCGC>-0ZjTY`-$`MpH$JKX#6nI|AT(a!eF>xwQ}i1j6LEk z2Vzjm|3+VGNu6@lag~S$oW#jXwR7xT#gYgg@^EzY=dRwU@ZTet?*>ZxFB4}>HMp;HQVK1u>{SR}W1K8LB<6L13Y!v%5I*jCkcw;2_RIO#_IZb> zv9I1DZa8_6M3X>t!-)!;{Q_|$U54C0;<3cj;|0Azy*gq?RJgDrW>`xVxso#+*QCy| zrMl@n(m+HX`I@A|jl41IGZ@7{DPnQfqTsSQw4&mA%;ip;C##(2XNKN8P*3}vjmdgn zypznYgTf5&?m!G}A=KEi0t-1VE;efl{@3T$uqKC*LoNJrjYHycn_utnQho4mxkLTp z1LH~41-9Fpr_MZSep_eCG9&8}L;b>$EGe#Gi>XZiF532!>^IfBJQ;Y8UKx67Y}0At zs4Hapjgx(IRga0=?-{!R)lFq?xf20sTP=s9W~C<;u>@|!T`nFuQ`HVMCu*hbIzxrA z5%{+sH!}7CfrcJskgudVmW98QZ>(v+fjAPl6OwOV+_Zj#=tfLmthn=nY~~v?a`ES8 zh;2gU^!gG13_D!P8vg^toaV$ECYo6Gb%4DV>`i>jRPl(Q6;@~Y^mK#I&eZ&jY! z1+9o+9-HMxcIj!I&l4xZuk}$z!N?>Odyj85EOx&W%;>8a5c28`#``z4ZC!s{=@GL<6Uh>5dg~6 z_u5t^kVAmG(efO^d+1p8F`~mfhnKdNu8sB2OS(%k-g7&4;|NbcfsalxIav{_9J+B8 zgRE25^7}d~H2yxsW4n7R`WM8HrhI(fttOnVx-35V;j6Wc5R_!(#|jF(&`ZxjX&bEq zD#X1^JwC*Oa)PJWXosL<fpFzVT*&oJR%0_%y5*BN zQ=j-HI{NEi`N+BKT>7MkvWRbSk%8?*WqlvDgA2n>dVvUow3qTN)?|3)U12EYw}JPo zUnORYqc?)0sIcRF5K>zDOI2;&?wVsq`}XHvv#yaFdP-+0HVJe~)w7pvMT-i4TaKRe zTeHo#r@uFTf4J%9`lvz-i&#;e@)SnYP2!iCFoos!;|MNJ@Hh21r4Dr&ihWs}s+UK+ zcUe7m@Wv0gfOWFPVVNw2<&*~6d=aizmmlJ(i!MHSgdm&xz3=7$hiP_xT6z%8a*iV~4I=YaK%@05vj<~iI)_(^mxjdfg zU&`M-XnSsiKIt?Pfzs;{H`5zj?ep1lP`YfGaIB}vnr+l&Rp|f{_j8B(&JVl8Y-Jrs zl#%vo>4n30E4byjLKu=FzEI(#cAybUC(=?(4I>Az*)cT7WV1!4G&wH$;$MeVTv_SOmw00bpfCoJ7fX%J zmO|JZyYKBILySsWE^CbBwr?`^{XI~Jthq=FPqN3s(Drp(9KBGgvk?J3;z178a@Tl^ zR#p$YkBIjk6uEW0(3Z(WEM;Np=K~72fqG4+9NaCX@8H+VB)G_UH5mn3Ls+)jXV-1Dy*z8+{OYX(Kk%aUUk&pFbMwI5sb znZ6YP`tD+AE%tY_Qn#P_&GPbAc{JDAAHVa3YFUBzo+d-@JNx9P5{KOpX~YL^+X>Du zk8dFGrTt=GX5NR3^`Sb0kcJXzRB}R$XaONa-YMjpviy~ucN1kz>AP-ch#@Ex+Xf58 zSUMFlJBq3XD!77}$!|2?7$~asYxuaAAH@TvNx}X!b~5`Pp0((zOM}HG;))AEPKIA# zMRRUHMb-%#l3NG98>Sn5zE{P;RAY3SW!*L5D7T-+GrqAWn|-u&mtxp+J>Lx_XW-98 zn2=$w9O;@y>QE_aoPUchoh`>4>`) zRrk>N5a$B6mo9ozPZ2BzBMmi=CJ!H^O1!fQuRHOSp~i?mVPhOcE7#wo%xyUrj#_(? zz|SC8*L>1iAc+~}FrqG1J}0&m4XQ>i`pV(sTq4Il=FES%FYDT;&Rs5q$$M?KCHMhP zkqL#bfD0+N$DV%Rdf0O&|FW`joDBe#BAY}9C5hAsA)TMXJ zDngv;XxZ1&)?}`|_wG7jY{zmN)P-E4iundP`5s@?4Z=m!Mvkgei0VB08t>DU8#k?d z@sY*mw+D?F9t$BC)jnJGHJlPTcGAlX%8R++(%&E`gxpbAM);(!!q)V~%0F=JHPJ;J z4dO#jQOGD9;(8dJ$HwO}P5r_IF+;A;U|&4KB)8sq$9i&SsbzO`Z(Zc~o-7yiyP$e^ zSJukSZ98KwagR9N@vyNvpN-c=&-ofcxUV^h4T-$r{BSt6Vec4CH7n**CJy>0IDG%S z+0&tN#Bmz&xp|*^a?iQK2%h7g2XlFOtfxYUormF%0F25WpWCQ&tj*#*35)fOvREkn zLW?cX_*6R|5ovENLFv9$w(`}HRz})`M*;!Ja(SPV?-w71 zE@4FOndhTE|%yZq6^)uJVum*8>Xuow>kX zz~$Bf<#K3mCG#xpx{8jE`bXK>_d!CSVUdUbS3>Lae|BB*LE|GnANsFD>Y+N$b9WFm z9$&Uq|2dIm!0%U}$^SU6u!i&bp^pDCV#QoOCBJt-Q0%Xx1MByldrP0r2vNF=KRoV^}`ycFkzL<=HRW~Gz=qWd9gDjlMaZp zFdv@DsIT|9zTRkwoA&9s6cuVpx%QY_x@FOy3@RQ1>Mvz6rQTZ{z{vTqwT$zoFfE9_ zY^S##*Dam>9W2tM9ryK|MdFEWEoc_7L*Q0#!ed6xDm~Z4tOg|Z>QmWHsc8(&MK`JX zK3w2=(gsLH+c_;7KI3^rUwjO&&KqNu&CU%>e#gt2)ceXWKJsSbzH?$u-*&cPdMH?v zsDZAbR5l>{%K6#c{JQYBego>8zXjxW%R$9;dWiF;;PN?(UCRVon3sguda9{s%mY2o z_H>xE(nMzGJmizU5&7#GBQ4rIkix4HX}R3#0f~#J;8+-`H9Jf{r}&d6#c(5yp15dw zA1`wAz}Q~W7gw~p4?ggd7YD%>Mj6JbBJ8O=9|xiMlo zv%5|=$S#P_vtcKA`&&aZ553iUo-w@@=O$*U8Gv5g{DL7~uw1@FqigWlpBzexxu34C zvvX+y0~8$-)gC39n=9%RT?}9XwjfZbPC%_fj%6%A z$5V3{V%}?0Uz-0(!p)*h%eEM#YV^+(7TM!J+Zt8K!UBos7%Co8jdxr>N6d$yl-FTlN5FsE&rQ_G1y-+F)v-;*%LGe!@0+ApGsY*(}eReEndIIS;u zY1!(TFK;QLjcV_QpTAFq*|s9r_c$PkZ$DJ?0e^tpz-uC=Ba}H?%f)KBNU<+H(e#R`f+Yk?nL*_98D@8DI1zZd(FzV|bb^^6IFE`P6Pt z4AUn`ISVTBU3$!!qTMx<9QI<5mcv6W1zDEo^Ejytny^`8#w5If=hJpQ2<-r z;yN4d=I?HLZ)mJ?qvwi2n?^absncZJmG|m&T?8LK_1%cl)_Vk_dTh)w?a?!8Zs+)b z{H45$rkuq_w;dOp(H{H><<@A|zP zh`CrzvYu+VS1NKT5^((&c>L%7-YhF zO)meaclSYI%wBb5-|huON%~fnDni%`&qR3;)IeIyEtF21?(+=(Y;6LcUn>UPKEJVs zk>3}zo=+lv3pA%g6g>P5lUy$NgxqH<**1yw$BFa3>Y5Mpa-1Mnkkt;YG%HzGlP-Vj zyxpOMFS^S-fLT5a(t>mA;na@y2k_G{K5l(Ovv10h_t>iK`K}M9#wS?>Zsw|Tse$V< z&g9Y593JGYZly|$zF2LdNp^u;P);0=K`zLww1ndICE9AJ?-9mh&_i48;p<2_8{%&y zs7X_Ef6WERun=NOVmpM4O(wOr)=+$ww>EWzj=7Dc!;XNT`546o6Jwc;o0vp)O{LAA zMvQ-uX&*}*fa*%2J;f5&;-D28ScHo5&q!Nw8`~CFKwH%-dxMUm$0lVCwz!1(2l4iO z3I=^HB2XCcFlljKFRN|&x_YJ#e~5ex1t;{^i{f<|ePfKA`FEb*2hVn3CI+lGjY0;9 zSptq~pw}&^$NB@n_a2Z7-LI{!mKX+9acCs|lt-U~udv3!ya6i9s&ih8$Q$kwo%26>}c$ID}7Sz_v>yg5E=y-RVZGH3DfS* z!-3dXeodlq3@A<8%R3&7V<=2}vqxVO01VJkl{Q};$XWd&G|>!#`_#Uc6(`95t26@h3moBAE33^?;V=!Bo|uA*0uc+;Y957sCDI zA)zD;x1rZ7#x)Qqc6xO#SpoWEG=ud9Ex}UsJfoB7xz(njxjYU;X=8GXQ!I33&gs#EhbgbfwL z*!cN8=LJ>p!(JdG5i-&10_aQrUtuZXX3sYk5W(K_jC(0X637c2FXijGk;8#l&Tp%Z z)8M)pT_YHX!t#SUiOC7W%y!fLqX1z}1s$kBc7bD`?ZVfe)UI=E_&R|FlgPgpGTKF= zdlMKze6F?zA=++LOoJHD{QUgDYzyX83nv(p0u(z)Ovrpk+DMgK?l3i3(F?fQO~%7F zI30ixhWHrYe}2`q&no3_WD;s;*+5rQ@8(z zQ=58S(pB}5`7Z}%`&lU3n&%(nXnR(_;_zQ)45UU-Q5y|HjfG!2-qCb^CuT!10Mh?wb1hXHQFT z)?|ShS zc)W!NEiZ8euS;MTpPVCz<1u)p!4vb~j`Z&q7-}~y#`B1{j$IgTR@xw-z-uuG!G=N} zKLY3KmU-ajW7LKMI;j4A!wq-44w&PUj_%l{2YF@FIqd_#yX8rWf3aBo%ms*iqwaj; zvqohb(S}kdNvT(L%2M(jf7A*`|2sMCFTcP628BO`0xW_mN(8}W7?aW*_9wiziQrI8 zvLbB(IkjK=^MxoXj;@nFsf!tDaApJUitVAm=wJZ^@e8r?l8R~TJ^7!!a2w~`n!=n} zb1t$l{raOo5P6&ixQ}#{o%wC-dXL}$h1+@c(KUwH{X5B{;vyg{{aEdJ?TuyHw#d^~YRflH6=8lwHkfw3QeY4~e; z6}l|{{H6Uzc6*B?b8N{?y7BNRQc^;_X5q%eS8y|5ZWHc$inDO%;Yap|skkgXNE)xc z2Z5IsJKf<)td6RrY%L2qPy})0_r8kfMM;e95sxX7#t+NYL$!!;rs*F%!kPY#cJT<| z=mTTZS?~+SM7-gb-5*5^+iGBLQl3705KK=O5;JT8-H13c!?fEZX)N1P`2;D=!5Q}9 zm^23&cAf+NP!3EPIEyXF9Va-v+$_x@;CHUgz4nFC!&k?&i))YRI6b08o~5sR4lu)K zq6Ws<&@V~f<22qqM#NLedf16(M(oGp>vmS64ws;ucRYfyObQs=6BPel_@7S@PIem1 zUWF2u67Si0%5`*@vZeqs7Eth}B7Ty_dLfUgt*1$~-#@!Vk)zWP@B4|0h3z^^$6Z6as1>fEVxAVmJkfw9-q z`~5|c_+vyHnXM_A(x5-)&MNnMlmtw?-5LJY2Ncn|auk*adiF&<{~r+r;;=N}Yf}2p zw&;_#E@xIn#T>io5A+_JU!RLwJkMp}3p$4A$D>+x$eDOY=oNd>HJm2(8+c&nllwbj z-1b&21@8-Ov`B2ot2|O$QOfUFxFL8Or;u@smTp?bhweHnyc{0Nc?UE6TcoJR_BNH^ zM+5+rYe__e5W6-Eod3L1gxUii!|}^y!SrRbL!=QOlH%RX@L#QP@a|-R7#lLFVaz5u z&OVVbe;j;{#vk; z#F$SS`oZk4*zuxHc}w2#9eBkT=A#0`G#J`p9Fnr|--bm9d(b+fZ~qnjICp4chziTX z@%IUcZB~~5ZhOqKoJ0Zo>t6&?@_}xW>=e-d_m*@{<)?mFlgnk9QOulb+fNMm*fv^f zd#;GKf#+(c_wU{X!D+aOS#r!;`c$9nmev`BF#2pCF}Jm~=LTB^c3|h}5pRH1MR1sY zOuO9Yp6pjbe~JMgyoUn??IaP~W%jUT&y_&5o0G<0phf=NO8dFBB%d5;*?)Vk|Mrh_ zWzW;A#v){?)mWCuEM4~BWO#poTy(h(Q-*&<)7oy28;y@H7DviIe@Ip~PBP2>*f=On zl1k*wQoV$-uTXoR&g+d*j4ysoCcx7sa!*UMv7m{1EbBFRCj?&&PQzK#kaiSt=XK5- z@r0=5d;HQ!N|J@JPxMg;!8*sb<_GH3nsOqb27!V)nQ-NVRRh#IFel}{Gf`N2rtDV)NHSM0&1o|mTxGb`H49VbEbx#5lLDpEj)l6Ro`Nuh z@Gup2{XZG~BpzWi&y@68^-q#RAj`p%Tx<>^$yCnSFpm`PPN}3Y z#0_g|Y}cPEE(L|rwQmxBf{5y$ixeGy&lxj}p*YpP&Bbj? zB5s^gKj91hU=3WB!%e2QJRXi1>@#VA?8VLzJfnC=n?7kFiPWvxKmz^nyI;ns`MpAqto8}F!>k?12Ae<)B$j}x)%LTpy^ih!-&NX@s!M`YUA9yRA+06$e`pug z#%Ckuj86HdiVjBgVpjL2uz=Q;Cl5Q0H2FaG>&ymtB| zbbj+FJ#tv=0o^=X=$Tnh)PbX0vL!jyzPvTw9I~AWWJBbh2kW}~ybhgO0jmC#IO!Q` z!dvwX>EBdnO(cPay8@+*QKZ_X{e79irB~`CucZ8ir{Z7qIJ9M#J0`*&OzQ;shK{`) zq{@#md2)02i{f($T(lnN@GVn{jAu&r`J2!DaDo~J6_Ez^y&q2UmbzVf%G4Nj%SRZx zpfPO7>whj^^yz97tnNww#Em5_Tr5Mp!f|;&?*@4S({tgGwL8}e*yN)wK0UV$YeE@T zeD=}ai)C;!;5jpPh?Syx0!_R%bMpknGiR$`{NtB2dFP8K-}f_izDk{IGB=L5vEdp|(58L$0phgV^ z5+|kT_GMmbz!CT<=Bk8w!UC>aMgP=bFZnn_;WX*k6)gBsp(v^XjbJ?P-M**{8~uvd(YBTMdhhxqUOFh)r+$T(NcNJ0~Mmb+HV|oYY|3%OA9d9D1V;`AU$n z8AU1hUV>ESR>_6GsXP(;;d&H{I&`(H;-PwH%(`6sBg%mG`{T;tM|)7KgX(84_xh|2 zYArna@{Qr_!ifXL9d|F)KeJV3%;nMu(tef1;9~;2=ksHw;|bZCbTV3W{;o`$LTwV< zz4YR5+6Gd-tK>ydEmbq#PsB+LtOLcBg-w0f=_0r=lMwt_amyPO*w+DfvHL+Y2x=5p`K zm>i#tAB;jt1lBKkmn_u`@wu(#TtKHeniPWeff| zN~P!blBmy5`N>f3QDaY8p#G8Qcb5LF0{c#Pj99#^qBj(da_{Aw9$6oM=XyZCic~M= zo1MGw+Bt$92|&o%{C#wY_fNFZPO@3zOym5dD-3Vm%n2mk!ro5XO7F+?#Dw7ANGX<% z0^8vly;_#o6GQ&QXfw=#;OXGTl|2oS^7&ntk)BQTr=Ml(*=o$Lgbyo~g}O$&Rr^;s z(`BSgG500{<(`j9c$GorN)X;pkjOfD zh&SkG9Csv_i`Q=6FKKhJVa@DGxl@a&7?I((&TEwmOi#v0Zd~k2$hfibNi$JeE0M}b zZ393v$cu3`*94V36OF{4WNqFG_FhMlKkm)u`(>pGL*6f)*J4M>lT)(_NX5%m?<6Y~ zr~0M&ZIs5h%fyi-U(1e`(7O0@&YA}E+==lw`0H{Ucq+~;NnzJh6*F!pZdY62eDQlS zQg^*irpOT9XPi1>eu%Bi$;92I8Y7bM>LDJtq3EVF;`n|67&EB85oIOLuow7-N-qxF z2Lc#%@O(mcht8ZzaSTU(8AGRT+{T?Wl@1kF>8wi@8r=z7>7E_PCY5T+l%)-T=cm%Q zRf?tPx0Mx%r3W|!d#5mdG8Q0U1HjXln8ueeR2@tEj%vIN9Mz^6AG$Hyn7j4b5U$PD zp-|hhxyx0=Uu!DEO&0!;>wQn!Os)fRy$x35#dHm^$H%)-llGObgV&2XP94ZD3W!2! z;EEMDi|80&O#KAsQs!(jy4#})KNQ5M5rz*Q-1lhSZ1St_E|#3Wpa($u7d+Fu6>epu z30JJw7MA?dRdh?o?ynx0O>QBo8bX_seinAF1UWaGKY^*3t+jfbXB~pakkRMH_PLGj zub-IJ_Rh8Dl9s9{@#X;*?L-%_kb)lC{qvo%n!m+Y#rU;t`=3q8DQa+^Jev`8`)1C= zdTTB{X#DCIm1;Yw+upy7)Xl#p;tQC5(OpY6_P<#z2wlCO2?xF?=&th1h@6$6m78;K ze6bu_RBfUr_BVIGTF+7GW%q|Ta9?OTde!rg2v|E=Ts(B0@NJC#YP1g!d)3Mlcnk9A zSQIKJZsklPlBLq=V@<0-N=EkgH3?=JvvFLF&!h}eYGnlhSQ$DKoaV8HGwB7Wokkg^VxhDIXUD%*AV(uX!~hQ?B6da8yo5# zw^@qiX0X83K3VA#n5aP#3cqApm1-}QumBa4c*F1eeruUcHasjsfVRA1r>TxR;_=el-{iv+M$-sjdyZ1-F3KpI_KH8;bBs0fgTB)9i*9Q94t92HCvo}X3>UD zQBSCPeq253lP2pLb+2Y!L3Mjw_Qc3~?FW4POg?Au)UzOnti9q=H-^Qy{tifDmzn_l zxA)U>9Wne$Mq&$(mf1A9rL|55=>;klt;Wm5Kf*eSwE$_yVFt`;#JD&{L~>xg(AmaZ zN*MLiox4s*fu}-jo&?}Azlt_Prvs=8XhL9>q*8g^okg_oY7o>GnUtK}AaxPwQenJC zZ;&P?n-YY0?_2+91dN&b8qcF%h{#E*-J#MU!gbJTopWn%+u?Uf^=?b`?~bO?-*a}* z?}(2HB~aPkEchQ9e*aDEsNR`1u`U$2i`Vw%Y40H)_g3He=Ie)xFy1C7%sws4|A?Uj z;1q(F&H(nL_V3Ag=R%UKx~47G;`CPIY<;n(=>bPu7Fv)N6icnrOZ3&Wz=hz?hEXjk z5jZTjWs+y<3U+;ocZ$!UOgx+KW(6=0TY2*QfZR?9P>9uvJavvKFvYPR16%LtjPy3W(LJ0~-3vS!p9wrU zcw7>kmq-Z|6hjCG3=<6WhU6B+?z(Oapv3Hj#BxB1G01=96FrlM={0V!)UC$DinrTh z=!)ZeTtdKvGVZPcoL0Cy)%w;TKGuu7&J&|JU=25v1qlmOkHhT~{6GY{u`=izi4WC{ z#C9LuUnm?g;F&K53!#5juB_=*0|C&v4$S#(*Y1@WKq#qPa17Wk>Sw%Pu&|$|qQ&n& zeugQ`fsc)zK*v7nh^K4xPJi1_m!TKjt=bD(D5v6C~I{%Pwqt>uF$$p+wmgA(zV5cP3sMafH&tWszgfWI&m{N zyKO*AB?;HA`Y*N|h3bC7Ne9qiEramxlN!KL0H=T8arcq4&r$$Yhhy-536L&;+Zj0w zTI-*x0HUWo9=A>S>Uaf64Hq6_(q$8}=>&~p@P>}+4xr1uCV};3b z4ifkUW4oY;5my=~+#oC?~6j*ZsF;{$wOTsl>jh?p#H;3c>%}v6s4(m1n2#ulxHU zb5zf_wV}%CFJ&$dzs>LUk&UxC>^sCOlQ1cLias}M0hgLm{&8K0*Zi-iqDyKPZ4yyi zcup~f5rxIS0mH;+^3{2MRdmz*Gl>zqJseWR7zpFE-OcAFCD}yl!y-6t%I-(e{6Xq-^zG5h!I%K?O| z{?>wuZsC9E4bUcaOT~Zs?SDnT9({EX;*o9w;o83p1mdm*NNnzzK6NCA;6;T!)pD^P zG2V)R@Fk3SvZyiRvlzv8N%bJ9t9=s)zYi0Pefq6)>tta!-POd=jMePv_Mw$QAM4!%Rl#nJQzhLt4R zVk|C?gV$Kv@PGN8Iv@J_tVB33Q7Cj5;ds#UE;(%^gFt_TPZw)$7Q<)mm_kvG=1)~4 zy?XMrE07tpB%zUCd_};MJ)zfV#(yF2oMdLzuj1$C>I*)Co%HKIv z&!Q{ik^9EhR5_xcpZ{4mQX=N>p2wZrSTTks8aMW&%xacz+pF4*QK4av7*JR&|I*VjO0sZreKeTdH1|@*@clU z{ow1m>Vy4@dkgi4Y1`v5{Z_>8#e~FwV8u$X@%Q@p0m_~Yv2>QUprPIGL4o+=Q5?pm zjJJLnpA~P<5?z9g-qv-ki(=pQ7UJ2d>ODZ&R5e`;PTTg*0Sz8N$MM3cBqB+#*y2VW z3r|HOU!7iStRK$PIEVUn`DlqjFwjb6B5F;Wz4VV&_=`bQvK?7b(~)OizB~XS>y`}J z>a72411|r&tpIGxTzaT39J^NpOi(E8e_0O(gf44OHm&DV3JX4?-{^fX$~4p9cGC^mz{Ub7GX-YmtPPqRew0&X)&4YAJVZao0`DKn$oQ*gXp%OJ=WM zmQ{31lk?X*v>*BI#PD~k3jQ4&CttQ}w!vx>^fm1S50dr@9pI_Bow;wpj1yl1m%L(j zR)N$czEX#@v{y01&!qo30Yf!v$T04ivw!~(ji70%b8>DxDcq#pH()o-IBk+Hz^oO& zHkOw(W7xZ&q)wN24!ay?XnuCu*b_g3)uvPYToTK0Bg|3##y=lr8PA!#FCVKJP_yk> zikgc$Ey9#QvbtbHadRYlKSNTwBb|JL@s8>|I~;#J{EsL~_Z1KLiuQ_Z;6Gsl_JBkM z1;*p$dV9ZwI%mO(!wexF&bNIoo~rotU%epD2}8pAqQ0j*e^vg-y!O|Cw~Cw3^d0Zb zTPSL!ws$IK@Xqd>dhm-iZbCYUW8drUc>Tn8q{SD{h{COu9m}V#ZB~E+Yol zvEfWMUe3hhHPTN?Mir;ybo0d;glQw|d}D_B*v42bQfBaXp6=PMpyXlSE@Y<+>ewcw zxloA4a!YfC?6%p-mw)Vp5s2?{z$dejL~k+rX0Rh>gP(-2j0uej4q6cal(_3$e*uSs z|NDzBY}?elmsJOfjcPQSX}o;puj1q*jxO1H1q6`+wmQvJD-yJsp#nTw2eXV5E_}{X zCY5i`hC?a~Y;*Gs8J>!(0(Gu|`=JDiE0@4@bSQ>ulx@Ems5l)Wye$+3S)?ILKOY+i z{b>^Lc6Eg~T(62dorsk>K(>7#1=sKZwecUIdpUCyHw@z*|KIFTP3d;KC*jf_zlym) z|DVPK&awgj0;n0qFIA>L0b=b zWb5`zh28=XxGOs)B`QsR8{j}fbSr9&z-2M{l)zmHdxUw4b^w<6Q zFWH$*?dB?Z90+9v4?8wYE98Vu3=`Gf&e1&e`0d_)!iUo{=f#oxOVh{d&P*N#>C|Ek z={1Kv`%nTrRBd4y4A;^67kPqkff2uimGq{J!nNF>(JP|iW+T#jZU+avyt z)1aj1mr8Oc@%oyI1l^&_51GX8%KkW)BgK?XOE!Z5Jtn%_>Q~s^}#(GtNe@ zoH4RA`pyDxH4Uq-p`)C)$VIDY>5S!>6AB7$(F(MXiD*b>yFwqh^NBs(UDU_#tUBRS zsweguj{L;Cn>fPV7T7Ghjsmk_4CqgPiVpZ^WLk#7Wv`N~w#umWAL(b0!AK=escP1b zPk+Apu~n}pGV1jfx1V6Jqtd!#v-SK1qw;s6OBhJ_ql)PcE=8Ug-0Jy;xoB%m93UTe z*4W1f>5Q98&a@21;KluaMf4*}cSHW-uqsBY!eA)_u;v5>#g8L7>;=8-zSbfaakR3Z zqc^S`8K0{(yV^jt=>cMHO(uDnbR-x$MAP=^JtKQrQRJ8R`$a{8iAqF3!5d;I< zBmSk+dLrI^$|F??bix3z{sfSU85iYVaHZ>=$@Orv;=jV^9KAQK;O#?)7D`*oHa71$ z^9TeZhvVcxTNsFtp43IkMxRFUi+!Hpu!xEV7UOGhVr^FZV=m5nglT+E2Bsqrsr27T z1$dZ%0H2|xs!k~TgH&L%&lP9>x_(a{uS(M1VsKSlWs68~lbiSOdcY*!`~H5QE`UI7 zU*+*Kx$a-^b|3q?;;(vte1P#5vu!3yos``1nLa~B>ZPi&-NBlkh6%jEZ>2^a=?MhA z`P29qldo1L22t@`5^2`TF^;Qxhr1D zOKD(AhGDNKYB*jDy14|vXu|LHRI#F4z}@{8()Q>JC71U|%a*;Db|?74k68>#lctPc zRu3Z@@7w$ha{)C!jq|;(+xpVa6cBh7M^IqTPJ4DaO(7z4-~Q<&$x2>6?H1vZkGwE# zO`O4I4QHj2s@|{_!-3ymj-t}jg#M`(I6$CU;2HuoMFQbAxRnWlRw2i?+rHm#9%=BR z{LNM|B*LBWAJ<+{;9(><1ac(yb}|HuPwuaF*GwJ(ybyfwje{%w3E?lg1I2=?#tE-v z8X!qE@*u$>#(e^y%F`1Z@p7|5FVRf%N%p@j5x%t8Qm^2yVW5!I`R%DcOc(b0?yen= zm!8I-CMTAv3leIXjVum)-vr1=^wocZA5F$kRl@UkA`pV_tEUd}c-dX^U&`C>n{bYe z8Y0I-J_&)f*(5Uia_Rz$W|2_{zLJ^2*z|AS9U_3?Wc;GQKT{Dfu@VeP#-?Po?Ye(? z(h5fDOF8jb7HW1YR7eUm$WwFiY#luV(blnA6v1U41Qp2TQ_Ag=L13rdY7`vEHqU3N z&Uyu&w_QG^dz=JY+~N{%j<$pvTx>h7MW^V{^y1$EMk)>WtFdFky+TOxZR>GOVTNB7 zi6BYb3m$1OOj(G7xdtg%H|^b4`vD$zq^?cI=e#M&V42EqtPl+9@Z`a{k3!(Y&}a89 z=oOUfl1>CeQ;OHNPoSK$dHAAaR8@4ks_?w(4Z;{aUX8WR!it2|t3pf8l7=aGDk2S2 zQrE6Wc5ux03s6r9Ne;-wT5B|u=8g*)0TL9`13CR-+m7uVC;u4{ri#vMIc3X2S025t z&JX@@{)AJwcQcYu*_x@-9nX{7U><(*1`qM(PlY7jwu-!#37L5zltN(GXRRi z1RBV_LEyl4|8qKapk(GBdvg^uouTZOm%W^#Y9BI?F`|`o?rTry(!?9z_kA zYiP_~z}zyhZ6u*^C+!|p&e8q%j!2IbT;A>T{yK*gH;qaT1F%d}y0#LSxlwK#_`c*U z%{U|^0Hs|H2vgh2b1!h$SXTXzxAD~N$L*nftW)%XeKvxytHs1fJq zdMm%|nySB821D6%EUZ-?nt8-`uEUG|85UxmR<-vtZn1K3Y=ePBK)V7zVOn53=jt<& z{vuT7ilO7wtNmfr>lv%S-O4i2D~7kGU({Qx^JI5tx&>58IQCfYei}%?UvL~4jK$T$ z81ZW)`^|A?JMX#Cvi`Sn?+cm1^BkCpePg=Sps;7IuGcCdO-+W*d;!t&b?kI> z-@W%a=YD@{ty)i2O^rEbtt#JYl5q?tDE96zcG_*QMg10F!$r2R*h|Eie)-?#TgM-Y z-G70*3_8$qa6E?T;UT98lJeUONms{IMNGJ{?t{F&O>l$EKVB+TH&= zDEIs)sh~6a*IO>}mxiT3mHzN%ZQtNeB14>ZhqDfI)DQ&E;8m>Vw#4^r|I0?&qunpI znjf#^aCf**2N&Z#W65z%6I1fD^Th)HtIeG_;j!Tmm_V8>&a#(sw=qA8zj(?7)u#Rv zcwL(_p3yg~HJJ49@c?RgUXH*=;!D@~K-=egw_#|V7QLuqN2TSIsnN??wndWi`S}mT z`v;biaiR!5nKR|&3IXkRS$TXztg>9$9O!^}s*iaj@~_T^qzbWJA0uvRmUe6Z%_J;2 zZfVA4G?)Z&k5Yg(jV1Rf>w(Du#Ke`|z#csNfb${CLTY=URRfoihHesPZ&A5caJ*;K z+X@(5<%kn78V`Y9kEfbaaOmzDs0ovJ^2&wrWdECx9P>o0I_?XgxWsh-CAVXj2bOSy zwf=*!7C8%=K11aFbaJF!{r^MRoS+X_u!RCCua5c?wvgB?YrutjlJ6S^kZ`f$n4$3< z1}5KkoLZCkjxSx%`=bA7^Ni(-P34OQtL>ydFd_b5yj$s^Fkq*HK$?(Vs5g-{SmyL! z0HYK{=(XYSyV>{=a+Cc(ybFKnUTgJ!t(aL1RT^IZTlRn02Q61}{+Xm7@Fpnk91@liuEA7UtEs!V#F_0Jqj1JM(zt3ajnurgig@EA5kpE|*Hx{m@TM%k+WCO(znikas4 zh(KKXJt&vtzxhu&ttZp~34UNDU}pY5#W?0!Yn3}zr4wwY(B&cpUY+$nIts{HNO9f* z@LDJSYEY0`Qxws+qvx*m~H_NZK`B{vXqK(o|o{`H#{H zF5`O<{~tAZ(&Qn#i!AP~JD?p>bOYH~l=qagV3o0u@~|0p^Oyjm&-4#$;HfSF@Yu-A zM8gQlkoB)j{G%!gm6i%R^G;->T1>@Qoz-KWu;OdY=cbZFpka&5>7K->kHX{&J%_ui z&sjefvN#pF@dLujPE58dv8cF)to}vg2=c)BXBvsW@DQW)tpBqlPTK#|jcR)NgW4b_o89xq22>M^6ZOS-qx=qnog#Gt>zJ&in08Y`U z*LwYULN6RAk@|;s`VRyZpSx&e0?VOW5xpu`W5AruSh2hnYJPJ zt)!ts&Eo%&BtVC&&O|ke_twq=++kOm5~lr+znHT8-q9>fz6B)b6!rd7k$+aS8n|PJ z{r}jjf0o0xnv~xeU>Vn6-SVG!QWlQK(&l7&YPmnd@j*CSyo}rFY0A1!8Z!=?URO>- zNE;k9GUeANDIlAlfBtC9Yblzj3j4LWWU@A!aljac25jd4p$e4A1AfHlu&(^7khq4b zlGltO2aVPJ^{m93EPhIOu2V8J>1`R1x{=DQRLulz?b!*ePxXqK!)z#{?0Mw;!xuQN zT2zmXdghdp{E{*Sw*M2?CkzYAOV2NR0{?B(IsUg!Qa6XK2BfNX1aL`lyzDhyoPgve zLuhnLQAKO(vVYsF+bO)^(iD&n$`#=Jd<77VloEYjDt;d#skaj-z zd^7iUj7^3_fX8Y8_Z}9RppP}B644|+76f`~J8b9c!rvV~lU@heStmgM0ktF>-0!DDWOqbYYXg8`I`~2K12A1cxe>Jb?dqM~9gkx;kq-zOw}!H<`R++00? z@B8~blm5r!+03&M+vm8R;MdDS?brL?chi)-d-Z@XPhTIO&ujg!hlPbwA%X5mp&{9a zlarGb{jZxxA&;+@hrg{%`aZ7@M`uT|xnH*rQ=vDjC#f^a^S+)Rz)y1#_3-z0^?3h% z|GQV2yT9{w!1FnvFXa1*A4Syj_iX`v;?D_@@0*j7?}yL~6QKS3*V7khVmvrHZ2O^z zFhM^E$aJDg)jgPgZ=+Q8Ee615wBOj(@66Jll_&^pp5WDS^h+f+z1%!U`G+4&qUSSr zD1ImLhzFR=1b>}GcZ^}2T54bo(lf%UC@qNs%=eqaFosXYrpLY!vP#v*@^3?rrioC) zbBzWV2RRyX4fQb(uXR+v9~vszeAwpzRFaLVGYGoyLvWgPxt!7`W7~j_(z#BJ8f?E{ z1Ez{u@0}$PRTR69CL~98Jgv#tJO2yYH@_}lcO7s7(2-8LHjQray6bI3Q-tyg-$hg1 z$DsqqmeQbsC@mP=lS&_xMr%a%YsJbF=|9LP3Mag)2b`?d+k&37>KvUfuF0xP)6g*G zOA(1}SFJt8xyU4lN=h*FacVqv<)R}xV3t~iD{woH*NfBqt};JX(Cy)@e*hR5sAn)E%mz?WLFia(ml-bM`s2<>o( z0y43jRD>CLn2p6cl|BC+N09Zh=xEw6=BaL6DoDKe`kXj7(umwmV~~C`cf;kKqD+Q{ zj5RBmjUG#cc2c6dpT|td!^NR;Fr7pe_M<7=-a5BZ-`6<+7N!mlIIW8Dfo*yw-B-RC znIrrh{6tC{Xg}8!!1?}i@Faz4R4m)DeKkSCPv%H>LNvaEVh4bD=O$aVc02bc+CCO9 z+9{RY1t#nb4RcoD0tWRmko3{g;%HEHcqAb1Zprw2hdBSna^(iiJANH6Annt?ex_4! z;K)!R+%7NxF6)PeSF1vZWuHCk*LMR}E{aW3x-RWjb|twJOV-Xh!Iw@-l)7CJI2~o2 zo12rF7Cu8ZRwUPNF>^G9B@w{=o30`ex*i{1B-6Q3hC#@v=S#(OtjPSk{0ZE{9cXb< zP)BDW%aJA0a{SVg&TcaPj2jZvMam(3Q*fYtu8HUYM9zvak>R`J3yM0R#DNwws8+I9 zD5@=+Nu_0pZYz|g&@roB&CD#lxkUZk{YEPb!+vNa#YJU0EwUzuZlCW>nZztxvR1k| z@Srv$kr7gn0A5V|%ZemyhGH;R7yW6}ovk*B0(a-sA0(YLtnY>bdFN0>(1h>3RLrL5 zcusrP)eHdUcblg2`Sa4ZC=pNa0)VfC;=oNP-usS##m$Uz(?K6>v~KFh(g0how;Mbh zlxtw`|9wM1reR&A^4n)xwOP|+z4;;+c!Y(J=>&M=q= zaL29JIB}kQ;vm4xC1TAc^XieDv^EF^#flje=oh-RfYzSIQ}I3-Ta&(1bsX{gzCzS^ zewQjMjPwTFW5q+;_IjivPG^fdrW#gA_5y^w(T6GJ+Ak5kg$QM-L9ANMi-RBn2RWXR zn*_vQkOjW(9(T-$dNVzSm5jCo&ZTt(Fvek^mVPbgOFSL|aK(5TcnFP!abLMWr91Cw3>%-doB#gvp*ifY*2jg@YNs1N=GvDd{e5U$v z?8|GQ@=H(+iYH+OrP-IxqUR0!muFLM%>nF;tT(6SaP8W2C8Zl<6e=G-Y5*&Z6^)xZ z+rcy}T@F9t%}RN0QzRf<@K!eu6s<^d#x$1z=*j1E<<~Oe+Y5n(Pi(mq;co=u1M6!BBsN^*LaX#3wAqQTEHR^ zmpttV1u(a{^ef+Fc7h)Pvf3M}#^5+b9;T9y_x`X8vY$0k?1PssPO^#B(PSl(BswVi6FA0{M<0aD_i@;@gQIFAt@z zGvATI0&TwpugmZKenacI{(*y87xuXkkK^g-GZ3>2tvpqHJh&AJu-5FFf7Xf5Y0}2~ zpwVLkFOq`Er;{I0dek>Z#^12Y4)`X~P(S<3_!^9Q96zO2d5}=$o<_n?qk+&9!K!sA zzi3gW)@=4s%u6V@*{MM=wj|^L!K^g^+CPkM2-~e7?+^Oqj|Z`V|RM zg+gK zbS4N-Z&A?>DUmgw9uj#{X^sW90+H1BRKGON-0y6QDG{=r7B{F~lVFvW)$uU3wN)8I zAV5E5w7rdg5GP7NZGm(hD?ZH9lveJj#ho4v=0QoYSkd8!KJT&{mH~z|QmhkrNnaq@ z(h_`fzuf1WE5Nh`psz%Eh^k3FZYVKuU8Z9DPX8np_?oEJajOYVI9yBimv_ut*ebWW z3V0@^p>o|Fsl)RW z^)MwTnEE!OE?O}^rzsA89519c(nOdZm`3~<24&HoFn}!r)=GsR-jS`<4Q0~M$wYDF zAV2u&M^o2@T4%wJBC8V+!5(f95_o=x9#kGL(}IV}%6lR;F<4ushD)zXnrg}y#rO_` zePdi}5n>-sL7yO?hfuygUigjFkhFf~$G^QR`iu6x2~y1b_l)U#(#7W?80P~vdiHw( z->8m?3kpEp!0&gQK()eIjEs2H=+d*!re9L#K9VrA#k&d504ex722L$aUmfT8Z!xgJ zY#H6$;X@WlGLxsiFr85WUhjvFp!DT(A22F1!u@MzCZ<+M!sA z!Xzl-Mt_nK>N}Xoord9YuA=1KE>gf4$i#}5P#2m!An%36X|Ljeo$0M-hAFL zeD}FtCmu$$mTyWHa;iIa$g4%X-+)f{?17ufpISSbR9-u;q;#HeONyuf(d0+#6p3_r zhK2(`p+V?xX43w)*y)1QeT8NA3wm6*#BCKe_Kf#fRZ7usKov`nUpK$|V+SMJ#Tsll z78zSX7Xd{ac(V*KNE=oAVz?7I39i;BFx1Kr%h%nrd=^JeoR1^%CeM*|Cu>GhO*BsS z?vKo2A3ubs?75HVIk}JE{6l5rcnIqygg_HeHfRwIx$x}3(@(dFpCFUM;4AAV%~3*3 z*f%nEPNrvP6g$q|I3G9#QyHSfpf!_*<@z6_ft9Sn^3araP7Sy)mNJ(y!VG zPwV0;&vPxLp2je{p=@&Qmog7X)aD zDP7q0-66$I%nWUFeVqwoV2VT@RSjqJ{-^>frLg)8N_Ldg5UwkEw=gg)%_(EVOBW=c z+;hLiKl#(^u!p}>{Qfc~g5OvgSBE?DH16E6eMo2-bWFvDfA{ZJ3C|(Y(h(go)B~6cH zHEC%MV@sE=Z2cR>c0C4o>aB4S>2gLM<@!HDH)QMdF*G~eAz)(YAw3#i=tYqL{TL|E zspMSIj7cPV8)J;+XBf|*Pn3_^NemRiEIYi->QLZs8E6%|$Cw0}Ehb!Y_i4Zoo=hAmsRW&VFx?Bzb)S+a0&MTY- zz5hHH%n)jgI)cZ>lx-;4c;l{4tn}_w%9?anVOhN0JqB7?38k7FUnM`_JA^n+n~+NP zh_)uH2X5x+e!9FhRFOpjz$AHa5Ysv~tRy279Zu>iw3NVO+2udvI10iIg$2+s`o1^6 z^0AmdxbR9XYZ;DOqGxVPFcRX?Zk78>@@K1SzO6_=+0TIDqM^Iu*aaMgVWA_6boY$6 zjK)Ng^=O3|z_qc(zM>);93Q&+O7oVUPR?nZ5SL zl1TO8hC)(o+6b_c`LP~4-a3Mbl)Cc0VGGP*ikLODs39j_@951VE5B-t^9~RPSO$bG zN?kELvtg6Q?XJ^F1{dt;V)9+yvdXh!+-0s4R}C;j;Zv#_@;n>dL(Cy3zv&zn#Xl}V zDnJKgz(KT?@~is+sFj)68c2-5c}(V`u%b}z8L5@RnkQgKs0{=3P(WD3v z^i&cjEg^hYa7&(z=A^f}%%|@UU@gKzjzxy;Za5vg9Q@L>z*#O#9HlK?OT&VEa-s{lA)cet7joe=KTEZ*T>2ZN9eGvZjUXyJQnL11C}EbE-&1Ef-=pPVZfJ`c|F=hn=%pueD%P5Fc{jd04Ub0is_ z9rk{WI7({FIY$yDniVrayxkqkNw2VPmFXiSV$9An7*1cl;sIB zG<<@5z^V*&zq%@Xm_OmYJ%U}UPls@E0=_z4-FR@k3Rt_&MpMMH@VHroGU-rjfOugt z)B2z!6e=@VW~FauZoR5r{`P!YCcAhOtWIMYsPF*d=H^Ss38$nz=C>~$|ERIi(#Lo> zLHz1;^eY#3hBN`MCCE~IKhb6{drkX>GSfA_TkqTt%lJRb zg{A!Mw#=~MZ4?Koek&1mJnE`w)MKfhp6L>xWq%6?@iGFA))Y;LQzg{mF%Js5d}jGN z0Zvm<=KKPUGWD6Ed57E~5Ym<<_)Q@A1=8RRrfS#T@Q~6-MVmUiTU0Cuz^y;k>Xo1- za~x^3gK;Y?S4Go@3301fyXksWea0kt8u$TY8u;g7g|x>o2fKE7Gy;vfUVnHqet_2D z&#cQVP75$(@WCBFVk)^vfv0z8$gQD&e%H0>xqW8%VMIOq;ZX~-G1a(}Cr?vH1 zUtTJN%h5wZi}4^QG}_B160x71Bll+9j0BZw2@>kDEjVbF=Dcf(IR2UJ4OTP009X<@ z_rJben-kx_7nR2Qy$<_&yfDKJU0dxKodpNa%9oJo=U%LOJYw?9D{&}LS`xc!X% zW-lL>3YQwx*jh&0ZtX$TnG0H22`fgF_5C%~xl_VHcyV{MNj67sBhQjmiw)IP-idve zgRXPKSMEtibZBl*Ivfz0Hb0r^0w4u*j^pa3L+yn4q!MY^ur*?tR_+TsqzId3g0Yf3 zR@Iv8kaNooZv1}SF_~b3$Dj-uGD&lc93_Y( zGFKVwpcP^Gk%Ehy(blq#2F0(%1h$QpQkf%!VlA}vKOkv-YzhE_-$OBnX|u{mI;VE( zeK4Y_9`L=Gp44O5f@Oq7w1CHyQl|$OqZsRzLaE1_Pwz>?7#7wp-fUsBP*?qM$;J(A zwqr~8{`GrMVy}T7{{A>W8Vpy{bkw6Y$$PBC4r7-XDtawmJ40zcCCJ4VV}&;J zZ&mVlzvdA*rMS~TcAavORgvYU94W_{_YY14m8Q^12s z-a09p^TI&Ka$UAj++`)v@pE|!E0);jSkD%)uAsI;_9@&98m?T046Hpm^Ww(-oI@tl z^IhqmE;p)G!9!?65(NmJ(7&e7oPLsn!lw!C^#4wus7(R)qR-k{u?#eWI&LikKxHC$ z?AxoiZvS~c4uBl4d2Pu(vS;1Zg3>u$C0XU4a<+bVjkdZEx?WS+#!7Pu7L}GVJ@{DE zC6J$QZmEPAPBLA`uR=`B&qkHJQm8Evpb_xakMgYx{T5XGRSTGm`?vioW4PuQlCNF>?MMW~-R5_Z%e8W?Q#>YcD< z1pc6Rd^{F2v+MU|N%J>)Lo25_p&RsipaBc$rz|UwZy2hTdo!h9QJ^Kcn@~my1=g*O)xa@uL92_4Sxw32nMq8TuOuLClHTU4OFZ6+W8Mq zYHEvmx9e>P5R;Hir-jgn?0mt%d|Cd|B}L4$D?Z8U*T6`g{w$<%1$(~<^%qP6sxDrc z&=gM;^;Rkt0_t?tbBC9b%U>+aOdhMk_$ZBX{x?-Rb)SF=h1M5k{{BKQ4J8`^8@b=` zr4GxZ3VKrnjVESb7v-iEJNM5Rl=D$W!57dGf6Hlf9Oh+45VttBoYbF=|2~YRk|E)3 zuc1v7a?5p45!fgdjxNOzQx(1c62itM*hs2xt&8T~Q1*(DyPrK&d>V(R;^)huwsPS$ zL~$#Ct1$pnkv9BE0^$FHQ@b7<^E&_xdU-fWViK8-Yul#z3}L#7tDevb{v! zt|bXzP^#~VuX>MD(;`TcN{&)PzPPmI*K(D=adKUBlTOZ(0=(7B%43sPo*5XnI9)mg zoPrMFFE}5#yd%xQ;O}-|2z(`}b<9W>eB&TO<7og)9~Ndfa3@P_kNs$^beu`;=n7o8 zhVaENNM&Iu{k)o6y6NjbZ7yR__hu5eHq5R0cbQNXu?Ri2k4OW??Dp|(;{`dQv>D*( zuI`t(j83M{wlYwC-1g(@F^M&}aXG@ZN)|Z$@tH_z)<#)V&?*|#lkD}zDyVU7YjtH( z10Vq%Y^IufL92v@*{f3AIQQ%EREh6uN*N?`UE`Wz0I@qh6ontq4r=8QgbS$oo9gn_ zddR_b3e0o*%jh&Q{BHIk#8%#*)d^+Q|;D)0DH7ZE=Ews^9~fe-`2eMJ-u z99025pPWyGCgMCh(j+lo;7Kf!x{vI(jy=Xh6hnx1O5e4qAU@Ql)?3dKtWJpWD@uZt zUtnlzAERyfLR}4G##VOt#Oa2p28qY@nyPDZbFWfru64QANw0!~_XN7`_4e zEu9-QaUi&l|LVex3Stl=D3Q_UMaVC8MeI4-a82BFWSm#Q28H!=y>;SFy3-W8N%+I6 zxg+7yfCSk?@J8uX6In7oF2~&JI(1dmrgsl2Rvv_1iWgy5Y;Dg&d}5d4AbQ_VEXNvw zR1}NhrQH!T;&U{xG1>5S|BgB-@F@kb^?q;RR-7EZs|CH#Lt5jTQb4&uATQ(lb#C&Q zX&ex=IcfwgHLYM63zOcnK^&r1f_AT|Ke=q6?gsN)irN#c2TORlS-b9Kemk0sCWrT- z#v|_Kj6ZGvYG}5TEHBj_R`e3I14POW( z_0)z>^G6!dru}HA6T|vPg4tU3Y5(2>B3=G5^;X9ZYDFyk22niBz|x1ch}xwZ zH#3t@cWMoHkTCL8>Z;_3I$sMwJvst-ADBc_9Hg@3Gw~($v_+TgDG!_C#772!K5P!Z zm*uCW^6w^Rc6HYbYg+~JPkBD&#%KM?{u*WtVS>_mtgu6nU7claU2j+Hn~j~_Wf=_~ zi~?nkZz{CElvCN&n=T`bJqP||xHVr~Y+b;G$Ge{4Guk9J%;r;DqxSg%(&mLAq`T$p zAsJ2j^&lwb{3+{TM7LsCLMf(LbEVbEG!R-nk+|`wYuko?Utf=MniI_B9@qWWnW>w( z^*cabyc9elNjFeFF7;Z{-dh zCN3RIlRfxI=Kxz59u^$$(P&^UhJrVF&FUfUk<%@QpfvF3r`jS9WZ}tGbC{Ad#`aG)S3YpRASJ!G$Z6^+jYp8U&5V_Pk;F%3( zqUBU*SG~d^%CBK40LhViPN;*V!EvRxfwi{Jg9PKU9LEmpCTy0i;3Lp71n;?Y}&!Cq-1WP5s5fI{(Dd8Y;ooyZKYq=7*n9-J&~EkLQ*Q5`&r!hrSjNq)W4yy9SPn56^|#G1 zf-{H;)O8VyUHLJ-m;o8;Y}+=sxunhn+|vj+#F%Hg036iHU=kyobrc+ueS4{+cFX#~ zikaVBbPkr!2vT?9+cdTsH_@;kEWYZzEYc1Z=)}MzZsw9pIj{%6cx_&9Mm&k_)k1r_ zRw3+Kqs05P&pGTtLb>p&c6j16<6(*Ol>On8AnMoSoF_grjo_N#%v(fE)t7Iidyl0v zN?X714iE^Y1nPz7km-q1u?#z3L6D*UVGe0J_t02;16l{8H+xj~!{W`ck}bWul9>1& z3B0NhqwZP6z-`>s(6{<;fx!wJ)yxTXaG8O4S92zdlXE+J1|-JODOq}S5&&ViU`NPG z0+Q&lTJS{-t1zOfC$M;B4$NY^;#VmXdUY5GKoDrDOU~Jq)OniF+ScI|OYl>1C3c-M zNbEO6Wf;^mt$1V|e0@WIlf!wjf&hV|#o{p7fSr~{g^#S+4$|(1y9Wqyy69RD%ZkJ| zvswh~C(gS1lXB@4N@lGvhN$eBCYwtC`aRcC>I+MqHBOKBD(MC$qA=&?eWPHc7M9iv zfW6VhH6(7VXEb6q-X!BU>2*S1=U%u2U=kY)J&!t<}zu!N>*$v#K>o{aE zuHKXuGYWT9i9+$yE9XojtAijBEt!h&n#R9Jd<1S3j-jp@x`t9Nia-pUS%&3CyFZ;@ z`O*)Nkux#3?;jDS#4UVcgxnBLQ%X$b1IFOn%Lf<2d__mmF}6zP$LV+r+~)r5^`4#) zc&$+9o3J8QY@K{qOlDn_&Uy9nkwRkpo@H*^xY*$J_i6d1S6c$YkUMKgTo&deoWm9K z*Geo?rl_&{P`Pv)&l-Jv_tbOPdGpzYoygn#(EIxxeF$DnKyeQGbi*TZvCdTzGC;sZ z=BL&qb)(qi`-T&9t8=`z%R-05QZ^%EW+i^4N+_Hyc#jpb_;^mV zgoKIb3bQ$*DQ6lv4l#Tw+#SP*J^>!}j`r4f!$Epeq{U^2oQ53KiJX!ZE7`C#l9wan zt-tT{I6AU~>PzqZBJ0x#7P}>fmJV%LE4XmaigkA!w5ilpq_~wnvg2f-RXlV*J_O;0 zbFxPY4G#u$hoQ<_zDlc%(D`PmO8@n_XPm8bgU+F02MEcTu-X$Cqg;Y~@_@qG?9sQg{{>z7C;rkm^> zD2^nbjRb!JOQl`U)8DMx{VK0)kh{9xLG+9u^HxK+b#powTi^>u_>EeC;?8bG4mt-d8(PSgV&cIL8C&s0SJbl zGdN@POHK zmom$5)w=hL|CW5=Wh zG3^+h`qads%p9NMcp#hlV4UrVV`>KV!1;#N z!RO>Tcn3~-O%vYO)SO>4FJQ(NZrfb)K6eMxL4$B9w!d9&gDTv3;g1>Sf?<@$JWb=G-lhnY3oXC;|opJQP19FZc-=zsGP9}TP3$dKyNNG9V)DOPDM!f_#LFJ7+yNRcqZSR+k$ zagUFP@VE)=H6R3>FyZep-2?#!_4k{(;?hAl{lpU%>w)R35oMi&jDh|NE(EbUG}_rO zZ%edsjcnz0j#yse(`5RbXBO#H@@tob_v}z#ZvH{FYucRed$mO4j;$6ubDU_gCP{CT zDdHs1br%R=b>@0<{>R$qf5l)Q%@qdIvv&)C`*u|{DbN9%^lX!7qtm&_etODQzS)1_ zksCR=@W`N&tEpX3VC~AR4DT>BsZ!>( zp-8Rp^>_h9gSX*;2eKV)R_zaihdK8Fa$k%M(aHhx^c`pJ6cepp+z`-WS1{UK;qXR| zNrJ!dM()blwW~MsamveT+yug(-*=UxhYwyD9Xg^fV>GxSoXCm!8LqP#_M|#oHdsUX zYBvf@k;IPHk-KmBehBXoS?40-i^L!} zMXpG{*9{*t>&z`T5uIwYqBi}J%F4+nwc7Yq3G>}pkL5e6QZLE?&G1pc-is%^wlx?8 z%dAX7cY;-so_&+0=Ax&IfcwCcJ%;tKhAHc-Qvn!djq&{gG22ezdG!`5D)qX!rRON8 z`ouus-3{k4rYwaV*fW_lqTRez5$5B|EM2zPigCL|3m&h>uwj{7KgwJe zyWgY`Fa`H;>m>=idq3Kg06pZ+)mTAE%AfgT+oE;n8VLnYNii}$qH>DQRbN&Y+G&Ev zpOZv>A;D!MTz46&R@5F-3<$x~BO*TAt{v_GJq>M(EF2aqnLH~-$t4O-m#rU<;{7hp z6d}&(PgCI{zVPEbY=?67t|}PL%1^zDd|VXF+e6sZ8igFu2J%?SpTeD2ZnGt5;n{|W z_`GzWDSd2X4pc|jkGpqjLfqzwx4wN!gd_6P(%>S7q~P3Z44d4@NjZ_KBj|&VQ|&GQ zmTbm*nrfsv1Q;+-L|!AY3zq&>UMf%Ko5--*%KWb31&B^~5VTU4vT;LmHzLjIa+6Dz z=fj~6HuGr%LgQzKEp}67<*_N6dBsDt>1k(e1Ztr`Jmns<7_Rd8y=b{(BV_2b8+d!s z_;{~<_Aqvvm$q}v=x4lXq77B#WQ5A` zan>oF778AYh0z99ZlB9j*Ute2bp$yK2?)m9F?D@n`JZ~^0bKGaQboUYe-g@i8H+2p zr!{F#{Jf$pmNpK7(A*oMAZPZ)Vd7^y^#Jr*;3$>iBrnQt4v;X7%4&HOa@&R@&^_QlykyRod`fDVH}@d8SC z_Zm=>lA(i$(hHXR|0q5pU@NHg`!jeE%a0sr_X$CF!fVdw$ntx!R4F9t09sqo@2v8+ z_D79Y^*2baNYA?rq?RdATsCj98(yePStHB`XJy54Sw{4P3%{UpYa3`4TjbBp-cbkG z!>#J~o_Cm7$q{DYgr(!i;`58~^TVeDX9xF~gj+0NbHCR=;(W?4a5bU~d@)^__x6qi zpIdPES*MS7z&aB!Th`PT0`%S!Gko>c11DbeFseJ9{c6h(eOM#-Y6h+|y)btLzaOF8 zT&ybq+0Tt_XmaM)pI%o58M!%Y^vkoJ=ySO0&sr>J98`5r2bL&Ue`aoc_V3w}xz z{q=*G2GrU2QGW9xk_dAwTSCE`I0bEwdwl;1a|yE2P?+AZ>={JS>BC9>@hnp|8w>rM zc6ar3LT=|9dklbo%2CdLwuVOwP<)tmU;WjQo=1zxVGk64KdO>54r|eoliw+FcMy>u zj7k7pGfywZ1-onWoC-T3qQ2T=mO%t z)MfQBY|YzNKZ8QtdL@3AS>}j+D5=Khp#S_0b;3>E6rf&*lg*OhtkKz#fa5h`1RHxE zdE3w}v9~EtXspL6f94PC7;0D?nshvE^eRfiG+&@E^!pE(URp?fq3J_ns&;gCB}(1Pq&Xg7O>YxKwV;KKJ$$H5%>(4-Ag0XyWxocqw~L5cVH zhRjgFA3t~9xd4KF-BAWAY5+<#?=5`)TrJ=gb$dWD)mB+lh_R{w+ys2qgNYfjYUq(jqjP$W@9w+t_gbkAesitu6_G z$UreynAP$CF7Bx+p=L^NVwi;tHvIU&--NjC_^%wzbb4!^i~Vtz*24Vu;qN4gKj5u0 zs(=&|5F67C#H@Qo zXHAM3h4(AlpOk>>6S=Wa0riOs&o51Sm|h|gW*1f$>hf5A*QAtzJcSI#DXFm8t1cLq zaG8gvQF8b(HvDGM%;z1MehC*yH9beGdqDaea-Ux6B?QCGOF6o2A0))<&E86DY6$2W zXt(B(7D*ALIrF|&SoiMzm>^!NwuOai{E_)p`@%XWMq(4@{H}ON!}#14Ex-2_vF7f6 zF8;2aq-wwM!qi8+Sluw`t%>Z*8>FX6*N)HA5y%WEG^iGWsC2JiObD%<<@(4UEe9aCYD`}eij)m}C=m4hPsfl;RI_m@A& z=)t_gIZ;dk z=hr=CJeV@fHML68EP@4j@Ff3PkW!sVt6AV|wdX+9;!>BtfP{E*J*$EIe2Umg%kVpj z;I*DyvfCJVPM`HmkFP74$ET5DPD6@8fy*6|B2Nr#zlL?`SA+Fg!#I(1AqDu_FrBHX z;ku{Is&QNRZl?DQpY3KX`^p{&4FJy_rnM@I3qW>rB2Cu;#XFY2^nlU@C}*9%)r~K! zDSiuG^|{4RBE2tE1Me~HM)d$LC)j?2|>9$5i@r!;5G!8cJNcGi!m@Y$}b zjb+L)N1!gIud;d2XJSgm?+zectnheJN=xwp|BbmET}aqe?%yCdVZXyFZo27aB=7za zie5o!$jUpy+a#Ga)SA-;uKf+2jro-J+~@s>Y9ZG(Kf}%nW6C^M{GtV^%%5y5#M-tw zi4%%TjK$-)rXp1OnJjSBjSWOeiALS^OAH!=`sVk7o0u6L!xpOP4-f!8nG1s{W0TH} zHeo;sHnuENA*u{}Wxbe(V(Bw;TLM4hjxY2W| zC8gTu23?q4VE_tstY9C&B9_W6!Cp}Q$YLP#c#<)jLM~lW2@`n^B0(A1PU0mIZHDfr z{+a0Aiio&W(QIt>FgU zcp-MtJ%~rSgZSoVt$O=HSD!3$6%Jh5uW-W!w_^LD+qh@0T5$kXPDOeL@3mi~4HW3( zeR+;IF-m7SHo|DI*#}{s<))aAa4XdYV1%PGkzXnD+)gTPgl&u?iDh&X8>u{Jdx)~( zn=wKtujAlwu>`~z7;Ta++{;`W{Dm?17D>xp?H{i#Zj}jde@I(mMBxeHQCg;jCMtfa zs=Opm__D~D+U)@NyI)JK_>)pi^L$$UIkSC2&v0VE7YeO0L*~KlGtfA+2hAK%ZbU`7Vr5{o_b3M{vGQWSNPw8;&5M0TOS$0mljdf4wwY{AV}clezuzA*4zi{jH~D|+~=zfzq@RhTr0+Slvb2aQ6cS$5Fmdaxhv#i!Q4*zNOti$uXw_E+!> zT@~c<=g=e|qBWg?b%Q7`?JZqb)vJH^|$(XR@b|Ph@ zn%uUl&E#ruXGzdB&>zDblrnvcDRO4N(#!fw&X=Y}jIApfHrYG}VWlAX+2d)=Id-|f z)V^Y|uJ&<(3IY5VE$JjiCcODq(3tkN;HQPsK5Y{Ktil(w6nq9pz(%!S+&>>0RZST7 zvgyDT6SZQ&=dmjGGg6U;0S@v=>~m8K#5Et}jH^dpR>92c z1jJe2Skj-wA&VgWG2K6+auLdH@;9_culQdpD2h93&o-!mc`5C|va`QIOa;O|M~)+d z+H#`+6@HRL_;Ne8addFVrZ!O&Ez#L#@6m0Ezdvd+5jF`w%DV)9hHq+E<{wW$CsnZK zARVQrNPla)t&dL0n7m4m{uU0N5q0Rt-}6Pl3_IR`1NGJXVtb}8H22+zo46>mrJiF!I{$Pjp>dMkKP^nC@(J00v`7HmEp)rf{7M$_O_^o4k~9x@aGp ztqjI1^%bJd1%vopN~|B{!0|fDy#PN*gw`9nmob5_7M(CRY-E>>M5rH^%E4e$)m8s-I#pIW)T{ohvpgU~uWVxoGZ? zo!CDI5pg%f6Bb5<;+KmIvYO`l|JEBrrNN{vN4Q?)r$LmxrKI+vt}v6=#B1iG{{h$Z z0m<<-rc?qCK-wF`0rW9MN^3#$WG!K-0?>@&JDXsa=s~g%IHSnw%P9yJRGQ+!u`A-0vf zfYr1`6Ju0Gmwv2yRA2YkBtq>0c;`)3RL#K{W)6!mOv%B`<;-!o*O*%KQpo4kJ>E?KqT?BApE7Q|?DIpABip-_Jn9Fno#FV(-M zM^^mjJ7}|lmfi;Z8hv-euM~Vd{S>Fw_kMTQRw6myuBE-!J{vh*&jG3 z66Pe?F@p_@;rehHv*P6y7haB_;$0;-2~IDbrFU2kM3uN!bl2bILgVEz&H(E@Xj3#z z3*!oo7cnKQF+`UI&6AEj%0e*L8nKRrqrGAPkRUl_zvT=^Z`qc=;S{_v z;V3$}$&WlPO2Yv?z-CE#SHx^pFiZflkdUU+xjzE9Xa~h@`-nf?Y4ShKUkOcF-E_d$ zGL|4qYBa$&JJ0LYzXzDoEdLLG$57UPfJpzle+WqJU)5p_oN3#cxoqpN*HV@(rL3Dc z^wZn;s9BKVd_kSWoa$65I^>{=C-|2_{v%#7#k6epkqi$%9!ZVNi1x!%mA(!E0fQ49FX6M7zm>?5 z)wSlf{#<9kPDUxu3|GmH(eY4!%u6J_oloyxy%Tpx{jl>bS~F`;DcqvR&Z_uYx$mg> z4H!ZDoL!dnXVt7`PGoIEsN;0eFCkxGa(76LSasgWiHuAaQMz1Ws-zkg5K@hwR^2D5 zIz1<2NwyPc?rp2lGKBdWdBt>Uq6`Rt5!fuo25H_D<7<(kbWW>*Vew~w;r%H7Hd}u@ z6{Gx)8<$oDoDaS;pxh9$v^V+@#G3MyhMA|Hk?z1p32)U{dlGg#w)NFV8kJ96h<6`Q zWU@U{1r7mP*$C*A^>nz0r3T(R*tN(uMs$oQri5lww_qQc>J=m!*A00%!1PLtMgpVD z5H0fkr1kPDXJ?O2=b|8g9iUj;kvOqC$_h^QwN8=U>bCcRGd&KhOPP0-if?^h&Nn${ z=n@*7`>uM+p3pML6@OD_qK}8-eim)Io&M&CN|0Kl1_nJB>H%h!bmU#KGLYt-DIsRk=w30Gz=;1ftS<_glWM(jQ&1w$^2?z*rJ~YYviL)Nx%)*nC4z zCFh~{^=5~u+`kGaaqz>acYoLePY@7vIB`K83HLT-MxsVx#px;yCzty29Idv*VRW0% z;A3I5vVev^oCptpLhGh}(-@H1>i&QLIE7w}oWm*t6G~4Jc_(xv+f6bPe4P@>P5K8k z8p>?V6B_$zt7^n?ujS7e3}>@~+pJzMUa7Rh+W(X>N@Eu!Y*7iTQVuY!opQO1r!B3Z z#mMx%KAnhr-O~xL+6j%1Mf~A<5&_+N z`SZp4I3qQ4TO435;{Tcxfz2n>YhlkvI8|4x9XIks|CH^DUNM`k4m-{}0-G_r!8qKl zc>P+0yWs$T6RkCFnekL&$G2?g6FDUSPW!NjE(V7l)b5C@ogaj9FPsft&pfsZ7T;|? zpch?9Eb)Ywe>E7&viodC^wKeI>E7Ag(s2%H=SD9@3XNG7onNH+PoRB8HOi`BJ(~cq z0lI~(m<*Z2+X@KRKnlT~1b^=qMDe()LdArpK4zkS>B={0;g>tgS%xp192^Oru50&v z_D55K?K(4Gk5W3ung(ias@7<^mVhEzK3#kh(zY#Ntu8sa?u!fcg#N{G3>YNhJ$#uS zY9!FC&lI2rG^&2LaYqa%6LDiFy{o_!E7!p5P_r80i0X(K<2h1 z%VWNO;M4jGplfqPLQo0z0F@8%A^WZ|T1`RZok-_nV=v8urV8@9YT#T3+f5>O<`2 zMmQtSkpg~J_cTDU%`6j?P{Z!noo+{giEq&>7+0!n>uN-<>1QtuRj9 zfB}cX&5gLa(sy)3P`A7PeCYj`#ghEl#FKka<)##XCS!yCJFMc+sjtRD*a2@tUz$yS zA;H`hZaF7__3|EJh97pl1-`Kgo`=$|Rx5(6%whB)pC0gKPX*SQ3qbR=%FE@9EztD< z@Tm!ay;Wdd3DCq>7qy; zr*@8lw3$TQkBNv8sCO}g1@8#eNb{+GJi3u3KdFS;fqgQN6Z0EvW5(29A!Sa%|Cq_w zW({*$M%_hyRz}ax5ZPeOr^@y%y{qCnvs-p_?ecZ!pUrOk1Dbe9RR27ug@V6AfyT{& z9g2-PU*1=lCE)ym8v}N(rr}WNfSoQEB>^>$Uyh=>)Qv)9_TCrNt9=g#(s=NHMwQV8 zXq;{JsfA858OIFuXc}0xh;F+$ukoEijF$)w!S*r=o{l?A)lMp{`V#XL@2JMyE`H8_ zCmp9W>Ul!x6T8@Al(*_c1j6o6F?zo(s6d8TAyx;31jxlgT7y~Qd;9*+Kjz~e$X2(w zwPb+qcJ*zM1H5bd_Z4;`tz5K!^=22{U?c?gffBiOOBNU~&<$6}X`BIh2>(k6eyk26 zf_hjd^lOFbpQw(g%5`3yGaxfVSuh%_}S>Fxs!EylxGet`&-h^7&zg+c|&z z)2|$t)DSVDNS5<6FvXvLsE8kK`y(A;-i`wb!?jFW35Jm(-MX!ZCWYzKDUq>ZZuDf9 zNWv+TqIT8jT9)qrla(9+BCc$UNoPUYFJpZqG33YxLIr( zy8lWfPYv+}ctPLKtz-}eWGfi}y`kf?2uAL#D*}JEJr}y?#nnYKQ2_IB&mb;x=@~~>&Q5*6TXf}(Sy1kaKTaD zz($?_0j=mt@_0d>U`6hwjKWYU-{s81u{bndDQm9>rcmtn1L$zSP>DOtf0L%uou~2~ zwcaAzuY4&=3_H9Y%Y;3n>shfv48Tt_9O{|h!Qz5em~6IxHH0Y%Zp%>x7W-P_JAE*O zQNCr|e1yJ2ek`1*8c`nS#0&b1s<9!mW_fKdxAh_fk928ko5>>-8D{1PPm-HnLV~Xv zY@5jr?LdmEq86ycs%zxYbXPNh%(2`%W>3vm$4JJ_^haZf43pzA#|SbYN+BCWar1N@ z0Io$}Q`?Atqk10=`RGhB-6sx3`c7_TmI~YxEvj~=MQEO5zZn*NcfHjPA+EpE6p1SPQspf39vXMD*#7_btk#UQ>MPBIlV#QA4q=^ZgRPi*C*&J6$ z&Cq2E=f)DpB4JfMGM7^z(v$w-M?nRrQ>yVjF^5{o3>Q~TCCi(iLk^qgG-kGBHFxCE zEG6Ha8l-zt{iG5eapVKX;U)})CaE&jXq48H+iVV1Os|E_;xy(Cpt>&C>0|D;)mr5{{M=ZhPD~# zJhdMVV8Ym0Rjot7;XNA5GyhdS1O5ajKs>Gva2nO+B?@>poVDU^D9`(I-TJvHPt)m0 zI5Kf3e{a-+Ko{Yd%J(a&7s_aB*^JtMdBrS%oY+>sypPq_Ywtm8N zT^wOH68xLT05Zp10O&_J>^5;Vyx2dfTYX@JDe8%P8F?_dGFLNvq1X|3W~CJZDt z=zNlaLAg`^k2KfF(_j`Y$3t~{_x`q5DWxgQbgucv$Oz*o9VUs{8Jm{fm>3qR|^0ka>k3D9- zKU}XJZ84XOQ1FyrlOZRon1H!LUyCgR_pbpf4!6QS+kJK~Q2i5t;mGk#$yper;iZIi ziBH2m_Bia`gCerV57e?>(;7`>SGi+&#zulF3~1Gpo$NO-n+Hi zx*w(6c)=0ZQlIh_0%KHvzX}`%suJYy9`>5Gdu&{QJ8mN1_J&3OQ}A`^EBfGtmdZfspa$iPD{b%aBDCQMUs&iaW_N-=C!2bqrfa|`Pq=cT_ z#;l_EEtZIQAQ5qY5|KRj#TW}D&cUi7&(P}BWb*m=hlc=o6iM@}E_AiSe2FUn$9uIE zC|QC1`kgNBtBlHEsD8~&cVi0V=50I#S7L0}p)`SNF0>TxjbZg0TebTGZ1X35gw&iI zX*aw16;usD6l-?|H=ww*yv;?oT%GYpIITD(a^S*&O+;6J6zMvn*fb&yXP)m+Jd>B}}jjPX|i2(`Tc8*!_H+Sw3%?f|DWqJ?3!^wUml`z+FyCKgikY zzp4JJ%6DmhQkZQCO}Fec`4kbs7xNTJ>dGAf82FfRq%LyOHol&q0=T4_ZTO@kFe zLm;rGyAE=0=70w0Gv}VT>|j@-KpQ7e!ns;M&9;rdTl^G9nelJk@jzzdnX8`Ex7&0( zLCh~@3A+t>=Q#Pf)0WlpTEfNUG9;i2rXSh2&ftP_3zj#d%?=RyU*6vflec~Lqp7Bz^ zm}}sO_5Qb?ZgFd&E{}?~Y(e~sJnegEvJH%-79C)lH3;vDP@=uY;XB06H-SFMl-Op4Ym|z=1#TkS}YZ*YLaM@nCqp z{DyN?YuyEOA6v&r^ENVR0vvt;)geHCK#1)VMe``T4j3>KiBcM(P{ba;RH<2bEan+@ z1`x?u_!mBA;0ReQiK$J)jtbO!UB_H|e}ksTzHZD7nNwn<(SpYp95{9c68zKOjr%_K zqyaqe^Kn)HIg%?7$W)->0H~0wN6O z64WkX)GRj#umea1S2G7#FW^IhikKkb(~V+`d?dJtR=NH{-1 zZ_;=wgX4euIf0e8KqzYMn-m?u%*>Pgga&y9dU~7)2;zmqJzmKwS2+wjf zw(V=`Z&SHFmQd*Nh+A~jsWGyDW=;jo9H^#}#ZLEhXx31vnqxmPnolJV&>F~ET`h4UJpz>sr2twNjD%3GB_(_+ zX6re<-_GEkg6oNhuxG_16)NB`FSE5(Zi1@rXJlc@w5O_t`q3rQSeILWUKbq29`vP7 zm;P}HPl$qK${rQiG_F1hr&2yf6vw6#s_qH1AAorhBWToj$HR$?UsA$kG!YL)c$Ef7 z)pC64NMF21(TD8it6nCC_DO*1&X{`mk(=`-zw#1@|adoc(@v zaJSQCC!fj(rWzcA)&jnN85nWN62ty7v(?2SRn0ozbVH+fx-q^yl%O@Yv*QYbpzo~W zGIsCM%zDOF85|) z;TtL#pyuMT%jDU(;N?^2h<(ZH#m$syn^x0w;RKIekxy}d#@vUISWWS&r_R~!m%J^E zM51%=hvuB5zGMqNW5(;0qNwD-%%fK7l&lv!{e(ejB-v&S#gWxh=X|Epnmb+W#~k&Y z1Z%d5S9KcCog?}s&vc_s?2iOqedYmQH+RkeFS(^6fXe3aa{<9&T1X3y5&qeC1(-|% zcVaKW?toN(NpQLlrwtSWkvgIOox=+JBxW-qofb^Ka$74LDjCQWcB6sjWO##`!jMDo z3b;)nc#33w0&L>+bPA9FfOC$NQB7JPnV1X4b23nTY&$gq?HI|K3rFb`@x%;-gBYq= z^~k0FcHf>{JG|tO?BZW8gQYa?OKLyQd?MihRgoxvEW*4YEG2@?oPk6_F(tr5wp<}s z7=Qa{Nh>-mKal|50-PRsjUSfxTQEzNX+*)^wLhjW1A@Mh{7?@=xzKjI0%-KKdCuE3 z)*{!OUq+3qXSIWKAQ#*}D{Z#{rnf?Yy!Hu|xvY@(i@hqHQ~BXB@} zRS#w2R;GT1fB6ZwD`Qzviaegszf?L8gQhgD~_e1P^wI+FYS%GpW?YYsiLE~s%3oCTjw zCm%;;^aoq{O-;i?>;(IRSb!1?M8bFP;O2ia8Obh0`%+~&e8EEID@+BEo~8+z@S;YY8cWovz#KaC zb)7EC5Rg8Pz|c{AqW+a_8LS##d&qgf6bo(}7+-mv`D zFs@5L+Z_^!aeLt?VW5-s8rk$cDt|ZaC&1@L<|~kv8$t7bf;9?&m*tKJ6%mTmQ_2~c z8353S70Me_ejR|@sZa<{-EE77fhrx?ya;oOEf}2>`uYg&7qvC(r-A^0QNT?_2Ld=V zi?ss*e@bgc9}W{wyuV3M2evqWvS4oIb5!=gK|h?xb6_(E3OtxL{Gs9blFQCW8BpXK z1WgX>9Ht>nDds5jlV60v)RUwFV#E9y*$|t2`vqCUbPg5wI|8Qvl7o?B4HQ!*s0TJH zJ4A#Z!f60fwR&IYYfL1P8({_Zz*@urZ4@TM?V_lVGT_c{4yYGCVq)Zfg>AtKI?qBp z*UN785z--tGEM;T;F4WY7Ad|q$XC@KvN;9q4s(Zknf#eT&VVs++jbr!98&0N9tkOR z3d;}#2AB*yQSva-;@6y6Y#*uoOzFTevxU@PaGTDVQSar?Z(X%Q^n(djz9gfcz_boL zv2U_gj76^tI^&D3FSv<+=MvdGqlQg!I<1+Su&iLB9JRo<*2fCsTH^fEZ~;yD=?&IY z3`}@DmRgtUm9Csc21sLQc%ou$hqD2Q$4GGio%r^VxL+3R59C`T*5Sybqo@u^U51zc z*y%oG04U0z;qX^{*WrXU`$@-mh=|d@ku^rQl^EZ(iX+BlG{onBB{#uwjT8%juQ3q- z{&#Vt{Ao;gI3WuKf#G)?OemoAuCY0thMScbPchLg){m(*wzGvhj+#@CxeIg}7bzL) zrF`}c2Uq>~8pX$=5&h};$Q9u*r-DPOJ%1q3Bn8$`W#^Y)Uo#s4x!6-$f~b)XFQnyo za@$fRr!NxcGiP{z1@Fjo;hUOLbKUo)o3@d-x}vGXrs;~0-sikG($*%V79S@0i>`+bi7tOZ1sR!4*D&7y}bhX2Rj`~uC3eD!B&OM z-5LS>nUQVD_r3e}x zm_Tnoa2(P)40{Y{A&%7_0QawJwzZmr;7v#aLbJpVX>-P?0=#_g@x3RX$NqZd)J4UV zx`PNfT(_{Rn!u#HE#RL@P0}Yu z;0)=@(A7&&hv)k}wo1N3s62Z_r6-B}qxvf+JseJHK(q(g0rhM0L5S#SJYYgy$n1U=Xmq^XI^&HW`Y;%P+$t^z3b63>@T8tHX2k4YroA zp~0ZM!qexM7ilJ+dzB(l2Jn1FklT~-ru}&(uk3U(6e+rXDLpk8t~k-yV;hkqXl}m9 zzATle5B~PU_MR!p@gXqgAH1SCs!A*rrkrbE+fCMpX;BJI}mQtc9?>m&-gT3}O!zt1Og$Vt_vPivy`lD<4 zkvPh4r|Vp2QCrE~lc|ynM}2v_2uZ5SLZzk=V!j3)FtJI)N73a= zKFh!3DWMX>AyvPfYra2~ut_f&Y|$uv^T*W~WzRWJfz^+KayP!#5MKUIgJFLAJA}oBTo@tp^A;E z%f*-|B2a$uawZ#`SX96%-q8`!OHCa7SMu9%gm(jp7OJSaL&*vk#&;AyiEdo0p)lIR za5!z)R%wO#L0hG?8nhxyOvh0};xuKznpLBVN_}=d)!Fh9zDYPuRnpjh9O1C$xX48E zxjEl~(FRbn3cyqFHpR(AQTBF=C|(cTvmP&LOe$9Tc7P8jr4`rj6I4`qWbqe&zm)XV zdcT=%64oacz^e1o@Sk;8NkE`OPqstq$SyaQ;H*n`h5cz;dx5lhJ?W>5W;8;x9FlAz z!p+XCDJ{IyWw%z3{|bA5`6#f1EMRimQ_R-3AWr&No3Yl%qibpT!S&S5=D#0y6fXfY zPIZh_-*_}86RZ9I{QqRxw*dRmmvDkU2|bjl`q{>BrJ25FB53$I;&ACShG=o6BUlf)Wa z$wVi2uDT_#alMQ|1Ri?S`Fc{PNBYa$>7h&x&dTQhX|b;-(iYeO*P{g5UncR$}BIayK)l}nf;>mXB z3|5-3X%cq2V<-_`(?NS*Zam5!IYyDQj+=-Qr`bW;>B1TM2UTiWl@3uFmI$4Y)AZic z0>v8QZ?yKJRq zH7H+4s?!QY*b1Hzxd++PF=W6@#rIMce@X<=mzLbPd?;!~*9?&+(LLhjWe^Y0CF02L zmu}kkIHJ{?s2BQd(r%bZ6d(qBfLEr2aACnE8cKnG63c3^cG$Px1F*P&;c36_>XU{X zjou6>U>@>P-UQKsRB2-;4@FNj_hJvS$`^}_GjI*~6xjp74G|_JjpPB_;WNP61Z|x9 zA*bx--C=W&SNt9H2hsw(L#h|+yksAvScOvIw-mEwM*xxSnA?H<$kDGSxcHuq8rOI1 ziNAP%+M&t$x*(o0L+TmWJ%oFKl58m723#lfGbZd5vB2OXzHU!D%IQuq2ym8y<)&5! z^)Im$p152P{4#;h5r9tJ%@Q37h=kh?rF|6mltmd$uY?j69f{P@6PBe(u|H9AVSmLX z-!2Ix6S;4|Vo4F&eBM5-PLo$UJMQ4zSR%83y^}F{W9Lh@A~Iye%eY?&y(#y=( zU|VrxoXs3KE3afR`Ek8HP)(^<(>r$Q?|~&p%@I6pkB z3MAF6#)2g10Nhv=^tk=42*P{i1V#vM5l{o+YY-_AEKJ>n&i?9bmpf9t2*Fzx-tVAP zFhdvD@iNN=xaT_us?2rh>WX$21|g?%kxZ(s}Fgugrw}Ws*-~q3IDkV)RjGo zJ~h>bSBOg=_t@OuH~DAai9R{26k8qkUJz;mh?FoP1it{0FPatQY)idoE~W&GuOvi8 zWCEHa<^MlTN$nJ9^7!weH-gSz9_{ByrPpZ2CvA6kG+-q(-adBf3L0~g9?r&bh)!bZ3 z`=VrU&E^YGC{Z01OrzNWSM&EVJuAvs**T4MF|K8gj`Fp2&9WSo|3<$AVLgHmBgqTnxP`22(JEudB z(Q9@1zPHZ~gX_UlK)fe^`rSP|&)$xbw#sVqBX@fKeC=J~1ODp1?-1IeR*Z`VHkGZi zU1aw#=8m8t_P}YFXP$bI4#Maw+UMJs@r1htZlpy~%sXbmIb&QsupPZb;Yb0hYp!2Q zf*T0du)|>RwAr}1MmJZ|&E<$qx$RV20E_bp#wSz{M)&|6iG;6z(t!saFIlWDUe(|z zLrI-&@}ZFi_R;Wl1OT)KK6MwFl&Fd+%Tp4-($0ZNOGQNUOurHnx6cO4O*n2UR;~US z1?n7tp)v*JJR#&kjMec1qp3tTyVH|lv;I`|qS@v%Zn7OIL=?rI9~nyN2Ny}{2NXVO zuqOQP7V0RmXKT=ZDB=x=l}eWd2Ju5jLNhfKse5H0r;7m)m4f#~8__FM$VWetP7^&{ zn#M9P-7{==D)|97y>t0{UnjY^C`YATFq}rSVK9|}}>=~Rug+d<$&zMz0tV-Z;` z1&nUqN;|2pPKm{Q0Qf85n?RC6pk&II(oxNLB9-oc)@qnOd2-9a&qx1<*&l#nVd_kxv zaKMg7GDqYNxG)7S3LI3t_n2f8!CK-*1TZC$kwO2rs9{52phP&k!&wA~DGuu}tr_yT zw6=W@brltVfSE9V^aDM9!1*Gr=5o?`E3mOpL|l>@-;qa%Sx4xs+k&B#fSYgtJP}e> z<+&Hpmp89pb}$#&7rHM?&Me1k|K{~=^qGLoh~hBOUCA9%DM2Xv-xtpWQX{;Y#!rq7 z2((tkuo9S`YmZl!{i!SDYJ5fA5rxUKEw)=zU8D9-#;G#$;GB$`MRYbAKoEs*w_fl=jw$0(}y8%FSQ@}@ag6o)D{+u zyF=-Jf!55$Bs4cXHcG6S^vyFIjpf&lxB#avuCjZSsxvCAv63Fh-_HQ9K;jHwDt53< zQD))V@Eoi|<%PW=P;gv4t_o0#xY|x!0*oFF5#jk3_5_`uTW|rCZQ)lx>^s{XTNT;2 z1tDJR?ZJ^Fa7ayLa^>Bs_?B7mtOm@*5{6TMrt8b5s3bLX)SACJQ)t?uvr@i*bMs1K z!Q8E={D7u4n`fTvxoBn6tl?!H9lVinfp-NsMfipKs1N{+PXx?= znha!_=beYl7q#8&Kqj@OaybI$u|&d&9z%X|VCBK0dr#|BMsv-Y(MTf3+)+^(*9B6b z`2R3>X5DS%$d~^re44-NOsR{jmNQSb%ZsY*vfA?WoOz@qN@AIdniOrRKK=Y6fZPy3 zE|feoFLladCNdI00)dDd_hyt47Z1XJ*1bLa13q5p8zl?|E9`Rin|>lavdYNNz@y__ ze2vib4le$<`0eZ4KYwvP#8yfNSfJ2n*mB`~^?eNtAr`AoJ&YNbeq8ADlwTwH{n;q} zPk#HgTQvo_w_vSTGPIO;6p0&$NQa_srNsMDyWhsZ5}EH)ZlihboY)#6=1vuV7KwcX z;z`fQu|j~8e_p&g`@PXAP$m=c9ID$z)|UOHXf|+tnsAyKk&7j~i@Zy=o3^MC3NGEx zs!0S9XnR=ee(G0_U{v^2!eXJs7c#au-blZcT%y{!SHF2hP&^G2llNG&rg#S5kT#=^ zrk@jdWCJpjcTbRV>>KNhQXY+eA|NU|`tVdapj0Oqwf6)@7NHv%-uw|F5`8N?-@*po z1+|?&&SshI8?`CA>Nb;7$KGR`s4vW6vC6??onYSOyS&crGGW2cDm4188d}cjH|r%a zW6yBYJNPVcdE?S-*`!5H0;fq}bCSP>T$Gc6($-pT{>f zBC|MSjO|`(*oxJsT!}HhZ?JHk08Ry;BzM zoORH5TcwtZ+xb4I&1j8JB2muZB{S<-f#q7>J&5^Lw)QcB4tC1`OsLpKcuXoZK~3C3G$#ahZNy{wFq4WPTekdPz>7Ahy# zI6L%?1no1r^@ID_^qYi+u^)u(e_K5KkKSm~@2$WO{`S%A*3(E6)zPd(QY&`ECm|YU zu}LUnxv%|ylYY|vtUNlhgj6-F90sJKc4ZvFPz$S->{b7CVjZc-vvbfz_}DTUqtz1! z<4DLS^29BL-%J#Z>bFG8su_z;f3eV)m zGK3VoxmdsRryfp0%=N%PYqGfPz{YZ#Xo?s&Dx8@P2m4CO)$YesT+%XCzoD0QEdeKg zH`VL&h3w3VL?>Pz)ez&pl8OObiWjCbCb~RlpETydGNr0^XCHx|`kZ`(x3Ugcl3r_M zg`O3BAd>kJQxe9XSkjp{{*J?+U}=*v#(n#JwjlE`VO!gxVW|a3IgGyinyb+v_{OK* z%3Y>}Sg@89N!sxJuWiHW)jZO)C|?PGe{d__Hh33I^3=WA(a(CbO2a?(%_3vwqzSXx zKa1&vl6Tor>xM$GBftUF0({SYpP9~~#9<=(p7B-^lYMe(4w}EuGNl(lt$2S4cM(0= z@E3n)TYQf@L5*=JR*lNufzUi?vHry|LgH9b6ObReQ#EHO9(`%wu;{O@+olu?Du#_DQPVJtXe&fANNDg1t3lVRq zy$Kb5&CV}xa@jQ#H+=bjx+gckv#B4gd$Qw%uFS3Ezw_8LzHAiblwUiRN^I- zOZT$O1U73X9UG;8kADg9Q)Xbb8nAH&sxFud>c?8x>jmt&BHgtvGgUv{c@=NR516mQ z?n-G>=mpl;>5VXSnp0uwwje54Y9qcCjiDzo$F6eYDafk?Alg7|!^Zc5(8g^aP@o?F zrGIJ*1}n2x_>v&QA|XkUf-rN~fK=p?pmS@bMNG8pEjXipCul5n_9!2=hX>vYtN4Lq zxlC|l3Pve;ubcpzC^F;SG=UN({N*hLwvIR`OUK7guiZGWGJF@dYUPWNLI??lCooBj z;=tDIy}gCi5?Mi!4k&;(k_y#eg~s;m*E=iSRdw8+!Mk~E#osE{xuy@-H;2?SBW>@Q z;}hiqlVh8IUU&f1$%)fEebssH{dDdrZm96(Rz461fOY&lOB`@@|I_h~nV+Zva<~DXtWWqyy>Oc@> zDh=VL0Q&575yGijIUHeaaX+)Y_D=svMgZdPEA14-@?|@mh~S{#djb;aPGs<+M(F19 z$Jl+Z)nh2$m$Ol}j|qR#f{6PhHj7dJBsz#q-3sfFJV#h%+CM3>I16*_4C2G(jJ}@= zMybB!P}I0CwaiZ>1Kjqm%WPQH0>6N8-|*!q^Gz_%n=2Tzt-Wkod=+sH9*Heg91IXg zFi1!*1#CSnAVoH){$3=IMS95f5Fk>)a2)EtaMu&V+?Z+59o`xZL)Bx_e9m6=nMY%* zuW78OK=XEmduHR*Z@y(_c{S#0mGMBI{_|#o5Qb` zN!|_WpdW9t9O+RZS}PGBe{*zcIl;7+}jRE5+QTrSpEh`ZJTWEJw^FZ3PbnoC4fCN{#?#spk(k+5Ds zsYkx?PzazQ-ke4<=6++DSV`QD&k_7q<3r50%tOADsGR~l7T!c*Zj}IkZ`d0E;Z%`B zP)PF|oPS4E31f+A*eW7?Fj?wJmR>e7$0#fN7g`(-W{h1rak{wN ziF{GuA#X(tO~t4Ak#O5|wMA7vqO-ebl;%l_@MH#v92t~n^$&6v-%gjy=^>{8G?$+A z#S(V$P^lY$WKzNruyJUm?@8tM-7nYmTWaSnOfG=#u5&@p~vJPVD*bgT7HV z#0<|AA2#yoiaxO`n1Fh3C9hwWCCdKBOI78KoFB&3=9h}_k;too+(I2q8jr64{jsfh z$*q4%%*Ny_Y4<+Gc*kuT9NP@zPwj(=tu>?%SCgy)w8g@&FsYv!cl5xmcjBcaF-PE*8ZGo*;^UlGsg=A$Rzfk%f1@*>Gl;8aLSmIkhCd z&ZA+(ZGnXvToZ|9nWU;+$+RnTb7moz5AWWR0`Ui7LPP6+zn^YNp4#Xd4n?9(M?*Z2 zsp9uK(ekM-{car>X}uOPgCi>v{bBYfVYN84%YA$Cu!K$*y|+cI!lutZAZ`g{@A>b(Sks}6CB+S;dhwEy1LU!og0XoRc3#5J_6_(0!q7%*vGAVycen!=dF1J3 z>MH5Xpyk9KcVc-7Kb-xWY#0F@RkCqPe&OBjn)2d*dQrJv>NngbBwzLNNqF6}_*H&a zLMeH8VmBBc=owkIN3jHv7x^@WE?1dUuX4@4g7k6fX-3uI$*g&`?^If*HYybDId;asg#h!Lwpj&><%f`R2F|0V|+bJco zmTSm=6Br}_m`FDf!p1XEl}g}G1%XKK;CZzXA3lG2b@)1N;Sl(3R|_pq=Zjc)_9bbe z^~Zphs1s4dKFx9>5^dDc62b{Rr^if2?GO&4Yl)_cF0ZO(R4)}&kdrYGhowpJd^oTQ zw`W;#@;&5HTGytazWenf#f#*hIW=GR&ffihd8lL=W^R@b5Z}?9cHC+i9eT4#gNYUX zX=l>M!$Cih5T;QR?QGrX@P1s=u0hSTZdX2=w7q5mwQYBpZqvk!TebQ1&v%Kj_M6#E58&5z(A<=IsT^R**ZS4J7LsLf}BDtWvq2PKjL$In_sWU#FgZ3qnVV4 z1_58*#JrksdLQLqz-K11zQ+r`_**4*uM?YC>tt<ax1)i;L=r&0U5KHH0K|9#^YEY!mclwMmp8=xG#X2Qc0;_&1Ob&UYSFCT zf4uovsRv91-y-_E)xKK)z-3Oz`n4$q(Dx{JeqDnZ9>%7*&pcqu*Mq(k$~;n2jlms3 zgn~JN|(X_0WshX4T^yeg!o%ffn$Ar36guE*J7y^R?>~={$;>vv)OBKJ-;D1MdmlR2;y4qf0na^ zN%}~)q;xZ*lEQ3ZVEo3!A~K9@X%AO-x=)B+>QnEA z#4lS6WH;oKao~XN=4qHq@#y%&c5WrstG76pNdV~8)~g#$;vQ+f&6zra7xv|SM`k4c z5V~kla|0FRGz8O>cFW1_1DHU4*e{yA}{=28q zY+OS}$ClORkAlaSSlVuJvtB(d0Mbnhj=kEAy>vgemLqND#uA%lgk1WMO!Nv^tZKr^ zu9zpu4p;_m*ZkY-(-WL8mBBjFo5PhNDaaX!R$qRtncc4Zj^=Z4=*zsNJO9Sg`9~|$pf62sBO8?VEX>!=>_3R4mEyAQxjF@EISG=_kD-`n#U>+EJ z|L3qVjDP>`i&y4rv9=%El<+@SP!3cRf#ExvG~qYyNvtj>_6gbPILY~b6amZYSKJ@i zlH-WIFO#H|mwHx~)_9l+Q=gxv^``ETr!{-!$7XKVM-JQqoeD?1e=E0Z;?o(}677$f zupJd2Qf#YL%=ofeF~(j*;SWXl6=(pgv7+xI8uTzD*`k_K-qe4G!9Jw7Q8Jl7khzd+ z;5Dw{V;1r7{XR|wIkcKz=8!6f7*g>C_SyRW^!H*#N3n|GsXdZ?6oBb|3I=V;+m%=; z(R^am`?gp`j104C){Tf;KYk!p&YI^mQc|4x0 zJe(71W~`~ee`l2qC~xl2#lHn}pVbs3{MZPj#uzVx8!R)TW)QX_KjpF$SajiZAj*IG z68tIQ6dgqtyV(y;Qo?1I2={(0E|@vBW=ybuY~l1xPEE}8qZW3?JyExCC8&h3L73pB z6n7(hyunA)jhBeVUWO=YI2tDOgoXplaQy${3k;4;e`K#bMwN&oHG^m8pH(ylm0nCss81$L z5HM_KsB^Tfb;~a;HYRL9_a}I-lvl*Zv?#=1P9NvcFzPv*Ln>dZIOB7t zlVB{Wy;=gYy9Jwyw30ue(a6cb#=bvI|Kc17u?}Z+r+5VB&9dBwU;b{z)+*axaVJJK z-{&*^eOq@{HH1~YfZV%6nVa3hl^mmZf4w3kRd@J|o41`UZnR?jTB_q04|kXxYrENV z8AbRWKcS&P*$J@;DUc33%uzpj;XtNA=~9V$-VPj^_xn~pnD0-4uzgZpov9Ofi_!u?&FFTwR28%4kL_q+ z!@Y@qioZpvqk0GX8=a~p^yj|_e-mcXN{OB`$ts4iFDZGbP13oGtEc~X7snm6qrt#< zznx4=_F4Ao0~2=B_HiTcDd*DjQBjf|8ksEh)^}{zhBKr;v9dQchKRtbBP5MgDeq%e zeT%t~CVTNIiv(+xn?E|rXYT^VQt|O%=0y+#md`7XE9==akv1HR>|w~8e>S%KQJ7XR zdxY#CQjvBA-R<-$!bQ`aDnyz|Okrr=>`KeqQ?cMY{Vf3WQ zCQjC>GcOfKx?F$P6aGt>dV%bu=&Ig2}!i->KU}@*0<|!w6>G%S5uSJ%C;MP^UVv) z0Bt8_n=M3ZWgA0%JtdLx0_MS$q)jDzFS6aXn3eODQ2I#i10_Aou1*<>X$Vb1(A7l2*o+1OZxHv&=8n_nLq>V02bf`70dB zssbV_}?wZ5LF(aL^= zLqD?;xKNxur;f`m$*I$cf3BmrjfSdXvXs?fjIzwdXW3vlG9KqWWMNMW6kU};ui7*? zhXpBum6ThA8F7`Ny?eTjaCARFGP|{Rz`IP*zNcQUK1hhnf6WtOs)iN%=4u-Z1r)cu zMYB8DAKKixnIFA_$>E2ySFe8Sefn_zzV}6fOJ*g|pQ?7ayPAy{oY>TU#E1|7es$=Z zM5$L;(4bb^SZ9Unf?!^ILu^VZZpd%GNzwSQec^+r5h9pGYub77w(Q%4J)M~0C$^j- z^7P8ovU`1Of9BPZYsGCD;fL7m-Lc%~t5A=qpHVrBS`?E)V~NGI*yTzuvU)tn zGZ@r}T00vk$l^7oO516OGLxNZ{Qc$p`dVWA&q}k`%TsfdnSFD_Q&9!$l(BZb{WQNW z<4Kj_OVU!LaD7oKY%=T3?Q{iS-C_-;n#i574P1dre=?DTa#L7FA4$&$UDkx!?VS@+X?@vTr%PV}Jl zQUJjew^cXH{rhPW;rFfD*IDJ+E>vVEMO?3UfAO$e0`6Y)GR}qzGDkvOC{?a!Xg5Jr z2B&BP{LzUQZA-USJEIld=;+860DtOYr>E1q{tF#qUJY<*57W(2%NHUaS%L9SaPUK} zCi=o4=OKO&+!m0kVND?H6p796_yiQ`umA9uK?0 zJ`cP(jlj<`Tej4~Nvwzo@%hbb&-Rh{@&_jt-79Lqki1ijcMf}Dnd4QcVz{q1@tUX;d`R$(tRUC;RcK%JsZQ@#NF*h0zwgzg6EK4f`?Pk{9-p!=1B zpnA*ZOraM7UPT+`Hdp~J(1N?`eVsi{x4l;t`dN7#;sCc2s!gTE2K~61+(I6GG5ybO zM&1sGPKyay5;A@~YL*=}!c#3je~=hnYAdk4rq%c~olFLiVXr(w&DH)ARe|{ej4aw9 zn7iOj>hSpWrlwkK%sXJRaoJ>K!X8dN;QvMEGuxl@zGk1%nHU+4XS`d@)On`$rUFE* zmsp!{VF|*k4)>}3CLd4fNaImq1vzwla`%siw&&(oYfZFd%Bu*RD?}|se~m*y4Dv%f zeL{s)Gp{$7qUmR;0ifM5EqcmxC%!}XWndye;Mq@Y;4~&S_@^?%Xg0Q&UfkU8=vZaa zGb_1GWhu!FR%j2g&0Xzt!uh{trAJ*f5ptc3?dAp|+GBbdEXNGz7(lbyojZ_PB7MaI z_v+%S&HXnuAZOW@Iwk#Me_LeuXBPu~v0B1QqItUnb!lEJk4@v9@|*%OukG({-DP(H z+AkMLD~|+Us*{hru}$`XgbbITQpD5u!)WGQ6f zfV9p@E0d?N)OE63RlbejK?z4_WI2E_cl)%umec~rW@Q_YI?*3<{6qIoEgqF3D9e>l}y=8N@ya{t6kdVhF2v829rub42X_sHyctRnrBaQgC_$lem% zSPg*WU7R{nS!%&QDJCU7BU|*{d~pqMC%hNg98;T=l{7U+&xaAYXZy_F!O?$Lk?FpC znyGqv+A>hCqODBOJ5reAhws>yYJa8%R9qBU0F-9yo-)_Se|o%j*D(ThS7nfSi$3zt z$xna@5;CDB-6AUC)Ei{+s}68h?i~PN1ZDU*zm{NP^_MX8hy6jcl)s$4fA{+Qa1`8{ zq^2dN%NVVIIciA6v&*T(L`^;kkCR8qX&3he8lf557!QELa(}66cm`#lwz4|FuI)KaL@i{r9%pG1sNUC0%Mven~ZG8Ak65muxlb)J#E@*;NGw9C8KvswGL zG8*r2!9Y-uheDYiLgQ}K5YQ;0%6BI(niXaed|Rw1RqARiPl?^|Q--2UCwL(BN_AUS z6TNfds@{#cu~F?vI`~ZF3hivLIe_;3g6o-iI95b%X2o|OAhIBYM4Fp7rzZ9 znjBikMVrfKj4lX=vRvuO);=N;2IyPL+RvANc~7@OLx}$+Rg4d!Lo8U}g#SOV$+*v# zB2&U7dSpqAQl_f^fx&9`-4ob8c>$ef$&{u=qc*kf zyF+FOsxurVf2@m#`TeibNVV6| ze+7owuy_vOb(VBjLEr504#xJB@cHIuOX`$Rd3lQrhcVbbpONGr+3MTRxLk)CbVl)E zy5l2r$u+uaGd*0pghaL>nQzM8tSdLS26s01&m^K-moje6j?2k$#}~#}TdT^y2D^}m zCI|1EIJlxj8vasm5Air*Uyd1Mo+*pAf4)S1Q=1;Lk%p8-d}8inppy>u8Tw^~FC@P{ ztVqqj^o&}YIlcoCZ!gykEpP~FNGu3%9(SUD$L5y`m{ZZI5DA{195pFz^eL`Tbe zi3ES<*Ro&}^8kD}pO&A{q8CRN*!)?wt6e@Eip{&(4>9sV6hyDqG_UD7vnY{Lf85L; zc_OQi1dvpLMi|wCGmGZER{{Jb4DpBMllw5B#2hG(2*qQlJ50_NB^tL zuu=kdZ0^HQ%@YD1~j*HjUSq9txrqL7URYK58T9y@n{o zq;C}@tdV(|w<`@sgO)S)JwHg?98j1$XkM2D~D*`>a6 zb)_YyyM*_E(tFbol->@{GDfGKkY?^c#f}-Kj4A!1-V9;-YV2(HF;5~vfAkjZ@7JLw zkrscF^klbJXxT-s;r(nkDa_FJmyj6WUtHV-o2_}zXRP0Ys@{6wvae8v>@>N&s-Rgl2 zg@>->G!Y@bX~zy@!`|nIe-|#*^s_py^nez9X2EmkQ@E!erjN5l&b}|H&J_24j>0n^ zYosAXG(9XrJ_Xpr0w=K3llt~Z z9lxJfNWZkNXgsz`i~g4*i{dzUgd_+yNMI0d$;@FVXp=KMg#9C#3}(Hy>T$df%YcP_ zotIfy0d9YN9@yBq2EstJ&XG5jV!Aqde`k3|g?1s-;z(;b}^14Qv-Mte$e|`|rqxH8Zh*0!^ zMn>iOiI(Tm^8J>YPH3m)|3MPW(T*!DYN>>3Uz~r&a(Su6j_t6g+a(ERKrp)m0TsA{ zn%-?h@#I-ISCO9hvQDjj)VTqck8+ub& z>xt9;FtQ;SgEW-EF1iC1J%ieac}-lCd7Xc07@DP_@s4h0qEc;+Vds#Iz{xBLJ|)J_ z;Iqb-?80|)p`Ug6-#~m5X^&$3{Mjh}=m*?;q4MYMOFBeVxMHArVvX)nuaGTZmLUCU z+Gvr(nDotw|D3ZFJWlXq-cdKlV_9R~z5RDW_+vD*`OQ=dzrFkS8<&xcPa@i~U!{MX z>{PI*$ozox0BfNu-mAsmEK$qZrtkp6wj-A?X~f2Oy9wLI6Z^%{1~5YqE-cZN>~q<> zSLqd}<0N$)gnPp$M6bS)Jv>LJR9e5fBfrx^wsX|C$MJInIA>s1Tn?&m(h~FsB#M~T zLh7V9h{r%eM3?G-O1XKmjZaP!fIELyV>=D&4eb@CW8+~43VV`b&03he#YMgBJ6gcE zPcWa@J@I@)Wer6lS+SQ0Cveh{3Kw?z9(j~COOj+#oMU;oRBw}iXC7wn;LT=zw<>1; zuYnu)YvJNm)H!qS@YmiJoe?rHg7W&cr(Wow@Iv|ctsD4DZ7irHNm}+nYy5xPvKM+$ zSn~{@G~T0$y=!u04+?YXJg;x|_0Z32 z-zL#3Bdah|S7Md}w5dDU);}T^M zB$wHMgT3=TV=M6oC9?{CYioZgs2r1D4lM;yiI*GE2mpHUeg0jx5jHcrM{(m z3hyJYy#w7X2Pl>BBYMvS;?!p;V)Qx*82DpjTk-6{$+4Z?xe$pLADXRH!d=NBrGv5= z2UIHuQWfeYet6bFP(-@sinLZ?^5M z_y`WhktGSd9|U5uv+kvBA$Y;k{nZ0dE^AgB7vpwA)T~0YCFQW z)Hr(RZ`hz_8?%~qH|*xbF3Zwe1VTMFYcu;n7}0#(UQL!Y&SkxVxVvwx`q%PFHQua0 z?3~87sN6h-KzZxf1)w}9Y!$^3R|+62SIT1E`4!?z!uZqzNko)Z0LlyDE*cCEg>44i z8UsZM#cNCVC7gejlZJ=AS#MT^{!@_I6Wg;DTQAn%$d&y#{P?uCyzCh~%=*;QMuyf6 z4KKA%uh(6fwQpB`xl6xiadHo!db(Ld^sA*iIf%S=dn`XT2>O*=7qZ)Tgh0d%)pzO4PzIQmz%&RB~M}mMu&-Q?)mk0=XT*vs15SeSm+JWkus< zd;8T{rF7gIi=%9$s;i1Kom9%=@UNN*o0{sGbTw0V4)JP^sb!5@d=&Yn&E5(xHf0%7 zy5*&u;DmQMvHQJpb&FAF6xoh1RmRYPFzCjeGLInlG~dKZeI#5NTp}~=i5i&4l$r-};pRXb zv4G&CsPaKFDAZZzF||?1x*Hqq8;`Biy@!1j?P`Bn0mJdsr#_ls&FgfE<@X zn6j_j5ub)X#?W$$7sxhEMAp_fE+EER%o2C;OT4*jh^z2OCC33LR{R>*a^$yEEW^@Z z1f72n-*8xos(`{gSYduiYwTr_3QOCNl(~BrxKZXu(r%q(>nrGjVwV*L>GockCM-;B zQI}2*`N#bF;Vuz&II(c-pZ7kU$Dw~>b8=r$QCSpXzU9c-xB2yI_LL&x6!{fM1f=eF z83a_j1bh1g8mJ2gepu`i0`DYgf^jpx(gGV!%|TUQ4kQl$wbO)HlnRTs|=5_wh=>jWv*6d4o%mbn~l(Z+U-W z0X7wDyRsIU;CZ>V=Q9@74i}uN_w1kKzsN5MYWm(3Yepx1iW4e*8FFqb_h5kMLCt=nIkoHuOS!uTgAfrAgff7FyZBpVPliBJ{P z#CAf3msx~GU}EVZ2`k4od9cCV9|YADBtzmzAuyBFi)Yic6+K0LBvi%NJ^=Mx>=yizBe z%m`;f*=$%>rhm(pi-tV-IGlgiB6xlv^d8@!a9hq}K5%I{K_<_sIl->!+Qa11-HGvz z)O=KI%eY`vGXdsnQ5AbyqLFvG;7gMb&TRKhtP9((yEa&1#BcMJ_X5puA zSJ~W0B7%$QEl3g0*ri@9lz1EXkrJC-Y$t!XW1Qtu<#`Ea z=1HnJRQ@L9I`rS6i`c`q1t^1vlv9Jc7uG9gmK47^+OO|c)-M5HbFEgJ^Zf7XXs@rq zI2P?XYBXzO^^z8V(m~`5G`~ccoozNp!2>mq%{l#RFuRB^xSJFGe>}8%%6$7xUhYxO zU70F8>q-trmIHhre0LYb^#7)ggQy|+R6PtWXSWbHvwBkqgG{sV&Vk9TTQ;}lM*OKL z+DgLRIE;?hVE)2`pp)MAFxF8*A_QJ30N5>{K?cGwIIiK50ed)Oh=*sjK-d)ghoJwupq%;onHnWs!t(?v&-JzT&Z_zj||4XlKg*EtwB~@s%&9mbK%eu{$dQs z>hBbO-lt)AI4`||bKEmwocb}Xez3>T1TcqWM5KlMDH4eeinH%GZ$$si?q3~eZv zD9;a^@f!*aw^xoT&g|6jMr4!p57hJahdf0kRh()^9f4N-TN(E)==_4Z9~F=fYO{d1 z+rp^2L0=Fp$1oNjXz_gcXqPgj!I5RMzfeX|mpp%_B2I+N4jtvEkm*53Z39A%$h4$+ zBBaYC_BjP_?qI%I(w(!%E633)OSnR3^e!ed9JN)SQg}O-vV%8%QlnFwQn|3Wc=mhd z4WIgyQ`0&ZH2{Qp4OJO&d^14;T>M4?T(*J4>Ue6?;t8XKfxxMdD{P^%W+!d)wZEq} zlbL^bN>#0|-9sWB5N)Qm&}wpO=}a%A{E!5*vP_WqLuD1^kMbJaqM9btB@z*%>fHIk z!RwL=rBGOGKM^1sjl2N9zgQQQNHPZSDVS`|pG2y<4Tl@p{O;6Ad}O`cuCpk&7$z{s zTZGQa1AA`d7+Q%Q7jwrMOSNFuK(ik_uwcmUeO)t;TyJklZdlol+PBENJn~WSrx$;k zX(JPv`$=yKY3u`andj%ajip|VN0MEy!>lgrB z72*u>D)+V5o^5A~8>l;!AC09lyGIa&4-Ygc9<2uUTzZOib+*|E*bsM~^hFJC{Md4w z@gjUccuqhWd>TLehPUNQs#}c%AjN-$L=p$yQ%gp1aW5=tmq=3d$dxMnoEL4-&7!FQ zt(lUxD}CeW)Up^}0Mp6%RXARBVSA7qQS??u@j1K?W4oxPjjY&gX1e38s19z@?8L|( zPi!=**`90Yu{cuNn*QvEz`N;gm5nAo2#x;s@DC^+v^?F3Y&juDrC99E_#A)W^Wd9P zr5^S9smuT4;_&NR3(?EUkt3_+?y^kFQ=ywe;jtoPWj*kkn}eZB>slptyz{Vq@OcE^lz|<5c`kn&*LzJxb0xAGKB0VR9_5sCwrQV+wA36$nWrluRTnB9 z{*vF7qIioPVHLe9*p8kc0p1!JLj5nSLpYE-Q6kZhJCB(l|MdaADdY$B^vf@ zB5nGAXuEdiw1FV}S13ur7#XBMiWD9f@r>QcxX#2L8y5)!As+sHcJF_Ir2BU7PD1YD zAnEqr`~1EE7 zyn(6$$#e9M4=A}`ECfSTo1#I5=DN5SRhgq-R*`zta`W_}>sxD%CTFjH^eQ@EVnT+t z;)x8>IlJ5br~C6uJKz=Zdik<<1f3aKf@CGS5ExQNJRAe2jy40p z|LEOywE0G9INf8^)bxhQw@pl0on@uFGVQ|`oo|AdxR-EghkPCf9a@=g0j&w7 zBfM&tou^Xi7E6ER=rP~9ZV&>eUhAOhJ*u&$yeZynDYP7m1}MW_s~=3xN+EzOK0@G) zH(>yq7!G3&^tC+nMNxng?$H#Z*o0B4ol788vVT3~oC>f2v{}D~P`|7GTp>gJF2w1x(r)Pi^uPab*ce8NB5xr|SV9}Rr#wk5d(2t8;-~uGrx;H zo^%EgtD=AS;>C_2)O0l&J9YQ8-C+K+M9kWARf#ENPBkylIB@tlYfQ;;p1Bf})^j^a zs5%KZoeM?_y!T2QS5#V}dIb&tV7k#blf7Ro-;ymUD|aqzJ$ZIBI+I#Ah{$rO{8fo= zM!$SY(6cv=&HUB{KqlwA*Ylj;=G?u_!`(gE{J(#{f!#%(jy^6h3-1Y8$qhTTsZ}o<6ToVjU(6nG32T?Cyu?Uk&N>SD*5S>3dvYl2&(G0StiGqV*Yzd-_cg#Z| zJFB(el;^9Zm2zRCTmz3iu=j?@1L+^VPQ`y=A`I*=q}XKjw^x4#H9;{EGICpcCp-hm z3YndkVX(I8P~x|L5_#HzU4wdJOu4S)i_Tv{cI&}56`qa(+jlWbzSL)tGWxn9~RKGJ^$<}KJ1wNfa~s=Aym=w7IBD#*mtfD zhri$d1Cx;h6a~PK&^=MNq;3Hw0e?|T!!Q(u-v$3e$$Oh--9$^uwAmkg|{fMjw()T ztsqB7uxMFaUuCRGnKtlZbOXi-uz@Ejo3bWHd*_-IW6Sm+sg1ltd9l()Qh(>KW``Tf zKIjhcERJum1V=e_6nDU|8HwnG7j_!jMqp@w4>!;U#)KI8yR}4^*ah5Uz)M-}$_39= zB^U%73ns%8N4L$ITDSI#uS*2*`(sgVGyJ>ivHcVS8+hPzrNb0wWt%)amMc`uVsaP8 z^N_?PS)>b+CiC~M>Bajl=TMNR*8d@ra+ak2BsUY{8Bp}OFaJjI4U>@r6t^gG0g3|( zejz(*XafKM2?&?GbOAFP2SPzc{Q>|0!Uq5V4FCWD0000000000004xS3UvWG0j!rr zbpa+EID$}hrm;9Q2_t|XaWEL5dZ)H00000000000038Smk)LU SJptdBO?Ckz2BmZX00008{^hR# delta 82637 zcmYJZ1yoes_diSw!XPavr7(bmfPjE>NDT;51BlY8v~*n=kPaDAQb4*xx`q^_k&F^2*+2F4&R1_m((28O#0kDI;I zI}>~Rciir_HbvTR?6ZW)eGIMtV*e5CTx-YF;=}i|;_NReP|ZCQc0xl6Kj@hzITxPq zdA*SNrK*r+XPMQ}#YmU_e(#|FJjiES_w+TPj4PDMl3K5k(~P~|7Aaw9zfGd&Z}Fz* z{uFQk5#Pu3(Y?8uK36Sh&}ZM{!q^CejJ-N7UnY?2*B4CbNpmaHP#WVSl>O!sXyAw- zdb(b3OGjn;yGq4*;{!=yjnVf4GMquPC)JIkxFnslIes@U!+aBme=R+Bc&zDWYEMW#X{ealcB_$y^k| z-Fj8D_t&JjN6Wt`kWhr@^xC!$5@&4zCL}U0&Y6MR-b{~X4{GQd}X^c=`U&W+J^(s0jvu`tw;B% zP!aVKtdmBp-%owZj@YILIU(IykJ1N#j_xSii@hX|on-a5@TrJ}hQ%Iy3#*-$;F8z| zh&m7CDe>VD@goAa(IqPN-y+i7gx8}pjIV9p8L1$@s~}eiDLomg$3M@6ETCf0EQ?^H3UDz5FtOTzpt<+$(h6sy$Q6jNq;`6s`-0b zy7~Z#(=+Z-=E3xCMQ4voEQ7zP|1-m)M$)Blgz2bVWMyv8Z(hf~(J*ByLvvRC?i!%l z@jZX`e$cwGCY_3?`QYcQnk%Z9Xl!zT_Ijyw0Sf~IA9OXs|6J|8vxklO`&&o*s;zH7 z%1iF6uq3JLJLqJ6?-xhU^J%#x2%fd<(%6fXpGiE?JCWoaz`C%~w2CaRyn(m3_rUtz zYj2c+8!}6wfKZdKeNp=ZX0Xs;WwONYP+Oi%ni|7;$84G7SVf7n8XQ#NKR<>u4P+_F`?tq z55Gv+9WlK4+V}wT&(Xt=#P*PVv3rsKQ!r&|wu~4{P@e; z@$K2S+FQFX$7OO?tveO7V2j+g*x&UqCQ(kl>ju9jK*Z2t_8|FKRwG3`SEPKV1Tn}G zULd3ml9Zz@V=E*53archw$a^HlIBdJ<#cPX8{A7fzq7w47bICG>EtJ*gaZL5NhOz0D0>9bt; zSwgz*&0P$PzcI1cq?Pr=04|Z8+*$y290rDOA_RjPBSFO#^FEN0s$WW{fciR5HThR+ z|IJd5SKI^ZFZFn$_F+vDnm^UUtTcY2Z1QQtuJ^V+e^ssXL8x=3qmN!#kjD8kjm(aU zkNlYiF4w1p25;QG|1KUk%r|?@`CRW`O)cA(&Rt(!)U^1VUI8~zj4i*!fs@7MAM?Jx z=WDa}QS;(|CzgSr^}i?Az>V7c&H3*2yyVrz+1Y_!-~M#aUfSP_gXO*XM)!lovC=4e zL*KKD*}bS1oIgJrPQkyz|DNC2^GICX+#IY9PJgMfH#j0DJ`AhjG5mXSHA*nw*kT#! z)^hddVr+SHwh(Cax!PIIRhpA*_Bel1^0&RT6!^P8VFTD3&hpPrC+z*biJEWmJl@^e zd(x>^I^TG6R%$!4J~-EWu{QtrWV+#$2k^Y-`nQtSu-Wru@buuX&(*uLEz4@auI1?D zxbSpOqVaNddE&`onA*hl+MeOIVWao4K+H5SAuxNkbiK@2I)T%uGWNHdJ3l#X?Ke*h z;a_ymS}xEtE;(^&e{*oL4qkYkG06PNSfbDHT3Aie_nTOFP^s^k@kYyU->ZXK{R>9M zf$rJAUN_e@k}Z)G2F0EyHwOvevLT=MyE%5JSDmNxcKRDYlke4`?8V-oMDx{V3wU4e z0fs-iDr+(*~9kwp1*@9{0D~1 zxCUa^GBW zjiF?hWNQ0~%c1w-VT)=Mqd{j$gz|a4A+R>qAoRrY>awz?bfSSraP|k_TYsXadGZ68 zm=%-gyFR*_Dg?aG&USYUTaG=>a{bB?)2(NNl7H*t7q{xf|8(XW&J~F@U7h{8w4ZOe zJk+yktqmY|_DT{m~~iD{Eb zZa86RD!-tFG0#$OI=AEvhMS?ULpnDAw5?j&bb$|g)sT@bfx4z`Hi3F(jm087A+emE z``|*juA|%`1npDbA$}7|vsES=iDeR&a-VsX!_;f;I*4F*RNHm(JuYVXW+aw@>#Qqo z3Z#QU-xsR=C>M=UUe#57x#&{A5dOD0-vAM>8qVyYi4ea|6tuu0j{t+A)x?ec)3aarY@)34>Y-TuCD4*81 zuHWAfnc4}mKR!HmdkK(>t~}ZZrgzc+zZ7kli;tn;FSneoXg2A|v%Ox%-elbFN%pIr z&QiV}Pi~W$JUhlJV(eXUK-p6&-#^${9#H9>SNtMVMAqSB@A@6N;?G=NlbIvuJ!n$7 z+9`fI&2;HDjnnltyB9y(KKo|zvsC-#_OYgzeKz@#Nv^>=AkxaPah%TU>UNJNmb_Vg zq#$33gu*wTH(T&#*g{_&x%o);qso$T-SdW%X9Ye7uinojeReO_6xZW>-@?&*{R_Ne zQr0i3Qth;u4MQ*KI$ZKqhFcc<)px=sIEYn_N}Im879)SPo0t|Eyo=PoJ+H<>e!<|S zypc3Obulr1%VEtehjx!Aql3OJ98?)nZGX?oJkl#J_XJ084|Ucn>kTq^c{@BQnR~kg zKJyzK?X!fwl~8_ps22fFjjJ77->BeEXURL~lJ2*BdMoNBM0!@3Vc{3=w?pOLZ(knq zAxd2GI*Q}2oKLsUega?e#v;wQd=T$I-dOAipYiQ%RFY>8k~yoTkKHOSL|-;i#p{Ag zZu55d?XBoLilsw?j9`l{oy{2O68?+j*om-yL(j z%BEF}yY#~?T5-H-iYN3#Ok^W9>BIiuwuaYzpm9#lTJ`LP!}NO+3f#ICa9WQ{KWu&n zPx0g&wu$Z1QP8ybM>ml!xyK;&#RwwrQ`f*@l8}Z-DkJk0|jR+h~orf7q!>Guyrz#dGOqbc6B#20feN=B8kzp%F>9 zlRkWw6u7<2g=Nh1NAFfKEWEM%t}<>J9Fa|iLG(m%dDA~)@G}U3lh)2C87?gn%ur`* z|J}M8(7%<0^#QZ_Bq4<6Hd)piy&@zBOs)X9w5wF3Y_Kufo#&f^42OjOuox4d}A3O5931 zYT~>@?C%}Ad_1oOAbsAs|D-r?5n|7ONZ;Bwf%*O~s21Q>I9vy|Yd1K3-t@eOF0GT? zmaPfjwBK_q+Q;vAbN|HT9lhJC!h>OYFz|s^t?)gINXg2NT|*lea>4iHId13`i^xd3 z&zjJ*$^gl&$Cwrs_=#u(V?kYTHXG?0+~!SB!r0VQQ%TwE7XEZo32*#O`26ksrpo8t z^qK%|tBNfKzW_$pQYwXNDzytv+;=f$n{O6(jpRjI`@H`h%M+HnriFFNRX*lP_rcc1 zxvDs_ty+X8a>A}8J=KuI(TBxwz)PZx;!a{A_J5z+auH>g?a~!9qCNW7*Z=!`)KoGM zoYv^UNBrqb89*o)>(hS(Y+cB!$D+f{CiZQVSvYljdgubxTUDGe_V7Ly(c-Er}Cj<~x2o98rdfc~&igKmGfWO<`6U$W-xIz8Q`((Tw=JHr&=~ z5s_aAg~cwtsBE$mojS0RL~~ot>ORww)jE_OC9JX=Xr&QE0UJCUwv}G!Bn6hbA}I`>_&D{{3?6j zYHh=6Zj0J>?fXW#xhl){9*j@TCZ2N}9F`a|s`|{FmAt0acB9(XJhq0xUxr~}gbB=C z9O^7xsAAQO)st7hqB5%IZgqb1fwttGPRJJLxl`#N_}9+b(6I9xYTE`Sg_^$nj^oq- z15rA{#8j1!JMIETTyr%0<_ECOdF{3vcyrN!$!UF?jg7GYt^S8{chHtPHQ#d>18l~C zu^}BOq;QL!jjvgw%snTRdo&KfJC|ExhMVPo68uk`GrFlhx9a<0Q7K#hp$-)BlQ*r6 zZWy2p3~yy%GLZKFG!5#z_M1ptSxdrD!+I0;B!Vr9!QJE-mW4~{Iq*ThP!oE2Np}*2 z3+noxs?{e!os9q1szCY-;0NLY|HdI}9{n+@12Tg&Ewg;ND2na(W(+FI(u=tK3JR4~ z0X_W`-#45m5laKjD2k#LHXUB)|FaO@7&^a8=S01JQ1iD34G1QKwux2A>oU^g;rWN4 zb`>8qAc^kd3?ZE_Wp!8|`zapTlt?X(H);0ZpF9Kjh+WT!Z^csG9tvts5m9EJc+Z|I z_Bo@I0q?%pl5z5mliR`3LbUKK=6;%>qjy%)l(-hkKO&Vo=~!jSdlxoM?bulG;byEbqgsd%!$y4&JhQBvhts_C=~9U(({LJ2^u6u|b&+Ok zK#S$g1_NxV;S08d5WM^HL~|xWqtRN6#X4BX#VPT{SjG;Ni|*r+vrp@rYw7OFPi|{x z@;1L2IP%-Onr$RGYe+5KnFh|D&org4aBp%Yt`Hw+X!K+&6Y)OrpR`bxzl8U=BkGpY zG*Z|Z4%Xn>Bf-1UCg*)($lB7_$kR9tU`FS6$?Ht7JlH+j%L+1nyQA7%n4uAx6Ir^X z+oQ{l*83Cc1wW9_5}JEbXd|iZwG{R@$hJCcn9GYkq%!yg9j6DYubxs{tU zW$(ZXmsZEYkLq;>Pq?ZzLZ^q>!|lJVG-#6+7{!{AyL!G&-l@>w^82VRGN%J~1Ul+; z**keSL*h8h$v>5~MbJ&FG2IZIzNXF=Rzs3>!vod%nq49b^tHd@bFz@ms%qF)zCpYl zTz=5;SefcYp&w67kouoXpRHljxMU7$7Mga7EONIja-jt7C7p?I)PZdloaW<(DWR(( z*W6&AwU%e_^hn;MZ|JS0Ytk8jS2p!W8uG)d!IBlN)Tgm#5S{RmgOd%v13N8-`EN~z z>{%pliiQme_dYDAg~avJpwAZO)EuKULxq;L*t0gAo-^*4pAgm3W-t3(vhT{X&+)-w zjZ1=!kC$2D`plfDAXUehd=|TD;=^QhWKB)Fm5TBM) z2-G}aRRV5FvQsiVCl^(d8*|!V5xaD<5_Vu08*Wdl-TUbI1DmQ)8{C<+T=JSEF3^CU zW!08ngZInxiztG0i^nnFe6N`^y=1qe!Evw|tc+w#;`X7yYLLt#nJO!`+ zN#GBR9-HUoSoRrF1I7YewFx+>ilyrab=c4=Gg*zY~Ru=#4?AdF9MuhtxD_=F?M-b<2H=ThBdpMtPzc+PL{!(lM5V;U_i za);KbyKajwr=mtARQqQ8CXTGU>Ycn&2jlFc&K(c@!&|=@JJxj>!IxKhe)_6DuOuQ% zd;q&9fU;KH^HEyNJ}Wga7pYmut#6zSV=k*qOU-MHh`}*jp!D|BPtj=9b}=}f!WUF( ztvURXn%5NJ`XIKp(|~?Z!{-coetpEv?`p`NLDEw*ti0J;ERHjiCPoh43q}W867(Zp zd&CK)3+{|tIt;?q8RXrx)O<5sSgRSICmAI4_0h-IvbZzh8Z(hCPK`7y%R$xZ z*#R;gzvUU~3A11eJa(}Q+dL`4prPa_P3LLIJPdWsO5NJ|#~V!a(3g5oUTHMT_LdKA zpmBHwDZ0?CQP;s+!A{1R4ce#skIUk>Zl}10!(Fr<8^YD;FuH9y5^ZcVdpVFJ9cvj;^dUsN9 z8w>J6Cqv_Gr|0S0B=6ZoKHS^-Tdo0!%rWGCm=3`nqp=Yr)4^#*sz1wAn`0yqZwXOI zZGQwB!C`16InZ_H{EG%%6RRGaH@}kYyns-_+T|9vB+#_Pc@=JdJOeL4rat=n!T^qI zN8H@HgQlt#KjTO%7_ZkTT$sO}R$IYjD;2@6!8KesS-3mH;O!@5CQz?UQ3e=kMQ+6C zq{^8(ERjwwpS)B1Ho$(IA?cIxskY8}jMoOVERnMRH!0ZRPXWKf`^{GUsI5X_gS=?vdPb}J6|YP{aEq;{!Rk+bn2ICeYX3u_hHh0*iCOOfT%WW6(v4EMkAkcFic zkb)?J*wv-tix@oNn0Sx_8dtcq85Ot;tESs!q54{D{2){vRsQvT=kII8v(7fSQWx*^ zB|FoAa6bq?HK&ISIkn5VI;|AxzvMxWSGP*prnNjUKmCbH-R89Hcx?O;>#K)k-+X~| z(MTxpF%EOYWUQLam z5?jT+@~)n*%)!$q?e5dQt+v@(TooQ^1z#zrLSCej5@Wgo zEXY~+XyW7{uWKbeBRmwMEbG z@uq?+(}QPTIFz-eS_60%Z-rBYTfoR`uWh8W+I{I?y77F#zz@fcLU#f2?}eULFjLlu zN!<`1$a#(5_&&=?o_G4R=GN`+%N@?xD>+o$8|$8u7?zuv3UL&1e9}4-p(pTYJ6dPF+js?^{!(S*4H;F@XQL~WF{}^E6 zdge7nQ)^Bh3ci+;<>TIxXLA1=ic9s=U&N`UFd$bWguJlQ(fi&8U%ih8&msMsa(fa! zPiyfuL8FUG?pKqkkl2-{SuoRDlh_4rA;0t4N2x8=TKV!1k*Gt0J@QByzCccS=s*-e zk_t*}+dBm;|0(T3d8ZQG|fz9dNsu1H+;Or*C_n zhWtZ~gv!EHj2Z>vg?M!Uqb6Kt-*v(?F1k@tHDqI@?@nt5wp|oM>&`HCEo~fslB>Vb zSQ03lr&yAik9*_zX)(&L&BWdvlwXtA$cDD^h)VN^qE5`&uwwbun7ct|MEj$SW0!WX z$=wt(&djroweq(f^2PGMTQrV+?j4`q{;0D!ns7#kBZ@KRK0fe|+kpQQ@DzFuK^kvs;7J9Bwkou_5^^0wQ#hpu69aUrAT_i}%*s_w}* zmTUMZ{c$p7%W}wK2(BzrN#Vqq>Fw=E=G5+?_Ka?PT~wq3o@xmJS3Lt0y16kccE~Zn z((@z2M~|J8^PZ&x%fJFW<+)14qs|Nj z?YlqP9M#wdxKf1uIUVolEJZB*N`UbQxxQj&7=5@azZ%?<82F@1^W~XJqoZOukCK7i zc9^>Be!~BzZ*OwUc~@-!I;20^#N*y!gt7D3RI+5vW^cK>Z6Yf{%w=H{(qD&NpjKA9 znqLdZ;Vq^0(zKg6k_WkTT5EP(HEbc15`9z zCyPp{_v1*fu~rG`Yd!XGp*`H0h>@6t$9p=c#%(z#r}9_N9D#;h-nm`&1v{;QN53LX zD54wZ)q_`7+OT|zw02){jbmU8yz;V1p zfp+R~MR=RNDr#`wTY3pXBe@L;UC5<)_A=v*FlFKIvB@Ta2NVr z5|ePv0r2V7<~k7?mEUOO3QOoYXb>*{F zn0n128~3>m(9(d)bnQh6n)zxECa>^l~-8#FFuxdEij1L*FGq+q7bV?Q4KT=cCTqyzsrea?=0OtI>Zs zS*$3&SH}tP0~1J)xHwU2ORZ(uq_#ij+DD)aG(h`sbh5nvtM!F!axDwFh@|qdCH=fu z)?@-XkI+d>)}%V~Am*D@fsb0&B;IJeRg->_E*>^cv zgq3&7HJns3r_wl-3{IGy)m0K>k*%YZm&DwaW;7(vuXFfhTS8Ul7;~SaoGg3$rfsMc z_;h!J4&pB{Yi88;bAlZ~GUaVyAc0rg@A{-y0#9+~O?}^B`$+lq3ZNYs&nNr+M|?Oc z*skrtv`x<=w@s0`G*Y=gPL^#CM1V`jw-ldmqdkFv3uRAl>I9!(L)NGBodDNTRAPTX zHOylwY-MFY)#{#*g5SZ~qYuehB#mmFToIauimTV0EU0)<(TrJaAqC7CIvj`h>{ylN8>M{b5~vO3{j0UlT>?a-&CT% z&P?HAKAWTa7+FJ%_4`a>%*8=1E{TCjsg9p8!r*{Ye)WFGfL8dEo6!GrN!8uP`1~`9 zET;%#h1HLmQRl_tENB0DtLm-_K>ZbWcMi1W7>hOcQ(uwh1EkdRRg`i<_y?Sy?Sj** zX{N=8iZde5m^|vhZ$-<~G@Tqwdcm4x2Rk$NJg8Vv(NpD_x8&6JPw~;o1+V`>aBf`d zi7-jcTa+SVS9e>?v61HEK{0~IEk>=0xrzS{LD5f1Nt5iK5; zYOK`-n$~Ym(1GW|KDQRf6WvO?CD$op=|9wBKhOxIIcbHONN9+dP*3N{;m|i093x?E@fJLUkbwwNKam zrj0Gp_BJhGJVnKMNrK^@UT#3~ge$NMEZ2!d@6HW8f};|fKnYxz@jJMYKVzQKEMWqR zCVIK9?xT??3C~#A6R&8XXr>a&>wz83$4GGd)_!#i`(qHH{%@hz9~?V1u%PJCVd2*& zhD(vg(T+|SjPy*2m1DRj4GA`ICasS`d zcr36$KsEis(3;=v4mN&-B5v~wy}EUDkHaR)aevDc%mmyN9twwLSca?N%9d-~MhW)Q z*f6{-7_(71KX_*+$%T_oc#UHWZ{!}`jg(<(rs9_yaoS_yTL79h_*y2e&8~*X%6==O z5@|30eA?(#iLRPSe!$zEtlaJXeiK=<<;$YfX8>+$aGS|WF074!Oj0#oi)o`ewn4?& z?_FZooL-0MPspy@kM}CyBE0JE3)+O*Raa{JI(mm6JCMPV{@=6zu>b$3L}CE9IZph^ zmij;Ae0-V{p*(}+?9%W0Qfs~Z`)Y>@^8c26{ZMN!8FF@2KNYg~~|nn;0(F2lTdVyK_$kc6AT2neDve7+R4+eQ$t`UL`pFee15e^#9_N2={tDEUr#oftq6dvbKbVu8#StZ=$#e%60%x;zDWIAx{uG40wRY2?ut@|A zUCjioruaCtTNUTb>ouG~(C*FI%b7}C^18@S{i^j@0It-gjb!A_mFZKK<(by{}x5*p#Q? zN{oGzwn(*#Gl+{2Gv!Av>|#T_FxCi)*%nX&7Ca+y#x%P(Wh$DuI(HtRQN$#TW$XbG zbp`;JUcSM@KMAw`I)c)*CW&j5VsGwe5I{sRnFDA8<50xWWsPqWbBJ^ZG_lmm0*xQk z8h;)VEP};M6{@UaKV>D7=WY2;)5n7{3XFEBqj%?hR+*Z&5^^%aQ0_i%+T5 zn*YiEW07yIo!2k zg^FcWaJ&~D2hCrT>&i8mw%Kgu&MLh2v#MdbV<8Y_iGU$)lK3iqui=vLEy0hpWJP>Z zNbQ_}PgE<12N2bv&>@!VK7%8kcHXcdn66_eBy33LyV_rXCZ|rRz_gt+K9nI7aGVl% z&q#u}F(f7L2fuTdBbo6qles*u)vl{p5EJ0pH~EHV9JsnG#_KOid`oLfv3p;n%YIB! z{G-;+ixnHqIS#8m9Qx_Mx0CMmIYTXoqO&aHYYmtc>QrS`lWvHGORXD2C@CX`6vYEk z8*5zy@lTF9E107M%DEg^GkTBw;KQONlQ&Xm z!`nWk%^2Qigma|Oit2YUrI2pyM@R+PLqxn;1k`2-Sy%=lQVFx#0U;zUYrd={uAc23 zA+AA(_A>bHlcHa#J-qSx%dDD6?S0!j^I?f-!XKbHXgftolRs%VlWgdLy$|-*fGQ;W zshPp{Z4ULILIi~?4E}j`fp7N5%S}+vUh}I!bFz*2&q9@^vRKRnVq>2Pxz2^I?a6ua z?>^9fLgN1Xyd!-dpopRQ#aaE^c#bhcPMjanr$J0oLd{Aa6Dj_IR|Tp=aC>f?2C@3k zwutB(@lQs6;gI(XFx>~5ZL*%m`iBcBmGuXFNyeXN&0u8^OMdWyq*WkfH2v&#JD=Y5 zQoo>2bz!aE9C%W5h1io?5|-aSJ z1d(;#q|4!w5zk0KQRSQ~iQq@FaIP|D*3e9thfqKfqnKz&1TIO5E-T04o2^ghFUgK) zCawFoW9vx!{DO-tC)AZsJ7_@iaRN8svqJa|0hfB7#9#8G!ket9Ko+U(B2{bhIfqxN zf+{|ak7Rg$TjbJeP6}z>4%59OgEW6ofcfjfsPE;-8MrOK2F9`x#O*2U$4=8t+nn1J2L`eU1wR zl-alF)3`n&Sfq7D($w#csvcp7`bJs*X>Eqv$dOzzU}tEHJPz?CV(O)d*V~MR6#9NL z%GM++D#{87a=tL!t3dr(f6$w3{5kvlLE@h$mb{y$%w?k`0X`ztciQ2bL3#G_>Vc^z zevo(Z(MJ7zWJP+c0sDeLMEpoWzQ^Cnsz(li#@kiIFkO@yvW}Rg!|kN%!gD;m)>xPQ zoP=T^Pe)HZ5%S|esf;ci;`%G-GFB=GMYhq^9I$bApQdn@X^bYm;q=pzyf=%or7(zj zr(ke&jjdpa!bnLmAp5K@%by0L1Gffj&=exVhmvA{iuSQwCX ziaMJMFQ&%Z6_c{^jMDh?up;%1cV5RyCXDewo!HfY7kjI>oXX`+nicV0G<2ugR_VSo ziS+HjvSf5}GOR9pInFv@S_Cqus9&}AA zV2Eg>@Mi6LDk#q-(72fVE2`Y8(ASW7>7V^ve zAYtaP*RF)S6&jneX3|;u7Q`d4Nq+$-!UTr)B!^Xbk^_bJEsgo#dOCLUk<5S}FmT2D z4OQJ5f!`1}gsLB~a&1MPffj-&!Sd@zR`w6gL}WvrYe}^8%||3jOj0f08CYl_0!KE<*tf5;&ttk(G1-^AoW9u~dfA*&wTZW+#xyZ(^E zj%cHQFX&c zw9&ftN8V~Jyg==$!yD>ivh)L!CZITRTu?>G^RnrPcUR8%CZLqsH&dIOdo!FU^N=RU zrKm_28Rw!{RzU={`)tA3fPis^L=Z8ZfIa}jMu)Y*bh-P|9e%*j)=(~j!hl;@F0_~= zl9f>3L0-yT1<XB8%o49P+;B06c<5*=;)?dVSN6 zm2P*sI}FneM#wZSw!N((dnJ-8tK{u$Ixnbl_nr>HJ(G@l2*>+usQ;t~_!SuEL`;fF*xolEV|0@SIXsp5UO|#>;7A8yOtx=~ zbymb3#w2Vgf~g?mfB@#W*3ov`KOR%Ar+)Sf*0rLt^wcY4Lc3*} zQ98oMTr-c}jHsLY*y&M7?Gc-1Qr(}}2~>LJ(9cVeV$XWsqQX)VUD>=Y{e)8dp0&lm7pm?jB8{K$r>iUbQ==~`TVf=ma&CM9eJzoccr zq(t&CtWxwBQJ;*6Z(zDeWh6_jj8#j&2H8XU=dh|Ui6$D>hm!Y~X5OWsUo$`vg5)xX zVM($|dCsP}fM~LaFfOz1k#_#D)!6WAw9&8*-i!RO3>c!mJjU3!&)}#0@)-1x2$tyf z0NvWwiMKndvx-D0qm5KZWV$2SPZ<@G{uh_+y_dgE8WXy-09@HPxzSL$^S& z;)S?AmRCi(!+Nx3VzQ-~PX6%aaw%R+mrH}r&!R;j)cC;}0`gyck0ZOQ%@6_q>>>Ap zO9jJff#5_@1}Xk7+F_~?&n$aJ=9^L$fl<8mf@SH7u)`fpnD}Cg(WRx$N(uF>haMNhkYTcwI4R4^et`00|G! zBDq*kp}dss&k-iiY7%JuTiP!@tKVqOU((o51#gF$nB`zZx>LDbDA{-fpT_-z1OfJc z2S_RIV1mhOa%OKPE7FBpu`KH=to2!kLF|Oq67b8QFTmBb^y{1ZED!6j8`q_fV_y_` zgXYsPIW;)+^0+rX-KR+R`VP|tlI|iouRb{(5Y_H$?0%{L;?H^Z$;g@u>U;Wbw{_&w z5L2zH!Bq`^tNcr~V6Wl6bzS^AmUV;w1J4Pqe62WiV(`kvA5FuvMaDEjVSHS!yBob`Y&0Vb;PjR(@%XS zW@7^J1Q4%%5*hvP6)IkulH~s@P*>mjBd_iG=Ih z1GL6nGOlkgt%u_qb-s$@vBV^ zEOrr~?#Ttdsdvc73wOQoO6JzHSZ|4F{fWjC`%5TuGeXW)n6gNxlRE6ZI0-MGkTTje z0w8JiPqE(PvIw+XKaG!-6$1D3F<|C(;{^xFwzrbtR%x3wI{AZbFTOg?YW=9$M6I6q zykG|ZB?m&;8e67J>@pb|S0E=w+lvqwb7I~{x8r&5^I|cI#SW2cMdtn-3AJ7`Dp;L% z_UN49P4#0dRs%E8cuNpJHHhf7Pl5L<=ez!-x?xX|wsJQCwsP7;woPVF{&Dh(q_Fco znlQ$<>$|;Xn#~;{l~~znFd4q9y+gMnnx)?TDfv_9OcrS$r^y}4_k$v`)3XTyvI=83 z^z7PX`sx=n%wbK&)OgJl()$!KH3}N^@Fo)_VdvLV)|?ecx1*02qf2_9Clx%AT!tJ$%YZ+?obMPMjX1fyLXR} zUO6-4){qfCLdZI=F-WRP_^bu58xMaK_7TUh$6wPhd{0$`52JM1?*`Is(j@-G2DZhD zwaKvTfbK8#3;oB78iA+ss zJ;Uxq55lb)I<4TUY9d2MpWl_E+oEV+*@>>!=gMZ_Sbz3euwN0G4b~*T zrIF`eilI4dj5B801wp?(R9RK;^*_A!*MAlS@p8aKOWZ4zjGp)PzYWO8Vr-Wx+ll~E zfv;bD`(1&cze0tWEZx&u-)g(p6e4$pK3foJVMme>f)hx%^j8QNdj1gXC?Yfn=(UUA z-`_#wK&mMsQ~WGZYVu`@tdfrHWxY=Z)sLled;WNl^?7{)Arx}R023JSkngUlpwb?A z&xihFTTkAjyAZ_^Q~%uzxhh|V0HXVbN?PN{WfkHMQ&dV*0yqPev`v>Rl}&k&3xVcs zgzfOUpk5DE*Lacpb4z=r)Hx7*mY{!afZG&jHv{=4X0t2`rb`?S@fwHuSsos-C6yj3 z95y>g_1tBOfsWdYW_$G=>4&%8sVAM35^C#|whrc23XJ3wH54|~1$eQd?ogwznS9$G zV`o_Fv7f&bAMA+?iGrP3{9N%5U3X0ITL8<7V$&s4C4MkqK0O={0JR*O28}A6!jevdOJzcY^Ff8}u8Mal~&OBlKr8>Z{=0m4cA((XuR$k}mh zjqA*-=dOi)ecsRYzBD+5FBSduFv92_0=VnWy;}LQ8GnA=U1=n+3Pz7+ z?q~5oWrSRv7+F*8AwntxUVW^preGTD5eOFFPPd%ANV9^x+`AAg_@JsJXI&V zORt^x{v_uv-kkG8^b9U^4eT?`g|U1zRpVoC=eN;R7HcZ0P zDxs4d9`1E_ON*%S;<=puHB(GG;rT&up8@tzZ{KkkT1Vv-2miEsZZs&sk@waNMBMow zfk=+kXP5fiV6l<($~__cKN6T+d*zL0UWfuK_#RNyzDMULMt@ZP9_9fYiFalB@#)gtQxER#;SOO&>O z0E_l5U1~p>0CIZzpcXK88n3d|Wj}q{Gc;v5{}4?$I@8{a5c_w5q20;&|B!(lY+fSi z#g_VZcT~9$UvaOCG&1)rUBm4pOKk$7mLUIP5 zB!SlX$;gccieMm-8QhlEBJoYlDtK_Ppr(MBP> z(0D}j&~Mh_`>CfqpW(jTb1#_CWb$N1c5tLVD|7%QaW6x<9>ytBu(m#;N0<(&QGqjt zwRE)8%<%Qyma7*)Mp9asP%qf)g$BBoA>3u#E^2S z{nC#=mYRI(?3&+@gYn-u2?E?5g>Q_Mle%|lU}e^4hWTt6!_fD4V7g$l zV@n}sNaR=@#Y)(u@`ge?W#U6y#K5tPL8VCfLvc))rHG@c-;!@=O&_46GkS3K z>DUGqE=>O1+Zj++N^%CYW`{bDI~D&&12Jeo_0W!GYR=S-}k@v86-%?(fEcU^Vot{kC$c&67m|<{@4(72$r1FUD}I z>R1`?JhMbr$`jWS!8a8%bEXEagECdy(S4% zC~W}{s0?qDJC`VH3Yq@EMWPTdm3u*)fyQ^-{;%!Z%Mb%k-rYWAkT;rY$K&#%_A@62 z6Xsc(`^GHm4?|=T$m^e$V9-?VEqM%O<+XsEV8q@2NMI|Hzq>IYu?P0QUqrNK=9B6Q zXy0ZO`Q01=Nt7L)_a3qWnULEIR0oFMeZnFzxTsbbyK!9?gdepF_9wNY=#x3RcTPv< z1I0hwgW4FRNY@(cfmmfdLN9tZ2pYf{ujEu=O8kIJvki=l4($~he=Cg)tJoP)6Y4Kt|s4;ugB zlMxgTd`V$_v(;nAR>v7l^)VBTWp(KX8(X>^HJ}H7zV+byxiR>kcDKU>2%fon%+Q4*DO}N z6T$-}ZACYoaRUA`pPT^BQyRSfr{KZ@aGhMstqQDBCZWE9{-vJ>h72k-h%#kzL}QNb z`Wc7(^!^Nnr_+l>bW`(@;VT7!T-3;BmulLeM3fzb6PfpEb3g)!8lc%e+<;H!)@Hfs zDQyZIC7DZu1M+1|c$VM;ML-^cDSTOx7LNMo;nZ(^tYni-Pmvz-eMWmn8wCA4ztmW= zMzNT0YhL_pQouK*4zsUJ4S5UdCF;v%kfUw2w2>HZz8* z0T(N!noh*`1*$OMbN9mmf|l~(K4yOTbguJ89*9*fn^e0v=7l#02G5O2)@KEa@U$k~ z0a{(H3*GNuKI3BgmM=3KG)`KrMU!T#C4}P*v5I5<`pPDie1z$~XbLW14VHNGgh|Tl z2x3L1^1<~T)==pug@-xHtl<)Gc$uX5i7|8&&%tgyYCQ^o%n;co`*%O;aGn~*rK;cB zV#g9Vd;rb?UwBf<$93EJSuH{veUE(js&=o#cF)$5JU&U^l4o$g{3URYg3veWs&duF z>GRzAa0eWAC;5VAmQ|UqTLSm&2_DW3lY?08Kaldr#k?}2;Ij4fN1l%*M=>|`su5K^|XD_hEBWQ(yczt_xE_kMogKkmbI-mlkr zopWAid7ks0hV&_l$);(9_cGBGKm*SSU86ax;cqG!2DrR8swt!$*}Lcyt*SG}RM1Cy)1@kyktbb`Xfi|<}$|GwE`SahBL%XMbAh|eW>32JCC+V9$4*qUQ1s(rx z4(mGoW^(!zm7NPhxp7_b{Yi5P<<*WvJm-brO;6B>@tq`^@8Wg)B7 z`}ORwQKX>q922aHZckJ3Yb*AiROLIWk3tNN{ZZfhgG&v$DeN?p=ts}fD>ojJJ}6w2 zHu+VotuxnG99E%zLiw^aMMVO=vLA%}QKlKV7bx)r{!DMI>(|9~+?VOCwj#n-RBQ6v zV_r>42d)mlIZ~sP=RVbZjJha1eZ}O7|HtE&^vClo=;`Hdsl(!6LM_iP#5DX&c^1-m z{octsSBLrFG^V)V1v^V zo~>{`m!GeG$&R+YBsstzP0RKX%nQnK?SK@dm}= zfn71PT$#&nI?|?)^Jy_Jc;eMfox>)e`WxM6JuXJUQiC6=7%);aK**yikcRuiceF(^ zeW{7CB3by7(|wAKkMFoIYdm_TLgBZ7TMUr9rdr}$lX-{t&9tWO*`sDg0Z3Sph|T1k_X~JT87vMGbuW-O8 z!@TN8^wk>YYjMGQfjb+j`*W6GZ>Pza@06yuNF{^+qU6J?6BnElMls=`2w%LN8xt~X zNM?-Y+WN(I?wjjDh>VY+^rOdVl|`rbw#4@5oT1&vjYIo;?a=-N1Z_L)PC#4S`&*Ci zfLPv9aJK-n)rKF3=gy7M@S$iP`%^XEFNx*gj^SJ@0x_7UMHOK&;lce*6{UDiQ2DYW zMa6u`(f;lqYnOVPEKhr#V0m4s-fUN2Z3*1QKCwxR^-;AfiXk) z2t4%~GUEt4%+ci76?s0c3JaYqN;t=HL~rydI2&Yzg^Ht2}(f$@WuIX_*w|Mw7HmBG9 zX{`X;@) z%}V3k$rr11yY;J8ORPa&@C}tH80W78lTq;A#^G;CKWoBMxh!pBz2E%@|^N zT5477TwZOVU+(O3>k?gF<8=yMkUmx=An}dX;Ac>2$4{#m#!qt>Egk75i;rGR{1DS9 z{_mqP$t!V?_<}p#n*b+@iXKr|V-c`5vZ)3ayXR|42vw|m(lE-3;umbXAK%w)Zv|Ac(c$kW(RbHg;@C5B4llRVzSH)a$4r4W*916bg@P) zb#&f}Vfi?B5gSGKCM5`#&R%y5wWQT$H70qHK|y63N8wT`1Y`39KOUnVbjwXVx~VDr z%<_klW#Jk7-NaR_g77upW-OX9Ci8lVuwTTJd^U;yFPxF72he{{cUZO{8N~Z9K1_7)|25qXSD3> zEJN{3}m)wC;^gMZLKC zI+j8h)cTLQIWkNyB^rKGQhC<#@8=1r(;Z@~>kQckvwmtJSG|iQI47cDDat($t!6Qu8`~Hb+1Tfo zPbi~Up%^N=kHeD68}IJ(hn1pNT$;2|FWyqwW%iM2;iYJYOf{5oDC`GcT%|1vn9HW~ zwy+5|gGoJ}a_bR2hbZmFLJXr~*_gt{^3t@Sy_2AFfhtACsh{jT{uSvloUM2DR(sbU z!2%t5QEP5QCt!CF5Va^dQ-sXukcZ%=>jZj6MTtR#_UWk~&j!BErpamZqM}J>m1;pA=-@C;3ulaPZV2w=SSm$=}pjx8bx(f8w&*_^pDa` ziA&s!kh?ZnuE*F0gwvU4V^gKASr!v_u!+Ek0Dt_qJrFA0J7TE5ww6xulHyl9lmBT5YSi zGt`&ujWa9v9dn;o(+2c`Bq(9ZWUDOf#DriFg7_seHA=_xhVp**@tfR~A!T*OXxjUh>@f*@gO|1nCT}~6ASbz@ z;tq2tY%AzlAYW5&V85(3#ZCSnB^I6Lha@RMg1-5png5CQ4KeDl#qQJqSC#`+8uXU+ zDO-GSd=!lb^^Oc_0ru5A3z*Z`@^jCm)%DOl z4B<IqbXN;FU7T@KL!gk9~YcU$}yOStBsVwMK~>8Y%(DA;6i66|@|!zmXXM1Z69 zE;7rjzPd~mbxMRPw@ekrTwqKgH^+Tvvnb`QSD!gMg`Lk8>Un9V46&2YQI^aHs*2Xtu_kU6PK-;m2(oWP}=|4ph7)+oPS^+ z+FYiGvvLgvOfP2>^U>1BSITXZV@ZjX6mOU=#hCrmB{QS{$OTq2J9zSva~EUnF}1?+ z16QA?(x+B2_a5Z-@v`YZUUFo^)`VAC(u+dMeUbfFdv#9tZeT||yXWh))3LCwWW>W( z_+%UxlgpErQ>_}~Pm!K7 O?0Xpn)n4;mpW0zW#}&#l|8OeqWSlH!iCQ>Ta1!g# z1Dnda=tbQ*wy>aGIu$rw`aJFty_*F^jc^Os#<`6{Zv(fk%-(RAX@5$qN1Y7iw=PG3 z#Cb!KYoU!v^U!1a^twycrkt?#?y6uV>0Il7yQ|GozNXwr;0x|HF)E zEQ|NjY#1eYpI^YPm{3&QJ)t~)1!dd?w`)NRDTq5R30_w>NHTyIah?ds~|9jtyr0v60(d&7+Go3F`EL<@{=Q zC_GQp*kX3~*0IRDUR-8So=nti%hT_{4Dc@_Z+g3SHHGgvoX8jpkVnIO1mM3eQCJJY zbIW_i+B5uKj7;h=(XG^$y&u&1r&gpu2WEtMheCd1I9rjX?3X<<*&5sJH^PFhu~8k} z%}hB7&zC=t!S&2pCShujVT6CX2Ub!0fs?9AGOTvOr+?aAFyw+2baoXg`?$)(+`n+f z9X1K0m#}Nrpl-b0$-TvP%<;JO-pJE|#~ka;pBD=g`>SYB?e)pLI`@y=DGYel_}JZR zEQt?RbP1MP2&>4Xx{0@Vw?d!d7?n`_?Jl#h z>@iP-2F&Y`$9QW1C#tw0TDA8Ty=?8==|~upE;YfGh-7eGN#(U?R>l!8mxc!#%QKcY zgL!M;a~)grv+ZIjtNl814t9NXi$~criKvI$pboND1XVPcAZ~#{=%Mf@iD!X`kSZKEaNwaUI91WDTZh6dX`~X#gA-8h9wCAg zS+GdoW=I2-jD(#mpCcMRT{7_v>z(_KRCeqtsPu9oUURo$8U{ziz(n~G58eNNR?z?D zMfFaWh|*+jPXvh;zh%sbIYaR+os@!!%uQ}1t_p_1WNkrp;Ky|eylj1R6m~O`m&hl3 z32|)uqpalRdmlZejynZAQ#1?_GL21(|{u@ zSnyX2n;=oSjneRjdKns{fH@!9oAzpau$HQdVk3OQNgGO5Sz&=k~xhHLNEsfbmTTo1pwT z^kYi$1y!&P@gsU&E}_C&FmQ+{l)h=rZjPz^D|faqO`|BvjH#F8i!&U|q??q1dBE#n z9EZtwqH$*+VDX*m1Y*hM$#(teLx$Wm8JmX#qAH58?aQkQ$8j5(+r{vKLnBqW$}om- zZ*`Np2U11YP@Iz}-Qj_D_>#*}RE@z=uZMNF-W4F6ecQw=vB=m zAKh;>#vn4a9B|eA?fYU?YVgQTH~t^3N;=^J})KSzfz4oD~5bp=Z%`5V}KjWoJbWDPudv(Ri~>$%s4Shdf?+;kN)w-rx9 znT3H1r>6Wo6*AD28KPA>`T2D7{YIwL6+|oAzz9a{T@#0KL4hlQo_!hvXYwlPG7G@0V!gPNc;TNap`^%{TZ!& z>rWmM8ZP$sw-83?GxO<^p#Ii4&|q5oX7dBUSi z<*&qle{gr1>gCO4tv5l$HaUe|-}86`I!CzdrhYTLxAP%taU20nWf5#_)CcC7nJ}1~ zqxo_tI9A}_ZE1VE==sC&I7L9*DHK)9#%sd~u4nB||77p|3M698)9yBj$|=I1ijAR9 zWoH7**ZXrO()4W9ixk&YP&Q#yb~eLgdD!&}dIA_TQh4F1>_pGLog4UbIt6J&+xznr z3_2NhmtVQa4LW*5eV!TZn zYUSNsmeNQT0p0OrAJYG=mou7}a8eMl-hz0kjrh<>3RX&99w4paxt>Y5?qN4lgc zCU9XIn)OpW9*?~8=uocWVQP?7P^`qvbK2-F#uOa;_@c8l2=QK7TlD$eFJG%oJ*4?0 zQ%_aui2l2n`lM0SV^evy>|%|FD&1Od*1c1j`Lkx*S$km54+dwtz;4Fy{7pgJdDp@P zd#)H^HV77lXO{bUvz7#d<&j zlTGt`3`iFQD7=1OpTtEU&!Vmvf7zhFb>Y?H#s*P2)62Qqge0n$R4aL!QY%aCTr5&{%N6qD(ZBY(^E#eAWGtDT+Od0EHqxl&a55qMCwCKOVh*mewj zb(`Df1oeOl1+AWe(HL&dC%nnflN+8oR-mbVka*Q8`P<+Xf~V`cHVj&@sK2Fb!d^|> zp*eVW+2hJU0GD;|^-Id-xBPyxD~A*(%&89qfPt`R@o53L^*XzD#c_ZpKoHhpw;BvZ zF)wmOhPkaDjxqOE&u}eE+L2kL9IeP(;D-$<5}^nGM5l7b)}Wp!rXjbcCxl)?mjX!B z4pu|JM$#nq0XKn+AgW}^>~Wpvu~$5?ny>|r!ML6En#eC%Qy*`{Q3+r86&%RfDk+xR zu=tNA?VHGZOt~SifhPe+S{d>1m{EZ>9${17tp$1fqqbyUAm{up;*Ghb#P`M_&y_+W z0$BR1Gx}E^19$(GPm+*PzVAbou{6}o%0xR?_saINK$d?#z1Wm}{wbpXg~hXzKPIDL zPe&G~ZXnQ9QHs(OZ`e>0{;j{ABYjZ9pzH;xs7$h0}>uP#G5q2@!~ z+`{MpUAWc^ze?a$L#-}v<3dm~X*=y)?I-&Y^;)q6Rqi=|VnteAj<>Qw>p2cx z^5)=6q*MZ45~fb^YQgCtafjXV*}75Ico&!<^o}vZbf%!yj99}YfxLs0Ok9}j+b6bM zDKd;saDP0a3*=IX3ZES?HG!JpF5G%3k$Wjjh95pDamR})Y6Hd5dPNN<(_!;HOc}c) zWaNTWlpcA!G>k2}Aya#hz2Y{1#%Ju9nor<_kwkOO42B8QJ)3!gy~3J5!>nxn8Mv)k zKe_DHchOiHha2Es+tA|XVy-bgt*XR#Dx1hVtC_XiTR zLtx#+Xc=(+-a|3;3)7+`@WStZ*CT0ZRbj9^zZD4XOaflOzKv3}dREp71!zj14?-F4 z-3m#zXY;ccOSRYbfCP6fW2SHQ9?T^+_s^*mfV|dat?*k4b0PFlp>4py-Xaw7re1q% zY{;_~p%A?XBVa`+Uor-m#xcM(A5Q`_#& z)FSA)4)>WdTr9e`tgqe6&+pHr?Z>R#!h1AnZ4J!-$wEJ`AAqq3L`vr|z@;EgG9r&& z@_BiJu*ahub%#RgKeTU#%|H!KqS`J0kO49R8(yG9wX~|`W4tQJdRy_p4}4lyQii6@ zj{Nn8JXSp`L)J)`>7`ZTSkm1F-P7`%g`(mik1}24U$Z^F#gP*>`oQq! z+5p3Ak(-8(sgi1em^05Ae>WRo@Tz;YD?iq%xeqY=mJX{*`b6$P+HkYiz-I((PW&}o z8?Ga`#jlHPTCW*=2oUxMc*`p3jXPL2w;aWuzLDetupGIgfUNv6r_o7EXWN7>vkG#; z9Gi&KU{iOS?w-D!K*ZJM2Y)fdQLIqU6T_(X)Roy5$-mt}+lG7qUI^}d8f|P6Dfk_1 zB5OpVhl6V>&G!H0_qNB>sI|)DJR23UX*r6`5n+N~ucOqYfV`Hc6IL!gEYp-#iKAck z!LPByrDOy`e9yzj!WaBb_bjg8m3)iK`)qsn5C>#4rpS+)2~(g1_$Q71>q`GT@q+*| z0?O_rmuyJkRn!|(1TN_gnnf8>Tk?BZCBCOPvzixH6EH*U)BGjX{4wDF;~|ucAe?f^ z`r`D;U%KMD8j2nZivj2SUP+{cx2#?x2%wiTkj@H3z5mN_kMn> zBo7BRIJG#h0<@&E%lksUCqz=&y5Lc52t+2M1*EhWnz zi}}9{?y$hm%dnu_TZjXRa*7eu z*8WqeF>T9Pivw0ZeBZ%`NQ9PM5Y!CeFe&KrcN{=0bA%qYt=uSV4pYWucd8{9?~1|C zW?uH)?ny^iLlqH2&t*XdkA9o+>G{+{)J*N@DFajmrK(&PU5+7>-3w` zoPyK}UaO_81MRd|xrLMi>PX$3M!H_*Y3yot)nX_%UU;rh~by6izLY79=h9AZ5WX0rEwUG>!8MV3UgD62u;tzdHwA8<(?~ zM`8GUf5T_x-TNHayvupF?ueD@dO)<~%s%7fbMTGP9vvx@^E2k6-5>1>pbGrqRo}tD zDl|?a1i~9c-n+`BdIV4@4B@^+_<)PPg#Da$N|_L&S;tN%&rR{}7tz0pWcgWg(I0-% z{wWW{83lSP$>l#4gGl;DJvM%Q(g$M7IKud+?`MCeD40&OiUDbZ_RkO`;=rjXH%OO4 z>cZcF3O_42Ko)*0C`aRwhwjr$NMb3=!>wO_{fsnjXSw)m*yQhNH@qoWvdD#ieM(XAW(zL_ z0+P1Zg%lF9{9kg=4(A1ahbbvBqqmb>4u!*hv|+bK#kLYCI;ehxwde=-N`8WzoV5jr zwS`@Zld0GLfTo_L!3Ews(Tc?*bORlfhIx^$-TsI{5{fBetG)UF@?;ucMml@pCg-S(b-W zZtqvwN5WXGevec5cZsgnZZUU}?T38FUk4;nbHwo{yAtVBk2Cc?qFb-ROq7uAcprfh zVWP?fg$i`#-9Wn6bc^7hcray*fJXQ@XoN|sLEb7B&uw8iy zk8qv6x=Mse8dW{>nYDKKNoDzD!6;C?FOUaM$OVIDY2ZZVAnE@lf#6C`VhivaChv~QpiCz&?_)m)FEB0(|;w3$R>UYxS<9G=cm#K16jH%TCxNM>44#B}FvCu6K1 zey4N+?Hmw7{wnQb@C%>(!Dno&R-p6lr2|f%y`SU~H@zIt^IhGW!kaS({hEH{Yt~K% zc<|*+F&utt%DOj>JP#zv@EDw5tcsd}PLbOb;b|Ni}nf{m5=1Ngfs)w5S zpQB(e&l#Bu7D11UvH>pcb^N*Ls?dl9e~bs%*j?GvPHd~H8%{ep_41B#6e)3cD+E2nD4&e?t20}a-;;| z!X39eJ~x$%B*(XQ)wcI(;gU|X0#*{JCOeBBtrs`LM6HB#5t{O^%l^xw_a|}6rvh$t z2l(61hcG$@T%E+j`4!?ERX_OZ(;~&K50Bd8#t-y5iLzU7Qh6jRX*2q2)ag}LoyNj$ zD8kNI5MMnfj{6^nGNTiOXe(fMK@a~e4Fr5yn7{z%qVHq%8Jz)=kQRb4^E(?&`1&ZvQSp=< zuRq|Tm}$2E6I__(DNS%;c<9p+;wBj%6`jiSu!-NUN6K9QM(nDQFcUh?IGq$K051X2 z{@^3zf_rV51Yu7=+2Hhlh#;iEx(ne{@6MCK1$sOEV9x5bXDHU9RORNYKg(?)r z%&e%21`yrcmabQK-TailBwKFxidjIF z>(emf&xtJ-m(|Nv%&$nVjMCFU`B{<1+)g)zJ{2k=YlddHGaGCTG!MTb?&8gj4ZjX{ z1>AHdC=WYqCfRtsuyCKLWM?+CtT81%5V9jba3*ii$!!QI-Ex`U`qqRGdO7q<_)7Kb z(ZHF?l#_-8%>o9QVtmX1EB!foWlO&-@IgxvT4>Eq2os`U3)l;L zSP|}+V0GWCY7zYSu>&eU@v+w%3yfij+?8%W5+@|QRJ4YFzJCHMk$PXkBnD2nfnc~J+4G}Y z?%uqb;Me;v6z{Edx7@8fGb@`B$dcya^WkdNw$}4=NLzfz)YvpeH3V;~o7SP>_4HA} z`el9vdq20~B3~eek7L`hu^ShQF>2_>t31u+A2490MH;)NmvOuoVJaK^aCj@wYfiX|#>-LvR6b!(H{brq*upqa19dC8TSLr`g%Et>r z(t&(Chs2Qg3&`51Xssu5C?SRLeOl~0)%$mY?8;uAItbk#6-sBj6FU^quye2slRLTC#Ln&{W*)>z~e#)Yd^d6bBto9$y4nCjCw*q=p z2p}n)eSX1Vvan?D3IeZcv*;;z}R1U3^nzCN-i*dsw4e1d*U@Y+;7xi)2|4AweHjs zx^p~$+Z|=s^C7x9{fskvrH7Jinl{=506I*cd&azGr0#RYp={vaE(0-~#fpp{F}}kF zNz{^|^yW3?%9d7#k%|Omv{#ldIT@#cD{?&1EJPm(Ek%rw>i}xjFktJOR%HrjaSigL zaoYOz=UP1-Msr$~vhJx1LIhJj-7N*or}b^%jVyh;*`u5hyONww&+~@2Z~sn|?ZA@f zn5UL8h@QpY-YhYum*1tH9=$%BUAUQSMj&fuQ!^*m;On*}&;yMR$_pW*B(7MxD({|z z;eRDB>qOnY60>B_?dBb(qwY6q%V5qCEt~SOBE8=s(q$fvhw@=NUO9Ui4+=_I+Zts9pLw58|zdh2-CmBlQK* zn!=KbP`xwqezgTO%?`hPYw8MJL8){*Rq(*Dc|f59oADKgx)AE z74U)N8Ao%zXIorG+rA?PoXhn0s~?{e!#24ulcj&FAbjXdO;Zmk&17%AuYFQAz_xQ? z`j$S+UC7*>>8@U>Gv75mmcufm4n%KC3nTtNT&krHG#6x>IR}Rn&#MQlub$Ral zl$lx8U5B?KXNkPDAjYtS`MYZFCp~nT{@h}Cj)zbYey-_8qaM~!{;mS}=UBfPd=C6p zNm$mZsCNicP0ytX*XU#eH}Pxq6chot(y@M3S2z!@mvL;TVU6BaLCCyUx<#zHugNW$blj{B3+*aup zI>ur%+Nr<^vPXWfckOz4#xt(rdt#+3(a}kH>=i-;G>(^)ZTMM&m|a!W@!VG*y|Ep^WGB*<{Ia>IK5K!hYjn5`^k zZH;i);>i3O+NsUoX@*Q46i<-{xL^p-`kaEsVB3 z_-*O^!-)Hs@^HyRzPdKDfa(Kpwv`WEdjAr4>vPXwCAi;T zF?H`dm(V6*<#!`NTD>sjO&!V7$( zLvEe8iXhb~+2ds6*$L%a^!{=NdT3jFHBy9Hj)7qaoy9p-P|B}EsJ^gc0nz&*kx^f1C! zu@QvI2*>$8tnrNWB0lR?ZP}LDE=c&1#B^E|B)Mx(@ad&PTF^m^Q?mNt{>!CZUMLmG z&sV<=s1Yw{^!rRX#eS7cKXIu@_eulfl#u`kXClV^?A-02OUQn88C{?J8zaoi*tYfK z`+)mC(;Lv|&x$4;41S`Fh5Ca#zw=02|NHkd#ftUGN8WKPM!p;( z1O3h?0F{bN0672GPiOUV0OZii&-%8c6BMy%$wo{zeORJQ$nk2v=4lYf5D_q}<_yRb zSwx)I=bjtw!l_u2q0p}V3eiSFcq{YT(&m~tS>+1LmY=S=AzQa!C^;%J`0_SOT7z;M zQ0V`hm0Is2cz=`2y{y2DJ?R<_( z519&ysi)^M$c%g6t^n|*2_v~OssoMc-mL|gK@E+QCC4Fi_Bq_TMZ}Uk4Fb3RI}L92 z&FqZRA-TjOm*jKE8Fs7h{xwU1X3#)!iIXe)3nh@_gzhvucZqknep)mmCB74v9J?3m z8Nu&;T96(-ihM>N_EqB6ZJzvRdcL}Hc`JTm3N-ya5--jG|C4QGix3%#9dLgKk{@3z zZ~?O+n?L6-M!GbTD=t_mu9agPrd~Bc>FSnR`Bx~n)JGsGsC)me%wXNqbQ{6uMpHg{ zXndUnHaf#c7k-rc^+bBkw=rjJm#`vw9+Fj^Vc1?@4UU*(dze3 z-J7BM-;**E5R1IbQwpJEfVg?}b4TQR_5K_&9idv(bT)qQuNQvS8i+v@Ktj#@Hst)b znlqn`*FbCP{B0hIH<9n8?yVO@f-_|Id6k%dj8RBh&8_PGCvvUZwRb-V0(3|>Vu`c- ze?;j4m-8>Ft?%J?V|DLXTC|u*KocqFMnic9ptcpB8kDEu6cReMnY74CDsqbb_peC` zfTDn_Nyc$Fh!v6f2LBJ)i=gZ=fw#0}H?UkiYN zZ^bKLATNJOy-izxi!D=V@2EDSsK^4u$vcOV6mh~*iaJ=sr0P&W1}qLUY6|`*;t|B{ z?!Q5dgN+WL=_7oK7*nl?K1@7S1;S6&JYxK1$}83G-vp{ybe_WtC54->nVK!O_fKA! zF#izAAJKU5D}0j6&;KQVFw3xir`o++n^^*q1BwRMKcA2p4H-d5&e|(35?s z=y8zVwO`*h28rK_X-dSVONAhyP%=Q32RMkTZ#&S!`bpSo9OV> zwG}2hB%FpADoKtgW=T|hscxluZWTZ zldl&=ENvTyxsx@eWn67r9U=O*61wXT0)k zE!&GoVT806v;UlmS=B`?eZEa6>)%=^`&(Q|Es1WH2=Fy&2utz5H$`JZFf6GxUJJWz zqN^^kc=^u_?j5KNjj$g7P)t}lb{V+r#ENNGxZF^Yu=f3K}g^!H=qAF^VCWM5Qd~hZ1##8+T@_R_w%d2wV1smr=(0=Sa&U# zB%Wl;tj}#1GKHsEB$Vu8k-D0nHj(PtsavUPhbPPiNMc;^klXOAzYaR0`Xk7O*ZE}i zet3ABVWw5li@=IUej7itZ_4teS;Qq{9oJ7GuY*g9W2yL{lk3KkZ}VJZ z^HTJ}p(ZDIbK@=B2GwPRJeC!i577427=9 zDM{1xue)Wj0>u-$8ITRPe>*1dOZ6Q7*`1TOzq6%%l@I4sTqIvB*zKhh!=#>GC}<^i zgO#RMQ~cj2dx>6;IHCQ!9aBf#fOnIav^bv@4Zcn-sXJ5mc)OBj-*cu@mLE-u@=V-sZVgx4_uT3#AKkmAJubo>UpjaCT~rM2mW?tV2i*DVu6+F-j6iUevW^n zv+@GDi5OJOOMfg(Q*RerkC9k8VO9t(<9H95o}#DuX_<=8K+O3Rw~lN2iUm^WuUPGg zz?%z(BwAhbX})$qzZK`7^=69i^z&iZyfpzHWXiXv^XkU9>vRF3=V-+ZIB|7K{B4&% zEq^n>JmP96hW(GEe5DKab}NzxrVwbXFr&WUyr^Vmp5&S>Hd-jl7wZtaYC7+5!~JK| zRL)Cjnzn|=$0{#n8svuep?&#wSdtM+p+#U?0$3&dV8KsG8SHMRNe3;B(K7ywY%3vq zsCH(bclAHUdIX%gL$L+&XR0nikQD4pPgU!C{CLVrm14NVp7NP{I z@Fe(HlJc0~N8t*=mA#*dL6>Ig`4ZB6{k5yddm>)6JrIu6g{B3o^EA;|(0kh2OVbb) zBT6G~iz_jH+Aqm*XsY%X$)+Nay3e@W@8_G85X6SroAt8pk}N797xVbr3ofLEFyquC z)h;-p{!8vfqHrZo)V)J>(2MkBPZW>~^_^g6nmQtZY>*@;BGNgKt<^YXe4P;x!D^7? zCR!dGVs#zo1_}~?aar^~0ZH!<{UBkX^1nF{DAr#~Oo?<({z$qk zPQjiBq}4y62TmIWzh3GuIJVO81r(q67ck(qAblM1PV|g*2&VU~aGm&AxY$uLd>lG6L0A%K7A}|L|1q7U*xEKAr@PO8+9AzqpNGy>)pgCd?9Z7k3 z@hC^;&3Rj81I_w{8|5ik5#W`}Avg zzD1;l`j)swES(BRl(-SyjYx_~%dsj3c>&ZBSz_W$H@=poT5qzhJ}f(_jTT!c(|)C^ z29%9Q#f@)_y{?{t#TTvU{cr5ySn%^w zwg-ZD-)syp{eznzmr5=F_X8hdSCc_AJLD(-{Vg%wJd)43S^v`yyap0zghmsH*;T|x zmw(|l{_*vh663W(*AVo?U2*gfNx?c}piKRcth)D8wf~Sb?)~!rIUuBv;vuN{r&^N? z2GXM(C>Zr7G8P3g6hjtw`zZt6L>9d`fB+rn2goG?CgRsl?PHEgZH$3DG&1DJQ#YY? zc$_IlayXSz(w16E`hHjfj^(k$SzD_vB-$K)sGKiU?1|ukN?`0y>8iCQkAtfm198@Z z;XPZ#+@LFBulsDgfRiubMv3l+*x7U$<^J*pTt&hR3qJ8i$(h;eY?1TB;!p9H561@d z*b8>qf02LeA=vEnfV~;gYa}KJaI*^E@y~mFr{_O!W*q=Xj&xtfOwUvUBo+q*69ai= z69yW-0aV(j&1YC_VJ-pY=q9rM+M5OQcYtrsNICsvYQL+8#?FB5TemBy6uYc*s3buu z=jx)-VWh=(MluWm+fxm4*M0QRCF{hygUE>!NE%R26TI7d9hlFYTyP#q<+!eV&J#g4 z01Pu1Kq^9jc6HG_Q02>4LF>bND0eqcm@n2Qz zRZldFSpN?x5diG$WqWzE#g6#GC*&FflnN-j{T?Hwcmj_<62E$3GwIi%c=n$DVKc4N zz6ge@%{n$AbMJj|yq}wZh)qXO=_2VWfGt}EfVc7a15`-P>Fx&!iU6kpv-fP1%L&nC za0-lC?GF(p56LwmTQ+8cGrr4@1d_eN{$p8skhee3y81uS(BwJw?Oz5W2l$u>ZmOKv z`>q6K`M>%l`iPBDI!Ixso{Pj%FZ+}zc3^H7u7A5U^P3Lt6x-?N zd2K&=O8anUgY4R0_3In=ub>y-2Q8_8t|Vf1oBmVwy8Noc_kfduk&MZ~e`N%yc4Pd( zUqGD=a+jqz^gqxPI4PgRXWQ61E6&pXSK#gKy0LoFkzdiacMabWV?rj2GznDq6jLil@3BIheh(A(I@4@nyMmd&4)9iuv}s z#PAXs2LZ~ z)l^Ds6lFy_pyO)bGO75gt*(0U((4?Lk*TFZw*07N{vPq}(1ptdBnJaWxU!!EX+rVxI6OTn-wL%85ASLik$gDm?*az;g=NYsKr5n7k>Xq>qQp z>(ATYWCWuL@6gViB-?}FNtT7b8^OBAXa(~%p{#%=94p+!xl~RS;-{5Z?O>Jm z96sohaVM#86!_@5#`h0Ifp56iCBCyi=&c>l=h!CcX%oBgEfrcV5?B=89&gK!yz2VA zcgSyfZbjyT$4~yVue0{x(D=rU-4|)R_gbaUMNi1(-@E?TP2s|E(3KWF343{D1-z9p zvpA-eojLAY!`^JHqc;4&2aGpFOJd};jGS{`s(a_>yIv3VC)0FV;__)g@>UjDA?E62 zXh=iiY5r^NCdQ6B8c?Q!a!-XuT$n48#V7uJ5^!9sk>U?fB_f|=!uk?xI>(=aPg8&$ zL}+z2;DZCdnC5`l^IM1l7W#i4H6H-5qwbu=17m_QK%8Dz0L73yUhJp4Uvruh?3t;x{d0{kUnm>;8=ONG;k(q8zS89 z&-I=&(-?G)VsCcPaRa$R-IL>p*z_wRY-oe<6McS+dsCGk*uK1OA5Lr$IiP|dhd++x zkdztl;{OZ*PAFbvZXW=7M9!v8>tuP)q8ZW^ysHOB!WdL=+^m-qzF_7)1Dg^#fi!A7 zXTgZ?0_rz96L{pGnv?>OLR!EGB!6XFoHEq{V%k7qE1}Keo6K0_KvCy>6QMinC-W;( zLnL!RnBrJ8?<=~$bx5r33gPT{aDzN>Sr(3sxw$){RrKsaxJBVP-3V_)L4+g;cYtvC z@&Bm$%CNeYWm_b;ySqbhcb5Rc-66PpfB+K+?k)>=cXtB8-7Pr5o#1xK-sjx+?%$sM ztu?!=t7?ofySoM&BVyk7d`@=5@W$WN{Tr;NIEt4Z)4j;O4PgT}n(B%ZvCQ8SrX@(# zR#?9?17IEGnjXj^>@q-Cu1e_~E6Md&yrnuXnGU^Bm4El%3SJ%;FNN|jMdje9rEDLL zyiIRI8RU%w8|%5Wzrd#4Q$hKt&FgZSmdEFP;1Aio8hUvFdmKiT>9a19ZHXm&s>(tn)OU`Bv|arOhgb zT=EXZk;YxZ0TY7vM0qYAcs~3$d!AZzPSU;NzLV?GCoR_7-3u&?Pz)Gg{?7eJpa4Mt?up0MgQtC{{^w{U7wrOpGDbj#|$&rVcv;y%0K!0vp2r) zs`WcXRF=4(DEn7h%9_1c)%Xs3{uO=eW#XTd{63EqhfkAT?`o~o`t>6EdEY#zYL7R2{lP3woQ3eR|=v%4sC3_N95K(c-|5c}`g`(R3 zzU30eze3zUUbSWDO7O13eG068PZs~^Um3x`G$Xchn(hf=kS^NauK%)of#M(MjpKjw zKH-m2;{Q$2d%RK1-kQiC_{CK_&ul#R=@$MYYIrL2sY3MinC{iEbG-Z6e+ck@NB6FP zcxxK`H%zEk3mrCBLi7GL+drr#i z_umr?8F{_`1D3{J@GE{4d95w739~N{I{!c0G*Ia?NJh$cwpuwo9uI|LA;hjSqlbd2Xm$r^o5Q`l1>NH5iA->0Af1pM18{zj!U)sQ-ZzWDFbowfc8W84dL zXBr_wXb6#oe)B@8ZMeK+gcX4;7Gw_v`=$<$$4K&RQ+n;wzYb?6h4lU`KHWs(zA72k z@bq88Qp9Wbs@@G>?5ATrcWSH}uPQ6+IRI2%bKX0qiTek8a^wV$|yq0ly)cDFNLcYYF3A|ITiH!FE zzCOFR@$N2^_JvOd>q+TH{vOVMnFT#^hZ*PH-^{)iPWW0*^)G6f?ONEJ;}nB#@{5F=?QIw?2QUpyst3ei4&2-KpYAZ%C7SZ)>e6lC=Aj zqK&rPQa)Ul%efy($~4fqUklo9@XWK|sF_fRjcUg)0Ya;aHe2opHB_^>-jLTw$uDVd z6mN6(dmxo7ucjG}=gd*=uL1Yfy^UOo0Ko$X``{X)d8m+RAJ;>#qj_P$$!k%M$0vcw zS=6Tdw)ZbA$$e5^l*$MuuQ>uwOAw9u%Mjib9A4W7O7+gQuPlM5=19f}FMrVoA=e7X z;^yl)3qfxgfw-2N%X^-;h>3c8$zJt%I?e8SI#2)F?elcDpW4F=WHV;_-u&L->NDKN zp}GBf_bpE30)O^-I)FUwHh@Q2>1p|kVXi*n)!7|+z7>Ow51XBc@!$X_RAaW_E!Il^ z>si)sJS6RD`xJ8UmTQyW>Gvt6v?VVmwbfHh(4KeeS4DIxueF+BXX`pubpL5T`+7Iw z+%O`{b(SLo_*P&+HOL9g4K~_1&#tk{aFg58n82=vy+f;)Wn;r!1H#)gyn^Yyl%zR! z86;!=i}z6r^Pe!xMf9z|aP1c@D}3!9w}P#6uT)o&gG`{nVK z*l8O7+sZDwg*6mNk# zU-j$}WxaeZD#3=$8M4*r{8Q~gR6vCvO|XJBCV z7@H%0=eOS#;2E&kh4ANh`uaRrmql_#?>`-n zL5)xpt|qc@hK1IfrZg-w(IbDu++*vb>zl#UNR}oh#GQ$vbBj69xmo?_;A80Dn9~tA zubM4BSAJdE8E(1eR$5%8mMD0NGHWxDD6K}MHy<(X9JSIEA!DkutQENnq)*mA93jD7 z+h>tls_VR8c@b|Mkx~3*yeXtYE*?{jz6`3VwQT>Tz%Q(xM_taf_lJ5kl`Ng5Ap6&& ztH!XxHw?sb(3V1(lPz-KrRHT02!GUMBP#u!2rk%4J*6%d)=8il zj&{URDzuKZzSR_tFM4V+P$O|Po7O+JUu-v0P@a#XqdzTKoA*;yak#KIkL19=#5xV0 zG7kR2y%1JOdC3hP+*nVAgJ8&3d{)SR2d#hi- z8do1e{VVmFZQR|MhS}2XXPY6chgcX+z@LRl&{S;cMdZ7<(9PZ|5H74UQzgofUNHIW z6HfT^hMd9cuKZA7Z+PdyZ>4K{qz!**x_UTQLPE9CKK-GX(J1Fp!h{<43`GR*11VUg zT03JIMpkk;bD{5dF(Oh-EM~4I<#|}D+ZpeBP|uKj?aGK9c}*P276DV!G|=%tnV9^< zo$ZTiF?=^ESUM~Nv^j-l+grsjY7Cikeo$^(99@P^`DxBfRZnXVv_o^xrg4lbY!H+)b0(hxH&>z53Tc`f zfcF#^zChnmWBW)In~R`g9L*vKuFNpI#krW&$7h6-hL8OV*i%C_ND9LF5oRF8!@=tv zxJ^z9DXUwgVWpN`(lHS&!WT52slcddRPrl3yZr7LcexiwtqIj*xIfxnVWjeVFNpS1 z3{R1^Fj4-e;&RwwX;y>;vU(+qtjdy_9BTF`DVV$R(wF`5G1X)bpM01A+i(`hzEu(L zgqVle(~E3mpz#4TNFa#tpbBGAcL+jFg7+`GzR8T!F?dVFv%>v44m-$xmx{*inL@d0 z)%5zNy<*puIhww8;RQRp(eJ|mgR}|sM4R|4!Cy= zFa;Mg+-l@U$x+G{()-z%7r4-YFS2;(f^uDJC!MLzc&*S+^n z0UsFRF7Wct#>emt_yMKha7Q`p1zX8<|D_2uy)c-iyn#r&_mWtvd2fSkdd~Pnq(s98 z&R7NskaJ3hVEGPF_>41^Yi14J^!)lzIZpX|UtPr<13_;{3l$lH*j-Wa#>Bk#ie0$P z+_xUY0KHi*8~5pZwj+7?6soEDepq`a$+4Kd+YV0?^)qd)c;eV?r&bqayvmZV#II50 zd9~9UciJ+MpS_!bU_a3YSvIF^3KDYtEcr$vftECS+;!qli#_UQQXCISiKxzHei84N zOz_jsG&T!wl|=}ljy0fv?ooyD|pSYLHbuPiJ3h4yS$FqG<#iE|&}Ny3IGLK__i2 zvL_cZup^BnRKL~7Bl&46I<7o=42ykdm|m%hl!bQ!IbnD?lx}391uTV1jv5w_695B( zWu664)eyzBj9Q`p5f=`H4>7;hvug$+3pku&bA~zvC8b>^z3JW5#TE{d8ex{ahmQtk z8hS7ujVfCH=e$yn(jMOXbf=nwk1D~%@LLX%%_Kr^;gBn~6|UifM%&)61~~mfe5UlS zEqh@dPk$yF^Qi>LtWNcHUfRKaX=C`yJ3 z`y}FzB1eUIN0y#_bt?KLKr(#&gZ7NXyn&r37|6tgz=TR z%J@=e(?Jqq*4pk*vBx-KEHPPN6$g^|Jdi2sXj|?E&xAQV5U|s}izAylD5T06BUiU= z9DGrr$9Ydb;ugp4RG6zW54uS?@?dc~H;AgMy&_bvc*@p!8K_v7V?RrLrd`vyA?6D@ zv+Z>tuXwD}!wKV2PFJdC2fkEi_&aQptWmL2U;R2@brW5?SkkG);HNm*LUhy5i7tVV zV>~z~O#xXn*|DGuRcCM2#eTY#s6>`Ui5q=U(_@kpLdI=6e7)%RGr4zHVbia=?72{m zKbesFMZcbpGFoYAp_t8}4EWSa9U^z+%-$0ef*s(xOS_bE36~oU0LdAHFM%6B>go98 zez#H8Sy3=R+v0dt{ko_FyuPI-!kN+e83l(&e^N?9zZ8Fy4Hl4=Kle@hIHW#J8rgr; zqY)QJ(cRG*Rd#^(TqmJ1@SAMH=p?rcXSyp?Vva%8n7+CHOPWYd$Q7MWc>Uu{ZC5*3 zxd?=31_28cG2w8HIZ#4neznoeQ2+82;7pa$Bc`0pfbT0!{zOc_kw z{TfXAlR*_XdF-KNG|v)@4c6haNJZ~`ILU42kbnr(FIDf=tCm>?$4ul;5a=M~h7Gko zx@tGLEe~`|2?oKX$Qogso8C)`GD0HFrU=@}nNXBbtDO}q z-vETBx7pvymBT$Nr{1c=?`KLqFEO|mR1kKG>3_kTfzF~1f7$uKFR{;)=Qv?_6lZTW zSNnRJv90AxnW#u#2QA7-m}BqV9!l?Tg^J+MNn=4HwF%ucd%1!mnm;0$Enak$VVEf6 zeKp^fapki!jk$ZMKAB8_`=;DRTbHmd3;}qlZ(hoWdFf(8k*;iQW_&I}Y+WTQA+pDi zEe@w(H#}Xm@3rkR*g1?Efw4JYbxk8bIjoV?ZO9FCqe6=z{s>bmF}qqPo{29G+nV z*J+lw*q2Z>6xGFcc{Kv0+H5koHJ{hvwQY59x%hVS}z5JV)4TVdJZe2XN_7t=o z>hILb^CJ2)rZ7^73L`5#?;y3H+frJU*WfP3jk^WGBGhaqagsdDUJ)8olZQ;hPZ(sz z(Jg52<*5U98C-R>HHVN^eglTh%%gmDv_^>uTYjbOmF5jRcwdRjK~S6*GP84&Y7`(` z=s9*}@Q&2*d1XGtEh3xCAC(x zhv*jS97Bz5#7PU!c6tzOkstqcD)SbYxq|(ENP$cE1fh=`va_|*ERZ3~>cMl)NJC1@ zmskf*3$uGGQhQaXWNWz`yy~QU>>^s-Uafl%-cK-+BIXq=0`HO(q*9Z?Jn7uj@_5b% z&3DE^$c`B3ZmpTSm?l#Ce4B+QCh*d8j+F3yAoA8&QP{CBJ2(ARy<86{jBe_=LxL9sm(EL`nNGtm@?J^OOoS zX9-F|hRO2mRy(|y_FB!Zt0vrdhAf!l5fnW}1(_HEMeJsM;s!M1oF$%k8m%W#jg~Dp63V^F)srK9DS#!@BGpx76 zye)x!&r)n^>DV0=nb)hEyL2{n?;I10H@ul!MF$uNE)+*bNh%ENIyV`?orw5p^IT@< z7gN)?^*9<|El^@e))yi`QIZrtT%7QcW0+SK1okG+TTtK=D^+SO;HMW%|^4G7uUq>mx zH68ZCWVNuCt#)(>6Mb!sVa4hABGP8C+UazB!Kk3v*k>&RM=et#l^M)*cfAB3?;SE` zpF`>iOOFs0Nuc)S>`PXE&GLg(2gY^&^U3cb3Zo&0>CGXcB)M%6Wb^ZwdK_<}k_h#8 zu#<2+W1v%j?Z-4)cxE7*K4-rl?g1;x;)VNaF@hTXuyP}KxgIVZRcw3X=WKRPPZ*}v;XqJqV}R2 zYbZ6+TZg2S@()$n2u_6BJzaQw+4lSm{^j3qmfm!x+%yv&$+2}7aeu?HIq6j@?;T)v8Qa2NWN`8MtMmnL^ebCv@ zE;Ltk8u3N2^}m;jA$k_>C>+T%!G-yNXC3y#3t&Td^^>J~_vc3Ql$k`cAip-n&9JXF zHdp0aVS$ZaR%A+?{+i8e%~z_Dp2NiSvjEtRc19Rtb8v15FKwq{Zp^pOVZ#oz>cyDi z*~p>%s%xe-!6+XpcEVHy{$QP$jg@P0EXSVZ#b$keSD(d=6lsAXCd_FYeM7lt6;x=E zk|%}0u;ccH^|QpGpDOVziI8Nx2*n%^q6t;Vm*sGPd}!I;&K4&-QHa~oa5ffYGcfV2 zE5kXEwIE895%cB?4KXR=g%6kNaFP;&lCSh!b<3D+par{T%6D}$9G$7@5J!QezGE67 zrDNzic+Ʉb;z_=)FRMA<@n@?Gr{9!ndD<vX*ZP`AyIVVJfBGJ^<1j2WyRC!<9lGz zCA-;YGgR2)3{qz!5ITHFP_)KJbR2MPCZDf-H1;Y{5v z?~*Jz+M`&%WChby2$F!+ai5G*Ai|}p7;7feDQDSn0Ia3_8v7o-@j=|;N0e9C!3~h= zB6j?Hf!~^XRwyT_*Nj{Ozr%qE-NF6fu#4{@{)WWNi*BWXsTVa*@dX%4pwt=yq34_^ z8!2|)ZC%Fkn(wgnh8``7CVAMU#Xj};I&n@g@6f&kL~sZCd7T@eESoNUN*9Ma9Sq2e z$BR_!B{jkn#&Ik9?s(xb8?8$|`Kh(nB_HOGDg1sbG$XwWqmwS!$p=M3_fvbG41LAo z{L3LMB-ZWUUl~s_=x+h~#%aGN(p{H{`0R(sGez_szlUo^!i?5uYu=i{-UpvdE=zMG z--t(xn&ns;WKFl@PG1KmEu#~V!;>~L4P=&Cjbt=Y!1%0u^MJ!*376u17UORpe{D_L zKvy-cb;Y&$X-a*Yc3C5N?V|A?M=W?NbjG`9f2>y$X8P{>4`6_AEh1WvZzG7qoSE$H z%_#TXKYvN!TwbA&hC2NOmxZ45|7g9*v$>gU?jF>6u?NhRZcf^ic_R~e@#We1$>&qNSxFwZh>>=mm15Arv zki)c7Z+U{NWhsub+c)%C|9IX);t+?G32eyg_zW*mY)~B*O{VL~lwAU+rkO*P zVzxK$Rn1nW;MR$MU%|JTX=u)Hy;E3cv60E!@43^ppYgsStcKPTH5LzXpnQHctsZmi zt=|dD(4vT950T{n=zs^35-;sitqDlNu}fS3um-wuL8@RK1~CVujH4mTe-#ROysH0)Dv6S zhpK%g^Sw3OLWVvR?q?b6m2}fzX^`=3z@3Bgl@n6U`1CP`F3IELqdtD&&863sgxgQ5 z2+!LBZda0A>9lhARfDkcKVZC=eU956a)Ggc%^ScG5ev5S~NQmQ>EG8fm(wP}=Eo8(~&;Al>mJQpF4qw76O+CMoxR<$&^)0Ar} zB=cSXSYBsFrH}sL*x}2$s8r&06z2B5un69lId#Py>V19XL%@`-p zRu6Z#?F%h*jt*agKOM?;uQCPy^-R+&KrrUPwDOhjy4^J5`ls#3H~gNno7m3T6HM?8 zk$|?oA_a|ZUTT@4sE_WByC;~pp|OYUNG397e5^4y{kBLNZXu}NfqC3p-@r}v%b_Be zPuF$26W{613=li{A-v#HNau)i5FB?Ghbj@LZatmMhl{#?r&`7>0X*C6 zVq?4)xKk?nVO!=eM^;`V)8;s5vKkAAcESur9Nx*?x-< z@a`8R`%Kp)RWkgfX41l5Y`0IUlB-=jMcf@#o|>Z*>*H0ixK=3>TQgjA2mn!d9X0q# z2;KXIQ*)yqG&jYlPb8Jli7X)^Nas#*U9@ICUWci1I?p?n-}%-1Uxn)uKEFoWx-6i* zSRoU1+#o&?qVOP#uAQk8$HQTp`Qp=3^otI(dqVQ`7?p$Las=QLrSxKPGo&{xNfaX3 z@}y0XWz8mk2L17?BgCes&jp4=wd`S+Do=J#2=fKd*~@P!SzEV^iMsh3g&PaAW1$$m z>`JSo83Bta6cn*=ODdYs-ZuAte^iVC_G;RcUF3j2=&rAu@iTlf=b6}hu6F1bSaps*D zb+e~*pbK*R{dmF)%C>I7eyR`Zm4Y9q+fnYC`z&2Vun@ddNuJO;tjYEIB@lw`-#V$L@)w0o3>j6DviFpBh#iMP( z^|lh3*6F;1*o{5E0?B!@JgiENZxVkp*OxpTKk>P(sD$jXZExXXcbsE`QN(#lSOssD zxOWx~Z+aF=c*2L|bfxM9EjbVhgo2|d!98gRtyqt*4$N19WRL-~9u?E|>5xyG?pYKO zw9$&${16s_gB0lcp$OuH(1}mjA(vz zhN$-DNNrPaI%vkge(#?>IbIWs23vJ8Y=)p0#ys+195n%AZf$Kx_J&^}zAxzvf!O9$ zOLltoQ!ck#hDrbsjdAj-JG*h>f(^MOP9kZMh`C$`_U6|mb2zJ9`tO})<1NBm*s*vq zc7%lb8GMNgXv|(`1b#mf?DbDZdx%cs9r~#=7Z((@if0%F9JZ0Fi1qV~%qnZ)j>)U1 zjqPND2@i_siogbVmejfbc-R%nS86-T><1H!>+9d-@oxbS(gtKNy+W@bQ}CJCDh64h zIzN;M=Rqr~FK9Y)WlX3?5MZNc(&>>%tsfZ-WCA~15G69O@GM@5nQGiwu@O#)y!c|< zK=(%0T9l(_SHhd_!xw&Gw*QiWW5SlHDCsM7mywceys^ANL-*l84o3FR$uA?CPsQT! z&Jcw33!DH@8&rYLKfa-AX)@$ms;TFWtPYZ>r;x?PmN}z~4^zz`q~p&$?v?Ial2b%- zK>j_T0>vqTN!-hFvon)a#Y2d4XwZS$&Z2eDum(>7S6;*0vPJw^YMk(e2pOAg!E*Sp zQRNRzffB7|%?jE~>NB5+es1vn4{K&rJoPWij~XBVkQh)25)r|5)Y(rv^DT&eNLc&4 zPN-^W*cJ{>0Cmx_i5f&2mxTpa+kc6LEhEJwNJ+n>s-Pd9N_uandpCYrjUJ%Tn*;toW?Q42%u?;&ZARAtHTmAMdKfSh5)1yRn9!x`HEu z4hZLg+4bBhspe`(li*vGC3ZXNtd+_|jIOefAM`PlzW(u5YNDBP(xhdJUhC-7)<<0c zMY-*_0^GD}%Fm?!$nC?ZQ%Sz1s5~Wz&ioXic?LJ9Ymv3|${ISUuhw>`hGtEdv5Q^S zfzKI{8H_AtU<-zpmBnq^oP~<4^q6ov=Pgxq*SBZYtnNdx?4lxlro)v7u==KM+PjHD z<0%68v&GG}HlZ?q;5fv&(HiNfHGf?J=adc;j+Tb!>cmw@S+Ey2VG;#u0-A)HH>{cu z4SX(6>QJV#sG-NGy_#d> zUr9t;C?Nagv%uUrrfSjpg*d*KWQcApYiW$->c2WC5n5=4QdD-ixwSZG?bx#e(pkPd z&1#Q4baRhSDo-p2PaS{=0lz5gEVx~;y1fPPLa9XLF)wW0C{7ue#%bFR?K_Ge8486f zQFvO}=F~rN%lw&|d+2e@a?Ha@r_ke{Pv5|Vx(%zWd~(`|Z8$%gMv5VRp*^D6to55w zC4X}#!u(ZtV!@)UlxRps?Ag=-JVj5|+8@|FE6z$cpHzFiC~?1#_9{pe`C3WgG~b~t zu^uPFLo0#HaBt3po?AVM8abeA%U;VZal~SOU>?O%TXT@6gsL7ErxqpEG*c(J;+x*6 zRo%4{ai_Y_O!;h-ngxC7GJW;jFvHObW$Aza$B8=5WMg~!Qh>+>_IJHI;L`r{S*(#Q zw1}2g!i_f1%u_22#<;!e!;XeVnB{W@b*Efrj!#8BT8zk%{Vp@ZAL0JKa$&EY?Y^wpCdj=L*3SCZ75!8fCKNf^XT|TWkTxVJ=S0G z3e|qHE+RT*+8>D*^<0L$0b#yJ8Pr_Jh7ee~{PYFQ9l0=b4&&xF0k$Lg6m@d&0HR~7 zbml#lr`e<{LP(HO=**`W^O`NLc{Z?1@f*Z1M^E^VW;;$V~)G~pZ{2f3Fz_D{e!_R3z7+3hZQj@A~cTsCxDoWUHgfyDNW^~|NSpkzO$ z9Q=w{sO&3&=DaP5N0w^-g}$QiMf%PI{#*U6JY2I#F{Aup?Jioa>hHG=iR((vbhn)> zkc2=8X0T;g*fhMQv^nTHQ!Lg!VGT&|1k)&7hu)Pr2h!xJ9VK(*pHVc=@ilGK4ONiq zQr06gt0=Rg_+H?Q0Xxq@6wgpu7cuYKCT^kGFnXY4W#ajovfJdwK5#L?ogC|Ee0k-9 z=Kc;=aAZWD8O3ZT_E5$y+rFm^^Pw}o|5^z8Fn+gFA-?;13MC{Y^+>A|B zlz+v1J1){WdpVwV7c99`6zp~^f^JGrP9LDneH{zqsmIWp1MYr`!j}gIq?-lv5-mSq zKuj^nj#sN@g9nhJ!uwW@1b~q#chyNFzSr=1`@X5>b6}``>wlE@OOmb>*bWNg{>t9a4W*o9J4)rBYs}BM-)ZJl5=E z$(d6S`HeyA)D+w*o-K;VTy~8`&;`df0)j7w90K43%BDRCH>ebvYu7H}LyV$71Q!49 ztfzXGX|~thbKG~+Z8$M5(Id#i@uf*kg@fXp3BfvBqXU}lPWpb~^wg!Ra+0ci+zOjZ z>z1STVvTnV?V%phH-%eRA~a`M0o_9C%Si>ezl6@Rt4Y|U+hG}7jWL*if;i$f;puPD zV<9w*5w-d3M+(jNsZLWRY7QZq3n@aUx(dc&iMYxn>T{FlI8i4I*^#Wap6ieuj!fIg z?QQ`)b{+7T<;3Lf>gq9>WTzQw&o zof6!seieQ`y6x**$&X$dJ&J{r@8``VI7gEyfmJsFv1}v49Lu_}8ZWXcb6GR2rHY}4 zhgmmp0+>c#@2vKVJ`A+u=HFO16roidl8=yB zF1{eIxRTehkNJyRQ1zgDQ1hM@5atu>WgWrn+p?{r;EwFH4C7gm(#o5H(X= zI2{400WDp;%}hnJWK zlan*Za?Yd*!M&^wt*?7ycw=8qx(d^aKGM^-@=892dG{`-DU`q0V{)VzSsc5h=49)L z8`eYI2E)h#SDf;CM*0MF^x-}IF@;e=xUfbahIuKZXSg$rm_S<= zuCuK>HI36&9{H7l;X}n>LIL^N_GufVWg;uZrX{z`zceqjhf1jR2%#WsG(zH{X!t6W zqa|YWy{1Iu5FAPZwoTgTS^=ijSS%PrM~j5Sttc{O0YZLT_zZu*F;%zdab)gXxKA{& znt^!@e_J7)OrwV+TH|9wp=oD?k`4BoD|M(12Y6yt?A`Y^^czRkxXzHxjoT_m_Nqv{ zVrJ45S-_w*F_(77z(v%HTu*VOt^47*%e5~{V*N6C*NxH1JHe{TqjtkMq;FeV_?c5B zt3u2$op^nP?M^%oi<-;mtS-TH5#0l*2^S`0;ufFh37W7%Hp+xN=-@KqY)s#%x15N% zB+fjK>lrpBEf0WT?C*k5tJuC0pTIfwERHXj^>G3CQ;jwIClN2Kr3FdUNpNRQH<|YM zD0;MdMD{1uX!JA!>aP4QC{*WkJYGt>!27~vd1}m13JyK=5bpQi?J2jS8U|P}2hUqM zAKxa686Y+25^5tp+3^3=m&n998ET`X5$9^l2m%5C^)d`cK*jqxd{Ijunt*-HV zxarecq@hVFwK5~u^XrpjaKV-~I4qnqC0j!x1;?}}Dv0M9Y6zQg%Z088~EHclxeA`F)^%ud}MJcK!anpdVi+hFmBANQi;DbMM1~uK?q=$y#G7 zD0|p)9+iu1!^lwVtnt7&LAVSwl8v?^YM%n&&8Z8Y#pHMO1iSeHPrzu%6rUzh=y83& zmYNdbh~bJ>p7rR{3BimdcWC97`MjTp{vPYc+kSSkMxy=zH3|P)rg@}k?B74_oJXb} zqK2ptVRMd7OKPx0PZH|}OS~@C;C(a<7b5p{+br0pwn|8CK8~|I*5V^URTCP==wRSk zfrtJI9MZFS0otb^z5of(KXR(^Corj+`NZtw5>gjyD^39U((e#?7|t&{=Z9^c*tz^e>kIYv56H-I?h>yP6k4} zB;AQPF)(v?lTcFmO;mS zY|Qf+t%yFCbk6hqaO>7>>4#JKmh^qr_8Rw0X?G->M+v|umP99R;&mT2r>>;(Nmi)J zr#8I8g%ro{6H1-jUwVSJ(Js|@=5JKJ@>HUQEV3zCa9W{H$A`-VU7wI2< zN<)s$hiYdy_CNDQNQHN0Wi!)#?4if3RYSyB5UuPt@mjIai`fBhWFzn+%`HZ z=>n-hou$tvm(@tTZN(pb?6t`#h%lluBPkp6k==33&*Ao2X;PvS%ZiR^%oD%(ylZ>L zQF1D6SN&aH!;s5&m%}#JqDFVmUoz+(YKpDX^v_8mptkNPV2c!rkg0Cs2BT-3apykG z7CykDtz_clGO>oO6Q>1|c?RceSYE&Ke`+ZKs{BUe6zqiF3nDHZ*Jb8F5ep~vBDMID zk_bIN-p;U)^5@``3oryWY$8etAk^Y`3oTphs30KO(bqkX34YaCEi#E;5W~+HQqtgE z(GLolB>I4$_nZLvJZ>rLVcXU!>AdrB~NxzyUqB_t$p*?*KmbK1E zG{b%9PbUG00`in#h7zWU%5D!+^QkdI@LuVk0=5qSsDClNw-$Gu+2zRE*SI;J*fk5h zhlTA4f$(y+XcCj<`Oa^h$y1t&zNvEryfn-LD>3Ca>Mm!Ns=FtSb!b}hx4RZaKTSzL zIaoQe=#9D7v0x?}By?3!fo>OQgLM2@n2Vi#9xadXX5Ciyu&boVkBiE}I{kXqnbsP6 zHVkSBR55Dwlr5rKAML)~3t{Lmv!gGlfhefpps#LjzExuMA+cB zD`5fWZO@=%27Q@VzR&|86!Wom-ec3=hDZD76=j2WZ{i%k&0V8brO^vw^|x@l%rIvr zHoCG-&nBrv3NxJk%le;V1zfI)TO;3$|zf1jiorf0sGvgF6M^p{T zrd9vV(3o+J5U>n#ln;0zjx_i>r#SbhtHh_XRvk=>`V`Z}Ps;ZI7|#Ck3)gqI=sBB= zw;Mx=ra&<~Ts7o%H2SrABunyK7eZy`#<4tutu`$A9!OrR%Z)lX3x%Tz$i?3t=x%17 zPi!=TzeMTcRxfGD4LwD+Y9R~qAQnrI2OrJTE#{nvqh>(d&B7bE_Ug`n{?7&F&>!E) zdKVrnw3BRP;k%uIWoGKqlhgEK?l-llkgGbxhI6i|qWW_d!9FJ=FW2#2B`+|Aggp73 zb+@jQ7TlKCkl>&)N;ILJbIMQG8KJQ!rSS)pE?-p2fKQoNTdDWqN1F3`bx;FOZPEp))p z$FKY;ic|i_Ru?s&hsavfhAxzjo7T;8Kzsq#&;2l|q=Ein$H^zN>RsQNLv4|(pom@T zAdQ+~WsyyVf;|tTo%U^l6Aj*u+uW{96XUfY?iW$+Nw*;p+%gvI^#q(8LS$3hn$Lw^ zb17leH)t{e6Zo90@>K0hu6jxHCrC^e;d+K4qV-OUMNcohB$sRoA7~Hx@Y%i(i@Cpz z$ND&Ym#jAh=puN2#|)NFt3p=5tByVUk}b2!Z&X6|>h3~px2y&9|E(rLI7 zniNVuo7TCIG?t%ujB+Zt~_A+sUTV zviuPVfTzvPbpJIW_O2aQzy7%>Mi!f@|J~<|J(59$*#CfUb4gbynVaK1l+BOO!-Prt zGSK{Kc-Z!w(C^GVHQ$PDc z60@Wl&^t@jih$D&r!kEuyRnl>Gs*G8)}$qugKbMjS#Fov7;&rjU(FXzY7SwDd!lEY z^M3GCQ6IR@6_`c00_PTLnpR0z)xQHj)y7@l?8e?;>^!3J`h*A* zh{-zH3YtmLBKA5ob`uHaGeL$WCjdp{jgJ2Yj49V^n-lVS`)k9c$oUwyCO`kY!&=7fQDW zj;oN5zwHv9WnDl@bIp8FyNspa4Am++VP{!l&?fH}qiWnDN~h@;rCa}Ch9Ws%0cVr% z9?~!C-_)J6CyY0exOGmJ!Lx(XVunTs9FvCBKblyJeRNLY$^}8?xcmxsqU35U$hXA^ zJ8N~(y^i_rP*P-|rn@vXGHpaMMoc#x-!~3^f@90|;w%COS`VcRD_X}-f9(+;92$XA zA>$yl9rpAqL{!JP&CJM{=I&@kA91g+tCg8*0{_J|E0IABT-x(Kb@Vcdii9u%T7qFB zKW0sgJO$>$!jQaSWxBw*&bpeJy$Y0B>M##wSZC;9AcUs?wsNSJ*WLIJf%74jW5KW; zR*#q1(rQIx*yRw~Wf4@Z*bn6qQLS5U-bOfCNz-lu%f0N-us>W0yIz(BoS4(fnpUPZ ze7bUkpM<2s>n{D<#)o z{hG%cs%(vmwv4R<#?>qCi~w$G zLP;9#hqysWE1n#frH^#y;i;AI!Ehqj=rgW-chX=ur#UTlB$vhfpI?g~7;@>#(~<9W z2GC7EMN!|I?|XJW-hrutfZuOh=eQ&IsE5EE3V7*DxlV;YyB$A!irveN&PZKhq8mnt zuNMIcCjwgrb4fy~Y9_s82%*~Lhc}fW;3q>-YVx>H{MObWg;jmB{3s*AGpsQ?asJ5?&NKecwjiQW%s!0F0q#nDq+$v^@U6 z@;?AZK)Jv3WJA_XL1o*>5~Ag$x)mHsB?N|piR^Y_Hndx=LF~(~(_({4xbya{bR^Pm zA<@D|ydkCkLkERXv~bXo?xGTW+%6vxs-Pl4SV&a@=f!3jp#jl;c&gIZAs}FIg5xE8 z_VTw9IkLLe+}5A#4A{vi<(YrsD%mkQ9*TL1q_^|w-K%%v4yhk@zC~+h?J0#@^w?Py zUn}<=6~6%^XrHsovi_`^)y#>kZ3uOoF8U?p3ry|~sS&Hr8#$4Y=^{#(OH7qi!vaF8 z@zbjNBvq&9WGu;c0?oZ`HCl!+Un8%WPEC{n0Wboa#n>Rtn__$|Qj~wrX*Dn`{w%y7 z#ouP@kEddk-*My8ih%RMcLtOjLYDSMKZ00Op3*S$)HBi@_$cA68f#C&ZpXI1`beYl zi3{=W1By(xN2 z&&&BH=L}s!gLB_iZ`l)C2D##I>P+ z)vDOJvBOfU9g2`ytmQ_rai)CD$<-T^-8aJoN2uTQ56Z6$4X=M?%~b2A+{s6UHRT=# z=iVnjQ+b^AEU62>^gI_=iALTJL_#*H!wXE7sP!%oP|*!f(w%(u+E- zYYCfg=&9s9^uFHgFqQjP0VNK881?QCd*BHIf(|Dxs3YOtrp!pxD6BYLrQzgKU!J4Y zmN<-V^BH_Bj8=aZ(C~*7;X!EK)NdLCGF#mr5CEspi;;6!MPNedDI)KLj%2$@W`eI% zBDqQbfJQ@^t$9LYKW$ZwIPSIl8H3?$R&blu>%}XTc3AtLGDd0af`lz9VO7cjrnOTp zm+`cv6|@+czSpM{aj$zi;Z-}K@v(^Ce&`Wd!EvRXz`lPYsKxECw_32#W;fhe`l-q# zIi=O#zT~8Xk!uDB$TS4Sgb~1i)z@_Rz)P(1Y3?akcY-uc$^@ z6|83y05(9kkQI|5b9h?;;TlLGxRc=T-GV3{S5<$gn9$V6Of+5jCN2DOM>)&zg_DCL z!P9l^p3nYhO0ZpL=Ic>P$5_)q%}v!BE!PrIB+I9ZZ$jF(1+3L2C)a&(p`OscIF12> zM7)PD(?g8}n)R6i)PP3S?>6p;;bbCi?4;LKXRg#={_>L}Z)Oz1up^kwg#{vTR62lj ziynW-+;(Jn%oluGe*tuDjz|b9!5*OUAwFc^HAbr`h`bZ&d~EEcSAX7+SO`Bkd--%KIGE_zU-;MI&%SNzE*j; zoUsME9soWy0kF4f4RfKgA(VyjW%nl(z}3Y?{QIIy1i2E@SF#`22X0U(Y9ibX&K9xr|vg9X~P&=?s26AG4gKf;1`YWW& zDfk~V`P!^uF3YI9sL#si*%=}mtoc;gzNL3nTxWL6j;>w4?)qG3U$sDzgNfUvOi<&eb#=3LUW1<)S2@=JCr>RF}F@h|J#mf_i_o@8Lii z58kLUx&V!{tvIp5h(V znA^qA+3%#|ltw*ID1BlVTa5Bnorpl#9V$lew*?i*5G%y$fRF&WSV(IyOMGwN|M|y! z+ymL_7PpoR(A}=SEpmW&ZU2A1!cL@>i?-hEq8p5az&=nSw{FP-0|vU`3OS84AP?bx z3BixmK}1jwD~W7qHdO%@mJPVx1~g{0Mbs{v0Ce9FaCG7-nJdx>a~r0QWM0g0tUTu{ z@#VD{Le)y(Y8c4ehw~PoruaKc?k4(5%(t*+;bs7|A|oT?)S{hGLvepwB=wFZQafgK zVm4=g1kh;3!(k_=Eddd5kSbHbE^hM&3TF`bX_QD_f7>Hjy>gZ;?uK~9b;i(Q>=3s{ zaqDz{{P625z$E<%I7uD){{V);D5h;35 z*8?s%${X0I^FN>!T}d7<$P=u{y_8WHD&@PJc{mn_#w%s*^}rO0{eA!)?iVU?hxu>P zbh`6Yo}<=VWc!sbMTudD*JGKmXLLO)R)_)kX@)~R^E-c7T+j-W&9;UxCBbbus=#7j zOMIsfhA_&vjGK?pSICcr6ICP1o$)Fzt?^Ua~Z7(I7M?xgGoM1pL-w5$ja#E+KyrVMD-?pGyxfgSfLzRzZU(?Yh_k zup6?_+t^n8w*TB6OvfSw6nV>^y%3k9p_3|}CNf*3s)dsEAdx9j zl|!Ctx}+JpOyS&E;#efCsz>H>3PgI+Kl~`D;B-ngz9;5TE1BWqs;Ojo^K-~y^PI-a zmaOKEJesBCyHkU7PpY3(!XplSREHrky{vzpv9N!<2{meh`!}*$`Tb!9pijbBHYumV zXsLA|qZHD3BFUD{*A>$9w{YJh-FK5=TDGe(>Wv(kRgs1+}VkA$9ICo#8b{VB&L_qwoT*3ce zG1JgC1D&V#!vRbfJFBX72spe)V|nJk%4fiz-~@=r)d5bUy1YaI&xW&B+zsVvzCG~$o8Eq|_Q9JK=Yz(R0HNCaMR2ED7fBZO8sv&t~ z49*}^iFKP(5p=F41e!iVI*R+QO_0j3uA_cioPUisb{czY>CqmFC2-wI_MI(kz2(zW zG0WCZn6ArXK`lh<{)w6lrClT6{pWwSs_|^(DKW6OpO9y-=uu&fA>Ak#hQ5Ef@+h(; zj~QOuW`#23&7>9!I|Nq?($i?1E8hIMbqUCs~ZtvdT_9~?`g}JWz4M^FJxNA5ViR(4Bh4uqz zoQ~>?Po9qG8?C1Ug@)n-;9-BZ5)5|B_rCc8UHsp;`Gh;8wQMKde09n4yH7t7Bcm0A zs}n%z7qZm;7`OX4pPbU%Q2DG}l~u$hV7{2gUQ@ow_(~eA$pfI+d3bn=V;E-G;TutK z>fttw*10{(m+`%P_jwRr!}EH?m1IbtwkEA+-sm84E0yVeHzI5j2!($KJv1$yFIc{o zaqY3k%=d@uwWBTOk`W4?@@q2WWEB%ISLkc8W#IlbV8!89*k`-X?ggrU0x%poz9~5i zgEYL9urBdw*vB4+-Fr|(*7$*1_G?=?;#z;|Q@%oAjOtf`!$4Jn{N2Nz&OVa~sDt+b&GA|yB!16c@0OI_ zN*HrY4W+0lkrnz_6*{WLL7Wd0R^o}evSW~Y02P9OgtDo~{wP~;G%ifF>drrUK;^dk z+&nJh(8qH*NAXy~mIuy+uwz@hKqq~1@dlbo1lSVhQ=mByz*c``;w}NO<;jh$%Pes1 z|4!eGqI*+$TJ7o$+;=*~VUL^)t1=K<;KaIv$ymBZ%<_q3@q37wBZrDeR+__1=vA!e zEu{wKbGYeTbs{m>$Nln7$UDM3a%U_?;7jhyNU8r!T^Gf?;z@Om3(B6=>ktEwgM$9uwTE^#eJ1g84T60x#@09f!w@}hu}(#?K+euP|byw!o4x9eq*b4e}HZN zq>qrAlOyeBH@||aA&6q_&fo?VmzKA==$5N9{s^ZPr$m1aTsW|a=!zm;XB3-8q~Xl- z9g1hN4c&Dpv_r)qQV5HUU+%$V7?s;-?*fu{x&=IQKxPC&w zMHN;6Mr?n!TsfQG5G8QD4z7d=cH!wj$#(i|)DOF#uQSW%O;d0(gull;&Y_l4aSyo5 zN$CeUTm3iHUsd@o?N17`Eura_ohF|mBKTsSB1v7jBLD**Gmg|nPP!ba1eluX@FC;V z)JFzUerf7}*oosOqliG6KHyeik~il6s6$x|Nh*JXYngucCWnM5k6NwR(SwpT@=hzQ zh@xq*LTCsC)^yiF&dnUq;C$xX6PF$AN)%}01WGtp>!;ba@pp@#;wUrztvepbY&>(- zllpd>ZYPNOr7U5$A@3X~Ki7IFQ|++s-2)+0GKV2D+GE^Pm8Y;ez-sg-zUr*08yOij zdq;n0;jxD(00mupqYhD!95x`PW28j_0oeofhVcw{hbQndaN-xQDdPQQe8bv(3b;?4 zv(UvWUf03ts4^6g#vDBgiY_kU8T@gyOx7`tpT*aC{ zbaQm{Wtenu(4iiSQas*ToPg1xm zEPuuA8aFo?JA<&pvXog%~ML3$!^Wi6ltH+wRC?f z{BoGBa=<@ivl&P+VKjV)*!d>VhyNr%1YPcmMULReo+8s45Q_Y(I`~S6Xyj+Dp9z97 z`ktYWwyAk1E+-yu&L0~|nBVW&tIq2$akX`-oVJjYC|ljdY0L9kcNsYF2OjceP4pUm z*E}8!ub1C&u4=8jfbL`K7-`-{CQW~U!!MvZ1PBPReWGX{W!C`%W+G8aLllbGfiqP5o^ux5p9+Jsy8?i;g-qM%K*fA)#iQqjyox5wXIt_7XTpgm!9QoxsWY z^y6z{Apx7U_U2RdY=r~WRI=FVo(|0#DphmrCr0zB1Oi$ES*xohPNYYmlA#np>w=LG z%C)3~PsMCKr}x_#+*5Ep5fS#Rc%(uF9Oh-Vw#rRV)%}btOqupnwNQUQx4N2{b$J&y4}Xk;pieW2hT z<%+Z4uMX~Zy6ogr`M`fvgG10-z&8UUE?HvOUuL$tSfr|1=bLV56i+wCmxmIx=5}^m zVG#74Rb0mIU7A_X*lMHF;M*`h3~%I}d<(8oUG!Q7QByXwR!@d9D2Kof`QqjmFCb4S zmv2{3JQ@x}B61}?ktQk^JPz?59ELz}LeV*MtB7SPhwOjJUblZBxusu`8jU4FUSsU6 zizF;6dMDc47x0zL)c?Yiob&*w2UI^5$cx4d<3T_Awls1D#X}=NbAy|k_CRyt5fHr~ zI$z+ZMYIkwXn#L_+S0Z#Z9|{P^7Kw5zdA+!qGHugpnl68w;IS+6DbAStFcPaNUiH*D zyZw^4g^@^f?)}i5lhl`N!Dq~Pol+E)JeYaZN}ZDRVyB-lD2*iBtf4rvdg`3dR9bVV zi~X3RzLQ|hHu0)X+iR0L4jJbo@9I7|y^!7;)= z`>p_!N#K7@>?PP8kSYmI7vi*mLLgEn^uKdhfuF=|CZyAX$yaV`g+nC+nZj-~(3}i! zP*WIk2wnlVDFjcEtWSVVoSser5&&?{kus`D3nUYB!FWyvijQrlMxY%dIdkDCog$u? zfp8E*HLD)E^xy8=lWT{U9Fkr9%Vn^X#(hcc=b3*`BpjeB5`{&WH-x1`u$eQENGPTR zc*vG3{z*~URBd_tp@_q|usWOcy*t_<}^kqQMHGGwAAU|{ql*i*I(ZX<){fYvYkh7F!9uFHHznW;bSp~ zsKfrmDZP;)-rGloD@vKo#LR>`FqItKi1_Cq0=k4Ifp!B%$y8Q%nv%tHFVz=@eO3;| zlaDC#Fau7|i7YF+W#qz&@@0;g;6iLKN>+c(DT#o0yoa__Z|i|X$ye4_35>#vkAkt*W28_lxaa|%~_u;VWtdGAEEYERd!|fjfkoJrByw z>7)FKH1)s#>%acnfBU!pQ4s|B7Z^zR(mNyBg=k-@EQc>x$b5yVAkxz`AroHIs8eH! zIu)2hhrX`UMHvFp=Mfk>ici$PvMqyE<7*E&513-XZ3E*g5Iu_pGU-dK-*121>xgj5 zqjY`bArr=R323`R0x@nc93>2NvR)&bzDMQnru_u?yvTe7(sCnc{!g$*0r0Zi@t`6? zk$OrwBQpa4`mjQIgUYW1a61(W;iAmC4F&FI5n;)#FvHwo&%7DpD$t$dEk9ysWS6L}77=0Jf5(}q7ZJYRCz z87Tvbe1o9LVV%P?q$$N5g?{pjFqnFhR6uN)KO-ArlW)HuYnaZV;(kZK^j~r?a;$-3 z$^`YmW@U$n@IyEaK&n>n>wJxgL~9WVl@v6;cM=`OSX;^}u5kH=E$QoYiZv&aBx3=L0ItnF|%0Pz?p4xkg?J`(rKg8hMfYs5Mnd2|%j zA*svo@*g|hhYSEk`7<2;itjp{ux3B$7!MIK`Zu!1=(ZB$yHJ++j+8%*=?*7kp&&5)j)MsWl-@Nqr_*q=65}Z*y2bi2wZ?X~aK}+|>M?hL zPU9jaL%o#GzTx1i|6Zf`STv$PJs-Iu9OhJTNVVq=1e&D48mjF4^6P76BOn)hN=pzm z^5KQF98Ydrs^ow4MdEzs46ooFnJ#=&Q);gJzI4+z5?5C=mDn_0@zML7_eR> zO_DkmLOH#u zn>yI4u(?|!fIl;`E&1Npz<0w(95umPj1es8_}~b2T{VA9M?d)(=wnvL5Wwn!1hM_0 zp!a|ZGFq?Es3Yn;vg5aw8Mx|qVJ(YhPK?*4YRJO~<4g9Z~t3olmu7HfN zAnT3XD*53vP%N__I&X^kBh~z=U*Yh?(ALN>U*gd2tdBXk3yAYNa)j#^c2yIYbhick zQ>jV%#0Z=reHprX3F`2CzsFX|cL#{7d<6i0tmiG`wkrca1U64MCTtHQ%wI{T$F_ND3x z)d$RMtTT)`x&zg3aTIL-}ZPoOdx-I4c+;7D{l4POQq z_8jgt1G|wvqve81R*}V#THplD%zvuFSN`n^%zNR4eTnLf#|=>dGQrPG*;PaZstSLb zUSR$sm^3295_y(Rfk{nfhihG6aD3~py~^@ z(Df%Mh7D8=nAw_=+V!nAp{`bpdFZD;BGiHe# ze!>u2b^dyw)KX%QqSAbCG&_<469IpaAZ88RjnGm`6y<$~l6$b%zGgT@dY}-Ye^?f& zcTj(HEk6=R`R#O_>nv(3xqC8IlHsT?Zx}k*$_{+wYdXXVfTcl2v4La)pVRd~I3QoTLm+EGf6Q?w>S!QSLA)TZeyN$HjWu`D0>UyOHBF_3|O;jbWy3#&ZjzCKEi)D38$$_8k-{= z)*Kg^NIo~`J22V+YE}Vw3f`tTnJCKMZV|=nfqT~DC5=hNO5YCf;iR8`LpZEG)(Hm@iBbkU4P zXqH2gO+>ianKh+_ce;P<*6Q(JVJ{yAc8~>3ZhMN^+7`q~A8Rw#`gn9LEkC%Py4n2q z!;a!5V8*GAk?I={rhR(u5NfRj&cs-z$dWG%UME1#Fl>xstErUjPIoYWFl__>2|zxF z$MXGTU)kVF)PucDak7mkGEvldu~Scr@>!*1qlZq}B+uV?;?aK~?a^T2wd(`YI1_zB z@^O+_gDaWnhwr|nL9m{$-!CK{68)B^+b9@#2^(nVi^X2 zjt&31qEXhaxCO!kWa?M3qh^u|>_qv6yQ6CAxYhUDJc&;yjbqw84)8Z{>Nw}soYsrX zND|9*UM^A6UPOO#jl5f&RpVR+qo}W|Xj>560GAnbngTgR3^%DU)Wr9Tv`_pFV8Rt+ z|Dg!MjVjMu~fvIEvcGn z98Nsh?wr9&6E;o4PIn9?!fQHc@5_xx*(1j&a@KJZQQ|Z^NIP9PL;s*kEvwQYO2ZPN z6LOl~ds?7aL;TG$gR3v?Nv}lbo>#T|*S|9c6HoZZFUb>C@u$p=GX-R5(!1Un^Gh`v zNH8G98HsO>qvE4fe2f{Ga~mOdpd>;n5p<)%HmInAo|jh8~H|(j>Y^yu1wJ z0lGvS+5OT@`yNNMdK2|RpH12gGl>GkU=Q%hbP#_oEVx8NDNtfr4b~3()_VXJ7ce~S z*Ij+mkfYI?0R_xMUdo#wI*=-D?Bt>7iRNDHL00)RCLjjR++o80N0-v%dqv@4UqM{>_I(ovgG%5Bc zN-pfLxa8XEj-o`}-#U3_Q^%XO&{B!`=%*O#qP+CWPP@Ao4}CqMU81_sqqV zfbo@tsEABJbEN$LrzxqO0!<#D{*~lA!8Ac>-q6ucS}5o#2`vnSH-S=StYm-ry#47K zZ#JsM$W{}1<}3(Ffl?e5%vmCHoXhcH^)6?h89C-m=o^;4sgr<3d_D0Ug-An1_;!{3 z72Ze~E^zgvg|wWA`~hh*RzY|vY1K4n76O8eWtP!hc9;_(VqHi=jE0Yts++;90e7M= z+heBRDrwImE?=u1?7)Y^hB@JQP7%M@2mKBi|y87n(XFhM0Y;T=wSFqo6u3=4+DeeB`e zmxJDT7((ZOa!4c;UDG}{8Is5z-))R$>hJ{e1c)C+$DQ6-P1qo)$9c~A=G$@Y>MMS{l)JlkW9M^b2R<3^%S~_U z{N}@L@lGCD`*-h#2}v?j>AmyK=l}Yb|M}m0yCZ+^RIlUZHGlyjHcLpnY=saLY6Qv_ z8+Ye)=rMY&4&V3o*&}eG{hb_4fD)XFVaC6eMS3x`!b$zx4@0GD2jQcM{qAAlo~@KrkSz~d#0 zwZ*F%9Azk}vrRrU(!f3%zK#HZ*1)IkB9jtTF=cs50$AEPFlniXXrAd;V&eAMV7Up$ zO~tC!KchgM129ykfSf0UJczM6USKqp$YytXGHlkLs$MkPe8x?-BZY{f*z+SpDgEFg zDgA)LCk@tw|J{E=9VPZ`4H`wf;jmKavcMpI=tyX$h9Y&Z4CHh%0HRXxo@gU_WeWM| zN78Acr%TgV2Bv$4?M@{>;HGyjfA8xg7Z>HIvfhZBT=fPSi!>Apyp;i(SIsI6vg?BT6zQ?#C=BgWz1sSzC2IZX@&IA_jB1oV!Ra}p z6p}9p6$K91@kr)~+yNJ+z(s+BiuWFqY$8}o+=u|CBr-DS{}wfD=nIqxXLmS@05Qd3 z9i}xy9+!XCw(p^?q5?1z=8t}$#}7DPq}5zbI&TFw7K(^VQsX=F2r=sjopoC?^~(pbBsu)%R^K4}_`eB@@*uT{!ifU+(8>W6)2 zyJM>&`?es&YrQ=kiA=7%TNU3jE1rMVfVo)0aLROj*%XzehK^eEH)je>J9Jjc z7jSM~Ni3MV6_p>*v}W_nlRX!$Y??K^tfPZB5-#wr0H+Aw@FjSFINHS%bif~;7`$qx zek644q(Y|=5T?XkCptiZ6Sc2f4b)x?r=ClsqQ(V%4l!ADx<7xseJxs`uYLvS7ae~U z0-*7UfLW7)Ec3kckolsvn;poc)>JM>;5?Q{IMHLsPY$d+Sak1coyusgSu+|*#F+oX z+?jQ^kt1LJtMF<5sxzf7u3FAK*(xupw##nI({tvLk|>E~E^1P=rTX;qivV&%0J%`| z%)Hboirp&WG4a=>Q89`V3nxoUgvGfg!|V^{Iz3l!rT@uqzjmvpAomum^-6}8@{S^L;}Gdk)UA|wKWg{e7+50neadY#&z*l0TO-8W zslp<$k3c->897!6aPrTKSLeSsIt9vPBA!EayU5zIzZA^|u1^zAGb3`bgm;m5$#&Bg zHA2Cq`&l)KAOdX$kpeS!3y#c{12spV2;;(H!A;PHiW@5=EE`T70=|JP zd49|J9hy!4b+MYw{!Z{~kr|3i7n{y+mbwAw%`|RysOLmn zg(XGHsLv_$yl9&!^`U=+{J|kG3+8UGCtAcg3;c?8siO@jhn*a?8Ub-WfpruCZv@urn9ZRhu~x5u+6m13~88JRFKzClul;Ge?o0GRBtZWL5vr zOnn~T)QHUDj4`%z1;B6;TQ7(xNb1BRdn(}AZeSU=U4;j7gzSHl?I-qZnAq&us@hD3 zYxGW8xO3J)-))szE^g=hpf;m5K8Zv*gO|*#V+EeWwxk)%xX?_4$Y832V!K|vgM^?C z!gRn!4!IRKBXWs;4!%t{kLweCLo1PX7Vnk<3X&AQOiM13(UU;;y-3A0E_xiTBa2?v zQL_E43z-?}k0gH?Cfe_--SU!10Q-)A=WFs2A{VqJZJ4FI+a=BOE+{<>xM%Q{?3qFz z4Coy`_|rO-j(>Zia3e4A2S>y%UVL)QYu~S$bI+B^y9@eIX%9 z3@lVmu5otg9SPcJbn6HAv*|Yp4P!qD+yAzB_#eH|q~BYCAN=iu*{!FMCaR-ZiKJHS zh)+T^%wm6&P{wj!`zQUR{aJZ*WC^KiRyhnvMeWKsf}s{xE7`05>BKrxk!RX{iGY|Hal&js3sko$Nsy?Ha zJuU$!f3xcK`9gMXMWPcgk7|f=aJ`l2z!u-*PEcbUidCbs zcOY~TJBY;DU{%D#Dxic{1RJ`j6lr01f8O|fc~2}iO?Nv2H*RNVgPkOMiQ_CHDcZ^U8B#l&FRy;^TF>y&8VZP|P9m<&SI*B5htbblP4tyooJie_(@l zb=;s!@zTly4lS?{mdz>I5m0@_RN}#s+&u_QBGIGoPrp>yIS+;@rmYrZ*eNrAG>B|- zsTmi4lhTyyr49E>-=I^+1(O1d4{;*!)AX9CmH2-KeJ50>H7sREgHyZbrr&rk6OzN1 z^+LoOYHvb?U$gVen_PCy#0_7*f9}c6?`-Nv>z?d5p(}GMIk29~xaw-BzLeCOVWR~d z&1>v{L8R*?MJ`1?u7)a)2OPw7kyM`|rNt%NZ9H~Tr^r)ss8tlga_GPjd;oPtS1-J@E<;e_jEUP+&{6)UfNU=(u?&C zf!izNyj2G*yKFCu?3pla5#vO@2b2(@;F7w=`AJ$I(9BO$$6-w-8P5uLXJ z36*$B<Q{FE73tp;qIfvOAUg8H!*_Id$(u1I&S%S_decV5NY z@dM_ou)9*)6ncR*c6uWWo#s@Sx-EzbmfDDKMPukm%(1K7cnb0=0f;sb+pzJyAhdDY z2NbBsf9apvg2BqH6}}|Mut-Q!q#(>3HXs$bBH%*{~34eJ*fvqDB%F^-i(`z@*s|??Tty=jaq!2=a z;R#Fqyq}zjif>~SfQ~!`}NLBcU2v?XYg(wTk*Gwb*|~d_01vm z%t+gN=J-Upz~tDbe;3}sZ^BC7W;p)!^y3Oi{i_5I z3Bx(zGxDaUf^L79P0f^QRA&m@@$( z1Lx=Gm%K9paRD2bE;Io(0nL|WGyzNjo0qXP0T%<`zRQ=(Gyx_ZH?RMEbvUrtC*ITH zXe+dMu@*DE)x;utVk2B{1eXpq0kb0>@z?>k@d7BjP)M|bq9n0^sq>o^Us%0IRQTbx0jDO0iJ)m51$VQKjS-|-cs|hn1AD_>pof@^Q_O- zDqHVsdgF&{m*mCnN?zz^b=32E#t!N;%x&zP$b^UZ)PW$%R2srf0rc7FB7{@5ayY`; z;(lg(?VbLUi~z*nRoW?t<;!+B5y3&f_XH%;oyg!tjnK{IkFon+tH)5hFK44{9}|C~ z1rhg2Y!;*bNpujKx)s(Td5*Bkw0}}$aTey<8N`Rn8GSz$j8c8cp{Q|PYMGx%2Dt5A zm)WqY1%3hHzTwMJ=9^%iH&-xbTYK5G_$uNYJQ7=~I2a&~V33er3fOvDK#FWo{hdf4 zi}aA|AwZ;p;W*TP;jSl!xiQnAJG>ejhN{P;`JBD#GmpkrU(;Amf#&TB_sqtr&zD6z z0WJx5q7d@CpzB>V70sWUCJOM6$+2L2qB<}`w(2qA+j`XMyt(Az6 zzd1Z7#*YviTQt~0Cj98g)(O97pOV}~jvPDa|6@4meS8168EJvC%cT!Y&MnK2u*T;~ zJo0(_-y3J$s6R5tu$UcjGcp&%N-Ehl2GJMETCg1cwuNDB3l_*^TNu~3VCSS6k(2rs zj9YGhZP1AC18%1o)O!KH$S<+s>o%wsGHDHw*l5&_d{j*o%QoVJo%QXQbxqoNaHrl% zszPcDE*I-7#9eCvvI_a|7y6EI%_Sl#6C2@cV*;+YNLVkR)Fa<`Cx zo^5Q>z4*~lY!wkcm@M@qOD~(4W0aNs3oVWZGsZ5RI9*)sM7}8Skhda+rsC85NVsjf z+M+5S(b-)zO7kQ|crpV-jtt7P`Ukm-Z>P)U^pH~knoCdmVhOu=sMHNWGAZE_7wegS z^{C^quaN24ReM0(HOJHyEcP&8bjfn?_&pR9C-(gJUf(DiVuojm4;%S(MW5IeOhCQ2 zlGiWG5@mnmrK<8q&JW{i^GikeNaWQ(ZlR7QjmKAj{@7N$T?W(_38L+YGFp?6_9LUKv~#d4LVy zS<&Q_E;W5noNjl7>;%o^(KuR&CkTOH$%tPwU){|w=W=x=+?SX*k%H#;6ae9U<>4Eg zFt{RQg0Bg2*dteYi<9CZ?v?jwxXZ7sgGly8^D@KZq4iItG)cYj*S!PkJ6LFc^XP}g zMZ+uWbjYPzMz_)8Zfe@4w!l`adFSBR!ZoB@vWIJJNlsYlE2c7a`v$D_WMW0Bi?+`s zOtTZ@hNF|n*fGQ5(`RZ|$Q}M=WZ|7}Hk{d|#!YrXPA!SA^Jo}xTVSCE*F<7jCaG#y zGVRLToLR`_{o6OBK>R_N(9rsS@26Xmr#8BVLy>6H(GU-0s`$N5w0x>dzgx#eTCYXS z;K+(Zzn?uySS=3ia^GG&ETPjy?`;vQu<7&nh+6_zC(^+_E7LT?XsCjNr+2#MeT7NN z3~l0OY}!vv=``ZD@eI-7*e&rf6e@f`bs1+rXjtU@?TGVgg93M96WAAjYooaXk0Pfd zV_${X8=!Hl*D7y>Ijt&k#(kS6l=0ITI4+r^%@#OpXN+jI37J##d;YsG)^uoNNpVA| zUc98_0C_B?U~C?SotH4QeFOf0FtpKHEWD@w9qzzI9(j71x=K1TXgRURomgJN_vim6 z8%97!m28}nUwF5>ro6a+UR17^`VF@U$ydF65?=Q#ewE*qP)Z)2*bT-9dPbJ*Q7l2^ zMLtcT%T*@Tt6a0MAbp&Ano)Il@~gDgq#$oJ8)duJW%Y?RFU0zU_8Z6{$K!~1*7CKK z`a1Q}e3$L)+W)=lp8x!Av8UY^=$4=JvhnY03@eWLc1nq?O>T=PqUneL>qOq zgm6O7=`oX0JA{MiTB50<%d2V`)k_5xaL`XAglW`7J6kt8 zydT%JYfv+-+m+8IZLgU?ZQC8D+cYubR&9R$^KD|R{U$fDMLv1M1tWewi~OwU9S9G9 z+E{a7)HYR*TIapvP(66{;g?L(*6B!OF#p~+)YYa^j1G8z$p)}reJJ0?$}fchFc4~e zj=!mSwvJEiP8hY5Ag9nu8EYNSkN6zl=GQASaV5FiXeQ;MLBN+cF|X#E-beWt@R^CM z@9}~!{#J?I>%=D3I$7Id5MH)-EiXeSdo!BKTq4=b8Dp-yWzV?~U+uz=GBw%rPZQFR z%j@*F>DCp0rk+Xnb?ThraZ0!BtXi)qarVzgx{19kwL;`p#J7&_FCDkyH@8l;v&GWL z?$smjnqS&@f#<6mx=qpogp^2+ET@}T>Z`1tGH~_IRS%_f0YS~2)JTvRKmw^fZ{fBK ztqOq)05P7xJUpm_rLa!R<&2o0Mq>%kZisi8fYsT5*@sF!U?TVy(ci81)%pi6b3)dy zO(}rBN4fLs8qDx8HqCwR0b9Nv^rcYdk(z1@?g%0`9{n?n9iC2h9HdSyk|1pJb?>29QZx^$h)|OzsgTb71Za@qRl|ZB2q1r-mP65|^C_@5KPsn8U zmfstmA_>Gi7l(~Pe_XFHi*&6m{R1BTplL9^3!lgE1jBacR+_R7 zm+oV3bfxPwZtoe;K^JN3H#%`g`4D1)mH5}l_fb{I=%L3_ES9Ef6eXU$EluyQHwmrks zes^t9vV1K3_jY{u^KYwq32o`5V22EBw_`ERIgm+n4KjU?SpkiZ3GsKsTjxe)WtUzJ zgi~2(4DFaQN^45JZ%^%3UOhKLIkQVGW{GKK=3Uv(wLtq}k|MUrsCP9RdR^l;mmiaK z04|vEO_{KK+_Z6}71Y*=lq$_(mf~rAy)0U%GQ}0-YjX8gI5@)ozO}(-l-)SI9_XMx z@L?b>prQyDacMIjw)367xjS!_-lB4!=I@It9CM?wD_{anpuX=_NYOGn(bd)4H>Fef z7MQb~+bvVDe3nj;(`85@;DYMGM0VW(Y&JwITbqE}#4HB9Gy-Is>$N!cC+&ub{ISEu z@OHI}pqoZwdJ}Da4aQl-+R6K>e~=@*ByCHNTfBcc{Mrz_@;xF^cWCh8g&qITFT22O zi5fC9*(iHoomhPGVWx=6d)a$&sEQXxqBcfnZL@O8+i2Cx4KsWWwJ%&6KuUBT zXXQo+QKS^E+^s~pv+CP}y~S1|^n1=!)+&x;x#0G}_$kS3mnjYb=D8l+H$*Okc(?wm znqidgMo%GES6WBgi(AGU=iXYQwd znKhx%{qP>#>FiHW2pXTIBJ5IvR&%UXX-*Ho$?+1>%ic0{5$=AGyitjsE{zEfetu8a zv-@_7n`5}pTmM(}^o{R?=^a8Kdl+Fu2K&1B?}YKzM_AjJpMG&lM?H8JU?Nr7-Ykv< zP!C0G8D$@vv1Q{qjNtfmtR$x?9i##$Ea{t$29Cd^ef*<+R3BgzjA8a_rN}D_n`Fhl zcvCT8cek6)GWl2?IL^(>$vQ@4Ig9fzaoUwvK{gF#?*}tpNI&|7CRUKLVaG$zR2N;i z6^@Y65i@olKSl|O$a2R3Bi}eCY#BR*SusFuj>v?H%$9{bK&#J;ID5S_=PRPhzBObl zB(yG02Q(2?PV{H#iXJ``jAp~5EJpM`&jfZ(S@qDBZt`M(qctz7@+nluC|#<(lKyYJ z<%L{y{ki7VlZO5=#4hv?MIzNj>+f$+Aqc_^byQ?q-uk@CW{W5Q#|@8edoMDwZxk|r zCn!#qp&o3ouPc#Dtck2)HRsL?fgM4sW9wcdvsO%m(0uYo=Lm-+|5|1@G8P_OFrJoWc92 z_iETaPhF+=Aa3rX`+I_IgRne#SeDT7)eA8x;11)$WF*H{idXLn$FG$AS90u_Ex5G$ zKGg#qZvd`ZIw$|gTt7P4gh_395;2FEj z+fg`dHbOa=7UQH1&CIs|ZOV4?S`6j|J0IeY(d>J@5Ue4NZAj^FdZ=-&{u`CWoP~!C z4||8(DRpdVc~$f6soa4}wmK1~F2x4n>=Z-!#Ksb^V7jYdZVp24cqpMozOxg3@vu46 zdgS(mEzLf52&`1#%K3AXOMn&Xk`s_-l69w_T+(Khk@GoDpQZ4MsNP@5 z#b*0b|H-6R41VBV&eO9(=?{xMDjZMg#+I7qRE}6jX)yW&-817mL3zRn`I)mvO~$Xn z4=M#9OAbWqH$ziPG}2r4rp#P80c54t@jW^hYLN&Py=$;+ z={UlReOp1gq?2KqP_rW(huNZ=gCjr0Roc84F2m+h>2mpXYiE9FkR7|d87e=rncmQn z+3oqsW99vN3$eQ`n;waGv~=G^=naBkU$WRbS?t2Rp{?D^vta*wHPZZs)06~uBQ3e*kRl9(;PegE6g3y?(WhgM^Lj6 zwNrT0&md!78)jNF+Fy^U+cDE*i&t!84FCQm`JeJ`S9X>ojMd&W=6IUeKJb;z6SeP3`378MUo1c=?jZ!&^1BrP>3Y^x#7i2I9U!GXCq zsPVJqZRkr*sh0x3u4l^6oP2XAy=CrZhDhGTUM(|1h*WMs<%|@Km8~2fOiY z*^|BZc_iRVBt7)yYSjDDR%PPFG@eH`>*Y;s$P8A+qQn6+N7#~ zHlHI`$Lu9KDZ9-QsdZ!N{%PO*1e9}6oJ+tt5vHS@Lv8y$7vSYZ)MlN_=45won9236 zo~~kxGPF3TG~MoW%^4*o{bRB`@1v20E?E)e85PSxegEeb}qfS_=E%p z=&MmyFF!%ZY2UBUhf7eI_v~9_?E#-}lJSW?kPyZG*p;xMxqaG0?01CLonlZd@_!UC zz&RgN9cd0NXtMa*geWJutxnxyr(!D5T;4|^aEroz zhqPgd*ZK!|M5O@e2TlzeJ$x4=r9=G{>|7;`&(ti`} zvgcNl&kUU4Yoiu9`W(Q3OSmsD7|-xEsc}o+@|id5FK&P4E+D-!w_1W(@`hrvunK34 z{5ukdGR63tA4dXoVj{vsJ)g=>8eo{Gg_c^5I*X+bT7UK7G6-Oo(-lNg!KLj^NvB!WH*Nqpyhn~V%O49YdYU^1Qc7fef zFfeqbrXPIHQ$JF9Y{40Y=6`@~*KnU%g)&8GVlju%zX|WG7CG9;$FpQ+z73rkKS@W8 zd+%}r{lO+!xb~j+!1EF}Gc@KRyuW2vF~e2Qhfiq-8CnlR1!Ea`epf!{d-9Q&AxT65 zjTP^w_5i|dB7A*%_9e9HMpC~GKHGh^1ISR!k|_3$ahb|;d?8(Uieg}NsPhQhIrRde zYw~V3SX^kB*+4tkN{;4!v2NfND^z zhv+DF3C9R$dV{tKe5>c{KysP(7ca`!5%4}`?Lqw&*d?pyOY^9fKQ)#1YsfB=fxNgB z>Aqn=0NWte(DELxi<@V%jx`L;Olr~SU6q>0nUZP#%hR=*$KO7s_Z3hK&PSY?5h=C1eprogJA9T=v_U@6>Z8()ia#Nbq}d8 z^j7mPgA38LclG|mVd4-Ot5I|O z_CZ3skg>z8^|HFMY5_mdxG|9p>wAoZ_nsJqhl2%$rGdr#Su^ih=ndvnIk?r2<6%*RDxY?=WjfsOz~Lx+^iF@M6AFL&Iky+ zyek?YHOxAa4K4FV!*yPc_Lk=w>oZF+Scun1P?UnYe8<@Qm7b?zY473|s-*C9<$YKJ zn=u-@F+q{YPHAfL;LrZ;-lztDw}fW{U0|{xl~ca(J8p!7S^sIc}?mIWv>?)O-9Qb1Tmh&II9S1wY6Q5iNxq zs50n_e4>+RKBO>}5>)$3yar-3%T(<7;V+Wg?hGou#vnw4gZE`fJO0dlA&m|lk5d!i zeN&=qO4r{x?59@VFmjW&iY{i!FyRq`sMe^_X~{EpI!X^bjX^3k&qE0hazFQ|lw1tF zo-jyK7FS(4vD)w>rQlEqywc+bY;N3(2jf>w{-(&5-ZKVSCc*&l4`I~=Qc*L* z6|Bb1j(mXG&hB)FeMxmSrjU)nHHJ$|W$=>%vX89I@azcAdF#s1a_xC@`=T^dT#Ojw zT&+yT5QAmSGX+td*N#Z=c`D&A+YAL;J#IVo(_SHqh$50&H$1&+Hk@4&Jvp&S{=bD- zRo$7md1W`q*5iRp0Y3_k8lOkIeX@2wnBq13$qfOMEcDpFP)62r-uVBfKV6zQC?gj- zIdzmNA*W|{j=2zpp5GG7y(icAzJ*PCR*75VQB(+ta%LKo*77b4wu5CYNK>9F&ZfKF z-0fYg-9Hqlx;+{9m(RZEk$DH0#XN&9f&Y>*T z2kfE{gomcP58x-~fp!rFKhu77rM)4h$ye}b`;jSoWgWp4GhmOs9N-5+`e$!$tuW5tyeaMRXjfo(0@Bw0?>qqeU@}1X(8Z6>ub9m}PLOR6 zF*MGyOeeDD*-oahDjG*-yeMvIa3lfex%WVFI~?0 z_1o~UV$)jAL%_(hNYzO_A}c61F;PBinL^tBGg@E`2Gx622c7>hi!Ul19}ts}5xY#F zY^y**jcfNtT5po&SfJBSUdEa)$ZG7_zFq%mRmJB>UI`a_FW2jgo%ihR=?WMq&k58T zP5<<(WR}_I;ui1XIP!SkA-VMuT*EaCDJ;F38YQun#YR`fDr(AR=iS4=C***!?8EUR zan=n8En!+=mRBOL8#}gLOjL%xZ~BRR_OGm0L~Zo)FaA8+Ifx{&e!k@6V622+ROl-X z94QSuQm4gX6K>l$@uz|JWCgTVBmFymqbSRt1HGb|l)BJPz?(o*vpafNu+2B=ZH3v55ynbsKt_Rm@0RIai)SyypUm-T;O>i8&P}XtxgS8BG;DrdT&*;RIiN0 zOGvm@tMX|qsnfC~F4?n?C+>K@5JO3^;y)QkRWt)SKZx7T8_IC#ml#<^s=*ats4(eC zt8AO9=X%Xlq-VAjpC4R_bRBRL=aR2xq9PR8{Ot!sz)gw0tpC=yy7sj&P~i1bV@cv- z!pf~W{qW8{z>GX;pmI!?pG$HZI^id}vA&bGzt>?(Ee`Lb_1?z0=7#!a06kUmw_?UcLxc#_%!DuMaz16rI*362otn<6@;E642^$icGQPF zu8N1AK!vGIM#P9vcXqUVyFkRZ2nRSNE4eF1jzEM$o(>Db-gMNry2%fOy9V;(L$C8bdIV-&u3V{3f;lvKfJ>7*f zcn;5V0s1g8X^Gq&h4!nB4WO_q&LRM3F5`^}IIyS;k&-$@EJM^mHM}-rdAEwzo8b*d zBj82$s)3 zFOfgx6SU-)_KG9`(n0PBR>KEHDD*7iz?YIJU6wK>zfd1E8cC08jHemtcsfG8JFwA$Mp>sCwoib176^6qqlIyoU7`JWobb7IJx%zY75)>P`K8UiE5 zQ-TLV58RjKdVRlniLah}2H6DjEXKS#43 z*ew$>1rbn;oKym;-(%}$?xdJG7ux>}!Gi6CF@FNl(-8J*{#dM3%RebE)w`D7 zy^Lji43OMB!AxZ06uPoP+FL8YOA9&1{YG4=89VSYW`Fs`dlFin_BCpoE13UIH--qJ z1cUItx~e7Y@8afQ?aeB=HymjNN_WwAlRYkS7=d1z2-XPqi>4@eT*XMNZ@pSWDhzvA z2A5tfKdxvy6hftP6{ReQ9?%DD?ris7V=#RX95q=SMpMg(>QIb*(m4kR?P(|Wz`OBX z^@g;hjjl%EY34Dn^Dm_zgOR|0L%M#dJtirwleUxZ>f4ct{Nr;_X^q#N?k4qeH_NmeNU#N%FVFNPKgPPwUP8sf@&VnZirSTwlYf;A_zj&oda60^E+6y(kcT zQaZ?zJ%Sb61LY~{(=K2P09@p&MfER7k}Vc z+z;J53@^vt@wr)wVTcLWv#|LiV77|3wnjW6aeb@Mi1s|uW! zvEJ;Cl`yCpw?0iKqK5u&)RmNrxqjm!^j>3Y4u6Xo&tS(3;%0v z#Xv=cAD!X!V!p(W9CJI}eF6%pUfb5rfmlV|2)r)4sI(6t^%u`DELp96p9SlrQ;m}^ zBR&7Fq0(7kqrsM$MwO5-R5IE7wdbl6M2Ewi#NetM{bDnMs;{YU99gPkADqtNL5bGw zS~*2MCNj;}tVV&XjgUE};9r7p$WeY6Z17zGONN>9k)b9a2@S34L-2J45B4(Kg!lxW9$Er93c@I_YCUUfG?!mVx;wHD>#iK@D z6SNK)zT!AvknA!2MQeY~_Zz%6mj>3h8&9+bwCXKhGZ@{fc7Zb5-R(AqVq9wI)93jY9EBJJP~=J ze`31+Y>h6Gyjxjq8yw` z#JAJ?OuE158y)QL<8r@$zg<#rmt%}0NGeik!1FZctL$15m||z?_{k1TG%G%(^|Y7) z2a#S{5t)#v^mg1S1q$YU9!FCs%xY3}mPbrWAX z_$EDZk`-%poGu6aEvrHJy4;12Ca}DZ^DUkhsPMjYv6oM4WzMIfxXP%#F+Z}0_*@P8 z>VL4;>YbB1{{=Jn(+>7B=`i~t7S6H)@4h)4?JwceireehOzqN{8l<*U*g<}=WYaOb zvvnRI?@LMpgpQs`(%mfj|IBE1N3b`UuhO~J2nfXF?Mk#(b0x4fREP;R_Fs77sG}b| zUS-~dc|VvL1Sl%P?L^A(I;bKyo&=PH=4zjWr4sKdFyx}2PW*FTbDK*-q=*D=_26bP z!?yQH@th`orx00L=*RvD@X)XF82V=!bPI88C+8%_I1&@a+0p$BV5u=v26NxA5(e1f z3}m18MthpRc&;FT;vOA)Z;XN&B-L>?x!#glE}3#)WF=iVAn=R>#663#;W*B)Vrpi$ zr$aRw1;Uo0I7+rVILAO&?l}PG9oK45Bh1!6B`k*@Ik6LF5cw|Tf$hKA0cDAm>}IF( zFyJ>lm9obt^K!Q}@l5;MzG2DEz2L);{QQoGXtcyoCf>@i&S)M+MKCHa_%IWxwRQTC z!Kdi3S)dX?w<5fT_jWJ&NR0GS&UWq_pA?zs0;z{v8;Z6cMs_`@URCTmj?!#A%y0Lsf@BrFyk)RQ)?906XVB&*@7GvbGZ!mp>Ik?+yGAD_lUIjv!# z?VL$qGX8Uh!RLYQT_PCztl9Ft{YB*^dFYGf55~tiLZG;4iOb*0xL362zz%CIp>8&!rX{E5?p!d6KV1tp_UvFjqJg)6tGd8t5tCGwHRH12x4z6W};4Trjred-H{EN zULjXVF+bD|76>x{_B_qfmW~1&eM;Dl?6IAu)a*L$zW&l-P567>m+m!k-U>ry*HKuZ4@3 z2T6g*r!Z}ny$9Ck+x;usm}B3rjVfeYZlc}2*pwiSF#Q+F3jK`_#`uAn{#kGN z03@_t?ez8Y3@+gG-l^}<%C=RyaWc5tb=QngEU>&zGkd%NW6evHyAGLQ%S4wOff9vJ zoqkG{)$H7Lfz92?7mQA<%iQoJI3O5=JM@YDrR!@l8&4(yn%g(K;5V-(m?E*c4@D$E zTZ1&(A10rkvy7vIHdJ2-d^2T4QQrRnU%4DDsNBVl&m*HZp^RJNvpos~>k&-Sc>DiQ zvW3wp=G&N_!v{1LNys#3KOy~oTJ<1@4XXW`_u1&6_kO+g+`$#rGxDaiS;Oi9DdcK5 zm~Oaq>1P30xw&D6mlT?GZzi?3YB!!jKY`0A3=?SNe(tn__YeG~e#M-8qP6|#cxj#ucXSZ~8F~GM!Z$1*zODL}xgo^j zxt&k%(8Hk_l|soZ^g~s6u@K@y05;%LfP2kisi>Ie6JS6V_|5#YpRRzLMf;{mPK71qLI5hyN0b{?NGvIr{E-^kl74BRLTR=rJb-8SatTsNU2bNMd7vUEp-ez zvxZg`LI>ZIga1@csQ#FGlK10n2>I@DXl9Gt+B(JiQwOGK;_qC}rckz7z;fTOvD&6V zQfrVtjcvL#&uxbHd?6_#rTcy}1kEB)hga<)5f-Itd*9S8dy2?u#H%LO@A8h=2stcPBz4^ z)js64F#20Au0VFYQR9_b^0$HA(->Cc&(lj0KYbO6hCc0V z>|Bn%F$Uyweq0y-tidW&9f25x&Ue{LS@1VOgsyA2R8kx%8ebSQmVfeQ= zSAMh>%DiU0E)90x>Y(v1GB95?AH?=GKlE-MO`V}M(**F0f2?AMo4rm?SF?<7q~!usBif^ zg5e7Z?{W@kA|`Pa6eRlP2dZ$3X7bll>f1GDr~#h*Vpur?xfTBG)^A_M+lLe*=MdEG zQ=S}v2u#)F7$-=i2Iye`8$F#C1A*4$77N*j^UkE}V@ho%_o&?&S@8M8&*-aZf$M@0 zfsPyvk#j7Kj)e(^9PwptRTr!{7V)&}1YaZz>vn>?n}GH`k?evoV;5BbxU}N2lqa&%)3sgCLm5ow@{w(^DH$iS&n|m zC?mR?8N2)K*l|OO{~N6=Yt1sUJ(@y-l=DBON31?cuwbJ>@nejwmU0@;xUH53&ues- z);W7vT{H9Y%J&VO4qbX)cC{b7u)TGwydbpis-{A=CR5&*yV+jWe!;vy8bEI@n%=t) zgD^QAe+xy1BgtDST((5G!kF~7sW6hUUS^hduO40isMKUwJa{Ug>O-y5&Ka5x8t7LV zWXF=clzo->;&Tet9{ z<`w*id_AXR2@!nJcLKF@&NfD^U2>E`n{1kYh$1^=Zy8mDd4GcZ8zc?vjbK*dS9TSpQE2_keuBCfl81Xo+4?w zvf3}`HxW~nxInC&^JMOx^f|2(S@~(ESAS=fhtTbjDZfvQr=@npAWdc z`a+|Zs$z|;dj29|{5&_{hC&8f$Lt#gHi2|#JeW-Unjwz7L6Q%7;XES|SnAUT%-1t@pEcR*Ab zC361Eu>}W}5tQ%c%d_*Jo&O1L=ea9%3@pk$7ABJnEELo%VrH->G#4r9+g{^u7$_(d zL?|e9sQC@7o%{9*qeM6y%nq8GFXG)X3oH#9ZEZ} Date: Fri, 12 Apr 2019 00:28:32 +0100 Subject: [PATCH 3/6] remove extra split delimiter (||) in background trait column for GCST002887 --- .../study_background_traits-ALL.txt | 2 +- .../study_background_traits-ALL.xlsx | Bin 96059 -> 96138 bytes 2 files changed, 1 insertion(+), 1 deletion(-) diff --git a/trait-representation-migration/study_background_traits-ALL.txt b/trait-representation-migration/study_background_traits-ALL.txt index c93dbb3..9d65ad6 100644 --- a/trait-representation-migration/study_background_traits-ALL.txt +++ b/trait-representation-migration/study_background_traits-ALL.txt @@ -180,7 +180,7 @@ Colorectal carcinoma in primary sclerosing cholangitis colorectal cancer|| scler Mucinous adenocarcinoma in colorectal cancer colorectal cancer|| colorectal mucinous adenocarcinoma GCST006411 colorectal mucinous adenocarcinoma colorectal cancer Common carotid intima-media thickness in HIV infection common carotid intimal medial thickness|| HIV infection GCST005184 common carotid intimal medial thickness HIV infection Carotid atherosclerosis in HIV infection HIV-1 infection|| common carotid intimal medial thickness|| internal carotid intimal medial thickness|| carotid artery disease GCST000555 common carotid intimal medial thickness|| internal carotid intimal medial thickness|| carotid artery disease HIV-1 infection -Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio) unipolar depression|| schizophrenia|| bipolar disorder|| concentration dose ratio|| response to anticonvulsant GCST002887 concentration dose ratio|| response to anticonvulsant unipolar depression|| schizophrenia|| bipolar disorder|| +Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio) unipolar depression|| schizophrenia|| bipolar disorder|| concentration dose ratio|| response to anticonvulsant GCST002887 concentration dose ratio|| response to anticonvulsant unipolar depression|| schizophrenia|| bipolar disorder Pharmacokinetics of antidepressant drugs in severe mental disorder (concentration dose ratio) unipolar depression|| schizophrenia|| bipolar disorder|| concentration dose ratio|| response to antidepressant GCST002891 concentration dose ratio|| response to antidepressant unipolar depression|| schizophrenia|| bipolar disorder|| Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio) unipolar depression|| schizophrenia|| bipolar disorder|| concentration dose ratio|| response to antipsychotic drug GCST002888 concentration dose ratio|| response to antipsychotic drug unipolar depression|| schizophrenia|| bipolar disorder|| Coronary arterial lesions in patients with Kawasaki disease mucocutaneous lymph node syndrome|| coronary aneurysm GCST002026 coronary aneurysm mucocutaneous lymph node syndrome diff --git a/trait-representation-migration/study_background_traits-ALL.xlsx b/trait-representation-migration/study_background_traits-ALL.xlsx index cfcd0b78f6eab3813decb164db368229ce08f8d0..f54589c53b3faf8620827aca7116b8b6b069996b 100644 GIT binary patch delta 22650 zcmZU)1yq&W^FK^VHz{;*=ypc#w&rOmt}$pqY#1Ut8&EATks;#K9zXZ6Zjgn;h{3L>v zCNyzQUvvp=zn(~T3EC-YrVuP5o`3LIr}_6)M{wgaU7L*^6QxE6+Fh!MjLc9MY^jxw zC7NeQKTC5(O(37-%GD9b-{qP1sEez9iz41N*;sN?qD|S&N++iV^!qO|%U0-hZcr4O z7ZvCqbCf1yC%~S4-TXG>ZCfbdGCjm>{MK3U&yQj463@&O)|R4roAFr`lBMPSmWB_A_6*7zJku)=}SkalL3ff)v z2-io8KV#4$nxed!I+zGCb3*|8n7?u-or2X0QPPHa>@gkJb4uWujFc(+3NuEVEHUpe zL>g^=SHPUR(3$k6`!r%7_u+~)az)lKaC%N-wN4Wjvey*xYc5bI!)ZLxZ*XinU^#%X zR%;SZJbZn*{**}1x%>#L!ULJwjgT64XX8JQU`d#7L)6&Ko!FF&e7iI}D--sd-$eREfw#k0>>cO!3TFuOc2_f>`S>_t zO?^Xtb5oBFI$FDP`Zzg$)iHKS=Ozxw{`$x4GV_?=TLN>QK?2>2?E>Y!ycTlq z?h>guH_n-?iYPdOW-*l5sxk!)E>4XTdfd^ z;Oi(7lv@vFQ?_i*6_5l>n*pJUq1c~0IQb6{L(43ic?v!>IA=N)Jw8h-DGC*OGZsvm zx;<9TrlxE%s}|f8v=L)0o!U*+scKdD8a>CQE;*4!gP=>ZH*LB`k2J#3OCOT2JP_ot z`j$a9Mrs1l;Z#zYA|OezQnl28WF6bp_ysY0?z^pL^TjGv^n{OrHk|%pv z;>HgPJTGZX2C*2`Vt8wkpY+l{c3@1MhnyKdIVTaGt1uYcq1lXe4M&+W9^~suR(Mc` z{M(-*Uhao;Po!&#gG~r3LG(eRYg2`1lPMFaor`WmielgTmUyG8Wk&l*$YPsnip=>R zQ$0gd98}(6yjO2^0DW}!^&juU9MalR&Q{ZnQ5zu_p`rmZo?K;|0@Ih$9#>%oZYhQj zf0uZke5@Lu?##Qzdg4CwL%esjQl19Cc0E&O-~4l{yGdrj&;!i^$c8KC9(1zS{*l3; z2nTlDWZB$Qp++)?JQ=d-wnY}7CaZG2Q`2p1AVMYC@0*z{ZD27HI;9r0ro+%_6pZP* zJ{>lX_vt2ZYT1)0N=k0060LIL&tz9lf$&mxrC7V2(sm_9e94N~tlRD6H4{5R<(;I) zk}Ui4HB|OL;i$Gl?#+H>itL8+(p^CsFh^1J*j;<#)sb`FW!KMVIiEbf*P9<>L?Q6G z#1_=W*zflIs0F%cv3#jMXB~uE^13}))mUSQrzz`O zKBj}@Ai_3d-luL{1$t8%9FGoiON%5zE6#Coa?J=;vspUl#g?i6l&}XP!yBl&5f4Da z^%PK%`o6W`@Xs(^`|kFr;nUH{USXZ_~RCM zbI7`%#eKdL*wCx1?qV@~F=Fdt%4PCc@Xzv4~=178Uo+#IidKWGd1b6RKXhSu!@giC2(B<`n^lKqM9 zm%LqLa@QRwpf&H{?ZW#`yi>`2C@)*Key}Lzf4u^`KyJMXar00pj85e9v(CumVP0K{ zKH^)IPraUAudJ-OEO6_%b(}z{HgF7+=BN!}nO$8Yd|y7z{(UHMgq$6q;jPcEsOq{C z!wfI?COmB1nYdnMe|-K!zI_KX0%uuyzm~RMm!k407RjPt9myhoxL>JZ(0G|Q8mZKw4Em|t4`&^sgx#SD}@ zqWi-g2m4YRGOZ>6GgZ(>WQm|057cSB79EtPSq+YF*%h82g*H+0#hxeKJ*Fs~G{Dd_ zrqFm0#v)IKN^D&;(7Roulk;LSECtbUzlhoEoAM6=v9&Vr2l>$*zY@mej}tXVwt3#q zllG-GuHHJ9nY?8D>gkk0wnayr|L%FxGrD`7<|^wqm%uQ^kP5oPnUnatIoO~zJ$n45Q^@qAiW(fTz;cf5Nml0bE0HY1bmCKoLQrC~)u-HP z_voe5X#YNk^xgs?e}DazU`fE1!J}gVMBCwf=0r~UG*4^G-v={w8hcTbGri?$5tF>* zwkkHjzOHy3<<@t5V@KzVBnr`U;p@P`q?U;aA0pdP}yE5XLyAzKUwNtNd(`u(68 zkh$&I%@xq^Y;q6wY;xk3*yNW~tZpx9fmZ0bzr*ui4vM@fl5Fs>Mi|Ocq@ADYM~>NI z_yH3hFNmU+@Bk#&3w({=Y9}pa&c-6H zaVQ-0r}|ePu74Q8SEyMrGWScWExVRE$R>GSE3DlC%}kWD{nQ8~EkG{FXC7PHmwlW^ zw&XB-FzfNv#F;S|$0=irdRI^@_2^+PnJc2H;?9{)&eV_I;#m1hdb3`mb^yC^%dTPJ z3t|7mW>$?}!OG=ozr;uxtHZET_aAZ3yNDW8)Dg}r z>?QGdq72RvRPLE(iWmQg29ghJQ(va9#u4Kecw7D=g$2j@y_&QmOIcBa&)y}cLl2KV|KJYN zAn*YQgEzErtG6=M2tQ2~i6H%ZuA**CDxE<_pAA6cUZpTw$GZ<9o>Kz8)gEQL|3jof zAJC8;r&U9r-E`vw<&|{PicYT<%-Opk1u%q-)`?jgW`Pf;KI`K7S1!eYN6S41pG3Gg zE>I#?uOp=1!OffPt>fB9!;lUH<<3|K{cQ(8+1ewp0oVu}EL!1Z ztQ3nRw@auv)=;CF8B$R>mF8BKKf~(#E;9?*ZoK#A*_S+Mh^yF;pqau%9vnyf`^hL9 z{!DoO=#?ez0ad%vKc6@03C)hR#*A!w-*nwY4XNHZc@o!-YfR}V@+JhVOnW7lnb8WZ zb4MfDBp|0Mfak^#=q z1tPD(aGC>L=8GjSFyDdMSZ|3PwTX?U{!5PcwWu~S7gAI_33`w_L`jzUK?~#hyJ7R> zkWGz9J2v}kGCc%a;0|K6sIpXR@V--L2T64jHT5%=>q_H!a(!!D1#p-48LM)hQuM=T ztXwCdtu2JCibiejgtRiyniZO!eBX!N20LERewVmzVT@&5Z7>;NgODuTh zTr~PPJY(EF06$ZY&>TzYbM?hUcQ)7KtpcK8NWzAhkSS2%JQyp-|ANU>>RuFj`^JCX z(M#zOx2~eOSOHcl40p-O6F0fCEv{mnvR)K;-5~nUr+U0N^fn}P0U1npt?1rn5R=Xb zubK8lj1vT?59SDvuPs9WlKL4);qou z69;m;d+@8Mq|O-yMLXlpLgqxYtAgL$Op{2Fun#o-D=r z+hM_UupW@AxjiTPef^G+gxyi$8hg(^3F&^UY(RQ5M8fR&`RVfRLa`O4N%NC@-MD#WQ)^Rx>< z!czPsY)s>-3;Z}@Uo#e#j8L1GW%LB}rYHAoe+#Z)t9O%Shd03z=ki6co?OZ{CuzUh zN*wxh3W8ugTO3Fy~CNs;x zw&^pmikW#*EG$`*(v4FGaXplMnFmm>=HaeZzDW*(`TC7K{Af?_(YS2XiBg;i<^y;cg!%2bL zfTWhF|8soBPNhx&r4WyE5xp_zyvqPvLqXZVi+4>O`P*a&{^pg(oHkR+%p}8 zSspY2btd&RRrnH~Oj4UI=K*bLA=;{r|Io3_?9nW7$=YhJEhY&Ir2Bl{v&2Sjm)nB8 zh`2#uz9KH9M9D_=s?TZC+HqjPPo3k~7FLlIp6^7)NC0@`64!083?3+KU6k#7*~}w} zP6*$x@z4N_DHNd@XwDcMuF%ux%`AqNU=|$4)F4 zopfB`w7+ziPEOc&oD4*crRmixx@UUzn}YPIdS(({be_UT^4EG8R4$wp^$m_a>6jGz zX^A>4>;Qzt`JU8qy-rKW_F{lkZq9Y)A}-wu#iX>`$9r0I!MK*PD|HN7lEf2^w9@U~ z^hGm);G(Yowc$hDxhmI=>r-EQjTh{~m=T*dO8TVv!nNv-Qa$Bb$QczlTNllRI%D>` zaw=}e?rrVm>gDy>*DuNy0%f;?7hPJP7r=mDbf0|wKq8h_tQ=x9SIT~5y{?|})oGpu z(N|g(tea?Qt4B;wt~O-nSv(Mfl0E0RA-pLCQxVCm*4T8d!qc;tRIWl0-q`6CZPxvZ zEfUw^>`V>zVyRy5h4hr2H4?ogogh@_1w72Slu8T#bJjk(ay<|xb7uQ~h!Qve8G4^$ zppd@n^Or~E(2|}L3u|SJDk72Iesw!!urlghq(t-@+|)6$Y?h-2EkFccnPvJeO5l`H z)PN7p9}XVM9!Xr zLN%)=a}{|Hrz4Ek*7}BnKpH$E5`O5CwpV$^%6zY^0nX^bg6ELA5_!5C;p$-Mx(`+> zDPXLumIxV$C%{dQws4Lux;vs~bTwt6I$(o0?h=ruW3M~*&S-ivnYTuBrBxFI_LEBY zvLx`wNL$Yq`OBlbB{tD`zVEHe%roIq)iM;ZGHx%&5$YPVmM#gV6Mk7S`Mq=B;B1Mx zFjT{>-M-Z%YypgrKaMj$$kj^xWNF>G&gI< zpsEU8eb_|j!TzlJ1}r%tny&mwayOHh#_NohvaWMS4C>2r?Yb9j4VMXIkIH*=$AKSauZEDsV%m^}88trC?a_Ndv2@UTT0D z%00$X;MhILs!I+_Lo^4Hqx zJ7@b%LFdz8owSBUp@1hEC)-nk5mX8Cu6m-9tlH#oVF%dl_HhuQzoh%GrMt+72h_gUGPn8JtW(+BDI0Z&niEq5O2AGGF0Pe+LV-nGpPx|U!h!KP-zRs2-H zs1<3;(ID?tRjElhs@7jmMDRULen*dm%*CL$J0O4N$TBw>$m#GVXk{m5B$$sHqstY6 zYLM5HzW;lY%+;6rsJS}l8=C9Gk;C1W zdP*6b>B21(M^^b)36IwYoTEEq{1}GcK3y?l0Y6LnqYb7EoCgbmY}XD+B$*M{kQxHO zR^Are-Vy*I5#HO6tqkD}RTQ~#uDy^NvM#t%GNXv|k3x{Rf8ou7ngtzfoufi8PLAuK9q^$6h(O}^awj+l6b4KaGy1}P zlSj{dKHEO0v77hSt9?G`*G-k+RJQ9z&4TX;8S-1M#7+uTmew%%5}vW68pDcVaZVTB zPz{#IJacqiw2T|3tf|M{DQ)HbT{iiyAkeswj!)owJ((Lks@0@R_3bLs1Q)B|B(c(D zSo>ZUk~1u6g@Vmf7Y8)s$$>X9ol-+JUTb-^0Na*=a<6&k5NX@r{Ri~T1ck-B;3MK( z?2NlO1wy+}w8Kk$p=efXVmiGBK7nm&VVcPZLj|z3G!RC3Bjt0dDsLI+E48*-&`tKI z&V&i-qLEhTi<*F8>+>iSYp`n{R8~J|7o9!Jnt_jN8Mfe5F^Bw6m9`xtn>Howhv3fS zqPRCX{aN8l3N;*f)sUR+6PC2jd(GRF^gwpBSuMXZ3XeAhd?sggg8L|MJMkBU-MjLYuWW(FtYgQhXCy8uOcPkVmj6`c zssi8Ie8E}!CBaRF#aTaL3Cikf<2EA7;iv@g5a(fWGaE3Yv8Z`W}nY3(Db#B zjwF=eH+PrujLH&DS*ag;Jo`^ihY6bri$7*Gi7&JL$24LdZ0SxU84j=;eK4&%eqq-WtHDPXCzt8CHPH3&_|odJ`d zX@jyUuyZ{Ey|*~Bq@HmQCcQ}p_wyIF1YhT%97Od^9+`_&@=@>XWenjp6Zgu6>1)JE zsGyrWaq1%Fo23A)$Ox&x27fg4yv?sPi7cTK%{xtRu~SXKe(lQ@X?=tqy6RF9>;3%xUEp zyhYd9S2Itf;Uf`4VS$-^*M?6L;ft7VZip*&N-J|9*wpZzh9=@{1%XfM=%AV(V2Hpc z9}^e4oHl2JN5sXGxkMK}Qoy1LzYtt!8Wv4Z*kJ5lVH%VpOi&m z!!sE~aqdxthw)lse1h4T6#jIqJT@cmlW_G0anE&WYGYFIJ?*NuxpsqrN(1vGV^1@BAvNDcS+19n%2~&JpRej+svS*+#i?o8ef5nm_6Nl z#UPOc)&&Bm##geQAk+1xQ~bffvAhH`5Ia)Pq;|3AsN~Z%D4A^tK!Dt5&QlmgahVTf z>;OTK1CQ85l2Ax7=xD-2YYtBgdE`p#p233`I7L=3afwvNWV&>|#^$qs`!HhQn(7U@ z!M&lS`2g}gD~{P`pBZGqU;Y>7wgk=MQ?QvF?J*BJJod1x2*U`~-i-!RW$x-n9RtX0 zWp3&<1b^Dy+nB(#booG)P_lg6?hSp9CM8oU9F=LFWQ8qWP7bbjzXRJV*f0*@J{}$~ zfdRe2*24q41Y8NM7>4Wt-TS!yIBpL~`~re=>YN7iKDgX@69?N8a>858m6-5|&tgYb?3~7WfF~l(fFW86|~hS0vlW-hY#4sS7e{KfK|h%d%p3uJLD0cJgC^> zcf@M>PSDZ%80yH*zX3CWAv=Q)`E_6{C|%`|_y{v3IIRUt-);b~GI93f=)6^`*H+X! zKpEfN+O+OH%LZZH+%quH=X<=d;7`4Eox|Hz;4B0u3AL)od+<3EEu@Gr7vsQ}aHE!U zj~mHoTEnQ$0}b7KwD>3R|H%;FmaTc;y~k#BsNDhA%H6g+z%e*G!KJ7dlFa*npiDe9 zTsnitzS@z9=P|g9_8C$pT%K5N+>bi8CNv%TcM6qvVz!6Re?6f(BBG88{Sk^I9Hlw& zI49+(^n8I9gF0rWo`%my7^!15-b3-jRSvlhVehVdDlaG2^`;$4lu~L3o_T^_$p&=dG^tdw9_K@l*pQOVQ=Q}q9oZ7h4C7H|BW1o( zI5EZ#2ATuIyq(;Ok&iEQw1bOLPMCaFPAo!8uRGLq9K6FHTEmvCRSC;tm4hYDze1~J`mhV+K2 z^sfVWGm-n&q&D^>=z+gdP*fyC<0dK5RL0U;lnlMVPEA2!!;UjkQ>6Whb-Xp};)Rj; zNw@}}NKja!Pb0WcDhQbBWLfUO z>B4S(!~^mOok?|Apx9CV8%|wGmFA>2W|}?OOQY+D)SBnt)&j#4nBh7@>S9R}f6-+b z4MLea@`xQDn11mJ^Y4LlW`v;IdSzxxJ?X$%#af3#OBSZT4Ip-g znUC>oO(6@PFbQHOj${-Vy2W=lHwklxzqTQ@3BpDZGae$F@VFch=@y0|ZgSt=9F=CiR?Y_?Y;EQF#g0c16zxIYql-NJ_sNJ<#|SZ7Kk$2UnyP zP@l`oUSpW@3?{-vnZduD@K{U(6^C9;%9)QH=_BkdPdrv);8SiOSxy;^02Qa29qmcS zP(mJUEZv6+7Ysw28XspJmMwh!QDL_|*!wl&kUAsbkVVtfjyhU&{qOmCYNFwSc6v6~ zaVUn|gpM@pe0K7=c~YW9cea%8KYd5;z?(@l!@Fb9TjvbD5y(t8-3Tn=#*)ONq;^PE|)A%-?O5_&_PYF%zYpYms_(H zfvn_*M7~!r;_J#IAv_AY%i`0!m&KSA=u1d$WGP`MuS?P|Xh4Hv76$Q6X=oDeG8f|? z_b%k1_yG)B=A-oxK2hZH9~vfKn1;nrIyS)pWfp&W&2`3SJ8-2`-i1hj%0$ z*!xsTaXJ$!W4R&Q!MLB7WP=xPKafwoW!hu9*>|!1Mk5Xx%RPGJEFkvXzH&>~)={;VR;+lM2>!AgW1aHpVPiJ_%=1FGqC9cYBKFNq5<9{{U+_FK z#tnJCiEMgHJD6!XP=v^XMyb*S9pm9!rAjnB+O-4A_eqLq$*5FnKjzUVXnV0uN*FtE z-HMOx+zCn8bOtE3g*>b{&Pf5pk1=TUFJ3%Ts7&O`=n(CeQIf(DPD)bLJ+E=#@hjJP zBd;hW_bhnaLAg?a6@82LSf1_l?rFh5PVQC%9z#7W?w6(2_^BhG-ZrgNJeGb+o+8>f zDpj#BAynfyIKFVuk}KG(7!5=JMGgapXwm-0H_ewu^=s7hD&=m=kM$e?>EQf_GD_cf z;>U?=X9k>|>BN+sPzoL@m^qk(Ul670xi5L_ja7zSQ*(kyT3GblHIIXOx}xAEDPqIJ zDVi5!e)D`CgfiTF5m7Y8ylm|Vxtgye`J3ETR%Bs8?Hh#jKSbtIrRjF-?SdBeKI?il z(TNM#q7>jVOaYfJ^xU2ZpKiy9*-O`OS9ADg^lZ@DW7>aOE12z@p{#>BYr7RlNs`s| zdP#cStYDTsi9Sdb-99Icv6YtP!_2xTk8@LC&`8tkEHec&L{*II-C5JsoG$(P ze*VLBhf7i8m!ve}(d}q>^oJd?7{wot^)zvfr}sR8CfJX`pz)c+p`{>9aBgwX3YFzi zik6gZ*wyIKw-;wdgTq(K+)yJ~Hl43wo8(dP$aP%~W=O0~R7_uhTe^;wVDN9%j1C;4 z-#_LmH61=xW#tCgcrbJ{(_yTWD05dZhtAEv50zB}i`tj<)(&Mc@&oiR<80dIkmRLp zy*Z%Aa;9gcK(W!$H4FCpy@*n<2p(;oTF(~-N_gN0*-CadzFD{kvgyYy70SKjjLt^1Y4gWw8M z^c3GiraA6@@v4LkJwhDg=@|1T*)AyVuo4W>qt_SHHr(D^e0lQQUl_>miv(3LxB)tj zlIin96gzRwdPRCCitt#tR>@=GKwSHWd(}2Hsoc8anBgn}rL>izV@^~eFoz}SWtH9- zcFe0rqk8)kiVjT2jE)3(!m{=!p zND&bws#g>nk%1R@9_vEro!n|1g4kL}Qc3t>K}%u%`acVVBg*v#B(x9R&nLZ~PJufD z-nGHew`|w0ywwD99ZhVi7sKua+GC^W=ffzrmHeqFDj~@~1}t_Gk{RR`$FJwAR7=Ts z_cMi&XB};?G3rzUSHi6G*JM$p3?mApwmTT~d|#t{F9DP)k6+^(%$u<5vs^y!7)hgh z{)J4SZb=c-qW>xPTlL_-Q(W`-Q*d^*cfV5QISt0d2ZWAUK&IYYulNv7E>?|s>~sB& zPw!YdxaLnNIP^6~1OMvx_&(-9T=oBf+Tb3JKM_|qH4#s`fXSsc@Hj*hc z@N}wDb?hDZ!v&EunT-+$+ix1ytA>+jWN-;5%Z*IlyHLXdzO|+=Nw15xH--(Z8T2?+ zgMW82=nXK38e!xzh?BciM7=!KA;WlBs9Y(m7TjYGA7kM0{mo%X;EX%iEZdJe_>KLr znYjUmvAZLRWE;pl+#GH_<4!QUwIkd`LByDN_k>pLOe5h5PK)Yv^m)8Jy-&sj*)ILh zj3DFUs9QN3edToiuf*NFt)?FQ!I@#J*znu#3h-xKkhg5u?Gs~JDH~U><;_!V&~iz< zlqx%MF?8;pI{{;-N zgoejmmgi(+@rFn{np zL?nd5OLv2j-w$&?(ApI5@!mz)&?q|pAbJ@FMNk+EtrOBS#w~E6A+>Q~BJ05U`70E# zzN;Pr8_xIVu51Zyn3e&L8oR2nQ|9NI48$39>>mnduLU~=SQ4#xwEZC|_TxcZk9thB zkzS57(I2J_qWeG5k|F$$T2T)4~u9NuZ1sOIVh~MMbFNp$q^s`11*m;0GzL!4_+dj`= z`^Llc4jee{>gDh9aL5#uo4fXYv3Oj$YmSm45#3((mQd5}sF=YCj%BWIL(LQPcc)v! zL4c(HO1OJMEh_7*r#$1KIX~JGu+W9h{((G5UW>lct^|O;4jMT>k1?_-N#1B^S#>Gn2ghYvS*1|K`hxtM3_GxtIwAO+27IW_8ZZ%ymcjH}l zN@cK7z(Y_3^EAS#l!n)?mP4$b@09ZuVdqjWUnaZiEqG(~5bNsv8}%vnzdBBkx`;o|f@j*|FMmr&e_ByxuYI(lF>#xjUsH?qH# zVH4gM<#JyJuQ(MdDYNauAY4h@VU|Z@9>KN;=M~@>Ho3B@{*F>EoaehB_h_ zJjHjL3zAh%D0Qkt*j~<^A+MKGFlZNJ7-N8+$|MljxjZ@HZWO;l<$QRy*~^V!xE%x1 z+Cd&J*?DP7l>+n~Ui28XHVh0cRmFL)8mrQkoGMtzf;{~RcLf;fD`UYIl7F|hrU*D? ztbYZHC75x&ox*-NqW#;$#ieBmyVyFPQcge#cK+f6MkvmA{+=ZYY1`pSa}ZDf5K$hp z$}|d1H{G+)%uQL@kvqKU(eH)i6=3H$M}LJX1IcWs^!PGA`MRs`L^FQ+`FuM0sbgdy zgQH#;S=oc&Y%l}1-|qEUH3})WMWDd0KI9!*7fi)GuAh8=r*iH${dF^JVLsVpI_Blq zkz9%(#YrH>OdkJ*==|))sArfgk+%m|O42i?aTYiM&Kd^)5SF3KbP9}hRcSuR;mw7< zOnZ}4Jr{Pq9!21D+J(Nmz)E|Y6A&(}d!928x8G7N7wnm$#0`@Mze3{zm3&xPGC%LG zKRFpr*iPEtJJ}Qr@k|kxO(Ep$`~-snXvt*rCmi9ca>4nbk1MM^*0KG2)^b9%i>(Yo zWwFBSt%NS?JR80G=eP%#77$UsbINU>hMDKDS&T|JeV&zU;0tOuS&BfZ&9dk@By!eM zflsB@PcjA2pEc=9OKBwZ^^-q;1-Ybl>o{V(RS>4xZ%#5O`nI|JN6V{Lq?QesjL(F~ zB3JJC$G;6@Xs_GG>5e;_#F=_pCvm+{Rv6f$7j>=egnW!Q|2)G?hnJpDh%e!+%&*VF zqVh|XHo$`*zKyt~!By}Ot)e?5rr;r&OyicGO8zgJ>+N1F_w5dZ!y>fTH0+Xl!j7`* zAu$%JY#WlErLJpI80 zv&c=8?@e{)tib=+Nq{(W&iHh;716F@&Ug3IM=98sK~f25Wl@Y{W7_%&tQFhxXFncN zvlb1xiTIS=dOTUKE#AW>-1I0mGuP>GspYn*Bc^{j>7@z?8RCGRD!ZU=%(o>pG2UjM z%F#i3J_Vr^|3C@!9~)XIcJ)k8v(-_TdO~7ssMC1-&dqpSru4M^fH-MBJfs`5BaN+3 z^&uK={3qYgM~4{c5sY~0o~ECo6j>3!ek3XQ!PhEyb3GC?yPWnZ^c2Oe?g_#zrZ2I@ z)wj^mAyj%K{uAKwQ$9Qdz0^w%fjMVWwfDwuAa`mM?a|87M^hxbb?FB~;^;pH=@FbJ zY>heics5l@=SdB8@gABQJBoih;e2gFZS}*I=Jg%lk_6%D2H!i7U!QD<2mYS#VF(!h zA4}4&AH2inaoUK?#s8^jljO|#klCE{fE2^hR=~%ZkpngXlG6_{G|^1T7E(213>#oxR;4~tytp-{Xc%AOCe_n zMBktmJcf)-Ego3A!Gp;YVAZ)5>kC;R8@DkS)eHkWxX$P2CL|A1@ zGOeSFXNU9|M};xJ!qYT4cD;PUlYS%wrWlcI<{T$Bv z>3vkkc_6U2ixY5ge-`-Xuy^1?y1ADTt`+4XMfVz$OWqT$WG-4~SmK3Nq{<~VC6Zx` z>$_V`HbOUSN27}~O%*e?JL1bypZ;RA8F?viYY!V9k&&yi7-;o^xzL!nx~`u#>-^02 zI=Eq%W7xKyY`m_+;}ZVZ`ktr8PV(3Oq9lLlWa=7lNS+wZ3bROadlutc0k^uYktl0! z>cEg-8CK3IEPO6eF&M!|oNgxzyk<3p^ocwU_{7d}5#$H*?!M zE(0EsyNJ|xe;)9kRiPCkau>eOhNRCxW&TC;Vp3QHCYFTD0yaayJ?*sc|I+>s2|sXg z0N=#&p9_HhF7S!bcYhkdW$7>qiXIq}fuX0|uaQeKnf;z>z)#};Iamu0 zv4k53=GD6jf7wJO6zcTX5Kt1z1Yi+>a`lscZy0(zlemEKe<`3GNWl*@bfkS-@sICB zd0tPHd()6W&k2{=Z2r}D+g_Hn?WsPn@O<}WgwlFI|G$2;nbqOP4?^cBuVV7Ca7zw+ z%hzS80xj(cjs@p zQ!QYK_U%FW{n7F#qEt7HCS@={?qVSlebI3IZwfs`#Yfx_JBbKz{*QRqy#r;bD|u)x zsPc;?f6F=N=dx*~VYrfx>d{OHEUduq@j%OXw4FnSrNjSNX9j4LkzlSJvYUuZx{6p{>vAN)2RQ#Kk!&%>>Uxdpqalsh>dsXZ_hV|Gyo1J@Z_#4%kdsCeqS+* zT-C{*dv~MBW~^Vd&!oU(;8vyCCKkKQF$j zPKVEfJ>za0iw9AK*y zstbIRyBMzg$2YB_zKobO*--DRAkekuzjN!}W%3#Aif02*9}Teo{%JPQjbBY*3;hpK zljRDZAHe^UeKeG^$qh;q_!APf30XPp{zd9*KU5SB@O?Vh3 z^?Al$PRC@bbKv(!>c9FYV!xQ!3jCZ3sKc!m-cyzY?)_GnUv6tr6Qyo8RS7K>!Yw7{ z6fSE0U9%INCR$q8l1w+TCYIG}zH^I;HeT24l{{BO3N<_+i7%ZD;DEN$tfCrhZBCeW z8UeQWzph8z_YY5|4Bt4SL#6ugb!bgpU3U#lnjp^F(Je2)07=NoGQj(Y3Ae<>caOC} zW3}UejMYNoW+B3j;p8sU_S+72@b)03r>1&pGf~$1Ll?S0nrd=NoeiV^qiI|utWvZO zzjndY^?AVem#dzB`aIJ>`Hgd{YXy2KF}Atq@PEc0wR?Ok2213e=YxpbFD2g>Zk(wk zs9#~4xjOysn0q?ENjuNqgjKR`1cPCF#^(DBY-tOi&6@G;h#y@^-Pi=#k6(Ij3?nSM z6_Nv47OLPR?E8WLV#6vEQH|=X(RRotmX7!A=>;FaR;;nQ+})A()7=2nY%-f(CO0MW zk#?8z@L$!R7D_4Ung?h*OYdtPejA)5FYedp%J?5KLVa~qER2o73)c=^46S(yTzP&% zo@f`TPe9#f6a!&SpGBTB?A#BH7QK(_1LNOg`H#O{w#1Q87OoA`wEA7HcWDEre=7`(6j$bi zb_<<&n#b>o<`@JxE*)nmbmMG(8!ps2FLN{e*+-3D;rGfgY z2IM~+KF(Mf_mcwW#1180!kNjuPx%765$LA(MSpqoqCL9l0l-Mas?a_Or7ICanly3v zMHQ%Xu+w5C^G48=C+IM+@D|drKKQzzclh~nMp(ct%LJwL6v+=}9_3~0XUakPQmbjA zGuDb%n{`^c{ZPNTo8bt$l|PHN_p_uhnZNMDy5d#1l1jKfgV-s}s`GIkuw0Q5%PAwP1+XJk>IGzV4YVi@_^0f?|f6qVIw@$pBNOH29=%z9; z0w8uQ!^Cu@(eDS&ScZcC%uX2{b*-W0kA$ebyQF)!^6H7B zS|zS#0dn3|jas15OP3pGqBLGNdypBZ#de~p)_S5=cFBZ+{| zL!b0)cp@DZv?$A){N@v@ss+Z8L5c3!o6sv0n_ngN&(i!JCy0gp?*%r*@`6h!@Zrd+ zaYu*MgpWf6^TsV$B!f^j_egH3bO3yrVF-gyjhDEw@CVxv3*ClMOS41`x3|Fh|Lfw) z!=Y^3cT<%2%`!rIjVL9_uau>XHCZCrvh`9UNwQ9ir5Rq2N|YLfO4cdLSVBT7GbVeI zRAU&FWhTT3V_zn|`x)x}zTf;a$8pVbFVA&f%Xyx29Jd}iyj#My1zz#Iy+GD0!q>8u z6#?t(@0wK?$WzA!H6%|JXgGMgIeF)8h=J*$rxiSpm)nE~#lsM0gD_d+v%zNNBeCHF zX0(Im`(3N5Mn9dx9fSCYF&n*?vR$hIL%rWY!VRqX%{?^8*OD{ses-9b@PbWlT^o9c z8?g}08S^kLNEwiH+j|fv5Z_;fig9|ol2E{3?`s((YRJCPkO*s0*D=BEE3^g|`%KJ9 zwcKZiO%3oDM-O^(YRpsD&Yjv0X^@4|E>5$`#20&qFN3tBP1IKv1B#Z7Hu-)zUs{QH z2H^x4_$=?^{EFdATW1w$Jf!ntxLO zOx@M9SkJTbrAfDZl=Nqw7oAQ_^`B6Y?&-RINL0riilKc?zR`5c9xLQ>K*UXDKrklm zpQslztxbiR`}$uIw)xgkmcQWzeCsrf%g&l=d0JB!9`^)QNMw}GTOKlE#^S50im`aV zZ;*LLi3e*m{x;}*4h*fQM|QDlVHJgVyr#!N3_$YLnhz}Jv>iar2QU^kTfk7rZ)Z?0 zAz$+P8BfmQB|S&<1JQ*~;tp3VYW1fxoP!Os<07PK!chgY(a(fcRz6ffo=AMK@#?+o*^(d-`n~>{)c@>7T z@2Pj#=CEd5tW&HXRl1fvIygH^(w$EpOxSZ|MW?7GGb;SK?_Mwcn4>6FuQZh+hAwQi zwa+7vW)EL#{{h1qOn$OW$OmbaUE)w9#Yw5ZUG_J}8I&wKGf#0MO%=LO5>z3bB}G#s z`_ttw#~ESX3?(WjL`hdKvBPeos1EUUZ!Z(nBlSnDYtr&z)6TR>i9^@UjdXORsFT0( zB_Ea@Wq;o=gV@m#s~sZ?BoEtk(>j$YYH}8aQ(iY3MNWolKD613iGm`rd)ATKnsbTc zvfM_k7r2sMU}Fu+iMQzcG>o@Br9x%+XBZ*&dPo5fZN`roBCGl8f-d>OatCLy7!{kSB<*T@@mrWxKF9)%{?59i z?74=zb@5M=AVpYr%ZkoM*HvB1RjO{cPza~OeY!lKK_N3S6$CDe`LL6jSOb2^ix~Xw z0f0Z&=T-3Lvz|}lZHmnUr&*;TVOqm%7!bl3R;KvIc(Fkkm&XI?TON0!Th7^%s0|k& zFU=O^KZBiA^=0aw>5BWSK`fe5DvS3NIHuJU~dM8etb3$Zdp*agsq*kRQUGf&wR5TFn7(_kN zf$(pq+#9l{x{81f@di9^ydL1xc7{@aweUeDMXaAQ-4BmsWHD7W%!DA@0kN%_g>bIsf?px^x) zf8(mJMHF~b02BR=K9PtbzYlWdoF$rNwoRkG`K~dIZ5R@P6R4Uq<)kU)|=(j&e^^}#V<^aaVS3ko$ zb=en@eT&WtJmFU>@1H@xAN2J)G+u}jkGSu+5*aOxl^$v&XKv%(q1WPlIyI|7I+^z3 zF~=0J8Xz*Q#!!owyY=3BIiZ=>Y5;k(S0f>VUZ2rvuWI#LaV%K8FL+h))g=@4%5p)_ z&K3_a*Zo#Zb;-?kYoVBJERIZ@+RkgL4-^H<06U?B#Rg5Iijs`y2z=b&1;B&_!QXh! zTt>VS14B%lvn8%GAp<4eNKmFS{Vdxow!JHKP*vX}diZg4W9z#3oDB-eGm0C4HeZ@D zP>QeaLmC_FDNSOiTCbEHSFrnq6#D%yk~^U47Q~Hl24CHwd#~84RgNo!m+_%LJbd2i z(|Yl4G(rI$%P%8fKcmj#eS?w4bLcZL03mC&_=gGrSy4sjaXsXyBkx`yWUbFmmI(`N4g-Rg_4(n;7t2{it;1mz@GCOC(kC(h ze5S2869~%=kUN3nYx?S02bZ&5WcOI?t&01eHhXxdze6COj$An3I?xlO9#tWQ=H)7` zplDEVa|vj}Ze|OySSiM!%oxm#$@j8y`CK5VFx0jQ>I<7#jS=8d|GnavC*r@vF4!GG zK2m*;EUrrWm#v&mN!mf{`dg0g@O514Z)=_ve?>KUm>d4kBQbW8n`x$pB;$z{oxY#X z?^Dj94n9v2EK@vv-sBv+a92}wn{23I+HPPjPGObeGY4&q4~}|6)l1u7r(Ed_6U{fb zO@(6ibvm)09p|Ox>mqL)y(gQezi=wOb3_#4eDYt~s%^xKixp~_gw=)nHKsn6rfrkD zB5pc+fPEPBbr(^TrJe(JcB?SorUt=(^u!SBALccr{T%&-Y-C=o$xGb`pbOf!bf*KA zS|$qBHq(qeh4TG@e6%!D%xzg-)YAVsj)fLzx24cQy}tDxgAbn7b(14`=w#zwBw& zX-YkB=D`+?{pKcRtk)5hw8k|n2oAv*rf1h zONqz+8HV0MqzQnDNn2;O4%fM1BT{j6U$To@K;(E=nzXDv6v7P6kq)KI`#~QrnHze> zwVywHY5fq8pMH(VFqBcX;e8-vMWR%r>a|@@*o3vXYIY0_=y8ccI-zRDKtQOo{wFwZ z3_T*8NSJI%ovme0BTaTrnu;&=Q-F`h@J|O0e&sdcQQ{b0HH#NZ?Bti4TMb=QI zbSl?rW@5g96!CMgeNeSTAiZc4uYHoknS_=X$fOMYpF=|)OUjO!1_lPSrG=QH<;KMZ zay#vx`QawAs^`jc}Y2k4RGjuJ^;2?=MKi)szKiy9sY!`F=DY?8P-@=t& zTHrPfp5cu%dPo?I!SZ+)>FNY$86PpT*`7CoTPNv`e^V z@c19~#|i?CGq(sne7X6AAFgy?QlH45Pu-6_b5?o#N$&rgC6lE8!Ya3~&mj6&Y5j3< ze5Z#p7FUWZe6q!*@@jO)Ta~+5$4-s+&^)<=b)OshLNKkCE9L*@K$UEb-hSVs3fc;S z^6@`nayLZwZt=cw7=6>+c>H$TWv>y^IwQ|a-^X3$`t(nuclXXcLg&$*%3eF&ZgN_i zIllBq#A&@sVOyiz1($%sCcCuy*FT_VpEUO`W!&4Ck#{UmsBQD{Xr<&dHC|;8g&)yH#8%DD_w24rL=;H<(Oapik%?HdW`Fri0Ad>gO0>jw?H7(7 zTQ?&w{8a+|!$$b>(@Zm+sXJ#82_X$v?hT#1zV|N$_u9qjL_dw-w)7Bo!_B1I=6`?9 z7~bP`;Lh|uiJSO6n}X^G+kU8XDT@ad_iZ|R5pCb?wo7|wKt3(PHnkTe>>HnOp>MZ@ zBCh0a!tooLA9Y`x9+A{+zn6Vzll85A4dHERB6Z(i`p!d^ zI4nV*&=G7Y&^BD?wZ|ut?KG_9b4AJZ;)FoG_Kf{5F{P{b66}&=(_Azf&b*@MCeZEu zMC@P2?g&CiJxY)loWB0C2)pj!9ml<@E*c|7M`l7#_1-hWS)VJGY+*tr~oHA$o( z1oPi}e3K%B5gMrff3+yMU3B#mpVShJ&_;A6{TYJTh5Fyi6MsDee>*2xgdj{1#!2xZ y2qhFh-9SiOSi5G8_)sG^h}n98S#ynz6T~QCZ;OtCf|GOyhY2{!CN4E%Ve~RH z5*B`FgkhH=~?x%d1_8)S`^z;yl4F$rMo+A zYxooFwd*|kDy3A`rlmkb)d7i3c$KKglYPH1d8Z!vScNbh_#L^_qEEhTC+(}1l#fWN z(@}r7K(cebWL!OP!PjmKjC7y%KyhWZH#@+3x*_E2*Z#7|T;xF*ydv2#0=|J=NN}c$u47*r8#a?>Q8k0%i=GEBUG*3GrdN}oks7WOM z4pv`SSB%`H9fL#$)d$+_1$J?3-poxIj`Z)sQujA(;>@o8I8-r^q^R4&`925#*_y?A zKV##Cb&8%s5_u-wi21XlzFFl*W8`p2bcf+RnlF~Y_hgQayMYsQHFU`Mn_jc+#9X4d znDOVeOFCF~`rDMaSIcSAwbzz;Ec=g-mDYo4q-RDu@RIgR@Mnxerb7;Y6-4cg&jO?` z8NCHJE-*q`WbVT$Qd_&upOF-!z2+cD@CV#KRKDWJzt@U0VxB(oC6u03Q~vtFSqN!g zEXR=xgpHA)mK50NjP1q`$C!ag<_SG-eE2dg+sig_>9!a&~3OLi|RMnjd zd_4V79sBD~lTc)_QVHUXl>xt170HnE>b~dT5bFfPdwz!JD;LRo0&#D9v0}O+oGS9M zjqewrM9%gTYS=XxMrJD33Sa$<*VEl2&~Uf*+m@Lh>=CbD->mUp;2wyV%g#A9_Di4r zOp|jXGB9%bw0k*coxrzd{i&4q=cOxpl%zy-5&%o~k-{|^3Q9K?3JN|73W|>-ue*n@ zqm}!8pO=mwpS^UR;3K+8=ml!7q=r;8$90w2=I)QPJXE5Fm}K|bRbH^VEhL7VA7*8L z9GQ8=FW=ECotx`_kaO~&c@IMoq0^`~ND@hos-TlvX6}}`rqS3eGVuO^ylxm&Sv%kz zPdhMd+@WIVzVgdjvGfrN<2=b>oLy@Ba;gNEl7Ai**J`1zArZO}{B&MHTdV#Iwh}~w zA!tIx=K8vZNKC^O9UVHz4Th5YBn&PC&eD-Y}MmK4gr5S<|2`Nbbq zCmqAAU;3=v-W|26z05&(e87YJrknjcCC(ebB!Z+rh)C)ae1ca#<9EiAAe4R-W~e-o zueD#K?1~}(5+~JLD=@KH3N0L~n%k};-@m&HVkV=i(wCxer!e$$_&28LckqD>7hPNH z_y@#s^nP`%Ta$EG7@>1UyvskgXDyXcBmU42g*!5`tzYQ`M?WFMGeD~}f1fJm_@$;D zkP>=R7FKn@DbXS0^o%3gix&!+AjF;YL4muVV92W1&>k7>+%UM=+^Vj3eP-|Gf zU-h@|jGdzIRVldfx|vl4(+y)m4_tBDfC#JC)6U#C6qN&XU4~{ibYz~VIDaS`^ZpDJ zsy7nbQ3cgh@_GEOu95w8`U3;#4~fCkzwi9XLuVALPcj8_7Ll?>=q2gqQz~cwen!wK zEg=8RD+5m(yXTh_5<6M8B^>XbK6a?x+C1|}TRZtJRXJn)(DhFB>pf#itVB?d4eY;j zvGz~&+I(?$jI!Of+90OmMdcE=u%7S6Na)l;rn>DO&)QUfY{~AFbrNp~hdw}$zW`7) z9{fSgV9mO3L?CBCI7qPJJla6=T39L&0ef|pcFB~1>AcQ&^i!G0Z-O%2|74cs?5Aj) zaNUm`uF-X3#Cf=d*ilan{ZVQ_8`~9i|;{NQuMQHrF zId_78JB5)6rW&MN*}*g>=vp~%Ht280?Du}lbblew<$3w%Ql|3872bHWe_fYr9ONS@ z1;1FX25!zBp1Umc$jIFM{8{ZReS;|JxPCh@4cvJ0TO>Tt7d{q|`2(z9ov%JykTTnw zzIKbR&ROcsI?f$iYBz3s=y>xMF!^)QsG)ts5 zKo({%T?@9)3&szOl7oxF7zlfG;U&$7+!x9ZxyQvQIo~!zpIf`gm{@CgGcrhpzw&?# zDm4$YcC~mbVj%p|^?wz-(*KnNe!B~3-9LHSG`wQWd#~|A^Wk1p(kl!B94Mr z`FPJ}_2J)CKJLtY5ilL1CG8^+!x1-+%mROC=J0!=QC|p|Y!SYR`$Z5lF2$kp=S}>S zLuFV)RlFeci?IA(#4+Q_w>lXe2eV|B0p9{&oJaeHMjo}au(&CQm+Si6$1i!mD$sPC z7<$xZ={+6tPWs?i`I7H)t-ir*pt}C?wIODovCM$Bc~Xe+{-nc8<~j1}`gp0JN*?i9 zIP3dGqYySqy=8@Z-WR*F?QAQ<%_LUiMI3cijulrgE``eij}7OW9ta*A7XNk}90sn- zI1moPx}XMolQvyn^?YC-^E=(sWPfBl=0GjR<&u0~JI+Gp>T&G}V+TRsg`NJ8o#IrHxJ(i<^A7i+$)IV-xg-n&JgDvw!jrH&8Y6@SXelg6zq<$L>+UC~SO2Fk zc#JQ^i;&wB#k!K2w(_kJ&Wq4V1fBjqirN5XS`L)9a@q*TM2^~$JD&8Tzi9>LuxVz( zx1mb;n!I?y#n44-T)`!CA@utzySDHp6%y(>(Wws{0LF0I-8A5l2rbXFgf7#pY`ZR8 zLYfPum>ykCF*V`aZl!!(QQqux-WQant;Vz?E1*hH_VGi!?F*af@|qXb-5%{}l0RnS zQ{Fec$?T~1%)+p~TrDi{-xaqiI6X9qcC?@dT5=A^`4)LiTb4aO8auPL#LsbB>|m!g zGn>wLi2G{g0hG|ymy9CWQpK-drOR*)_xFm?Rszc^KGgF^-%h>YxbvsDk~23W3cIJe zYx5ka!x^l&2rsyJhO)D`VRhp;FEwjBet-_v@D(cGNuw;51=whw%m^ z)Y~|?7TyiIoe6wW7&;wIId6DVedBH3Ud2a`(0G-8Scts(_+{$3u%HRnZ~!eI;x-PD zW$S2XK?JYq=I*QXYV>}uW|a1-$_#BBpe{_tD=*Nj3 zb(*vR{NTRE?8r{n#(~$#4@hZKcdETa5fnn{Uwc8~B+kEs%a!PxI%7XV)*0vVD*XZ} zM=>GS7%9a#FfcDa6-Alf*|s&J4S(rr2#6Y!%}Gmil=q&72S^=Wbm~%=RuTODTCw!> zN~!61L+$Q!h_bo!_lsj8dBdu1pUa?2wmoBFc89~Uyr8Bsp}RpGmbiCstfAZz^KLVL zq!|fc5>2O?8;al{Y8H!FtBP*To9fMTO5gBwQd1#tX&4uU-Jq)qfRS=<^wZoLL((v% zIist%>gWk-ufkuDa_Cm_mv=8(#JxhO`9?HnfKe9< zp%K(9FqW78IG4JWT0TPV9zutnal-DFztV2S(ZlyLzvH%wiDwWBQM}yzv^|-nGPA5Y z(>OiXhR<+;hHY5zb_;3yKAP`ul1 zJO4ynT(AT(jez*=y9k*AUIL^I>tA1e@FDM|Wv0P!YBsW4>(yfEbkSg`njf2)MJ$(cZ~Tr8zxd~he_QVrLE)%O|Fh$Yov->O>HI+Yb})|nkx}~(v>8tnh}Et zwAW#MyiLdQnUK32wXucDRXQ88wa$6G5nSc}o&^_r*`lTUocW-I8M1FcB<9{mU9_%U z!1Y5G!9cu>N&Bi*Q+%m0cg-nztyD9mka20!uE$ZE)-boTTa!b58f#&S-b3=PFL{E7 zxi;ddGOaFf=6Pw*9532)&$XX@?ckcl+io;O`G$y>HRXBB2Fg9bD9?s|TN6&oF)qCY z?HIv6=A0@W)_Bms)Ujdas7sX}J|>)ffkg+OSz97i1U}SOL;2SgUi+*3#3XBDI_FAA ziA#ZGu~s*gkZ4fBj}r{6E=%X`nOwhaEtd1|L zed^^@hMwSmKhA!av}aUT#Z^K){MbOX-H0R)S3z09tfb`IY!$Q*qEAt@9#}-8m=&9% zb=3mXFV#{&#ept-`f$y%cIY}5t{HQ}g6&#iNx`~a=dQDu&-6^6GkV(#W}m&^qJ>3= z#pnbWwAdQr2c%2J!Ilr}6kk7fDl<*C#G_W=JW$|ty8oiLx*-mB+^ks?C;RKe9SIh) zLz@OWofD$QV$BcNB#8ZzCTAI`k7+Hxv=qM969bmP{0E$a*urt+$7kEY$4)vD?L%-A z&H|zr6<>|Z4_~e4M5ovbh8%anbJys=kgNkboCVu+QPOimd$cYhDg&2i+6(bol7cEM zZEM19JnL*KM$AyyfVyi^DXY^w;Yp@u$kx2Z$M$wdolN35-SB<+T89mX6ZW-+Yrds; z*fOA`SC*_9-+XFZvbf}QqQrD@9E(k$*LvHI9lV&U8Ra-LW3))vGKD=fE;6qsJNcx%R0O}&7oFUe5=WAZWX@I zPP}OBd?^3hvC!H@6qnXnqdmr%Vk%(_o*Pvj$bTMlXU_Jp)4S7GK23BCA2Og4x!^kQ zNts#OxTGC>HG2(ZHMcWTQ0}E)*45IEP&?t{nCS!$F{;Z#A{j? zL9lafJ|9~r$I-hLsNjT0O~p%kP%9{RE;nn2)OEOQ`T!y-8EjyAhsl!cD@aVwbGDl$ zv#|J|1W_C+C{Hkpl!3N$E!nzt(YlzFHuUnDU7~j(nqZ~(H&BtB&^W-k;Z2#9hi;QM}(SS>tKjU>e4a z`8lyZ>rzkt!^T^L-iT$ga<&5IJOChdF8kJ^6}z&0J+HBW%3dx0Ka0Wa0#v!u(td|F z+q!34o0l8UY`#)t`Cy#&9&e8GFFkLurzlP^PbA>JHMm+lmS`2+va&fIZ1Z|IR@7`Y ze?HFCJorI7b9oaj1l{RAbyKrrUnVZ~LAq8y11v0w+%zeTlLe3}0Oc#2wU~#QkxCUh zoEAi`J$CDIPB3DhO33=6)vk~CtQ($%%3&#Z3^(fD*nYo?vck$T8@iK$sLN0{=HbLv z(c@TY>H@#$ zZcxXCZ2A(Q9UHa=_DV=>QmL3%Or5Mh+Nk-K!Ld`%`-VIG-xX5qiI`eNXZRrIHp2nkIw3d)-jJkC-OW6neZ4s~qw`*26 z4#spM)nD1XeurX*1MRn|cHZT?$ zNF-WhU4;p|s3w7MlN6dljYwXxBWwS}O{S~D)E-z{aqnw?bjIBeT3}_lkOnUBmC-JP z#tPsjT4!C&h`IPb$8u_>cNw}S8M}qx(}BT435k`nCV~YwnH8tWz!&i_Sxa_-cwmAK z(Mv1}{dkL_9h9s-?bj;eiP=#P)Fq+xAbga3l&2_adI=uVk&qs{RfBE+nBw$=UF5x1zf(vYS5wIH;~CZTa9_INsFQmC|$hH|xLkYjT* zYKQ(%6Ah6ve%!7VbEyL0<)$LIy2LO-r@kTkZ?xs>nX{(f@v|oD! znQ#trjN5A|2h`rf{4_iCImX|BvdN01vr;>1xr3_mejssB8&D+A=5|&q=mM2MZ@m4u zD_v;to9T}}Us)ybu(1~z|KKdL+Q2ab-{bZx=KbuJ8*~D8rRrj7s$8@u>(9&~-@@H^!l@^Ar$C0?yyL1z-pp5+-r6OX8O+ zURfkfQhrFqacs^++=fY*1%(Qxzk9Pe^hPDS!TGv=9VP6t7j}2RX7K`cX2p({T$gKo z=KzsB$>HN7N)x^oq`{f~`a;;%Ph@RS<&<@BC}oi%ocdHL%gSo)IVbqFVqnm0BF}xe6a>Ar zPfkgRzElA@l8u#B0yw$69|(lMYiIFot_7$I-njIu)Km71e*WA``8>L=3QMx1go{#+ z7nTa%gKjf>E}!KowN|mqDQ&g&SuU^nK6uOXtL&|{XS zvs+7^3pFS@b_nMm3dd<>z22o5!#xQ1ano<-RW`2LE7xRWf0U(&8ztBTvC#nZj(>g4 z2MxWuR6RoB724|2w^#%{xc|b{`-fYtpalEZw=BGRXP!lBzNn%@qpKWqah3zP2kGmJ z9AeGsRL@{-dyjv**_5OQw`x*2Q--f42eofs{g5*?fweuK9Z^}$5k&);QYGV_T1NW% z%OZKmNd%HmvaoyWLJx!I0V&Ld1I|7X-JL2b`Hm>1r9%#RH#eJH4g%Oys%1Wd%N?3>Mhi zR{R2wHYp9WHfmPN$M!nPKWoVc2eWC5*%SOXF&6B<_ZpySO9DAu%Eo6*%FTjSE^A;( zwt)x=G-!o@@c~;DrpZdGCJOQv=}UW?j;Nbe)Sm?@9U zFTq#9XZqgRK)trXk|GpptV$K(delJ0)dYQxzS#iw(M<_gFB#I;PMwXsL4R)M$*b3v z4|8wMt{ac($Cdy@8!snV2iA;xcE%(Cr?)QGfDbg~p0^AmE3CK->{Xm_4)ue*^&lyi zA=oRUREz}(?z7?HjKk~vM+QwrER3e5k`1}wyQQg!q>)?sNa}&`ees}W9ry<%aUM2H`jWQDYd0CwVANIN@t{(yg{&9bL=2x;e9d^k4Zli0VWtfc(h8T!yV#@x~+fQo9H<9qMDmmFY@!)6@&TB`ujQZL5eN;&g7u zjt2P}`ifLeSc*TFNF>PYzwtiQyL5uay4fh z$9EP6LaYzx3l=DX4X^fQ?g7hDXb51IJbHK^-gg4BY|GjjEy!2+4mYT~+6vA4ZPiI@ zf$cH>6I<24mA@Y*?3(k1%_#xxB(s31&3Q*W1y!9V9rj0L3Xm z_6Y0>6%w%45NJFu?j$jpd`g51G~p{Eaa`c=0L6xEAUk+v#K(`*B!=5H;obflw(zLuzj zWo^EB*_eeB!R-|RhS44zvI>koWuK>zfa6sMnW0l$(`C9h_*p78+a^Jzz$4&{&gvFb z^a}Q%k-htadSE2EBO)~S`D5XMEt!kTbZu!k3o+@PBbq1(|FTL=kXhaK zW|vN!|H=V~ek+}XxcySBO{Emj9GOvGrlfHHviNf>nLRLTSY#3!QZCR$)J8+`qh0kc z3(mx)+!Rv^ze4S7e=+&`9`%fNE^2OH0S6q0SN&&DWG0Zpm`gL8Tjgt=&WA7jl+3N| zw3H!r>Amh8B;=295G0pJ`K!2klV}y#hBP{Lz*ww#VJVTtvcHubBf$*DH5O;C z1s~`Nk0C?^j9cE6wB02Hr5JXbc zVV_#!M@gS(yrycffuK`sa%`qx67GfNvGdF~OMING4N@jIVN7uLS_*iYd8-OFuTj98_#E81H$`d2UMQHB$ zMlo1DZ}L=Bt^v&1aCAp7x`xtaDX8i>D0IuTqByJ&o%f1X$-iHZVv$K&2!^a2pkw&o ze8-zbKgxgR`v<*-!zjY)%$^A+^#W$vjD?dLfSsq|=}RUx6k?V^>0_q7!QbO1f+wi| zdx&y@PwagJJW5_UXNR3%~z@JQYkt18Wy9I*a~iT6e_5ptp3NuTK1z8*w@R-fn+0us z5J#|#?UYtX@L}h7iP$`zlRhBPgWto|JW!+LEgbPdjTTxQh6RTB+_)E9RBbZTFWTeh z{+Zo~uiYJCmKLl`3WO+T_V_E!GACV9s^lYe;w_2ms%gdgxbYw6VI*nQPzLnPQT`-_ z;!?|D%r7bg@ z`W{104%Rvu&@#-@Fa?PAJRaD*`zBApMwOMFU43UY&)39A&O^D#ohW6rs_t7Dv3`gk znyQP!3ZnySAzFZ(a;dwO$Wo8^Jq4GZLW}WqNW{oW#31o&wU3tizj*KZYbNM>oYi-G zw)DGQKF=fOe!~*YU^D%p(e*2(Q-yxfcY&yU>#MR0e@H-|(CIsKg#}B7^O)cy0SOLN z@;W04O-y{~6B#E#ZnRuPB!41$Qu9MTfJY!V{1oWp6Unl|wy<@V|=MI1}Em=$F35aQ9`=f24!`g97V8 zBuxFsXQvPnPnQIRn(cCxg0EYabl6G2BVB+X$$8o#Z9=d%7P5VPtmh$T(YFA#|5js0 zf!$8}$fbG)S#>JhI=(_Gue@H{Et#S{M7OC?gh2KTV#9WgA2UF|la)Q8>cgs2LznSq zU6p!x1ji2HHBkNJTnqF0@vb`${q+rfylHTppgse07g{7=O>!Gg5dKyktGemfIRoJj)wJk{85o2b5*+8I4;hz z8Zbu5jXWC{wwqxwsIo}%j4a;hGxx+os8skwC*>XoCyrOL4z{m_vnCo`23A^Q`@D#< z7&BVI;1{7MWYm-(Hw@T|wg>-L{k-YUO|ji7cSRb|0V{}{|?uK*A=7d)k zyDpLj=!klFVA4alJsG;RuviN#Ct<&~-__<81cr=br;5AWQ3Ys~Y9=3HTb#KzH$CBk z7T3Nj(0iv`GZ~EGPQc)^sDb_R{e-BF79Fh)na3|&A)HM~aDOmHP`p-k-iWcOekplA zcm$_~kVT(23?o*KWhOL|=qKWX>gR&c&mjqH+fEp}L>6~=r(mX$O*+0G#iC$Qp7liJFBuq+1!#RArK51`$ zAb(Ud85&l>r3oXW)j_yhmOi-u-0gK@(YGcSBJO&IE#v9G$3xOT&rN4BvFFtv<#9QG%w9f}D1|pD&2x#1=yw z>-I=?C}dotOg`UmE=J3P!k`wf=i!QbH1Rf#(=Y?E*Yl4L551#?f`=zEKNs@Awe;Ebwf<+V$%y_ktzW`IGv9?5YQG zgmelkp^?PrD|ul$Pkp&LBdhk#S{D5Q+s#h<{Xy%ahvAe9HK}i?b+rg+pM7)xXjnnK zGO4amQ~4>krt z)9l9YQAv+f@p7VMD;)&B#RQvVd?ndmI4!uhc4`WF3{GL;q zC7r>bJ9l(M)m}ee(wIm{v;P!Ew$H;WN5Qn#x0K^dr}_|lq^)~s)Ljd3`w(?WTiOWa z1A*grr;l-bX^dFJ554KQw#5uir9OYF)!TP3W6?id#NIqOz9;%5?|D)m%-S}2;(Pa# zx&>@q({;R5ZkQ>iFk>N4m8<49H+Q-vS(069^~8hB6xaqka~k65;FrNVOhpP*RO322 zr51GH@km|f1%3#~GGalN(MiY}X2#HD=JxF)r@A>b)s2w!D(m``mPi&M!e7E4y;ubQXQjocGucUt|~M>~b* zXM?(Vl5(5O3^*^Ic8%%g|9I`khoei!&{Yd?K`JB}!gL$SRYAg|bL3u(t>dUL!gHP& zqAx%+yqdHU@i*H6?^m|=UI;)ct`$S-*&ZI9xqnmPWR}qx;RrC57E$UOGZYC!P=;Rr9U4_VecfI*%M9oSs)9%Dt@&E$x~Lz zlt1O0Sh%Qory4W{B@WpVO~VO^+A`&l4C?u`j@&HMn(rT2>BiP*t1^R6E;vaRlQA0A zYG1#YV}}mLBmiX>&ASy5gxwKVTEAy5R3)!)8u0`R9duP>bSB)l;suC=xs!fbfIr-X z8AVWP4XIp2#snR-Y2QJfn4j@2iIZ7P{egGk#Ldc3_PhB+ml7xSZjxy;A5N+OE~8#I z2hQvM`Q0@t_%nr&K064vdXlNDAxKrA;C6|YIzU4zj$x*RF3!{}Lr_0WS9Y3)I(Uqi zm4QpLrOsI@jzwQ414H7`!;sSgaY$*O25cw0pWXV}^N!xl=_xk9j!56*)$DT-&iY{O|G6*Y1pDKa`h zrcmH%S>Y4$GMDXy$|^p!B=j?K5IYprM@>(i7&i`+c~o){C2?FdEhjk;oYe10rUueD zx(8&)R-BClb+(<#hWHW^JvWWR7?KWi>8a8Bnb(~sF-^|gl^yxf*z1Ol(8gu!>nL*N zRL=8}_gV0dL=11bjP{y7*9L%c!S^FL5wlqB#x+wEy{mW?(1f)_3GFKOX4bHK9=dF~ znrs!Zfc80Uk5ZGcG?|U-&-#Xj2sW7^JdIVxi}K=_QRi+K(zNaKVa0A}fb96@DnOG1}#?4wqb zb=B_Oy{B$e;=p6`N*E3OBQeFhc$X)iSq$(zO__C!olk|f?JMp<4A2T0ZB!v1Kne;8`mX%al$WJ+r@BI0Sc$*CQ@t2It3ajFW zY6G#A*df$xVQ|ipS&$XqGG@=$cEqx9r#^U~2~`-a$#9H6p5Re)pS4TR93`ld(_bx? z$lie>%e8_6o7&xu#bLi_f}(1l zF@3~+eIUY}v|%|`{MqgrZY@%W7A>@XdfBH(dM@=At8}1{-KbR)2VV5- zJQ{z?+CxJY3!j3AzH|?jVuzs{yg;^ho8QXg=%uwwZ{^3 z4{YJ3;>s~SKrj?x$bVNveDlVUQm7w>5J9+68M`1vO7AvPpAiJ9mC3X;zILSU;+en* z&CWbxU}&GNJ2NeZV+FT6(Cxh4(>(q>5^!zD0>Uv%ll=aIAEHgul!l8YF z&%_qzjd+FS>bMWNM3Ar@#Xyz^M z(8HreY}wmGiD3BT0{$MVFzKfh{-$PQyRoA=j~mj=e16?f3mHx@)hu8)+d%v zQAeEldStJD>7`waWi6U`W04BC%~cc$A$=qoO8Q8th6x*IT8VH-g)-`M+(D%kSbh$B#f#x5~4w>`AurUbD&+1|4GI}&NakfFm8BZSn0JNiqB+h zXJ|2*KjGG3$JOM^LkxH|GTnTMvTHvNCw=C9eKtqaNd=G$4loZbn+?gYdmYN2_f3A z3ldbS1Dr2g+NeIDYw3#CaXC`@!_>lLDNFR0U;JWGWb^}c{5TFwb!bK;1!O(k2eDD! z#$kV9lS1X9#9Rq~9dAvS&d}0qF8|8Q0s9M`6zW_h&chB_y6`k<0W%Nxt|*idNo?TD zFggmEb&x84h-HD+(&ZzElP&(n@56#XhJ904>L~<^oG>%z{j^p#J8!? zK0R`3!k=w--=$+w3N2v0`-A868sqw6m>FDm`u;8S`*3LAJ23o0K1A=jnB~;wo7Xsc zeb2TC5iUM7)bmzBlrjl_>d*iln)~=$gC;?BiUnA7A1t{k@ytN zSaQa8GZCjCbBF-L=O~INK7Rg^{+VRLaWs~%y^iGntsl&n4!zS#P2~Z%p@d?+&fWKo zlU1Wn=WF?)ONHhEjYpxAbQ@cDd4nbWAj7~iWV`>Wmg>~aR51k0(|!`YGZY<#jwaz% zkTw5jjzG&-+x;IaOweqtAKe+@Mp-$#alW{By>!V@@GB8DpZf4~Db`SFq-+Vsm*Eh+ z3{2Ll~jpBaC_BlF1 zA~D!5M+ic;cc#`HRVn!$$lr768f1V1fFMNj)#1%I;nQ)f@T*bdvTyf6B`{d;|^ zwc36V`&Xi~AOhkb_T!My9V6pbTj|LIZwS7bu>*EFKktA0mKp(pFyBhXivG5hSHF$> zC-Z-3v?40;R*h8&5Qa=;TrblTpB`3^9~_BPFT$Ozun~q&^5)Xne)F62ZV(Iysfd4{ zLA2?f4Tg7p1TC2Svk}8zb6i|bHk(L;o!MH zXRDZ4lL&!gvXRKS>-ortBdR1Cz}Nz!`Q4aXaI}>F5NY+Lu6K75^<^NG>8gDS6KkM- zs~)`VGO#=xyP7}xh^lV$-S5AO5tU?2ZT&3Wdczr^JO0MyI9jdCjfPR6R%{b~2ZFN0 z|ExNC5Q!}_Rx0)$sf@7Rf6Iok+d&OHTpjjYgO)!N1?8X<9A-avaoGcnL*`YTjA_9k z+NHYkuOZ;2hn4_iH#`*^G56Pni>LnM68}HR4-HU)+U*?6vvEZFkMALqqb!4>+6>)# zYD@ur75{3ZPn*()A1KdK#{}{a54Q3CE59V)BV&U3R$m%+eDLUcbShOn74W{tnVTmh zDp(!(=07`4m!sg@g?b9(C*2+M6rTl)P;vZ%v3pC3So#nd$bGP$ekh5{$omvM4AaB? zTOt#=356$eVPiB5uu+W>q}pr)4QKW{w@0CvOl?~4|5~u^!IDk?NWQGJT5RJ8{_J+^ zlzd63$#m>#4uHLEM7-)>{@4F#^~f!;`wxAX@)`f<`1!2^q}o}(Rx00Z8%_N!XAkkK zyIyyR2V*#m{g0Nu=n%>`H)aq&iFa3f^50Ua@vcct>q_U0s?+45e2O(?ge=-Vsw0vRk>PSK+;=jaidz^z!0roOefH$D^w_m^h0Jq#Fj`s7^3VOiN z*6_c#f=zWg$78@B%;EnXzVQC>zviXMpT`)uo9@}jYZr`ul`mobam8W&ojh|*GLq(R z;(U=Vi^#-7p+CAz>yyRcISC?NIVSJ!z zv|QS4|JH%({kQIrHn!j}=~WwFRv+jhgAKIl3g&8^+T;#Tl_#-D$z71Hfm>oq5|=6S_pz9cyqw8jes%!FGL?&LEPIClRwAt`PbG^W1#_Kjdb56o*f#d ztI~fO4lG1k4F-YJpT$4BNCw0XNnO|80Z1@GW>PX*X%lW~K%?fGwG-^K{*Q0}$lD?V zY7RxG&^2=`Mu|!k0;|(CO2JGOi;nsd$_pH-5+opDl$7fk;5B~yX2J7b!o%})G~y`) zB9-#%B;{qDMn7*sOuEA;<*}{FP=*B|flPR%7~dIu0eJryk}WHh#Ws0wwWLP=oYV2v zhZOmer-UWxJ7Wk>wAI#oOaV*Nw^gs~K}EP%uYS7q!lBBTcrT+rL;JRVSif>kUbbN| zQD4?kV?~Z#-nJ7oTK#xvuubODk^%OQok&n*5f5*$T*?g;AR27L0+`YfthbO4$?lhP z(|!#CC1bbu_rDQGnzp$YU_T~JiM^b1Z?*O3zl!tl-Mz~6s!w@mD7!TZ>~GQ5Qaapk zc(&9yTd28I@fIg05pD%!NSgsh^pc{T*3;hqG!nR3v7LfqU`fqipIm;xdG|YYx(Y^3YT>*KXL37jskRzJShPKa(k}j1P1^Fd{ ziXUM(q&qM5S|N!|DS-Yya|a%|u95r0K;8%TDUv0}+q80WJ}Ghp;FNejD)$Zanf6Ba zTDo?g{8_@L3hhlF{`!%xi92$vgC_HzNgqZZrGta;pQZ!jvjk2~uNyd8SNn_M|D?@+ zvxy3HVjbkQA?wKt7d?8s%K>RSz~2f(MyhBcqf9T1J*ny{rI8qkKPovBQBA0{vlo+} za~?Q3{GLHy^;G{050WKM4?PKpjkk#Y9}&^g;q&N!aabisyUp;hBu(BYTTZ@qshqlc ziaOYV_rVTiTHHIh{rM zWpaiRG^VCnrZ0mTyA_R!m5sA)n3I!l*G5uXv2{<0{@QDY%U9!d=CYWk{MDb!irZQ8 z5w=OvvGlU&nR5G;RYgog7zu$sYtpG>QwV2dzv!(1##m_%%7hOXw z2qg~s{Q?PWcC3e-dc1+(6qnkw33))k`X_tnLQ>pS_^_?Z_znuL#bx7Mi+QFYgon z{O`aSvFpX64_q3$a0$@)I)%PUDgYEoVr3nx#s4<`>*41dA?dxXonR&1VOXdI_ySRO z2iq}*(|_D!6D6@C?RM+{x{y4DfS^&E1W~(yoRI;#D9b)>v3KonDeG_TBTd5A)A+Bq zkm(Rf{$xfYFI?VDU=k~#n{XdD2kYj?Jx<%0BPJJbg z65K%U2EZQH$Xf#WD!B5QhQ8SK^xs(kYGyw%&Q6x<6IDfzWS@h8bOG6wOp{TsVdrgn zxt1EPWmx~sPo&cVhg0m=MiEdkzRS&j2skoF*VoQW0eb5Hj6{I~U9kL)DbX^;P{(aLxkq#qSK1favEB{VeWJN9;p{_L8Jp~_Es}I=zd)0v^!of$Lu?1S!sP11@1@f<-ISRe4zhg?Je_X^t#lU&W zv71FXHaU~xkfDtc)#7)m?A4I3#SjUebUsN!CUV3-rodCL+F#47q1cZBJmHg>`*e9I z&hWtqr#7Ly+rXRudx41+?R@VaTk~y$ilz-yY48w#Z_5RX#JAc`op{qm5CC6hsO;Ta zfg@cXkPkMo#~WGYZyQUfYW6zWVY5E`uT-dRiwO zh$gkC6sz#;sXRGdK|T*xhJPUS@Tj%NHFDp+29b}o+t;AjW2M9~njh0_IGg`p7v~<& zbo>ADc6X9c3LUJRxusCfIjo}GIW0LwOb$85WQ+}4Ia7qnYEE}Kj98-_%CQ{EnVOKZ zIjoTLoZ0Uh>ihlv_Rk)VYuEMJb$Fj%&pmcYDR-(9T@C8+n|er|6r!|?-kIHTZWYxG z75t+;M)PHjyk5ano#QKBhv&(j@QMzogD}b(Gfk+8!Z|e#(SmQ*yoaXQ-*1(@M5Ey6 z?^fP+G}rVtPt}3wDj2+}Oukl1Wau$jBQJ(vUUn5Et zZ3QgV50>}Mne{0vF93-qPhwN|V9?UIPY;aUpJpUi%zoOQ>O0KTSk2WTY)SUsN-6ub z`iSlCxVzr{t>Ktw&nlY1sy^}Q6CKUI8O@~xt8wByS$;}V`mYkKhbV~aBPF?VA3z@V zKPQc^XQdTKcH%K!vrA7!df3CMZYrD7-ND$h-HSnceD_!NXT(B*t0z?-H$wB{pZR3t zI59O{q$+p!dF&XcjZ}uvotn~t*1Sip?aA2h1)tK@%nk&TpDm`SJ-SDJ7Mf|=$VQ*Y zGE13Ha0k*}vEru#+fBeglo!rWqSWwps6xFS_1QeLVA8AOVJ5X&iJNpJ)_JJ}gpN`5 z?U+AO5UWQ5F`rd#gXVxbRw)z}ENy}W9y4(#K!Ec3)L!aE*!h<_9ub|SKBH{u+O{uK zG{XH{M&ChGNtO)1iQuR3Hgv99DQVtFzr~i#1Aq-45Sv)+%Q5nG*lw9-3QpnqyE(9G`wZBuaOgjGuVbuk0oGpme(({ZE=dF zd~C-Vgn38Bi4-6mw~|T$kTTon%2H!s`PhzjGMFOH?H5&vkM zxkMW8>6FE>$9>)p%w|WBpDU`J!e5Q^9Vy4c$t!6-y_3Nt$8&xzA8km6N1)JEpkBm{ zOQ&ge6vVg>j+PPgP+j#VYV^sLM)r?9B5qk$d{*_QAw8xFAdgqnOy7`lB~+X1dSPeM zv^)ym`JFiSkrgCH`d$%^^CAPr`-?lCUC4dQI|jmuNz?u3RNbgZAD_!*csQK<%WDRJ zHV8?!OW>3MOri7qf+Z|!-KbFPqqTA8;>bevyr@0$WlZ@~eSfuC7lMX~qzjr$k#*Kt zD+M#2rtq?rwEm*v!^z1O=)zH;Kf;pwtvx(O=K;k^G_64LBB6EtT&g#XfHT-`1+pfT zMH#C-3(JxqQVyHJ@|zkd{P_aO)c@T3ZnY;OT+P1huHl|$8as*S;bdiJDE9q|oN&2C zrDo@g*lTxZhiOvm(f%#Y3R9BN8I~nWPEh7MU%@!W8~iYkn+|QQ@+9SVvJ9;y?A2fj zfu&K<1;j<3ZdWrI1eD*H-_H|#qV;VG3VdI6&FxH4^QDO#`9r4^uf9ekw!0tD4zOeu zgsd7?M3Gx#!BHkT1qR%=-LSq}Gds)B5d|4IK=h0w|%g%fJv7+E|Tq>fau~tHCx(N;MuEY%`>2)R))# zyMW}XCm6^3b{IrG6|%TS&FmDgghqaS!_-)j-|}TtCCbQ?rq1mhUA7{Ml-Flm@C`BF zs&}36$qa->{m6Kc;fOf@sbh*$+iLMjAPjIWefCITGv`FGU0i`~x zXx<3*Tq@m5yTr2Q7Uw0m>?N~v?v2(!J^!wbvoQu$$eWzPanDl`4T;s6sI3GhuEAO1 zrf_e%+cb1K3BS#Q)JTIxWEw@&AzI=Yf8}b@w&G8@@^w+Da#cgiH_Ci7-z&^Giv|b) zbhk_R=W5%Ql}8=Nb)PyJLT!wYVH1Uuv1g|2nn;DLgLP?ZRU>_jHZlgD-52>MDS;WF z6Ej$eEfjAH>L;m?&BB2---;i64KX;0%>hjg%iFHsuYnu!H9vkX~VD7aQ)8w!rvduX=AHkEMPJ1nL7EJj%X4vw6YxhF%2 zg#l$3fVjGwoQg3BQc4G_vsggcH3|KO0bp@K3Z2FjM8jHR7J|EUj>p6TcoH6@8Z}a^ z7x`XoTSGZ|D2bGX@F|zrp0(Qqp()QyqN#1a?a;AhV{6Z?*yS?UZK}yFVkCno$y-$T zRu$D?)Cr6d<8r&B81u=7r-^SupKr!KVwIzxTc2%UZqk&~92HDOAH@~7pgw18r zkCc$>u=}*W7mVG$QUeKZlYNdAJjA#lN-ZBA=v+)Rr6wxEm7#&*nRNTU>?0CNH7=XA zJEuNae}b(Ren~};yS$6FCn$^UHs25sgcevHusNK0s!Om^RpNpuYwY%X>Z|}ChsLnM z_HO!YK5;aECf=-VpBC$JxRcvZu}RW|;%B5g-pby{itCg3 zIw0Zf;IA>QN*d1}o6oA}S!@n#f4h@~^%>yD&UWiVwG7#fv6q z-Qt1^qP-Tvcz-xz%SKpRN*1fkmj460Sli)F7FP3ej;SOUZkFYuWpu<;Ad zT%7qy5J<*F@0}mCjz7@9F^EeT?6VZ|{! zx+pvqjC76LI}Y)%d%S4J5wlhs5jccf==5}ol=%JmCx z8>2LJM!RHrP0xOai@iIzgQsn)|6&Qo5kuw3y3=zpRxKwmlU_2cxn7RecQ3~5ah9)d z8N%uANoMPgu=Kb!EG95^VywmnnS8O>Ik2rs?jO!UBbLZ~TUD-EraaMvM7a}xdFhIC z9mFNffnUU0xK_Csv}mP@Cj2oO$sdg~T^wvJf@J_d{T?Cr&(QA3esd&`$52S?4Z1G7 z%hYnVxN2{yL^-z&-5~TIhqB_OEQ$d`JuJ!QI&uRum+V`5@+IJ8e^*u{ZsO)g-+D3< z@G3}=%5fdx(s!G|;0>|cYfgslrsb;-5AK-Px`lUN*H$~~n2j({UB+)r1*|u~;c$uo ztPHoZaKKt)eQ7=g+;g_JHYa1f&iL7~Xe+l-kI-N)Q7O!|m9^XP|IV2NGO@UTfQ>0@ z<~)^3f~l7^!fJHp>2!LBHFKH)!!VcTSBhk;1D5AUevUj!Vb07qg-v(T2`z?SaaiSb z@N6Z4a)Dxo1nn}s#Ft` z_w~wkJe}eY#$T`TgKPS9G%|OWwu(28&xhP&5kG>5?`SEeWK2R5Z89$gdh$IE9}uAI z6#12M0DGJEr1Atmj4C<#r0Kh0^kfikYMxtnrvA!N4cJHIIH?2Ib}iH0jN@AD-S~4m z+nkMZcFT2*)$eXG5j(nzf4_LuVeO(OqD9fd1B&jh=~X*Jce%BaG4RLso&3H7sPrlx z$J+^NYVlIWjkcagKF!5ci?0ghgN6*ohU`#HA%n9b+fLgLVl z1{roQ-iU_h#7=a;3%|5|M|VXD$RIRcW=?V?Nn!QugDBOWhLL}j?JHoc>Znbfl!iSB zJnGLW?VD50eYNN31GvlMOV!nUS+#u0r@ox~{Pc;v#l$_n_rFl2eOWu3ox2+Ft@7;y z0kX&w*m$$s7^#^LKU{NUhU%{AMQ0~7JMy_422u&VXB}>l%d3CnK$s9>Sy-r1L*F@Df_QA@cnH|AtU-N$B<~m~aveIS2>U=pp?@p{+yZ>?e>(KvCD{5vg!iO- If$=;34@^c3TmS$7 From f41cd2ccc2d5f8e0fbf78a08bf2158ed54564ebb Mon Sep 17 00:00:00 2001 From: Trish Whetzel Date: Fri, 12 Apr 2019 00:30:21 +0100 Subject: [PATCH 4/6] remove extra split delimiter (||) in background trait column for GCST002891 --- .../study_background_traits-ALL.txt | 2 +- .../study_background_traits-ALL.xlsx | Bin 96138 -> 96174 bytes 2 files changed, 1 insertion(+), 1 deletion(-) diff --git a/trait-representation-migration/study_background_traits-ALL.txt b/trait-representation-migration/study_background_traits-ALL.txt index 9d65ad6..a24499f 100644 --- a/trait-representation-migration/study_background_traits-ALL.txt +++ b/trait-representation-migration/study_background_traits-ALL.txt @@ -181,7 +181,7 @@ Mucinous adenocarcinoma in colorectal cancer colorectal cancer|| colorectal muci Common carotid intima-media thickness in HIV infection common carotid intimal medial thickness|| HIV infection GCST005184 common carotid intimal medial thickness HIV infection Carotid atherosclerosis in HIV infection HIV-1 infection|| common carotid intimal medial thickness|| internal carotid intimal medial thickness|| carotid artery disease GCST000555 common carotid intimal medial thickness|| internal carotid intimal medial thickness|| carotid artery disease HIV-1 infection Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio) unipolar depression|| schizophrenia|| bipolar disorder|| concentration dose ratio|| response to anticonvulsant GCST002887 concentration dose ratio|| response to anticonvulsant unipolar depression|| schizophrenia|| bipolar disorder -Pharmacokinetics of antidepressant drugs in severe mental disorder (concentration dose ratio) unipolar depression|| schizophrenia|| bipolar disorder|| concentration dose ratio|| response to antidepressant GCST002891 concentration dose ratio|| response to antidepressant unipolar depression|| schizophrenia|| bipolar disorder|| +Pharmacokinetics of antidepressant drugs in severe mental disorder (concentration dose ratio) unipolar depression|| schizophrenia|| bipolar disorder|| concentration dose ratio|| response to antidepressant GCST002891 concentration dose ratio|| response to antidepressant unipolar depression|| schizophrenia|| bipolar disorder Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio) unipolar depression|| schizophrenia|| bipolar disorder|| concentration dose ratio|| response to antipsychotic drug GCST002888 concentration dose ratio|| response to antipsychotic drug unipolar depression|| schizophrenia|| bipolar disorder|| Coronary arterial lesions in patients with Kawasaki disease mucocutaneous lymph node syndrome|| coronary aneurysm GCST002026 coronary aneurysm mucocutaneous lymph node syndrome Coronary arterial lesions in patients with Kawasaki disease mucocutaneous lymph node syndrome|| coronary aneurysm GCST001878 coronary aneurysm mucocutaneous lymph node syndrome diff --git a/trait-representation-migration/study_background_traits-ALL.xlsx b/trait-representation-migration/study_background_traits-ALL.xlsx index f54589c53b3faf8620827aca7116b8b6b069996b..07afa2d1c896e338a1cd3d7d84a5f3879396f5a5 100644 GIT binary patch delta 39963 zcmYhi1yoi26D~}bNO#wv;}FuJbR%5~2c<;1mDqH5H%gaM(%s#HbW2Eg%iZ|?@Auuc z4(s5a{fnt*o*5TmN66ogkSiY0fNgmXwNHp}a8zh;aM*BgaPHPzZg!3z-`UxHO zF4MNL%N4}=>pl5^+U-W1UI%AYg+aT+dZDUazVM(Yw2D;f<5c@$vh=cTWtQPX)7#9( zrAR!HOU&r()K9$`z`WbHv-Z68ob1L;%qFZoHuW=aUKfd#1ZD@y{13)cI>5R0A90@F z-f0hi7j9Jh?-FsYu;9+E{_q>v@s4R~cL|q_b|+oH^q@0<1+2BD$IHm%uym;ha5s^*Wmr* z%l9emxt;>zxbFsN9%^(JTx$S%S2T>|enSEF*-5L9jU_>EkJsl?cG7O0X_kId8{^W> z=~z5(JbvFdoh(al;M%`z9be}jQ}$Rb7dIwpS`lU7j>f=weXFVZ?1kOj0rT5n+d5!k zRI9`#Gl{jOtik-^XJ)&`{%q-UA?q{WIv7N-y?Ad#)v+~Bb!5ib@&b5{c7ui;<&be3 zdxB&#Y&c@7_QEj4$R7*a;h}7c{W1sli~V-m1F!wSm&%vMIBXF=26q(SsxJxpTNi%6 z(tmZFwfsW)amc`~tEO&FJ+S1}e9%k(Ee=8X!549u^J?&O6F*Nzb~anaxxE(nB)*s$ zq@KISWOE0dJk~Y%y*70PwDuB{u4m%gVmN3SEZfN|TcJi|>p zTc^@}d8@HICp1i>4q#>Y&U*Sy;jEd#DaZemQy{sv#3lO6lg1uyMwObA>L!25W~;Hl zGI#RZRF7Zl4>@{AC)+{VH>Z-9X769NpF!qC6&)$ydMX$o7_V%Z$2M?eWJsm)HQ1BX zZO+WxMJCAnXIkiCFY`7pomotHN$cxh_u^P(WZk+ziiuRzk`;kDgICw4m<^fr$u zi!+$4q1aJM%Nzg~AB#u;6kOO)K)~!2MTdiX{$F-FIe)S?b9&0nA36iJ3s9UE;vET` zW;O%%hFV&oq60Lv7$W32gqBG>GyFBW*UqeUJ8f=7JvvE@s`IyWj`FRac@c>|u<%ni3mHb&jbn6IWAg;Wfk)2o!&y^%9Qi2l0cCj2 zFA6dmY!hvYX{J+IivtoRKfJ?-;q9%@gtVjM+pYfl7~vH*WWytA}?a8J9xgaYNznFyJ)LdM2HuN zxD;{@M9KRA_xubJjxDQ3`!(M58aq~>`^r4ssfZQRFwCr&RQ%*#{w#pGvQ4|C&O=_; zFT98@rQV6MuRxm3>`Pr&q(_{5wdMISR(jmEFV4PpW|-_59mz`F*4CR`*E%(5f6LNu z11gU6!iSv^;SQF2(d!2#i;u^D9}z#Um(slKy`f$D3XHImY;ph0|7uVGeYJFLZY*g8 zdGnQDVx*PW)sAoO?v?YcucAYeAyK+n?iTG3{}_?^5(hMODs2m$D){-WPX*x-fg`q; zOX8W8K%{{DZ-ZTm#@EJ8waSK5qFXWj|=ElhJ6)@t`}@t5FW zyn{D22Y}W}n8&P(@1|;A=Nn0)FWYl|2f;Yr0@f$-<$wzF2-*o+Q^Xvt(JxQet;3XxUw$shgId~o^EtG zKF5NIcfY0A94ig-HMx$H+ECP%j76PChA<%q!PQ}1PDM>Hk<(vthJL8=N#0XBK9@0f zd?b<{)buM(ld;<(YbnYZ1MUPuA2v}-9qQ{tCN0~=K5zK%G_s&}ygRP^n!m5I?rIJmxe2Vy!PnnErve}#DV@#XQ` zcReq7krfclbTCBP-*L|_5An(*8c4^pa||RkT2wxIarkNFXCDPXrcicDM;*p09I<(y z@kZmX{2h{5ZvAw5*L8O zag`g3ElRZB-Yo>XQA?Z8%Z zhewaU4|Ni4QG`ZipD+KeB_Cxyj(a&B7T7-C_gt-fH{1bQystN;&f2oQJa49qsg^~X zZ?ADAro@2Dqv&Y6$J0N*t3JP#c=7ny#^G@~vJC)@`y1I*)Q`2wSLNKtoZh!}$wyRK z4`*C$J+^ulx7XJTfYAy+C2VFZS;Yg68C;C_ly9} zhwl0Sz`f3B@3TTU=}?*CU%r9tslz^!zkoP-6Lr_(HIvCfIFr-D<3r)D#CL&N(07-> z)DSjyVV}U`-NhI+5Lp`a@&0BlIT--XPTC~?o)}XZJzo6kNfIJ@H#e|ye?N8?j9tD? zgc06$n4JCT;+kC=rN==Wgg&DhGV=>1gt ztl(bz_0bsOc2l`PaP#$feCekvE(xIZ{_nz7G$0zjK;wNUbzjq2?7Y(5e|?m)Kc(i) ze=Nf!%;_IEjv@(OWcROv`rk{e9* z>kdO!jX3ecy$Nu_z45@GY#<_GNR)t+w?28O+Xj3rvd%!0`I1M2(+S;M;8BS9^ta?L z8WQCWIzc{LfA60fy4knURU7Y1x! zzkS>omM8wo>=lsXj5nv(GNXuQ$g^E2V#mitTlDs0xN5CbT;=C)HWcBI)WILkVoK&2}p4wnc_}hB~ zRJ~UHAp95Wn8JB^%a=vOFh}gCYcCXmdnckY-u^Or-K6vCz=WH$^w)gvH!h=(t@FC}t-{PJgu7m?18&iR2V1JFO%p z5IN0bz8v%72i3x>yX9}(AGScZ5?6YCra$mxm&HE|J5>VNkfIy*S0fgXC+j(s+U16W zdV5-pS9)5#KIhT-?o!nKE%4s?YX9cvm!jz?Q+6+%|27Qb=Q-G|CdePdJAVoMJN;Yt zx37`PsJHAg|DF$m+Ul&&(DX>%!oR|fFbw1AHUD?WM@#xCUv3?BabjkxY1P!5C%fa- zf%{QjW71o?^=Y8OW`rjvJ~t$ezmWGjikil1cYfou+W<5lmZ-m4~&UW0bb z+Fi?*MMWfld|q&BY0jnqy1^mKyNb{nF|+qgy7FtJCS~}kTzf==52^Figk#HlNF2we z(sa{CE&}Y9yWQCoT)wQxN4{V=qEQ;ck-3=PdslQdpCb*l~xS)YGez-02Lhm7koDhSLyX zxBt{7UjbU{sTq)Nz=gj`p=X&a;NpeeIxeGf>7vk^(Y%Vc<((14|7`6Eu2v!9BB_M%q8%q9zYoOWTFI*4z;W9u1mcUhHdTnGyqdip1gETR@6vsNiy3p()9SOs z>M6^}@##Xs!n}oeq88}Dj3L6XDIwIqrPI111D=TqcT3UwZGZCg+(OIuilsda@C%ys zH)3UUxHw>0KW8JW_&KbA--nb8?)}LqhCn8X3vyz=sFHP!`7@ZTaQiUe`6Te+3NPH! zLbzhDoc>JVW8>od<6Bf`tuP0L9i~lorm<0f{Y~?>WNXG%^LsW-s4nV%ANwldCdFCf z{z#!_H#jGk|2_n^ilmb7Y_RGMMfF29e|YsDIbNSop(iU7BlO zD-7=b3*|8D#Tq@#kdo2{eC9awUKjoD+0E&8T^JKgM--m74=G|=2vLhgexKu>*2k&fpnTg=uL_1tM&a8KrZ zXbJEt)nO4$6B16l5|&LD;`u!M@3Hh&=!j$B5(VW5Dp>@-lc}?nDrEl%vTtaE1x0)Y zLm_IP%WlK_m8=`hB@jH_NKk7)3~S_UcYf=G{|l%o@4g81jskO}_}u-#^Qpn?;D|5kYKa&q@O| z@&J{(?15kS({DKwb?D-JCSTRs7GxrC4`IY36?-drzFw^zC9l!L7=QHfe_&zuwAk9Q zOiF?_G$4>JQPd{ZI~AECKf4)-C!uEq%Hz+@H%aZcF#avrld}8%(!>cFBc1K_>>J!5$iU9()}PdBKGMu(Ws!7aQul`GKd+yj213qu69lQ% zLYc6gm)=6u_2!ZjtJcXJeo@9+j`{VA^);yri@zv|<8*ezJ9#?}Ur(OD;dRGyD9e&X zrmaA>u9C?=%s>700-c>AaNXIf{q4i6zUmmat!oB;7q`TpCT7O9*@+7wyrQ@ko^*%H zYL3ZU>?xbrCmI?9`AS$&Zops9;$y^RV%$lYV~<$Apr+{huA=s2$f4@Hn_*GE`tpRR zt3-`O-9H6ya+*pR@Y(LF@OW*{>kAo-VI6FKcY#qiVockdMrI$Y@vy)W&|-6oskp^YIJ|8uHKO3 z3#$3y^eG0Z^N5ScO>?kn1SZCX*fJH*%yF{0tUBPVC*_A1Ot&WwbTQvNhbSIl_*B*~8kn`h372T(O0)bS6_1Xt$ z8!5!S^+9@XZ%DR=w8K(+R+XViwv`{Cvt7X6SOS%3a?V#I4YYKNygc-57F%*}1235f1p)4J@2x-cdq&3>sx{@4A~l7 zugz!kl^T9cd|dWd-okB!yk?#&_u>(tTj(748~wQK!!_HN?i6|}D>c$$^OnmK)I*5o z>uE38Z~^;V0t+tIA1DS#4JJQrNPFmXbY{KrfQf^POVzwFSu2#_-0_pk&C=^2^@Hoh zyU_Z1V*hf>FOip6o~Rje0ikD$G!A9X{gicYlPg&~_QY!XvzJ;m=#py95~S}ZA~hDX z3ZZRac2s}w%Zb;4D$+Innv`*|p*V1$s)zh&KbVj@DX@-wiXgf+{`s%dSoLBz2z9{f zvqiu1)lV4)&T|-S5K`aFi+$K2z8)nJz-sc`qP93+bje8%Ba6<&L#i6@9T9U z4;N9Ti#4Xrt8};2$~#5$K>5~4BSlo(1C~`H55g6wB3{&Dk%lB~r+sdV%o6<75)(SS z(h03`dHs=i50^I*o36}03u6(F&{z~}TrZa6f)LPg3mmd5pdPY8 z(2niDB-I__XCp&&RbA&6VYK)Eq;2S3)ll9Qqf+W5AkIeX_Q za-TW?Ow=ld)mDuweq zI*3>`1Vj0!-KmDKeQ6V%Tk^6wrltk5LB!Z+TZndtYQiHUS3Y7Ls`2V2=sqe>Lc5Zg zMvd^*m4gMfO?akq;r~bG%fv$lEahP6{X0)LQ|7(>I_~V$?MJndyW(9b;8v2>!D+X| zBtLO3wVZ_r*gM~g+0dVB-NXm)ADiJ{=J4C7gz3n-O7`Z9Tx1?zNg6!%F zBciRop#4xM^3l|GzKnL|DltS<$r+dO|a7|Cje zN!KJe=W#=6zu?_&b5~rp0R~egUytg)yPot6ERP=fG^xiq3= zz} ztO9KneroTBXpeQY48nPQhXwDHl?Xi16>mspziKxbQ&u8&F2lN}0Uem4wcw%>%Is}# zNKL=$CLNQ6E7sF9&>|qh91Be`9Vn*7vfUL!dD10W97>5ok2i)f4#oNmk9)3%6s^*< zG@>HxXH5y5oTM+#JQ4sf?VOv-pEBIf!XW>xf`p@)vCiO6#n3xNumB8qjaF)e-6^tU zOr2jjNVIzpq^GzFZ@y}& ziiK^0V1tF2cBihZ?r;0-8^L@^#+%g7WNTjd%?*vxF$&!^fC(v@U!RC*H zz2w(V3bwBJp7N%|E`;azKIG%7&JTE78S+(~DxGFrNQZDz6)x_Vj26@9i-RBAzgZ$K zD$cZPj_HH1WByK3kFz;ec5qkiSsGyek3p3Hb|ECct*Kug5`dsx6xXx;GGCuJd*hMSBipXdaG}`x8Xh;d zs%!M_OJ_N{s^hNOCYaKfZLBzXgV6%?6lw6&(IxVxBlcm{lSAerLLVKQ$)}^*-T_)H zW;B^enMY|!^ z1(!ZzUEGV~vhju;O(ISMy4vJCnFB}H37pl-6!=9dDAI}xvdUW@Vo_q$IOa>dWD4W7nINa9Af}NQ$5K$G!=U@!7 zlA|()k&{-9(=53H&Y#JfJi4y$3GhZiYa4hU0SxCQH8Il{S(!+Z% zL!N>i1hud;2g(gV|3M624Qu`i(lDIp#XXqE9C9Xz;DDmLzK_b5C2nvY4rktRS3}xm zYoGkRzR9^~DWC0-^Q~&2c{Gui0;khcvTBk0RGU&p<&4O?mfbBoft9sTTr*eEF}0=N z>~J4+fdIw^NABy4stJos2`{vLCC5~@CViGge7RL}0L+nq%mHDi=5Go8AB?z5K*sdu z_o&s5n0-^B&w^O~b+6)*mj4bh{NMs*V88a^zLWi)^@w642(u|=yuEfH-i@^wD{xj5 zHws=h{=WgwBBcx<>GM9VxjS;~3G3Fa_!eiGf=$_BassOh#BIRiK{%j$asL;2 z#Ez7#o}7c`kw*MtC^K=8ds*>!_mY}?XkM{Z*At_&N))++!mt-XvXcaXuM3cz=C9uJ zXxq^xvSm>~(_@W3C=}G;v1RGuP{Q+6^NOmDS`pB;11scLoEJl&E#jcZ=^-Xs;YYnJ1GMoAu@dsY5}4X)*(kEwJP4ciT?_+sa_x~ZjEUjarN4Xhmt4V?>#l7D<5{MwSQZ`}RyQeO# zVX!4M?7V#m0Gp+D151+pdJl=7cw!_v*5o&h(w^}yMixzrPGv5=Vvr5}Jxs92%T@5( z2D_%0`XQQlCkKmmT;RDxB2SIz3yf8rTpUsD^FRL~3%YeQy#rfp=;H6Jo>7k|fm~m((UZw$U(>ZIAMko$th^ zXPCeLm$|1fjD9hDHv$`3d(f*JS$K;CF@$5(+r++u3vV0y^#Q8;3f?Dqul;e?D2ZK- z^J;SDmxdKOdk}&mcThpg%5a{o250&<<&NJhssFhCubCY^1)mXKb&a-z&q#ZGR}Mt3 zVy1>C^Wrkhxg3*GCH65FDP_{tDVSYwuM*Y|ne${PknEPcAwnZYo1EAQX5x4Pa=s@s zfV1Wzwg}?bt>!-o54QI#>A%L12_!6=Z0?5-MDRmT$oux+MN7fn;z<(2?0(1$O8nI0 zxUWqtV!K3Ve=X){O*+$Ivj;8X*Wsl`j5)RayGs(Pj^0L=75!h|ZEv;iZ_+_0moaFf zXaC&<3SfH&=r}z2ae&0#;DwH&!_b3|u@2rpu1c}h5uVz96I($A^4Iny<^lP%sqfII z60!K(7nSM#oq{a1A@}tnWgw^^(ioD_t<0Ayko~V~az0U2Fpg)akZljtSM@!dLBJ;g z33GTVUGS%4JW_jO7LenW^Z>!i_a$5dAHMGw26y`t^U55aw!ixwy76t#_hf4ld2H|h zTFmGQ(bh%csqaZwA{HHER&-2j>DQ;)_X5^uF2KgURif8|)&0McSev~22d{2X6*Tmv z8E+K$TW?*}*qHAY~(TNEIvVT{RQ7on$I!5d%0Mb z9aSgDaJJny`tKlpSGO`*sz}&_+vw`oA{F6vCQ%~vuju6VMEPZ}7`Qfc4_c(~08z3U z2MP0IdnCU;`rRnL3z-*X4C!;>)@E;rE+;0?h+?7s)SV0+!Y7LIA{3C_VWT{@CJ~7s zbcDTcOz9n`x_<-6UE^Wen@WjDI-6`=(1kFDSsjLsS~~Pv!oV1Tc}2XmhfeQ7o=)gW z7|pegmfr`oGbZ=-GwXoxyABl{z{-t1EFsd&sF$JRPYT1VCKq}uvBUFZnP9X0tY9<^ zS2v>}hK{gQ2E7;fNL&^eCYC>QV0y)hv^fb&lxhh<#tByd^J!dwhnV>34jj6cDXF< zyEea=+v>60;2;kj+IB%zDETop{eD@W;Qw83z&RykD>l6>(fHKoR4qrJV!VmDMf}RX zOHgWySV<$bMc$-0Zmt*?Z{r)|hOPlCMp3 zt!{|NeuE=vM9r>XaY<)0w{&A-h*t)E>Gy&%aGbNhkgIDBVv5_ykUbaPY(`>^n}+nv zltC|mNb>IdvCt$fosUWEMKP;_dUnThSaIG?+V zkW#R9G7~VGu$q_sat1}n493;d<&%v2j0qVTNnA4M{n>@4EEduJ(;q1*c1$s3!P`(9 z#=L6_A}v(phZPdQ&k)%z$3uS{tBkITS(-=XZ~4*HEfTG(kjsq}9)8UfDNCLgVMbJ^ zOa%yHObTnGCXyLRcPdF-`c8sf?uYZcuQ2jdp==V(la3c*;Xzg&iyISyJDTWK$&TmQ za-561a~#=jJ%Q$YttcOTj18e3OqCLC*FCW%#j75#2T0?O#*K_)1S+V|*GHdsfrX3@%r7R;fJ z-}h&r?t6ON3LNVLJ1L}k&L-%-*A_m zX8oaAPcZ>f@~LR7Nf;^Pqr`kX{&okMoZ|j;X5)-YsYB(#9mniqkMV^SmZIVfe~N+m zDx$A}ku97P%X0kP%P|c)5{m8*hM-!md zC<4k+?xs1At{gyrHr%m0r<#lM`_zl1g+i>zRlq|X@N0>z9>e>sVHf7Tnts!abub63VN6C`n&cvuw)zrSHYVCS|$qDYwud=*#p^z{OQ)<9{ zN0`i4TaaF_GbDS};l6q_rWFyIkRYn-T5ZZ`YK`PXlhZ>AkcFFpRw_VOcEY1j(ixPH zR^|OZgvW+gRv_gkmgrkyk{S}=Hb;8)HE$O@@Q zQDL6H9?b04>te#yV^eU0Jai8*(d%iW@>=T!W!GCj)6*GzDc#D;UTsZ+G;`C%qXJbH z>q1L2w^z?&~7Q(?VIWQ2`fR-V} z&TM})yC5?i5lF|RCyw$>ibMxhzdm~K)+`w&TRt^iE9o@$e!>O_6+`kB=A`H|?D&%P zxq10ocyN@`KD?N~`@$u(q)jIjCu)Y{{*=Gngk6dQ!6DABCk_&qO!5^J*+@et3a~;i zoK8^E5RB#!WO69RP!m#~Sjjw0y66EzxuT+5n$9rj64MzJ(~95~A2efQOqKG~7z7cN zvYYxCpE0;B;5=pYH6GI2xnxXt=`1(kY1%!(eJB2nrn~=5okI+6u)0h3ahc2 zMpBmzNhT9F?ChyqD6a3kGQWqqvJYfLz#y`?R0on8n#2#*yr#v+bTfc{g>rT9b5M=> z;1K`bz$S}sOj}a4Vlyy8c077r=5qPa3UYa3V9$B~1{fBg%e#^Q%%LIQ_sy$6br@=i zH!X{!S@2%l{>1DNN4Mb3`>4YTgv43AsrSH9f$opr`jGCAH{ve(|B#3k5K^+r@h|%1 z+Cpg{;CJIW3hRhK0?uwEEwf|z9+_FfuyU?RgY=>F9jDlM!$8bxP|ZzWMyPSXj$#jY zScwIR`5_`wIatRJ{gFz$(boob*z>7#_U8i8P^&%h_MI8gTM1uCtT{ZK(eQ%UrFD;U zF$NtL=3;=AXQAM+m(z8OPGOh~YoP_nOr2elaA14^O{yoOqSnkDLE6l$>}Mx)FReqs zIS_$GcSb5_Q&uMBm*^s2QH6zWn`%yd#~zpXLl$)cO{EnmOYjK!Ye8H-onqq1OmC!S66nLL zN2`iX>owe`0@(~obi|&3d)_s?5)b>Eg>-f$X=z3)E)Z}3l97L1WSyk;KziWWdUN%G zG>#{e9}Hp=ORpkf%gc`Nr7oB|_Sr!#X8aG>5EN&hG)-bHs0P$Ne)y$0z^TeQ{{Ru{ zS>+%eUA-bUKej=WoN;9N5RaAfoGfWhoS}m#0%;-m2Gd}Ic{duX0!@5U5!;COONM|60qrsQ-PReC4 z0)&g)KXkv~RW_i-rQSIb^8dFu)?VLDb*~^qoUBBOwgYa0_li~!=Sa> z=TQ7oC&xob6j{pG^@C=DIow-^X$^DhSfM|wh$w%oGw|c89T{Qv#XIo2un*!oNWArK zuO$uixfDPbJ`=9@!$$YM`e+5C2C{x+A2+pS(gMfK3emmB_0y{)Z#sgJ+U~ghR~~4t zmjFX9Q`}Q_>lcxGs7g=TJ0nx$vAfW8XrMy!zWt0l-}zFNo$KW{iIya6kD^2=U-9!5 z+WSj~hI$oNwt}iJxw>BzDt`JRIbqSbFR7u~6io?gX;4vW5jme@@S$%3qTm8wB=1O# z@~G0gf0M*!pcNHJ3u-LqkKo3myJT9IGD?Jr%^-FqEp(LlS@s< z)L~V_phr&_aE|jy0r>3v+H7Ltd@*u$SxO^1R(r}Ly+Z@LA?Qti6@!>?5$BHlNc?Pg z9C3uG8I=bvl9HHwe+eGs!^A5W3ArSLjZVlFiN00jGt>@^XL#&2IFbfN(PafVzPheX z_;U(Y^w1h8g61>u>$POs?Q%1BezCz!vYwP{D==uBXUugShWWEjl zxbi6?%(P-t_}DV}>GFte#YyE)d}{keWII9%t{$9br}*9FulgPP<$L?Ks)aps_+d29 zV<-Z(Xhb_IHYCq)@V$bNvsqnGL%f;{H~d1puM8zZNoM>P83@oavdT6y3M!}AM*oMa zYRcVR1QW5NnGSu6PyxD48}Or8FeyMv*L8ysdy6o6*TC<$mSW0&0-yK0^-sU6@xGJj z>;^}$QV5^mIG3e3^D+{7bg}utSP0RRG|*`|`XV4p1>r>d3b5VmOlr z`7N1nNzS(E>5VMZZH$!tjHY9;1!t1(LJ#lx+qsc2{fi~EtwU{m=k-^6V2mub49E0U z%H*6~CMY6{F_pH;%^6&>s%d1)SNv(h-Nz*ZBqj(3U+A-c2$B_g%elxm6bVD-AB7Fj zq3gi#CFj@4hyzDE;}p!fQ_XLL-&X6hC{QT{kq&$Kz>GDgNgeCzckGBTjYkX`0j z6!tYfbSi?O!mTiXEhtd~JMk<-Ii1mfxk^{1vj;8dvpve$RSdz1xDWYA+GN~^cd&JU zZ_jze=tp!ESqIe{Egt78F1J`^#0i1_@dn zJD;LG)tN-hOlC1B3Wa0&f(F!l3%WSp)z~t~W^7p=iExR*wzNrVF7AE@GH=B<`!Uj4 zctN%&P%Q}_^imb=pbS!&exK7m1Pq{Ui3$3D!p7r_RlQozY5UaFr7JWxfHWlc#A{%& zm`Fs|?+51Z8Oz%f38Zol*#0h_4=Q|dRADDIuMkZ^3OALkf2YTC^%`6>suBIfnj269 z<2D!(JDz_8TP(KUR3%qJsaPIAhFuiCq00JQw9Bu~i9Up$yZqf5Nd^wNRXCJW%t2Z+ z&ZztziGMt@9i?0)9P~+L)PX_+@*q&OJt9)M46^ zCE8HV)ATwf>XI!X82A6zNEl}o-gH6l)>&HC=z5<7{7Ry-bDk6~uVl=(lU5=AX8!#X(?D9ryX1ehqoKnsAt zl!I5W|1spf0z2rf(XMn()(atzsX!zpe}#%XMYLkmUwV@mZ|A<5xCZDXid!5t#K6Re z@%AfHa5Ns$1RFIQ`|>uS9%C|rq81p7-A3I2rVa&7$7fDSLDTGV3gQo=erMx9yF55c z&V@8r88N#sleA*NnlnWAA-;uyNVw$n_Pz=+UfC{!pTJvr=oM{%Cs$Ipq#S7SmR$q{ zLR(dSkQ+SBs20?xWImr=wiHQbR-?~$f4Z)XdtpaXfOL1yVR6i#df%N$$d*sV3S0=C zkt6kiQ=G26ZJugMmoZX)%#RjNDRuFhWo)k15$acAlCsIjoA1>L#qnfQ9D{sIP5LP* zr~YT({BrAE51$i^oa2xi=O5!VLVvsQ=|w5)KwwnKZ=vb|!X$<1cjiqj?1&u{;^<Qw55Chs~MNel_v(_HE3&15roU z8FHz#Y5__)IVT!6cL~jBws`0|*Ki$83JiL!@||WXFA_NDvg)`}6}=Ce(~`ttm?Yigva~MZnpF9%D^prrY2(zHRDg%u%lfLQYAxh+X1SGlQP=EFK2_ zmxm)HBJS9-xrOulgrOOOUIt^wIv+YwVc?S)5ONxGMee{^nV;964m6?yA^*S+5a*Ff z-0OQ#)(OgHy5#*Xauq7@kr?yg~C40<8I+t_)$z!mn6Zk4}#1aeB2S=K} z<6*yTpXON!UPbmhqlR1zDOYeE$i4Cv`%-9NwE;1eqS48V8*DV>_sq7BPV7I3$(vZT01np4N zcCR@hPeBfte!ld{-w%XoGBy#r*Y+p^`?aG=3XRTMZznPZnC0!e_%4p?+y(u~8IKxG zIr7JMSnBT*y@Y&zY>@NI(T_vvD;TYj$O-~} zRJe<#>|Gr>F>|Ah7cll z(Eq^OKcf z2{Bn+*+lu{=|DIlThm-Pd6I%-m4)VSQ{Gu4Et@H^bYhEP`<^PW7_Jw1xDrL-qy6^= z_Uf|v@r!uU?|M4L9?Gm@jdg0tG2l$D6-(-(rUD$Peq;<_OG>Q5CS+QwQvO3`*rbl$ zlCKR;$A(OUK*1z7A@!2s0)zpz$N%_wUi}#G(jFVZ??{&RO(mFu?2bi|sFkflNPZV@ zBVa<}78P20=(_A|5E@pA#=2Ie9qzDQe+UhO9)hGFgeK=Z%kkc=1AEZAiJ2{FQw<*F*CDMb!sfq82e^b<)Wez>5kTOPyq1 zesZRt^=I<#6p#MSOOaNe>rt8KEL^O*yDT1Ui^S$;4|Oy7t7Uz<4g+(BlslRZVI@g<2?o)`1XZwU z!~SHU;G%d19+(aas55Al(23W^7h3!WBMxtfx*g~`G$e6m^&7V_J$p9G;#W1O;KSk{ zH7MZU#ZzcPfXBjpYbR6vDEcNs-)A^YtvsbjaXyWAoYG&ebrI#;BYxbSlwF+*A7q^W zaYfk7{`jLRA__AcZLGq*B1`*7PZ^V{jD6Y|6E6BQocqu4;+|2q6IgDsOi+xtb6LK| zpDVA6lY-B}@KhJ=tEk~>BCZQDH?Ulislf)dB~}XDc3{K%-FOB%CMN~*m-6z6cgl98 zlDGD2A#fw9XyZllK3mH0_4~ED$He3#>^!~aYo{3S;Ic0^#t1(S$bBvcGZ%<3Zk?!y zA|`TC!zcTs1g1oRqai4j@Xae9w?9%{;i%*zqCD@Tu6E5;`xr`$ z&7bzk6zJXQ(x!*QqGD$x!q$!KUqxNuZFaAi7^dfyrDnfrUO^kTSMv$-KsdkAf-@4G zwcLs&&6UF@ItxM#SELr;vD|v)L(MMEx)H*C0o37x^Xi>NT+o>L)N9{1x+xqcUXI#zbKtA`GO&mBko zONT!wgtsi0Z?sAM;@_q>O8!QDAY>x=d;X`t%ZD7=(q!m%Pt-EY0EJ>aKv_ zYUdtD{}Z{BYzT#ewU!$m5Lxm_P|4@@h}E zHD66X<|OJz6wnS%u#r_MxPy?mSLDI)J9S@cmB+J1>={GEn}yVTlKPP>LzR7W;@~a0 z5WY1n$zmsIK3f_&&083usIM^s{tsDi9uMXB{*TWLSt1N&OLnP5S;~@~h-Ar5Xb~b& zmN2-dC?sSp>nLU4vL{RS@zcnje0L-IpT> zhc z2`ovWr}()Y22=Xs?|+qkI_$cPm&94$>MXCK?>hpj>X%=l#{BmTU`iY?3s0OdLkd0p zTy)rRUL>n_-q%f-NNbNe27|*mcvvKXX(X z5?t~e{%`z>zRzn2M)pSIb_;|`b}`Jam?sq$=I7;O=Rzwq3Z zf;YeDl(zc*KtOp0VndYp^VI<_zOu?UR{U`yYnAonYl3ih-6eDlHAS60&(~C8fzPG| zb+#5 zVonv(fo(Yti?Xfa$G))a_9=}IUu1)Rh2P-39DXC=BKPNCT2Q&LmUG0QDy4#llx#>a zkv+u+Wa{@PurM)7hlhf&(zkmpm_G}{d&~IRKIqTNpPky;-FJI<%-%`?ROuWE64Ab$ z&YkCL^u6+X-E+*8lZs66k_(Sxy4x8w_|nU1m=tQK6qyj9ZsEl$8P%0=)S-isgZ>xx zZl=X+Q9{AJ0e74!>OKXG4?P_%n?5zi?&-mE38A|i5SD&ClE;E^LR`|GTk(Q2RYd&t z#aHpvRu+jzuUz4;U)`A~rl9mnY7IFs1H*U-qjnm-P<}tSV1t*>KRa7}(bqwNL!2cQ|fn!4?f3+NDJ<&Jgq4Am`FN#1fFme znR}eD?Z?kJ1Bam5K?kr2cLlU&m%urH#Xgk|sfRvgqQyy`8~ubbD7`3M*Q>x`ny`uRUy9sf##uLzLDZH@vOX_jOI623qm$ z(wwJ*b2`y>njJ;UrRCxWKJMKvfB1^xGwY=6hTA)Pr#>jex6{YI>qs$P$U$Yqj}G6H~VAPP;^dz8lT8BT4C$+OCK7}%+m6r zeorBvnHMQ^rDwPq*2po#uFcUcV!L^Lubwt5i)pt~!s+gPgjJnahIz|DZ&(zcVXyJ8 zEc;#+Rff?D2T)x`Sl|QCoFz=@%o5j(V(cR+puxZ7urH-(N-UM zi%(6&_jeBRlDFd2^!x!>ZIW&03B9K#8(&QY-WLVlN?5Lex$?@t?5<3(q|aN7EYL`@ zrNx`l3hBU4f%tH0uX=O#CdWGi z#qTx+_mcHT4hk0ub`XBZI>*9lAvo?Mf%aCh#LuE*)KG+LqW}(OCIc(Vph?Wtba@it zdoGGQ6zihQ?&3F=#!6l1Qpa5=VY=1F%sk*`*>d9Ya>&rSU^Opt)r_%S`#gtx#0US; zP`=?=(fB32!pR3*9mX$kBFbpiFiMB-{gTQXUp)n$z7JfXNO}Uh5<=Ul4rSP*7bE91 z7;e$_sRzOG4$^jBA0V>)O6GW+l}9VimrtN);AI>7G+>5Hl7f{>(mhf>Qqnn%?3F zb7#!_OHq#diw~L}tmWQ14%}S$dEi$NY@j79vuP{Mv#IjHQHH>bnUm5EAxRBep$@t_ z=w3esimi>WW&$VPyF;&oYR*tPoOuc3aO!~J1a5`#HZY6b5>jr`Mn5mLzl2N6Y!JG2 zaNRt$c0q!L7f-1y9l9dyUR(hiybHy|R;cUZHgi$D%&8HEtA7@nVnoj`;tP(eQXP>l zVM+~GMavz859aTl`0A<>oI0Zht58%&H^rpD6?}guM)G?peuMylN(~{^I1K{3LCh1F=q1|DUoT)s=p?lkolW-|qr;w`ySn9gFx^7~Hb1n* z`)DGZx3d@0WOlbXaV9OPPS{7?f3B9n$w9F0AjV8NVv$^jvkeC7EA#LKUfIh(mA zCn+<9nNw3Pp?&z_$!-yk5ijYdF09mj{Rs0f>UU5q_9UF7QsQ7A5I!mzBKdA%cA6FL zUzCZ&SPk(9U`UXmO6lfSwsf|PG8%K54g0GlAF4G+n62yxDR0}RHLIw@Q#!QUED(z$ z*6YOh-8lDCk9&<$Hp%6Kj}nGc{h-Zmwj(ug7aA6ZSD*-tNT-VIHm$$GLRiaK5ox&$ zW9+}ah(5;SUy7j#kJ^j7w3VZ7$JqbDIPdfs@e1K;yG&C-*qmmvrNnS*&bV%AixGre zHD#E7$U~o?82u@Ylf6dHX|2)V@CdW4A3@mAMo>AL8qvc>JL&mR(*U~MFpJHP-m;ij ztQMbGQKPp|i&DW%9~kL6W@DkD1?jE!x!>a%SlbrUZdk-dI}JaB5zZk7@}-LQE`1lV zn%Bm)Y@clzX3k-is1SLi@|lypG6s5o`|$X>`of-Iey)1^(B_-dV&V=z7^%kFf?pT! z8N>}osi4>fWBJe~S+Bz^OOz~Lm)#Pz9>jei?Nw= z!4pK0yrBZhtS`}4-;QwK{XNKG@X+8HRuz4`g0e#7-NOZKX(mOBSbN0a-q9Ds_Ll*% z@y&Mqsc-l$NeD3do{aQhvp%p?!*m_@UI4-^r7|-pOW*Ei#`)K;(OBEBWF?K>58m$|T`car4YjXn#(=Ep=SD!+X-msFVt-(;~OevMA$=DslsrRXf% z0My~RH=X%UU~~}|7oPN)#kj)caA|=RLft>a#GoO7N8m6;(;i7%(;v&d{(BEJ14bMpI+qUi0w1rJxz2`XjP1^GMK#8f;MRb|8SwtKX>K0U8V5-W6dO|=F_^lhy!~yPbkn%T(*k= zb8UYb1H!75DEikdJ!XgkZ_Q&yZwUoXGVVVOQKBBXt**Ln1^Mv0a0wdXKK)JDiX z<7%OlLxCCM+f4dYnO0s+8AJYOz05Adpq4{~HQ`jhZA}j6%ixJ`|5F%22+{M>=P6g2 z2B1x(S-A^@z>4%GGS47+>4Z{?6AUi>jDp``OVRSytIK+P+>4cuBfm0Ao!-A__xFhV zeEuUdjg!tG8G?Ps-^cnCy;8j9eWy7HHh=f}WO`@X;W8nX&U{5~RkVB*%o`Gf7e&F6 zdI!tot_#(E;U(&!FqRr~=1&JKR$G9gVUGGy1p) zEbjz7qcVSa4#t=)V>t_a&U1+}t`6XSQ=UKHhst+3YB z3+Ru3d)$PlqoU!FbxMC>b)>`Oa?wt-nHR!H)B6)>o%U^q-{&CuOg8Z$*x*Wpgo@vDX8rP=JQmV@Zg7nCEtU352ySqGp3<_{Rl`wx+%WLIda{Q^Zd){x1JpwN= z6ArMWq?E$OdeBjA-#WWv?KSWwTLg%onl}9m#z`-kHCuU0Idmb6fWm$Fkt@LOH1XWZ zLtPzq=qYGeWb#N4^2NF6Z~3|Tz7P%XtvS%Q7ZQi*ItXucy>jCvJ;$r#g}CTB=}}ZP z!w~r5aZ&2r5s%*I5+C2&8P*5jnns(6ZW!L4Sg-#~xL2v^-1LRXoL}hMv%>7rQuiGDnYM4`Z`4PX9h%GlsGP-W<)8e0>#`P91-)1eE zdGUg&&9fHecMC8b#uBu%>8<&~gMHV=(=X^yzHnO>PGDZ+1ZUJH;ZV}a4&GgJPnEQ!s_?6p#K>sCWH!$(y zXNgcJDW1~PP3S31Rv4Dwuu6YYzP_o(Pge5OZ2F9Y36PfZt1Pe}kF332$e{bNHf?lL zG)&f>i1P5QrwbEBM8N{u7jA3B0iwMX@$o~KD*F5g&3`CUBVV)u3EHPwxY@Dx?@4`84<5U37|C8YqrO0SxEN@fcwi!=%=4kNEGvHmAiO9A!RyRgcKLq2G74$ zP9Zj8VTXcXlk+je8ug%^{%3Y5G#mM(hIs^cb{%ETnW@N7$3~8W{Cjfk?}_x}=y#7m zYc{QVCY85v=!Enwb62no9i#@6=PINBF^Y^MHqVNBDh`WPlE=tJ_%)7#j# z3TEzMYV3g`8J^-O6(CKeXa&vZt(wNPcJuXIZ5f!wCCIkdc<^WfJw^m>L+`Kz0+Y$u zYWgJZy`^Q}t?Wj4rz%3}`)#YdNDqQvDBGx$Ua?pL=<>glIBvhQypz*tNd?fdtfYN* zzG%#1e|z2x96Jj8D!a)t_>h1!275GPi|&1jChhPvUa!xJC?_9dWIWh>9EXEY9_#TI zTtMm#mSnek&H73Omu$n02ARM!l!x)lK#J5Sl+YWuc2N#TUirIuV%1TL3M2Ddcc~0S z#V%1^*L!hH=y7(<94?;UxbM7yCt_!clE&Bdtq^)P(#h^=&l}&oSQxEF`zk6feJA&v+S}$+emvjRP%$NQc&9NJf=C0YcurCP%0^6Jjk^x-UXkZ0$xu~(IDhN1A7@q4R6?bi zZ5vb8#fQN(sqr^DUWjsw8x5~5wFYN9IF-r36F3kfV=UyNA&`3Nj(NRXb@PM9FWOYH z!tlY?vscq=T$ZFX-s$AUBaMHQav78IjO5@3!;4kfjos{ia*ydBK)MJy{PUR11xtCq zjtl{b`a9nb5Jcb)+EYN=1LeaZ8?967#hE6SX+x?;ZtXPQAb`4M{p9!s5>65H{kZ7= zE`EMJds3;?OH9~L4nd!*lVJO5`?mQXEoy;y>!3)nzB~*HbU=AFSO7Dqf z*u^e-_%4qCs&0Iwjq=e2FHQ6s_Xj&FmSfFBA15MbU9s9~U-5g_#@N=P`J9hK;q!*g z{w~l}t0D)i&uUI2C z@o2w+ZC1k)mVBpv7T3Py5&jXTAr|Ge2Jr=s3r50PSc98+=ECQf9G^WBsDQQ6_zyo0 z^shp$sxSOZ1capagWwWt@c@N|?`Zt`^CQ`Yo{mc;>fFYgOaUmb7QnvXaW?v}Lei7O zb;=|L_kcPDU&ekSf5`=oQ%0KgJwv$o(}hNE8TJz5vy$+a$KbX=%#=sU9(T2ix|xmF zkpY^Eao|2H#k=FuYhw={xcuV`A?shYa0kzVdF08}JbTD)NH1CTMkq_&na3%${pM{)1~k!j>(ezCcj&F#OU_~aQrtf(g-k0VK>c!a7!(JL+T$N7 z=K%h&6L(ew{#4H+*BvUP+Z9y4g;%Az*g$QqbQWy$)`JwTyhkbJE_4I)I=qX&p-9+e z+?Iy_O0H%}-5Vq)cI%h#L+h|>v95`Ktotfk<}5)NdfRDi_6Q$yT#z!3&7QZ_Uq7BI zxhBv4&FtGNcjVj!_ZPlo^Qv0DM?1#XYR$k00%Ixa( zI3KCU8ROY?o)I=)H{=CsTaz%xgi;hN+~PuCVujJ3Q?aM!_c5T5XQmDuuHpD$+l8PPI+$vt#MtoLgwhYY+;x&{1xO()B4sYGU& z0xjd^Jkj&C)XFGR4uKMT<1EL}ToE<>R8xg+(t?o{*YL;Zr_WuJu$8UMcjG^&4b~2FAUAMOwG+KvkVjr!~xT|j^l(f?B)B7cvejtuFb#4qm zDjLj%99t|jI)%!$k9CFp`eI4t9t(PPpk5fvacNbdw-_|@B40%1lb>+|l3udiz4=8u z^ziKP*Y~;TE#L%z6VhT*Q5qXYEAJa=I}g&pdW#haEN$zi>!LAuyeO~)0g78BilPWI zTap(r^lCw~0)VHn@yo>m4qhoR!J&j>WH3VyublBoxByQ$#+>@&1{w8{L|h<9_p^=8 z=h_>a!vA5jdVId6^*jmH%@&fuZ&OF|jeFS9sU)y6l;R)a!nr;C^bB^z3GUjMOiO zDkI{{^iwbwi1Np-nT*-Ub2wcE_X9Gs97Q?LuRfj!9HuwGwKB+f}V{GO6yWhLI|Ha?z80yczw7q2T z0YagS@V}eEUSVfRin^$aw2XM)vz~K?=yuui>qHYZZOHph2LY`AukAly@;=*|SE+sa zB#&aC>R&hw**)+0oZ-*Bm~MGw!FJJ={bMP42-s)981&w9djy^|JqB|(E;qQ^sQ?bm zzeG9GbmrU4;PWHn0m81@>)eIHU)Q+DDY4qlwPL8rH4eCxv|xab48WgEipy>EOWu=f z@gTO2B2s_alg3SH$p-xEpZ4<*rNce&sRD7>1GQbvm%Gw0oweipOS8faCS^Ag_O6NN zQ)C=ebQ4x~12@0y#Blw~5``Fwp`@=1I1<)Dgx@6c#xF*=gfGH&;~z`Kbv1O*=fXy6 z5l#SPOFrYil1{HGzX0ck7`j>g<}-*@$s~zmbY<}a4?>s zK^?nHsqZANSJOnNQ zvvkmL-^e}(7F1MML!XbQ?Ys(oAO{cdLXZO@RWDb`Fu;%#4a=OGfFi&GPCIq@3Pup)Qm>}92kN@xse)RMY@#R^K zxkt2>=}FuUr6r8B1}3#bbj?zm=Gz0YuKp>fV25mAoO?tDGI)V5=&`oUdJ`~&IgBBQ zcm*<=6cN1r!9ifn3dR_O!k?yM41!5vG8D_`Q+bYpmhwf$TB)VO@W7&Lg>=)+MOPZ- zVk7^%9Lf|p)Nl@F9G|6Exf|^*qeEqtu=1Gi#v@~=$7nkZI1!$tNk}89WBkeo7e<6sILnA)jZJi~p8MEF z+=!&Z(r!Yr*|~5{UVZqlFP}yfA#imY?n0|bfxF|B4Kv0m`kaW!H8RygpHe=<-f67S z&T(JyrL-}co6@llkp6*@ zQ#P=B-b8msx@o)xvK&d>3KXzNIsiU*vE3v`p@g4yg^4oAzXR%M6J;_@l|=hLq^l5d z8LY6*&`Jo*t*`Xp2?YVu7vh^`xL*Uws6JLJO?h@}vU+KIaSB`(7vdt8pjRoFqxykc zF|Ne=LoRmUzFAfPn-S>bc?oR?24?kdX~dX?+%)ome8N|!)iT%_O!w;*a1TebqR_Q= zE!g@O9^xPXuA{UWvl$DERK|%H75^>{Xx2YeO{ssQKx6B>EsmtEk;ZopoT5+?K6WOw zY$N)F#+85LbKrK2>!Bb@&`y*;lUv+#$Q8q!k9$F!;ZMBCt(j=4H7_^g9;e3k`FzS& zmw-!gMX7w|gSVBlM2P0&@$G>1OXUV9uYAf7@;3o}284 zn5ZRXwgU9mR2;cA-@Bu>&Du9hR1)Y;ya_3pc07(sZC-308&kLe+tgz0ZGn<}m=-qe(qWArW}HX#i8a90yZ@ zylLL)rkF*_Rbo(r!1^`j)g!A%UC&ZCCL>gJ`ztHYIB*%!KT}lbClslM$~z%tjhdS( z9<##M-pL4NWw#>|4*9Ce<R7RM2S%~CZ!a)034j5ni$wKLXdJF^a z0zkoh(0=L9N!+!-cSAhc$zlm=@^Hn`Jf2qJlb zIbTi~Zc&L$eP`M6!s>Pmk5Lfq*g~e8GQwd>gGzLeX7c=6c|{85;Xfwm^ioQPsa_(q za%v|YO4@xCFd^*AdlE+~1Ei6jc*Xek4=9_%w>)N`F%>E@q9>(RaVYVP?U$(Koe4z- zWtM}6n%6bY*yqZ2h*@6*?u*}+VgL07zHt+@>moV<& z@pXWyE#DBQg=J#ZBT@hMc7Y-M1J9*r|H~n85@{>E;{NvNmFz?&d)> zom=4bJVd;<+q7$-h;=2As9`Vj$)v#TYwcoI$W(~H2p?b|iJ3^0T!B4(W~trguev9+71yRA5rpa?avHROsUCg2-|&pTJOj32HJ;oStu~{|5k{9B-qAb{SK!38MohBft@ak z1q%!va@4kz!oeD@PdAYDUiwZznR;Z*p!8G3hZn=r{TIsI(8mx4A-`je7xsKDI7^!^}aFjvgXAC z4wdM0kHxl$+!ZaWKGYfQB_Q1`ApTP$2iYiVN6}jbllsTTLcTeS3*oNn2+WrLF6?9e z9+Nin#m+kMgYuEx>jYerhbwn^=H6PgO>vmqnY=Q5ffR;?4cqD@$(7lD$kMOk{xRzk zAKuy0o!IoVR@3&@iL@#nQD3J&ht2#B#ZufT7%z~D{diSrWuO(Ay@1bC`~_9iu$S)d z@HHjwxS>jjkHH2V?duaaVGOK}t6gsVByK-Z${}m?&M}8kI$sq-r+QU(~s=2yk* zR~Z8}b@=6Pu5r!EN*1)~yrwH|KTnu?dpgFbR=8fku0w?Y$iH9HT|S$*<$l%V@_B-? zmq(YI{w^?=)nt87@fAP0DJas1m&n5i*yK5T<%y$tJsHv5S=6Jc!{sDmD@SE!y5V%U zu=$T)KDzwwyi-T0u^mMIP62#k-^F<*I{NIg^_o{cp74K zze%cM3S?6K58pLXVg8VB96}weM)+@{#4a?TqK ze3NvT`m>)Vd@hamZMS99;bV6g8zMdRC%IVtZS_>A)@FbX{>8o6Abx`qt& zw_9&Z=1#s5{Imt(+%H|E<;1O*;z8uJ*uDM!dTX^)0Juu}QSI`%n+CgJY1!lh{Tadf zkF@Ij8ALOGxSP&n#o(B%&XuY6()jpILZ13;`!CYcy2&?Y4O`>x<|b-RZ-whuiiwsG zOFXH;c3U8>%>4)8%(c25M+bjoqDD@bi_1@zl9y+~63Iw{BvyhG}wa4*s%$!d0GNk(}z%#7?qP zh92Tf{Qdd(SYJ=5^Iu^-y& zliAVk@0=H+?dR^_bLP?YF=qNrEPme3PkF2ur&}M%m;mBkk=LfG}3;n$pqQ4Mh>6xqH@B>mBa!x@$ z`a+Bi@3&ShOn#pypwwMSbe^efkd^ zH99I^Zo#ZJN!RDCBJz2`Paj>fH7kIiVLZVgw@T$@K4j@Ngp*W_*Xj%4RASNuf^h77 z$b$6L3;Ykax%;$?kk?ay0O{F4F_i3{z-0B{6IN53^a5)!$Ln*V$=*O}6B!_>r@NgP z9e2oi;ue!nZTx_rp(mpc{5L3szka)H+FR#jbvdx(5bVCb&;lv{;+x$SGNUM7S48;K zxZmo9zL%H%744Ib=}<*sDX2=sq*tEa_u3gNkK?8OvVKuZm~(2!>pvQh&!mXUmwRO~ z&?RiHIouWy=V5A!IST3V;14 zsCmWl`P5iD{v8h*Wd8YeQhB7mE@y~05~kOs@FG!v~_OE)tV@Er)^ z$_I@zW$lOROR8JCc2a{3)1~SgC5%XJaTG%t(L|Y3>F939ZL`v$7|7KzP_uPE&#p+n zONuK4G_pj1ZT^MvXx4A=ysal$y10A3skDLil zr3cNz@;pS5Lx!-&#@(Fz`W%-zmL1_S7bYA;bhrw!uVN8KN)Tu}_bZR}IE5_I#|H=a zgGTz(*gXq0*7$LE!-I~ccV(vLX3ty;mYG}^)yyua3JtMTz}XDv4qcSLi6M` z5uQZ$^+x{Q&E83u@7cP|EA{2Ds#_}?@X+#rTz%}c$D3<3ZQ@TlQ|jp$vU$9n^Uhzb z){UWitz8Q-CEThRA?>FQeQmvziFHGFav6fvHXs$hI?aql8x_zq@Gasv=Xb8*KIfESDEVcRIff+V6w7y zYeq20>FF7n{xyLDQIW8+hixx{ApydOjF%J3`!V#E`Aws9*Rt0w=^7sSJlM#aBj?Mw zdw1TGj4eGy%!I6}L&^%NZ6=!QO83$0se7eR1QJ;iI~y>VTic>~AYK-byU8WEWojb2 zRG44BgRg$~y9;_X#7WZ_ykZ|1D0e&I`!kVdiukX*`| zuY^J@(6i3QwQvq(&%Vx?)5inx>;FW~=ST^b(Z`6`^wASt2ErR`O~BF8^f`r$ob1dS z&Ny0*cha-0>+TRy(%ZN<{xlXeBTMh zTWPU*ht58s1o%)dQ<1iIPmV6`V|z2rzzR~ zHB`awqb;-hV!2ImeRjM(^^&>g40!=+7&9I4*0t5}D^R4sg!i!E%sG)mVbh@CTB>%Z z;%yy!Mpr;gUc10ozgq(Vb*uaKQs>gFKgxXBjEUEy>nJn<;ksKxexkff^=AfibNKp_ zEVest$M%=X8M%hdD;vn+0>}72ERr@)2Ufo(Za?!! z+0Q3i5~CN-SSs_-jHciKs8PdUanF}&cUgd-O(BVR-qJ;#J9(djCu`W0oFnz4mrg1W zE|GG3(O1eXdkspe_sa+$2BwsVWz(%P%;tl1B~f`z%Nm`)z8lJ1M(Lnw z`q}FE4KGOU-jU7JVZnK@Bdvo7#6B^u16lYc5Y)j+^@?Fq>mZW6n4wZ12IL-d2u()_ zv3%w|0();5dmHlDScvBC_2xeQ?}H`pP8Os!9TQI00DzI=bFM@I=024ARf^}-TK=TK zap?b}>s|p7&|}L-bXBH**>KXPev69pOB$3YG6la1WcumS{yeJ@%4!BthSv(LE&~Sp z;qNw~2FjTM|7wpZ+Vux?rlehw+@BVs$i z&o}c4p*(NSE!MZZkNHNyegP9NEi3}~qu};|q9znzvENqG8L;?o>k!e>yEWvo>2c5N zE%&Z~=@YW@AdqI}-VjmVZpOr577-&#2_VM@z+)S8}(vx~ErC)i>lbnNs-1Og*{oZUaF`L}7mSpBYU5nzT|Lb*UAp zysjjXvlQ@KK@khH+P}KmjWNNmrv!u9?jMQeZEwI9Kj_F%$YSsha;@H-()W{@`W85x za4YJ62_9sTJdEN8S(Oo;!nmctWJ3(60i72XjMJfyGM_3=%1*tNH?)v^l0q?U&taGW zqAGcqt|8v(%e3t8MK4S+(cGZM?3KvXuB!)rLGl0ki!hY(bh@CdSU%+Z`rn`&0NWXL zi2LjRLw!~EV*CK2jc8M-+sE}y6wLx33r^w5UklEB3i+nq zlcAs^d?9k|dIP=mkef2eTT^;7D%dcZod3=Fv&DPgY0|iUV4vcBK{rT z8<2ez#LKOh-W~^Mvi8sJo<7_Qu^{u4K|<}1%Yfa8x)3tu7W02du^D_VdBKZZ(f?t{ zfX(PD$~Kcc;L6oQzbP{J&6UoVbGF`2vByVWQV_TcpB;t)VenHXH-D95Aes# zSfn`p>Y@1Vmjk8T)=_|PHo^raee_TCYuQwH_YP>5`B^1OOv&nP=vF&DRdq<`4YWH* z?C-xz@vW~c{Ei#Yv>guY)WIDff{wK$4#S+Bd#YcZp8StQdo`y+5OIG!UY*a#&kK}) zfdU2lrXKK{)z9NjONR?=i9FwhxluV>qhN?cLdW|e{JYq4vydP7;)}((n#*d2u%;>u z%eF^k2u(tg%g0eild)El4f79~58XhCsPzv`gVt?n{n6oZ&;LtnBGVS|Ot^>4KRNz3oSl5<4UfQ@>U`a7##_U1zYeE!JdW!%Sk*vK*5*sk zQDfJuOu8|iwQS`~IP1%SDCag6f^8fPF4J)~?EaXKp!u_stxv z^>d&p5O2nvJB~DFn{SjDOX6IyCQ9w%AuRtv9Hl0{@Tu4&N(K(~tg8#I)cj7}BA;SY zXc>HIqI%wGx2X&GALzRBnxXc62@OA$ocY3S8SICxR}^#n=X~LxY2HPwvzi*>py=iMgz%+z`>I5XC)Y!-HQ@-UZthf2e+u7h>ig@Kjkzi> z$B@NyK{V_CO!Q?QWGn_$4&jk~S)pVGpYL2Kh1(NX$}-)87c>6ZJX~sFg=8I=lT{Ux?6Q@H`)C6fbb}YYZAeis z^!<)}VV@ip^Dys&&&5I~PA6Sb{KTqf=r62r2j89TxW~l>DK3zMPf)J$jPT0dZ1kf` z6J$Y&VH!1gcp%CfT5DDo1Y2x}UXrY<<<802d_{qOM?Q#VIF@X2qG+#*SF#kgZFzl7 zbpsc^{pI`QeCv-a>+0Ux>-IECVcDeckJ>yuEpDIT;{kR3PUj{S3jN`hFbhE-w4gL0 zc=2F7%`gW!#fY41B*Bnk%kOJ%wy)dCo?Gort$g(tc9nr@`*oG5^4UYq*`~td3RRin zA%Bw%XfZwL1b!6yn^)Rz3^N}Re}v-xhKERq?%1Qjep$D6RG0F9inY-9lO-Sem?JYy zr6>G8Z1y0QnurCTXhux#tLf6&ruGb0P?=AY6$3{_A2F;xZ^)=Fv2dBexOVM9+Wg}1 z(D7r8L*PK{(IDf4Y`}`k10GE}$yn&;kT%k3`Iz2VAz_c)xwP*YJ+IDNfA$qSQxm5! z9I=GRb9bLPb0c4pW_lMd`*6d1Hc$0@U^V6zP0oumGBRtT1y(}Rr<#UN+4AqCyyhdO z(EtlIw!F$S_E+Z8$U6Oz_uT#q4Kh*Qf7&H~dr+x(*oDhw3F{2e>bXIo(#YBf^Fs_d zZessoHO-}FmVArGa)I1nm*lE*U(K5MOWRbK1{xoHS}2GAD{GI}b-CY0(3;jZds~u> z3g_ppzE#2ekJym0G1!rB$|Q*f`!#Dy{+=y_r1x5?0gRA9k+6zvg# zks08$qmP`% zTUX?c?rX((!gN~7<;usO-Lyhv?vtF=cBi4?Y=%(%z1Cdyjj4yk!j=(R1ww1poX30H zQ?Ufpt9}3R8)fPNKyxYDpHDUl`;VA!Z6yI-06?a)JF#6kKJf-QZ)KnO6g)s*mzK68 z22l?e`!+{MkJ*Ay+a393R!c9?^g(2;{1Z2G-CGY>Wgqx}S~+oe+OJx;K8K5U$8*|( zT&Td_t+}398XIuOyWci}rkU$vwY=P81dpE(Th!SZ0K*6<&N+L8^WL2B%82K(-fw(bfd>ix-2B1)Rf2kX zKF(dad9tZBFF8s{hZ0i$A2}d`HIw+-+VLrEhK1h0XL2ra+(-n98G?KDZBm;i`e6vK zfb?g$1XTW?xJ31Rh*tP7=~*zNMFK#(M;?$Hj#LJc$9L8H4F2W-&SFS;2=?mK~;OPjJ7+0nO4 z-sgExyirGrf1|go?RriT#WU66zozgnw}{>(p;F;`kb$I%Ek$g6DWI<)B3CbvyVF}p zHf)0_stv_o)g)N|@ag~5SfCF9xSHdEuZgB6Z~F`K^4|&|L=F=H_enS3S4~)o{aye# zV_H!jSJw`Yoj$~s;&7Ra7DPhy1r)VMSFHV_6dJSs(?5wiSD9i~T{xip-*vNz`v9Ee zr1jd6MJw6AE%CVp2)_nB$~cm{wrlD=?<~je>)O`BJcimhyt- zUs%Sm7T(o@qbg0voH^^hm?g!pZPn ztLk~JA3qYNAAt@$>g=!TcSh0?E0v)Ga0YZt4M6N%GA5pg$$oiMDHOkyKXP5dNxoD) zX2l;w$wYO!?8R4@Ht?E{G6{?t=cvCB5%k32NVk0Jp%jZ(A30Z2xD*#cGV#RWO7hg> z@7Jp5El4LWaz+O)&uw!cu<^2$V>(+V38zX6Mb2RZK05(yE|~!l8I_#flo%@Ft#{G^ zVenU$!+aMN-QLfA~SK|MI<4m_G!YZRh$sO$Ssd*6=ki#j?{ox>&^HZzwGUY@*I5)s}%qLJWYddB|i{e_
  • RiH3?w$_e3F4dxl{j-G}p+} zU=}UMLv?%i{sr76sH&2K=;cEnx7!AM-MsV%f0K;v{&Uwra(MBivVe;p_^6dwQ& zvz1`5TfXu#?2?(8LeeI>E^3TmfwB)kr)}R7+jqILcfru_Q$y0$NA)x=7!2= z<*KYAHUaa+JocLMO~zN!U`-wX#m>XSQyjxE!w%nwf>RH-VYJTeQNE1t<-5;=@EV@i zBd#Pv`m{A^HS3qTRwTx?zJ!ZZ?T(2E%F_(-`@RVPZ zAt$StfVo0ni!B59uK_C#x57T#eReNU{S$!U$nj0dSs0|@rG#~fPs2X;IPBhoBC^I0 z)UsdG8ck(cTk)l8P@Zs0DHnIE9uU=6u(I!8jiVuk1yS3Z8e;=jWc)=0ZQlIh_ z0%KIa3LFNi66Eh5_H_1{Oh6sH4``0p5+U(>_IkIZ^j5-{V`?ZxO^K|~$Ewg#Ee_&* zn6MI0)Ri5B+ykf(1SFJAMfOM8f}?R^s#SOX(E}>C-RI_U8HYZe%Q=e261F^WCWIZ^ z+66l4i;FkVR3gBZe=wf{&3OQ}A`^EBfGtmMY+Yu7YyWrpW)$6<%F}9BZ{WVuDGqz& zWLTAf*a9ck9Zbg3HDZ=eB#Yle%p5sXM6%KxWb6imNtY%lh{|0V=>%N$ze}tag#;l_EEtZIQAQ5pA zkv#Xs7z-rM!Kxw8(CXA=^7;6OhX8mKN%O2ObhX2Li7Nodd$koPS%Llfoi6UHjLKlB ze$7pHV+!QvZ9D{5Vr2R1HBCYj*}W zpt!WW%|*9df1UA1IITD(a^S*&O+;4|={lp>G$IXWp6^gRlWpj(L!lii4v|7wZ2WQ$ zCc~)QMtc{KywfeFi`o3~MQ`%cZ_#om_jOEpo0^Qtf8Q&rumUh*v*pU!^oA&b<8^Q) zOt1@22THcnXQO`D{d}ESK5v?WlOg;)=5Y?Sl!|-6T~10r$l2<@ss5_UcWHl8m~9D7 zx9l|e6cND}^At(y${hh1_?U5|E^^Z4NF~73OotB{pQb)Ci1JHQ2gFVsKN&>?%Jc!Z z3X{AsfB#1v%4$eb8C=WsyEi!`M0wO|#f~17tdVzGX+;!GgB3zUAh4#p4svehfClF? z=bpIiU{|6*8z)f0xmrKXwvE4A{1iu-@o(MnKxX5atDe-i+jKiY%r9jLyA65gIQhBO zLz!xab?+VsnUXmSk#2Ra$rqon4k8Oi z%q6~sx}eZy7YPVk*CXM-Icc6!x=eO!e}<+=`<$+&Q{k7xY?TB4A)C!WiV36PJH*a6 zfj;~v0V3#fS1fV_NA?t%)__ptU)8}^LPR4!YyC_RjM4WDeY8!@J8?Pjcys>PNW%Pn z&t7$2e~GKDQ{}XUoJ85`E>2sX*SgEVfj{t&FKeRL@Vn;mV0gX!hI3VG-34?Xe_O{$ z^ENVR0vvt;)geGYi0uYaaI61lK?hQ zAXNeRYaq}!$mOYWMhuAY^1=b=e+(2|gr^>%?7$W)->0GiA`Ise)GlGvEH?+R14so| zGY42N;6tFOlmi`!os0ZID%oSYRxp=8?Uy=Z4CPFE5L^yOI6pye(s(L^%7|_(i#<%)abnSObHaXLYmTSlModV*kFswF&vG=j?Q809e^a?VmQd*N zh+A~jsWGxp8vO&fuPc>xqc4 zXT>8GD&R0Lv$a)jf~xLke`I0Gw5O_t`q3rQSeIK~7aYYN^rcRh{&5LUh=OFw9u?R$ zu09H|35f4Rpl?F)Fa(wAXU%W@rhwSC6 zUM7b2Nr39kn0ok;oAV~W^Eg^1o$7In2SOuLQS1W+_b6AK{eE?Df49?RC!fj(rWzcA z)&jm67;(uG!~Qa})x{!J%{t$7L!)@QF}^&Mpf$I%;|hbI@2ui7cJI>6dd5~8l?LC2 z@nLu)@8nx>jq0M;Du|l0p|yH4ltDQJcE}euzjy(8Lb-gqdg9S=AQF))>4`K^x!`e# z_uw!Df)k3)nOj9He^WVR|4a6|1<5V_iqvQ<5%L;iXI&&=QPDfm=DvWhWTyTXrsSjt zKs})PsX$&dW*86p(YK|MD<~cs0h$}!+_VRp3y*;41=0BeM=hdtkU{(V>C=|Bg=ri5 zM3&dLXxI#t1}x&fyt2<&BRxVu7gn4;ml~YWW^gD%&A!A?e~4{U;TtL#pyEBfL~1n@}~wivk7Vp3s4C);7pqJ$JI`!@f-KJZIj^n^x0w;RKIekxy~P+=r1^P4TLy&e`pkye*7GqI2(u=A5LyWD7oH z#_N=#sN})SqgLvatQR}|gh6Q}*=7yJk=0Y@e5TTxJ6-I@9QB<9Yqp73bsEo|Bl;!J zbfZq}j|5(Q<^f+fcg_GWxuqh2%I5KN0l{HfNDGb;fBxBb1(-|%cVaKW?toNDaJmqu z4HN>AI-&oa!wUQ)W-}q37EHc!TPqwY8ORiNqk-mRc!Qe4kVEhaxJ@B=ie!BPY~u8E z3XlMRbB>fzO^JckpSKT zoE~|NAC~u9FiVwbM8V#*Kc+7Og1(XbP!B`7(0025X!Nvs&f7HBBG;T>MvbdywS#jY z7u-K9ZMOlYw?cuu{5B^-i1_OJw|Dc}N?ptNf9id(i|!tMTxIYDtuxwREnn41k=LFB zx1ps@_wJWZjJ^K)RwzeJsFCeFdV`6lZmUr|#|s~eK|~$)Cr;^&4DsGRDqK;@Y$j$V z)Pbqw;6}th2NBREGzqjDFiNJfy3>>_o_ndjFzmB(D4u*onTHv0f=*;v(JdnvR+KMu zf5ZeAVtY}tYEDT6yyHEzrFvTrBuc(&AF-*WM_Eu8H)34?Wj^falxHAC{5OBjky47= zm(m{8cSf+1ES`UGFhr#GwVD;UnVFU90Ck13pt^J9JA25p1dFqva%a6+Qwu6JF zpWr5f(=x`*C=`vLWINicfb`5i3xV|Qe>CpP6RZ>@hqHQ~BXB@f4`t$3rhbKg`3bix zV_8v(Jf6_MR5}lXsezMkyG4!6QfhZqL(YS=LPCW4ADy243pl>=xaf7GYmlH~GXRk$ zLpESEzKQD+8M_aMRcEz)fc8c@lKcJ2*-8j&4n4CjsBsXS1)okQA4g^M2V40~NKL~- z>;(IRSb!1?M0>xP12b4L1#9@InB?{aj-0XQ!ZcZQNPo$~;{a^p}-~QXb{f~+u z$iKiq!k69|$u30uQe`=O!I#_?0c`<-mr54_Hxj3U0Dw`zO+^O+I5Ug20|9?Zmy;I( zL=qX<5Sx7a1zE#%4i)!10;d0xm+2P)U;&wzN*Dni7T26vY#*uoOzFTevxU@PaGTDV zQSarKei#8G0z9LaqZk1`9+9|T7VHn?TO-!t$fKjE4oO{xm;c!5K4btW%Aetv{}=%l z0kxMF839TG4VPgV0Tuxumv|WgUMGk80i>`+bi7tOZ1sR!4*D&7y}bhX2Rj`~uC3eD z!B&OM-5LS>nV0<;0c8z8a2(P)40{Y{A&%7_mv0&YJb&wL2473XErnh9CfhBR*zN_` zmh|&vEz7|Nn}xK2M(~T>Vc;%8Ij~SRV4uOUmxBmu!G0nHW|iiVgRXwt>0*W%{+tkp zayrlneTY8P4BFrk7Lpu+*`!-i$V9yq1Xs;BDjn17spJS!NEx8AT|RE$f7M(SirIAq zWP}A-Z-3-g$q%1_VwwHWc~i_Espe1p3Wq0#wnm2e5{GtYeayjKK%Cc+BV4zztD3;1 zyDi|KN=?!yM&JzT%h1(JP>1LHJ+?}|L#RA^M5QN*{G<9SCp{caX+X3G*a7ux@n1V1E#>z4Pb5r8XIg!^-eQ3mjQMv&W+@uvNGC9mvsG88GgeknaQ7p^$b z*kc=!Bxr8F$i6IiY$)Q0w-u@{! zRoL_b^B=*a5h0eyvvdkXdJ7zw(~;b~h<_F0PN96{$9is9>qxudC*bc6Owm}H=r5NA zRbQ}$u0KIBY@lku%+{3Du5Yy=$0?G?)E)<$Q*}1%3$~97KnkHih5{h=zh5SMsXy|Z zF-zp|6NcET^Vb8VmJ)*$mF9b+*^v~O2!I4JYv68#mQtc9?>m&-gT3}O!zt1Og?|YB z!?H-dgZiUu`H?uvZ>Q^AXHi?p-IJ-33`c!=y9i0D%0i{45n{du9Wb#;!$;Yh51$4M zx?O|9cr;~FcHkpl(;-#>EDb7(4I~rzoURAL0r}D$0$B_CV~#sfM+2D(;%%*!5twKc zOk{F~=o=xi1%X#ofq^a@3i%@hAQ_D! zt4kIgHGebg06xpV<0+vM!y#3_ool{7m9R-K8Enxgee=iF7-i2nPl45sf^s*$)(~F) zPlI89I%)>b8eU(C*q@TMLP`OH9X6L*g`Lz?xN~i%NZVKGoUs5xz+{O;ys^ z9O1C$xX48ExjEl~(FRbn3V*;;@HWNCL{av3izr?X+_N4pX-q0s`gVX1C#4nF?-Nv1 zcx3Sxf4`LU)q1~~Z4%Ze7Qm|W((s>kS4lviLr=Ct>c}oPmf);QcZL0FTYG`Dc|GZ; zi)J)JvmBCaBErqitSK$L(`C0-kN*mL`6#f1EMRimQ_R-3AWr&Nn}4y^$D?a$`N8$n z&E~%!b`&oGGfs7kRNr_o?bCCIP-`u4CdM*FmV9CGIstNqVPh0qO{Hvix`X+HX&d-Y z0P;CJmhUI~$_7`W9_(d`lWjbaiK5PnoqAf7&nhJwJ#@+@dH%)|j|ORv1`DrUACShG z=o6BUlf)Wa$wVi2u7A2EuyMVNK?ELp)cJZ+r$_qB-07iA4$jKv|7o$WC(;`t2C29a z%P;_RZ1~p|jk0#dEf5|cQ@@HGHIrOmC(19}9aU4ut-jypNqjnK9Mk4;fWLuL$2qU& zv|eOJl31qma*2}mB9d$5-Quho=Q0>YeO*P{g5UmXB41ZRduxS!@x??C2UeiH)Uv50g9yvylvyPjH5~tZg+Udd>`Uh2NS(Oe^ z8kPv1kkjRKV^2DDIi0W-u2Fy zU#ihSf&nScNJKS(@I^W{EtW&eElo!c31lkYc7N(|&3_W6?OvCq!Zgs8W!ORskWkXJ zY3`4>zq@RuW;G~ZN2=2bMA!VK1l9F5)#C}1A)Qr-m7fmCT@Cl5tWH1}c;vdR~Wj5BZz_!QX#zzq>5B#q<& z+u<|7+5~N!`XQ(6=G|d)k5~L1^as)cyhExN>%3$iqgaJf;kOjCWk&#!?U>tv{m9X; zC%E{YjvCi@?1{g4+M&t$x*(o0L+TmWJ%oFKl7DO{-v(SK^fM;x6tTeIBff4=JId)! zF$i#$g5{=G2K6to6rQ+T5d1QM&k=x5-OUmm3W$W;4yAn*_>@H%O|OI!6&;Dx(G!-X zNwGgsa$$ePCEqRyBon!Bz+y=e+I-$Vtxl6yIy>&*+*l&By^}F{W9Lh@A~Iye%eVKi~XVS~e*I-+5W1P(#I4iGYG5ekWnk*qjG+9-BtHU(osxu;JRn&_WNO5(K5+M== zkKM}{{|3lxlp?~70E8G0+Yn1hmE?v8yaY+*TNHjq6xw{=y}XS+%*S{fc19f?{K!!t z41B73M2@5)<_aX-RV6~=@>Ek8HP)(^<$s<93{$qwzM&Wlm7ryf+9hki2Tt7T)imR4_vq*YPsT1-R@8p2(K){;)r8fryN&21|g?%kxZ(s}Fgugrw}Ws(+G$ z9tr=s2h^24ias^fhF6G7ANSbY-#7VZ;E6sts}x%u_FfQb0*I6_Aq2kwkuRDR(hK_#HLP1YSXkj3{36wHpCClgS zPuF;}Q7uNcn#eO}K}ZUe;;3NG5`UTFT#gT`cRBma$T4R^->~#eodhi6>xu6uL>el> zx2x>0@J7OLfvYDiq~%294@jG_3c^cCtENG-5D;uEvyASt!<+~a>p~J@G<>8~-3(q0 zxD$QZ9y9$`NqZJ?`C9E@2R73x_oZaea@E+->*%nYm%}E`jzD%p~$ygesUKp6F_`ck;;Ezk4@KNRpXK@11Wx|JT3#&;Q=r9r=5wdL1vX0SpMSSwiAvD}E86GVm+^$V1#YB8QOrAL!8v1GJ+K|U zMBzvQs%x%aOM)8+*0951@U+>uxkfiv(#_?FO}Xt4@UR^9EpUl(t!sa zFIlWDUe(|zLrI-&@_(U`2KLeLbp!yk20nEcnUtuCDa%t5z|zivNlQgU^Gv@I6SvO> z%S||LDpsxj83pPbfT1!4-o*x-X z=?51{=?4@(X|N{z?-uGPv1e=0DB=x=l}eWd2Ju5jLNhfKsegNAAg7A~5S4=WL>tj7 zQ^-d@l1>vnU7E%+Fx@k3cPjY-H@$QDdtWEHxF|=ZT`-(Rvtclmf#h;AZRu2vv)e)7 zM82SaS7Q-bEd`8j-by>Eu1<-?d;s_>;F~~_LZD>Im(o*Lsy*W|Z6cNK)@ zPR|*okbFU?C~&}zM>0p`4!AG{E(#n}y!V)76Tw>IMg%Y=k&!|Fx2R!5U!X)dyTe%o zh$#;1Fs&K#xU{x?4|Nq4fSE9V^aDM9!1*Gr=5o?`D}S)DP()mk8sCveh*?MItlNU2 zlz^LX06Y;=R^_=D(U&)`Uv@AT*%!JmOU^9EYyal;ZS+QjjBXCGfWOC)*s`!>!@vH{S#S(^7rt8b5s3bLX)SACJQ)t?u zvwu>)fOGRoV!_<4sQiGYHJfLi?73)V)2!iT9UZ)paDjIPI7Rq|FTn%E(Jr2#1OD*D z;8ipABcWp_6*`T8FeUCf(E$pasD0gPp!Q-o^;{wqH7@9Lh{>YU{rThVYtaII^(#QX z=%^3?jZXy3nha!_=beYl7q#8&Kqj@Oa(_7j=dnb>i5^3Ka$x1bqI*y4R7P{nn$bui z#@ta+8P^3;p!okVcV^vfP)GNtCllQw#$pE?XueP^qhI5BuZkLi<%T| zsXqPuB7ocwKrWO#GcR?@VkR;YKmvh?8~0|E5f=}_*1bLa13q5p8zl?|E9`Rin}2>H zJ+jKk(7>bPTzrkt^bRimxcKes+dqGCKEzf^2UwucXV`M#eD!?|3?UY)Pd$tomwsI6 z^ORpB`Tf}_{ZD@TwOcg>xwl}gS2DDecNB>mhe(H_Zl%QgQM=#9z!I77Q*NVq?wr^f zA?8jM7KwcX;z`fQu|j~8e_p&g`+vRBDNrU8@f@n#Mb?)6rD!&AeVTBZ8Ig-6yowfB2j$l;yRKjAR#1}HQINnIVlw6|PxmUk=MNm8q6O;E? zv!-|k-;g$=j;5azcw_@IlXp*$a_k%Hj8YzrA|NU|`tVdapj0Oqwf6)@7Js1|8Q%O6 zA`*QoJm10w-UYRtKh9>E?Hjczy6QHQQpet7o2W0$VX?}=W1V2$<-5Gj?J{A(&?+?g zt{Pg-={M^oF=Nkg(>wSqaCzg>Y}uqmO#-J$U~`hcgN&FfJ?>+yrf?xUoXQvf;!b z;2X%2=eL~Sq1ohL7pvLq?*zXVnW4ypVdr!p|2HEIR=pXgl6$hr`b)!{rEb7^GmV=a z>NyctVM)<4>T}9GFWM$beJCM+a0twTx!dcB7IDr3zhYhLXamY&Cx1t+MnIfTU>!xk z8v)mEDPZCmQrnWTwq;nAInzKe?97F9)n-ma#ArptK#(~%4~L@G35B@I%u%GLjIkv; zS=B!@Q=i8-H6pV(V~p)w0Wh4z)(avEk~;Coo(ed&8(79|SK)yiA^T+ei9H)8HhZ?J zHk08Ry;BzMoORH5TYsgNi`)4=sLg1NPa;vy;3YHbSb^uTEolZbE;Q31GMMV1*sd4v zAR(xOFdeXwLvF>*h+LwdgKyK#1L6#Df|X_GO=efxd3AoDO` zTic>xsRc+mjK2JutI;9&#;4uNU8aOsu$B}_+VK6aZNur+Jkqo%UkQJIa4X(6co$6a z)V5F|@dTaNW5Y|mhHOv1OG2({75 zCRO0L#iJ8TlkvNxAQ{0Y&8Mo0@?SgBmTdB@3zgsO`c?Uv&TD(8M?d#1ncMGDa?Fihs zot+JKlI$glD`vW|=_6+}8+ndg^b+RUm45DA5B6oZ?`OxpIQM(=vGLU)ME#Zyk_?a3 zs52pM2%@VffRb-ymoy$R`+bY@_#Ktp2fWTJ&xui@8jgsM*X8zV_%TBWP3H@CC{^-Tu8%z_z>RH-PCda#4dYjQ%OiK);9!h zuZ;6n9kA@Oy)3e4!n8$<6Zw|^?B**@t#BaJ+7({Bmv#2snYNCE^k#iSlw?J8-U=jC z;w6eE|?4I$6DCy1?;&Z-L)<=RX^T&6>rB6 zn6JX_N@-K*1=iT#`l8I#%&)^ zpdSCFe`*T`E3;Pkk|4t(AxV*fFmu>|ROFJNe{*Z4MNG8pEjXhmXe@R1C?B?m2i^*+ z_<>`&OmJfgMk#r(oB*3BGUMGeff6SC6KA<%^I)2nmKK zFiDK!z}D=&y@k~hSwWEwD1bMT3e{kR#`f&jJ1gB)b=;o8yLoKI-zwI*rVrOQhtxA8 ze{JuX;}hiqlVh7+cniM?D}9^c_}7<YOzDuw9B6_WZ_2_6!L zbHZojO-%*e{;<1FrAZ>VKL1)$ia{w8e<;MwbeT}|19U;z=nr&}1A{aP5&OZ_8Eb+% zf6EYCuIwI>MtxUQ4Xe&>tx^qdO@v#HZMfyFC|W;AXwYTVGyKzI@74L|kAs4fw{&t! zoOn(w_KVg@JxS|VYvg~W=5=i-Xk9&a@84%o zhGE~>E3mEglUl@vZSkpZ{jl^N^W|~}N+IvYgSW5$e04am*eBl8;b<$gc(E2Uz174b zdSWA7Zv}Oy8Ly{p=J;vqxWsrX#JR&>5gGhW`aIBRIe+{DMCQeXi&ocz$>ulXqHr__=>TKU%JigBKxL9MtX_-Wh zN6C;VQY${UQ{xTQnU+pUCCxM8gi?n(`3Dl?Wr}B;9IX&QbJDmX)?>H%F1RRJ!{zxR zD8B9ia%H)M#>5P(6XVV6rUJJZ#&2B4k`ayj%y?vR)bF6tP!}{pEgnvkIQ#gGwD5!` z0Xb(%Rd`v?KrY)re`3=2ZMwB;NPKP?8u$I4Z36K5v%4^<*Ig^ooV~imgz?^qs*Roi zV<*M1d-J6HOe)0WP#H{`rsHOOyhf*%#83HHcr8ReOC4lC<>3n$V`f^TC_YbUW) zwT-n}gE1_S%XRj;dW{IoS>whH9YAbc2RS8W+9Fkl=GQ1PMdnGM2v;|) zYk@llXA{gDNAzY}iQ=`|VESTv2peg%9aJyf}&1yprxqaf~~oul&Z(f+m<49iEx zOgbgAuX9}9B$?d%`j|iw5eP@gF>%W8X)ktfQeXBUUz< zL|o8xe>!8~7wu?lM**Ao*iXimTcxpMg$%W$v79uY;5Ypd9sYy>amr#_i(O-}Ogm`* zVkY~-#jyo#*0hJyhHzC~bH{f1P7l887cH!he@xfRLd$;ij-qE+`DV*|^^3D&7F{x2 z@b%DtaCsSCy_cCNzAaZqnhM*55iC+|D6JF2I~o`y!}}73!Lzep0&2U17EgHI>+{@5 z2O1AO-C)k9ngB+4WZcn-*&oY53yhQ~@!kX*xIDHK-dud`_s1t=<874Rrai=?jml{X ze>~C{z5(cAkuqoJnWtVZfhVk_Q#dy&k26zTR^fSNEg%qZ0Emg6V$0-<$aJa0-tBvyL%gF<)PDP^6M)8vb@gqRt(O zH{Yci)?;j4G)khFrF&i82p?;iz#%||e{CmRxq$f1$%)fEebssH{e|gqt zYn83{HNEk}wM+71cO@_MvpVW|J!1#;8Rj;2PGrJEeCj|DWhxEfrU3fvbP>X-S~(nH zZE-)dz4lK3Nk#zT?<&3_c3P!2E;` zuFGs#)dIhOaNqFdDDzD)&zmb4v#q^sT6`684jzduRU8ZuM=(f8F9mEpEg(fUsQz9g zkVSgP^$;LZ!EhYvzi`(R!`zr@&>h|lL)Bx_e9m6=nMY%*uW78OK=XEm1$$=W)NhxG zI{_|#_o5K-efy8zhbMBTq72IyJQ(CSaw8R*CeB1@{CgkW+zR{xAMOGLqw^XA&^?ey4ZU5%#mGSHblBPiV0#Y zL$|?yH~*V)0~tD>)|2a&uaxg(GYea59@1f7-!8C>s7k{S!~=GFfZzlMN_zca`Z%=? zTIq5lDaaiRhb#+Oi`7dKu3Drl?89_>HwWmpMnCmQxT#cbi?{;PW<3TE!nyxy(AGNc z8()cFM6aw_c34#`>m6{xo5Qb{l{^6?f51K^xr-b*cF_OFaMJts;cqk20%ey=ADEn5 zmLFk_&y{%O^Y*_t&bm>5WR77mJK|vTY2aFOs!jIs9!4!`c=skjb_%u5ZE4 zNi!lR^(`2;+}fZK-v``IGpP3hevw~d!`E$4Eo9OfBC*k^9r>u5D3)!+2RrNAe=+Nt zwDaIjy_Hmj)D~PW)>nwT)&gV|^5HM^9pjoyL{ug=!q>(GTyc@GUO=fwzVT29pdsFz zMl$ApW0_b<+>Xx?{8r;b%(l!!zLTh(0z4MpL}6}~0B_hE0O3@TLr_Tb8=QYfRS9E> zs3RK87d_k9q~PxZH_+QQ#qOMGQ^F zr}>d^+jO->RX(D#yJ(c=Ns91f28bLPlxOu1au?rDm&@rPrvNmUp7g~McJWZD8-Qd| z!X+-&GwV^uV_zZDv#a)ixNDB7D_HDdzUY$W;PHDXC{FD8?}NTkHpC3ie-s}!^682` zu`8H>dT%AKUzR1x{>DpH<&B&l#?|JRitv%htAX4?9ZedKuK@kAt$4|;e@e{8%cNwVX->!-K4ytf%xJ=t-shP^Vl zEb;&wzO$mqDP3y%pg7&`e+bzLn#rSav=C1a0>P3Izh=I=n_tf5>PomTF>xXV%^xTL z!u!g@H#lK%MaTqS6XLK(uJRTq#Y5aH@6m9VUs(r{?2G1QhQ~wepGs+xdgHHq2h?}4 z(B{z(i;IR=*6EN-wTy0~#og4jOKpLzR`brmv4v|$w`333+LD~G5z<#oW$N|~SnJ8e zic%MCzmbNngbBwzLNNtc&E0U!Z#m$*OyI12N-#h!Lwpj&>msm#7m_#6Hb(A`)%X(GtQ5J*US^ zM(q#|qHBq!iY~9JWmGQ}RFIP~5Qn8n@q9S23b$ujaq>OnQCiogpuYR{BgKp4pE)&O z_s-t^d8lL=W^R@b5Z}?9cHC+i9eT4#gE5H}{%L2@$HPHCkr1X)6YXr>=0y zv~E{Eo3y=V0<~>-m~PX=j9az&_0M;g&Oresf7QodGD%yfBay-Ud*4u3n@TY{;3XTt ze)X|@8!NvQ2Eah5^*R2g=Gi(vu{&YZPJ*05D`l*8JU`-de4Agd$i$W8Zljr$hXw&( z-o(6`Z+ai)U%+Q3vcAU)zW7@ucCQngSnFhMi$QqV-nG08o$SqMDszcsGiQvs?v_30 ze?ok<3qQ)#WY0fMNJB2K)8D3BSD1Px-PfseipMG4va@QvqQu!hAL%CcveXKZTM^$n zy1#VXir?Hi)y@`6BfD3Ryl;MK;{~3rZs;~i3lLHwJ+ho`VyUmPddk4nJ6AoF(gg%H zb5bKgVgL!G_PmALGPEiLE&#-M0`u^oe-4(yIxUws#QZcGOMrGmyvqcv-n{u(sRv91 z-y-_E)xKK)z-3Oz`n4$q(Dx{JeqDnZ9>%7*&pcqu*Mq(k$~;n2jlms3gn~JN|(X_0WshX4T^ye zg!o%ffn$Ar36guE*J7y^R?>~=fBt2_X|vgDa6P{vI7Q|+w+P}|?v}HJN%}~)q;xZ< zTROm|A5#XE6A=5@l}KPDPWnfdueXh1UM`EARkuzn8&|Z^CZA%9NY1L7xzu#1rss_G zAc`Z#uHbTJw_ZO*lSc2@ro_v~Rp$iS)X_R7)>*lEQ3ZVEo3!A~K9@X%AO-x=)B+>QnEA#4lS6WH;oK zao~XN=4qHq@#y%&c5WrstG76pNdV~8)~g#$;vQ+f&6zra7xv|SM`k4c5V~kla|0FR zGT`Y+eobSV{E0di%g{=28qY+OS}$ClOR zkAlaSSlVuJvtB(d0Mbnhj=kEAy>vgemLqND#uA%lgk1WMO!Nv^tZKr^u9zpu4p;_m z*ZkY-(-WL8mBBjFo5PhNDaaX!R$qRtncc4Zj^=ZPrLbYabl%vdP3!O8?VEX>!=>_3R4mEyAQxjF@EISG=_kD-`n#U>+EJ|L3qVjDP>` zi&y4rv9=%El<+@SP!3cRf#ExvG~qYyNvtj>_6gbPILY~b6amZYSKJ@ilH-WIFO#H| zmwHx~)_9l+Q=gxvfAyyBk*76#<;P}j*GCTA0-Xv+yeqeB;?o(}677$fupJd2Qf#YL z%=ofeF~(j*;SWXl6=(pgv7+xI8uTzD*`k_K-qe4G!9Jw7Q8Jl7khzd+;5Dw{V;1r7 z{XR|wIkcKz=8!6f7*g>C_SyRW^!H*#N3n|GsXdZ?6oBb|e+mX|%G;G#Dbajl)cdwr zMT`{C43%Uer_AZLAjV04C){Tf;KYk*}OO7D~RVvk~+E_a^G*H^A*EyR0q5TVxmIHUMVkQ19Zjze<% z4&DHl7e@gv2JO>^N~4FDOh*AC0`-)aa7O_#E8%n?%76M2{3+oS9Yq$q*$+-q!ey5T z_kJucm^rm(Ot61!;q*;TP0aM8m&`{2907)x=|=$@1ZU@;RhI}z0V97k{7J#!5(8Sz z(+`Hfw93+(BsN`^5v(0df616AD&FUm!)Wy?yixI7t$R{pYkL)ZKGjxwui7B_$D@e* zEO;M)paG97s|ZK;-ImRh7_~x-d`(uZZ$d&IVgkk`*^*3f1~RRWdSG97)R z@wE`BsOexz_NY%LOb~xCY-gx*w5@f^FD*7EY(V!Xc(En?Nc^S~Yxd~KqJWyLqznyW zNx{ZfRfH0_6&_({S`&cx+3dVskBrdr+K;`BmC%wPl}7&8hchz;qB_Fcv~ekVXY}Yr;v5LE4rg?y zcm(FnvfPJX{%*zAD%)OhCq^~j=QI6%TX$A9gjKzO+`B@Vo87{d9HV%>A|zFJ_>7yk zoh@#(V*FaF;};Kim>g@n*>f31_#Qu@p+VURu?Z=V4m-?IKYHPRK&C& zGo(MUvNtt`h`_2NB#l)m?_*Ydi@A{|d+{lY1Z$O>KRU{1?*heA@$q2hMGym)&nu5B z>)A7rHXMxXVaS^{w)|0;Rxo>n>>pB*b_Lz-^eVzd)14|rnn_GyXx{8f*2Xen6~MD` zjCrOH_pmX4Zx9si-Sj(Q^rXoqPS&b3FBM0+Tz}US{!5sA35S}vo)QEnbibh5JZZCW zV_Vr=xPdQVZ^U~`nj2YoTFi=TfQ5Wzl<`O0r0#Q~)SS>a3%IcP#1IKdwCd^^wCUEj z>u$8Rlk8Vhlhn$#8+`N43(Np*CuN&0L~CUmLw!AeC6Vz0=E0SuO(lCTvfZ|rmGhNQ z`bg~qB~qvhKfHvkp_on5=Gdmxyz)C_mQ4AVSf~W#G+o?U{*x@mZrQL~js0T1RkDuC zhW`Qv12f7-4BAId^C_~EBk02S+P|Q-5TbOUdo}i!eq;0RxB?{S!RcOh=0_FQJ{Jmq zf$sHxG4;Id7K`d+KR02!m;q{u_Hy@?wP-BW$+lFw)ij16_vS|BqbD z0a{$M%rDmWnt(W9bXHUOD;&wHw6uoXwH|@tDk${&@Ki%&tlEC#n2(Qb+Wb?_+#FB4 zf;A|LrZRL&eY&;2o~F^teuP6mvl6&aoIR(1j>|5|sndynuA{h(hN@z+l+|I3vdqP2 z*>$x4cEOJJ=uE+_{+_y@Sc&hqG6&e(QbuaQ?pcMS@FaCD5OL zs&=@$nvEEo*wlW+h!6jMb?BQ!saIIgpjO*hXNBv6U|xGeY)UC^$Zx($(fF`^;e)3U zBA7&L+IjJ|?AwGrotWV#wwxmJ^vcw-dwp!?)sbt(Z5iQ**zMi1+~=!MkEowfIg45p zlR{&O*vqcSfy3D4N-wf{JjXK_)QDPtI~yp-;x(p9+i8e0lbve({pI}nT4MaqO0(C? zQ*)G=eRIT9Q3dOiv39-vG`}w6NtNMC(o&>weNifGGV9IlbOm4CVhyF5$epkaT!Bh5 zk%V$nZZE1XMyZBc;6-3`GPCztwoB=rI2>8TKEX5J^h#}DyU%)U>xi{^?eo`vzrQuZ zBb6KgJEiZUgiTDi_znF$`H)kxa!z4a@#9JQBu(>7!K{NAtugI2xq z=5=&@{a0EU;BA)?j;|f#p)HARwRW6iXNN(1w)x_wX5V!=)7NTZ+6^)o3OHJ+wx0c_ zpji38T*~?X+F}yfv{Hw-i1X2Z`h9X;!Dp_I@jZ5brNN`4h@Uzq6)uB;JK7Syw9IbF zlD(agPp6hy_tSjwtx!=;^q}=p0KpWuRX5E2`)Ly4_pRF3S>@R-RAeVbT(5WWuv-G| zUi31~h6^%BLR=_Su4iaBK~x5(XaoGwi5G24w^lo&72W9Q$QA&9>SCvVr_;Os3msx! z4RC1>)6G%K7a|{7f$>jp@I$U9`obXRA$}0t7Ldh^(geDPpTi~5jvQqiJLm~Zb`E=x zMC3g+BC7@!mJ?h0`-wBJ0E3r|3&9B+n@8k zW}nfS7#WUdyj#uGd8YNI0z|EsSetNR3Bs!m_o@9RA5ZB><56J+Idpt-_m79R=jK;y zO|)dns|cJcL@h*(LqQDkLp*&#g;X=IHOz>f)=-{WmorXW5oICH-StWcX(n1AVbt!b_rgy99M< zUMr7H+LYC$ zxkW4a8@6~waUc){(I0dCL-$YQNmwTnNAy8-kw~`4pi0Z4SKQn<)mi3?^?q{y#7ugBcsjA9zICsd zFsS#)?0Bpq{gZI|@|(!s65Ln~faG1AI#OAGYQaA#CM7*1TlC$0aSd=MycgLVQ=62P zG&M)hhY`7F`^?_K(SKKw>ArlLsd{?aGElCftxV86Qkdh1@7R`Vf2IahTohRVlxFLm zGS|p@ymr?y0(Dnqka>$f^3TanfC&;Zp(WiSD&f={WbvyGa8~Xe0AK`V_&C3oU}E)u zmoW5){Xw*pznr~)_xk*B6x^DmrX{A!7_ERgYDmPh%c;afO+E>alSj#E7xx7kp&8m3 z4}ijQf2nGC24%W(a;^qTq-BmtypzlCD_tK)&CQxqc3>J2XvydIUJoj~(S?bQG)Q{K zF!5%cc&9Xj{3|BOHQh+%*i;1Y?(e{V4PD7eRkj8vH|WF!eC=O66p@k`@#@%wq2|QA zTuwedFMdpgqdQdRYT_5EBjVP{gD-zCvWa$jx{AghS-->)6ZA+UpSP;YoPCkL6$D}U z3Mj82c_KTl`9QjhmQLF$z%FJ~r-cu6G_TZBsM3q$vUHzBj8R?46@{|Z<6$y?6l?ww zR-_|!o{_!sB6iud%e&XJS^Ks!8t-tyKv0l}LYW>y<8IUt&?uqGcPB5J6=o8ATdXHl z>S`=ciQVv1hN4U-cp&vkbz4>wy?%U>kKB7&)joJpz8SI$CF(BBuZ}_l5}FF%+boHY zdgaS=Hrz`N>2hkAJ@Oa74JDd?99qXko6Bd6E(nLRT%5B@pqNcX~ z4O1P3t@!zZ5~nz01vTu!lz@kXR{U%%(LQ@kY`xkZTT5*Oz^M3>61{qVWJ!!trmFve z!D{#26WBg^0i9;al%_?aHnr}%LuLr7u_{NQmHHwPuA!Cmvy5~88G)*MIl)OPpKzA! zr^3hUiTF{jbtUwb#)FhS{)q4&Zf`bXP&&?C}o9_LT7X=4MOklu&tjiwuV` z*gl_;t_WcQ*IWB%)iF zGH%U|%gJ%a7sgmytIEFyyO4+`2k)CWxS~WF{!(ub@i<{$ju~X0DT}tgM1E7797d)f4Of}GF!Zdghn;C@V8?8`(-O3lPU{N?&IVW5Z z$+;44FdR}M6jvgjLDI=YN6UMO1b^n&vS1VQ0DL%~mY>j~7e^M@{8_cDT|OL&&AZtT zG4eqaM6cE~ujx6nD3Ma!%pZ9otB(YbRDnhq)q*pN=Dk+4wF-nM_GqM%%w%&$DJVuU z7I!3wR=3cRBktzZ;-?#rLg>BR} zjn|kS3ZfK2o6^TVY9r^phA73PZxtl0k$IZ8D-A}2mNWJ}%lbk8#6_K>6O4`s5~q_3&#=8=fFsR0z%++^=J$E6#KUpVa=zv zf}>ZjPa;9|7VYoXp(c?Qf0FcMw^wM{MXurfY&R*)(Ds**7~fx9+ytAgdCzC8 z--D{&df>8uviSI@glYX@v=+kPr|KZ$k7{eOm)?@MKydS?=xDiUZSj=Gq%ks~*1ypT zhS}zc72HAU(y8O}RafiX>VXY~hpyx_5h1>5#|~q|-sguGF4gq2IJ zlQTSo{Ue!Xy|(Icyb#NPg?*i)TS-8z032(YW|0$f%M?&NL}+M!<9~4wnQw(agB~o% zyBlYJ^zhh!Aqde`k3|g?1s-;z(;b} z^14Qv-Mte$e|`|rqxH8Zh*0!^Mn>iOiI(Tm^8J>YPH3m)|3MPW(T*!DYN>>3U!2Br zd8x&Y?XaiYB?)FgFuMc+6}W<$-fcwj!&GMP}c6-(KnmsY9c+6%f)EO*6tK1P&%s5pP zWLco=1*aX?mkKW1kX$3>8+ub&>xt9;FtQ;SgEW-EF1iC1J%ieac}-lCd7Wt(nx&!f zj&5e6Qf-c5=a7xS$t(#zCC1O-v&NR}!gq3^pLO})KztKvk7E4%*(m<#2i$vqq4MYM zOFBeVxMHArVvX)nuaGTZmLUCU+Gvr(nDotw|D3ZFJWlXq-cdKlV_9R~z5RDW_+vD* z`OQ=dzrFkS8<&xcPa@i~U!|PvRIsSX{DAZTYoRONtHs|eQOnt;@BqWMBbP8~#Kw5L z3ERdK`^C`)FhdY7EYX$hbJ@FpSLqd}<0N$)gnPp$M6bS)Jv>LJR9e5fBfrx^wsX|C z$MJInIA>s1Tn?&m(h~FsB#M~TLh7V9h{r%eM3?G-O1XKmjZaP!fIC)WI}Pg%?G>hD z<6#C0dy-1;uYnu)YvJNm)H!qS@YmiJoe?rHg7W&cr(Wow@Iv|c ztsD4DZ7irHNm}+nYy8`?7kW`x^9-Lf-lK`VYjR`{3V_Kxc`Rj+@{#XIXRu2EWZk-@ zCp{!oC(gCx&(=UZuW$B$_0Z32-zL#3Bdah|S7Md}w5dDU);}T^MB$wHMgT3=TV=M6oC9?{CYilW}9Ft!TEd^1DmmARt z0DAC!{#~{aHZ!_Ma*)#1QVUn@^!RA?PpmJ_!vzmUg4Q7b;?lQ&iR}(_gK;qRtSBZG zIWFko-{jt0{u!Ggu$P3LY}+oMPE-EEam2_cj==6jUM!NOFS3iOm-Q95w61ViNs_j3 zK73?ucw(aL=h~F?rcd-`oK`Ig?<23h1KlkLD3$Oddd~#n)MqJT^g0O`_+w*R@$A9L zv7Ozy5Q!HbnyplS!d=NBrGv5=2UIHuQWfeYet6=7Yfu-;vowPSKS%hFo}LOnKXGy6dp(R|!q zO_nvzWxaxbxVvwx`q%PFHQua0?3~87sN6h-KzZxf1)w}9Y!$^3R|+62SIT1E`4!?z z!uZqzNko)Z0LlyDE*cCEg>44i8UsZM#cNCVC7hO%hKIdbZ&rl=``F`qa`!hSm)YFSSpv*Ik*lZ&!YQxl6xiadHo!db(Ld^sA*iIf%S= zdn`XT2>O*`x64o#U6AZIvvgPN5hqjBr>}l{z~OXC)WR@Qt`*i)a$PT$Elf94 zwKtf50=XT*vs15SeSm+JWkusJ6c2E$uKkj^EW4??<)xh9gm*cy`@M2? zi&3HO@Bl<|_{Y~_yY*tljA?Me>o&M^8;bmY!u}>F6xoh1RmRYPFzCjeGLInlG~dKZ zeI#5NTp}~=i5i&4l$r-};pRXbv4G&CsPaKFDAZZzF||?1x*Hqq8;`Biy@!1j?P^&8 z$>Qv1D&K+0&wV44zsTN*Zf388tx)1k5<_qkAe@P0o@9z(Nt>&G z{Q-GmA!A>Jdsr#_ls&FgfE<@Xn6j_j5ub)X#?W$$7sxhEMAp_fE+EER%o2C;OT4*j zh^z2OCC33LR{R>*a^$yEEW^@Z1f3Aya9D||fWkajVSY(#>}8P(OWTl?xqBA4QRYX| zZk=T7E9in^mlX!-_FkDLEKF=smrf3U`N#bF;Vuz&II(c-pZ7kU$Dw~>b8=r$QCSpX zzU9c-xB2yI_LL&x6!{fM1f=eF83a_j1bh1gGV!%|TUQ4kQl$wbO)HlnRTs|=5 z_wh=>jWv*6d4o%mbn~l(Z+T(?HWh2TvKE=(dAYUcGZxhj7o4j1?4RVn$S(Yepx1iW4e*8FFqb_h5kMLCt=nIkoHuOS z!uTgAfrAgff7FyZBpVPliBJ{P#CAf3msx~GU}EVZ2`k4oARTG;!msN`$0juG-BOp7c~Hcc@3A1X8}C{q?gNQ0UKPw!RwL=rBGOGKM^1sjl2N9 zzgQQl;!AC09lyGIa&4-c0EX#qI}aW5=tmzP0l0UHtk z)5-W%I9_yNdypJa^j1dkIhSr}0UUp8=&?9b+M53Chrqk(Zk3HDJ_wEe_V5oV9<)5& ziEKF`Mx|Kn&G;PP^Wd9Pr5^S9smuT4;_&NR3(?EUkt3_+?y^kFQ=ywe;jtoPWj*kk zn}eZB>slptp8kc0p1!JLj5nSLpYE-Q6kZ zhJCB(l|MdaADdY$B^vf@B5i;Ae`vdQ=Cpwz{8uPR!5A5&K#CL|7x9eU$+*tM9vc@4 z10f#%eRl7Gr2BU7PD1YDAnEqr`~1EE7yn(6$$#e9M4=A}`ECfSTo1#I5=DN5SRhfUIUsjQN)N=Fm zqU&30jwWZXe)K9jUt&Urw&IBl(mA`_BA)&_?iosp_z(>br~C6uJKz=Zdik<<1f3aK zf@CGS5ExQNJRAe2jy40p|LEOywE0G9INf8^)bxhQw@pl0on@uFGVQ|`oo|AdxR-Eg z}S%-Wc2OV0OZULeUhAOhJ*u&$yeZynDYP7m z1}MW_s~=3xN+EzOK0@G)H(>yq7!G3&^tC+nMNxng?$H#Z*o0B4ol788vVT3~oC>f2 zv{}D~P`|7GTp@o${NukDgEBdNKa!JS%dq0lTS5z_oZuG18F2w1x(r)PjF_6Hgv_>3qUJ+qsNSi60Go z>$WAi1LYdS9vhCx8#BL)J)U$15v!v3;>C_2)O0l&J9YQ8-C+K+M9kWARf#ENPBkyl zIB@tlYfQ;;p1Bf})^j^as5%KZoeM?_y!T2QS5#V}dIb&tV7k#blf7Ro-;ymUD|aqz zJ$ZIBI+K4|H;Bk`sr*%mZbrX+O3<@6j?Mhm1wba}yVvua-{#!C&BNV2+5Er1f!#%( zjy^6h3-1Y8$|=^OH|p@a{3MbLQ&1vQ*@E>qhTTsZ}o<6ToVjU(6nG32T?Cyu?Uk&N>SD* z5S>3dvYl2& z(F}jGrip@sU~CDZjCagKAUmtI;FRa9rIm7FqFe)yJ+SwN$OGvgy-vkpA`I*=q}XKj zw^x4#H9;{EGICpcCp-hm3YndkVX(I8P~x|L5_#HzU4wdJOu4S)i_Tv{cI&}56`qa(+jlWbzSL)tGWxn9~RKGJ^$<}KI|8m z{ebK4nITls@)mK3gxGhk4u`+r{{xee0~7`PIO*C_x36yjCINrJPQx$|MDIxaL*#qn zxM_h}X(|Egi3%iA6>+odO>2?Zk!?u(_c%!#Qo(_vcW2+uteh?nRT+GNu~MrAB2kP2 zP+SYCb_=x0SK%EBtYb>BQY%=XBUrS|uCG#FQ?3oX7+r&L5^Uf}%2Hl0(B8S4Vr=;y zDrO_EP`+7cQ!#(%pJs<^#y{8&@Fb3Ja0QMD<``~)VLcGh2`Tu1tUpcJ0R+cTLIuiM zOd^7Rv<^&V{~YK#BV{GsvG$oxcE@bN`{tlNSUCurriq%Qv*G;{{I-62?V^TKwYTDc zvQ%)&4KSxowwByzs|y!A7lq^yY%G`*j}+}SOJ?2LAHGbGAnuP@zD@D(s>gOIdNzo_ z`=Wh{b7z}8JmxEuO=2<+<7r6ZoXqHq&}91FF1?s(Q%0}1Cydrx@-0017B)^!0+0hN~}b^$s8<(FV~0VW&g&)?C` zl>h+8nFIhB0000000000000000A!b;b^$9Jx#U4W9l`(r&in%a6aWAK0000000000 z003y0=XL=n8~ixw+EM`k0B8aL01*HH00000000000002DmnnAvJ^?_NXm Date: Fri, 12 Apr 2019 00:53:51 +0100 Subject: [PATCH 6/6] first working version --- .../remove_background_trait_links.py | 131 ++++++++++++------ 1 file changed, 92 insertions(+), 39 deletions(-) mode change 100644 => 100755 trait-representation-migration/remove_background_trait_links.py diff --git a/trait-representation-migration/remove_background_trait_links.py b/trait-representation-migration/remove_background_trait_links.py old mode 100644 new mode 100755 index 97d779e..97a24a2 --- a/trait-representation-migration/remove_background_trait_links.py +++ b/trait-representation-migration/remove_background_trait_links.py @@ -1,6 +1,6 @@ # Activate Python venv for the script - uncomment to run script on commandline -activate_this_file = "/path/to/bin/activate_this.py" -execfile(activate_this_file, dict(__file__ = activate_this_file)) +# activate_this_file = "/path/to/bin/activate_this.py" +# execfile(activate_this_file, dict(__file__ = activate_this_file)) import cx_Oracle import contextlib @@ -24,37 +24,54 @@ def read_file(filename): filename: Name of file provided as a commandline argument. Returns: - data: File object. + data_map: Dictionary with the STUDY_ID as the key and a + list of EFO_IDs as the dictionary value. ''' - data = [] with open(filename, 'r') as file: lines = file.readlines()[1:] - for line in lines: - formatted_line = line.split('\t') + return lines - study_accession = formatted_line[2].strip() - background_column = formatted_line[4].strip() +def process_file_contents(file_data, efo_map, cursor): + ''' + Extract fields of interest from the file and clean-up values. - delimiter = '||' + Args: + file_data: Contents of the file. + ''' - if not background_column == '': - study_traits = {} - if delimiter in background_column: - background_column = background_column.split(delimiter) - background_traits = [item.strip().lower() for item in background_column] - else: - background_traits = background_column.strip().lower() - - study_traits[study_accession] = background_traits - data.append(study_traits) - else: - pass + count = 0 + + for line in file_data: + formatted_line = line.split('\t') + + study_accession = formatted_line[2].strip() + study_id = _get_study_id(study_accession) + + background_column = formatted_line[4].strip() - return data + delimiter = '||' + if not background_column == '': + count += 1 + # print('\nCount: {} StudyID: {} Accession: {}'.format(count, study_id, study_accession)) + + if delimiter in background_column: + background_column = background_column.split(delimiter) + + for background_trait in background_column: + # Get the EFO_ID + background_trait_id = efo_map[background_trait.strip().lower()] + # print('TID: {}'.format(background_trait_id)) + _execute_delete_query(cursor, study_id, background_trait_id) + else: + # Get the EFO_ID + background_trait_id = efo_map[background_column.strip().lower()] + # print('TID: {}'.format(background_trait_id)) + _execute_delete_query(cursor, study_id, background_trait_id) + def database_connection(DATABASE_NAME): ''' @@ -77,7 +94,7 @@ def database_connection(DATABASE_NAME): cursor = connection.cursor() - return cursor + return connection, cursor except cx_Oracle.DatabaseError, exception: print exception @@ -88,7 +105,7 @@ def get_efo_id_map(cursor): Get mapping of term labels to EFO IDs. Args: - cursor: Database cursor object. + cursor (object): Database cursor object. Returns: @@ -105,14 +122,39 @@ def get_efo_id_map(cursor): efo_data = cursor.fetchall() for row in tqdm(efo_data, desc='Build EFO map'): - efo_map[row[0]] = row[1] + # Key is Trait, Value is ID + efo_map[row[1]] = row[0] return efo_map -def _execute_query(cursor, query): +def _get_study_id(accession): + ''' + Query the STUDY table with the accession to get the Study ID. + + Args: + accession (str): study accession parsed from input file + + Returns: + study_id (int): STUDY.ID, the primary key for the row with the study accession. + ''' + + study_sql = ''' + SELECT ID + FROM STUDY + WHERE ACCESSION_ID = '{}' + '''.format(accession) + + cursor.execute(study_sql) + study_id = cursor.fetchone() + + return study_id[0] + + + +def _execute_delete_query(cursor, study_id, efo_trait_id): ''' - Run the query. + Delete row from STUDY_EFO_TRAIT table. Args: query (str): The query to run. @@ -120,14 +162,18 @@ def _execute_query(cursor, query): Raises: ''' - cursor.execute(query) + study_efo_trait_delete_sql = ''' + DELETE FROM STUDY_EFO_TRAIT + WHERE STUDY_ID = '{}' AND EFO_TRAIT_ID = '{}' + '''.format(study_id, efo_trait_id) + + cursor.execute(study_efo_trait_delete_sql) # commit or rollback changes - # if args.mode == 'production': - # cursor.execute('COMMIT') - # else: - # cursor.execute('ROLLBACK') - pass + if args.mode == 'production': + cursor.execute('COMMIT') + else: + cursor.execute('ROLLBACK') if __name__ == '__main__': @@ -148,13 +194,20 @@ def _execute_query(cursor, query): global DATABASE_NAME DATABASE_NAME = args.database - read_file(args.filename) - - # cursor = database_connection() + # Get database connection + conn, cursor = database_connection(args.database) - # get_efo_id_map(cursor) + # Create map of Trait labels and EFO_IDs + efo_map = get_efo_id_map(cursor) + + # Read data file + data = read_file(args.filename) + + # Format column values and remove STUDY_EFO_TRAIT link + process_file_contents(data, efo_map, cursor) + + # Close database connection + conn.close() - # remove_study_efo_trait_links() -

    • |)RT&jDv(uj0oDc zjn+8aRfJc!d|bxO$2uq8;J$e`HdL>vl!XWNqc6Ytiu7h|=z?>@(V*n_wV#LQTN`d` zWJ?F;y?R=BWaY8i7e!S|)b#B>&X>#3H3g=!n?umDJfiF-=Nk)gfu!OLYrig+%0XJa zft~b3zPpWJ+U+l|I=?K~@k8SN`qwX@^JP17neegP2XAHK`ZUsU3)$2FlJD1iK#@q! z)+3=}IYssy05TURX@!(aWpkHPoyPwV|r-MX8y+ zbN%$`y^FVVmC5N_3l9hBZ^S<4%e`6w-rxYv(;?aA+Mk$APJ-KqK`|LnTRD$3AAK{l zP{~n0RCG45;MGp-^x^Yj_Qr-RsWuqSJ?d07~IQ#37u> zap>K2UsH>@0%1DZe|TEg%f}Jq@(MSXr$6-RQ+)S|MVp(&ZjEu(eL?8L?Ae#uCI|L&A?X({lK?+`xi{(lZzuf@FVyXG}y%qg%8JV$@xqRQOHt8Lvo$iP-*$Rs?N8%?{vGdB9@Qg2HX7&qe$)Vh;KN9w^l zhZ!McjWw}Y{=_;C8Qv|hs`k2nSKoQInfS!G)@@Y+0RQsRUvhNsi@Ppm_6vUSxo`1N zfs1gT2ndN7HmqMA+UUnrd-?By{I%3P>B5+ou8~YEh9wF3!%r%6*m%Nj_G3lrKbi#8 zE)(aD3~WQj31O@14Tl&@kkmG3H$}$Hdx!{n4eS^X&SA?4ds7FJnrOw`v-W|8n*U!F zS0B&x_Q$sr($7%*xw4`O4hka9BTWZ{`hvjK1vZT@j zmNJWem!4P}kz&`=c0Dy(tIZa_Go#yY|9#KvobT(L&v~EE`~7);&ug5iH43Dpd=cQ* zOy6H#(m~b(ua_CV-~uE-c8Mr&s!z^*{gN+21w1?bWlOuu=aF-DZ7A?2qXTNedxaQ) zl^UJXuH0~XLg&8P0bpYORRZ$zQh*yKZ@I^j+jj?orp9*zAE=@O&61gbO8xn}XgmDV zK2Sa`QGprF>SN#Pk9_vP4g%G4BQ!6Mg)X{WoCC%8Ku)R+erZW-xtbDWC}m9ttT8dn zq%mdA4w4jR32L&rh&&hOzC+sL6g6M@r~lw5AZv>i`h5-uX89gOiuNgkGV#MQN~sv5 z#)m_k3|Dc?Fu>lb-uw@A^++{Tm+Mg6t=if0ATLRwrdvP|INE8}|B#Xl)s>X5Vm6a( zpr0xY)%FvZ?#$J&pSrjXxi*p<`0!B} z4VZ-6)oI;F6~W^Z;%pO@4Mcq*&Zb7hwf{(RZ654PM_1>ASejnSnlQQ#+yvh7vL<4V z&;`=%Jr7nF|CUE}AOj9nYYDKrH~TQ0R2zvsE7g0V6%!IWf0TS)S1&+fY!%(q6lPg! zkDNI->8iVtj?EE8D2y$IdT3W~t!8tbG)Y}=N=d?aB3V>2nej$8R zXhIHxP{r{tTkH|KeaQjpI?2)l$4qjjOk~&?kg|TAKi1nH0>8bJs_nVGLJbU2v|wXi z;4RtU#iKoxiK3`)7!7-!Y|%Js227?o2#Kohvi^b%Up$ce;)$UG65-Y&(^~ZOk`wnX(uQJaODa|BR`$|O z55gvQ$4NQiswIw9wGt~mh9fmrop9$n>y^9A34;QNZ-cmS?c%l zRKEUZcB#VgusVC<)wRt!>~8h$ga#B?VSTKJ>iT6?M_^rDAE-n3N-uwA^5W=xVPuJE z_S2?t9OM{l&oFH7#fP?>=%%l~kGz+(``mu7_?$=P0iap3$3LkX-G*O-G)-}cn$ZvU z-#qS4?kK(9!u2v9w@%t)Now7-g7V*zZHQefGj0dq2xP7_#%Tso^q+*S-ls%FmAUXD zs-)V|VwA|ty7S`&(4Guv-G)ppW8PpZAcVRxkE_xbPkgXDJFu;!FENzpv4*IQ7GQ<4 z%^dgAZ}j%=)#?`tuGpX2uZzY3aJk)&f&E-PM1zCa1 zf^um_S{ymY*IY@b2d&~qkV<#FIfEF9{gX&0*gY)}oT*z@f6EVAaZ~Ft)xS5_Zqr8# zE1ew0Tdd$p_?TE2$}A|`vVQ=f6E+gB6X%&W=2mrPb8j8nY+NX@r%~P3BrJ=->{NGu zFBTRJ`P-M?OVaZGct__dQ%u*BD!LtNhlM7kZEHMp6*eZvkO@{t8Zv2&^y?|tjmaFM z=5X2KU?+%Y?rKQ=YGZ5oHhIpQWVqHPh#Q`6V{Ywd+J3cn#?wC+IQN_-Aa9?b_=cQDy$vQ3+G#bE?SA1PT0uepbC} z#}_j~mLEqhYDw##Or;>{#1icp=t!^1ZbtutFE}(kR7cgWv_3u2U#2=KFX9gITeyX6 zgFXj$g9!ez%v$Nn$$f>lQeDOeXXM;3Qd>`VcMeJUX=?bLXS)2;03RZy$|of}Zo0IS zlH9~IQ6ONaOj7Q>S?-OP7d*@!KU^w{dB7?w&TJVCnbqw?d_$6?7RxssF(&E$$? zdeB$d5PkzmHX;tRtt^IQgO8lnSru%Qbbri0p4LUf`6|9R`~la?m@<@Y=|!uC~fZT@cw@)he2SXAz;4~@atL89UVMV=9&yqm6$b)KB>7 zl3}jlxWo1XJ>4tocl=@gAvd(%e^Pv-nXoq1k@8q^H6t5;umFt~TA%m-ZKK{mtZ#qe z%fHXQik|9S&$*PC@%i_WswvMc^uVRAdHmsV$}!F8BJm3@Eki>UYWBJ#@IsBnBHy$? zq6Q4Mg279MqfE=BIJ4E@5xp1&(}jKiyTDjMfV;wn7@-8XrKyM~XluOygEi+Zgf0KR z8!VcUPk?*FV;FxC;8v!p4Gf0EU@;3|FoXZ=$7Uc?;2!WzjHnd2h34{P&+5ue`o?(F=M+uPBh?8ThZoG78c>HAx{wd@ZinauQ_M18`-Pa3eR>@LVhVOB&53hxTc zi)C;9-zIM}see(PcqDB13jWr{diYr}t(WoUyg+H)S~0iSzR}y`!V>S+oQB+rcdV|| zg?6T6I>3>`hBWWrfGq#BO?Qqz3y5$DEHob>56W^8ik^=SdP+~s3WqnL!AL!nWc6V?NjuLPx;~|hz|cC@mUEP>>j5K| zK!eshZINNRxzZ>Z4s4oD$Ic^>pG!hh-pz#%QbNAs1z`>uy2K~HWTN<*i(Zvqy1Y3C zm6_o4Ul444Z)uQmg#122-g$Q0Yb49cFHv#~XsKe|0p3cE)gfMn#CS4@I0e>Dko#gxx@->l_%jJM#y3Emvs6Lbe+te#{4mWI0YI`3#QF`2Y52u6aI1AQ`^$yY7fsPLr@|cr zpmBxKoZeXbEudMz3ayD7x_C1i;$*XW_@EEJ6W|07FO4eMCBs>>$e509$Z#A(M`aH7 zs7vi9AAOE<qQ zJotXoMQU%zB+-ZtY)~?}s z=ltQ1EloJ{{u1jG2V4*1aJHY=!H>}vY%gX%3kYzZHuetr%ukc;DzaGXx;;<7o*=zl zt!w(ie6=n%z0w|C<8v0@JOiL5C18*M&`Dt>S}-#Az{te=FEZWSUprX2-Nofs9b@NA zUK0P@ueZqa>;t0jiL3<%i3~3`id41>nji6YeUyoJ6|b_p^`CkIyZ9o!UDJd#-Etd| zS~a%`_=O$2Q}Q`Ik?&+gGP-0?d)SgrWjmJ89jAXR2^D!W9!#FLF<#E0u3|E$9^4qT8e=S*)%|74{~wND15E4VJk zFGx7^8kx}@4$hukNM-feJctng?w zWg)k9)~!!f>RnlvY*4evY8wezY*kB@JGnL0Gc?7!&p%A?>a7l-kIlI<`Yy~qy$y1_ zoN0W&0dW>8?mz3nQ^qYcb1v(C5oX|;YWVQ)M~}nzRg*Iv1=l!_-DXE6dzLE|X$fmq zvgLNnKDW4;WETx#Y84??T^?-vPSx0v84QYX;l@vu%}*C=rf?}zV3=;0=Ll%AtJFC* zUdINYRZ{%Dn$6J$79)M9)r0=%Fm)IOKX6%@30olea1}89+k-etMq#rOtMcdVRA*k1 zC@Qy7qRm!$qmnY=-E$n3nyCTjkG38p7YtC`<%Do_icvUntaNXI1LqLJA*V& z9mKI?x9mukM^5;EyL>**``|uMXLbOMLKAR~Evk*N+v*;z0Xpe%ymKdl9qQ}Fnxgkz zuOe0)IG%h9m?ZNoR>L7$UOwwTDUzw7C3YNqf%leHa!jY1{I*FiAnh|xVq3cRKm>8D z?H{%Lzq1h?ldqbe7MY;R1Mof9pt02NfdUkVqo(r%yZ z883Z)>4lSs|AWj7pO>5}di6j})9|5LqM`hFl|Sa;BFjhCYB&E+c{8qPb5+ec*1B7R zk>Qcw4UV^4udcTo%?Z>|;&Z_i}{uIz8GX5Pl} zEM8w73{5ol?&jPs?*pBO!1;~LZL#z1$gwv@HP_+xy0Jt&+{a<$=Z3$SDx8|GV}yjt4NoYW6?O1H98roBYo&77jH8{0?t& z#Bu`8{~mwpJ)HQ|+T!nbxM+CVN}o0yl#fw{twr z{?{AV6K{)6r30u1TF=~voNj)1|Lz{p&9!-Txtmc$3BtzJ^>J0;RO!X-G_%LVYW>Bg zWhdZLb$)0G4CHQJiva%Dhh8JMyK$XPS7y?~rq`kxG6COw$>U6~_c}*`$?LOayVgy> zuP*E4cK7^r@#acg$NS61%w?}>i|>v6=}=*2!}THABGBmc;r94q-IZhSw2l5(DbiQDlhemQ=m#EY!`Yitz~Fk>$N75h z60nhJzS{Hl@i}ZYy}jC>szcQ^<5)!MjXbvXm!GTLWJJDKDZx6ysl z*MC^tbo-0w&D!}p2?j_uD|z?i%T{(5W&AFePR}q}E<#-0;lLfGb(|G?gr&u|V5sp2~ML~!+}I((4=xLtj- zjF$B3x=;ZvT^Ki!TtCfLvmjkXVl0e*+22X|@6z(u6TVArRE06YmS6(gz{7V87UZub7u);j`Nv|7)`m|<*+6!%H2O8R>? zzUkz>miJz|lt|)F8Tg<$w(0YcIpzJ&Z~Ha{UeA(u09nn8w+>|{FPXo3 zIA&3-GmsReO;YkFPb8Sqqvz}at<-jsYj_ixU8DlNp<&InXFCEAFcDQ7>f58O% z>Mn#o`mY<10S7|&Y=#S2leiVrJ*+JL?#|X~Zbwbc_LQebOz}_Js9NvnD%P7;fAJ}I z)V^H$*6#+pe#ygn8kjea0ovmyxXQl4-=K(_Z)86{zj)@Wrv~o5#&z?*C5Yr{M;F*I%ZDeSae$rz{l`p;p&f|*hdKvFnzXRiOIz~52poKNFKQoq(Bxm?YP znS5E^Ro)WAEpezHoG}9X;itn7t^=#R5N_BSvVq!5t3Er_?*r99%x}!CErI*aedNxW z`-r4DHsvKXyX#AOpvCvZ&;HpDdnNuS-ecl8AzOJ+Ma}-{L z;h&oKZ`{h_*nq?JW&9HTb>Mrf9xx+Y+!-LHPUvgGdK>vC)?6HtZ}!E5e$@ZB9==}~ z(N|w&DF*LL>UG=ZdBobIf|k=Zdn}|lciWK>IP?o~_Gp&Q!mjN70)_<_5_8V|tBDhH zFo5TnwNA4o{5);{VLpY+JyWI4W1YO|(Vo&+#dAhvk5Ly_7WOso z@m`Z7#jC*S&deDxj)I%w4g77M&EgsDBGlzmh7qr?2%nHc5zy+Q1c~51~Aq*#Yx*C<6UqTH>jwEEx@;v`8*(l^F)=~ zrrDCEqtPjQHSw9lG!sf~gS4d97E4*NKU~pX9o)^8vsr`W*_vk=?5p*?1KToL1b^`@tU0y zQa7`~4bz)0&vp43n@R8Fq6sXj+#TN19Ou5Hbqjvlxj1rX@!v7E48azycTC#`r|t=u zVnuJiy60zXC{zr)v4#S`mK^mxfo8P9BXr(}yXc~?4YE1LTW)gxyGryxRX* z$Hop1mO@7KJ93Xx(FFAG4md~K4CE)W40JNY02er9WDwfhFrRwmF z1`BCOP3`z8zq0%(PVa!+oXzSxFTNe=-TL^7RVmu(2N;8s_x`)G%7#C~PRL$a;O|nm z8U62ilbP7$P-D!@q4!eW{h})P&3u~0ojS1{HR2EEHdwRDpE7ey ze+z1~Q9r{5*HyY3%Q~KZ(QzZ!a&un31WhB=XdC3aXW_ven1uQFe>&2VlUiTzL(&MM z1HXuqwasj3cicRc19rdr2>!nv$9D8>Y;l+Y^rpJKPhBvI#2(C1I7JtU1%l=@19;39 zKfZVn2cE`CbL^OPY&6Y(!wIj=tBuS=l#~vGF!P6~D6%u2LoWvmo2G`WzlpWsat2c9 zq1ga82%|++RE@#A4xLSOwW<4QpK)B48i13Ox|a9~;3oYuPUQlXc*bX(d`FS>wZW{r z*Vn#vjs?#2X-~&0Ve~8+qnVOvXkGa;Z}I%u+}PSO(M^lting}ExpSPe25BUqXCyZ6(3dKk5`+)G!+{4X(EU+REYo8I$Fc8&DE@{l;&>!Bd%xS69hQ zq6jDL6dz^jfuB;@8eg$ORVN-;|9@BYWNGMiNa!yN@VINlx7UJLbVm4nkRMk6TVCd? z8Q@*{@2JiGJNIFo;zUxa*)rt+hLJf_lAC`xkBs)_(#2BBP^0h_s`jrWBmul`?t-eS zY4b)w(N6eth@Yt_rk{B2t13&v-`y8N)y4}B<&~yAjME8AVJ^Gs=QdWo0PkwLx zDz&`-R+yi_^Nav=k?5MvNOH#&WgQpg!3dFuh&%#E6W%?^CD-h2AFur*RD|fly}cY^ zS3j+xEgJT|_I@YsjAOMWza6GwER7{jJN93vrJ5-uAAI9kWh%=s=Qr$uu5))pR$Osc z5>~^`heX!0txbf!YfRl{tnybI**}B(PRX$vF&_(X7D5#K$lTF(;OpLt0g;WGk;U*A ziDBN)i}9+}J#78aag;uY8q>Py0;Bt!e~d+?Bh(km6COgN#rtve0D$*=D_B2I{%9UFOvA>BhFGNt>XDV}H>^(^eZ|#*LgR>1M z(RF=EG)s;i8P@cOiqtkMWXhXU`RGxziJWY~dr+E>*bNN_3jhfqM+@}GB(Q@uz;J)Q87_q*Obv_PZ_h6j{MEYiF zNya=cjLv(>cwx&^?bWuxO1(R$;VOdIA7o9~i=5l5iOvLA9b?LrX(YPUi&EUx(v5Si;O-DGd0cj0!-{*viq1^DflTL3DM8GY*aj6!Ze%3g@S%TJCL*$q90BiSl zAKCH(D@88li+)xGI)|^34p{R!#U!;EoV|_UGOiYv;Px~zDD|PSz8_=G7#Drwwu|em zNZLSx%p)G4Y<$50@dV)XRc02>9x^DMQ;eOtiXn2i4$xWhaF_C0TiuqdyE0hQQGxb6 z*t0Ad#XW>G-<&(_+^t5jDAG!hkDz#?oE7sKg)_fI;&K|0=;~0GY|T`9%3(#4_eR)B z`5MthJI~rZ6ZN1x=%=p}xrZtIOLz)tO|Amq?%Ui4*kD;G`J3IPAihb3mqw#i2(O}lG;_a z!Cm+f5&Hq$Iu1(AD z`xM7cqsIOx+IB<=?15$+<+d@ffnVqAu7a%>Nsv$C75CYDV@wtLMtLwsLUlao5}_j3 zuH^?hYell4)FUYhW45unOLIATad*be%U=9Cio!Z-;IFp;qKBYfvoKVyYXeTxfS1pN z+MQ=@pD`76YocUUPns_Q6^!)E&)(c7S>#2)5}RMkM0@2ItS3;u01&JSq|So%DEzt# zZ9{YN8Ip(;t@#)&$-{uC*@f$N-LLy_8u8d|7AV#w7RypI z+9~mMbHa597!Zc3ka^vWmS{PWtCp>6ro7BNCl+?UB$W+Vtsr!HyDbW3k)g@i@Bb#n zp7Fx+ZJNZ`y(~T8HZEm+|3viu{8OruVdSi`5y{yD_%|Z|gPXv$b9KoLDiH8|Gjy{G z&v1G~inEFQR4LwsU#OcPu$(-|P&?yu(PkTEPonnqN6HJ>ry~v){}j5TPC!qj@e7&@ zsaR5Vw12waJ!SGbCZcUgmO%EyM$>1TnuXw2k zrFQ0~tgCnE&U`?*ldjc6ml&Evh76h;V??b~k=k$xN(;K0u3MH&sVv$Umm@-(|o}x`XFNMN?D)0P_#zFL8iO>IYw3m-uhWnvCg>N zmV&D5fm>@^xkh@~jAi=MUbuhzQh@rG0GnQrT!uVDe7o4^-;qz1n$={rP_=2xO@>RAV^BZMJcN zFb4+~rY2e06g(LwM7LcvsDi5Hd>O#)9cF3x&O{jf`O`Zb1diQVM9K$S+UBCbSViEK6~G-mSo91r|51_QO0+uIcf}j0 zg&Z(eQBOkjClKLhMw>gumfY;qFas{8Y}C6PcM*!#ifdPvUg^nzs>*hn^1H*1L>D*lGE*}rE}o&CQ94V>=KN) zld39gjbRfV%$+%n)zg&3Xom8~DP1fQnt@r(Wo32mQi2TO_vXdloLzq!+ZZSN-FvBv zuw<~|k-+FZ5$pc&Q7Cj^Wa5e4&CCwYP{9PjVdR^hsEATTui zElPvw<&q5HD$?!GJAYG>dWqzLncv%98ytU?RP7He)jjv?WbI?g$UC5=HU(kP((n0t z?+M3WN(S$GtK>g8lyK-U!e4=pdKb=?Q?9LY%x{nBXnR~e+{Pt{Q5(zaf-@An3g(*= zD;D(R>VYscuY9IOWZ})=`9g{36<$8#JnZ|kVa{7x36xXvACAYn1N%8zux3n~h8x-aLLLdMy?)%1PU>{renN z6wIofwUjQ+$CafaRe->|7t!YpzC|VRyJKH}x1}I@CPMP>mQ8lhr4%zME)561(ucam z=aDvC^@^TVm0GYd^}ae{qJeb9O+7XWz}cXu%fE1T-y%OHuicBNg_E3_Xd!BxAz#c_ z^HCjXVUUgfS>6-6KVRo$RcmE9a=7bU zPdSS_Q?!|K-?H!`k#42mDY_%ZhiUljlO-cI@IvX2)tfSL@BRwlxU^3u&5pPP5Z{OZ z8$}zC<|T@V@n64hVG6IWqRfwX=|Oy>=)7B$!YHD8152{Cn4LnNC-|KNhd73f=D9-F z3z?;|3pQ!1;$ivL`mfis;jIEz%Xh?2n4vN^IVb#ZELb#zW1p$+gjselWx+_WM#-U7 zIB!=tS}QAVlYHc2=Z*I(Ai0GHYW{ialjdV#*(@ylaDh6QO|S0$(O4d+D9$gC26=`w zx_2)Wa_n#$yLzp^+7a;mx~3YO#&Ox8RWyK>rMT`w;s~#@usXdX>sgy>G3-$D6Nd2m zYS2X%SfgvBF-RU%WiIT%Z7Y|h9@vavMgK~W}K}&hH5XU-PrN^veh`jYbo&@gA1j6Q3^#0y_ z?5vw4C0d(EwEas$k!W@+5(d3`0ig{VQQD~pLpbPKnrI{Zk&1a$mDfy+mCx6ku}yY> z>0?o%+GzCUg_6c$tCJ{*6&SUcmDQMS;&aD2vv+A-jw3it!oDz6wRO|Tx>Z^GA;_(q zmA0p5KEuDH(%b>BI=YixBI@}`k6Ej-9w?4R)(EOV_`E3Za(7M#$Xod%f0QKBS@VD! zl(5&JIvs@8P4-7rLy7?J8_5^2t}VsNS2hj5ySP+)z2^ej919`f_COGC@28$*ij{J? zqhtAKcVF>8Q6C9NC~3OQfyoYJXCq8)8pR)Mgms-HMR&N%hF4#H_D<4Jy(b)Nmf~QK zaS>ZZ^W|A&_4(7RA+M#a0Ct*%Kxfmdo9kL0lkV0 z-qE|)V6Od==&H)*q@RfLWp^=hziKJ<0U0Os4Y;5%$O(f?rEv2N{50O|2)G8A272qL zu>&2FuTKH*a8v+!Skb7&t*x-~JA@CUr}X-%ZD=J84PO}bC-1ijy5D0goj_Mm&h z&r>t4Y4I|G=I^gz=hL?GB#e1>%eHbL2}2U6g;{FQJ5PUzeqVXc_Pj4NXI__Yw_W!u!=AgSBOumEg>3UYfrfHOxbQp+b2c)91ZDK|8-Th8d ztxREEMl-tkTa@8l+kLtau2asiFwJegsAm6ZO<-R;I`1DW^{_hR>Xn|Pb^a2JjW8U+ zTi(XaN3E}N{SU|GsG#|?MLq3z!U3{7Gu&-wN*=;NU@{1C>Q=im^`+G0PgW=LyE3%$ z0Qsm_%Eb%BMifUQGwRVm=&1&}!Qxa@TflRJNNM@?nF zuU}*^)93vdvxfD2dQFk=5cM`Ys4;)^d_nW;SeZd6tw@-{rNnB z1O_m2@%*2Jk04;0qE6}@y_Urkb@GS9d*}LLME@oA8*GDrntm$8_$P^H_1<9xC3kIv zGcy~aCduj3**xuWcLoB^u$&0P2(_NodQ%nNYO?lz4308ajc-J^ZEmeB;IVXi`zk|n zUbp^J^c|Lr+$Yf}Aloe25?8YP5l8|52DDXhKzHvpxp#m9EqaBkM*xNr$Qvw~hU|3z z*>&`wEhOm+2;gb+nyfn@0rVmXwt;cqg`o=xY@dyc2=thGT9=n`=(Q)Tdu37${~`8n zw;HIccLXlTG>3ONCYR(NJA+;W2Mj6Ho+KHvb#3T)r8!zcPM*Wb^+lW^#(* z1a<{h#)C3d$s|Wu5y9!r;PGvN-0A1>=>AEIOplGYm%j?3o0VzpJGNC=?fg^F&?npc zvEWlrZO8CN6__uMkbK_jD*+Qa})7lBl5|P>7%mvi3iK5m#OUVl%w4IQkeYQ<|5_3Q#vvy3KIHKn!l+0ZHM1cRCU2Q`A)#jfP7n*Clc)bOn}E|h>=Lbg0So)&YJj2&3#It!;06n+S%W*U zHK_pOJY;TvMF8VGCzQ+GINU!TMVsIEMX4XEekPx2kmnWVVH91RS=MhKiIPiJ6{{15 zHx#PY0SS=9D5f-1h*>B9dGu=oI|B&!ZflvPVYQ2kKuKARH;XNoZW(8ulQ6wrqs-i%6L-%juj zsb?hR>_ry-kZ0m;#Hx6ngc{B-x9`H;k$mE^ItBv{YL^lG8O`5~daPyyD4;u%g2#K$ zKW4ROD@k-_wLH~KoZV8~;K!}D;fKw?w%zzm`f{)>zl^LoOxicsm9@|D^HvXsf%+V_ zI}QB(Ausx7BwSf5?n6O+eU;%rnh$wU>06>SpZGTZ14XF+^CpsAzGQb1T~CWNY6Bs3 z%0xJTVoWDGQ!Wan411v!C;L^X@hv>`_e5=dbYP$hKe|Q%#l4p_96yU>C1Qt%W&>e zcl^BZ8IPYCyy&Vfa3pjXThg*TR6Ed_mCXY@5MMo;4s541cQx_n9hDUGykbiU5vjOQ zH&$jm{X|j2Emn0;r}Ug?1q6fd1N=mPw!}|_xy3tUNI!iw!qof`Z7Kw41XrXL(VQsC zUqVg!23?Mkb$y8XxBb?hk0bfw+lp;rY7aZDT?W4Lj$b(<_1Vq|w+BC0J3qo_ng)I7 zL=7G+m6Q-q@;fXs5H!#ZLsBmL!4Cca}9XqM||t)N?aM&g@=`8$wA?MHhR`Gyx3)jZ>=&q(|p2+%F6O# zc{8WxVTyu>H$M)B@!LpaCS2lnUeQd@Dd>oE*#+R| z%}{8Z>4-D8_lq-4n=pYlgtsmJ?WVB~?1oCgTY$5AmJOP^5`ygSy@H+qPq-1Hg1tYH zdTiH(`$HuG$YLriSeZUNSZF}G(mI{6gW3`21p)KD(Ub*CTF(cI*r|V_LP2W|`p361 zT3ir|;Bqk2GK|l3_g+uu(zUQu>TwaCH-O60JJ9Bglj%g>q#W1<=7Y0b!DemPuAn0Ez2N6N-yH*Vvghw3@dA4o@~j5hQ#qOO|PrL{5b3bI+icq$y(Q$>6M<*Z{(V#d6+1-nMmO=>6s`7XBU%p zq?HolMis4I^BIsl>EvD1i_FOJ)+873)=YyeMxI5Ku^J^(P%Eqm#LnvJzlCsY#v`q$ zVe|Y$(kJ>%9Ck7Id8Ch0^_dvkUzrg$u?|wq^Y=;f2fZ=V+~ahB58(=f{(|=$J!)n( zX+cI`diaFcDQz&GQm0=^;kG(z%6^bnESadHxKgf-qKvROG+ugTxd`^E69g*Tz%a9w zT@_vs$IgA}zg7_ff=TXA9t&?sERol2EA-(keXZJ7AoODiMlzcvFsjQq32>snKYh!W zfU{kLoAebqz)QGAksxibeCgT7*wSwx` zD0r5mqS%_)Gt{c3K$;gyBh8CY?w1|+dJ29X%cC&;(l7|eWIVF)5v)v`F;x4hHLG3f z=Phdvp9xt7^+wi9{)4_cQSqKq7>B^%I>n44^ytP<#a-T_d!EDoCz#`~TS#SH zDyHvJ-$$F01KVV@ZJLQDpdAv3IgE^BVw$dg2%TzQsWmbnfJ$K-^gRpT+2KHxrj~W6L|1_etHlTj~L3?qwuvq5OjVu;WMOT1f|$p z21Z9Lvn=`xk$2Nl6dAjhbeP&{7*%+8W$&i_u@OTo6#^lV@8CuPodu+@{h*s10lj~d zp;JP=i75?iA2}b@ChHf~WBEQP4icEw)PilXmJ%NH{K|v)08G!##_A9PYB;c%sx{gT zrmS`bIv2bv_53A*W^z(|YQ2m&(stY(>g0HxpQ_{eAsfN?pHcF`i`N;C zrr!cA+bmZ*ATZHNBF6Lg$()2lF?ILo+jj#7QC>3G0jG;oIQpTIIEL!W4IF1BE^BKK zq?zemvFAFk=nurUjyI-4CvLPLKFGS<~GoG6u>#e?zGC4CfLx2 zZiltZVVN?XL;lIw*0-uoCV z#uqO@2ul*kY8UU4QDDx_MI6 zpO?R0Pry_MCIk!1$s-2=y$yPq1RVX;0wt`;`_!ecVZNFN!3o8K7CgboQY@(ci##SS z@sgd@?^-X7>i*C$s+PO{rqi>R4K92rr#!HkFiBD~+wbJWAfe(2DS8M;+M9tlgmU%# zmjcd)D#Om{d13VDIE=jC=zyT^&Zs+|6tm{z7B7e~yLz?)GCcf$bHuTj3v#t16ux~W zEnMTRvZM$LYFmXdj*88v$uex!*#`aE{;ccS$RH_X11SPI%DFQmuLs(P>v0m!Pk->2 z^8{w~tg+f++9s^v$Q>kP1w69WYoXL+d0o$!e0U?{GTs_<4Q z2a6HV7pQlCVWPUT$sotat<~@5&Y}c;#*ZbK9U%jymSG@!zM#+F2!1LFq2_qJ5FOF| zix(H7TB=-`jKH=Nvo;Eq#xc?4kK^imQfZ|5Mv>)mW6ei)N}W%W`)?k|y@3>df|RX! zel@M6a#Ao6tDX_Jm~Z2X;C?z%?NPM&dhK>0g&AByj-C4YE?M?TRwb_L!SIY{V$2@r zIz!w}KSIU#1J7oxdA)c93KTcKFg^Nre)olg>wPC7+1{h#xJmO?OR}3$umjN=W%pmZ zlG>wgRU5v^@9$WIuD!p;sm{$!(b#|$g?GGHX+7lIFWo?f` zzjh08KgfQ=oHS_8KXl;HU|p@1D4B{YkamjJ-cs~Y;E$8**dix+QAB5$8J*tWXQc8h z#KjaU$la$nrDx0VM*~DMgbJA_espx%{anvz zwxy*O3YMxXv0Sq>t^7eT`)&>;1*Vma*H2G`CKDiWmKna&Q`(N0ahBV-u0K$ReT?K_ zR?_Bo&pR4)Wol9gjMKKJQ-tIw+TQoOJ&{Uk`v5HOLeY`Plv%Ws_qG(zZ|5wIOQ1mQ@G1#E}+ zl)oRX-x;8nfp^yEEX)c4vSr9ASO#0s6{Myl5=Q_K|m1t?3C6O>xr^N3C2nI_zzQXjK zWopk6eiPraCzwhCMxWce8NOGHdeJ)Fqorc)4KxZeZkU(P%3xaM!LA95O)}@tghuQ- zdCUE#&(DreGh|}eCdk|6(v3ixjp!BA9&+Qi%1D5G;!Z?@1^NKl8?e;VI{09plLW1c zW~wvGFnreVxP}3=4Dio1=g;^?A`bR`OA4N&aPU|d^=Lp&QhCAx!VW@Od#l<*CHI#s zMGCJY`Q!BgHOEXnz9Hu`t!~9T=lV;-{#VRbKm}?Trn16YJx3B|XAd&|f9oDU;~Je| z@`A(4B%cHy3#n8dpdBk$K-9^|_J@O8-!&nHf%PlRZ%=HJhFRJR4r7ohPFD&O3(p1+ z_8;;QuZNR+z(o3rU>I4C1x@wEruR2~#aa61^VZA2Y<2NPu+mG0TVHCG4Wa&5dia(k zuR0tEGD4lwm{_X4j77mx_O8s;+WBCRTMhjY%`{D+58I07gnGhtuwO%gG2mCz;@zzI zW&8+VHGVAXBo>r_X@)2mk$G1gpV?B|y^^&EUL0i2a6D*aI!-HfCJti@YR&^e<}ebG zR#ibC%lrkbF+>TR8%lnxZmE;OIPo60C$iHQBpO?&aJXC5hRqNeytv3}UX=?zHd3za zG?!C8ez~;vbe$$Cu@l&mA|pM>Vsjz(B@)nc4TNmgWB-o#Z+T@@Aciw6|D0gAzGQq= zEhv*0S3ploG1!-YE2=>KBvEgzL@v8p#8|nq2nYL@JAM27Tf&28Js1x43mo?oa7?>S zYzFt?_cLOrX@4bkvh|_M)4T^B!;g`~tH0+EKby?bU|WZ^SwQ=oBs|&-WenH^AB7)t)tIj2i`y5>+nJ_E} z71pOeQ6w5st_LE|p4-Wk*OO_mtweBXu>U>RrL$l;@sW-eICI#oNPBz?`(zkmQz@7R zQ4L8M?Kj^{Okq+~n!KE^Qv391YbP5J#h7!jxrElL1uTVG75K<_{{_}gvhojZ;wlFHiDXq$7`6M(S-ozC&?9$4*-WRK-^G?(HJMr(t65A&2IcetIrc8xk zQt2mqPO!UXnv3ysJgcbi)oazF#9WEp$3ZB6{$ZrYbFlX4llHXBEo0&k|G2XHx%!bb zHf5^Hy2UEbKA6||2jf5Mvt2(^AITQ!e==REHXa8)0HE_wSSxdJ{H0~Ts6Tv4aW}=$ zVl|upCe*M<;7{Y1|4{z`ryJ4i60o2&d0V3TB%J$ZVTaI}Xk=M4cEyz9SPay6w zy~MF*;$ysKwVCLX1Up9Wte+HHj1yTw#-&l$3fB56nSx(Qy7*g6-35cQ!aOcG4qUzouvQo8FRUUWR{ov{YnkHhgY zE~y17N-t;@>RZU6)5^ak3%*oYL^0lV3VQvs-z5sJmjDePB%Ghcqry}ytXAaH>i`aIYPurei}+dc~$8p9SG#4dwU28FTFJEA{j zUI$Aoa%*Q6igvt-AE8z^)gWT_y`I>T|41M9+<;G=Q%%${`}4P~d$ZWMqi|%PaEB0E zk|n^W?T1LUn+)P1>o(Cwe>us*xR*YN?f3Y(+@tSBi8br}PC8xvXK++;dvx2;FEE=J zo`GJ^e2l%%>KdifBZ5AF0e^2O2;LC?jn8lj;XdWMOFU_WCq-G-U<>*m*ZLtMcymb-$F! z@s4o0ybU!=)ZdzE2?tpm<5v*dXvF26^i*cuwHC&j{eN|0b7njWQhd%>Y5Vc6<=Vjg zft0~;%!e4xyV_1M2)6G}(_rInXY~C#5u@yq4U3g(i9nK6CVMfMUKa*w+GfB8UQ2&w zvl(wnmpYiBjkh?dRKQ3{Op@|NGfRg}r`89$SPZdy#Hkc2ot~`2V8WaeQ)VSC4^!E| zE*$+l*kSW85nWHUO3ZQChBF_f>ilLA=1ih+($hi6X#2T4JHCsjA|dM(iC>b&XqUpq z4ghkYzd=m8lK-o6`qK+quJC2>f*W2*l`Ejfjtl;m=a6I=VG8Yn;Ue=9`6R#U6Xi-s zC`9!MT~LOhj@TJr>CM_N=_*G^tr{_|r&C8rASx9~zZk*XXfi# z*sp~YlbM*8z}Jy{${?kw7^EWM3-N`y)iIASd15bjp48;0ER$?^19zff@DEmoE!QD5 z-dUxEna7{+`!fAaUiEy~$x0NF_faSI)-QJY>pcH(QQecg{`j5dYK35rROP$2kVk50 ze1NhyJ6rbWt(C`z!-*ToJKKkA!XX~1qVoEwFz${Ir@mMz6bpx3;mZoag`sqn)$S{} ze%*iaLbXdR4MOE{!t5+X&TBmyJp1N(2T{N7K?b-LHjcu~3jdgoNjZL=ldcyCYBNDa zKx%T#yZ4CyG1Mgb=gh$G+vlD&Vl^C73E2pFjLJ>FgtuW#ZM7SCUEn{H<4r%QmAd>@ zRvgf+7j>!ah;cx$@GJ|d!_O!nB9M4o=F@9#Uiqa;8{k8e+_;C*`Ea77JbI}8cLQM$Lb z$&pV!p%fPH#7#x?UX1wOBU0#S78_b^=gET`^Zazho-`-!3c~jtME7P-n4iqG+_SBi zf4%kLz0B#CL2@bI%90p|hV+%g(-vHdi9Q1KrsuSeOeCjmR}v`lZ3rGV;%7#2AYEp{ zWq!9#@3Z_T0Vwh_Kf%$mB=yudg>_@Tqp&3So4hN>1{nq5BB_1>QrM%b&mp#TEKhPZ z?xVUxVytP>`Fu{0e9qH)+CD(MtN;P}6>?v5{X<=drmNuLckHntW=1q4eugKRN01Ur zl0Y(P;f&Xo!D}m#pxWj1PkfIcwzZGZt{=Q6F~9f@gpLi}XG9k~qq>%Ii`L3BaFiJq!WOKZ=qK#Eiq`b6kzgC!A2SPIlscNc6rv z1VF>1f!OY0Kk-!@w-|v?Uvt{tkJh$*y?DTK(R`{2UuVQn5c!qzoFMf%!JDVh_v!a31gq)Zf5M27L(rzn zHb{+WZuGsf|4`?6?<+Tb$i|a<-uo<+>RkLG?iNGuX*g~0%P5*~-UHN{{I<)yXxG9& za-bJ(Si_L9q0B>wZG>82>UW4OGezJD!~aLuo5w@_eevTnmW-0M6p3u9B!xmTh{#^q z2`#qBk}dmdWG_pSiWqD5r9vcoB>OtHvdc2Iv5vj(ea%##_xJmI{Qh)a_nv$1S)S*4 z?`vkXm;SI_y(3xFK6p04IVgs*xMx1fy3hbXePr zVmd^w>2vLY`Ob(ZDqL*LTWPS)tpGa1O2!eIrqj*by=T6RoyuHgI-Rs8&{cIEQvtkh z$@M)^fcI;ZivE6R_U(dI<_|vx&tU5I{eg&sTnNJTX8WxWyWjU;YHtM}?O;Cl_M~i- zB8AukK3UZ_h}9nzp6909>LWB)P4`|xM~rutB!V8Cl?-~o>Q3(@FqptsWE&KK^1xd; zGBc(0iVxB(pO8&CfMhpDwJ%&pSchy+L3=XL?uyLs+`W|q==b*Ty|uQr-+R3f_DFXq^xLrzzQoQ&l%ydyRN`=@Y|jF*VZRUa+d@g!^aW=fs5<#ok5Td7 zwL7D`M-~Em{g8<*b`-0FN))9ll})G8R#|q7R!eSwrV&6?y0T#8D-d4i5nD8G=RD7P zX3Q*A_Z_At`0@KK%(41$ojnR3bQ`~t?p`I_`I)|V4O5zYblUtL!7m_iulgkPgHzT2 zxry+WwGrZX-Mu}>&r8Qy{>*Adzmo1+-8iyxWgmk0xvt6^*no4T7>Gce$z>1-MfYi5!su|Hmb03l@M&w0aQ>=^k2o8fHvKx?@#e0S8RuuB{ z_cRgb)~QDB2_vIzTq*=Vhu*phfX#WSlxCfwbJ(7(1LR$gzsL@ z-0=7+@-QFOMtR{LEXGJL4gbXs3FCNqhNu?ryA~_!VO#u3@P2xZ!QC z;RA`Z_fkD|e^^0Jj$-aNiVyilW-HlQ>}H(|MrPcL2+TQk^0r%lZG9)R?E3dE-a`du zo~i1ZQ)ylf&+V zm%Y#O7EBO?Cgpu$%Vt&q5ndOW1yxH-G!Pp8>7ujN3#94!ig9MN#HN@}na57BidZSC z%W7p9ty485Y+FyLzj9#3qi6QqXj#9#E}yDA;(JnL>A(TaGrQlotk7Td6(77zn9kQL zZk2F=0$2=Q^lr_?eNw>;V+ey={vQlt=KI6_DwRscVjK`>IS~C?{^~s`#WhM5?8*^! zc<~dLs%MXJ6-gj`D8n()pF43;;lGElKMWNOUL;K4*X%sNEElmhl4BMnM|?9YP;t~T zxxn(uUYWo(=82;HB3{&}_T)%}5WD9-6j#3;RD1rFL+*as_LpxE>dqb{*#r=&JEPjO zo+A#XNmKeqJQRPzo{tN{>4+Ru=4uxP4XODikr>@4Mg<8?}<9xNc9mj1O*C^AYPVrmJYh1yH= zEoHg5*leiyU!7ZRH$8wHXyTXsHXtgy@m-%6^})YMpZ56&<`ehl*=}u|I`gREP0fAQ zX&KiT+UHIbiEryRSxOCVW9&Z3G^*U@Nhf&Vq#0@3>rZbDKfd3{d2C}vkA>Us=`lmp z4JB^b;{g~uEyqJAn>eml$xoxE_l<7aGm~K3bTo~U7v5POCT0iKYZjVo1<-doR z)f{`xLKk~%oo@OJ?{M?;itO;@vs6}cDwxSYsto-%%1`WrmW8no&2l0;^|YY#xuO(= z)gBsJvBy-t`}Zridnc8JI#S4V1jVGBb2}n?tvwi-6WG!H0-+@@6N{YfGvY2lxSY(Zomf!ao!O{029@|}; z(ZBdHG!M_aRfRKDmc}KSzg#7Tpd}(dmQfJ|UwHOQ*=psZ5O*>lJwC*|QoN_gaGQWr zU8wE$Iv^%ulsL)O-12MsSuC(5n?&MNvdo{iZ^`{roSfCMn`|||1xwgD~B=B zTn5qjHZrhvOUb}Tb>IA;vtA&=@ZAf!CL0QZ(ykDc{M*p`<*#Bh=3(`qC{+6>A5u!H zwxT+Bch#w_b^9~UtaC_RPw_0(#u~$7<;-Qf3x)Z=t%ji!eyetQ4vcq3?+(`ASRa;; zVHGK?QJTbFa1;M!CPZcRgB`)eiDz@=;Km-rNjYnOr?Iy|2SwdVyO4n$mA4C~bgN-mG4_?Pf^_1m2rVoW@ZM4UMr^?%wQU@L7qsDyM-O)D6@UB)fT6~dGl zQHvr(?auM7ogL?%mHd+ecE8 zEOkTF?O8E&M`f~vCp9@P`4V1*m0elJ<%z$x2T&M;$c?3K&yqyg9=+@BBfS;%ZmINJ zB)3ETec#`GHOQ)q^dcM8;qb}!`?e@%zC?!@@qh<8P|aQCeWAQ^(0xc0w@>&cdx0H` zsYvqt* zP#&|zjKr%-%hMadvXu_I(ntk_!6~-x*Qn9U-aR?##>&mM zQ2IiF&gbL!#E9d3p0B>*XoX z&4k!jSnXH$aW5~52OJaydfy$RaQNw2jj6cQUt}r@Da?Zh6omOB7|!h{$Ql77N}Isc zL5AUHdleikRmP`T*B{3p;`Y;c$~W?8qlcd1Qp~X&&(wjWbi%m^Q;PPh)DC(znqog} zW>4|Wvv?nBl~!cpQ*QTji35xNTW+2SW&P$!B}vswepb z!D=`J)m1&1IIs_upuYkSJpP2K%9uZ%IEtp1?X6ehwwet`uReLLyW@nI&Zq~)RgT;|ca zY<#X$w9icu)075G4n;#Ovg;lCHWNFGO}oQ;>%zbHWVoQ;`IWo7GS+Tx+v&3jds|a& z=HDvw*mzy_T&^L6dKwbhkVthG^TCw5y`yxMN3fqV@Qnh4ch8$W8Tf)=rxTr>^SLAY zj4N!-bM$k64lj?*WayyF;1>kMP6uFAhJBV;<5Zo=djggl7-zE5_=Of(VhAbrKEhJo zS^`o%&1_#*hMJk__Zw;yL=j`V2mY&3ye%OPW8;SHHTbh$D22KC3N@0YS6U z&JjDYH}CHy%OixI12C1@nk3fT7a%6Zw!|vmW4Pu)o4A__dZuJV#b!A{Ul=`9croU# zIfJ=tF5*;o)c^)1;1K@a_zstlJ^Frfv&s7NOZ=05qTJC=ta8-CgC zYgFGQ;Z`7NdD8c|-{@~hkJiTfRDlh@UtAO>zk%03B2F}_inDRfkhWdq2}07c4Kd0) z)y(%kNTV=^%8E@66Zb!@F~)+3#yMu$reL_Cx5g;nVbHsWYWHD6I=22-a)Un*XoCK! z61+f_!Ayw}ydX_BJYF=VhO;!>f?u{(`Jet*ee%5>Ilx@N-PQrca%^p;@GR-PiiwN* zXV%&GL4u$|QHK9lLhtkc%(~)(Aw+!M4{tB z5f@Xp)=muhk2WYybi9Idf1TlfN3j*HwO^YRL`d1MYaj~Vp-B}dDXKg>>OqBMr>AXq z=!40vr06r%;@>+UC=S;#fnUkay=lN;jHqNz9A!id#*^ze=B|-Tr1ZyjJqjs~NgrWV zN?bj1;~pssIt_91^^&@OAMkTv^4tzTFdRO1W1;8c$PI4}1Va$QP2wTj$2#7#vqqya zW;%Lo1=);=0aQrC>#L*)&^2YfeZ((S!H{*p>=D|6-;b4bHN_ua(3!!mPzDRPlc1GHF(kHBKwgJU<)8!mR!K0TYPOiLr%8go;( zH2RZanK>Z#l9rQdxS{}NPV?qc&KpAXAl5P+-g;a&b;vVVrARaG>bVHVZMijJSm8Xr ziHm>8%vk~HJx<81L$+UiBGVx`g{8abCi%4oA9$WLLs{G9T{OJLvxuI!7+#&%CdwNf zL~LH$i>j2nO3y#?X5fEtVo%?4v1KtAs7lblRM99IQhew9Yyn?}&^uO2j%lGc2kkP{=KGqdZgP9Y{b$JRc^+uIzPu^)P)_bh#C^R1hR zm1Y2DVWSqiC1$mxPp5168D8;jnwrkerFkq+bo7Gu@Ro&zf==PZ02W{i0*&qf#3|%x z)?&bvV`n}1jzE@3M1TFi!VAS@wHp_?T^1m1cp{FE)6+WG3=@;-%wxa1k&0U`Q$s6s1&N92IMQx_y#-4I6!?fYV6kp;Gt&r#G zi(gboY815Iab{&>{f zO_?Gr5GeuQF^G%qWOQoqUGXXqk?S5pSg}RQJTi-#c*w`AR5d@*LgjnKO$oCOl4l=F zd;_|4GG@*Jry~D-YEOUsNO+W>?McX%Q>($Jt^Ibx2veCkYP9Y8xve}1O0L|0*X8N4 z8tM_$ImDF>xYN5$Iz?Q#ynhM^deIaP^KfGn$Znb9)N*Fbv*}|YbjOeIj4;Aou=YX% z+ZAmAW!%ksrws%yEm=SH4+LsTL$9%zw$Q^_ zTCUbhg$g|>Lv5C+ih`# z`rs5>Rt#yG7~^Z=%KuH)gg7v{1BTiyB>){TG~0=SA@Fi7zoqTkipk zz_Bq$wTI8Bx}D<#@)vThnzEL}$fK*?ddjMh*5Fi(yUdz*X6gQ;W<+V=3(|1YyIFNz zhuzhF?b7bUd7~s?`XesNn1N=0Nm#vx^TwKu3@BkNi1^P+J9L3x3oqil(KGa4lkjK? z0MSlX(&rQFKp%XB&c>tL5T_m#c&Kb8FZe9d-g2Fw_TIL(FljHfI!{*xg*;@Oo@*}P z$IM0ASiI5n{{3}N9WfiLNzq*icjsI&(dPP&p*F*btGf>xYxc4&>lO~M7^$0?DhMGj0t?MPkiqX_ZlZNsbf2a3 zXKAnT`88uPt#iax2rEaHG@no0Y7DesK;)bMhAAi)yhP5^%25#i2aH&>>JY=5ErK>v7&s*7yN{GH#37KkAh*1j2iW0EMdFkb*P=bMYOBL;% zwb2;Nz-DXsI#Skl>o*egt@{@Kn)5~l5KAK4eq?MCsSP!U5;DEDX(MzjY^@x3PWoAl zP>GqENE2^h6OL&rZghXc`Ul%~zH-f65UwoY3Ddiq@p}j4*TN z=|8&*uGGMRRenF$J1S`)W(_!`fmyet9qA1KZyg|4hF_bTO)*U9qR>dfDUTjUUm=Zs zxqT?BigR8INm3By=m!}iCkxPg`%|815=i{m`B(ln*C&(w+2sxi5C1bx7N^t+E zvYx&7c3hlRv!?)@0`_NEf@TX~+zVTFINd+p=_6LB2H8IM9_FNwlLe|>tG7#vwten7 zqJ^H!NEJ7v4EVFj)_^$t<({a7bUSxY#D>rg5u${AU#c2xcH@$NROJ(&zjl{ZyU>3UJ{_*76tTHB0oOHue7?o|_U@D@%70N%v>{`1RDG7lWLbOIttfj<=6rj>59|2CLLX3p0~ zLD>o1^7@~I#Qj3sCU3!A@Gt#^MDKfD(pB-1{=cZ`c)^9{T>l^^yR!ym2maDnw($bv z!WKG&Dl5NKoYVcefgnV@Q}~M~Sny!8o8hlg0HAU3&?0K3{}S}02`%Y9%!D+f!wF^t zhojFrc}eUW0?Q|CaaVo4d-k+AXH_OR!0Ndi>&KLG(ola7oPG2H04b_wpxiJ!sM zEVx!>1h=(xOa0E!!tg9`Uwq7seZs0^K7<^r7io9^7Vr{9!pFVvMdOGrX5Ym_AA+JIrOUZLp!(R}iFF%H1$ zNtNORTU1so05-#%_|B1hgnE+z7S*IE)IKSz`ip!PxPX4k(7~A4c^GMUh6s1X)=;24 z_#|ShcB}l7^8MyJa^t*k8|U1d#GZjxT?#GlfB%^;fMllw{v$1AZ*i-Ay<4D<%I&<` z@G4U*c~f%ew-N2&g8=8fqt-(4rxDJFi>1FzP2qyow)*w?GxJ{L)fY(P>R3iZRN5GY zOupbLM-!&yx%AksAzBYokNgBg!(Y>@z;$W-m-Zjotxbp|bZW{;R5w3_ln_^|npZb} z33v0Q7NO23cuRL4eq?W$vg_i##L-Il8pK|AaH3sDMM9>U6%#0oIQW~a;aOoKb8Eyy zs>IO)vR|QU#3;+uPadHRe<%Am;8yC9sZ98GVJyz5cK2r?)3z!&<0ws?-3NiAju?Oy zKsO=|PP6RROPI(sl|MpCad3uxI4Z?K(LTokKa>TB1ia;@J05;PC&h8n?_7&}^>btM zmq)dWs*mb8KcGjRWh{RNAj4;@3dY&c+Qc7kHBuiU;!rXk_7^fD$g%jootdD+B_Qh^ zhge$zeub1;*&d=rPRKYzB#@%Hfm6C0@ zEzXD>Z9Qeo8CjqNh7_hLCr>SE$ch(}?S(99gk1(SS0ymF>iBrSV7&k2j4Xvi(+V|c zZ07rHBd4`$+)+A+yk+W&P=O^t%GJazgy1o47&-r4DTF!zC&K~EVa4`j9fQc{ zao*i@|CKUF?+#Xoxh{hihHR4G91@uGM!}1(ASx>f@~NL`L96B>T)m74>KC@;yM`KX zJ9`zr?6%G1>}eAw&|}si7;Kyrw=`*c;q(0e8p(HtGozgJPRb32P1}n57=mCX0%GZB zcSP602S@X=KF{%P?mIwi{#vk;$ec$ypo4R|Lfi8irA;}bRB*#C#D@YWVbD5Y9Fny3 z--bm92hcjAZ+Yy4$g-d3_7ewC?W`Ps?`zm*WcY8l#w^K-=VQMAMIc3=8zeJN8vJjU z49;Ip{j{N!%`~H$KGi}_40zcVdRhmrh?c%*s;9|&?}Xqq+`uk6WiEdDn&kGbBM4#q z8FGl2-Q3)BgUtd{+UFP%uYp;GaGZWlx!&cT=vBmgiUAMa!-3jK+-jBHYcGAK2%_DP zIQkqT{AX9%&uk?4WI@ON+jIT5f1WFSmR2zmAw#PQev8)1m3)7~`xE4%>vfni01-q^ ziJw#2ZV$hi99k%flzV1QQ94R8%i-uKC{2=1h-zQ|Pf9^mEg zcwg4V`DC~nHR zyg9!Yewl_3^UBT)YVQmq#W0r??+(etFoe1dZF}dRGA;py(Mh)JKcfHDKdGR1LG-pb zvyB#yvHhj9Ao_XdOqfQ{oT`npZ?`27>ZjC>`^JZk!(};GfB&Y3`H&%C?hyR038pL{ zmO%cMnAdD1IEpBVDE{Zi*y9uPY9OH)6s@+O zwcT}04|tDgN2)GyQgzv(5Q18Z$NteS6!Ek1;q*^TiShCjW`C|-YrHiA>OGc_jZwNj z7a@i@w$L*(o@nYrn=-}OmA<@H-W)O=@e~7;p8IOLdc5|ZS_bezE?M%W(3rQ%Ytr8+ zj3#o8j=K!4gjGQ8(*M597yIF zwF=L~@zHvNH}6xWKUH*q@;09O;RQ4d%OVXOa34+6rZ`DNKMYK`bXCLjoW3f!mhCF9R_8+0D9K&qgoW60K z>ZyzMFaFU>no;0$jnH0{X+hX!;oMJC`C^_T*DkIM(9vW$ebwc%yB%~SmlNeF1ikBj zb9zlQzr{cCva;FQ=rSMR$@WX5f4U;;js zEGlge%e3_TkskH2r=VDxk@JEleO7|Its>pv%P`%6PMfxF%151xMkL`R-Jo{Y>9v_C zOM6=$=Mys!2zy)ErLTc@m!q^RjCP`h&-7GpSO% zt4mKQ@k-T-hxsCB4Wr#K5;~gni>Il0Br<#^i(*WiuV^LMHS=D_txpi7f`VPmO9b{G zEW1P*tbt2EmXN9GuW<&qQpE9a8@O*zWQN?Eyzz z^>-3Bqr*1~L&O3xDa%+^tN_gziy(UMbaCN!SWDW9Kep zTIVZ`#%JN{SW17(2V}kDA$FJRvFoS*>Y}#W zm%cu=Q(?~G(g@OinaJd03WwnHLq+!ZEKLS!Ee8L`EE|F?;@mh!(bp|~;1{`bqfm>L z%y$zYyky@xkgcY`vS60AnU9SMIVaU?N1Ko1fLh8>yQkN3Of_EXoJ(fHCcv9^>JODH zJ$>v$;kzJgCe2vta4}gZQaa;sJ5w{Ln_HAuW6QebtL8*(Zrnkcusjoq#O}Atw=5GoW^c%$Dp=gZbP+f2<$g z(&X)u;$z*&>?y`k;X}cMxsT-h_|_4xGhys4F%v(9x3&Ynol)-j12zW)=5lGl)3WS{ zHGF)~tm~SrTiGHhHZiWwy_=sqS<&v6QWJTc5Guc(oUVZ<2VH{m3IlqFqEoH>kDMfj z%qe2wva;SlINBY@IW@FCn);Ypu7Xs>78@PAsjVErPHRBO+3;g{fcH-hVw`0%MOjAq zNt+(rxRD*Wb+i4}yUny-Y^uk-g5uitO#^=^J&6t|^ z<NOiT)8K16B{G^#6rImm(RwaVQ05WM*^>Ms%uBk>scak>5TXqcRL~_WT znLNMDcS7DTTvlU;DU(t%^GT4x_SIQN@~uj3!<#6L#>-nni@sKEO`$b$=Ug-m=eQH% z)cI?&9eK*mEK0VorzoV~O4zOh_(0f`mb~qKB3XLvefp_`7W>&solV_cE3v}yFU<*f zqJo>wkkk8lOB3jAzZx;hT9j!o@HI;BEqO!x&c|o9>C7q@#c<@6GIi*_CF;LZZc{!Y zm3hfhqbq(h&9eq(!%MJ8Qb)4JquroR&^TdyuC{-p~kxTUp|hxg4SHEpRFZA|!C+CK&b zYx^fIWi!>*4|8oo2v`cnoY)?>Ve;^?8Ex+z8!joyvSM!@V9`!=J}W8cp zR0>?Zn*j&DFzB|@i-_#ypyeC0uYKD&v`{S1FkXIC6{CAG+$fUl@#? zC@LDbzScOxcs1Gwh`p-i)_C)C8Cd1Z$8Kg%A(AB17-R2OfRv2v?Wq^YG-2bo8ka#6 zq}Y6f1JagR9yk;H&SMpCiUUBO@fT2+2L|q`tqJUMf)bFm3d}K`(G@7tcpFBXd6LKG z!_3Jc_ql4VSDC(-&eY-kypoBLF1zhwEH{%SzWUK}&&jbW0I4xsNJ`%p&9UjwDxZ>+EwR{mLMjyl4TfGiVFfp= zy#JIW84(NOIMD{4+%+p4JW@k{V9e2D!_0P2l}kFv|;|}W` zy#$RcPb5qcLBd?Xk46<8Inmk;rT3QpT`c4#gWljd*|<#2{9iLaBdk43mU`ckz(6X4 zMss&TnnuGzWJusiOv#t6SCn|mkejcY!OFMaGjc9gkA5wJLjfqjFXt?PQ9+ioxzseX z;kb2$LZ@bfd)@rNaE`IA^pGo!Ji0l;UU zmt9&2)FccAbMx3tFrW-jSc<`I@6tz}73&{qq;|^&c4%dC;+&oC?>b&So&9v%=m06T zKvT_ck;(|t%rFU-n30?*$~m)O%b=hqSUESU7WGN<$SN&PvnIb1YOTo{8(OdaK!}?L zlwk5{5JhX*r7kS1$ya@l#I98VgvR$%vTZT^ipC=I50=<8xuvvD1nC7T6t2Wc$319w z5@`a`wgXJq(}+<~tguAidV!0rg`^OA+?~5dP@bnuWRBeUeid$nP6eRy=|W(Yq*8g+ z1!ZnIbk+%I3r|SQ5Xo(%AWj1pq>0U<0U_RN>>ZAPG1EZfS=4i3SqW8rl+G4h2OT!q zH}|$3e-~HoHdX#^s~`S7YY+Z;z{mJvsB~`z{D+$#zqi^dcVA;|r-aT3G9El^k_nT})8LdazdSXvA0_M0R zI4>n2l2W0U;Hzng4!VUdxOMBZ{G%p-KT6w#S{%G#>e|_|y`A zj6VLonGa1yae8mkXvT)mG*78c$_ur6vDOU1K-KXYN<>TJV%lCe2N}j)IqTm`0qTMa z494GgDUHjdsS%7(dv55KR@ie_!Fl+Z>H77IhK-k4k2F#xyP;zxb?Pg*K=w7ooNyU{ z)@Pb5rD;%YN}Gb-Kia$`yAoKjDT7LBtJ*zz#Ey$h0?{*AN?R^AtzqJ}8f2((rc1%? zxT1gWUAP)a!xJpZ8An}?GA$7QiLeT}pkgZ(cxs%IVfJJ*0;cNg4B_fu>mJCi!~u`T zWdM)&vqKVK!2}whp$Nf*Wr6vf5vAo;S4|fdF#2N!TVDX9$0Gm9$GRsDFlwl?)~v+A zinm*07>eS$T|?f3p6spxyj!q4+5E;ZF4l{?#uKa1X9IVhd2vg0x8tqj{6GZSwi0MC z3Fd0XBD)XnLh}VfhCFjc{~fu!s#gjA20GV)IX~=My)pvUip%Gn0=5f#neXP$lk@pP z(ff~|VXi~{@tY@5L53&MG!5KTBT-G7QDC=%d{TPSow?=Q8HGP32});dc0L*A99vx^ zgCNsg=Fz1;#A>T+?5(b_LR?0hi;!SW5oqZoK-nwYlA4AA;X|IW!QDX|Wrxo}(WW=0 zW?NnOmBg!VfokDVK3sysYtISKKK*xZBD`DQXy>s zzcX|I^x!|$14K`{J#Lxu)$pDqb!PYsmL?OQ#UNlDLojkua|G@16$#ZhZ)C4{f_<)T zJ42nbfJlrz1M*p5jiDy~nQulQ8X#6`j%*L;*_bVZZ{7S|3A$56ibuZ&K6ubeN(~8& zeFu?t0qS#G7eVd-jzQce)ASil!6;{I^XvZG(tk1%z*$01R9B9ITbaOr_K2e`Il{98 z_59EM=Q-oTe^U;1>Re2LWx8H%n(NK^`fn9>nY4ZnOZ~%{kMfhU5^qD8Hxj zMdT-C!oGAV5iV=#Og3f!g-*Cer?87{;Gadq{RQ|X)#5tnHy~fzE-v7Grz>!kts-gY zQB#3@-CnwY85Sqz5wR|r0r^QsFp(}Br*f#$6P4dQcGrxJ&j6= zsR3Mo%YFW$Xqv9xAoz*b{r?lOr0OOpQ;p4thFs0qA^>)vWa8Npnwj3lw?C;Un$ggx zoWyTTesh^y7Mgv2#L;1TcaG+bsO&hqLvZN%&pxYB6?fFbz8`Fe3md)uX>Bd9V!z{a z0VumFQ~X>^q70eD0%CI3#490z@5`gPAKJSBA|;e>EOwtPBZBO|5^{t?dw6-^ z+DejZWt0_a#ZX>9%>94kDx$fYZ4TbOI7v;@O%zFERfh)3?afg{L&uU{=9@YXnnL|O zplH{iO85B%Z$bGIsMmTwu2rlfg2|Kn@tt+8&eQc3Q$?{1MV`af+%=%x69;1b@SY~w zGn!w9pBV)^2bIP(KG&9~*DGpy9ne#@rThOA-=Hl)H zVr$z~g^%|dD_n{8TqX_J7*R6@aDax+rG}LUhpEJ zIh&B{lim$-YvAE(`e5aqV#dg3&%xfUuy-IM7Tt3v<&XQ^f54Po=_NKsHN}Zd4e^B$3-O3=lV9%K^o{Pt85)tX_ zV-0JaZ}#xGazWxnE5yKLa++~8`f3Zw0)=$mnH?0*Ep_h}?x4k7(%9USmyhq1n&c1_ zHin*}hK+C_3swx(oi9tZJwn#7Fdh8Q?5`yIbKZ=l(%4g98_ps}E4gdb^u1B=bzQZk z0Y743n#YO8a$KmDb=-Yx=zq`F41Yfvq^9|1;+WzyY;&<=h9KN0q_FW+83gSj4USl* z%Mwptxl+J5>M6)m_AQ6JwQ2I!$^~kOx_?K7r>@BRC){Tqo%%QNpUA`rcnQQ9sJ|j} zfC*YCQYh)|`Maf^);0?N;mr&Fp09 z-&H}*WcAuLJf&6W7hL?MC=~n0ygI%bz2;cT`!c+->@MNJp~_QAOoEkthoC9R33B8} zHkE8XczI&XOo+`>`PJn<>8GTalC8C`5_%HsB%0s(eRS5FY~0Tb-WelW9*w%4OzNOv zeZzm@f)l1zgwwl@PieUuYd^C8ulszw&$<3maEq7s@0BFk4Z%+Rz3(Sa@UIg76%%67 z-oX-b-oZxpsxyA}SQ~&`inGYx-h7!Qvu&1V5-&Ex)|ih1h3=Tbs_xv_eSk-Yfqwn? z{qp?3VIll*U+QKawV`KP_@9dgL0QYRao1>8*^rX^By{=sYO>_IM`QEbhd03uljc9a z^Uk^CtkRlIy%e&NXfjBxm6Gq9y9^vy>+0fX*(30QBhgk9GuqL zm*6ep!=}@G+o?5JY1^=e!_#5o^ure44{$hNOdrCJiX~xDG6DQGns>>2;JX~)AE@OJ>o~Y3=EqUa_7yQvL{rXe13yNi+8MB@9YPKwd+= zq~ud}erl>Qx!W&53Cf>jD4eGJ9j6QVSN7(je6LSRGd7e7lf3(4T8#6>TMvZ|cY3A@ zL9)kT(=J#}X?dfLYqra-IQBNwV}W%Oa!A*Db6%IWU=tr}~1D78Ud zngkR8&5jja2S#7F!!wN@7GbIoC6^ei+1v8EzutF+jn?;n_NJ9l9~TxQ@Betq7i_JJ z49lb~vkz$JYczVg-30abr`W(Qy1#%50;j4!brr3Ueq#~-6B7ED9?bFID8GDgnv5f+ z`u+#&Rg$%=obvg3ZsyxHZ#%AJQjdkfT>*9@+Ta4travrRQ;4zQse$7khjj}Grg_)` z&TlsKnj_0+{+Ht5Xl1$jWzI5FRsU>p`s_pJBr+;~70rgmT+W7y%cFUECaz$=-JRV9 z2hQR$*XW-aM?H-e4@YMAdJB10aE((N&P?~1*4(ya?A~s3S|F_S83jBT;Vp zILsNDd{ME}4lUOK4w9Ca=Yz{gfIiFKeg4eno8#4sY-jFC?+k@J;#=8^xBNa!_XOX} z;c`p!O&JSz5@NOI@!=|9=g^(H{U230$-wuQ>lr@{f%Beslg+q`hrxyZ+#S0LhkR7_ zA-cORt^aIYs&f9G2{L5;LagMY?(6P4kIub0OkGI4m7?3=w0~ar*U_5wfWY@>rT}s9 z)DU#n02O@?sx;>hYV+X9f{HtP*xI}GAMv%F*2_mXV(+POIJnifGwMv4#Us^^ua#Q1 zScLP4tjTVO3TECMAFZv9>2fjznoWMZ%~9x+Oyr*9fH?_Cb<$8a2TxfecTF}a*WuM* z(KRWLdIxY<_eU6_Io@$4P>{)$-Up(z9G1>2=^QaeMl$MeyEk`K`~Pg0g|medr} zqt!BQ*nb&_4zA6uwdUG1FL^%@ONsZ)yqP^A8K$&&l)WaK!x1zI1sBeb>$g%C2*r3} z=Z)4Ngx#5ZyKX+cN!#QPGmTqkPPt12lVN3(ElUC5PYUopua#2G>qXqWI&^s<=}a-W-{oO zJA}Fo_W5|DA-8P!0m^idpXH2VRj(&cmN-SPiFNmJAKk^-a2}6l^%j}MDM`O}rVg5V!TbnZz=L4Lb_Ivr z)ll^xd}9zo=vst<4Fp^Bv&T#UdU<``%L?GtpZFWl)bJ7J(e0}|UUh%4Z}Jd6>hQ{3)FaiNHe~fE@rs@tiqvpA;}pFHe&9Le zYMYldL?z40{=hKmFn(7`f$@X8GS+ZyAl1OgN!D9f)S9&Dtn~lK4rsRg#J#zB_0DLH zp6 z+;ARf@S-=SS4>)i##5exmumUXHwAx5j)YoTcN3u(q#bIlr!L)<(PIGohZ zJfCX)r+>nGcF#x842wXw8+`l4r$}j;PYTi^#4`E?yj1|)8MH*UA~@IE82g$@N0R(Q zX1|BfwiTn53-J39-?_0zpSwCV*>jAsa^r?#ftW_h~-^iu_c zsb;sdZ+W-7;&^1caoL(53l2w9NP^>!+uH;VQm{XuC6xgakCCNHMI+}q}fy5>FIfyw~`7Q zv=ZQ`VM8AdGw7DnJX5#J%cP6WKfX9AE$KDHaIK}~QUih&J-EAUUS=)_&QKr?{@HT%sn_K7%1g@UO{=RH zI&M3ukQif{q)-{RM7>G*tNsM1NyNXihgf<*OtRK)zjDEj%eByenM9{KRr-uYbH&`) z$wPOAE;&&}{>ncVr1za%PrzTzwYY?G$o1TUtB)qV=^`~Z`4Hgr^gV-~aIp>VjjzCA zv(nJJ+l!V`TKCI)#nMr64r^mYOxq*iEz=sda`{{J2XI15le{+Vn|(we><&^7oG^(y z(c*tht!wer6V_nw{b4N4Xu>_Nr}1}*+2K5s*5~6x#Sr*(LffGYLGw!2Z=x=f<#UF; zsrK*OH6Jnc;rw_FF8H1r4v0r;9A6uYdUUe~v=tex_U4Qd<}8j;UD-IhrbqC}R5WGm zV_No+gisp+^!mqq~sV&Hp~(I=o`FAuoo>VF$rEM==X zLoKiW&Vh8%5Z2A2V;}v5JLlGkn#EFM2Y{^?&%6*9{X;OO2(_-uwo*8zXm>e4G?4zNww% zkwBDn>z#*rjY)RQ4cFEqf+v|8%Jc+&^>X|><4hgOzq47Um#~^=RQ5s`y0XWwD6ef? zTtdKkTH^%DXI%xPq@((^4$xl-D;*i>11v!_X)NFfm*<*cOApZR9IVx8b>c}$AQY;oO!e|pT<)*fvJdVmq9h`Qz78E&&i zzkABRQ9X&zy`c%<#G1Z2&cs@~?290N*VE%^uxl=SC!r$8SVKD6OQl==?gv}lDq3Pq z567(89K4zLMife%*-gK>#G1JG5lHSXQnA>yHJ+aJYbkW7gO%JV}n*21gLn3uHK-l)TnlC{r{R z)i5}j#PP`Co0h)(%P-4-cDh?bb;{%IO}GT6B^)zn4SksZ(rZ*iXJTsIQ}p%z4cZ-z%jArb*US2V@G=^s4fBmBVeiI2%`%-e>Z~V`;1}aiA~iD|nLS zGc|1vh`+tfXBXCcmhU2Od{A~=8!L46l)#U}gb?Pi>>olP!Uq}8rJWs6zs2FVhByt? z!!E;M_~2sO>HRKx!f5uo_t|>>k8}4yzurDo34)6QnDEN4#C^kqG&H%(JbKuId;=hrepC_Q zG9Snr>4Xdar)evXOEO!-kV|&Q1shDSXqHQ6j?r~X%ylG}OtekAS~_KExRx7%=4Yen znjQTzG6PCGhZq@Je_JyTLSNwrVZ+O=6U2;cAe!X|zq-d&I}tHKvp& zFwbsPQT@2Mvpw{+G~WYH=}j#oMl5zA+}PALe1!CIhrM~b3xaS7jys4U{h<(1C)BQ9 z64|3AsbJ=~f?{yA7rp;ZN<94IF>^^~GeZLY@pn6|Ym$KKd zu6%ZbX1Yc$iO0%lsV?6hajK{tfbz{TQw^fc+*uCUP84k(ZHIueQ)okgtUXbAVrU^Z5DBo?;;=nUKXa)8>!nn|XN#8>N= z7ya0#G|)lP95B_thQ4bcR}YF4MnOX<$2p~%j1`civ;hyeggYq$D{#|PZS|M%vS?qA zXjXO+O0}D0)WQt+7;xY5>d^_b*&bzw($wxg87S+)X5HKcgUvvDuFIROBestquvl9| zzJH6=QzP#+@_r$Yapyf!ue}$3o!c)}cNih-L&k@76Y8bZUt%rvc`L8_5d+tim`ZOE zu%55Jsw12vtN`)*g40w#@$(EIQ~%oQRT^BNu}DCfPA&DNT?XMpSOFMx()nTTa3_eq{D$ z)EK7O*JHut{*`!~-@Au$x>KNA6hF5P5#Z7Y6IK7;RX4;gi92FK)kf~SCnF>3*P>Hf zVCmWUU+-7M7d+2#*yEZHsGjp~j$dpk{rXfo&3QjEE2D`8g}n>fYxJOn^CVBM-r#i5 z!Ec7x%XywN&hF~_Wm2OA!p|rg$pV7yMMFo{M zi0dx5wJPkEP8G5~D?>AHBUZJootT;F3cY-ZxNxV#In={>fN!I8=D;2>J`K{kpEAnB z_C(|&q^&3&G=(JmA}yoyUPV{I%GbAuZf0^vMg9+fyI{iV^iQ<3)GI%y)0~18DkFe= zwEDS**DGGOvRmOsLQAw8o-`5nTeQtR74ee%3sdj+)q;{8YcMVKsF~;l2G~0I)O>!E;yvtVr^HeQxlU-ueI6las5@N zHnO2_5ZRZwz$9EyPi`hgVpw!eur7+=#oX0gc5gxY`X6lifu8&z*Yjh_>EmbAu(oUi zo$1B;&?pAo%(di5;`T*9Q!bW?8~;^C4=wbX^+GGh^A+ED{8$z#L!)+N3|z&3rpP!27l)M&H`+1Ye!XQPxR0rzRcT#2J$Uf6HIuu#CGoUvtKt!-@+H4Z z4hMHxO~~J6l$~^osO!J|Ls7+{D20J-hf@vHSMw}tBPLV=4!a=;%f;`{2?+gxX~@l% zzx}yfoQ9;n+0_E=CO>dJ8-?nuz4_cAmw~xI_4#1{$&$TngUlP779-qpOU<8_O(pzn z15a;T6tZ`>!X;jA#6`giWVX0XY`q^V1B0oP`LS?w)Rulr7aj1(Re-^iVBi0;$Un!y ztv3y; Date: Fri, 12 Apr 2019 00:31:45 +0100 Subject: [PATCH 5/6] remove extra split delimiter (||) in background trait column for GCST002888 --- .../study_background_traits-ALL.txt | 2 +- .../study_background_traits-ALL.xlsx | Bin 96174 -> 96145 bytes 2 files changed, 1 insertion(+), 1 deletion(-) diff --git a/trait-representation-migration/study_background_traits-ALL.txt b/trait-representation-migration/study_background_traits-ALL.txt index a24499f..9bdf57e 100644 --- a/trait-representation-migration/study_background_traits-ALL.txt +++ b/trait-representation-migration/study_background_traits-ALL.txt @@ -182,7 +182,7 @@ Common carotid intima-media thickness in HIV infection common carotid intimal me Carotid atherosclerosis in HIV infection HIV-1 infection|| common carotid intimal medial thickness|| internal carotid intimal medial thickness|| carotid artery disease GCST000555 common carotid intimal medial thickness|| internal carotid intimal medial thickness|| carotid artery disease HIV-1 infection Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio) unipolar depression|| schizophrenia|| bipolar disorder|| concentration dose ratio|| response to anticonvulsant GCST002887 concentration dose ratio|| response to anticonvulsant unipolar depression|| schizophrenia|| bipolar disorder Pharmacokinetics of antidepressant drugs in severe mental disorder (concentration dose ratio) unipolar depression|| schizophrenia|| bipolar disorder|| concentration dose ratio|| response to antidepressant GCST002891 concentration dose ratio|| response to antidepressant unipolar depression|| schizophrenia|| bipolar disorder -Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio) unipolar depression|| schizophrenia|| bipolar disorder|| concentration dose ratio|| response to antipsychotic drug GCST002888 concentration dose ratio|| response to antipsychotic drug unipolar depression|| schizophrenia|| bipolar disorder|| +Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio) unipolar depression|| schizophrenia|| bipolar disorder|| concentration dose ratio|| response to antipsychotic drug GCST002888 concentration dose ratio|| response to antipsychotic drug unipolar depression|| schizophrenia|| bipolar disorder Coronary arterial lesions in patients with Kawasaki disease mucocutaneous lymph node syndrome|| coronary aneurysm GCST002026 coronary aneurysm mucocutaneous lymph node syndrome Coronary arterial lesions in patients with Kawasaki disease mucocutaneous lymph node syndrome|| coronary aneurysm GCST001878 coronary aneurysm mucocutaneous lymph node syndrome Coronary artery aneurysm in Kawasaki disease mucocutaneous lymph node syndrome|| coronary aneurysm GCST003560 coronary aneurysm mucocutaneous lymph node syndrome diff --git a/trait-representation-migration/study_background_traits-ALL.xlsx b/trait-representation-migration/study_background_traits-ALL.xlsx index 07afa2d1c896e338a1cd3d7d84a5f3879396f5a5..b54bf3f8f0a78f2f294a22ba7dd11270871a844f 100644 GIT binary patch delta 80365 zcmYhi1yodB)IUrNjRGT`0z-Ez-Hk{O-62v+=S8|v8YyW(VrYaBdZtN8?zEYxHFM$VZ}2c zwOCYX=mPh|wU~6#QV{LW*BVDg#Kzr*Q^Cw8e5hyc4D~*eucI0|1XLH@4Yj}7;NY`q z;GC{V`d6}4pQ^DD8BXJ$XZJ0cbP56QXc)L5-AZOY?%MR&40T2sPXhbIcJz+5f>``N z1l|3nY)sCwnsU;gZavlAA9nx!N61RL)qx~1r*?IJ+VOhPT}vW z{d1ZhGs@F#dVG$=h1@NaH^qn~k$Vdn_j!FLdxR!5;d_5#ekND4-ig3(d)G&RH1$d+ zkJ9AR`s}AMuN)ig(|@_nl8^tQtyrGU?9SGM5*`>IS7yDWB*!^JtLpj|6;po3z?b~9 z#Ak19j6A5{M(@pO>`yOx+@-xVdAVXEnNOn;>6_$HW3=( zVooO#6eB&E>L366mq!mjY7o871R&q&{Cj$f!g|it9De;yc~HhTN9LV;L;OyV>JEPd zLG0S|k7IdAYHLsBCfG+)VezNjitRFltOM8s!dg`P<~;oYg!esXk^2}p4Ejui#iuj_ zzk>H}ySZoD<`wt%J?SrBNR;$*w%(CUq`Vb64}LGnkJoR_9kek@)*dmby#joQ$y-}m zHgaG!Q(gP+B%KPkvHZ)UItk1Dg@QJbnfD3>OL2`~UPHW?04u>uDbg||N8{}U`%BlF zpI?{8i`ZzK^vW9NnP=-Z$`ixnr=oEhH}-oSv|jkDTc4Y`n`r7yB7ZS+M}B0%wDl|x z=Cas*u_>J~KsNkI4LS4O%vlmpKtLCbpB6WX6r0B_dCH7Oe7r+vI&5Lce{=HfzK3Yn z07kK-oMPRZ)TE2g-ZE5i>C?ym?F$~JmpGG1v;rR#rPod=l{t?^szx75JFZ8XGwIhB zk*aRxc=_AY#EgC~dvn-rJhr}aQMhL91mU}2bU_im+PdAd$J&tmT=b3*h#R8N>&nRv zHm2U&E)5UgQ@ck^{D4ZB%H)BJUsHqIj*WHpRB85GG7{2yqA!UNhI+$WJU&;~#3d3< zwdq0EZZgKH;b${sRVK%V)E90W!?D%qstI||#L89&YWSN&3`9ixlF}w`fo1vX#P^)-=_b`ndfTtzuN`w*24Qu#RI6s+AsNSg#I3_9<6SC zDb8NF&-l92M{-CL0JN&E6n?pv5G-)=+5OV)CU}b>l93~9cyDyres%LZr``7+04P1y z@J`>{@Ai9NAAea~^t#;*rwP0Na?nqseq;Q1ZSku1FEG~r_k8OoPj|G=*pkHU$>J%^ zSLab+@%w&G`{n(-JJwz0PdvcS?*5`Co(s4h>dpw)qoG-~{kk=Fe|LPmZ)(zNWK;RO zc=PYy25Yspt6TL{_uHwpwdIt9djayLUiH7{CyU)R!2L!8{LyQ58XDlH60hA)RIDXZ zSHi8?OVOn5`ttfB9Kc!i90PoAFTpdr;6P4t{BeAM_utDyyu%+=6*30Ha37tM;urUO z9yFG>M}Rm*b57U7C6oDnG?VN6-@D=+i3+@#_EzA0Y6uUnxL@e+&7UzEAXcNF6bQK7 z*jQfnyFH8tZd1d50(b6J)^U+=-4h{+zo+-Vy1#gZbgfq2Y}lHJwMB}rNq}AgS{sAB zP)zPE?+zuz-DeNm4mOXSOzu-E@9$|3l!pJ3lw{E|5 zHx$nW+VgIWW^9!wV)-5)D0g996dI!0Xx^HbEzY^MI#8bFhq1$bF3oo=9Es5bB3SP3 zZknAfO}y&N(HTerby&+`GjzE(bT>&z@3aUPS9CUwE^(DD(zSe%1I{U^irRb=RO zGmncL8WL&ywERx-gEJmi^*-w%p0|vc-?xgeG>_=?CtpPddWnA{-o8Mwm{?%quudBK z==9@ay6N%36thTKdww9?hY6YMi<7_j0a_2aFpgI`Z56HPz=$B^!U7c_Ueb_My;71? zo%Em73~OS;j}F87>!Zw~W4}zMCY#6dr%VtgQFGZn}zY#yH+yDuDdAr1LnI zvgaq}JEw9F1`!h?-PjR%ZGDveK2FNq8kSWhS5YtPd#PWs50tptBs?3nWOg2D%?6p_U|0dpui{QpOT>3bMkduaXNyk zXO*p=1OZ(s$C|X->8koSzoRW3*M1CRF5nDevTw)T3%vgFut3s3*H=!ZyZ(kHUbOrt z_=}Rpb=iaNv4#&kjXlyfEV-B;mdkQ({@JAATJY=Muq~FoxXQ~@eI-Mx*9=a79NlI! z#-QK*Qa)|gB-9K4P+r)b-(Ix@h?1Jo9fypA^HS@1f8;_Nh)<@bYPKq*G`>(N8UDuz z+7KqlyT4OISU3hflgvqeu=47Uarq)t|CGEl{isP>Yf#nXMghg+_W_dQsB0;CF;)8i z*gkT!66Wq>9rS;fr@Nn&&Gp}VwI6mm#9}@zQmIe@f%?A{4S&0^<-UG@y+rkeDsZO} zY09;*+`T3FNT61#ZxSxmEYfGtfm{FTHI)-X&?Cppor66dt+Zp}axxcWQ-j}LY#I)B zYuf#Jw*=gloMz~YwRJI`WwO>*G^nZyDfK^&b@OItsU4kZ|JAM=1Z*7Eh^X8wm19Vv)%M9><=ean8;;8ye{SaOn^qyrtc3jb=;y%Ub z7^a#0!MjxQ)~WtI*Kbd=d!)20RI^RI2eCKy91<{lgFn)Pe+Q;Z6gys*v998mkygnzynm0y zeVSGKU;|*;CeoSj)V*W)C$j5*HoX)CUuz0L<}<|@_M_rX86rEfcACyqzRX~_Jto}6 zOxr;-DJecTSCjqcs?i0R}2-k#R5F)A!!4wX6U}5 z-W_kzGZ$pj*s9!VO>JzQ$G&!*m$5mFeFeJGuK5B)zzsgOk#W97f`RFCNH%szF#{rO z3zRWuFszPX_htlpj2IgBG~hL%$XxE7}#d&-Zk5*U1HAIC>TDhE&Q3$>AIJ0 zyS)O+SFzHF)H{ZGkS#q%0~1jPjT!d1*83=(NQrFjjv;9j@*Qbed@BwftmXhyuBVk4 z`TuFG@XN~MJQ>mco~y=Es1bRJGIam3kiisXNBVPcH5K7J%^Iq}r(k%huke~r!65#> zL(jx?KQT>=F|?k0(kXE|Ivy!wYz|Oldk)?t<^wBj{@xb$YC+G243 z@5e<@BpCs`ANO6UK?UQ(QS7L1x3!iUzWp3^)TS7Ej^{W-0~|Q~ufxqjPBpV7R%qdZ zY^47!6Qo@T9M-uK`;1=h4`&WK{T-Lz?5rguY~ypS6;M&xUNCxB>%=*)yzpEb^!)8Q zc32!3BL_%Gd;`eCFol)2rs1+pkR(HK9zIH(0fq!h4Yzw`*6H~=nad_NtA1yqHvJQz zMr#23v7;6B-U*Fa2GuLaRHBKw;SXgi@6(<*vnR>Y%(a-U`1h>M&2Q|i?sqx?wKrWZf$Ba81=fx*i$x742SN*0XUR@b@TnR^4IZ2r5;Zyj1{M(`iqU?Mv6i& z@Ss-_Lhf_i^V;D*sNm1Adv~q_o3DfGZD|jO&y^f@4_HgO2iw>s*cu3Iz34_SWfxj= z);ULvxd&)g3kwodQYp`L>YiIO+K6r+t17j11nEIcdwCLhw1R5ZiN=yv2c(=^EOqq*O3!;p z{>Hy{Cdt=77bdVJ$arRRqI%1lc&*AIt={n3vV=WpF=IDyEgdI+&Zieqldic?@gmpX z1GdZ&^%5-~mXDa%dhMK=Zh^%f15BQaYemtI_NuZ3q$>?;v*ZVc5K*tg1E9wjUYlLa zz1~kkp4srmB%IHRl{#sBU>#19b!%3tJNHO0L9GnNZ(uj(FGp`vrIsH!yqNuA`5}Xq zl!2@}Oe3mUBPv6MZ9{pN+6WM1rvUh@6A>&MTs)6+@>=}8Y4ZdeZ9 zC?E5`Nal^Ih~3U_9bQ8A%&%?blIUGz?&Zsu?P8|%@S1V9W=e>hz z#^BX-zEsqISt|MFEU@}hA1ltbH1?8y*(V+h zA#1{pD$%jI07c_#I*5m_JZ-hPrL()litYvK!BFK0sk|=G{TU!Wq`1>ovm@z61Zg`&D20&c8rzpui~QOQVKyV*8=x&qat|T?KAmskH#Rl=2{bgl$ywmTW&` zeiX9}^q}k=BUd46!&e*^&mG4;Zg<^JayNU!9qXWz?acHo@d9{d#~>5io0)0o`>I` zg-Wk(0+Tx3-0p(3VK`-=GmN3APMj2t zO%A;o*c936nte|bLJ~>L-pxdo=2`t#)YB_0_pwoU0or=H^vnd^6W{e8x z0xi0c=Lgkwt<4TiVLXLn+ANm%Xg!e^9+pKg z`XlE=Q zzq3@m3D=f>TdgC^Ehsn(tcZ@08!6;TsBZ0;$p*ZD2xkn0>Kjr6Ch6EGY_-Q=7?=id zwEa=7^D-%8XOZ%t>wk9j2yk3UVMM;zU?O1?%4X@DV)y%?&kka|-;I?%Q(o*70TPR% z+E(jdtk;boaI_7@vRV_;jXb-mb6u%7#&Bw)aT&TJ9BVZN@%>N#K!FITz<yABfEx9?9JdsoHYD_ncWoMXKmfvT86v8 zi@oBZ8L`|>TF&WD5YXaZB+CeZJNR7KL{J<4J#fSe^snju!nsS!35HEPh6+^dG z4dN{i?kn>e7r8&#m@3ObgGN9t6 zcLsNv_&csq|!gY({NVfTHge;1NuXgaQX>&IWb6wK!{YFZ9=0vAp*6*YSo<#|HOqDd7F<6e>w|26bd*UC;9|Ry@v-7UHM_=R3cwXc;gXLs*?X z3F&N~-%Oyoh`>;s6!1D0KMUdw##0j$4FN$Kn*K-m7!y62t;%={n%2F>l;~a_f6EF= zXCrGj_H=w!?p2lKS1t-BmU37ef%I2uVI%{CU8+j5TVh*B0a5d`1THx&uf~Ed^>1h> zvWP%Am}MOUYm8IrD~J`0md#ep-7hEp1pg)bvGhOF$_LyaB z=D{AKw<(R?79p;+EP^xuK>}|?6K#8o_xgP7BvNDS`NF8C1;E~q%qY_JwNz$jvKQ3o zCLwKeux*&|kS84MQ@Ju10Gqp|ZTv;SDqC;q)wuR|VgH;H-;Iq~1V$ zM;EW}RWwK5F&e`9V~LaRd85kD^Mgqu&s0uN`I>S$Q|OctFgx-||B(JbzD^*53TN`d z;ZS}cYyA7?gfts2i;p5~I;a=v(!SAJQ8iJ(kNYV#vxiNysp+d52lPje^5@9A;_@ag z9Gv+WEHdj)_Ag zz=6|782}G4022$ewn-1Wr$;{3v&!R~ne1@n4k6GO32gFUdq>c`aJ)yG%`(93C5aDq zLu6r0o|o|^UWgHZgQxtGBoT_KA~s6f!|p38jsf8 zQtagUKg87gKS?DIG#f8K8F&9QwhxxyAs!{SLb=wO+rcptDDT@ zOHk}yHBH$Yb!Ull29A+r|8%V8@fQmqiRV}6V|mc9f054-T8^sebXbhQRYRd6pkj{TzZ|}u~_)}?*X%csJfks z#mCkN{R4dgag+u?WWHxa!|tz#y5amqtW5~|vfTa2c{;RexOH*-;9W*Ol2aT?qazfp z-9o!WmewNGmunnFNCA0)GIX`fJ=?eQ0eG2Z_ud}Xsjj5lAU9Y*U0ex+ik%bx0hs@> ziOCRQ)sWaBTF%T8CE8p@K7NbyF0WUSvcN-HodQcv&!XzltE`h&%5;`$S}CUMK~7*t z!86qQlb2{Yjb%Vl^{h$3SE$qx=>4oIPiv9l8*s++pxP2n99V^Y!Kv?tCA;M*zDCpf zBt!m6>k_x}8?Od#WtS)Zj81xq1^(F@>?cW~&lm`n5AM$CJenHfrJ)VvXmf_K(!i1S z;TNvRR~38F7kuuIS9R5(Ji~WO%2pjC%qz2_4X~ow=(LTcvk#H;qa^!|TR00IZ9&D- z#QsXEu3%3QMf8LIO>;N1MVjxAM~AaZ2i(dxXH%sAs6z7QS0Nhv0^wqR64j$kgWW;HH&fymd-`ke z4X{qU>mBt1J0Yskhqvq7t8f270rj3%uo#G7gcn1jKnF*D;LK*PhWW$j8(~g;3-%$N zgpTrWw-+^-58|Zl2}hI)$aSFedvds^l7C|9-?)OA0V1F)VN`KymWoA2Ys9O6yXLP@ z9>%`;E9`9FcDbb!4+UC_G>rB=+y@OGEO)LIv=wLZp@AJ7AOXbCC|!!T84&u1urOg$ zx$9l;xbNzB4GmGS2YfiwnEKX)+lB1|a)TP3%RCHaOfZt63dCq$yns;R#wNF3{k@p< zgqWb~A=}l|^pJ;f7(DODqG+{jrSBv$CUEePdD1FzabWR31n(A|!PtASDJvJ(f6Ie}JeF)(HVHc-B;ynaTVaKg$EEee)Tpy4JmzbyxP{~2oqocA{;-({#^IB^;uiRLp$ zI)cIHjkvgroG-zcn=c7pRWk-&8hbq8HqTJ7|8Q*MhKHSV6P3%*KEzor*Zg6a0eRmX z=;JLI3A(sKz{aH>{X@HwHgsxFZttYSV(mktHSS!td#4K|f#*ngSO56-F6m$GOu=}< z^7LRxofoC_1iX=X5Ii}Z)fyL+fSVw=(Q?ve_MAs(6==JyZSAGqk!bfY`R`CO8dt5B z=9l0+D!1t z?|X7nynV6OZu~)LuyZp4EJ%AuNr-AtHP?=P#a?mD=jKzxG&(=BlxFihLHDgfl{19- z44~$t^MO<6L~o)Vx7&dw!A#`?#4rjrqe&WB=rGc^wiUlVo3 zjV0%%uGTE7`lch8;!TtYVY5syb615P{n|(1S~jW*v$IiovzI27Tf;Fg;DFYfSdpjP@z!X<}ASFVPI4?A=VAyneLn7hxoi27}B$l6&bJ zz&M&kv~UlU5VcVdl`kRh2U9K>riYUkL+sjZ*{V~`(+YK9a09d;(>fw)6KZxA+w(l5 z*~KekLueVNWYBbB2r&NQ8mkpJt;`Y)CgpWwh`rwem5zv=diG^Y0>WHyY&{s#iq$-yCVyeKYg$3{Xghcv4?t zc~WzjkJdKb$Te4+r7=D>sUT(<<{r+%@NwD7g=l>?R=8d7xCS;`U+YK7C^@=X3zAR9}f<^`{Y0>lLw#&O4XVaD_pdGkf zyK!EV$Zm~ywqln~7pm+9yJj0t-Pn#(MS2$%8;H|Dl1nc_d6$P>I;-3q&a6Oxv|38w zMLUAo@}VdM$o-Jt8KbjH9sJGK!xMwOfLk>h>fuck@_ACMyg+^RUVi0OJ3+$QeQrT# zQ#F?su`e%`9-PrVUNI@zg%^dYjbQsI`Tf!gjk0hiTeCon+%x)zsBrU$o%R8vf+0aw z#0LId0B1=?Ga4QvX!*3!T-mJYB7o}UO@nLq`W#^E1ZTJ)CH^yduD8gIzrf9a(54Q{ z#Sl^*q;4`#Ua*7{ic)mLfp}Y0EQ&EwpCkNO>IH5V--57Yx91oWBYVQl0jfb1ebmF= zfgR1;ws(;W-bu9}r4P58{ST6PH}`X%9bqS<%O@0J10|!<#qV9Uo0Fd>ECII1V~pv5W)i@I_)revY_!wM6w1SVw(Kr6fu!ojGlF=fa$FhxB;Lj)BzE^jxo9f*)vA*<|1`fdLV2ncYM1i@m^``2KUOQo+Po5it zPBYWk)^lh!Se?xGo4s(f_~yR2>34ohqZIfDGXW}SSrKYim~|e(lC>!*m2yHhTXQ;J zv!xS+Z8yTsc0F@bQgQ~Ny31u;G|QV5BBtl@I$g(IwuukjNeA3p`mpz7m(?;6DY4jS zm;HB0w|IJk$Ip*Wvxsc~kWX>8rh>Ag5=dV+rR5eJfnvSUx?i<}cs~6off%L9*1#Gu zxN$ql3z2bc#^G#F3XB-Exotg;2{HeedxW%R1(|=77yhVwUEJOYUUEsRoN1mWBCp0J zh>O~p#~)zPji?W2trN57UpU3;`}LX~vioR|K-&L9%PvenpuVF37kEH(%OQ4qd_;FW&DlwAu90Gn}t1 zBj$Ij*Nl3gr zh#w)vJP?)q=3&jCF)k%5(R}$SMlF4v`1lP`1}{F~px2j!Nc5mx->PRYAD0Rd%V)&h za^Vkh9GnSu98^SLBV+076c;=ej_|RC+dR&JxL(52KqRIV$4Y%ZP1p`25RQ=DDzbiC z3pIVRVj+uXLcFQoXnh&^y;}45L6esfTbA-c&+(zd@7|j|mc{gDH~cQ-ysQwdYfHKr z4QOCLp{;V#LJ!ixynNyWpMNmVZ1}c2h{HpQ2)KMuFE73-y3f;J)%Hh8$&+{lX#3LA zKYrxdkgyMAqMw`fTf^WCIU##778ASd?DA@l1=&$M?P>BJkpmPLG25LSsI+xu+PC;u zW2C8$g-VEWe$1kLUIa#i>XY|H7IDBdyfh#p%$DRNq@G-$9dX$CXs=U`-p6G~QgN$H z`yQWm3^6Pgp)DjmKWs#gc_5W!mihyOOeWx)KJ*Ed>~Iav1p5mztj$v;gqeKMl^<;_ z#Z%*G2B`@th*&o_jtvZcFBNo!2VFo2{!QcCj~+KFc_vTr2e*6J|Gn7(Dg>zXNHm*v zqBYWwDm;@3ky!Hy_Qu2aGXBetz%Y&am~-^?Uf;LT0?u-We>}!L{K7;Lkw^k%ucYfd zn8G%92n)0=OY;BRVQa^bb~?TnZ2B#lOe=^aROzTNg1S1-MakL?KY6Ti$^y)>vND;V zWOqfEA^sb?kZc}X5IqVcfo|StD;OL`-$_S?<&4nOYd?P~aNNw)3A*UCxw006{Hk{+DPsT?){%eH= z(!vqgb~Dxt=Fl>jYEW{B5+VVCKPf~Ro&en$Y!kJ3XKf$AiL51%NgG2iCYLk9pfsD4?+CdGM zj1t)@U7ncf)5}w|ATAmFYWma!{+*|jpUl(CWuOjSfFi;@?c!6quTp^9%d4?YuDL`r z3IP9BHWV_n5chd8&bu?4(ef%_hw5{m{&@!N)>MS z&nLKnVPygE*f0p&^n0^Ha@vBoyfRAFZq`C76L?gzuKettTe+`7X@oyvXgUAn8J=yJ z4wu8MMGy+G%y8pEgjBIa>l#flzTfT(;{G#QNp@~mo<@4Dt?DWI6C`pFLzEN|t;ATV zby1SKgB;o!{H3fm>FD>H_J6JZ>VaA`hf zr4&9IrbUmVUJwa7KnbW<{CKNCbFA;MCCnkYbBQEYKE60j7eKhtF-%4lbTAK z*zHW318Y-Mk$Vd{h=f0MoRNv#Ol2@XcrYlAaoY(Zf&-Z25r-=xV#D!IE~-GvFLXms ziRu79{vay<8Vt7SAhV!@>nA%HXJH8^U}|Uc{IKZeR>GApE$!h$56Z$%G-K*{a1Tq( z%f<1D*L5&>c?#sqbON{xvno+g@^O1R{0$SpRRGElj6EU-q0yt-c=4}E z^J@;vT{B40W7y1{GyWWxT4%NLw7ItV_ylJl#XFLY*p7ux%weje_W{>z=Z_0n5)(S@ zNIHHVd}OKNdQJYWDVQKlgqgN=>WOc5f;su6TAkm11<$bdP%IK~@x~cK+>wMBYr7NR zl+FqbS4C|vNvT|{3wyI>4sjBV>4*)7YD#Uq`EbonT9h9AKr&2uD zb-(h*Tn#s;wV4O%4Dm;?v}TOX(!<-xJ=ao8B|Z=mwQN3a$RkiPl!IQhGDO4R@6<4N z2!6s7aE)in&2`PRI>#at){oySIq@EkzAcl(FY90oS>Q+^lv#T!^&>B`ilUP>e7mzk z(-6-IE)vETmaK`F44h`FX4t?wZ^izN+4s~5c_RWuk0zp}xArMWra@{ZNEPIS&Gdyr z<{L3-+gfY=<3u^Jv(UQvT@hnF6^jDuwDCl%v{Tf3uS?|-Vzp=ZdXIP?>h!Mni=^!5 zaWF5~)I#vbtzTl24`up9QCAZ;wp;j^nlR-#IRMsuUxXq$iaOHh^%FhZFGi=7IwP*D za$DT02k&0Au=?``dE=d%Ed__D6lfi4fLo_D(s`e-3k5y*J2xYG1|9x|LtELAOemv} z3`$#>3CT9W7sMX3C^dpwxp2ebkp z)fINpcs};3?+Jd`tG5=yd-8}@M&Ff1(S2I~EP$OQtYVMxMLKsZfmh&*Agn3Ucb=y) z??bl}thO5wm4@g+hD8u+#~uU7e~n&}-{gNfiue+w;nxK0} zVrB*2(!*nPrN$$%xh{SLd;9IsPP3AdT#d~0`RSZy3gS-f^&Iq9w*S0+rJ5cF$qvX& z2B+>x_s1YnH63)JM+OYurWmvl{SPg#URI3`B)yV{0t?(D9DDaI|7$5w0o|?deppvi z6!!F3PH8qwqDhgqV5Kc%c(CK;%c`*f$fg4Le?(1OlfrfCIp=lM3lAesSn@74>&EjN z^8_fP7C=55yohEA##x3hxGl-&^Y<->1QB{HUFxTuj}sLUCrBIeT#!WvPGB+v4dBv= zoW(QNR&x{Fx%~k7f){8ud9|1OpEJd$=Yq5yYxI4C=wmiSF-4Tw&JW$doK#Mmiai?2CQ@#e!O zJG)%T^WlKaJmnldG$)I}@!+hc_hz=7(%&jCl53^c@&I+i@$|c4G>C*NZD$lJY$iP# z|MBb=Tfba$4Y%b-pUd=U<#(fmjge$Bcn4yVE{D0{ygRhMO6+dhxuc-b6cI8c&|&|; zm2mLPpB75&{7wr)24^xP_@7-|tEt)FA2Ye=|0#P&0?-RDw;WIe-_V$_FM~;Ner0%$ z0C+4N@$_)PTM5=b&rcbW*D$-n%-?SEo<7^n7IPqFwB>yDs;YokxHM^N&$%fOVV;&G zW}|!)V*d0}Gl?&C;Xh;Zp@mxX@n5X)7>HUvO>1ZBylsVk?K`zU&`7|c(iw8yq}78L zSwEr{3blUvZ+L6NuXwn1keLP~w>GspbJ%oXjqN`df)59J475?=GrBkiji-v>VPtI6 zV%m6aMR_lW(-@gV6~O5NMIs45?A;1p`hvj7Beo4{Rx;t6-y%;PNQ+8B{mZ@9)f>&< zt|pL!AVZ}y>bmp`>p6L61$7mMO0W`wAC6VdUSH9hP_X^kC&w`5)mxzJkSwPRL!}fP z{?e7Rikn9ginc!o<&?`#*+!PUO60{Fy_xrrE<-n>%k7+Vtj+f$x0PDo4 z(Z~4{coet=0QZ2mDutg*dc(|>5o6pSIHzSct%oJQjhA~@TY{e9_d_vgG3sfjliYjo zRPZkCS1KsQS*DuAYgngKHM6>;P-Lk%bqmCmv2Ry-)6>$ z!55PtDx^w^9Bj$r+NZ8RXQ?Fc1=$lP`$tVze}Mz`HaONM1$-{r8pRuYxPF<8&!R~> zW?JAqdvBmSD4|W{w#8)q)B(;|7n_yye*|So?LV$t3gFDlsT#D=1%m^F%ppct`7lx8 zQitu)cyQo3{1q22@v1ZHT6Zl_kTh}YCjf(R+LgJ^kJJ)KVd-PN1PtvU!949qGWjy`b zx9uPz%T{>A#Y$v|Q#IP!ocjq#L4lfZsmpfUAxWsYX2wixqSOmw;F2etTQw0in=3QM z%<#pz*&nBAMlk9MX;>-0p7Jq3*@u`qtNoy53mhT0)=de5JD!+yW~HaD=Vg2*!3mh zPW5yxy)bBg&EC+E7}H@p4Bjy=2#tsX1>^=o4Bh-y+`nq;ntyPk+tG7NQoKW+!;BO^ z(w^irp55=LN{EwR$&P{eM)zYbB(l&xveHtT2fLLpeX<-#n~_^Jb=ndL(XVl6!0KK= zov55~P!{71Nx_KeI0+SitJuf@!*=i5{vfC%A27^BbsyNUt2S>5Bui|rrH z&tDWu%^dfZ!K1c27xRj!{ZM!Rf!f;xXtlmQY37?}c=+&hZWJv%dcBkM!Z zeV1`pxbP4pu%H8~b-mAAzz#(2+-y_^Ye($1q`(pEX$$Mk(_u_EkA@@>b)V;oe5p+` zdBWIIbOxz&QHr&K6jtoOYpU&cwn$*99!rn;6=j{Qm8w*zaB;o^g$iz}j;fw(o8k;5 zA$V-BE1b@C6`6N*MDy+Ao%9*qW6P&Mhb&F9-u8r91C!m!&mW>q{A+_{Y9z!oHX&fI zq@CCmJ*ZNi)~Kp131ENwIToYJHT5NjcF@M<)0rk5-<2WhUsCH#6>wcJ-2&X4w>Y0* zr3Ah=!@>j~k|+Yes4`guYudp+{rnT~&V`Xwv?+2LGsuuJ#BWrYyf_j2{lR`TzdT|( z0-)ZD=HKgVQ$+0|8d829p`3KEpUD3NOVAcJV-M@xj0ssUb6_pWtk~-do_Vb-Z$`C@ zSudcKJk{Dt(MA1HC~6(?KV)9}b}A)As!SP1v~B6zuh!|CQcc!{l(GVf7w0-3$1RB} z+s)IVm-6FczB6fjXYUto)0Bma0k-BWKC4|G+m99w@FGaI3RpjmUPKdUJ_r*PbFfdb z`UI0A$}#TV}geWvW^UkD?Q1nf_pOyusOrVJx7+W|7b!C` zDNxR?+y-9^Aen6Olp|tIHmEQJ23N*JQBMK8%EpFQQ|GolbnGXIi|DoHEEoSEu3@JxtqXnETFB$nx=TvTi+e5AS0eVc0;a5BYZ_0Xv%&fI%;Z61XN87(`zZmo3MLO zQFB%Vc3RVmcX8DNJ<;tmcAFnSNdUcAq-S1LX>d^^0lHvQhq0s8UU|NFRTh85`e^{Y zWVaYH`2p7WmKL(tu|>Xd>@caAPgR8cs5TPij6$ zM!a;Ars`-bq4BXc)MPx@F1-;*`x8$-Es~?u8a@dO2o=TVX|?X!?na{rQ20-uO7h`> zk8k)>DhS97*H)OYx6OMU zJsk@NWq2>u?T>Ul7TBOTp5y$;s%twqzjjH57L^=;did@3itw4it|*0WV^Gki1-wI)b~Y$H&;^$qL;lx)8cA7n09>0IrF^L-{kl?+Bj{-}@tsq`dVX>FCw`VR&{>(1EaLPwvDL~#jN z zqDV(8$blGmNTOay7Rmyq7C{ogn%k~i?iGMX47@=gZyhcQqdKrz&FCvB>5{R zKhR{B>R*m`X2|iZsa<@L*zo|T-I0z@0}2I6y1>OUyA9J_My!RhGXa4C0R1D6@|^I?Z z#dSCoLUHRzNBSd=^mvJ#chaNiI=W|!o_M?w@j zI&`qwCEWIe>kPSpwe1n4adsM93}^JP^AUNz_Ynl;LZ^r9_S6c_DM*LbYXlh1VG6a* zf^&-zu*uVm3cDr(q~=lr*cLO18X$!^P8bqcX$tXKvwIAEp8Ln{5h73a|}zE z`ml}mD+(BbA^d)!nBKN_X~>^v3-4>*20D7S<7XZkT!Z$fziSQO#04oklR>YG*bE@! z*P-Aln3qE=!<;`^n^&1jYAePU%ZEpu#cw17+c4-QaY#|lY>@WOyN_*v{7N}`hO^ru z5fHQNE}u$vV<3q_PgUZ#eb$I^uTOLIdm?^h3>0CF7kofcBgYzddxmsZf0*+B=z8yX zs{i+Y{21jZnNdpFNm^D$9LkAM$PA$(LiV0dWlKg@wjz6!>^-tFGoy?{))9`3BdhP@ zd5(JZ{`_vgKVG+PUFY$9Jg&zz?$`ago~QFVEbjdN$Zm|(bnfkA(6^*CpZTrOgXyQj z4X-$)w!T2TxJdrko?W_Pg?1Oap`72l(CqJD z5VV`Ox17AUdI_qq2v6~@HR(DGo{F$6wd`A@Cv~=Nlbb_@8Hq0DXVg7^k$#4b&DFEd zgU!Lfo+^jpQZ!E>Q^lt33oStAebeLpVb>e#!o_u?DFsU%wOQRwa_FqOIl|_fy5zW1!>0g4X#ks zX%)1w4xepUV_JDVD>53#?iJ)^)MFOuW$7vvbT;qmz*Ng}BN_Q)r5j#;k_dNaHj>3- zq^SYD6&d3C9sU%^p2#4??JQ(Z5S7;kC=bqP3GnYCoLa__J;6bU7u4j?WBb;CUPt@m zHzLP4P8aFlN|hm1+G|dNKYKibmcA+;Ji`PojH-T}S~ZTu&C#m)Gt?UYKI&a_>3YDt z<*85`E1~iL^3SeQ{;V`O9|tPgR|56Jv}7-13m=&KXG0tEc$aD%_6{o};3=W^hoSda6%>GOL{ z6DjKt5u29|A|S&*kG**Ds9k8Z_Bg)$zyzuk@okpLYh05%WjEmdu&o?a^?n7ttbfbE z;&7c+4*C78-2*Zm7osm{*|SN!FgQ7^T(KMf`RRcavfBGzxVGkx^vthk8LS+j%<-G< z-R0JnE9?hphAxo#C|@}pjikJQIUQnWoYLLY2L4+Qn6Z2LD3X2)z3lpIqx-$nTI)Vlo-hgLcs!HR&Q$(u zb=;BMKH74<2%&DQSL0l*wN=v#Inb+6n#8ij zcJs_^?%zk~s((*9DX|3AWgsRCfB%<`xUeO73TG|C;u!>xgOgRtk~s=Rj~V&nH%(pMc>?U%}HL(X>$j#=liTnk;F%r$y`&8>;s2ybFiGe2@09_p^pzK0OwVg8V>G+?(N~2{ z2luM{IgKC{8=1o-*t6uBskA-A-Dg{^1KAqQlwRn8SwdL+GA?%Si5P4~Bb=^D> zn6<&g5S@~5)%D3-L-F~j8^PnFx~wb9!u7r1=*Z8V<+_IV{VDK?68J<=P7ikxA@!Y6 zTCF{RB=^{?f7Sgt)w-BFN)rs#5PzO3$H!%N$HgGTI-0bffpRXv?dZ`mqnqQg6tZIn zdMp_s=AudNIxD8DpJzwk$FNAs%0E?1UrW>*d zzKB|FSt`3r+ji{U<5X0O@h{F$=oU^aIi>gKawBM#9H8&DL-e1eKI}4Vkk6T=W?lQZ zHlU_)l}*}>g#59@GJpml;edo1`jBzU-7To^m$r1yL5e!ED~QwYrWy+_nmlIa-j)2k z9rB&zs#gD}pB&!pDs%_#4!3Sua+55|C8l!Kaog@-vzE+W>1>uJBVw{}$aK}cmwuLq z?T#KOLsJ=4$8K?u#7WSm)ZDDoGU#Cad=_gJ_^O&dzb0DD-RemX&E9%f3Cq{kF zfLvDs6m_*(xOXpv7iv{L(lMk@v7)8ysbM6s&^p2Rn)611PbHu4B?ITp%smc786Qc? zgBMhznv-WgSp^=iUTunEBvsdDmu~k&M2c`8Nn8&t+=-?dshrEFA}Lbf_AUuS*0HW@ zq2Bz~@rax*HR>6=;U7WX!^CjhUUdEdSu<4p`TKpvjqRU3&+~)tB5~cURC~Y3diHkY zwhuC=IobGnBMyfS*WW0$xMcL$H?-t{z(K3z1HVIe9Z8EUZhMvFx%vG#m&#VnE%W0d ziiI3uF2ee-=VLX%+B4RIGM3Lmgb3p$Ys*};Y{no44JhZp6~m1+t1yt=fX5zZWA;K0F0IT5W2IPh!_~kEAU%693xNbdpqv zn@w8nSrSO8t`qZ5GWbN4$76!6D$AT@ytYJH>x)Pv-)w)gK8pCWel7es$%p_?oz=#N zh@MnL*;d1qGdqW<6zk^G`)&9$Ra)idXip+WsXLioZP=x@?i4?#IYpnMAxNSl%m8_< zObwCNSu!AN3&WkP0<9~B_7fmJjL^QC7y%$>5G^5kf5iIMb(uZb#FxzK4zTzOICuzBsf1RU?d zT5XBRZ+c|!pTwF-v4#s?U;M;zqgwkGYySCT?#PL*gMOAvQVI`r1xOaLQxH3OD<@@` z96cK!Wu58hDd$#pmv*6(JMs;?1)t983ivK&=L(QUYMepHh8ZA=;-z(Gh9{afx^!oQ z_~Wx{n8rLLO(|j!7LpVxr(a)Ud5P(z8Rp#XMik|=vyhhw`t2IH^rtpcAign^_55y= z?enI(Sy|C>4Gapt{m$mAKL!bGHa&X{#s!1dW|H-^J+f+!k9j^yOly`zNGugo@r&oC z1{d>enUlH?+~y_i2_jEvJ0#7gAnjW&WKfi^`(z~4-=D|zxA7cunbcYhjkrjSynkcr z7-DpNbs;+Fit~HiUXD_b#Jr0M`?QtJ9DKn4Sa3v{8hk^G!F+F-=ex%<|v6e+{k_2t+fE3fI7ZEebyQrr|J!A?oa zlx&`z&SkoobvSjc62U}$FgnrTvh*g%BHtg`&LvTZ!^&2gsIP|)B3Z@E(*yJv>quI~^Dj&n20s}IU*kH1?w@h-W$SHSp3 zHnN0gbZMylxOY%$4V!SsajVxl3+spkO}A56;#R%z~FkA)>7g zSQ~uOu)BKr>zn$6dfYGW981oP6>=PC;vsde`p6mAxUs-=68bF5NXO2%I7&NO?>C`!XNm(+~Q;BE=u+9r;m+3!KO>yT4n_quUj{5+V?g zmqZ=xcv}dBck%N9VwUe?&E6c*=D)^Rbt^WyghlV7%(oYn2GVz(R-%s(7*R#`qCK% z_z=zz+;aauhkvAdv+|LEUt;^C!-u*JR<<3_G~53%1$gwpVOaZjwzzWQEjvgn-+xnS zd~i{L(Vy+F&6vKtU_Z<)aqMky=@zYY7qov)yE){s^Lu0EULpLIi$0tA8No^9$U1+vr=4PP+hGDN% z_~_wrNy5?G>QIvo{E4A1@e{bD#oo~s(JKPhX{V@L4}kW~s3S7OiR`)l3~|JtXzCAT zmKAG{xTOzMk_xd9FBJT#VxDvpc#;d*WBrBbZ^ec5DHc8wotv~1n9J2pF=hu~XQt&; zS45>Q%Jo302V)9aB^ye)M7)poOG&U%B zG10?n3??u~YiR8$I3G9EOXR~K9<$fW31!?IL^f{KG&SO}&+bxENFNUDsK`EfCjzs| zJ7->^rd7U2BK;hMk9Q`vLX|S~`s2~9EGA_y>cCugbc92(?BD?Yf_{LW9qwfqo(CE| z%{JR{mTy!+_d%+6R1EPB7Rq9lL>ox73Ts z$R`Ey8#>2CuUpdJEp@$>E4v~@sR1a}dj%-f)h1_uIPe0q8JonDy!)`;&3v1kn^ zm#my3s=0H(7A#p6@`?=*zQ)PPBbxm5k*m)lPhHa(-xCtNk$tiC%@6Xk_Z_*PiaRSJ zhB=2isIn>sZA;m^Ej?6Q+LMutUk(n))(zm2(2JN30!`YM2+63)ZC%TL zX=m558@pExGqE$rL(Y;vHvS?AZZH@hOILhW%KU)zFKsYp1wMo}A6LgR-*GSus8Db{ z-Of0mf#~T7^RhHP&aXZm$~*7!sar=7oo(r&qDA7}+>k^9+Qm+)@a!Dw{z=oIiXg)S z-rXKJy3r16MUN9ZqJ6#YOPn%k=Nk1dP#;{(T7x?cb7NWcx4Ah@hQ)VnW`K^ye(oQS z$s7tjo^7@53>l*}up+(;DY5J%0{c15uF5EI0W+U)Uduh#D9nz&N6aMcmdE(yyqiL- zjv!~Ys>`qj0ZYKd?*lpR9AHVlvf>V6< zn?S_DhCckg7p=(jPZfQcqz3`sc;yS&c2TKh3kerHpWtkKYsLZ`FE2ft5dL{>Q8bA} zA*%BR1^^Bv41B|rKw6CxlGWlAkj~msk6W(s#|%y6C%7UJDDjJ z$4i}0q~_3tzq7YtmST8y4tZvL$IgPXXN+^a1DC2`ddF?{Vve#LmyEC9O{aDMqT?O* zX$os$xVtKv_I|FSh!a%50xZ47Cc|r%&pvn_#mbIxtMldYK@E0X$xfpXc9!$nI1QB> zA7nVyHdZ+k{=<6UlS|l-5JaI|QtW$~sQQ#aYQ@}KG6x2P#IsVM=g*FgQ`tQvlr)Op zGG0nb8D@EsddcCU*?q=2%jYWhz%QyWI%3_$eGbQZcLujb4wO`cDU{Z8;K}W&3)-<=%9uJecd(Ar8CVo3YLcdM>f%eBy~KdW$BDgBfizse(XBy2!DSPT(OGIQ zEQ-_`kA=&XgdnG{=77f%xiww^v7}!O_*J-x@k5nUT=%uuy&RISlH4nx?D?TTT1u6Y zOye7ST-_i~(YXRj$D+Dt7k?-^u##5reOcE1*e&gRo^0Wy82}N-$ZvzGjJs$8N53@0z>8UUz03_K{Y#$_E?7WqPMLEIo|Jbo$Dg5}F2dlEK z+UTr2UhcVplgNkPHD5ZQg6#^)6HCeOcv?3?s#2^TndtX?x?PNSLr@zaW;9YAHA3eC1t4& zBvN6=$nA}5eOGtf*}x|nZ?mtG?CiuKqO$cbr!>j&bq4>;5~$LVxD9{8Y_tI{ZrY~O zk+^W@ZT5&{pzzu?08g?w7@mH11pm}#oOYn8`>ZT@JEl0lI|)Q|NbEJ#f?nS+g5|}; zeC91uzG1hz!&A(8kdR=riH67GX|L2lrN)6H>yp<>HqP?QC9$J&dRyqN+2YB!G!EWZ z20GVvAd{nnYw=e};+`_3FgwG%g($10Ptq+tUklhCr2;H%0V_wWXE$$q83X9`>xD}t zzhFbg6)$cH&Di44pPEiE3wbj1bk>zZDoM#Fm1Q^kJ=1*r4F|iDeaKR(`A~0u{lwP1 z-JtUEA0MEO^T}Wr5PP@fEHD>9k5~vH(R=j$6*ER{`xgD_kh|MrW;O_k6D5QM4aQ~Z z(NNMTO8}hRhC>*X4xo!f7|yy$rzxk2#G2KLS#|R)_goSks`$%WYY1^PPWB*ECF;QD z2^)6z?+IYv_DhtZZ%p#+zDyeR1ikROM4(GRMKkG!MlqV8IHR7IFT5<CrxQl}A z<2)3cbA`>5GC-9z*KkL#I$%5wPctKx4JBx)y?lARrt`7Hwp$Ds!T6ThijeHGLRh^= z)gvzm=8-<#yOXG-=2q815V~-O4kI|H`_i`~?zIdP`7gmInhsIqKh8abiD)pcd_h0) zDoLR`snIVYS>bfY`lq3iYFfZLMnn-QM@r7OP}OHk;4+ZrAs(-BgTQNiDTFSc-o6`| ztjZ3`ORkAWz%_`E4fRIM&6f2ox#VYq;_$0EM&JeHfk<{~r@;>>133D+V(C!$(awzD zo2}l6PHK?EFbyZDofy*&MhnaDlQi@WAT*YV#8P(in?t+e?mRv|(P{K2$6w~>)1COh zasX7ZToaAwWW*x$9ZHB@v2&^qLU=ezd-*roca7%Az&v_tcIhP}$p|e+UE_m%F((%r z_~sp(tKJFm-`(>eWJ{6Yx8{N2@64c@aMtf@PmkVsy}Ub{!;Vi z*?NVx?L>ryAj7^f6PTw~MNJQbAyW&X>RE-e^1a90sh~- zDFLDeLRi$({qs03i}l|ofv|{&#Ol0{rdA;LwD;Sm%7}e3yyCLiPlL#fjKtklMcoUZ zBbWv#V10uFQ8AQa-x9Z0A9O=_^YlBOo5QIIDQ z*vd7r>?oR1lpT+>oeU8FyQ~;H?i3}$O+tpll_&pQo4m~~?WgQTRSSE~$`}ghZk+W* z;;diQv;{TK!t*;I{Z}YUNs)3D|Dow8Rr5-bWb$@fWU_zvE};9gp>t-I`xkRx@&}y* z`D4)^%!N6@w$IF_&h0dTeL+lm`4JTDf)$;v9wkv31EG74P#n5~e?cy1mlu`1qCb&8 z&iY1dDQ0IeGD6_5w}6zG-iGd{QD_FQpxYPPM^p^($E;^rp5(!zDAA12OAIYHhg*PiOeL{-O*#R1(?g`VF zad#ul9+^i+Nkm1CdZl8(_#=7KIEvL#FseQN(^*PUDf>uSDxsZY0GU@hTcR(l$+2F- z>_})JPSha&h#|SO15wsXFAhsL9`o}14IkB|eIWUXjpwrqh*Qak#G3@hH0zGm@40dE z{W7Vu=(m%G{LZ4}6VKtbzXCp{xSp3%W~^((jEOz3Z)8Vwc0FM1ls#C4uZBPH=w0-z zt`L$#(D*x}Kd5^K(|ae)C0^8vlkxJEOY4EAZ}X_avyfp9PtU4m2+gJHW75OuApR%0_5BlBx(gCrxS{1sh4Ot9<(KBGpaCl&wiNl5ancdgTB+12kk_ z3qU8E*_^)4=#}G6Qa1gIu$Va<#myqQR$cQpfXU?PtPCR0iwFWn(AK>%=hw=V<62^e zQy6JUbV%S=EVf<9bzVIk61smy0SC@uh$6)KCig-7rQzWkc(|27hqZGte40_Auyr~# zSDh8~0K}%Avp>V9T@2KVus=8!d^d&uBA7~ikohxCfCOzlE?S9)t0wc_pczf%`6c;5 z>F?^tDfA(ybvyvj@~D!-Jp{Pm>9v3-$%IY*8^p+#DO1MS(cj0I<^|o!QEo5%-~o@w z#5ljr{!Bk!yj67mbk1>Ml0TS^#PecKfI0@}CPYk5W(Az2@j(SDM-#A zJCuSUmOR-lWy&G&7=UXy)#1yBv#K{pvdjd97e|L~sqlMNpVxLj)Dr?a+~A!Q`X$We zgw>Baig24wNg5{<-x7^nTdi(vrKw1`2bT(nlC&sn4hD^%-q^;jUDmDds)yilLW(aM zPU+cTYv4|J;&7c55u-}&&q}CvOmEcLCt3Q}~CJCCh2l|HLw~{0(4kcZ<06l*nDg$4rx1vq=mkC~&*25t9N0 z&gquE?`R4G#(J(|@&VL)k z<F5G6H|CZGmHurW4){IT0JgoW~d%a&kO&#bK=$Z~Eblm8$l8nDItE9-k~(q9?K zAI}dG>ILUF;87MH>66?4E6Ts_HFJ*KS@f3q=qaIRFu0U;Pp8>Q(~wGJr`Z+WRQF)< zno)s_5)0!ysNqfAL~o7viKWc0*3|He^AF|vl!Bf;btgs6XFJjw;G9kcUCLYCKS4>j z@p*a=@EyJ0JOTqE?C)lZePwhP^&HL3@;8lvdElh~H($G7?!3mh8HyPnWVtN&2k?1nn4i$u&5&K^#|x`Y$KOmTCg-iC>8( zpfa4s09@3oNb8z%h(JA$iuv$d3vqT~>e@j7dw^pp&}Peg+J3OrF(tPQkv=X3uMP9K z;c^0CeFZfzNg&pL6P#`tL^=y;O1$ame`I!I+bk*w%V4%&nRe5khuo<$2}KzoQQP2_ zKOzr8_H1Pk$OH^dL;qLQJ^iDXkwoV=Ekqn@hgEzS#77)G|39GO@1 zTC(1b2AOuwBn`v`e&yb!LbQ4V!HonIa0aTOk```szptB6lXm|&R6q_JmgHK@2W1jE z_~m??>MhWvjKIUA00^WMA+rJbJ4JXgZzo#?396Gb2J?j-b zLH-%pMQdQAvini$xrkY;$*F?^&px0z%ZxpnuB|gLTp0V}Ai01Jqq`?^vc7zhk2*V9 z)O2O$kZQ{_pPt*ovexT6LEcy%N1dv9zX~X?8L4#Q#YFB3BgKHSM6q+Er+LX8xdnz5Q}l;xdUdfw#-b{T{Uux0Q{uB`>(XD$e??xR-beuQ z>nf+jKfrQxBUru?d5U778*Jx;ZG>`YMDn}S^G+k(E+qd1R}n1ey!?9WXb(7MLFQZz zMT35OhC2kz*kLYsC$q-v9oQ$EQrCmSUOK}w_yS=gL*Hy^!*xuvKbE0hwe8AG5sSLi z>IfBU_9+c``xio`lC%_@#_fdN$=~P<=y;T^_}&N)HPdFJmhFfp!^-jBa3~Wt%Q`md z$?20{%iq9xCaG{LWeX_(vgd{tG!a>{rV}lfy%>lK7`7uQqcqph(C%ic$n)rhks6JU zTt|{O)(5X=okcO3GF}Q1q#eu^ndxfSKAup|;=uc@ zBZFXy2Jh^5M9=I3f7|+5sS@&|A&E>ID78R*O zSH!Cy{ph*DeVUDWAfnOj&{HH~8)KSN*~$gebZJGtn0LMpV+=q6{Dm0aqgp(!A z+}Nt}x&58c0duhL)B-Mw=c+HqC}sC4$Zl$VwR<<)QFSF1NZ+fE^vY|09&x3P`0|t& zx<0qo3kSE0h3qjsdoO~T&qGR*$b3vpB?;b}3cM)Z1V7~R^>g~^0PmHWX@dH)pKr*; zDtsN|ak$!c26Zg2iXkgq?81Sf&}U&vjMi1Z{ibfZv4s>xG89dIXV83Q8}UqR*^sUMv$xnV;IPgy9wfLmv9ZJ-8k~|4gV;xIbO^9gcRKA?n0lNU)u|sHQ$Nlh}n)`I_XF7@@VeONhgYZLo z46hDxHCI|hi1%qIO{-bP68jYAT15<&@1HgN=M;3E7o&zOEPx!PPF#LJEk~(0s-#*u zsko&)i-xEAbbqWHG3;3NXs{hmMKxKKTqQFF@q`$?C0zj)1X?G?26%h2>bs2&WWV-2 zT4e9qemrgAT4F46`93|ybKDLhg=cGPj@^YP=&vt86fU|B3J@;;EKSFu+9LC-!MYQ;!plox` zjqR2p?-NqA6xcS5fkpSzlJUu~g9{_Kl))7@1K;V=Jt)P(@leeC+Fmkqg#ko~V{CzV zqc-$_ZKR;K^nRNBSCGQ}v4W=at~ieaboxD~u zJA@Rus7I6iT^g5bMxB?}iW$u$Uaed)BFOgy1ZVhWci!St(K$R3_{gI3#b4=+^zvxS zjrWu72bYUQ`guK?u5@~v%Ma5d3PbeuzuEy@@5s97CSM>a8n57^HH~)G7$aK3YTh*s zz}U77D~r~(7<(9XMv_M>k78h^!?Z$R+k#SA~Vc_-SrilN`v7oT*KtfwL})kcSoFX%MI(c7ryXVE3G&#DoTwBvEbsebc7+-U*2 z)BMD^Jt#bS)LQ4lN%P)#dZibC@jP!nJ+iNtiEli<_qwl2*E}&KjKxQfI_M}<7gVo6 zKP<`_>5_QYhym(YF<)5I%Y<^78vc4)l2%`LohY}ecz;6I?iNQ?hO|$02{E~z^}XJ@ z8!_f=>ukP_X6Xl&v4Dwyalw6yDf)^&CarK7SWkV;f1?Oj!1EdLswz2;8qKXL>bpTA zjoYSeeS#`qb%Z733aI?!->4{G&m2Ge+VeLEayflnxtDlB-}s*@ijuT(hKF8@%^arA zW_7VRMW(nee&?dk%&Y5212V!G*4#f^L+AEd24{|8{1Y1(1`g_rc-BFK&rt7(INr& z`llty+_D|mYPPR@Zhl~3O1lYnw@Mt0QR9JB0GX>c$nh*kD+60~~Mp`*S8 zd}J&(dQVV-4&y>iw}dA~#fJpTeCDJ8P`8lX`vn)QaxW~gbPP4{>rOueM;gK8(S4mf z=E`X2BpIJsvA+*Xh-~Xim94d<8dz|+7j6Jsfg%SsMQOW{PTurz%`^9l;0dIK>{XMx zc5`bDI2?&^=T@=OzdUF+ktSY#jXWnPehZKZlfXL}9kvy}?!BWuz1)UbNeZx(`(ETL zxLakp?z4Okche)^Jh54kdhk@vq98xEWa|D`;$cctl60?6S+f_B?GeFCTS;VyN*SGr zJ>%n82Rlm+u%Pz&nK(=!Z0ly!>#ctmN|)&?k}E&8+(l`1UnOAl%(YQ_J3~paM0G8Z z6Myl+SS;c<_~nb>SM$%n4qV?}WaXY4#B!~sFljQ1tUG^-;e59UsEn!d;erR}3%IXe zow)A&=nDXm^ZeLIQ|0H~&WA9uq+(S9T$9fUAgiqeWWf5jo+7)C66uby*ag&-3r7Q= z3`do~4+2caP8V$k&juowy%;c254s^j@j9O&vyMr7uAG_F`j396vT2ef)MMC zhr-0lMdf)!m@;}UUYg_H3LK(t1$nZ+{=Z)U`sDcM3qYmNR(I{ryn*?LGxu;RpdTj+?ZQo8H~lz|&*gIL#f=ihLsRS)f@ zET-yLinjcUj8%Sam*8t%yA13AZ(m#g`)3C9MdYr#(s~iM6th#$b84GC?wx>TEeqV< zrSat7TPMfum)oVB`|NL-pppex&1_}_>AKuK;d>kGJ>6PU-xn{vqt!nQAgLBV&6*iH zFmIc78d+c@aLo)8+iQD;qhh&9S(mHd$X!8MQkCZ8Q@}A8l5r+E0C$c)zM~{3wR?+=v%sH51FcME{_GyMa&(&l_SR=ar$u z=E>_hK%_{-Y4Gff%mpWC9sE5S>1OfwguBq!5tLS&liLNljS*sPVpcoM7aza1rlZMb z4oVi-mB42Vu__+*?A za7f6UX%PIL1fYjmEdw|TEJH3Iec32z#4$4ZQ@gpJw=Y>UnS!xF(8wCt`!ID0Xr~~- zUDI`!9tK)ervkZh@L<7yvD)f$Rr$)@u*$+A(M{mH#j!NS;G!B_4ciTq|%Yz%zpvFZLNtsH{svD$C;6A;p z*J>&Dab#W@JkL)%&_f}~bFLJuQI@3W?-oc`0&yZY@=g$GiR^A1z=CXdx3k5JiPUE;BZ~K}E?{|M zRsOep@L@!T0q@ImjzBub)aHoTw^wvJA@kP9`Ntjd1&=i62JJ|p_p@GGMBfa0XP=~{ z&=BGH(*Ob=(qvl#D{?h({yl0v1uN@=KN|3tvRpHh%&edTv~%=ThCt5vK0$_b5*u7O z8j2Y>BwF^JKscPM0kD#PM9@zmBbd+_(qsO+4q$S{pcqK_v*a_=f6k{Wt;?uCZ95~A zMKngf430DxIl>^wrK1<>JT9bb} zb}fO&y+B|78oCS=G~w7k^8|36J(kjQ^ z;H=JWt`iM|nttz!2Pi52|70h^)l1``55Hp3GGFjwewPa*F)3ToLrQV{#jxzv(20hb zS3E50<3C5_1=FuA>oPY~4bom|k-&Iu={NVM%`3;_^QbWTiqv==j%@9b{`OZD4K!0@ z+nQ+S@lUi%#c@W(r$jfG-1Kt@OV4n8GY_;b$P>$~nJtdnEBaMl7Kntvv)|0ksk4_| z^3tU&eu#OnKH&MO*VjDOL*s|*>IUlLt2FzPuPpD}LYIMtL0{KS#iQF?_}V#*OD3LI z#@a>40Qck%JgddSNsnFUYm{e51B;JyWWB-;N!V=g?|Dl1GkzeP=rU_U+TiryNVxhf z?IFuY=@UYeP=fffzGgzalV`pUg4G_?QK=+zuPrsTzpF;R>cizA%IJ?h3`p zf-i1nhPV#@9wmH~IX3$$?s_r*)r)4-bdQ=KmT;9*>)15UF*D$|7uB!%m+CQg9dX`M zL?aPYzAEL13)0@dx7lh}H`=G0KM*Ho+<9$XvS45>qw}g110AY`i=g2@2HW(cru7`d z`gmiBPDn0|3&4q;p<5~zrs&5Dq@TGBK|tduc6TX%mZf5}Ig$p;r|UiiNH)H45sBw^KeT8yAC zL9MF-36>vTNzU)kV&KQqRfsNNG*cFrdKRFrRsiNi#TrB>pfeIn7j9JZGz@8?H%GFG zr@ZM~atUFet0^G`)kK-7=v>kE5l03(`KF^hqb}#5vom5uYcV7`*4A5cfViD3zS@1{ z$hvf-c@Ev@{=12f!8RgaZlk#v)f@wyHvIft**+CVeV6t4YA*cQ6o2x^8DKMd4C9BH zx>jbo+b^670+lM0f5isiiWxyv>z02BXY8aP4_gck^pvY~y?*pKXXfFN|cKVOpFj|x77oh0Xi8I$e*2H%Awqn-zJ#E>aw3bIs7k_6jhueRd zx1ShW;07OixdKd~2hDBA@rC|Xs|F^)37pse_-J*boPTM$J!6!Ck_xk$@W)`4<0K-K z4@WMwl?^%Mf&V9010ey`GbQIMC^@tW^xJE`9T$`Hu_i#&XI>4+zV}|W>tb?*fkhk1 zdiA$Vd4@!R^=CH+yuCeIobkdG5Nve8WXBD`DJ?~x?%w}WWv<9-Pwxa>O)~I?*U%rW z=Wk4nE?g8;E`&o(Yx+NhyyFwO;${{}?9 zMBvS_>I(kt5E)34b{aKMOKk z9&8Oxsb&P!0ViAu9)7K#C?u9efwomGm;qJLvY#tZsa?-jH58f5&Vb=-B*Y0{pwjCx zEkE=oRV>ngndl99`$Ox;Kk(ZI;FP53YB*I15zGDA^hmj(h$Bdl=|w~S7OsexSEr!Y zV}O1CQx?I=u6P}`FE37U%8kC#>$|(3h4S_~ORwrgo2y+dz|=VHVf4P$4z0^KsTVvF zajbGxB`O+Ki89Zzssc@&-9u?SLkL(F;M(~ zGhDR@3%p$&Wotrt7W8sGPo~=3t(L+}R9d+#o-e=CKH7w>=9u};q&oGE`6rQOM1RXv zu@W?r`9d{JdqoCCpc7p$PcmXH{GK4UQT|9N6K9Yy7YY)&Ma;@q?fgLgN;y4bX)A-K zPydv7mZD!PPz5#6)aod|67uP^qk6EKz(8FC-eWaW%&WFbJm{sp(#`KPu+2c7P1J(l z_N8k9sx4%K=8oFacguEEcNTd&IFZ?cw*3cUsl~9nbPr-aQ>~=DGgZ3%RAgN7MI3jx zY58i%YxZxZZ4W+x-LtLo%uL$sJ`F5T7eeC?Sx^x6SLD}A{#Z99J{P5O*HKnuW&VTI zqE&`BKRyMuiYV0^Fvc?0=Noo>-i*v%77Pu`XtvT6cpZIJxuuH!^iJJ!nxId&?PlcH z?l_P|MK5QMVm+c|fG7Z`tpp=kMwCQ`%JK&m4)^HP0Jr7iU2t?KX#PxyhTy-Uzo1gs ztG>Z$Z>Q7db7;LJJ2CJkwpw&ia@!FuhUJCWx3ZmNp4+#_wwdK+xUlu%{cdau>(%|4 z+CLK}N4L*YAUDWT0os2^h$G|7h&dswnAB(6ZE4V9E3^WNhDh)qOeJVCl?1+QhTfFO zn1NuFP)JhCEFDdVMSlH##b*&pCIA|DH?P*E#KE%dsolzPR277u2fsI9l~n6?wYi#O z$A^cGf{-cS#ip@u`{J^-eDGIIP}3U+;ra|LzJg2FkGS4mGyCmls~^73X@1Gmf^9jVqoH0il6 z$RjA`-cK+$q$6*4XuT~{i*@~8Z!Ak&<|Vj(!fUY+cM4FSR&xv|5aGdFFA2e5s?=UR z`x5vI{5<03k`vLjRT=lHe_U>sin5_|9QjrK*++#l zh!+{_qaV`H0kHz+&6`x^|J*J;SAI(8dJg{kP3W9)8(h_+fPs?LZ|Oyx`59&vOBfgM58M=S0~H_@)^2+2O+v&!e1hbKNg=yEe-Gts|D}6*>X+Q{CAh; z>do)potV46*UdfGK0#M%aFD=A1X8a{Ha}VW7J$A*6Cq;@_*&#aiqygu5Ql zr$B_2psU(si9q5<{)_4Vt%~0zFVI;paLRe~t}>et`jaj@SqZh&g>)BXy4P6jfcfxn z5SY<|p7U(A<3~Y<{)M1E!3QR{eS(g-$Ai%&pttwGuL-0Y-?j@1xZ?&eq=}qE%T>lW-Zw=>_+przDPic!>0>Q z`u_>Sbg>(EpI5tGqcVpIUBTO){c!C|I8z&Fqly0bw9M6JD&U(6ddH0DI`F_fzgjn& z-hedgb?MErS+!5Duzds%0DG!XXk9`vzenbSQ7qp5(+eV%oH_cQBws&4sB5Ou^@eld zY)8g7BHf-j+VWMe`p55P5*sZV$Y+@s$16f8C1yv3VDud&av^5!Ze|BPKl)J50y=i1SF6(~AIbrtWQ{{qJ-2U02H%FB^%NwjryiKI$ zjgdL8{N4q*5U9ut77Y(8P5vVf82e~7`9Y5c)l3(MPiJBC9-e48cZSZhcM&u=y80(w zUcMPquAswYWj8+%{7zsX7HOoOYLc{VfTR*AXKB?H)gg5cfu*N6n_)3rIlyK;Z?O>s zuF6>7HQ2JbSq#z-P#XX8H%X^HEVr1H2EB`Y#{MMTnxGK$;v@5bvETujyZCzAD{7(y z7A1=f%q}G?x{r+KO|S-ClkmAhK6G`mgP_l1!-)pIGs&upydOnI@?xLOh&9O#B+TBU ztnK1n5*e@6`Y2F_vaLpC1zA8ASV zF~*1hqi;D8Kd-c8?nlLHg7I=i)4Ze$eheJ%z`Eap&kDJXpHm9Ua$P_jZ*WZgBR$GG z<=lCvU|mqkM)l^Nr)SJ-_H3U<(VCu|SJ-0D7!3G1ldYeXR7Ws&w{E`(3WYA#)Ns}S zJTo(k91RioEXFqfc(OYIW-Ws(DuBTSEvK&=j1m$9{2GCBcarL&Y*R~FUU+KOozHiR zZ7v1Oci$^*spRqRK57QYBiJaZuOmq(n1$nVw!f=`;YQ7yF(N{D`UEk>*Sf9iD7OS# ztr)Gn#|!tzfUlYmtQ2%6BnNaptC}m4uQKuO@-mT(cH~0Uo)i)_JiR<$_o~_5HI%3e zUZDwchyI)h*YR^TqP?}r1)l=pE|!q{z*JIJ#k64Jv@-H#V+u7x9B8d3JZ$f3+5P-t zYKFm*{ZiV^L&i6*ElOq#RDri5KW!H$i{86TPd>#l1GjpN7Xp~d$9-ivQ=)gPdPb6) zC;mmF324~Ib^}bzc8rBPd87C8^*3G_l2|UEX8CdIMlsKu+!)SefJpax#SdeOPEazo zqqS(L3u1&R#sL`-Ug3?F-dhU2D0b1ydVMnWJ?;A-U_LpJbYf868B`NT!@%>Md5M$ymYadq7_^dT@X&95fbH_s#OvZ^_r9d|`eYH+wV!a6_e&3``JS+PUew z8a8Oy4uo2e{L>sQ*6G0XSF917S+BVFPdCL_*rm?2R)_>u*1ECfj>D-4U{50BZ0H`e zG$8Nt#&o}Vfdk#_vqZ*bXFRB^e)2xumx=fTf?Vo-j#k06ORh8iJ1$5bz3$O2KpJ;K zAH?#CG6p*!FSs6r>(kV_<3HU0l!!pHM?-DEu&wI7CDfQGx z*26fP%I^`k5`logX-k$3}F}v2ao#3-;ApO<+oTdjjh)@QJ1V zH9%^j7}5lCWy*Vm(qD6~fH*zcEaLJ2BQOmmpMp<+)Ow2rl!EyLC&l09^Y#m!ouYy3 z@Oa03SF?zLI&=B0Y*W8G81%tXJeu$7a0N-)}Z%#PWW`fQgq~vjC$UXDS~JLI2)sl7&qJEZ zl)-P8>hmW3sLgf58{#dw4-|twu`l8O@$`<-nLJ;#aBNO&+qP}nw#_HDZBLSkZQJI= zwynv{?|<+6e(kQcx>i@$IeVXdde=(H354i^%a1~7_CM0`gBjS)+L8BotbWMQ|JJ=J z>$r)WkApbL`w#y__V|F+f9u9oUCQOtw@8aeg3~JbumZ17tM}nz~V>dYX08`^53)Gt1V%X zx4DRZu=)S@r0Q`k8e(691gIUz|9?vNDH>BK5x0JV#J&P0|F=w<^;39St-7Qdp$*3! z2mCK>{_MTul!|owtE`_EHH#Nt={K{bpJ4a+#&$!c_TOql4s1m!{P|z4J7;CNmyC?~ zZMh=(J=eaznWo11bkyZP9Vkze@2Emwi1Vb zTSrp9i2NW&lTDlLpLuiunrS}Tm3~CFUTtFQ|Dw`=FLveEPaGsnvbUS=Ph9-Tp)T6V z_H@Yn*O9kc+W)=&|2K-7cwLetRL4&0f3cjlY&n?;L(EeX1Bhm$Tgg!x#`@;1ikz$3 zA4iW>InIsS=f=7*W(D^z&CiYYDssMRsdO!5z`Bn{@{{E3?~;P&yix0@#q-F#d64%N z9}Uo_=u_*TpqO&lOJ8;<$+g0WG(8ySfPV}Q_Yt7;FVWKWGiL{Mf32V)Z@Hn2{`}b z&2#euGca%l%sKwwMYsy@59=)?_D?-^vf14NZ@+@$`@1|v;|EWug^b+Z*NIIyG1PNm;;C)Hc6#b?5se4#~rLb)d zx;sFAGwLaHUcZcSF>k~NSjyJ0#0c*4O#7LzxO3k<&#w?*;WL;_m zku90?&n}b*_Y3uQT8p+wsL3L9yMt2}c}@8FhX0+`)haR|_}l>&bLNi);9lZr#7#pEOQ@_l$NvY{ZZ!)M4GCqI`npxEDBA{_x)h z{Zwnrr{6}2N2EQR_EFeG`hP`)x~wnPyS!KFklC|HN%8LY*S%-HpJHkiIgj4waaSr- zzQ(V;WI*|@bP|pGTLiEk$tD|{P{MT|L^rCy^O&GhMS-4^`m45~lSMN~8B}8=PS=FlxGJr;W>>cmtKkkxwO9M%ptFBO0&@Kq*!Dz|K0_Xl1+<3Xvh5JrPf(|h;! z!P9`ZlYT2wcEVAJqZ2N}c8zA-qQH?kigi**sZ&|H^%E2>$F%T2$Gn>hCZ3kXbPJ2Q zczQXk-vodsS{W%dB0{rpSDlF918m&2x&br1^q}V34tC^J0=3Re*_wj9BSDTxw{XeP~udt3BaL- zvhbKI2)(yx^C?tS7DK0E83*rgMZVjU>ji#Ee@CVMD|LjUn^=EzvYrhtPpQW;QP_&& z+b|zyj5PhVHDI^V(?9odl710pqMml2h|F>KP}wV@(Kiux!Qy2?#;ga0`uN0Q*9>na zwV#hPg&~tB^}_1d(vhO0BBaQFN&&6Cp=&9$t^(;k_sgt9Jcp~6o&8uC4z#n8mt)#&+VI5&@kyWLtX%nirBhX4X5hYSKQ zL+b+JB=RVjrz3VdqCN8Y#T>57K*@)XMa(2gyzrEYTZ5K55?K}F(~SorY(YW)L3B!Z*dii z+B~w}cBTiKHXXzY!X!$mIeal{cO>PwlTOuNM2CP8# zo`ieVT1s7#m`T~PyfN&NrTf1@mUkUS`imMRz0#>SyP3BA%im}aL>ucDsPKa$AKrZQ zP(Mx+{se4iQQS`~@~p-=-vVh__kNH-1?y16fc3WXD9WeOOlDQ>A^=2pbgl4vMn6v41zwQiCOD2?zF zW!c#2$D_ir29lkZcZ(=N#kNI#!lcz~Rtzc*`iHuG*d|6MT$a+V0oG4Ajou8?Z7g@i zt`f^Wr>Gr`(7lm$=abHQr2C?FAaye_5zb-7fdJR^p^PyX6F|ojxZ5C!ezW{#OkFt3 zl3O5pQ3qvnL2t0Gb>4bQKQG~hU)ZE@X%7k-E2WhP{fmlIJE|75;acg(AVy~7-iFjT zY0C)cpoCNd4~|o%XFNY`Yf&zrUyZ2R<1jWj+ij5ifdgvB4%21av9g`NdVdUEX2b_{ zZ?J`mYnr#S4B)U$yar~C{t>QaZ}|1`nUM;GTN$Vg4h=84;2dK={NEF}*KykR7qeDE zWswj>^m1S|F$urFmk*Ab62Yrkq;BM-NKXHnNHb-TA9AFoYUzNgee@`EpdjLr$~&sX z({B?$4`77ArfW_PLl|C8Wz}iLy~)E~2MzO&7jQF1dO)C2(WVOPXWaSz$gHsdt0te+ zZyX7>-Mts?U$x0okR^xf6BRXVQOzT5877AYmbxUL!lbl%oD~&vHJ(q4QEDC=_NCh6 zne@Zb$Uj*Om6k!-M>Nh(iw~+f2uXxyq>}g}*QRD~e9fm1G*k3eEaS-0Hu8E;`1CqK z%dKHw2he4g$|8nc_8GA2uX$HTXkh)lDU6uH&?3zZRW-;VIRHiwR|}(4>5D^6d&W1{ zQuSMpoOm8PRe=qe{T&MyuGMto-yEinGKohWl4y6f0;Iqgy>%z(y=O3N{hz5tbhun_ zf%H3-hL2>}wK)?-*Zb&eLIK=O@d3;#6Imw^ z7SLdq_B0L19PsEC3xOh%9z^RPfaVdi=|5bbecXnl`3@8o-0!an;p9_Qd`|MLq8iI&f@u0M{2>uiw)oP4XFj zDr_=03`3VQ5pxA&tAYSGq6Ao9f%P9o%ekjNz01Y0hK!32lwn~nYPqFRQI#wx5=Dzv zBtBiU05d?I>{|4KSYqzuKjgVeka!E}{EZ??pm_wy6I*7pu`L9lE5~fbB!CKT=9_h| zJBsuo%WURf1{Qv>oQr+lB;?PJ^0gAS}$3s^$CQp{^_70oz5%D1v)Hazg z1%Lbqi?I-e9umzJ=$X$OAzU%7;5ZAO`N9;j#Ll#0gs=A{6#*_-PZFQFbD<02`;c@- z!Bg&Pv?`25zvjY>iULj0*r=t#{l0EL67ZN`i>Xb{0-IZTM(_DR;{kj<_$*}mVB}Na zg_AHuXT;$z)Wwo?T9zQl{oXUGY8%I1LyOmt`*&zFSbB0;zsM~=uk?KnB!C|H#}V@T z!|J>%2JmO=f3Ys;9dxztzo?HHFLvC*-{a&BQCde6#{b<^K-Xte*S=Wpc;2H9CN*$d z<}&Vi@|m}Yr!_4LlmJL9>6Ekc!(Sd1yxr|^^Hg;7_1T@Zt|odCr`!*s@Q^g9p1!h{#- zW0>ifjt(R5(26pGZ)T4ALPIjTIP(aQ=Bl_JpH{jgs6=NUt48$?dO2_b-^~@O!U}Q` zQb0;aFoYV5Oaj<9w-tMaW>~(i(@C0jo@NPT_kQ zMubf&oiN=qVA4meFH=bSXRT6uGN^?{oVRwJ<85ndRmlmJn3p>_#Zv)+U7wEYqxzl=lF z$vlJ|HKd92FtV~AcR+C*bhdlN8AGAWY1jyfh!B0P$3yph0BsZ8#k`bh>Z0vb^xHcR z>u=}31^hr9!4rMqy01HVBC=1O8SVFOi!wY1>*A>8bHc^c`3Jqs>BW+_M{J9^IcMT1 zK_mLD!2rjx`Hya?+!0nlS^1b!S9fC6I}1B4p0j5;E!m?VhDxb}euv(Hh8?JHNHzSb zL7MN8&=(9A|6wL?b&4#1u4$pvjFKhTtHs0@=~eL0f#H!k+8}b^e3(Emlr(D3t|24Y zhZ@*eDci*ZZa8qI7Cr9n1nXm2dc8qbkBT!?y8zV^mmrQ`EA#Nbf`GHahltLdOz{~VF0r4e_kLz8)Ytj@ ze*yZ9C!Kj+l?Xz=jO`qH?14B+uw&8=wXczl?Fa6?28k~cl1kT_4zex}a1gzOq&b|# z2YFJc-=nWQ2p(v|re`?zb2A8zEEqWOfJO8pAtbKLb$_kmwjEj2L`@ZjfG}f$8EQ;H zT^uDs$HggLlA_L5P(cg{#(TAewQlh16#xb#E0ynGew8d-)mzjqt6Zdt5 zismOU?2Ji3p)mue)q1yP*Qjb~9jvD0u!;YMRBIhxml;9Y+xu?0;E-@ehkjQJj+h=U zzDtH?F(_ShYnBWsD5a=Y*3=Y5V1y%nY(U&C7*QuS&y6c3VjNk36OC#G=g3^9CjgEo z9(v;fTa0?j>xkcPuNL z#@sIERq{|dGD1W*lkQ~tY{b@bDng-C4rTbdr;317zm)dj<@)cdels6T5?4q@J1K4R zpXP40n~$*Msjru;O^YZxyhSY5c&^k5Zs28&|E^CZd+qh^44p*-SFfp zfi&YRu1Kv<^3bR8LY?`F7V?33la&ZG^aF=F${Qjqg8i#FPyiB=qN7=8&Va-eWGW!v z(AXXj!f^{cg_QlmT0;gCeZQjdFjtJwN85=K3>*+2;Wrky!U+9~4$b}aAVwhJEe~Q@ z-JRxV_cBrPG~vKPT&Qs^&fnvRS*~so26C?^!b{i$h_#t#oK-3c|EdVv-HvyJE0~^} z5V-ezKVMjoJRueqCHs6$dI7w?n4$X~%?|aC1Hz}|i;1-g?w4KO(YRLS&*Uhq3-3id zHKX8d?$ipmMBEljn+B?XiZrh}<)CP>)J6LDrR9??1A=Ctoc_P}Jn7SF+H?e99x4b-_8*NaQF`eQCo= zOiUTLtCZWQ4%OLK-2oIfa;SnwBy@y3dq}>_i96Y;tiYmu6q7Bhw_j(bu5M0_VV;vp zjaDLelEMwx5Qdp3(JLJ4sOqhk0j$R}uPzo#?!y+UBB$JdWc#qn1nPE;C7fkX%fsm& zTd57f3MYBP3}E?EOyLMr5tUQDCl|TixtT_rFXoHAJpug3jDS&0Ed5-0!bXwKTG8Tl zyBMqoR$im4H=u-WBLjRR$-Wer&IZ}Yd)wl-XsNAw?opI9+Ab_*io{mN61;L}s|_ZK z%|`GQaxeBXh-?yES)ki?1*lT1WU%Ko8_)4X$;P5x>neOKkv!6V;gu91vv?4n^KQiW z_$elwbYyYWUI0SHkj-SsCggK;rISCF#2JQe7ZKQ!&x`jM`Jnt?Txm-Ibkx)-!;)VR zz{Riar|C(!b6_zEagIA_@`m6U8EH$V(2JooEtJO=kJy}9vXC2A}q zkQuUVj80VRHU7jxY(f&{yQF<8$)RBpziNi+L&dJq+RkYlGke3*Q>%k~L>J>)n2R-(<(+ z9TDjOAb?N|34$VX0fMO#=qNB`D{CW7*RuY{wVSAYdBHF;y)|e}Owo^LQ)N`y`Yro~X$c?1 zbp2RNwLMSM88&DC7%w*bT0cO8HZU>}pwxX|3FspR3ra&iQb4Iw_X+6wq=9Z8(>VJF zgo@g<*6HB@0>mtG-F_xAJfoQ3uSk}+c#a?K`hr)y^4UL(JD&|{M#0&4MC}_LhoYZb zA|lfrQL&Mnfsisq^~CAB=-z^vkcD(JaFrwLFi)A^*t-<$8IDR0SRFEtEX z1aR7zQq&&Dt-CY=o|l-HZ{9v&P^`r3g`YvizLrv|InPQ=!tJxG+Nph9{N4{I6T{(e zE}<?YQ9*2HtJ%K5}fy)5r3e9Xd7^6(T;o4IrA zB6yU*H5k>A*WILn@&Mo!9{Z+!cLMv}0N(bjTikdbAvZ^*Q`% zJCO&IT;WJ;%WsC73PFNQVwwW-$-OzZn!V(gjq|LJY;Kt-&_lhnG&*tdk(Oqk-LaL& zCF~60j`NPwGt2@E@#YYMAV88r*O*`>AQ?0`mXhwz+6Wi=aGvSC7rB9kGocFuD8q?m z3{(DuR27vm!mGNjk+rL7ahHg^JsH2gYGlK|#fU6}MdYh?M(#i4a6)L6%*Ph5Mh`=K zc{|6ccR6{qmy7J-aT?QvO`ySz%^IRzJj)V{!$?fAHN~2QR$Hf*=BzbULxpc$ttpY| z2ieMGu5uK%jjxlxB*}^Kx*AIcNcmG!PA6FEo6!#S620X@QB($VR;Y@_TSY2fSCpzV zLgO?Dfp_mfUT_5tsR%#mpTtog4~tlebkM_uBBwT=Oyj)GNfVB|LVwhWBYE zAz^#d`d|`^vO0+n*&RD15$eTAuPO#}o4N{~kX;hgZs;9Y!V7IWO<${xP?H+Z2u9sm-4QAj^5#^Vs_Xjq_fTTdNe6zun1a(@X`G$@3zCM)~h@$ z%mCgL8eSmLBpK8dX)#TKCe5fYV8cLS?Xe)rVxI(eR0~#sKF4EDX4#SdbX+Z%LS8rP zcT>5cHg^^^&omnc1@U)jZu$C0t(uWW22DYn${DPvGte!aO%6Rj58UgOgX2X>We&`I zc^5bpT1&Z17WLofVW#dqx9Lu8_h)_iASA_HyDXmk*6gFr>0ogMGkP?0JHV_PE zBZi=)Q$ZAfCRm~UXvScYd8R^1MPg-`PB&x@e2T{A{_cy1X?A1Wse;SeZneeQiD#b^ z)VX{9eS&Nq<-?*N78L^X_B2i(FoX_#Ujg#cX&Y)yo7Q^CFgdlJ;ox`(!d*^_?LrA; z%2A!760{h?fU`)Sy%~kY3Fc8^hE_90ACg_^C1}Xoau)F z6!TwKRP;pU)>lT6+kS1mc;eZh6`FI&(#xc#C%&EPMAhwCNglznU#D74VGhP!iwX0Pi2goyA?69iCA>8@K1I~ zQo0HR`>m)@tk0T?&G7Ene)3{mFkr7AhcKup`Fe9f(q*>r3nlI?&AZBUECR8}V zo`#pGhx`wAh2Rp(W!GBo=hbbt*=yXFMV%=@(}*A9_+>#_A8@rqoqXRnkvU0t@e@x0 z!n&CIj0KymoH6lr2u!=woYG?IKfUj)3Yjm_sW+V5cxo7!TvRBL-tsOnjLa zx^c558@jkjABC!;0E`KoS!cf)sCN*+E+Yx6hIL72GxAkmA28)SO!A6AnP>@5837m1H zzow&b)P}~)dOApin`6`R`n&>T3wl=I9_9?=`EHdIHX+PaPw74pT#dVbz91D4BW6kW zr$ewD7KpZ!z>b;yu%XJ62$?sOX=|igu3yNhVuUgu-g*qXZ zCMB-BE!IgtV%(JgkOM>*f<5}Zq#i$FC7?O3k4`ZT`U|6{5P7^~~HE_He=EI7`=JM#lsX3-uOjfokJx`DzT&UY`Eg@-g ze*xqcioFk6*)3?Q8Y_0DWAzUiO9l-D*r?Ac*P`Pik^5M|ox{sTw$Kl7Mh#($+IJ8% zNE)4xhX!3ge20cEDNfHvO1-8cuNRd;_-dzfvos4`O|w8lqo5$zwD6jhUdr9>@ccKx z$N?0`Cojs>3M4snZD8$9cB2Iw6URP0W+1O6)h>B-Hj4D)K2TDFhF<;E5XWT_fnuab zuw{JW8tWhV@=2d(V2~GJ&GWgf^fd6|qSfV0zN`!18}RoFf9gg+5Hu_tOea}&uLn`A zn(LkK$!RRH9b2zuO7HtoHH*pPCu^9wduTj}peRnrL$8DKTK1+) zQSJ?Ce7E!NdhtTIxEc%DQ9lEThkg(7nO4$Sf5of*Ge;@D7mc%!M+hipgnV(# z(4-6qcLcG%ifgZEYffMvzP};hUug$dP;z;Cwm5C?I=0JZH2GN6nt1Ewn4VRdSr3~# z&B6r)#9HS8pbvo>j#q$xi>Dw=d86yZvPnWV&)b4^9w^Y#{1&K2vPO=EJDjB(dAjr-a!R_j;yZ!aN0>|x;dYRkH`O_Jg3;L4_Htk{&vSh-E6qDU{q2} zF(AVCYU%ojo2|D$wfR(7lxV%I_54!g_#zyT7cKP%Sczk_z96nKU8KN3C<04z>@Gyy zSbYc?I{ea-evnyXO+W`@m_$?Ea*!YeuN@a57b4U!QzN+Np5LigIkXdWC%e^1mov=B zgSc~e&&#O%j6dLRW%~V3!aM|gUYL6xgrTDPvMucsUcT{@K~!+TR|?~$8|NDIVEqYl;CgVLoTgR6B_BU#+DwwK4Ul#b)UME?#b4ER z8S@q3ewRcl1Z@h3qAJc_(KwKaG-owx?cikwoXe)G5d#O|U07u^95a3_rgj0rJS>r@ zmnr3gnXks77!9$2pC$1`y6!&R()`ik(*OhC@y6LSv6| ztaY7S0`DAG{6k=|yW>3HTB&i_(P?uAa(qbX+}X}uyADkYpfA9#N&wHl=WQ+86Mbg{ z)bgwhmIjyVIgbSH4YzZ$FT%%9@i8Q3c7c*0PFnMyX3c#gu~UcRm&(Ja^Ps3wb-SRO5#f_{rfuYxZLNE zzIo(X2R&2GG}?6KmKY7~q#yAgh`>7o0C$h!7WzA)cgV(pkOkNlD3bI~{nwJ7F?pSn zl%c`uz7ix@chc|!Kg3zmVYhrz@53BoczDLS-mnYR=aY!mHTo6LU-SLM80Y-;B+5ge zv~D4w=c#C_Ib9h&0A=C7sYuR76x}7nAt9K`kf3a{FfP3HHx`gN8tLg;m3-hJ03i~L zf6YV?5Rp<(g9Mz1%-Q!NePZ)pW{q43U-{y;c}Tn7l)rX_LfB^(eQkSeN7i7%#aoO- z&_WC95ZczbquAyJbW`HOqLN#(yW>d6e^U63O@;~@(06l$@YL;3@K|*3W~-K z%A5pq^54b#AL_`6R}#eVV>@IF0cwqPEZs6lAF>fflV~qA1{n*MEabO`QN5PF`pOUTiI>(MDZaPhu zM&-IVMHv1R85z*vYzyIN*IQJrc9(;j7<~=dDr|(xw0n_DnY}XP-b_iZfQUZwF+Ef0 zl{H**n!j1kpn5XmLGE7>i!7?5cG-4lMpjca=29T%9LAi(ZMuxO2Ju2Rash-8+)@o1 z%CSqZaqRFvgr^45VGX~=I99I3YZ|W`lIUDoOV@SG4nwkI;`y)y2EE}u&xzjM*%4fI ztDe@p3F5$uMXY=^To^5lTHi%Rr0~H>F~2pJK5sP@9os@YM*CNJRt=CA4m!qzN&I5jQjSD(Q7lDZuI2-;=}gqvA_FvhMmm7( zR@Qk_ic6fYjdvMwX5F-lfH7s%DVb$KP%&c+NZuWm0|D&!$^H@(xRalYy`F5@q_6Y^ zs4ZxaU_fx(8j?>8fU#vJ5+Cl9c>lthvi6R(pB}Vt$O^B*d2M|QQr(7H%V&zutNwZ_ zlOPgvU)aV>M8PMgTVYP` zl%iV5AOcqRbc&3)491m|#1MBw`|Sa?D&rr#f+g|??E|-!i|QEdQY)TTp$$98@MA^1 z=5HT9Kk$SdfHBdH;oq}KUWme54^TE<)iGD9Fv*|>-lHbfk%4YaKoy1J&{W(dIU{Bp zW;er`qG|BMnB7b&|I)hwzCVSxOO8pYWBIvGLg$*YOty6iuU2ReJ6~6`*>$)mjjV0o zrWwU}4cVC;^VaK(Cv5h$NJ5UQz17t!mT!W zgFT2Iq-@s3MLEWIN$HNp@-B0ahS&u?-mVQbz$-syKknl8<2VnzZC2R}jJLC8vHRo9 z?gk%PmVY&`v;4Tsf<2n8316&9eA!Q3)_WSd>dRAmXt=|MiA^ARzJkbBxTn7-WYcDT zkQ|`QmMTEf6ue3Q&0JpTzeynB7YKjx`R_UXV~$$`FXEzcSW{IIcf#PWW|8&e$0f}I zz>*`Pde3}0z*Fy-iS~IImZ%wTI7n4A@R@!Yejfd3$j*6U?k#qV3=XQ`{HnYTP3SVE zVYJ-)P8Y^c-C!l=M5n`oWp1yW(1v!J@x2}!9=sOUC|(-{%L+JRGh|HH<_pj}2V#;8 z(O*!DJ%dWt%0omK?xHO!bXl^}orf+DK=KZ4-jTL+6R=#gQhy#sUV_A*Q?#iJBii`# zArQ?FE@mtn9xFDY+BR}c{xEO;CAqPsG!@gryYWId;Xp|2k%-pi9}84ku1yw{9+lL zuD;I9J#LTJzp(Jj*j`wlxir%-<`YMaqW;f2X+#+*jAP_ZN_q2Ff+? zL*e+?4;OQ`NJJrsI1=TIYiR2hbL+RpM3TWg=j&V4{nl0SdoNW!0T1nf;bebjUVH(G zB~fU^RUvG$kzd)NgaLOj;C4r^&o z6&h}IPaisD8^DMU!IVp+N!&w99%c%5fP2vfYDe%rI-#%h9k^m*yYU@K5FnHuWy_o>HcfacnK7fMId=H#xCEt14by8`e}`|? zilIdlSHHq?ZRM?9D&>mwT%Q}>xN>Otln8m z`AoK)_x&rt+{DKBG4;keTVBU!G^a65;I&PsX$Uc^uJIEcGpF1KtZqiFXeD-G33!`* zTtD<4N|Ks(Ptc2tUW1saGYOLP&`O(KQvWqN2;V}MI?>E{?NFHumev^Cfm~a(NRa*8 z22#RTSz^<;+Tb)LDO~jCNr(ki)y}UH<#J4CiI>CWu+r4T;l*e+|K4Y}kV3YudDcnW zk&grZi$}FTW@Rb`FrH17g}TMd5*w7$n7_+xkkjt=Y8;qNAgHt60($bvf~P*-h|=4M zlRm!l!KLEdTV|c9cQZR2bo+q}rb3|-p7cIuB4Nb^cV2R~;2Q#UH509vo+0WGFFTOH zJE%m{KL-+@FTDq$E12*B_%PVf$A&P4d^AqA2u(oG z>5s4=dJdYU_%PMAE-aK2OUrLRk+<1Um0i%53`W74pqA*Y{5ho~*f1~};2hA4B?lcZ z$MGV8(2pHGluWgEgK?U8=l`;P0?G@C3uej&Mf3&2ja|X`+lrue2WU3X8g{g=vm>=H zWOEF<-d#o;U~-%VT!Lt^M-uQp)*JI{pUzCc_u3yX*!2;{atAa66XI^oyMZk#rS zJas8pTbj4P)noqifwkXq4$ogyE}k4)F!W@;w@fM~0G8x}4mK_v21_n2T3uDLDkp_Pea9e=Ei83^lIWjyF^TQx36mcVE=mb6T2{5SA> zrbAXHV?x+ck0qso`h6W^6kloi2{Uo0{ASBhN~KRHYd9?`Q0{Deq{@mG`UXQv2ZSCD zX296x0gxw6&nnp8Snlc9s!AfEs3C3HDC3(jYm5%ovn;3Y(fgu1qiQXs-rAf)_)!c2 zzviJdnLww`1$YgR>^;`zxe&hz7upil3{=e$!lUpj*R|O3q%qtb?`N+TIw&h6ugkID zllJi;$!T!*`cVqiryIiunl5ReTI%d^p93t@Jx_;tbJ_(NfkGNeH-iiUKNdQ$%f2d=mi#`%#;tyW@VHX!x-ON!o0!_LqQ+S~ z)c8a@2(UzZvVjAFr2jO8-*A@;1|sJ5;4tf0ouyGWg6v}cv7vG)+zMK~M`9iBQ}o74 z1xOZY#o|r)aCe9Ir*qn(d1JD#0yvQ@wu_(%kmW{G@$g4&^l3W*a`lMxI z`7@o*#;2%5MblyAF8v{k?wPmDW$2q;qRw9(1-V8Bgd3ukc;!yWxo^_AOaxRmMj|vq zv>6$u{sGQE)FScWid{SDwkr8}=8wwXH|+IXH*J_p@`QZ?_`*n}D^!GlNDcM~0Z6~t zf@Vpc;z}&Z&^4B8wAq8B+)B!8f415VWF~h!^to~6iRx)>_e@D4dMHXCx_>5)Y2Yh) zUIP6o?_;YNtnXPr26xMmC~i8QzM5_A)=Awoz^HdaHNG{BsB`-#rGAu^G*GMi94$rd z^KpJQEueN#*hLF^)d}Bpc8Mc93vk5Ez}IVJOu-LWETLR%^T?g$p@*pXE;K5n{`t}F z6-R1;mx7qor-GDwd^02E+(6kvjFY@4lXm*ym)yg@4&UvfC1U7BE_K`fD@xnbgh;x2 z@#$Kog}&O!tum6w@^sLnletj* zt9hovfve(#WgM6F*Yf>ku%+{1aWCV9m$g?dTh9An+lF4eGbIAFA>@%&$71 z-wM-E1=*-(&6M+lLU!f;`3y4nmqsC);!`6hp6AS|RrW7(7&yL!0uX?-Wf@*;V}fGt z^@RZ6zdyl9kG5}ZIibuJkRnb!Big?5R!WqVFK;pyz-yr(B|ER|R9u-?xuA1?u~^_? zLr(6dD;5ycHOe@fOppYJU%$>Ou~Np0Pxr9lWC*N~i%Tz1dLlrcQYZ0HY?z2-?qXz_ zOM0d$Rp3zP_F=?Kp@jge_e4GzXFBcn?2bNm6k)}M}_6zh7n)5RXvcwFD7o+0M z27OV`vF3_egYO;CJ3bz3LDD(!ZU7EhIme*CXMItyly99&ZQpf$Ugs}3vv-Xp;Al$1 zCys{5r5qe#Ho*@X+?_I-OO=ZtbC2g=+Z$YyB^|P!{VS z`amShzW^Qd#0CUs&Ps+-@*!dmE0hW?Ans8+ObKHZ8SV*2_QcaXo>sPR&et&ObFt=7 z_-b7E=l;vYBwDUb+&=$)^F;>8l!CKZ$t273>iRREWbO}oKpC1nGzhnC|G5+xOddMu zf)<+rm(Y^gkXzKug?|_L*2#|f2~CT4{t&L zF27Ss%G2}p0CO^V^(VOB;Q%V_nAxut0YVb>yT5`4fBb|o>Yt4Smh8$jUxY>E?DjzS zY-)1-8#`b#`O=E{oUJY`F^t;mImv z9*Pp>m~T<#JoSflao^V;TIJLLo+FO?GQN{2gz0zlGj{`&nFKaKybwv#)KFxwf9sJWYm zkoXwC_X6+@8%w%qj9aKN$$_*aB^S?lae;N4g7;he2J)|2-|~-ZLrSacxp!@_WD>~O zvUam`0qIZYJ0P-FY2TdyLrNRLlJ7wQ@RH|R>w1WprmHF4mZw!4s>w9v6*=7ZGdtfo z+A+tT0(oP3w+d7|XT@QZPZ^?bnm;&|A|yAW)#i@z<&I zMeSTIU}4%5)8Jl%)}!l?cZ}7meDP&9b5`kc032Y_m;xQ_ACrh<8uSBFaWzWcR5H94 z2Y9L-iA+RV`nkFzWhxRT0(rwmq4SrZ>T6N!ChF&KSVrK z@%aHEiH>OLTcb{2;qss;Fe4&0=p2k}vk(Z;kG((A2H^n#{m^mgx9gKT(uZT`+AcZ( zKn;r_MRAHnSf%OcsVC(zSnyJkrx?y}{+y4S{Ae^fwzwLo5!lK)_= z3=PN(+8jf?Ua&`l;|F$@|ST9LCJpADyFR+S6eQnqk(Qz4>ihn)e4hu{MRKi+JGe^F%F#=G1t-FMeYC1J4S#PbtClO)+Up0EEAgTd zw5pE8>zzt{$H$j(lD9Yp!6eFe0FQ_hwQ%sYX49${rJLgtp=?L^5GUId0xDiV?TU$< z85^x`8fP8U9MC`kEU)2$s@gaHldEd)#WX7`9aCtSG6N3NLJQH{H8#-M4yS((c^`YW zFBwxmG=RwvdT^fb5qx%`L4pt{=*vm=wo9iZmnf?^^?vUiDjVb#FQ;+F0PG*Id}(9U z(dTZ%QTBu^x0W2RL78>s&!~uRLgGw2rObnBRfyZAz5~QXGON9W zO$6-KVmYsyKf#0dY}FmJmoJ8CQr$H_@|nf0E`vhosEyPnfJ>WI=+p0-exo&EX7;R> zp*Yq0aPO({6yDWG>}tQ86f)F<7e0}-Jsy8jzfGnOU?bw$qz8f*17J1c#0+jlt=5XQ z;UF;1YagUxDUiAQPKNO(setS@#rvEZJDv(%#kKu?6QX<>Sl@k`GU+tD+d2mIo=+Y6 zrQrFd5nM>?GiENzfOn8~ojXm3caq?4|EOFtmti*lCYJRL^;bi+xC&;a5gG`mKxZs! zJb|mLI=~UW1Zh+17Vu&(gc@H-ttxAIZbF__{B2TYRd8Ht9h+tYO__AGILtw0w*j(po|Jsi)266!YJfW$AVj=9sBu;(4l?~N z3T!P{eC~ncG33aM%;COpQNf~dJ`4DoPvl^UGF(HRIvxN)25?g2^|gy3n%eU;@E)`9 zSNDQ+uuG7Fr5eU7z9A7b++Y_kql#`vy7IF>FVI?6AOZ9eh=6l&z_irf5!x}Z{;Df= zwZuvKL$_o&vc~Yf!BDVU#>SWcQ9EFc!0UNO4PzIicY^F;W)szPPB@7XS43*Ur(sNt zp%@Bc(O~wU0x-1P%#{s{PIP|p=<(Fxl%1vg9lw;fW=UK-evnf>%fw5LYMeYd6!!MkOD{JoC)Yszjf z%>_i0;Rf0K)o4{`7pHR9i}K34nRsjhSDfJf4A|gV*D$voh}EF7OLt}sL=O=tKMQD0 zr#Y-$aUE%5;I-=m1!mX!48-~_wuFi!3_3d~%!*BP@^=Mh!xeg>h6Qgfebk|o^$De9 zw$#v91|R}6&>MqA^EOT~mNkE(7)R?qS-Ko=jRKU5skfiqT=ol1`55&xKGWB3g)!Z1 zNpH!*?C}yV5q`zD!ggn&le&hb(@bKO-oWGE`sIi~L1eh-6N8I3>a8h&(K{YTZZD@v$jFitCEEZ1}25OIP0ma{gX?N1t;m^ zJc<_)vTeoC^0R!D|g`CD2kcaTUgy6^O zAR?%Tl|(i)o2mc{%LZI;0~#~hB5IdS0J?7oI685a%oXW`xee1tGB0L0R$lUz`10Be zp=u>?H4J3#!+8r(Q~aGJcN2Xj=37{^a5Df}k&%&qaca>{sG+zml6uDysU5RAF`KhL z0%)}2;jk0bmVgL2NR_Ez7q|H%g)<2JG)g3|zwME%UO7t^cSF49I%8-tc8J@fxOKWe z-2eI-FiC#`PEv>dKY(E{xt2c2J6%ZZ^a8X+Uua%oF@e#3MdfvC&~&X(Je1E5Gu+Pk zPe1;D%5g~z5fh4JIX?qa{F#dQ;kG~05$5eUpfFs^q?KS8DblUmdT3IZKAjR78|Fq& zW{D)6GAU|Tjjmmenh!j1j>j4)W zfUdkv8mGWKAJRFNd#CI?9dLRs48lKO02p@9!+;O6UZFPy<_&&e07Xu+)RHomdG$Uo^p&J1ELgvvOyF# zPv;TfTJ$xwjX0|J(U6bM6w`g;P^9nV7Fqk*UWK+1wa(VCnk#gR*9X{|8%l@+l>)Q0 zfv-Z1OqdVhM^6=Z3OXjYn>PoTb(<%I-)ldFxeVdw4g9E+CT~2IF7&`Yr~~*ojY_}T z5)=%SL~!bkXb>8c+>ZTr0)A_Mv50l5c9)Qdup!{c&!vZ#LEPCUtDr%Yc3o@%*bQ0e zZEP!k+kfs3rehHTioE5|UWm)laeKZugNSez8A8H$L~wF3(_d-cKyVWF%qxJ!Az2Af z>!hmTe;p44oT1P$afc8H5!}g-u;=Q)P_$Dw4Ajt6X##TENkf)t-vgXEse0+F8dPd^AMIGs|B?}<6oN@lpYYARXY{2X%FJf|_UC9An3 zk7g{*A0wet%d2=#wy(P0Fb-T525# zsh)QtI=lU1Ei!s^hNp+DAl{(3CNNigWm4LkI;kI)NV28#b%pf&E!_9Ww`ER+dCtsM zOXSnQlL$9qC^SixsYau;mfU7@sA768Y!;_6cL2>TpEyFqobxSzxw8WCSM4I2%5V0k zNRPOe&@iR$5EC!`mow|vl!ld`GS`(D!c%`~F_I@loV!1vb{VB&L_qwwT*3ceG1JgC z1D&V#!vRbfJFBX72spe)V|nJk&S$`%-~@=L)d5bUy1YaI&xW&B+zsVCqmFC2-wI_MI(kz2)2&N@+h(;j~QOu zW`#23&7>9!I|Nq?($inDfkH#^0q`(e2?o36Ti<+vF8*)ae8Qd4TDFsJzPe=j-Nzq@k8@RcYy^>7)amY%lKZt`8)`(;dwpcN;0HRTa#8ZZ*-8jmCE#gz8euX353Ff9-5ZU7c5`Pxc1m% z=KI6-+R+ws$p{5c`864GvWf|qEA*wF0T_-P-;|t%K^k64 zSeN)T>|>9^?mZ|XYy3bh`!%i6RF?JpTG1UT`lI{%U*Foq?mxeNO}Rvy{D3MxAbRiC zZtH%3ly2h%M_fyN%2x=CQT-}#7^q5+zkArz*(Wjqb?`o*IbKVI#BbT_-ICH<31g0_ zp%gVGvO=G#LPxbYi1T5>N<2|lb_{Y4ph6IkP&O6WA7u-U#)YX?-T6lksN8m+o5y7w z`gktqC>~4L^1zu8c5G`G=%g<$-au1{09(R;d-|3rC zbZ;t8t6jZ;`%b4g?2(gURR&@UoLF}-8B5oQSw4|0eh)Eo?u^9!O%fJgLrcLD{pKT><|axB;&FVv-Vn zdU6}Hir%+aBI1EW#7RW*+!tdkkT?gchCD;7QG@N<9L-9WAIW*O}$>rYSfX!rx;a=TJ+jxCh+jr1XQF zt^S+puc~~P_9uneme6#|PLod&5qvREk)*EN5rBb@8As|OCtZ$I0!+l2w>LY_F zzch6~?8NbtQAD6jA91TN$s6;3f7GF@h9s52wM@TzlS4w3N3B-u=t0REd8d_DMA0-@ zAv6R6Yr5+o=VlIQa6WS$h|3OkB?`200wtWQ_0w$I_`AhVag-VV)*TOIHlDfaNqxIb zw-dztQkJmWkav!gpKCposdiZR9)OT3nZpnn?J@4D%2QY!U^V&^Uv<`h)Qyacn!O{m z@YF*TfP${QQHLl<4jT~DG14M|fb4;K!+3_f!!vjpIPr_u6!HEtzG3Y?1>7gjaqAf` z1&p}{j#%%1`|%dH7V7e-Xv-GFzsS?RhbG&=SZdJ$wpoMlt_UUC+wKTPu42s}x;Z-f zGE6!+=ung$fox{-(`;jZpTCJ$WW1(7M2HH{7mA@vyfxT!Gb*HDIRYw)Cn?+&mcQb5 zjhmZ{ok7@P+66=)1v4_omIY|VccPfW{C!6cxZsW(z)Vx-Kz)rk7s2j4Z;-gznj|{k z6Xmy_+P9m0@d@i7vS7qq;#;T-3SD-QfUtEv68@W$<|(DiWVdF2Xo|GY=~_A!emTrm zIp80%*$kwZFdDu=?0ggG!+#PWf-ZN(B1dp!PmyU22u1!?9egE3H1f07&ji63eb3NG z+tj=hmlKaS=Z}pf%oNy9^xo0}uJKCVCCOYaS1V z*UN7>SGCq%K=-kKb&ND`Ba&ULk5nJ)smRnH0-EAz1MZjwf8q@itOvg+>kjXMj9=6e8GWZXCT2p{oT0l zV^12u13w>U1&}idU;_nG6_CFM0)2yAo+@X=fEX_?9DvS$K+#2b>IupYY_alvDk>nt za4tdZ5=PB(a{xPlRB$zOfb{}C1d2*I(2>}=$RDJVJ*H~~bNTarsWZk<&ZGyy<$#3q z6Z9sHr!qMH_n#A3c?*Q1*1k#65#6bb=*F_x!;~E-7A-d?><6~ycq(qhg!KC;`-bo= zM`PQ*rv5&EmD^(pg&vQ%MMs?)BWvdLkWjPD(Yq+;h*;rRdkLH)LOZpuPT=Hx{NX2J zApx7U_U2RdY=r~WRI=FVo(|0#DphmrCr0zB1Oi$ES*xohPNXNGlA#np>w=LG%C)3~ zPsMCKr}x_#+*5Ep5fS#Rc%niD9Oh-Vw#rRV)%}crEKHg9RJBk)x^#)E$JZE55Riibvk<_0%6?SbaPBOrP~biTk* zi)bBW(Efh@(I#j}Xv>6{pXo24}Px9Ewo0FEJE< zV%t>sh6)BKy7ST&DjDdoF9SJe4#^2MHLp(j0xVQFHsw(ulfSF>QT6zD#lXNjsxKrG z=PLO#{#gZHI%izM5IAGKsJsdZp9^HNZQ?l+#)IbwFO|q9RL$_BKtXsQbRe9y4YF6y zohlyy~fQcKao7 z3nP)}-20(9C#f&lg3p-oI;AKoc`);+l{zKs#ZEtAP#Q_LSwnGT_0&0^skG)!7yBtk zeJ8=1ZQ@m(#&hS0e#tZ4s1y4mfmfe-z}L;4Gr&u3sR*F5dHh^JaF`a-f@6e#fA(Dg zCX>LO*h{cGAXO5aF2rdAg+QcE=zr(10zZk_Oh~5%lds&?3WrJtGKJk}pg9@dpr$b7 z5WE6zQwW|SS)Tx#I6a*LBmm%?BV|;R7Dy)Mg7KUT6d&78jX*m_a^}KOIz>D&1K}Ws zYF0gR>A&5#C)W-yIV8LIm&;&(DUJJ*+RrneNH{=MBnpc#ZwO0?U^8bRkx)zt@R%)E z$Q8!lK3dX>4$Ds@fVTjrM_%K{<--=tQe_%Zuy^f`>C1qiZzSKe(ZGh>mP#`bA&4~~qzWV;{-MqF^*D}6;dLQhfyGNf^ z8GJ$OjP_T{S9Mb4wdcTXXsOe^`{g5Jum5x_l%pop$aWsR!NgOy)hM3hg^$G`q7M5L zr}RdKcyFH+t|(dgh;mK>Bun8u#T1Rtl2CSv}7Y zIH0PBGI1+Yzrw%#jN6s5tSChuPv~DNorl5Hz{$7WqDE#ZwY#bz=RsN_AwvC+PS5@Y z9A9}{^t#bCNKmmEfJl=e8!#H*#C3^`-N(bKvsykvdm|mm{eI>>vI0(*y zPp6ZQqcZw~t^B4)rr{xWg8e}(KnaE;kw|@kVl40@%A7#rut1s;1?~`T_B<#zr;qX{ z($xR{&;RXT|I5GrkBT73zraAkm);r4E=2oMWjTDtm-!X}Z2^XtXBPoC66b;dfKk9r zMF#>nGmEtY0e?)FuonSD5(U{1n|%8jS;KS=6%RWCrvIFm1{eWg0fm=m7y%v@mz-H_ zpQ!vy>A*3wh16hho6eb0@70%^7y%;!yr7rB7y&*3iI@Kv0T&%+04T~|;P6*`*WrXU z`$@-mh=|d@ku^rQl^EZ&mopgwN&yv@ei;E40VJ1|83A4m$NB-JutjvdRy%CmWo>nyYNl6TP(5N3$QKe=gC@@ zgAXk7yS3$osS z$gPqeJ^{rt`>yk*m_Jd?pZXOJPYi914D%%p?aum`gS&t@uOmmeZedq7fk}5;z(19m zq)&{%8Pb=bt5={7&-Z(5m3)U#dG>@#PZIeD^;b@MIGoaeXb-Rh>eu9h5Yf|kz=XPz zrKdj0UOHsD8FrrAoaZI_^oscrM+U%uAYgmvFM&&KG8BiGUxp{>+1tVxILM(^hnMOb zY%O0ygF$(Pr_V1h(o8<}Dn+6U;Q5RowY4RG_M`>3ht7 z1d~RDSR&8TDG=!`a9~bHa`Pg8R){-=@{ynFxnZp%?S`L#zdJBRV`-wlS{77&!4|sy z1jVp{ssS@wQ&PLW)rK6WNFq~v9BfY2*|0CzJ}v+$gaR1~fY|?jne3(h$aBUlk;6|I zVyn*I4wPC-3{q5@?~P_hQeYwg62z>5yAfJSiK4vkP;w9U+LsKcNDmZ$BJ>Z-BJ~dH zkFMoM;wZnJu5+D5Z6$Y4rb;p#_2um%B&jM3m6}F~`5JV<#3l_NWpD034j6R128Hox z%B1YTN4};*tN>UVR1_OXCh$334}=5ql{*Bo7WBs)ccP94G8M$zS}P+k(I}Y6NsDM+vqa&i1nmG8c}#3W~e?ROf zUIJ#E>KLiM@nG7g=MJIPTHs8KWr{5M!r*lR zPxh4!u0%c9s}v{Ocp?);ofkXxv?!ldN;Z1vluh#djVB%r(jE;KUb{XZjWf|FBp)Y< zHMo+APVQWPbxUC5dKrTVJoKpZ^`uUZ^q0BQLzx_$mCgUtVqZ_BH$)6laU+&t0O;88 zuPYj5?TT9Ezs-~Qe9}0k&Eo)n1E-F2Ud?H}$c!Yh zOy}hiCGABd*T}oYSvAgOFpB!Rinay84RD!3rzwzsQ^atS8beKdzexMU?*JxTG4>yd z5Zu_(?wJxzIso}1y*BmK1Xg8|@BmKdXoY*d0{I($5_G%7O(=}Kl;ao0aZTqot7MM* zDjKdj(bY8_H?QOibI3=+DW38;RhQCa)lF_BLZQ2#U)&rVzq&KI8B0aX*^;WM#^J=1 z?amp0tTbWMB4T>QiZ#UFEHk+J(w_86bnbaoyMO&VV=(cAfBcd>Qx$*8>^M_Eh9uqk#ki zQk;>9Y69VlbZlBIhn8EKjvf-oRKD&0)Z?0eB~07BE=z@JpexI;g%%*8q-oRKA8~(o z*-Fi7P`-{-rxl2>6+9zy53=WD$bgxO@1-pMlnA1)EV*&{P}GX986r)hd&JAjAReGg z#F5=E-L&suS^Hw!h%aQlmaD|)nM(gZ@ougaRI~Ae%;l7 zCk;6oy%|uzJmjUk38Dk3(#B36ik@ih#U5mpFBTbR;2Q8LvIl@0B1}jc$s@MICxEpH z+Bo$?PT9@7!{!06_&ewiqy>0~R4>+f$v#H03Z=qtDQ3%#03zElw*&i;qhC*O@jV?i zuJ70rfAO?Klk;UkJY$B`Gq8II_W~t<*-*X>xK8M2OxP)6fx$<7-JW)o)16`v;4B5p zO|1;-Ut%ddak(J)Wdffg0G+y2V z{)$V!T@pwpa^HZ(k|MPEynR}oCa-jM+`+lAL}q&@WAet%=WIn}$cUGDD~Z*AL*>t; zmzl4@w&KP(n>lb+UddwiJO4FVLW*dzs`^%kX~tD&M9`|J7b}qB>K-LRBnlq8mofeg zkl83jgc|_}F&wrbmXa#T4G(w;lFGLz{ER5H`Mi618-19M@i^>^Iy(4~qd*w=RP~4) zNkz;RNVuy?gv8~krZ8%(RWHkbJqsA7Y@K~YF&HXA%Nn&y)_@VvQ`JLYV+~f?*=bdOB?mnb{&Nqg zD|-}uYN`#d5SKpgvAMr(^3T8%eR5VQwmR&+Ak+j9DPckgegPt1G%L#4mU_=zObHlY zNr;Nb1T;s=|9_g2+9}ZF@#$Ylz7tFnl;#Z`{iKD0o|4eQKzI`9<6ez_}!JH+3GRL_bA6D;j_KA^W&V;^U>6lE>ejbNTscLQQ?^Dns9+;-xB;>IL`z-DON-@Jya zxw(?|Makfr%@?3hqB<&=MzaI1=5J$qR+O=_!vqslViVrslm~-3xy`U(NZiLBzI`?5 zjfWw04mdt~bZyc(!OuCn)zjbu(oeH3po*H4I!1k&R^^kiG)TQLFjdKyb^{141WuFf z@&(esi9_7V>@1LfI*7r}2H1oRf_j|ioNvA!*RHJ4)IrtH}@C>G|`2wReRN_^bQALuiXyF)kX| zRJO`?kv+heJA#JT1E*o0dFn+v2&1oPpKo8r6YdtckrqWU@0bPWjB)kIcJva3BL%3g zxqdAPZXj604uiqdX5;1>-CRjGmm@aiwo`2ZEY4>bpHMv*;RA3a623|Y9(cTDv9@?s zgQE;3b+*ZWhejIM2gBD90MHuv)Lmp!qAI2=Pe}kvI|n8$6%oxd{Yp&SJ{v4I;kc<- zwfbiisB-{@$`p|Egpda@R>upBrV`ogPEUr-`cu`5W}8pA$#$d=Q51WAWGJQYTqLFM zQ23<5n()6{sH4Q5twE!RHylcKM6XOCAN@!= zP4skW8q2_R&#>L8q3K=Zm;g+X>*aGxSQmK=qleX3VmKea@yA6*_GOrKGW(nmNwXOu$n z8KI)U0XrVa9FaTV!W6hDa8U8yW0Fk-Yl#~Xz?4Kr2L0cnh7Emz65;F)XAvN#IIP38 zX2|2x+V%s~Ra5|G!u-(>^!Neii?o`{N$0J9z{WxmaY<@?M;;+&9ig*s3x-kxZo&cZ zOh{Rk=Uzl#-u(2cgSp5)(|uWTW;tH_H$UA*p9$EEC=L_dmE0kf5`?n#uwBbQJ9SW3*KHD*&}v)Mk^|;R^vCwpdLjdp%Ke} z+>*Pbevv+a-nV4n5qdChOok<+9KrNN&PqOVGwIhVWv+2sO*}w#=Zjy}4OH33v0TSJ zu^P_`eil`$CGM5;#guaz_-3avSL*z60Fs#e;T^(;jg6puu1?rLeHilgQu~n)pKiWE zZDGNFNRakB~nr2fMJ1Q#U zx)RvCWGPDcVx~`uQS&ydi+RQ1Z;Y)GCXa$VdPQ1R{3qEnzTNVVARi-}MvekyS>9 z1|A*f;%kJacX0Xl%iq7f`}1$khuBK#01FiQ3|lUouYRn7A;e5sV6-N?0tE_(H}O#~bOFl1o%O_v$yV2#Tj+V)7nq))dd+ z8`5Uf(e!fyk8D6@^6m*zj(uaDQOcuH1Vm*=AD$`)lezd16ZM5TELJ&qtP{+;e3#d`T_!9TT7^d6RYS`; zeYRc_GxiKOy@M|Tmp3lWmQ7mJBygGpHYfR8$VE9BC~ZwCZ|sEvJhu%srXrZdL4xur zi6jYPhI%BN{mngpS%aknZxLpZ0yB3Dj?A?KHAkNaTH}!?#U+WFAZ~+x&i0SG;VgN=R{nE zB}L1q&nfe~XqzbYp@jUwAutQ(Zm%a=#5oK6igl@@4Je0yogB3q0dYQobrb<_1YEzR zfQe^FZA-@5mSI)qOasBNGZ)fTn>i5?qZJVYLFU{(9*SBg6yho~N0FW~#+K-0RsYaT zeIDP`h|J=QF}8CBz;F^ck^^D&W{|U>Ubvg$Htk?33*$_H3Bg?AfZ?OonUp zPFc8f) zbihUqxfM4fa*2KpzD+le>l1xLE0J~<@0J1zk`%s7OD>YplR)=_NX0ZRdK|4Ii(b}I zvi+ndhHe@R&jw|B>30bYV?PMn|F(GiAHC6}-&=tn{QZ;Jt*4PDs-sznq*m;R zPeL@zVv|tDa$ox={iOX_d30n6scKd^3`j+P?aDZUp%zvv*{lBP#5z)uXXl`c@Udky zMyn?d#*vUu4&6hDH`UMoc*%6iuvB|m4^d6MXLt1*dE!$=UNBNV^Kx| z6`skBWe6#FbFqHsPd%K1nCpRo)?{(nfsN%f(G)RmR5&va_LY>Y-H)lbq-Cl;qq2ht z!z9Rn(D<4-K<%$dLA@E2IxWQ=j&{+KPuJWSZuwrE&t z0a6a5FTdt$bO^rjdAD+xDIpfDB}I}peE%EUaC$Y5G%d}Z1&G$I-%rUcGS9|5bOwW0JQ+$v)^Z?b0~3`h`wjMmBeJ9oSK8? zAG1v91yC#AU&38PPd5C;-x>LCC%5Qf4s{BmnwY}4$pZk`~?GGtASUc$v3h~8jqO$zD0TbflBTpUgx#v#3)e>N5seLa(gxWn4y?M;>#b|97Ni@Zs@eV zXm}G_#wNf9?drHem*SUKc4?qm*y}5n-~p% zwwM8IVXZZkhC_>w_+yUaa{Wv&_G-jSo@YI|kcR*8F}$a{spI~MUG~zZl8|1kZwcI98|SS$ zVA*ARS!BW;E09o$msBo) z-ODl)*sPg!Y?MC!CBRRafz@ij#u=!(U@oX1YhkY!u;+?&*SgG9{dnh9yd6Jaz6!f5 zrA?t1SYxNR!q90>g{j+us9>p$_*OKAp2Qrx%8jQWuM&W01F;Po-wQ$;w|zi?dixrR2SG0&JqljCa!nN|^AMcNEw<;-D-YA3wcz4pvKK1w}fb0NzL{RD%^7+p}NqtaMk^aeD#p=CKujt61lnK3v}(QqPQkw7qAJ zPm~Kxj%|A39sDM&^lgUYpIezP6rvwjNa|lDct{w|37?TS zH5GLG<3q8tO@G;EkkU% zvU@}t^<7altU9~3N;SMS5pFrQ;g)xzX#FUmL6=p}@J~;@Hy2+%4GK=)(#a`t;yJO{ zFIp${B&}bsk^hyN*R`Rbb@kZ2f1RJ72mSH`1nK`0g;4;XLUXGmcm}0^mNy)^AhD|) z+oDrU^<<4wBOV3d*0LW~@wz20$#T1iHTu*-O~oAM+CrAlyUqG1b+G>R>2@2 zsBb{_yn16J+6nI-IJ&SoNi3r0)IOC_iCR)Q$w+Czpm%=vA>+<}716~^Upq2u~sU7G>Dp;I6<8~FA$8cvvp6|cpJH^vweT@_&U?$VvPx>WfD0aB}1Y} zt@zwdjW<+hS~@9}G|z++N*(ItA4rUsDV}X|v_b&QN#mN3*K#TgXz`}`pA+BDk*zkKCwa2_h5-|+KP%M4*t$@9gKbhjP7Y@^15rF>O2owkKN{n;G$#=m*DH}(KHVG74VVtQ00aeP}Q-Gg1Covj>@}7``cbIEFT#&>6FaA z&T)B@WODE8V**7)ARHyf#3{e0aoO3D?jsC;@qr#r26hQvQ%6tr`V)8p$H?X5PDC&U zkbp{vy|*{D7$Vcr*5zDK!&cUwW^8<7&)n}@z0&#`@+Eb_*?_9XWRI`M{g$H$@PcNt ztT*sm<)~-gvwRsx5OReYW+t=;VX^14)9)wQQ{@(NRm$>H5~Cd{pL)L$5-h6)#$ca+ z|M4kohg3rK>gxQ{1y(g4SjaM&Ot!U*oxOPxn2as!K#hs63>i7Ij)uODSlMI}aY57l z>5PS6w4<>d1#IGDKN(wYmBx-0GSrU7a?*T;-}Gm6_!9!eDT{3_c8$d{?V$aOnd}P} z#}>3%(;iM6!c}$69oywQJ@~F)w6H#ZGF>wZE&I`Xik@NRn=K#IFV2ctbjfhR*F*oo zF`v`!4~Xkd^GA4(Vo&(3}YsO=tFJmGn-&vPRkXgu_E zgE^aO0vO?uaYrX+e=GwnFjAt#dlPKn^4Lx|yZqMgk59(N+bF+Hdx%FHmD3b|c%(6W z1JJ`FWzH`$PrY0MPgqH(aCVxe8UQ^o2?q$wxpy!a_C;cO$G^-8-QROaWsSxV9{`zP{q1NF~oS{Oy`VojVe5en>T} z$Jn}PlteL0_qx0hKGrgULx2i@+fKN00|!iLlIMc(xSdBzm;=#-P7goAH;cXbe(!AW za^Ebk80lZK>>Fioy`3-g?TFe6CWWO%GL_KKM!;|xiI-jJ^Ir_i$r~{|wZA|(o-`t7 zi)s>h`HoW1HZkH%JC(^yY|=G_Vf_sqtr&zGe;0WNok*aRsE!dJGpEx1~&uMu~x1;{Go!(Zq-#x<9Ss7!2xuZ;<~;v!+afKrcq zGO?1l9iJokt;UC#ZJCGsAW=I7cr3h$!rUqW-mo_S!l@#MppfRbIRB2S62=lyM>Lo( zdbY7i_u@xKu~kI)V6xPIlPtY#VvbQ(_Aj(J9?clLbmDYzwG;WGz(d}O7@CSt^CRK5 z>1vCrd_-q=(J0N66yeDX5IHg^&*~rKF20*Cm(xQ|0cb8g>x(7q;-OME0Li3;OI)mH z)}xNczCxyFSM33D*Bnz!(it&!y zG&r^y#$Vb86I*LYAINc9X$BRf=>iVU^n75GWXE~ePw#Mf?=rA@vg29}du4E0agU45Oh6 z4xZlWhL`w10V@HAmn1*|Gk+iW@4i^mp^YWQ4W)YVijo85v6zCfc^GzH!qD~&_yfYw zMr*O~f%2>NV>CB+z#2$BIc?mzB|BGxG0UcGcaY}yS-R_$5;(A%RUg|g8 zCL~|=@>zJ@v-nkhS3)Uycw#pgALtobwnwo9kr(+ig)Uc_RIhW*zL(ZO0X7QDyTzV% zU!hxm&6gHI0VIEAwGkh`e13EIHg4e%_-$7UEl=mGSa|+5X`=PVfS0HfQN%vYav~CK z)X@^c2|cH$Oh)Yx4x$^0riw1Fs%2C!6;zOuF%XBPN%4F*unM>5S#k0M9`fYyLGCa zEtW=huO9i({L;n?JYU_?ZITusq(pjTIo-rkUuE@_fvb0}dMKp}2x{h}MuNlu5=iZN z3%6xxRR~-Fi17sG;X!{LEQNJiE@#C2G#X2Qc0;_&1gy@^K2_=g6T!EL{%*Ce)<1EX z6S977N&)me%AH@=V1|dWY3_3m*z)zDuZ1#?)Kp_|M-aL3=wD#$D2<5soinh(#TPuU z3F2uZisukqQl_?8D7JcfbFb2+FhD>IxI=?tAk0wYAT^)h4px7leZ2CG4qt6B@3y$O z`stmYz4=_l4X3tI8_-ajC7DDr;pi9Hm;73jX4<7$VE@;|pb30Z;(P^BoaULQDh#JA zsR&X-`$2Zn{Rz1&SfaPfS|AK^InkTM+sdEu#x?lHHz+YnGRGom@178U3o3A|uP;Gz zFZ5b0wZcle5#4{k3^;8zdkwDVHw351{N@%xT+7{Zo-j!t>6Vmk=5$L3*z{w{pmG9Y zAG;C>jKoR*$ny2JG0e+lk+bU7X=USzHrnJ%HkuB}<`d;@5(Mx^q-IDlai-GKhd@>Fk(A_)@b0r=f zf7s5g#Cr7>=Q0TZz1n(pqe-GE@KE(`YuXp`&BVYV-Gk$Cp^zZgIO_ zJud*#O$&~_+Ks(*Kem=5ZRN%in`MMt`tOCj2G-X;INoKG ziKUeOhl|qWu-BW}HQHN*NuwAs$-1w2Yado9<{7{|F!=t@VPhEo;r&;y%-3RVKej31 zf2^P!s3ro#cQk3j@7$AET~6#1veR*r^Zh6Sme;SiKd>do5qn=JNh>e)qAacPFcYS} zJWYS=P2D3;Yxc@d&D^d}9JmEK6^?jUZr8-8Gq5GvpE6-PDn6vxR;!rtWwm0Ay@N-))BS%G4BC{pE3s0d`NXLAZLx|NDWDlD$wW?> z(``YF!=j0#`JvLcsQ&v6vhFtke@$jgY>Bo~9q;nwb&coTFbRu?b}fRwgBgQHxnOwJ zVyJBuEJ}SKr7fg6k+{X{m{N^fSHV-$P>{3>TWx_;vb0a11e02zWE7o*7lW-t#9%HG zy_d4>lu(r3C-21`#W-EJ$CqeF0U`qZoR^G80WmA-bRf!q`WpNx;S?Q37Q5L`PEx{Umk9TMDlV8gwPsAP ze{A9OO-@bB^plt9M*$olhbU?|8Yc9Fh6BrR{Qu(%4314?uRKPTh$A(F=NDg8mn295 zBY!jeMZw?_16s|~4~Bnhm8CaHY`QEXSUZ^hEn}jnc%M@aqt&bMM#Xcr?n#NQ?M?9c zR9or2X@le+k0S1~;C%ps20X5;A{^a!TQ*N()Cw{3HCeU32?=?K2{^Yaj7TW0OI+hw zLz@{@2~=jwbo7nJ*FvD8rh_Tjqdu81L4UxoouSUrw$?4bwAh%i0o|YA#g_0R@taPp z*`p(i0&237GBk)K1sh*g5lY}zc!Zs4O#t2(v-5U6GD6F1KlV0OLQ8^F8u?!z&dd~u z>IiSs#>p7Q8%%8d$CmZ{(+(_LOOEj>&v$vkx1daSi|;T(hgULzh;gq%tPErZF}?mtC;^$zY~#+qqGHd^o!dZRGVk&DP_OQWgwlXMLf!UU;C znw{ulTZmcd%ZPwO;H$M4yk;t;(v_Kolb(WsP<|J$nF+wD$+{+ghnGL0~`DPJpDK4 zK!|lXqdUbTFmIOSJ^{2OOWXYNcPqA5+4hP%F{=4KpXu-0y0fYwtm*~i-WAH+?iQ}( z7{%)qA*s5eYPq>Cnur@M-D> zMl;jd{6U#!G|A;REg%NrH2EySBHe$*#XZxHQWzZ$Vnu1qEHy(Iw^}~oDO&e-;LyB3 zw(`OJcn*Z^lj`bBoyc3176@uax4WgPm^FWFM*|z~P4rXzElM5LJJ{doR4t)D|3#QE zlU7RfoJm$OjD1PTLv51IU0gl=$GbT0pdAec#{2DLTC&fwS09+Lo3@V|`9Oa;m!6M` zlI+mPWU05lW4kt-A^nM!y{R!o1Xdj(X{<_lAG7LP%#AeJi_cjkSgYLp(NR8o7bupB zk4G~vf*7!TUU^(u&z_02;b3GBL*BHp<&VO&g4rWv|B#BbYv^vL*AXt7?o=VtOkxT{ z^JZ7FHkJvi0G^Fw%rkwshmC)EgP>^dr#}dzCrvhSvR0jWr8v^%`iGwIU&G`pIMl@T zlpr{v`vukJNt=xu+sfv`4SWTABi>um+{nVyVpiM$EaWSrj6dQgb)OTZ=7hdkz=h2x zhDb=FRaeiTO}D;XccZnPWWSo4q*k`w;+tYINliHuh;53VF_ zD%pFH?Y70NoUeq^M`|A^kwRVg@ilA>#cYx`$2O(rmER$=WXiwBLM0%l>Eh1vpJXw1 z%ZA-*>=)~;l66!z{8um-m{B%j&^~gSPm!G*K^MN){spy#5Ty&wx!aorZEJ$x3?-M z_X?eRnKzcSGPWcL(Bg(=ezAVg1jGTOvzp3Z;Ye1cr8V5H^#}}CL7~@&ry3$-)%F|5 ze0*%v=AU!s=6Ko_tU*yUm7!DW)2;ROG>umFBOLmfmB5AK>^XmRTy{xLolg979mQ=l zR27q@tPW$8WiCF;2E&o@I3FMjdtRXEstkJ7rolNZND-{0+#<|~s|@Y^^G$@K`w^1a zt-S-@Ws3Ga^>Xz=LS$~95K}d*&^K4xU?`xt`s!T!+Z&dvPj9ZU{Cp1*nXd++nd zix0i85?nGXf&PC~wZq-jY{cNiruHL7eEip&L*FDyy~2V9wc5ryD_j=@^V%C?Q%Z3| ze)mm^#)s_-A3Ti^!6aJK&WpEY-zMzo#0)>Nti#oj$A8l%LqTjZtsre zK3|1;ME#7)S=6GK6dFs!UUo$e9L6qJdXd%RIiA6wM$~`W*+4-SuQ65HPD7NL>{R3L zFXuNm661eSn!R40nxo9@yCa^8Dp;qCwd?KY`Ar#5stjL}mLi4gi&9~eS#R#9EBNXb zYbe!3?u2dN8dQ>rB$S(Sdr@^UN;T91F9M^JnY}NvT}t=F;m9KP37+|;S84;>ebH-M zN36|jU%Y?)r%8n0w`yN!m1nz9 zk)0HAz24>HZV9-1(aSg+F3B7TaiLVXo}=9aQ5l?~4e&=NUbHRUTJ4NhbfcpqTLApI zi=BU-PVeU5=n(U2fJ=LrZjM^M5c$XojDLoMA96L(7X~>G@q^&DfGlQ|CeS_n8ZL=; zOe&zyM$81%9jk%+@oTL~tDvT%ekq{PN`96?%$ zpw$CDx1X<^`lX@q0(7?0dboFOAz*`Ko) zfbK_}bwA&ve9tOhq%A<$YyK$x5H#cM3HVzBCxYq_;RhFv$p%Jl@Nsry&E8=7OgM2l z)lL@mit7c?HoS6yB~hAp{~Y#;s*#D&{!SL|R`+?}&1nRFmf5nU7EWSCOo%UMZ#{q8 zN8-yLoLGEgJ}gB;LZ7;PR&`f_YGp-N`31?h%de2!ewP;fdq!ePf1*~X(b|mqabGv4 zm0xW6o04vdIpVajw5@~k3mg!0e!*U_`wr|Py0e>^3^b(0Q}?%5o)gXm#7NN7hq)32Ep6~Z&HWHuQxT-Vq@L`lZ}7NCL}83H@{wMq9s#aMc`Z^Y9VSI3Sy8S;^`AAq?&oXxe`r3OAP?+hH24Lo;&d! zx-SD00Rqo{Y6GV+vB5u;8AgAzvAy)-=6*-VDwCdB$!#i2NoKG@dx&lBYM&F%|1B#$ z>Y|B|>tt*@3($VKNLqO$_)?wB%#?r7#A=5q9igKL z_O8M?5nPL1W%dNQG&RetE`$tXMbuvYQ6n{PAS%*8`SDV8=f6(=*Ck*I=wHIH6HBHW zwtKb1Lwk_ZrmQZ_En3Onu*GYN1A!F^PhlZd{NtWtTNcQe~P zcmfKq5Y@JmEK;B66;pqfI0T+su1G{V#fB$KAqxkjbxvBDJcXsMlijNFZ3GWWI6@=K z0gSoZ=hcm*7C1I5+kn)G{+#0Qp6RUr}grPs|52B^~<^03@w-<+_;MOEHEiqljXa&qsLn5ACP9-L4@=17{ zJW5WxxG&HM&Ctep1QeG0OI5=&DATo*b2V5ZEptrbom_rj>H0WoZq}T#1Jj5=OFqB% zc2MDsE=+W!LDD;hi8t%Sd!-rVUolCp=|(EYrXqm%a1VcO=vq#yvNbrlK_@2QYyaY* zh?K;LSH~s{H7Dlfa`N$c@pCF1-Jv>H6Te6u5w}hreEA2FO|;X~RW$z0`X!E-php_{ zyj4}^{Hye>APB=(KzRkp6WM9a2hv@%blO${b}^$mEqtJ(d8L*@m0lc|rTZjejOs$J zD3q-p50ihPSo4ptA|0vojO>*cvCF1i-o2j9+P9U_c!vuHf`U90%JdK#cdLegMhR8E zJ9*KpFq7chVm+x+S7Uif?1rB*6lFTW1F2W4+p?PI_0zL_8@-5s5HB z-%{3ox%#*FbSpH3_+L`R_$WHWf(1_a{{x$h`*I~hRXDJRvcBvnNGcb6OT0W$jvGE= zUDpt=+_s%8YHI7>Fx64mik~kiaf&lmP{STf33y0o#m~kP?X%a!)~oHYwbVucjEX-g z(W`$)mc%G!s`?)otajf&gYA z5U6^P6P%>-31`WEDtx@2=&$<6x_Fr1|0<1CdmUY1m<@~P0A6QFcNO%_9`9gmPYGXc zZ?~jQ36+<($Z!~g?ehgm{*kS|{esJNs6l^c6d$HLJ~EeFqpLR4!?jCDWE+zCrtHnS za&v2NXLJ8dBD!@c5 zvS{l|*Km~!3%oJR0Dk>OoJD(nL${-(F%Xn zt$g7M7KMYAbHX)|oNM6*!yzR?aV_#0B%Mrjw7i!{@MnG_3pOziz=!i``3Wt0ab$tb zUsSu=<-?)ayr2CPBOgUU^mOVa>l+FSwHBX zn8^MYCcUt;dr9L1jeogqNPV$_yUld0{2nMGXZepjy%M+#m50S=;W)zi92kE|KnUEf z9&I6?V*l16toig#5a>6?&X|&MV!4gz@YOuK)K{*qw8V6m@E%ZlZyJKq+u>Qp=+qO^ z%pIuMF~gKGrC-#WAxvM5o$Ws6NhFBgqW%3k)Fjg4Pm-SO_6jY#$Ths5?Iwj8+Ws06 zUzCfJ+h(j(3PAfBE&cC*kNqg`{MA@rJ8&a)yVneK(nw>!jgBHq6{{a9S&mMc`#ES`|A4YX`Nry`dr<|1`Mxg#8#~uP7>L#d@}_cZ zBv7z>T+f|SyPt~&Oj)`l%kC7@R%Ncwna5LP$UzJ)fmV|`+cJNn&(@%!S3M;ayaM{H zk6GW$ZuzVQd?bf0uWO{)-Fw0F=LZozT7Q3r2t^NQWK?dRX?ZR!KWwS#gmzl~A0)vX z?YP3CmP)Ah#c3>;ms;%D4tu&?l3)e|vr74`7v)aplFi14Rm zR3l87VJlI#Og4WbX~1PZ_vX_y-UxOP{e+TRBA}88WASFtw!4x_oK&Z{^rSACE&&i4 zEt_Scq3X9*O(N*OT;uW1Jet@ND7O>wi~00?Wa8A8W5|oHA?D=)#ey>0oe$g%#z?!V*Cs~Yi!9bd@mRJS(pC}#5a-lD8|p9 zjpC1f#JztPDu3?2qC-@LD+Zb;*61$v3fTf?3DTdYjTSkKN#C6KFE~rV;{-qEJ#}+D zmNn-6yMHBwKSo2F-%Pde`}=>Lxr}6d6493ZD&=ISf<;B<2c!pB3tjQvEdFANTFy3w z2N<>;xr9k0Hpbgc*fyTnFOD{V8G>+OiLPXy%ie#zO0PH_C#mBg+#5b2diAaB;W;{` z()#s1`JEQBouj@zj$a_aIRmrea!`enmY_c%QN*kkQYXDZJO&aXx>N^L%FUB)d~%uq z+_4(lX;^P)uP_}O4>M5MvlMIA!sIP3>UH1I0=|8M`NZyt7aJ;TC=$tvy+k;Hla5rl zu+x9{$fK-Tk|dMj9LvL{dYk+^^Duh{XPfo?s+j%11#aALg^O2F=ghss-+EhgM##Vj z%ImkDdZB~D3+3atZs6Z)V?iZJ(y|X)0BlOuaj08Hk|V=04_ zk9((tj=^>#yajqqQwg%#5eY1bBhkjA}Hi=#tS%p#B5&5^QaJF}F`R4^F zSNU(FmnefExy%L}?42JNTZum?nN{#xTT4OZ znEY~RDTqqE+=xa1(1RcIAF_?GnbAFxgOsk8TDWSb$49GwVtsKQE_g5!vqupy24>4N!r5s@R7OUiHWjbXj9UgKGBzPTD2&=kG%E{bhjL!RKkzwJrjsipQVV= z>m*>{kBx1`vj-=~c6R4NBwl=Iwo-oycO{3E4$5X6P^}zDRj8Nv;fas!@Yp&F7e@Fb zytiH&g}27PzGnLbn4AHXoc1X{;p6`P{+)MF`L{raB{NSPIr72!K=#0DzgR0#7GDZ) z%w6p&*=T##i02;PwIEv>97oQ%RzAi{W{17mwzJ|RI2cEkB=CL^h{?{nm$rX}-~~(f zR}VnB1Py5>>FvbC8d=Z{Lsl{CW-coA&*(3)3U9q!LzA{_t!>E`8;|;vVdRKbwf9v8 zJX&>eR}l}pOt*Q1cH$jA?dJF^KpAMS=Kn0^$LID?!K|=U&|-ec(eYna~j*Ca`O}d<*j2EfbyKMRTM{D zDS)h8DT{gMSBNhO<5LSH5m8zJC@+M&XfQk!wi$G53=}04uPxn|a9U0p9(K0gtO)(5 zAhRd7XDhZ|uD_Ej`+4~3d2M;wGkBQwsiln!ts5F%YM)-OyE1FvuKa&;mwwOU8{u#PNt|&U;qAy!|9Z$g<+&z zE3B#Hx?U_>m~N(OZ!muaayx=&r(VnY0RJq@ipI>9{u*N7+bKR~2VEsg%Xx zUo{mrHPtieYNqZS;?*2e%Nn=%DDq94y%k<;$}*(LRYRowpM&1#0)8K-)ZE)u{6#0LZ{Y_3NvK?QkjG+Tz z(2YA~9zpJDzKNCkNVqb%L}uDEH84*pH4o&%&4D;#0l`O6<%48UsI$ytYNL>KH#XWg z9$Tk-5BndmZB6}mcnY|9SLWws?48cu+ za3+#@k|}~EZLWXz2jq!`jC~dEVWsd>_PA03a$E{w%D!?>d>Z~3L(45*Aloz%SzF(@ zfEaHvOWegT@#bzIuEHag90#0O@oQYmk>66W3`>I%bV7W?VI`^p3iDuv`6aEfmqjWp zZ9`J#?nU56nIB2Jb&{>Gp$m##Rv4t)du5uiFtJ5lIXQpipYxl?`$X8`#KN(E-TQPN zhyIDp$$dpdWl@OvmLq51=Qpd_bBc&l;L@I z98hYkX(-fBjO3B^(i+T?^F$ZBh>hDdC1s7JY56)6Y^ZFT?Cvo+;jpRKlOY})TTJO! zil=T|MPq-0dN1eX6Td+y{SyB1@YJ~dG!Al1Fi7|;`*8u8EL*uvaBUQd0aKNFEyYq$ zY9=aB-z{Tu`M{9h$14Rl)AA zf0F+qza*&X2UC#e!!|?9#8b9&_5{=ooGt$JW`2LSc!mlOPAJELUh7>qz!!qUT=tkm z0A<*>ZhvWV-m+~AiRrycTcQ?ku?n}BS2ygx#WNI9nz%c?9C zbF)iaClT4Siskk`yjPaGQjtaTi4QhlgD)*xN48LqXR`R7pH2F z_1nrTv#Qm;@pit1vR5+ftAfR%cW`lb`Hz=eV*w@t-3ph4V*ySP$(D5puASJ~Vr zB7%$Q9hW#{0UcE9{cI<=W1Qtu<#`Ea=1HnJRQ@jHI`rS6i`c`q1t^1vlv9Ix5Y{VZ zmK47^+OHp0)-M5HbFEgJ^Zf7XXs>U;I2P?XYBXzO^^z8V(m~`5G`~WZsbm2h1YKV4 zNtelF0W*KKlrMXgywBI7#b6+6vq0sKrgPrM9+W^tLDhbkM^|;2ZkeqR=u#3iEl3)} zSy5c6dKJ@}^X3nTM_9Px^NO5--K?T!$qLHUK5DQjzbu`-Z!*XX|0Q}Kf=|ZDpyWow zaLiQ!Bx`A@qI(Z6*N5*SNpkmR#<)czDQ9D1N&}aBWdRH?p-skbYh}~7=`7k!{_iie z$wXON+Z636G3ph1%6xa1#Pt87j)SNn_*6X%EoXO^wq*e=54nF!1H0|9{ zm-1x+Dg*2J9hVfP50EBr1m#Jp~J%6SAkOZ@` zOpy6QWfkR*@*3QtnkLgF5)q^7-1*7D>xv4cP*`j~5g;3lyac|#SQo@Z=l`I7FNgF? zSQnrz^DRGX_YS`GenRex_cBG2l~0_rdvWS*69{&XWD0(J_|~FCcM{P?+{5f2>>X^C zTIUaOp7?X~zuaP*ed!+ER+nXH0X+dDm!oI_EFM>yX(JPv`$ca*Oymaml5NbS^VDfI z0Hd@CCI@*bm+fc)Bo14sJCq-dr82um5QLA9mmg^XIR*J3ENWMmU1XNH>hn{V|M$zoZ|^KbFDplmtd_g0GA&PqZVH9Rij0-@z-w*}hAORV zmDrK{R%iKgN6Z-qK=K~pU5%$`De751$mw(Inu$NRe-b(2Qne(if7hg7SF<9&^lA!! zQk|2xpE#i&pV+y(=Mj8U26ph}xolkTEfvj`$ZGh6@}+r{Q_k6@eHzkI za};HsuZ2`ysC4*Cepia(Ep~)e^r~csEm54Vs+ZXXNzv?_YtCJv-vf4cr=T15t)f@{ z_?UfcX0eoL*t3bWf9W0^c}JF%Lkx^)4HYTKwxpHmGM~1U)&GaKYiCXy2*Q7bk`#=Q zK?*8Kie`St-Sw-qm%gxh^u5Yb5 znw-7*(W~fui3u6niYGEi=j?Kec>3$OXDBV=Lo_^`?$0mnfLFxp<;&g?bY^4;l9lK} zU`QSDa159_+6(~yqj%TQ<{PEqbdOO}(;Ft=HZf&&mX+?xv=3i&z6oC9Uc#l32Ou(1 z-^}hGIC@auf876=-8|ez<21&8YRK-oOlz9jgH`V}8`mB8fvt`r(rg3;j7E`Vgg}dm z;J%qOS?4R%Q)>$0a5R+A**q4poRTUv7Grf&Mhc5Ple9+nlRK^b6{6m1hPFy zw{fqyV7te8&#>v|SU*!s6ra*YeO8MFCE@M^lVq6Go|aE`dBJX8jsM z{jU0Re}xS3kN;i_%H;I@NKS?=!-_v|2`!j%f?Ei0Oy=c4C>5_`RbZ zxR+~CIybF|3B9NC8m%$)x1RGz~SSp zF(t=&=1NRj&+R0k>LlEBE*LHF-YacfQE7?l6*T;V=|eCg8U6ApLC@YeHuGB-0GXWcUe9xWn{)Rz4|n%u^Z)(^b{Ba%`nbR> zyeDKOPp=jkVkfeOwe3UIqkE$&+DVj|Wb7f3F^a)o*&le5*{~*dedCF!zlQHbWy$M+XC1 zZ^cwDQDsld={NifMKxbf(M86OhKW49)f>KXO)xY;(}HyzM7?~)B1|eNMOmXr_(b3j zO$$qwD`z%RmJI2>{T4Dl9pp-74l&#rX{r4lI1#=%C*D&q$5xZ7ryYXIc3K%le>2FM zCJGLMu_cHy-Z2k>?5x&;Q=YGuR?3Bmat%E8z}_1o52SzeIu(bBFtERnVw2V1Ui}%= z1jR(i$ZhSN@C+m?WOiPL!P=%niQoQ7WQ)@In9cyhCeaasvU-qHI~Kt8h0DZHtWO& zMv6Clz?T)FVKe9b)_G!>Ms0#SU}VE{IjR{7_ejZ1FpMg zhEPSzTf`v}V&Azs9R7a)50jAt6a`M1s@zbw%5MQC0e?|XgD@0@-%b1vr0-A)n^6KR zQL`r(O=Owzt!Xb?BeYFhW&8IQwjql?_}F{T{q8w8%@_N&3BJHsp=5zb6r%tnQ(VYx zf!5VByhVX^RC3xV2?aWUMT_$KDrY)l%D{_J8jKTQ15c7RW4b^)=X8d#Wjko8jl4qo zX01$1oqvCtE!LEM&@JF3j&E=aj&kZK?t!5miRgsnY((l$(+mL4Ff`DDbQY6{;2*66 z)7n1=hR#IU3U|;x)5-3X&DpUzs`plm!mjJ0E*)%m{{+9So?eHjp^*Kp7@#ueEMo?! zQ>I)AW|UR63!dv*FbLKbOpYgt{+bQ7ZsiYO3rgVkhqBt__;=M~hZILP@WA`Zjw#Na zP5SUyEm4`o!i%3WHKA-AWv~yBj41k(6%fE)kF#0SW1Dy$8SF z|K9sN_za$P_TDSs{jLQh9AH!&U{u{<1Dnd;T5r)&Q0TEyPzX>^P`vE;JRM!$yl`}U z!|P>lSFUgGSRhLH$8YKmtH+Zfs{!S84KC9b=b5H{<-(nj7!vZy-?jeL)Ti@~l{x6E zmghOmOEJU}=Xh~>8E^ZtfghfqPdW=%^Yfb5@mlbAxU^6F1l?s;lG&Z_+TamY9(t6B_d^SHe)8MV=+=7M1i$Zs zkj#5alZ;cZ_&om5qrVMJflnq&MWKThfZ0R?1qZ9?f)vLZV-Ikd-*HU(m;xcor% zycy%QhsV1GW>tc-wWUad3mT5l_V!v_ZCk&$IB9K7dG;I6m8>@qZ?#EG=UEIC7I3e7 z)W7pH%{6HBoL}o~&x?&PY6JM$0dqcq(}X{*P}GyYDXCCi+7glf5y<3@vZBw(&+t?} z=W@_l;Fv%9Woaa=_nQW%>nqn@=4aQk$5t;Ncb>rJB~@K$QF^POFx)2&?Bi>M3JO&6 zBs$!w+E?n|gFF5prBc1lUn!oUXuSHdP$4Lo8n!gO@orI+^gv(EdNzcrbmZsuUsrBN zdz=pMSep}sqN&tDdfPmJl9Yf>TAPbEj*GK7zA`zMf`ZbYn@`8hfq z=X}TD=XA&Cu z-jR6xEub-Pe|H{taa1Y&N9y)Ua7U)W{N2s<3~zD{k#~w4J$h+a1*%l~$Q+ z?Q-LoSxjTz3S8cu)%d5CUjLngxld0&yR)kKDI+?6D>Q$+`R?!NiuvE$rIWumYgIHr zdfbVj%-D3C`QCotnxV`s{M6iC=8xBpgKLI^v68#L-hb{IWIAHW%*x-L|M{7Ako$MS z*A>_=cKCbSd$Cesx&^fPU9QQUbmaN^TuqzPFH5#wUlPhpO9AHxadD1+kAMHFdG}oA z(cixvJl@Bnn?UpKS{^;a-+J|nO8!G$zw3sy1Nz*%6TXgK2P2#7%gY78_wv`;_D_xI z>kkXP8pp>o{j(i1x2A+0-hZao`oTRZ`ha(pKGDGG@J&Aecr}>qyi*oZy&b;^BdA;@$BpXPPs@9IcFDRC{nzLG95`FW zUB&mhiaYE0dnshqanqdD-}3g#6pVWq{AzsVTJm}lAlzEhVUl-Z3y1#zk_|%7SF<6dcT{njp zWMYSwE5V0>cz(>mgr*)z8tVHA-pnIyZ%6=D40!QZAOLNg^xfUeI}rsXVsJ zys<2N_N%7Ev26$`{oE?-&XbhT^Z<&qn*Dsy-{wCjXM@Ve1r-ivYnl&50%mrdeG<6g zFd3Y1g=Q_qA*+4dG^)jt;oWUsNMQ+Kye2ahM_QAmal?K%(u|iR%8!&V%8wZQmlvHp zEJ?~M*qAolV-G%+ScNj?JQmR5b;a=$`71_o{7ZHl8$!2*Lt4Z&(D%EJdG2}K>nDEA z-vgH4lO*py*1it1D>nn)z?9wX<*6u(Nv%kqCV$|h`7~=1Vep*B1kBc3;E`>u*@ zDzI51;V8t%^zr$dD9w7g#OimS?P;T6?fbAF;cK2|QJSeIxUa7q00D!_x`)>0t>1-r zFYD?*ntysfw{vmyajx(^g~XZ3Lil;_8~c}W=HMnCjySI`Qs1le%`|B5sm(UW^WliP z@+xGwaSWAn(QpB??J=+K_i-3iZ%r-D<<4j_C;R0$3YuQ8y%#mhIj(YA+4g=BJ<^5X zUhRdC;MOSs7VGt_+0zz-CwmtBRG(&l^nKtc8%%8#olNF|O7+0Vy)g+Z%`8?J?$cSme+ zUQ4SzJux1<_sin%g{>NqJlMx8?kA%*u$O0m377LH$AT!(ZlBi^)jqGEo(dRLxPR>V z9CGV+v3vFH{l}SDOKx9-|8@)&7TDXaB`q2!K7IV}^v^w?Kg6hGU2`k^dprbMYq0vA zu~+UI^$9_=X{11(^?it(-`KKD2k;wcOH;7Fp3%&>x_3KqL#QwyKzE79V(ZzjgN67m zJ~jESDP`i3vhP9c41TBEGym--@KIaJ;iE54`lgJYv`F-sbmG--+qNyLLTG-7PA|>d z7sJ==;OxLO!tNyv(44zZ0bk-nG_SaQF>{19$Nb=U`5QaEi3PFHA^uk90~Oa# zdnS<_sp2^Q3>nUmz8+t3lfUgLhr;zgKkw|lBdgyb^Qr>wvSL8Jdm6OS(jTdj?%!*Z zw0yr|k-4y{56$IA{PZhy#0J5(ZPRk;l!)m-+MNU(KpDA3g`b4|d(Tr?CHO_b2KN8G z2U_>nE)m=6Gi_(IBY1RS!Pz@5sV^$B@pY~!C&t+DHRpS4V;p~0S9$;{tPzfWZMX|( zoOU-NG@oZpw^KFVq)g=a-iLx@j= zBgu(75OUQBppE#j(Sb)tIM((wWL$|OHg^1*fa&|lUka=FWHkY(g63EwK6LQ9?eC>?(+=zDiGDcFCn7FuL39+ON z4)EO+ZN!oc9@O^Lt|}Xqjg4qS)$aKKkTx^F&{k2kw1W$Nz*GN3uZ)e91}_`uujQ6L zL=+4AQ&FS5JQ~9l$)R+|NEwh+v#YayfKU|g9Pzn-?#~xhvZ04|!CgJ`j@IAa-R;Zg z*st~CJhYB@_IWwxW&@2^t(&s#*%z%Zx$xkISpR)F)rhyK&Y2IyhykshD6a1ReUUn- z9@or!q?99=%tyBE+)3*}I}DU8Oz8%d&m(LW^lJh`7Sp@oxalhR2v#xwjCB;v#O&uV zE~5bo*W2jUuOqndOi*Nv;h$8FFdW1scX=86PaWKa-|Tju3Y_Z2!Odqe_j4cpWI>qH z(b<0j3Y=WNzcj?Td2n^S*$~NwFpxwQ?1x0ph@opzC;v}LAB0}|Sw9Iv8jjZYI~&#J zlP=DU1Wp^v&gB1RF)rJu+REU&5FcYYiLQs~8|-#Ajr^G#DEHpHYYX=MWWXVrDJGtI zA+DGuCh%_L-(&d=AY#-dWQmq;6pK1q*wxbQwI*!$0Jdvtj}J$GfWRd0oX_hZo=r21 z;}Z#+X(p{Vp+GeAcDg^TeZ;kPN?L9-JHi!I*yYP+EEFWj>i#P9Z;gb*GA zWc6#4{?%SKooT&Eq=5OonKj}PEwg0SFCP@l&!I&Fy%Ol{+_{;cMc$xM=e?*4zXxo; z$L_nkoha9|_j+SyfBvV^>AwB{FCZaFGh%vQ|H!u62}=|{NdHt&MK_Hx;*A9cHtasI z6t4Ks=sN%3ule8L%THtv0xs|ora2y`og|+w1l}P&Y~lf;ra7u}GG8o!#`~=O7wr)6 zq%nh%L^9eR<%s`1M&!=6&JG%HiLEsVx^fzKeTW$edd0!+W3#bko0evW&+wxafqdJuCcf}%e|5Wy#JL$A zDP_NUS(rJ$q@Ng+vh+-7C!^W$tDTznrF1=DkqPmi++p79g;rp5|u0|vS8-dE? z*ozdMMZ@34&+=P7K}oo7YKR3LP8&<0=7=t?z{*vlK_iYXQJ-;j|)+ulgE8yP(DVhyLOj zWs#^>AYs31sJ4K#gwhNTr%p&pVz>ia>GyeFE_b9e;c9A8RPjt_+F&>P)t$8WsnL2d zuA)j`l|}NZL-Ojzl)~-nVRouK8vP-5d4@Mtaxaejtg{p!5jel0CR@;QUIF|fZ_cOX zqDs~HtVo~J94V1guH`01Bf8n?9OLLI4;1UxS{83o1aK#NsrTxx@kRGDj7o)BC=V9F z7&)sR32CMXL{`LX6|{{kqk0y&wK~f5F0uCt7RZ0)a_HU>aLE7isD}CNE~!X{$!h%_ zyn_nn)qW?xvoow%N7ZGk56o#oTNK-c0cM8Xf*NzNKNC+}RH#n&~opoUbvDSL*XeGly{VWRt`!mDvUJ5u#| ztEt*3{pXT9mrU;4QG|1QR3QVQF>Nz<{-#R=jgB3{FDZ@h9s&g>t&XRB3LEgG|uMXXREp8Vn1wvv6}DpHq}>=hBTzUv;%kW)sesgmkMj$r$w8CFH+!mHW&?vcKjO)~vvbYDamCk|VFeRM=j)#?L$&uV z7jGgOe^3Nf+5+!m&hdS)vXz1(P8J!R%iRX(8lI|dZ-%iHp zEasNLJHYCwt?18BGJvZxH_uKfxZBh2Iny`7zI5(Q${iKk#oT8QbBFMc4>S0UQdejV z$OnsomB_c*CT{b%TrjGDoU>i|U-sGDm;XeoK=P{b%-cyDt~n^`%2<#`{<-jvfTyeE z-tLlWXFu82FS0x{s&77f)@=^|8JWC~z`;#yx1c!9A&Z1QFYN-+*jFg#QWS?6FYo7}S z;9#g7fyvsgGj(cvYUx%azqTKR6S6fCQ+~i8fwWFu^|(!08)c`GSyxOU#wGeh^L9%( zI?=zwwE$uR{LBSY=2hlDk@gpwy=RUkpnDVJcSmn5T4`V!asPBI^C}p`@a*(0`a#@1 zP^?`3uQW0)Ouy|r5CHA@F(Stk&UP{?qH{8$L=8~7wb2{Y@z$06bVJa`*Ili7TL&?_ z48dTb)1Qg;dMpIPcUX^llHl#W9P9Q9dlZ7HNVpkUKX>Jbb%#5?zjqQZ^Bjk7p7ZRxqI{Y+r{>x zk)~iOe{($65qJ93g5sIBY>lUDgJBXq{>}lW-=&%SmzA#wy#dP{c@Bn_-iOSw?0d6L z6mn&6L2DhAty28|CktQ`pkB(yHTrj+VUEH}r&Xf4>FYOIqc^47a=^7LlQZDDU1pIk z9;qN+g}B$cQapP^~3)WKWink){dAYc@vvtLtj6*c}_ ziE)q>rd+Pa@siNF8+f%Q=a5L`^_h5W$!f>TbKV8-rRqVcP9Gy~ILY{4pQ?%?a)lM$ z!C2I3_$$W2^k$KQel?OEnt#G#1*XlMboCu+gXTl0cHzRclUx&(l4=s3-of!ZvaBv*sjTsh8S_sIT|-c zN;^=_#2&a5fDoxHsOh&$+bC6m-mpl}_{%SH^B){tuUSszfbjSX%b|(EN#u8Zg`x^m z4M|4dt2pmf>};|hB+d(d=_}F1k}H0&9AH4Rhng)ng`fbss%ydw)@VJrsEjUe(+^fR zpt;V>CgXvB{|xj9h%kp@(`{G5Cu&zN(Jq8;-F7%7N+3#@cNWGqO-9^yRn+G?1Itd|rvx=wl!$ZuHV&2A7 zjgB%oD~759kzX?P0OGt|c~qD4nwnKJ155`h45uB^)eAnwPip4D436d;2@%G$M)Zz588kP@trGuqO5!>oDyA=FS8uvPw)%DnY>j5KvG3cu=&hk@|~1i+lL7 zuyJabT~$T;vognUfnU3@H%Nmos16D=NP`-KRw7uJcxnw1(fjN+%ZH0YZ#qBQqA#j` z@6;VP24Bbfm8zX+f2i*4rP;eQ$o?OL0-saPYPmoO-%9nZ4*QEkwbE{<2A~h zUy&UkzYcGRPPBW`&E93)A4gdN0%~t<3g@dAiV7bdw)zoMH)1#-zw==_1ehMSwrlJ3 z?aJr6cxV$L9g;0s%GXw0{lIJidOzw2Gc%_MW})}vH`2i7qa*&hw9?GPcD&Hzpdrc_ zc^f85s;H9tb!~xdHPsu@YDE{Q^@_N9yE~`25k6@ z(HjyU9hOftZRwKpnlRU=6)NnxcuW!^&(l#C>EVzSE7XOkmV70#s zhCl>&ji=ygcFm+sj*Kt%u9`~*SBo*nB8d``1}u@_oI!Ed*3ZcUugv(%K*IFw*VyYV zDW{ea{{<W^n4cQM%RZy-mZMeyV;)TDrRY3^7}3}Hs5FGd1C|1n5*xg1@IZd)!lZk<@ISD z{}?$FSk@2!_JS=X?&MXwb`qPD9MP7%NF@>E0!0V#cQ4BD=l~p5`~0=P?XSI9kvdR& zeIFZa?@WqE!#OEK0ROV;ubw3><%q)4*WLGw?sba94IDwR2$G#t7-~bX?2K^jhIhx7 zA-MyG3bqkv++K;Ofq(-?FOM3rkCtz2ZS0DOz9V=;ejt1_4EiDwewY<*p%-;fy5g&q zZO*`$OO~YiI>R};Lrl9$WRh^T{qA3v05*BKux$WVH)8gU^WywYZZ-Akme&m$bKe3R zA(_^=$T=uVxm&+GXQh^1B*xY5UOcG{x}bH$35i}QTCOZiosTm4wJa|eZYmpal=>6} zRP{(G@A)a4C&aQpWUJS;%{C`$I?7xX_;IHwjO!CxheCUt`HQwBwb{XsW+$% zi&}?zC{5-NPVgq6>dGx?=w=7&=fRkckDW{}&jpF3R1wM47Z{i-hdRvz&-XR-Ebr>n zl#%_|-RwCl&)-FD0&%)gkF6|==kF7)9!g!le>>IQ{-^o?S;$PIS?tOCN@NbMrx`-*6L{9qC6m{~ce z(7`pA|5qq&sW|t_8>pi>#L6C?`U2JeV1sXY_)P}0P19x*lB7QiEEHGLzzdBf%nQBJ zZ6=pg@9CATd(tm}PhZ`(>GeOvS7dTY@vgMuY_~|Zq`eJ%K?xHjP|G8`$NU1qrlGco z$kTtlQm2V6Wl^KIOm7kegqbt#S+l%PlDnBr%c5(!JJ2TuTQlCl1ADvzmB3A~YkF)P zu1kEhx9G?Ro=Yxq--tfKMH&D6`ET3=Cs$#c~-7e3l^gO+LnKVAabo?Q(wue`M z-0tVQPJFg8)ZrpBM^sP^?N_xNX>j_ulTQW zj}f>7Qcj+v_KHqmSl4oi7fIvE#u+v#0)`fzHxC%o-&P6Ui~F1oyT>RU>)eoOIq#cR zn4LffirK;fK+h`ho*=_=0$K_tu9mdFT>jV0jva%~$S%6aI>BdDy#XtG5*P8)BU6Qm z+17k6X;?D5c#CujS=zMh?nD>KtNZMQijxq>B|n(hsM$I%L9&%Jv4~Q@(RVl9MFI)* z@oU|G0s#WQIjVnsAsfh7*15cZ{X25h;d|tL{!i0SU~h3Rif8xQX9p#L+KK#^7B&gp zl5?|*`Fc}s%mmz_%OnlN8PVge9shJm#WFBj%YDuACt%Z0tLL+P=+SvRw&clwn!pMC zf(@MS!#GIkW%9^C)p_{N-`s%sA62E@=mMfLIK3iS=pQzlj?bH9<$8TM5R3-}N=r zjQ_3y)3a^Bf?nM)4eWHHMU+q$V_pj;-fHA0J_Cc6iZwlh;n3XNv&Teu(xPpzn9z|2 z=p+vBDpVXJm@#^MZ&Z40_>aM!_9NKzf{i>Lv&~yLQIP1%DeHOG7mpVk@?slAp(mUD zWB(2^_V6rMq>n+|d5$4JeAEzMWs@Yw`G7;?L|#<>1j@H&xYs5}EJ1PSbC z*^U)DQ+QMk&6!C1_#WBW8tMEfO-JIA}Yc*|NHh z4gUnwcqAe8*VR%W2J2ki@P$a|oB_0}o*Ac}EF@m!hbnRA-B-UMfv@nDNXAP8y}(!4 zCv0A;Cw9S6H(eSAuRXaVlVhyR`k-CE)1h;^d^qhC&JWWR!mNsN!?1M#4^OjUXjfzg z)aVfjgwF=o!uDG}!l+c0DL;9MPAfUoJo!T6z~~U~0yVIOfN=LJP0*5{Gs@uC9zkcm z9aZZ5rwFLghFah+dZ^JcQ?T^RFXL182cfU5ks%rh4S2&#@Dao|pN&)Z`g>~!BaSOV zjNyHUZny@WFrIGUtlben@@KV)@R*FN)bhMc=WV}htrAPR`8wVP#S^D)QMnBYHJyw$ zWsAPV`BEa{5xzu(A5rkb;dPeHS4FRg8e8vJNyJ9>#|Y*U5meGRsXvntRPBVvLETZ< zR$cH>x>jDE%v6h}B7LZli9%qJzN~V};7y_(2sDWVGPYdJX%;|wkv`+4wka|96``yd z1GkFJIkWxz(v^iNaXI{P;3K+_3EqJczV3OLB~ddpZ$7Hkiqe`W6Y{_kY7|T^dvp4? z#3D0Gh)wEIDW{6Q}@WkZ`OP|X%^{HNeRd?IbDKEqnDWUR#H2UPUml;TD;Ag6jVBdBCp%yOj zQBHDlB+C;_FdATTmuMYO^xhe zAXga8axF_)s-PsO3?%&3UlMbyQa*+4!z_rlaHpt@&yNQq8cXr5<|g)OJ1ijDI*jSG zo5XgzR8@{UB!DrEr7Te^hB-n+)OEt<#;!}68mJblJVLob^@r%YnV04%`vly}(~0*N z;Uh?IB0#Xwg6C(XMM_P7)qtm&h&m2Us0Ajg{w)r@J^lfcRh;_14SR%3#qM{w*Nzdt z3eW0bZ)+H_x@wp8A=w+70mE|Wh*-Fj_3ZrBOX5ZN7-9?^V$RR>jKBOi_c!Bex7ctAIId;p^46BhBv+jvBPI*#Y)%@68) zHO`!%k8U10b*#~y#Mwkffr4lR##~HfNE%hu9Ilol`tKR=KpJq@v1GU%rigm1mt{Vz zJ0CEfi*o77ujQkwn0}PHP=X(W^wtIf+hS_RoUD2|dD5PcK57|j_pk+Z)R5Zs4ig4~ zDk-f8a-XTzyHR22IOpn$fnb&( z#x0>xg~kt1B-nAZ46O4F5@Y)im4$v26G5Q*w zhjhNJ9gA;AhbJdX8hX@PvRc{!5Ld?hUMhe($_jK-F^;+`F|C@xkc_;hV8t*o7jb#9 zT%c4+K$S&Cc(CU@)yap#ZScrPwQ?JZa4hDs+~-OhOWtFk_={ijRSi#-brY<8McK@KNC^z~w($DCUXOX`0GLt4< z7TX3MLCA6`6`D5ysFuJ+$DasEtl_MvmOzb+!ypS$;D-{J2tR?gVb!mBLD-I=Rt6HV zt|=cv^{aH5F8TpuoUn~KYCNtY2Ih9E8G_y9H4rL>m8-0&aK3Ys$Tk)f7U>bA(8>D? z;=L?c!cJXx#dKwW9uB1c=^^V@9SjS1^Eh&rIcHO@0%-Ff!$&HJ5?{ivpr|Pf+d0%? zUkX|mUYSzOK0>wVjljI1XI`4gHtCi!7?RS97L*>c;$qE^^U)asA(XC%;gEzitUUNM zee5YQ<11JCRbTurh02Z4YMi&--y&4Sn$SE6-u<|$3?KOVngMF5pOYxL#dw@;ks;2J-Gx0=7T!bfSNS^(`brg;s*SfNx)o681(qvV%D;F$YAZLLe z3?>>h9i6F*Hk|O-sD8k4`A;LqiyXir-BFQ4J(#wMhYH((38~d+;j+)7@kurCLlCw{ zs0BIbRU^#6*%lRKg07j|c~h#z}Ui`k%)dzR!5iO&Q8#> z^pN?xag};)*hA35A7SA^eIYG2J$MdO*rirr?reGYxz85}VHXzLR8f`5Wdi*b}a zC;|3}@QPjQ+P7V%deSY+(%3eFmk!_XdZlq}1Pk97a020pHqRQp2{qum6W9J!yA#bs zi$Pyx5=6w*UgrmWeCyFhXCe}KU=GhSGW;9a0Hi@%urLPdzw4hYYxj81i@LL$I-GeTaA6SaI6P z9?AT4zB^$Q1Yu3@mhfyGJ|fNsMO5Zu5_4BFca2TsT8!vnhbl~;oKy1Pz6V{ZprO^u z9!=HCt{&*9a4T;>$~zd1&wN6qWM5t`7ntI%TvdaQ#o?FT zQ5}r)Cnf;MP?cZI%OjIi`+IDQ@C+uA@?`JuKQ?~$l79swEMogMGOui%i z8nE@y6c>U?l!x6TD@lkyxsa0!Sz9Y6X^|fo4AUZJsse>U1OB1U4TxF0RKG%vR45_S zsIzaBSDa{7bqcv|RwY&`>-XdbAFQ_4?#UDSumu7Lm_-7MhKz$CH`@D#F#d!Gd-Zrp zUl7A^!d+NOsp5lLotTDps+r)$Cmx>!tp8zKmQ>$ zkUB37?IMqcEQDR*nM|^8gRc2Y)o;}ZWxRaiO}yI$!oy-nd`GeF6eFFyoY2_(LXZrO z!EadCGkP2YLNeLwC!-$($CARrz0J16Ji))kIl-45kQfDEZBtK9<-6frGx3NbYT|M|Fg;!e#}5sH{9-C) z$xgvhJpAJ;3M+F(bK=Ffw#$>Jq|!Ex0^QlU3D1)sJC3KxiwGHvwB=hryiXESBFIJL z{e52aE|fD)5ocnbf0RZY#TJQot}GiU^(Mh-{u8!k(V}dfO2H)}^%WAZsf4y-VYgE} zIfT8zxzaEo=A+XSbwf`61#O9U#=PfQj3oEa$TwA1v-Ozl8m_)WR*NA(4Bp$F6}`ql zzHj2pXQTUN#zH#W4hqD({E3hgkd88v$oi!gK+VKIdcEp-B&cq}M8vRlAQtp*ZGw}r zE4OiJ7LY%b@2r+#mFZno;zTVPLn#&d+XgW7>K#u z8M}0_V1=K*C7y1*ugNR$4V=PG6?ei^qf@T>_5}OoxpPya1}9f>&HDnw_bOH20wAvV zj9yDx*!CZ%MfG&(>Ga6mPH}~BHYCCK10a4eI+Y(r%|L2Tkq<7xX(oUg@dZPGC^_g{ zP#EFyMYY;cLC{cOEbEp7WQXu2Cf`gVBCJvG?H93#NHQ)f{4yHx8glPwl!?BegfdPx zmbpQyF$CQUrouc-TGgQft{a^?$~J>fU-JtXnAy5s*FlX~$bwG^->STGdulZ~dAb;b zT$a;`OVFS8&g#-3XbOEcPy>|$#6R+GDUT-2MI};1OIp!;6G7CZln2U)VXr2ixXUP| znyh_=T~Hdoj(LF9rSpK8yN*!S#4N77m@vT5!C z(7ug&qI46=fKm(`Zu;C5r{1a|{wU{3CVRZKFo8J5_pbkzOo*`qOm~H<(6XY>>=C-?&c!D<+YKFk{}w%bnKz5QdqN%16hxFR!OkQ#O+uhhl%eGcJh43g2ESOl=bz@e8aVs2Iqp-mSP zBLOo%l17mMxc96Xgvvr%@v`zw+d3nb&eEJ{glU3|g{gLmT$W(dZ!(I~@r8zb+@M&4 zsF;3V=PUzD;lN+&*Ae0>mQ&zs4Y)zOTA6V+$W-8!?7@pmX~A+zWcYM% zIqz&CE0LMrhuLRsqe!mrW1tIFJ6L}6)l7SNN#LRX-=a;X;4h`3sljrF9&2O-8)RwQ zCV{{7RMU5ph5TNuzWr58TtR8D9Tv?=D}F@iR-W!A$V%?r%@v5?Aj3)3!C?Y;`lDe> z6DhvN@jTtoNAm)B;IWL27E^qKxVGAhTut5_Vs=!Rfv_&lYq9DPx-s;B4Z~2R{xxhZ zpZ`Y%Na?`W8I3l&@|?P%C(2+$KrLRDziD}Vr3m*Nr{X?g>{@IioMJvRB7XRMel*hf zYzcc~U!TNn^~sKR761xI;`^%=@=wl_RWYR4KD8^&o1AlM>EtO_{ca)JC8Cy@BprHW z%>61;Mh_^q& zTz7`brJ-@lksL2+{70@Du>F&O;|-X%!vWWgmTz=LU|#j zc$vwjyhR33K(yP1Az1a)&5c$t8scbF3=RbzJ9S_O znqtbnHs-i`Dm6YB8xaS+wEngp6uIe~7J$qm3SLk5${t|fQ`C6a`shPoZj#}l3gFcL zQKlYnw9`I&8`nrXL}4Fplj|u17qOa5PLfw z0t#wLaytn?Lf>t2e;W>lMf%qBZcj_F7Z9_ympY?aSXZ*+O@rJ_Kl>i;boM{!i#26wT?tOw74ma*#{ zudJwLUL`HXtFge7iErKByk)0ix=2>MZoE{z1n_1XW`32_1|=6Sd%C%+K|x%;jTR{K zTp51B6zs#7+9Rt3y1Z>04UNn}Qy63*_d~q}?P-N~z{z>rN7f?3Y+A zFi4iFGV{W^g@YTti&h$E<1oa@iZAsyJtu{@t~QuaHJDif7U{%u$q{YXfd{>*@fUx= z-mKtvz}PM36UyS!-cSowWEe4c@*-U9%@0zxYBIH^FkHW}+b>`l{1aDIlDT5G&$}7O zw!eV&PH6vum~C9eCDp_HCEAa(`y^&8U9k%wZ9x8ST*Y5DDyLQ zTj|GC$!KEn*2loS&+^lo@8CEF^o(6KoW$jljKKyC6l(Vcbm&@)t!Jk=%5#|zXe2-g zwy0pIb*5sx``7sI(`yZ_c!>y za>frJ={ z-<50QNKB6l1m;Zs#PdiD3EqVcGatXbnJ!ih+;7d153Ea4cIsf?9*jM>%vQ=^(h61s z^7D^$>~E4=PaKGG3@%Z+T2!D$?aE)RG#(}MFy}V#WvKe?w`M^CF9t<}W;9fshM_le zMZPtOVqT%_yZ&tSajl{ zZEG8E#iXef)F_*^YgGt`yd>n_MQHiW1rj&lOu|iGN-NB1BwufOuA@;Ii@aL38>MPT%F3aVWsMi z!UEi|{kh+`-9lmr;HM?Tdwm_x;DB8AkLG;->09rik6%AX9B?EcjKTTvuO!4Thx_4R zvhPQytua$RD3E@E(uL8dT(v8Q{U6@aHoN-rgRPG8j@9PDkrSpT{T?1D(U;MqaI;}Z zr&j^zx7!a)X)lC>B;q_mZv$$fpn^i%V`sg}or<`dOfe~RrnDB6*!z+WJFUruDoQgC zm)-^if)Gy4CE@tg2~%XZeoRfJ*-h{HWDX$0uI$t;bavR_B^pG-deCgiQ#7%~(Rh>M zE9U=YjYe3BWdhDp#cBtkE)M=uMEXM()-68#|e+4Y*U)O{%S5KP;9@z2C$l^V)pdD!rm-<@euFZehE>V78?U8-9{q>}&+riYfg zDhnW1a=ozfVL6;eC?ej0)7x?$AJ9*U@6!801KaKS3_*n`hTci>K$xn@Mdngo$uk-SU&4ssZgp#p4Y#-MBa~ycawEoB?79Y=X`erp<>Zx4Dbz6Zctg1#KNp#3ygT0>PKMsa@`ZT!gkD_E z!ARwY5NWSvFZe%2#N;<@?o8?c1zp&EINyET-&%f0!o-@NngtTRdqyjn9G}~rM_x3M z6@|{#G9N{gs^U^(qx;KJaL!E6ep)Jv!e+#&7pMVm%GF|T5As+N?EhXNKrUM!K1!mh zFfu6hR_ByzZqQ1L2Pd5E_;P1;Rp5a74Qnu0YDx_O8QW5g`fqB}7HyoiB7JbyIBXdT z3Z@9i7?w;IU{I{ypu>lSjpL7<2+#r#6q%k?gC)rA@-YUhx_uZDc=kLRAqGg>ROuPv z7;ZBp zSzSEShGsg$s?;S(xbgdYQ9{r;idWHy79yFh?_*Sg>n+t#7x7a0?PY0|mym^+>@E)$ zoO)|0w5_JJ&;^_rj9OQ608|0);FReRjHN2pF?ijlM^8uW`FxDkH$RC)1Yg)39{IT5 zFE>ZWwmCd-dPXb%NcrMiKNAO}TSC1^nkN_8Ajpiwn-~l|(F=BStns{e;w${G?RwzQ z?m&?c)D9d&NAK^^tp1ZkTHFbYRaIMy%bjfGey38C1xlC{xdP@$@091N@C1z>LS(8f zKu9vZ-*CXqG0~3%XaDSx%Fki-YMLibm3((;yJt18h{)TdFtn+r+I;E3A>dKY`CB)Z zxga*buhMZ9g0z{91>V(#ZsMhypy_cA5UxNcOs>FqgaRQ*Vd+y-${0BXn;TM%*~N$L z0b9p*%B~v4vCjR^WAT2I((>6{-r82m7t6-XT_)Dh^c%)5aWz?G8K`7RvL@Ja61=rh zaaX+nPs{=Z*-UCU6h9{x+Jc6n_piu%oSD0HWC`btn>X=%de_T?^-3*Gg5|)UhgphT zHMlo>4Br3LV;L1P%q#!<6r|egz>7&K`-%nWCc%JCGh_s$KKDiMA&G;L+Wi&P{z10b zd%7-58JR)G(l|T)Ex<9o$G{FJOi`3!zctz9(#)KMFE>kSVnXhyjO`c8iy zCkwEmruyYXrX_)cVK}|`)f0cu-*VkiSTv)O z0xwUux?arw{JDxt`Am3K>yoejZv+K_aOPXfzO8P378HDXZdP&v!6IRendF@9MgmoV5&`*1C{~mzgNT5w;Kmbw25xE2B{EMq zXRI|n71OoTAT~-`H1-6m6e=eb1~Mcr#+p8Z@!F|39A)o2;d`lfNfmmO0E$uiRSGq4 zOQN1fuXgyhz1+dG@cy7>jERvTyv(s zo-)M@mo^ggqIfL$K)}`-6{X<<_@#B~eege#7j+RmcL_ai4)K34Jb7%0MIDm7ED&_+ ztfW-RHe4FAT8}Z&9E?|nj)CmWvlFTtz?;H)g9$pu6)}pGL)i;Yd_oh3y4CQZULBao zlW<}Umu?l)@=qOr*hZ-P8ziFI@}YfhSyCiO)qSuudR(|LO50dx22{@_dYzQwqv^R1 z#82%DUE3#XU(5gfaC2MCr4B(7Ay7|$Jyncvccy3!?alTU63Je!SDtuc82vD$L4<%F z(*_*Gq$CQhJ69A+`)vi)PN^R1St5q+}3P&Nii=}9f^oc0Kqdwv~M&x zPaPqhT8g2S`S`sDvsb7HiCB=Avzv>Bm$;Cro zxQRiLnfLS4!TTM95cLv(`?QsM)lA;9$jYmwd9V5X(MFM>LNW39$%dbchqsp$!^%iR zZ1VLe_1g-!D!q~xroZ*ozja@r5_ znOR-#q-q!0$9JaQT)F1OCQqDXRoFHWA&*$tC?yvTIWRw)$Ln36vGp_9384QL3ms z@KBs?uJx1L&C2{*QJ?@8V=buFVl6Ti=(`tH8rW3q1_Obk66EyJIlJL=)ieFdq#8xWRu zB9hyTVNy&2vg1;?s6-hNcXRPg9F>Jx!m(@D`07`8CX2}_JQG_(4$L6X?m|90jh;S! zKRFSDS1&w2SAE&nUY=d8`VpA{g+PE&DurA3ww~&=$f)wwib(?sd+h@#1_s8IAG~C9 zY{=B$uF5kCvQJ>jsUu|Z*O^j|up|ALc?q^B)@fgvDrtWMFL3y|xZ4=>BDoJilRnbz={yp`lBJy)8`O(!7#3ijq zGaIWTB8F~@QlXijLw<>zpBF?8f9s1TOL3;4?xa$qaJwj*8q;O28l0>%^i@cS#R4h$ zLr@6N_gc zw{{b|D>VPCFMuqi?LKmKP#syhQrmJeZ8c=i%sa9DcK{2@>Jv>JuN6Y!C}KC@+PeHJ zksh}{H)o$CH$F!xKk^9u%)m+q9^ge=SRsc>pL6s2wJa%lCn>$-j_%xi`xYu_F8j*N z`yLlvGr(F06~3uW6!rbuFhWK9Z13}l;)pvfl7oL5cf!f){O*gnpc4>&rAa7#f_p>J zMEG9+JM`3Gz;w0~nTZ1%>ccu49ag`E^_VPUvIM!4jpFpWjv5s!ihkz_S-sFPmaC9W zV6sjX=B?%4MzSmR_oxaTSDrZ~HM*7V)fFZYELV7U-`YoM_BT6Ar<7LSwu)=g_`Q21 zue^;zx)cf_*nGf`*QoEMvO}>q)K0zCS>4F6{T6-LIvgHG>45VwUMW9iO~3Chqo2`zOD1utoU}R&(o4| zIMQ^Q97D;b=HLcC?cFJV^oINk>y*rf>jyi>J}AVu)7#}xBZd9Rd3GM(aeQQ(Y2`Sc z;v0tMWj2A1QQ_fS@Q@suerV^$qN`)&5F2#&EtFhj7eEcyM-cFd+!sX>Vgu&OBQ;^qVODZgKuTo_qvD@ zf<`ES@+#5{%da2a@SQo2OB)3}O&2bXU;Oy;?Gc5dL6J+Y!-hRyX$lr?beXJqRfK)V zvze}VDNN(%4gH$J2Y&o3ppsp$~crKdkca zC+UtH6e<$vSoRdk#Rig0P<$0AIm5k=|L2|4P{Pa}NKM{$K> zoRy9``;DctQq?)vaTSOgZ}l-V54f7QoV>amGDHxl=3!bjVQAO9!0s0D(SJ0QcX(DL zZV4xU>LF)`;Y+Nr5{fm90XLf|SGiLs^ z2>XM@hfNRHbF5G3R1Ow=8TcK97-$L0Xxd8kXsSGLj6N`Z=9Cm6`oh3fT_ zC*RumX2O56(Cuwd%~=Zjv#$~CjvWXrzjYW-1GA{Lpi+}2>P4yD6>MrogP`?6f@w5xKC4%Rh06@`zLkV@miX zlC zc{+R5ncb{To=r`x6Y`dF?K!Z3%%J8FLt)Ovn=z-HwnvI4U3>8m`TE;b_GXUJDT)js z=9J_sC~rQpB-e;1$k%k!7gy@OeM0yb_1h~Hd#s(JRAfIoAaqP5MB>B3ES{CjzbJzV zZ85|bfQE>8qDt}hR+dzjv=Rz^h7I$(C9l>LX|l2-sI+a9+N`WfmfWG)W`OrgBEC(uJE)*gRCr=(2kwzKWZCrngWoFBy;iMlt!r3J{} zsmXS>f(TY_$IFin^g$)gFO?y0He+e(g2jS)zmwa}Z?$OIL3VQOI9e6@u!t2|;&cd< z@-@2Y!Bn1VL6uoi1x^ZtqZIe;PPc3jp?V)=VcL!g%66W@esTyzsQp)Y3A`wqDJNOH z2op~zzY^P`9DGv2#b#oC1_G+GzqZ~PH76azm z{xk-JRVkA9ubaEq>afssmKRb~oJ}K?U+geX8yFGPwC;5py{cAX;d|o+g287a56BZW#XX~Oev1nyYefF>@HifhL=uV=93eiti0@bl~Jm6{zbdvBX09~ zk4@B0Ie}mZ_MIq<^)7m&aKr0va}b1>zjt#gtuys-nIKDNo&wh;lw1_TOMt8>3X#}5 zSSDwg8o6!vY{1a;4lQDjGX~)#!h&KNXY+qINWt;6K!gcpL=`QTkX6Gvvpl15v4SFF zxdE*kE5R51rDd%2s96MQbn!RhL&_6R(h>7i(@*G~AiVX5EaQTy+ zM_~n8ei&Y(yvnaP(u1zJh@ zkD`N&sIehh%GJ{5yj>`s*TFdHFcZqT7O~pT22jgS4igE1xyo(J)$)lqh?d#qPc|A{RB#U~rPJcT6#7VHu@04*{<v`P50x$_m;-R1tHmyi9Wi2k!$UMu&S{ZFOsi+)4Q5wa2! zp#WP73Q0_?J1yn5^|>8O&w+PY!hrphRQz)U2c1ObY^AkQ=t9_<5BB5F9DY8>$rl#x zs;UU+&@)i6Nc52&rkCfVzvt!T`BL*(&w;wVkT6W!vGz{eGbc{MW1>1vkduys&WDnE z7y@5&U6ee3#J%^0_@_c!{rUiG(`YknhT-i=Lj9Mu`<3ecZ5d+F4_*}O75E0f6(4M2 zN>!$9v29fUwMa{(y<#Rv;ZU`+|5>@-P$^3tt95eJdNe}UwvYDNVXj-&!v{Og6z=xX z*E$C>)tM~=iPQxlNRau8X1Gt6@&r<@*n5{qy3VUxxK& z&fjOvnt5;nDb2HH<@fT@9fsmGvuUk)LW6xbCZM#7S`;r`mxbb)*EztQwTW0CsU&-^ zuDPdb6AwQiec08aIXMwb5{{f>x83~%%NliMkfwO!{?LYrZ z$!cKa!OgDE%+bc?mT-H^3d>RFVeR3GVtQd;gC` z8Mz6fW>#b)UQjUu@{PzENEP+!?Qt4rQhoej)OiK<>`O9{VtS);7w0FaL`#E|oNU9gEyZ_cgyzwoyl&V$t{*7YH$)$bRR8`Q7YBb4q}o zWhCsf@M?n3* zN2wDeoqr@*w9zUB!iAc0NPnmMfm|d@V-=IT3AiG*dN8zptYy z>$|&R(1t;$z8IP2ox~#SZTlsll+(6DW@SZ_J|g4(7#-j)!2R1Pxc8NNJp}`7cm(N z=5l@=>HOmLcYhpM16is)8B{@#J?yhkTBV*GsiGNH#BAi+PVKc-12uNb_{s9|$Ddx) z_2Z=byZXh=tSQA(Pf;O1StMPa8e`{;+ofv3-2{>3rYQ$iTS-IC1hfCGrqeZZJFu&X zS~noFc1lh>zQ$>ZPB-i28IL1y$X0Od=PT|^<~RYlq?Nblh1kavDcss2b|$Uia!=Xx zY^JyZ1DXr7W5j$!^hBl1hc|jgeQ;I%(i$m0&LMn|-?(z6C3Z5pv;{7{C>2-k8A8~z zM=BP=Y1!GfOi$4Iisy!{pzalEP;!9Zit~*|)+}JL-bZ?Pus(GYBW)CqFM6t@*10~~ zQnDOx9{My1Mb5flG*!Og_HK-^ty8>|H*>O`)xFG~QTl~h*iC6rfJ~w5GkW7TxWUeL zUiWy;>qV3BdHrVpmd+c^BTQ9ysIi1AqFZ^8;t#7>v~1%cEYgL74Rw46RA3#sm72z* zb5C6XVa z{+Pc4(MIh*{3Ou7ifL7K;a376B(@){D_lH4Zst20M|g20OW(s`sYI2_aFa2>$Fl_- zpZ_Eabyz;}X##;Fk=`w!PTrTHA3k1Uf&H|BdVS9jHttM;for;*xY(=&*=y)HnGN7G z`LUAwJbUaO(4Cu1?n%0!h&DE5f(S%z&m(tD&m9e>`;FjoCF@(ym@$ujLnVjIe8=PCjv5S~ z&Te$&&8+N5qAT)2%6^JyNLkqSG>gY85L&l07p}_a@G5x>6XWvZ1nr#9li6fMp5Hto zV_v0hK7}?g!dHU)F+NqFM-Zu{F2>1DTd$`kRbWF z+7F6>2yc&jtdtEdK%Bh0!vCjwo{3;zA=NIg{5`xX#o4N@mDY@H-g1!Kh36QB?8R=N zUi%Mmw-nZP8MdX!ekWD4r0flnl0xg(A43GhjaZk2KbC!!Epz6;g}rRmHhYAQJ1j^V z#%4kDHoAlpDH7Wvi8$Pt26#dsXHHJeypB0eciNDqGj5l)U4oHFkT3Q(ip`>U`IA65 zb(+7UH3yxQ3xeN(p;8m+DYA__u2^VIbkmrQtdscz>p$Bl!!6rZ4SFjzAE_gL@_%jR zL7%3`swTYhmVA;vkyYmrVdV+klH;#!O+*{6mHHsU%`Wyu{+`J1)vldQD@sjF@p-n9 zqse`>?(se5sa(3cWS)!7tlw8wehBdU8ujiBEl}7~YNKpN;M}z%&hOhBWIF;#$*6(N zcEZ>S+z)>flc-N$&)o!b6ZV5-@o!h*a@qP~G1Je0hT&_@A?TWD@3$0oX|gt{7VsNd zoh-Yh;u&G`Gz?dBMJ~`#Dft+)^Ox8ug+_2n@cTNTHR`(=z2p|hv?-mg2;3YL+rOa9 zQ9zEfaQ#}(D8f_n9t?Zp*s=P*7?`<|Jq0)sgeBn6AZ;@#lv2K4bZIoB%Wfod;dW-f zz5$&SoJt1tlkZ)SC5l%OwW2*bZrjD?Cp$Wl;2YWbv4xM#v&qV&*-LKor)*X();wLN z3;eq7*apxj!rx+Jr+N^TC83FQyILj^W5*-+D(ZY#^diMc$+=`+rSs()&veKt1%I)A z2UcwIFA8^u{k*xuYks6cYqqbqNQrJk-d5{{>3l%G@v9uA42_i8#oCwgw z8uV%rW<>#nwgeA2(X$1`3ech2#&2gcGVt<(ku3f=2?)`VRnBeGz6qcHL;qN{-#}Iv6!b&$1U~zqtNn9%9G3+Fiq205oRY~|*M@m=lz;^3ob zsxQAaJ*9C0f}sp#e>)YhSI9|%ye{f84Fk^ioCh?gk7}1GzX|K8X+zEz9|Ssuf1u&T zlGnM`+)B+er??dYFa5*fFFL-Y`!g@5nIBoOS#&x2sg%?}?C)m?Dm337Axp%MA>0hh z^{#iygG=+SP>eL4{XR4J;>bjRkc%dPt3c@6I@bh5fzfoT74?}~XD5@C5(w~?2I!Sh zVY!WN$!lso4mj5_WXdl)V(%&?(SUpV%MOg%?t^bcz16l^dm zxe{@EO&qTR!=QqzkdiByA|Hj__3w#3$e|bty1IZPVI44Zhluoz-wb5pzDS#me`hKX zR8T=*3L2?|IRFYS`GWmMyuGUYA{iHbH>=-#I-Hb@64^&r7C&+$O1A}|uFp?!HhG~$pIf@2RpK^g~6(3B=L z0X>)^=!4*K%4lLl@b*W0{&fokLy!;d3?)MlLK2;>P)3)+eGF8TuhN!^Egkv?7F{Z& znr<(;P%9N1_}^n!BFFj+L)qvFT&7OtZnT%Q7Nte}$`jsC-%pBVI0T4gO?7c1O?b8# zK_b~{2#4E27+`Q12wmqwa8gqRYOvG_5XPDqaf=|OCx)Dk-;u6=Z7KuU(Qj40Gt zMfd8sjcvRdk+5IdjW0GiAFj@$OZNNg=Me=k1`csqUx)c!qahhH$~^h((d!#0C7>y$ zNJYWKAl(Bar>zk8y# z%?g4y+BFb_uiS7x1(PjJhAf7HBIOA%`ul9jhRi zh>M*GE!&7bsdnvO?;W@u<8mm70@M?wFQgjx!UfHohkXh6|0iGO)J(S2nwFbzO;BO_ zygz5DijzrlMk#;cC2K2Zi4e)d;o8B;ucZbzR^Iz| z;@B}L+06&bWmq?YWkjXjFtL&g4-67ZHu>xYb@|aK7WOWK85T2>p4(4}kqJ&2yK$-` z*{sYI_Pok}YXp@%-!9M+kpSqVUW@-XOd>;F1@EU~;5Q22WXen4TCf>a^aUWCJ~NT3 zEi|4Ox#ueLF(ztBi7g-XEd@)e&G+xBY_s;w!cqd+;WVF|GwmY-3e>=<&(QFj<9;8%9WQb(RihYLoe?z#3w|U2Rm4SVU3*Rs5 z`Rn@OxKf|bzhhDgy(113pOSDqd^rHWvUQlGb|OQaqx?7`Lyvy+uIO3xI+oCo;t)U)DV`DcAgr^8%exgFJuOn`n=2^CzTu(mAU{udi00VDVHK2;u z6QC=QGtNEJ6thUN3Ogn6tKVauJu*5}^(=K`(t=fYzOiyo0F%M?nT9A)PsvmCm3BhP z8r3(I-Dia?y^@g3O0Gx5?ei`vl}Dfd&fu+D(J}E}UkPdAX(pU~1-&2T;NTm-SSaj$ zo*=+`1&}WvwqN;k3Ohdr;M6t09=+VDdpUfDq22Sd@%2LX>lip+aQQ$Y$3x{328sAMkz8#J#}HdydoL>=znLVl~UMG z_k#ILqq<`|d?|7JF>uP-KEtQ5#5C{^8omDm^5(F$`^=a!B?-|JL#sFxe*611YI$c8 zWJZ>Q`sz2;&)Vh4bckAB2G)z)mOlFXE7`_vP_7dtx**Nh+nyUkabAuXLj-66AX2)X z*RMZ+k)p0q7->)izjFprG4Cq#$@4N|o}fo`!oVt4&Z_h zIe(Nn<>UXL0?`WqA^}(ZMGqtrvhI7&*8oJ@AsF((jNfQ~uJ6N`lB9yP*&l}2`_VuB z>b=xDU{oqidIKe@0U=_qgFWRidA|4k|XNQjNYx*d%5Gp^$rft}8a`3v+NvQ#z{ zLcwY-&o-V1;Dz=~tMq2&X3o82x*>k-^W9Nl`YiMt`z1)NdO7E!!;6v1pVaL~tRCp@ zHfV%OU8ilAWwoKeg{rx%?ZCS|%&P8sROU8OYjcF9q}Gh4Y=xw=I?E>K<%m6zQ0KSL z&X>;czn#;V(3I)p7}(i(Ud?5Xc~Ls*iOBd+|(eW_+hd4zf|yj-s~orgV>wg?zW45X4^B;-4)YFX&_b5tBOe)z&iM zqtcPxn`_u6cNebmjJ@?}tKu-(v$ZD!f-|H2khx#QgX5MZ-aNCVJF#i! zEbw-g2{g*?QQz=i!e+)pG32-MC!l=E*iY9LR|Z;{vKDZ;3co9Aj+XB4@HK{a+`6Q_@u`CS)c+y7B<+PH{!nUo52+v zz*IbuvK7~7yP@k8Z3?(?60ewhEPYhW94Oz*=>(%iJ4D5ATe0-?a%6-z21R_5!QFT` zX-GVM>fJBr7mL9f^bv1VOZX>Q53PzuPP68UXfZ)uC$FRV?!KNDk6D^$;K+o8M$$m4HmubxZTa=UJH^}?Exr#sZ;s=EvH zWieIXQ+&-&b~@6V2R_39sN}`b%9F=(d(xx1GO0#WhRcb>R`$w_G<|%xkm=9g-r9U_ zJkv+0FdbDFzC06^jW(!FRA}z%NaLdJIP6W5k>0{H$9{(3gO+ndd+4LJze`*~=S!#f zAHHXx%=|IW+AxGFSY>T|G5HeDlK@!X)0bcKuT3|}Juz_7q3>`Fwl{ue{;spmQ35rk z>*qZexurVw{<^$X%jYtn!Zbz;H7tMc>#CbmTj^*kHk))U-x!2^Q zKR!MMsd>KYB|a<9ct5D{hW=da1)i!Ptw6iG@UcY|yE&wAfkc?z| z*upI)vt%x*L_x9hUE*P?FMjG|bE!Pi#mVY#qoX`0fo^;MPG!yq zE#H%@mc#kEYe-LbyY-Gl&eS_d;PV#N?aE~u4lJP*2b`kC_Wh5yTdSS?zzR~2YnRX8 z*4qV3%cdUc&Ir_hqEYQnhc)=|UK+Ory+e{JXNJye!xOjHa#d&Be-oG1O}#T|*qU%N zHBxbWFI2x$oDB3Qns7>u?GFE|GPj@LWX{#?S45&7q{enUTzGBzrL2u@gL1924Di*W zI6F72-}TaWg21|8pRarCX3og~%OtpExozz3%!1F?8YWWanz4gp@Y&i4&1%L;vDvt* z{PNeigN3uJOA|Ut`W~A4e){1WC*RIfBvY~l$$eU-D~q02Wikj=FW<0$!rp*CqVlQK zuZ8G_DXGHQ-x9V=@-4k8?&~uIe%*#IuuQnCZk&V`cEUy*H>upmKVI~%f_2qrYu{xU zG^J_oIcKQxT+Q>=zS9z>vZCESI4wlm%{{p9#I5aZ$T$w?H7}=U+!hS@*2mIDfH)CZ zHJ1ww@{`<)=1O0HtOS!~7xRP8h3>FNr4AX~2Sg0xoxSIjlj5kMIF-O{KT@omc|W6^ zB*Tb%I(*W&Rw#(@mgLg5q89ELqr1QI9Xl!w9_Vum4+}eDFbh7!i_`ePYuy5WuZ8HZ zurED#(I0*Y2iR2!j%jaQL57CHtyMFl@e6A{sxHL9JF>hOts|mK04Y zQF)b8Il!;iulVt~^)HdA(NTG_3nsPEnSlzBcgqN1FN`~w9GJOh!-u|P_ar*A2N%DZ z(xekui#}1G9Zk|HlV)E4hawXdzT1((VTa`Ht}%I3h7bAZd(!*BKgn79tNp9Sy>*Tj zR|7i^As*-oF2GJw8rSS5pAkj=wj#p2#?89-M|qh}LwEoLTkEry@lZuUDV#MxR4U>3 zb$`~v{Y0t1j9=6e`n<}C`cHbKJIP<=$-Xfg=n^tjAMO#lq^=KF8<2XQO?$gshz$-9 z6H0QEKf3VPzN6(ueWJFzj@c|Pcj7g{`s{~%Ri_tZI@eQG)32i~ecp3XFF?c5UocdB z1Nsc+&$~vlGw3WT^Ay$)6fGl|g^AOk960f5Czwt4)>j1!1~0XS4TAF3EGnyAAu6FlWO`tADAO^5USIsnuOtbk)-A97xgmxg>vnCN*dhmg_FUG^CGsV%W{GFV6|-<5>~z zb74Y3u*H?(!iPZ;%ff@o<2{gL$Rb@_aDYFkbiWMUGGRxVaMM5NP~7My;?hl_N`_uW4v|ENXixj_EUwvwOq=;xS~2a z^}%W@5K!M7XU3up^6BV#>3afH_$Nubk2GAD_g?cUm1m^FKZg0D!bDV+UAUsZt6WPp zswB@C&pTsWiP6aIwjJ}UOmTdsQ=h~?Rav_=BM{{H?5uSEI)A>1a9G)+wwJ;DYa`O0 zjx12&7;4M(w!!%uSp;+1hR5CyH*)7l@iO7oo%=L>OGg1cDRap_d4-gBOtq!@=yX&) zlgR_&BZ-kU;pW=5s2Yfq0pxB{B5j$Tj4l=8lk4EEAN!kz(i3!gd#hJ}ESSFD&d@#t z*2`0I!8Nxy@qP{=wh#H)nGCMT9P>6P|}jOgj_Vxqt42uU=BpdzHAxz6M;Aa$q4~#8hPx=!P2^DVXHnm*fzkA z!QOZ*4RxPm$jGVA+~M?N&dl?WwU-Ff02y1o@RwwAc{^CL zlJrJ9xu=U-k2x*bnSZpqmbs)UcQl`YslXU%h`Lqf{>+^t$K4v`NrER0;m#;vM4)0;XnsP7=h2cROHNVuIg0pex z8C?OMcH<&%{ca5qx4LgHWiHk7ll0fkm^dBUjshd#gMXhW?Lw4)X3)2XZ!XDTx?kHz0lzHGDEWD@$R^e^wuD=#LY8-)o%=jXNG~iy3tFgjWeyj6zYe3+&vBByR%qZQb9ONrAU4U|GZ8!f-# z1&Q6eG8tMdSofn$mO*Q9_Mgy#%zWe5RKZHsieX|wfJvUrrQY;Rd(0u!9U*W|%zX^D z-ZJ#k=e9Bv$=U18c|zR*{qM<=S0@XTB`qUXMh^gm;`1&r19Kls{VK(>Yt4U=W7&28 z(Y3Du59qPsg-w;=UpAb$soSFL^qSg7gee)f3V8bE-2Ni7F|!$X8BQaxx(w*+r@!l@ z3dm71)oC-`e57z&hyQ9 zx>lY$=Nju<-p70^e?KjWl@=6z%+$%hbD*fn2OP0qEYj#PxbFm5)4MgKX5~rG+by@Q z0Q^ZAIp9Y#bMIgP_5|vAsC!(n{-Uv}XVpG1*elsc!>|Bg;cC%x&@uP>J_1tARbcSu z8&&elaWpnEky=wKvHEiFfp);w?KIM(dI=jo5Z$v<`JV!(euz)FfzL0Va6 z#Pj*@1IA%*NDsgvLr8$ax5nFizNvaLd?e+$t!{6ZcTv;}yewGxr+*bV^Eu?ZYEQbn zme9q>v71l>oz#%4(!RB3lrdq{+5c-RSJT&0@M?b>P@-yp2wC@4J#`*aNBq0IHz4a6 z@E7aXUhW5HGXLI zQI?6s0T<35x=rD^?=G~y9JBSd3O(Ms5(2HJEIJ0cz{28#w^+K zcMtgwzicS^jurqYLit90bWe3_*)Hww9Z)axvq%u1meJYJu6BHO$v%xIFxvLzIf&+Z zc837+0U=J6*TBycq;&p#dAp__@XOOLUY(H&=id^3v5Rn}w7)@4AIWs0FT%fzEhm%d zBX3->7-w@?%@D>|nSR;ki1b>Mpv3YCpJPcFi>ZeBN6d$A`3S4@58*-SHMjg^|D@;t zr8NN>1Qssf7_pC-0f4BPC=H!dne!L=!8lp^tbhZ?8SrMX&`((9O&>?SLn|$P#=;#f zk@&q5pW*L}^QGf1`GW7Vx?ZuWz$IZWfX})eY{k?v; zUx(v)ZU;gQ=29TYRP&|hsW5~pBjAG`wQS{#Sj(${K2B}QYx4P+)$}C!^o3Dpiy_B> zpU1X_{w)S;7k195R`fArEzMnZi6@>mJS)_2v9?9}D;KquSjfpoLK4hb#gpIi+zIU+ z@7VP()`m-C0{BhE9%mT0CigjPbb^!B=`( zz(!|oOBW@-v(^qjd@}}X{p_jp#hS6_PcRwIH;RuXa;#XwOgp;^$$b>_Q4w4Cj3wlX zN=vT;)?Z`}E|`m`dWLBP_PrrVNL*XW2=A}C-OFh(ykd6k<-jhihrTze(8hC9k|eu# z0mGL9^JP>wytGM*0JmRMq-C-MPJ7<=uWtT-NR0l#9G2Gm7eN0m@C-9`CCRdy4tQg) zuYScjU#c2o`K#rPnIt#lKmg`iT;X)_To`{6U=4Ez4OBlW`oAnP=p#f6>;QC6x}hy- zAbN=AzZ9?yP#FEq@9_rZ@5|2e-s6NuQydaV&WsiQC&F%BPBPwI=lhUu4@6KESg9FL z*&><7s=z$>%4GGt<8D*e0iuJfyrr)#ETQJ3lr>$rW98$?F>!#Z=W3Hdj$+@mO=z0p zaSdD$HJYHhQI#)~QBw|k5C8NIBQ_SvWO=HGq;5zys-1yJ!4-8yR*`5F4_oQ#q@$c* zD@2`tICxR>?Ie+dcioY0{uE4^X*H8CzYvT_24qR1_qRCP>%-^kd^vC-*MUB3!7KNK z?D1q=1p*rq{Omuwu|)ojv>tQ?ls|drY)G=~kLks;{UWLY!fBp!pM6yH&Xc+kDV)YT= z68naBBZ^it#Dew7{<})OYm>LW0~8?Fe;fajT=H{)mT<)5K^RaIATz$-j*fpt^2gbc z)i3NEt*;{XGscwzmggpYjyAW3dH%4WH};Fzjq`x86OnAdQmNK_4q7T zBhjWLZly+8l^Z_B8Q&dWT&p25cfTicHJ5@Z{q|nZlP}I^ME;ozc9`4j5jD4?_`MuD zq+FivtBHaXhZhd@kvz^#c4Mx}(;;N> zd=NF^pNhWDgDi&z*;Z)eFRu{2_YY1V`8$)>$}(Jo7t{agJ==Fj>?#dPP z$zsrtazA=sE^y>}L-X6Q9hyBcmB49(Z%`F7-jsE1=o8i!eXQ@oNXziq?gYpfl(@cr+( zPcO9o%(SfTt-WbStr(U?bpNQ$!+0^fbZ_@AXgrOJm?(6ITf)o)0Mi0eYr%^LMw_NG?e`ir|tK(zg01dDv`kW-ei(1d(dhFHkoU;|R% z2OYsj!M|~(`A$FM5&ZEL^w&LvL$t>p5BAHrw)=D`{inhS{y0_gv5z@2!&qw4@8f0< za;XU}lCT=lIdAZ#vrX;kte~8oAqfVqiaw%WeLb-HQjv<=@*@>^awj0RY!Fy&Pq zvA;8xMhJ9A3c36j8lk6Qie0r>0I*91P+To(8FLv@w7<1_E44u70j&u|* zCfk_%j*i#~dg&@_``|3sqIOhTxc6YOt%N#LoHx%-Tx?IqlFKMS3o^OmG6(YKt{L&o za&|I$(8H*Wc(m?zBG0GODy$8D#^ekh}_Zz z0GYdjET?;fW~!y<_-nT>^l|b;tr3f2x8@0hjB<-PP1RAO+oj+ep*KvN+Q`W(H+7X(#wD%@lKY(6v+H&!+dS~+kGnonRpua4K}G4UvPeHp9?|38kcG8->wp> zx1(oL*pE4&A8!bh&i+lpL5gh;v47+V{2g@;ukjtrZwJHmAL1CSs(n{(Wt}B?7*Nz} zZO1H2rev+kW#b_=6evx?UfTSllx{XSePN&8iri^yhQK}rcp^M{})Ng zv({Cx9@4Od$weQUduUfN%3_6|FS^UNN!k9qTcQ9S*9T@HFl z>-by|zu)Sw%ps3s5n!m~?B#>+cj9%cu$zTl&Qu?{*>PY;EDY+HV!& z*6^vxS1X@MxKg)u$03b@v)DYw_Qhe8R+SNrzk zGsw^ZfaXfHKd(#_<{vT7(n1`(q%ekLc4E7-z2o$<-vevpKSbS>lCp)JsE70DHhV{p z$%0_pUAbjeb5Bt8foHA!V>g4~r319G4}3tboIH&8s}`!y=H%J&z?+d071+Bq*Aq)^ z1t!@0WfMr6K@hFw;Tl_W|HTGHeIYz0S*i&_<_Uxg4p0og!km+PIM3}#&-6G>%l*Qq5qNOTpNlWJze+$S*W0NpCs!t=<~4gM z@zS;A|A&t?$dXZPef`9=CjCP1e!g|(SYp4G00h$qZwsFoRhbGkH1oX7iUKtu^o z`E+d*ptGp}ez{5ycPfHyr+S2h(`GfgIyP)^&+V{y_bQ)HW;JYeE6!G z1nM6>`=1yKbRnP@VSngrq^{1>{*ttOTpqZ{VYo>-xakA z9O6v2ze++2!Xdi+3Yw!UmVQz4jhX+cpRmkT#^_aN_B?33ZZ=^bfD?^Gs0~@Pkoj8@ zUzh>+Yp|ofH%aUVj1T^gL*s+08$-`Q&-GW7r{19dg28D``F@p!J<|C=pwK`bSeiuy zZJP1jCUQSK1nUV#pi44!h2Sm@*0v9^W%}1&z@7)%4bLzdii_rdVO6sa2h##xIBn}a zP9l%kc;>j;%IRAh=iSw2;=$uFLO*{#*L)23H&tyq#Ex^}RCupN^}NQ;Eq({^phVqs^`s!H!gBS2QSZU zvm-HaGL>UmTSoDxOACb0V*@?I^y(@*>3c=puL#nNN7aNNfUtsQp3NuYZ*? zWnjU}(zWE;>v;r;pXJ20PHL1cX->$4~JGgl}I#<;!y5G~#7>0Ny#h>QhU@E@V*wNWP!*0YyA1ONWSJVKT5A*v(vN zP;GcnwV-&-uZk<1Q;TYMD){tg!P^kpTPL@YM_;`*)QYmc*GI+VgUjd7h0b11RYqs5 z7ak4L-HLs}n{&Mayr2Rn<3qB_H9s>NodOe^K~ZUtTRDz2AA2{nP|03DRCF#d|IJP; z{_q9SiSo(nNts6B#!O|$ndC#lfqi-lxpr;Z-k8fw+cU;B0YQGIvoEj!07svs~k ziSfy{bTFt|%Y|kvt&yMGjWUElIyp~et9|zT>7l_RYkTtYmsLOYI%+-i{J=wvCARj- z`Xztv4YAzX9qK*5+!qTVq)DKmfWpd+!<cP9089}BROSokI!Z-}+-^;hC z_Iz+p*J-vHeqvbbx+)HUe|hO|S=z$lt}7Y+0w28}n0=DxTzdcmLKwq_^{Z|`{pe~> z|2+`D=IW=M8FJIqlHg=m5|2Clv@)BGJM4BpM!5cyQ9$i7+;^m78q!Y+SyXS>$C!hl zwmP>dJYm`cBj|OoVO^-AJ5 z4!6_-PY{EgB`=4mh5zke;&GDN%^?KU9+`D~bkz?@aMBT565xI7rER@-B$_(^T*%_V zV$uX4S)VQyM7=YZn?2ee2dyMN z8!mfZOCKkbeDgl_!XpxDx#r8EF&sp_unh)%`*W^_^vG4e;6)CW;P(sqq)E_uhYhD} z&%@dhLNz=uwI*Ir7 zT33TLh+15D&JK@(!de!dhgmxG9QT*~I*#>~D~$)bJoe_<;*nx7P3StDWIVk zAf4mSjNhzP#A3Z*Z4{J600ax=N9J`e(NX!X723c@J(T z?=xLeXm#PMWs;=++2Am{aecpLQtHZRb2dM8`Gr=s=UmfJp8>=F$J0B8M;dHh!?A7K zw(Vr%NhX@uw$ZU|+qP}nw(U&x<(%_;@87z*`s%8C^}biF+IwwI1_k{eP@a?}X(C*P3@E?O*vt;??zE+R*sJCCK?XNj}J;pmZ7kvzOde#oX4?Gf|;NU5PrE%@h~p zNX9GWDcIah-3^4vHi{JHfq1Cvy|6;=kmboo&ke zmrXeG-ifc+tHpoS9dq{o8$$mPwb%cn!2EaiM}=7c)J-N(+<&J2H;VlH9@n1>7DpkH z54_s{tYyI>ePLKjM~M>YzhCDLkouph$X24#b*-`XJCY^@?>{otf1&t8$X2wifAUIP zX}@IJD1VM{QT%Pk{6B&gCF_$=tJa;G#Z#B|f0lUJIPG2|aHb1N=Fh*tg;>V@f5adI zut1NHRFteI=`{Ugp4CG0e=B0Oc(DC>Wp0H7@V*vN{zs#K0im)cM!?{3_qyL*{}1>IZ~0}y0YtkBWcSCU-5@56_!r*h+;(}zSAXP39U zBLMz4nAYkBRiv5%=iES zM(f-X#zN5ZlD9EJc)PO&@9Ox0H7<&m$_iEIx8nakzIk(;btK1HSZ@z0eqRfdpM4XL z`1HQc-gb73T{uT281qh#?M7ln>CopFm*Q3GT8bIcp>&H}1m+Y{lP zUS^dC_toL|ThGfAqaZ(jm(R!Jzq1WNueZm81%Qvo+ug%VkJr;miQrDe)GMv$+sA=I z&)37nLyCs~v>No+#oN=EU5!$Lsa}JLcpS5%BqX`Q;u6uf$7ACI<8cW~|YqR#xjq{rf%59U6xu8^i1Cm`bY)|e@s5%JxA6@Nt z#+gK2K@=-gKT&16q7(Ef>-4{Azff-WXUb?zuwFFhgoMOFil`WULn`aLLLnh!MM!W3 z!bOuuwuYIFRND7x#3dJ|zplLD0X6Qmidrf3JKB6L1AC0eFhY_FM#FJs&Cv!_0VNHyFtT&IeK<}zc%=# z>(_-VV82qUOd6l+Ocyyp!_5SZFVWl62Npdid?01RWEmsY0aBfF`ay*E04|+|iSwir zdwwQPVM|u&H}|B(wLuUF7L33E-;k{Z)V5Ua@{h@w>a?B8BcKmQ`q&NmHVj#UiX1Ll1 zoG}Bc&9rD1Qkr5I=a!K%0K1+_+KsFaIeB0t^=`hTQ)KjE`CC1#v&X=1)Fn{BHN#cF zAtWaHwat;i*EW@f5>02;M2Z+dW-*Tk#_k-YU6RBIt@mZ4>v$WR|kYj;sN zl@tX?kqRPh{M71=xIL9pfol61UX|+jlG(s(3j| zdb~aqLak<*sR5Y-pn%ujEOmrhmHR-4(ucx@ay*P6L5+c$?{IrL`~7(A!=tBcC7=Sq z9lwIyeN7OGhl{scIT1T#?|2ZYrh)+)J^cs7hzIPYp>$kI3T) z;!{G(3iU70n=V1UN@?TEIB?+7X6-Yla^>`_h}Xp+q`|;dyOZ1qbU9v`K_e0sKko?oGqpPR zE8S*vfF5N6+UhIEU^s*yr;?8MF4zRv&Kk-0K}!}VSw(B9GZV=0;BMVj!(g6u<9s=V z5!jIbZs_Bdu351^$`yYK2(QzdY}GC_6Jl4cS1X)1Um1ZWa1mgveEfLdwO%)vvZbeuE)H~;2wBoWGHE}4g*rc^2p;w#-!iTSA2;Jd?FG!Eq!%}Q08Og@Wv z2xK=q)C#OB`6Q#xze@h}Fju_HNAi*j%C!9H3X#v_&A82gs_3R$5hsyfq=>zk9HlW; z$9>4jQ8w6;kI5^MtfK+BCH&=dz=3vsZQ(>lMNPL- zDHW9QlP1gyp0AYuudI+m4?OPFr}qM37y|xH+i(Jm2VI` zl3!(kWF0du)ZCax_Ndv74i)NAQJ_e{{*NxtvMZ(@x)frJBWQ7N0O`^aTvEU6*Sm`` zpc$a6NO6dwPBpGCK5$d2Z1X|)EE@2ZpwfP)4oWawL;8YV`t3cnfGLl>3 zD`=R#pG$0iA*g_7<1k!JsY>0s<;tWy>F`Xs674Q~M5gbaq)GDdJXtkV(GjYy)u59` z)Yox}oe$d+v6UnNsvD{SFPdISZKNKabaAdtlmfnKuX}DZ%~?nf_&eI()HEn_I5m#j@u3myWxT0-x1Yu-@+1OJV;@ zA_SUrbEas~T;wk&oAE)O@Am;dfUt+@pxLg!Rfe(mgKqJywk@)`2vocRPSh7Efv&xg z>}e=2$0~B}-6A=Zo^)JrCJ@zdG|{izSKI_;TH(&t;YS7eq|KKN{SWV(b)sPeOS#4* zLC4x-``j9YhYiRyk8YTmys5RLNu{;(3JRwQ*TnF0Aay>}4&ey<7f2Wg04kX7W(G~4 z*-j_8_8T;lZ{X9y6;6wgp+}tis$#NkJ&I_&+`8%gg)NjwCrgn2SVT-YZ8!u`!0j^F zAWdY=tNu>JB&bR+|4<8k3~yKW@>whyQ69GVyBvGwy^INQ72!DPhaVEVUEC0YlE*%R z$K*b|(;wxL;~~t~V0`sbz@S+a_`-`lcR%eWUc7WNy^oBq6nildLGQ@eIjN4VLCiQ? z!+gLLR7J2Ny~+R&yD+S&5NwXO1*7h^XwpdY&&&&Yq^Av|2I7d4yT{%KWv}(^At6T1%4VL3THN5H*hf{6MdT; zA18uns6yeV-}fC7&yb$>R(5?Cny^+F%0F z6zcwL1T7Wo2r-fm|J9Pf5fY$EnTYJmaQb?F^4EiF!jRN{3F9LfbsFl!n3APy8@~q8 zUH1X*I!o*X+U$`h+5XRv4VhY9boF*OFsNucaQFIGIuXQv06OwZ3K?et*S(vX1yLb zNyO7;MY+WELukns;@|;oFKc@`3z_Wf>qgh>aE#EYcRap80KEQ_3b;tNA-P#$$FRHO z&`nkBP_gqK?ja{%m=YeQFhNsW4qc~3W#e*%^VNVV07AO^yxein>*6JUhCpM~0W>DM zbVJeF3ukp=rDvx?#;B_j)9n5JDZs))FvZmHI`N6aQz40}U40Uo-+oQ0bTnO6(APNE zGYxksYkM2-c>}aos_EHFDNOCSM=`=YOtyHm+kcVHKGW}Vm)Z2unMZP2Lx0p9 zEn{1pfdH3gtISV=FH2SZeMKC?ZUz_!70m_P*8eCJ6AeMQt9!h8G&+K`TO(8trj<43 z4Fy5(_|U~iil^jsa!&1ps04#^sthe4NTLff6r60`ijSGZ zhxyq4-X27#*qP@Aoo@t7#tI_@)qNH6}A-pe#boy?ElT|tz%1piCkHEA}A zgU;eAkFMXJr4SP-1_`>W{&ehW@LSysd$}NCl%`}Y6%+i~)lBB7QP>;E1_C`8vF)~p zKP2`1j>+-pqBzCnxG{>#DKAJuRbT`FFlLa9qnflV=H)hwrT~lTvVq)-EqL)v;E6K- zl2?i=aPuTBdNQ?A=Q+Gp)Q~xSXDE)`>jdi@u33k8h0?;U?xA}d5BP`9;x)?ZuSuQe z#WN<7kXfJyeLIsVDzgr04z_{P)&`aif)v*lYroojtLhNJ4Le9j zg{8EjD0Im~mNnd+%+0TNg)Gw=vJM0}Z;T&~W1gney zmsxOpM#qK+B)Ag=K6+EBjjWp6Zer#ydYULSxDg9fZ*?m2@&qX=9)8{`K$@yw^*3Co zAHjniylsnjyHHU)o+@tbcu<@&NSoG1WB9VrxJkGY$xw^GSV0ow`k({^3KK|1g-=IL z-EW<|?fKLUHnB!%t%g!yp#g-=&DZu54hcI9*l#Vr$g$Cqr#Kh^-Fy?TI;o(Xe5$fz zZS5#zMg+p=7Wn<50TmKUKwd&YJ>&Q)j7W3?1b50RBk@$y2>>6|dcaEw|6S8|@z1xX zt%Z$-BN8X%8z)w}6h4nR&{AAK;bsq8b=!s#;|-o`&)gsLxQpe2623MYCg`wM@`DuL zmGD|_)!(R8V<{dUY2v`8{|W|i)BTUu6pV*c#8u)j4)Qy_XL&mu0aKBteEbd4br~VK zhg`v6Qs%{YjX-$$QlRz5DmPwm;8KW%n_9bDl*|VRfTAkZ3Sgr-_Eeg|*cImM!s)~K z*j3EkG@Z&`L*iUDJpVB@yz|fknq#PgU0Ymg{swK&3!d~pz_oZY>(YzU{PgL(Fh?F@ zLqfoA6a@m+ogmO20HrGA8Hi7HTZ*sf*wAQp+Cvg*Qe~i57+h~~q4*h|Y^otq-9DY+ z&T#Pr_%jBWv$aHNMh>v&z4I&er)Zlw4I zJDCJRwzG4jp7h(1z)}qX0v*-`d-am+4-H|5i^-lK6~jw&0KQZI+v|-f(JfqINu2N7 zu#fvI6U@+!#g4&QP|&PgF{y6O<*NG=2KT%oyF7(i;gh)Q-xydsxzH4tl)#3TQkphP zcfyVw;DQQhQNqk$Zz)b4;`Ty|yQ7UV**Y7!<}4blC@yl2Y`g5V9UDHfKUFG2b9+)@ zfS(37lNrt=01&5G&K_En4zMpu;rb051LkR^-q1tx&{;+(3yI_38guQkt~o&szmD4{ zF)vETN2`&#NMi-A2*HiyUuKWC zl(yF^d@shcZmg6@AHf%Cpr%~_rTVhU1N8caq7PGNl@PT~ZB=`rL{i-0dN4ew#;^oR z2?}X`Y{^O-ADs=NEmsO8pKiarCiSD4Svq;LgiJzQbi*VXHn3Qa&E5LfAApHG2fF$C zV|}U7U5wLEj@Bd|FcaDhouet~G~8GV`TTNjrpKa ziL`v29zqJmcG;G*`7A3aE#STKw}bjC*TDm8Pfk2IF@NWfNOgQx`lrhbYLs!|TMBX)~u^WWaE#f;;_vX%jWcpq_M@J1gb^CJ@Ihr2vQwc=vrf)t2pxmt%kM;p(^M zoFhAyT@47W!&Tx{z9}cm50@y5hrpXPY-}7>t&CISp{P@w_ z>I|)%W`}Ih=>YpLpq(>RfNO!GMf{Hysy3 z!n5)O0`g?|N|qEb&aQbSs@?)3xcf5^$K~yOCsbcC@F_caq(hQDkX2hKnenO8exKXF z7GGI0Gcmfa3gIC)$okz@YSn&~1LRv?mH7G#Jk=Df`K@L9;7aV5N9A><@EcA{zAwv+ z%Xc1L&?)944T3Hq!~d00YuV3Bk05MuXgI1qAOCwCOCd$X-CjeTCg757r^L5bEErvi zCZa6-uoA?=!QV)%YpIRm+EDTgmwlK$RCpeTqvYewrm}G6(MNX8hpE=91d!BUBm(h$ z!>HU0j`9lPZ?BJ$>k%juTfjNm~ByI~3J(Y6nHho;H;1Ro^p+eLX``euZVJ zBCW(|SkqyB>8?>HK-~~0yz&R$)MdCgpAD|eaRAtWP;VhQJ$t2p_ZP=Afsq*Zjudh9 zH)tZWg!U7gjYGHL5cv>-t>Q0DO0Z9rsr8n#c#9Jvyz=5erB^8Gnx`mh-Vhi4=&_X@ zUNPFCU*Qp$O*;1e=o@IMt_rWz??9sYxs*||C((g|;rj3W0CT5$b!;%M#i$SJx|7R#s;*Fdl2jh3-IzklO`5f@^V?CR)Y&|b)$XycXMCyq*F&=%q`4_} z&>~mB?Ld+~QJdpH);XA_$yVoD(P0>2QKSN-gPEeDfX*~#%WG`09ZD``pxneJud2Yn zX2ZqM9KyXabgVCQJ3WdL6IIu@CdBFCj+82?8hncfA{Q=IP3utK&CMu>DgIo}ac!U0Ozq5_?*Y={mB0~knx4{ei64tH zo>6B8r!Od6Gmft?Y3ZCj^!qjEas`?~5^N25eaxI$6Qf6b`Heh z$h&^BCS2y>SeaPSe&9>RtN5LE?8ZdJ009*rQ6XeL3pdD6F{v2ptidN*d+6G*(4aW? z20c?zWZcOc7I!iC>@Hb&#es{zw(|t$%dm{RTiN;0jQREqW55de?;F4WiYP9v51@3t z+W~kZIUrT)aw(I_rAMdVT&hGg9oflmAkt)mWm9Tdna@o`$|zBBAA;tP!L%Rq#nP=VTfr#dgl3 zq99WWf0xiZn=z0QMC5~l&OY(4)+CM5hN!Qc-dJ>`ciNTJ=MAMEQew7&e`;8KWa2%iU2-+N?QI0TSk26v|G* z&;~F@&4ZS}J|Wi0u^8nnt6IyE?}moJX?Lr`eRD%)qUQK_`6u1LSbS&8L)~zja|~~P ztmfUVKLedg0BWQ$h~UrK^AAa3Uu&scGykw)_;x$xip@;JyTm*36cSPP<{4-|U}}xh)Gd7Q1A-`iaN#jze4}5~swD zQDj^6CTT>c3I!Gj04{OPKD(AYPZeC-I{fj5crL2Is#OAtfkjY)LOIijL(;<2)%P8ihf1QVl;s&O|jPk1+}fya90sI5CGlS-yw(g>xG z%$jMmuJEhda~Y+&G}l_=aQ~>3s%In&b!yr-2tsUTZn?Ar7+k^{WmH~f@7XGQBSd0S zrG`YA##n|Ew08UOrd&IXU*x^~)a>PY;>z*zcx7xob8*RG&38_fyIuVH<;4J-DW0ER+dsU|}V2cWde3sYa z?01(kCMV)z*BVTQfm6vc#GR@ME~5KYg~aI0*ytKa0gT>f(6UE)hU)KsXayp1OkdF# z=`6N4UpR&#aNMY1Y_iFl;nB0=e^SKd&lbGK3Yfh;CYpmo#d3sLoluoB3>=2&zvb_b z;X{SUJlN2ggG1ZcmBjPN7?Q=UgFo)<$?O2iass)MO zkwHp@)UV}Vx@E?=ISg7?Xe*H4Ngdg8Fw-a;x*Z<^alts+A%=tnfw)0Y<}P2S{#Z)D zn*XNz{@OFl(z-=sSF;5KXHQseH$$^F3uYB%0=_*LKJbn*e_WQU$L=6kOOMlp5Qr>o z@D(k@&U!0N>z335oD^}VBx-rT2J4moE&TIMpcU0lataVbl*>YdJAtOutmE!)`rY*= zr=*v&y53Is0x$huO|W%)Iv11g13~~x#ZP{3yCU32Kj8y`3NHSJz8_~g(Q)&NcM;q@ z4ESdAcAEGKUqN(UKqR>oGdfQ(akBUP_Qh|IFVh1;_jLkghY$x5Wq7u zmZja?o4q^HOaj%VVuG|_+DU^Pg=n=dyZOxkp+Qi43^tcZf#1Lx=Sf=6<%$bgg70@M zLtBCrqz>bb{;79$Eb`3pDYiS3u{ZkJo*0IDU^k3UXf0fJuDw^ll;$bHsp_MlzNlP_rlc`aa?6YFR=F^^Pc7S@oy;)*|#H56|^Q~vmdm|pVEqSYk ziK3sG&putUQ!R;<54lLWr4ZYhu&rph?lW231bvMp&Dkw3Jly>@phu731i*;5$9NkE z7}VWw;*3oL;_wxVU#$B%z8X-}+Dq%{uHb+XsY0TjS$UbGj;m!Ut+U7Q5S=E`Wxp^> zrI6h?$A4sn_;B$Js@%|I|Jth|9Cv6j+nM7)jWJ4mpG+1bhOE7W2dOpHk@Y*)JpU&O z{bVXXn3lDh-%W|2tWJ)$37})0JR6?&bI4_GZZCY_FlAT0}4GaB?vkUUqh`%iiC3&3@r^6-^?S}LkyJ(Hj0|mCYN3CRu1=XeuL(h7fv3Ym2pGHz13Z%MXtHR2 z>OIc64UqYuZ-`V3kfrT7aU~mR^xy;o7rB7Yt zP-%A~-)3z{c-#$?4A{yn2aYpw;$%4{& zA(@$-M`E#IRRQ(OP>1;!ieeA)0QK;Z|K6(yoTeoR81t-jd{?|hp^janx%#4qGr!xw zvmLsnRsEFZ^(jA;lG^xwzNk%y(7b9hC8cU@?9xl5V_iZ3Eg<(i+L*b39cw0oTBM7o zGTd~0nYq&jOCff*aN*MxqS-5LsA-^z1UfWh>rbi6V%NJQJchs?PMrk4SI=jwBA}bh zsR}bNQRyphY+I!ETrEETIWbz=TSQjjrSjY2QZrTH_-m5TH#n$tg!4ZAw*{5^6g_;< z^oX$cwoAL44nR%QEEAjALOR!iL1KxV!+Gn^lUTpA6M3*x+VfPHun*igH|wEnor^NM zlhSjK0xu^y)AkTnm0AINl%5=>(w9)jwd-s#YFL&&0v-=7aB?r}m_6kY*3<62iXfM1 z!ktgABEg8Qn)Wh!deCOnm30IpKENi=6!++LLIu>lff>Mfj|NL-xfK3gc8^>NWeo!=_x+6n&j zY6&H;FF?~*EkR1)lu=cq?OW3+dh{#KIKi4SVlrI$_&D>FRs$Iq+st4CGpE=2x%2M; zyehmbx;Pla-I%H_k=$P$GJj6FWXZxl?Y{&vo`z!bZmEsx6MwHMilhvK!PNJL$VuuE z9f*jvv6fU5w~_xczQJpn!WI3wblf~HOjWBjE{fi7j`% zZp65w2%NlwSh>`upQyk@!Rb2B8Wtr2?At)z&&y9-6*;HODjxYhnC zUI4nkvreb%qtp8H%58y5R6bY)(_1|9~1-~kl#?A4R&01S;9>RXJy22m`8Mk3cew7YU*hen&r+-K2QeO!Yu0cUUnE+$lzySgrs6gTBeP*Lp$L!nOD~o=m0(v z(tUJQ114T|(5pI}d~3=My;;I}s|Ri}JTZ0!ejOp-UargksGl3#kYr46e?71B({r-d z=$2lm}4%dV&}3Q1rZUCV4jo2e*m5`G6y+ln#h3jwLxN(NOy8I&aQODsi{D4#a`t2g1> zndi^&Ly!d5FfBo7tWAxsAr7M6}a^c*3@E$Tf5$QC+bJT3F4-gAb=MI zUU^}_S7`p@3(LO2tnhF;q<%njG#_BfLDp}!np*=< zbeQ>2_1&J9OM}5~_w)GsQ52o9SqhIFeNU0P0ttPgl>K3vxO>nq*<70Dl-URnbX683 zkOS*&u5*`!CV;R2^7ZCO(ud0TjtKYZ!>E&bBEATQ+GDhq| zNYuUt{pN3};%{rG>Hu0CtmgD*4NeaD>~HZSSXlE&+xo5vJ&n17W8IElMxj+i)}J$j?Ku*9YWA5iUi?X|4Jz;_@Z1=y}p zZ}$q;=#K3`g&v-dgV=Q;N$Ms2cgTo1_90aR6CUvNnIO_Yb^&gj0D<1FNIhj00ELRz z7M*-?jql@a69$iIO+H18*e{|PVqWYvT=s%m)Q0b@Cbck87L16o8u(*|89Q)rm`w zZ*@AT9ztOzXBKCwvKT&>#N>fo`E-UU$Br|$GPp5Tye5&1mmTSTac6K9 z9S4htG{78EuTIJp82#;Q8JbNmIN00m-bzbKFz_01m->+gaUr-V)4oP%*Y3lZ0B(w= znc45SBh%})g>??}ghq_{U9sT$@wsanKCf#c_1*m(yj@#~-~EOQQ=f67wZkNLMl!GO z;2uVuJKoPnKr_IQz#8x(Qa!%W!8Eew>mwJOy#UAD^?v5tY8!GUVonE<%B}e2)HV~K zvjL4)pj?4_#)3e%Uu!X|J*+Cq2ZeM4qm0`huNO#YK|Dg)k=Ke%3L|*zd0dmXYHOHq z3MDl-qyuWW`3V#ycYH17x~>$Aq=S+|Kmus93A_#H%Kg}zN*9CDLy15u$~PrhUkg5e zs{l3Wj*=N9rXdMYy$1D^f~@2epwb?{0s{67iW7qJY9G@djp^qaTO_C#K?2>mlP(q{ zf6t^=FL1Qjv7=~ks>)r0gFU;PRfB&$hi|2(`yPe!SWYh4ZVbGn&3dH8)fUg=QA;zW zB1R*_`qWkSTt6q zQ<`({k0Z(-U!%NqTMP6l(-^VKX2eoI(y?Gmo2En#2u@LE_v7mF5UCf^fKgXgAVo!L zRhMs3NOY>(z6DoN6I%K$6yrZYcmPsodSix0ty@h3|6(jG8O8z>X|{?wQFn!s7pB&D zO#gFFrmz%*IkxoBqHX=Xamm87IQDCll$vpamlAUdm9GujP}>53WU3f}UVvE)rE9#M zfZUPUK*sSTLl(JgnuH<-(i~X45|XX>YXa&F?O)w9k^2>4G0DQ&n5tn=SAf>Q7)df^ z-VthX;kHIc&5#B7g{j-tZ>tO0M8`O3rK_n1_Iy0*4yx!JaubTCw}xU!3tD4w&PjRm zoH3A@1|G=BoA|}?5mkG{4lv((US+=zhDsH?0UUDkwBSVf-`~owNfSQI(#Ezse1NXE5(~b>6ysd) z7C(+G?~pU>XwZcMON`)oP`h+AW1N@j2jh{U-X}peIu-J;TWkQOboz-{ppin77-iZ| z65{8t^Gc|ZLDz&Lcb$Cm?VV%=twc>SeV&nU`d0iPczl*R^5xPub_twU=eBpRK!PW) zT(5dB;MW|3iF8(`LjVjBHOYwFo2W_KMw^#E!e51e5Ni>Hu_>|O5Y3h+2GFHNWR(L( zfnG3TIN84~Mmg2@_+G+Bj&}67xe53{9pZ`(L=Vi9zg#1Eby*7^|LLw&B~TV54x;q- z`1C>|6RMXUG`bw@hk5d<^e=XKzuX~`bC>=TI79ml^z?UVG91v7M$fWAn49{ZrY(GZ zd!5xfy)aRl`HpwS+H0tsNkGwxK#yohP<%I$JW@qw)7fftJ-D+ZU>x9wZVF71HpUn+ zvtQw9`7P^1T`kJmnFO6=nhn2_pY-DXyyg_M++Si>zF1rHv_J_DYDGgbiJk#x`W-l? zxh?Qzrnpbj2m&bg!6*Tp!RELA-7n^s2Z^F01bx+b;DUitzTo{-5+dk~E0vu&jNz{p30*YVqjiUbFlR6Um#J0czg3q!}{=Z?HYUX*z6Of7JEZK-hX~|Nst#@@%$?22V@lvp1py`o^ zzI@%^_)O5_{kIU`O|Ld*s)BRB47i92L*1vB61xZQXMZ79fU+ziI|?DK&HhExwqZad zy^HS3LPG~I1ZM$@!K(|^N+XYOfwjs>8m5W#vf4AcpPw``(jI8CC(vY=@}$p{XZYRrS*|<^K_qMwV~c>} zmJvZtx5HKoEmeeO`OG>B1n~YUGx{3_d=G}_GsF*=XMxIwUHV{;Fel<#aY?Em_}n=> z9Bzoy*8i;W4^TbDWVCN`Ry>E zqt|ej0xC26C_yI8_O!hE2$_KY&Hy+;w}A%XvFbaQ27}4Q0G&9a z@}47&@{cQ$k_?ZN=SF(<`%2KD?|q_7AtS035HsWu+m&00Y2nIeF>Y2zA63?-8*3WX z)wY_1uQ>qixUGz=J{ZHuW)^}fKDfP_IS%t2Q)yZX{;UAZ@EOi< ze<6M=H)7?yR{_K%D)*cGx|QDp84Ruld`dUu>#l=>)7SeY``2_xi!OcvH_2=0Y{0G2 zb=6xXjdV)vY-Rh2YBk!9Ec;CC-W-tX~Y%g-M?k zD=WYBbO09XEWV9*eDx@~#{}3DR^V9B-u#jciIYP=Tkl4lqHbImmv^{~E@p`)yvlEy zbm&$Rgt}3SaVQw=5d{Dx+I=?quN=Wi+O8${?4fls?@{rzjm7XW$P57U_nJt%s|{MI zGRXqf$Ho>fviwU!*$BLycC?ad3!&1kxEzMw&KjyOO(Od>{}&#R+$5OC?P_4IqK)(_;{T9-E0R z=qJYNjUO|sib=CXMF93!@{l|o)Q4g4E*yc=X8924E=(#(^ z$zNn$Sqe8gU8t^7pS2J4nyi)z)SLMu)8((4Z8xQ_@L0m{ncB%urc0G3@dxDvVUe`*1xDPp5 z{Pgck_dcnd!o4THa{&%;v^~j4Rs|{G^*!U21fwaT!T7Id~#|HDT3JM zU2PiWkZ_8mDh@RH-J(aBc8*SlvjXqV)%z$DDFIS2fdrtx|15mEr!h5+kw3{N!p~LT zjN_`~9fy&BZjz7NI&XgQW93Jv{FUaK6mILSGtJ3udWwRR`CjcYkv+>YiVpZ~njaIg z?}K68p7nJcDif<&2m!&5c@Aunrum=o-;g(^~h4bdOP*9 z8=HblIzr| zRX{>=;<6XUhkoHOmdKaTA3CFfr%d^Gk5|<^s1I<;nAtVdZ>;wX7R-b~6uBt&S-^^2 zJOAPIMEMtgCW~BsOp^U&(mF3VDSwdfxJ2d*(C6E>BxwQaYvkn~0w*ho5`A2bd>gAK&VyhHfeV%1|uz2 zr>NZIK=SXkAq)^91dG?96sj)*{}m6bZj3U|a5{vAP5H7} zTe2^ShJdyg>U=Z3UKIm(+jRu&Q{dN-JscL-PA>rv>qnRMdENq^xVY_6rFn1~|uGf)!Z z9r1fLv!R(3QHgpbutys$Qgj{metQL;8d-jN=#rj$UgS@3Osw-qjs*B5tC~_g zp}TaG*DW+1wA-i4msxirAFsTe-CRP0Y3iKAor_)`OK_3S#DVzydG(lIsf!mW2KZV|4g(Fo5kMS?(Znd+Q}lFu40nk^aT#-pNeX2pLcZr7#Tm;ssRh&z98;i>w0Mit47z5%+Ck*l<(&KHU@O2NSwFVD3BxlOz12o-DO68lcB61jCt78o$l4Ohr%oB??V|4RsdtPUcAdRR$hL$j$0u&`{v z^){d}qb;I#*#w~bhJd3JSIJzFPMF&;eI)Z@hGXS9Ux_cT%@C?q0$0O8=02Ra05!$m zS#megS7N?}H48TbpcNSze;KD1?SvYN+ajrVERotVs}r+1`y+rxD;^FzL2U_$fP++- z3U+auKTtS>z)zz@^7`8z$?BD}WN|mdE3Pw!7GsCFJ&IeW`{RdSUjZiRPrym)(EkT8 z3?|po2YIIpiJe}6w&)AZD=a23+OMd*ZVj5Q6^e)Q`C*3JIe-1rf3F;u)DSVDNS5<6 zFvXv!h#zkIBOPJhjsptAwM<$GhLIxOx~+#Mh3V5Nk+ETJ^kkMu!YPxYcGc)wmhS(P zl^g*gu561*XHXup&+&yJy{}al!kG4V!7aCHSXi>6VK|VuS!^1*|4JlJ4e6E6t=q&`hcpP8f7<$LvmNKdB;j3zgswmv#3F6bGg`+*2zHjFEFq3#8xd;KN58=eWT+jnHO?N|JOm2lk#S zox+@yDcUg@naPc`N$<+wo2elHbQZjwB5 zhA@{bM?l@~%Q!DTE>xu?se|^qP@bym$T+PNzK%%IgSsAY!BO78MxFlwt>{YfctM_E zMee1H!cZyS<;=seI5b`st zggv9{S+PP4f51;O9O{|h!Qz5em~6H+geeJb%TWau`&!~VeK3SkzGd8eguX(4ES#ts zQ6A^S3;K(yu_3Z%d2KJZ^&$k1bZKjw$s-gQX66V_lAB&ag0C8Eo5>FCK#HoO7O2Fk zYvj>%S2KakvD`amPt8}yNXE_dM`MW$ljAYR2r?i_e<2%0ar1N@0Io$}Q`?B6dLIq> z=u9!)Ck{pWPHvI4pY2s>8&T_Q4Xe3Aw|I4ct+}CuI8Z4tOB?tq)X0SS5PtMjai^eT za=UqRfLXVBMEJe-Lzv4De%`>3I%)F8Q|Uqv?1MUhkJG61t1UsnKuH9r?uZ7VG0E-N zZztfle-?{ar)qZzi3l44j{IDDcp1c7J%K5h2F-t;KrpE@t{G%^L_#!k&2vus9?u0cxF8HTV|RMRER&}9ne#uCROVO2dc zms23plm6jHK?SE%s_{KBhg!)D7gtRs%bTA=4x8sRX0~KCcjVD5CEuMIqJBmS(tkO# zeobju`6+W(!q{0=twX@! zJsQh1|5ZK%{sbpLJgyFK8r9_`3V1f0wc>6l&--)T`nf4j)9FY!GI1w=Z`6W7e;47H z%J(a&7s_aB*^JtG$75qi?XKyq6{fOS+W+InnNkhOBV%v|nM$nNoQj}xEg{hK5z